PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Painter, PR				Painter, PR			Scaling - Rivers, blood and transportation networks	NATURE			English	Article									Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, Sacramento, CA 95814 USA	California Environmental Protection Agency	Painter, PR (corresponding author), Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, 301 Capitol Mall, Sacramento, CA 95814 USA.			Maritan, Amos/0000-0002-3535-7873				Banavar JR, 1999, NATURE, V399, P130, DOI 10.1038/20144	1	7	8	1	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					159	159		10.1038/35041633	http://dx.doi.org/10.1038/35041633			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089962	Bronze			2022-12-28	WOS:000165180400032
J	Haff, PK				Haff, PK			Scaling - Rivers, blood and transportation networks	NATURE			English	Article									Duke Univ, Nicholas Sch Environm, Div Earth & Ocean Sci, Durham, NC 27708 USA	Duke University	Haff, PK (corresponding author), Duke Univ, Nicholas Sch Environm, Div Earth & Ocean Sci, Durham, NC 27708 USA.	haff@duke.edu		Maritan, Amos/0000-0002-3535-7873					0	7	8	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					159	160		10.1038/35041633	http://dx.doi.org/10.1038/35041633			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089962				2022-12-28	WOS:000165180400033
J	Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, W; Yanagimachi, R; Jaenisch, R				Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, W; Yanagimachi, R; Jaenisch, R			X-chromosomes inactivation in cloned mouse embryos	SCIENCE			English	Article							XIST EXPRESSION; GENE; MICE	To study whether cloning resets the epigenetic differences between the two X chromosomes of a somatic female nucleus, we monitored X inactivation in cloned mouse embryos. Both X chromosomes were active during cleavage of cloned embryos, followed by random X inactivation in the embryo proper. In the trophectoderm (TE), X inactivation was nonrandom with the inactivated X of the somatic donor being chosen for inactivation. When female embryonic stem cells with two active X chromosomes were used as donors, random X inactivation was seen in the TE and embryo. These results demonstrate that epigenetic marks can be removed and reestablished on either X chromosome during cloning. Our results also suggest that the epigenetic marks imposed on the X chromosomes during gametogenesis, responsible for normal imprinted X inactivation in the TE, are functionally equivalent to the marks imposed on the chromosomes during somatic X inactivation.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Hawaii System	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	jaenisch@wi.mit.edu	Eggan, Kevin/P-7119-2018		NCI NIH HHS [R01-CA84198, 5-R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084198, R35CA044339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEARD C, 1995, GENE DEV, V19, P235; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; Cattanach BM, 1994, MOUSE GENOME, V92, P114; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; CONSTANZI C, 1998, NATURE, V393, P599; CSANKOVSKI G, 1999, NAT GENET, V4, P323; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; Gurdon JB, 1999, NATURE, V402, P743, DOI 10.1038/45429; Hadjantonakis AK, 1998, NAT GENET, V19, P220, DOI 10.1038/896; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1994, CELL, V77, P639, DOI 10.1016/0092-8674(94)90049-3; Kikyo N, 2000, J CELL SCI, V113, P11; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; McDonald LE, 1998, GENOMICS, V54, P379, DOI 10.1006/geno.1998.5570; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1991, MAMM GENOME, V1, P78, DOI 10.1007/BF02443782; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PRIEST JH, 1967, J CELL BIOL, V35, P483, DOI 10.1083/jcb.35.2.483; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; WEST JD, 1977, CELL, V12, P873, DOI 10.1016/0092-8674(77)90151-9; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	35	210	230	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1578	1581		10.1126/science.290.5496.1578	http://dx.doi.org/10.1126/science.290.5496.1578			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090356				2022-12-28	WOS:000165446200051
J	Fiellin, DA; Reid, MC; O'Connor, PG				Fiellin, DA; Reid, MC; O'Connor, PG			Outpatient management of patients with alcohol problems	ANNALS OF INTERNAL MEDICINE			English	Review							IDENTIFICATION TEST AUDIT; RANDOMIZED CONTROLLED TRIAL; CORONARY-HEART-DISEASE; CARBOHYDRATE-DEFICIENT TRANSFERRIN; PRIMARY-CARE PATIENTS; BREAST-CANCER RISK; US MALE PHYSICIANS; USE DISORDERS; FOLLOW-UP; GENERAL-POPULATION	This paper addresses the clinical presentation of patients with alcohol problems including screening, diagnosis, detoxification, treatment, referral, and longitudinal follow-up. The case-based discussion focuses on the clinical management of a patient whose hazardous drinking progresses to alcohol dependence and requires coordinated care. Ways in which internists can aid patients with alcohol problems by screening, giving brief advice, and providing appropriate referrals when indicated are discussed.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Fiellin, DA (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Box 208025, New Haven, CT 06520 USA.			Fiellin, David/0000-0002-4006-010X; Reid, Cary/0000-0001-8117-662X	NIDA NIH HHS [K12 DA00167] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K12DA000167] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adams WL, 1996, JAMA-J AM MED ASSOC, V276, P1964; Aithal GP, 1998, ALCOHOL ALCOHOLISM, V33, P304; Allen JP, 1997, J STUD ALCOHOL, V58, P7; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDA RF, 1988, JAMA-J AM MED ASSOC, V260, P2529, DOI 10.1001/jama.260.17.2529; ARCHER L, 1995, AM J PUBLIC HEALTH, V85, P61, DOI 10.2105/AJPH.85.1.61; Ascherio A, 1996, HYPERTENSION, V27, P1065, DOI 10.1161/01.HYP.27.5.1065; BARRY KL, 1993, ALCOHOL ALCOHOLISM, V28, P33; BIANCHI C, 1993, J EPIDEMIOL COMMUN H, V47, P308, DOI 10.1136/jech.47.4.308; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOHN MJ, 1994, AM J ADDICTION, V3, P91; Bowlin SJ, 1997, INT J EPIDEMIOL, V26, P915, DOI 10.1093/ije/26.5.915; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; BROWN J, 1992, BRIT J ADDICT, V87, P1013; Brown R L, 1995, Wis Med J, V94, P135; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUSS TF, 1995, J SUBST ABUSE TREAT, V12, P75, DOI 10.1016/0740-5472(94)00086-7; Camargo CA, 1997, ANN INTERN MED, V126, P372, DOI 10.7326/0003-4819-126-5-199703010-00005; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Carroll KM, 1997, MED CLIN N AM, V81, P927, DOI 10.1016/S0025-7125(05)70556-3; Chan A W, 1994, J Subst Abuse, V6, P123, DOI 10.1016/S0899-3289(94)90157-0; Chappel JN, 1999, PSYCHIAT CLIN N AM, V22, P425, DOI 10.1016/S0193-953X(05)70085-X; CHAPPEL JN, 1997, PRINCIPLES PRACTICE, P567; Cherpitel CJ, 1998, ALCOHOL CLIN EXP RES, V22, P1399, DOI 10.1111/j.1530-0277.1998.tb03926.x; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; CHOUDHURY SR, 1995, J HYPERTENS, V13, P587, DOI 10.1097/00004872-199506000-00003; CLEARY PD, 1988, AM J MED, V85, P466; Collins J J, 1997, Recent Dev Alcohol, V13, P387; Committee on Treatment of Alcohol Problems, 1990, BROAD BAS TREATM ALC; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; DAVIS MA, 1994, PREV MED, V23, P369, DOI 10.1006/pmed.1994.1051; Dawson D A, 1995, J Subst Abuse, V7, P331, DOI 10.1016/0899-3289(95)90026-8; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; EWERTZ M, 1991, CANCER CAUSE CONTROL, V2, P247, DOI 10.1007/BF00052141; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Fiellin DA, 2000, AM J MED, V108, P227, DOI 10.1016/S0002-9343(99)00448-9; FIELLIN DA, 1999, PRIMARY CARE CASE RE, V2, P133; Fillmore KM, 1998, ADDICTION, V93, P219, DOI 10.1046/j.1360-0443.1998.9322196.x; FLEMING MF, 1991, ALCOHOL ALCOHOLISM, V26, P81; FLEMING MF, 1991, J STUD ALCOHOL, V52, P33, DOI 10.15288/jsa.1991.52.33; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Friedmann PD, 1998, JAMA-J AM MED ASSOC, V279, P1227, DOI 10.1001/jama.279.15.1227; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; FULLER RK, 1979, ANN INTERN MED, V90, P901, DOI 10.7326/0003-4819-90-6-901; GALANTER M, 1993, AM J DRUG ALCOHOL AB, V19, P499, DOI 10.3109/00952999309001638; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; Garbutt JC, 1999, JAMA-J AM MED ASSOC, V281, P1318, DOI 10.1001/jama.281.14.1318; GARFINKEL L, 1988, PREV MED, V17, P686, DOI 10.1016/0091-7435(88)90086-2; GARG R, 1993, ARCH INTERN MED, V153, P1211, DOI 10.1001/archinte.153.10.1211; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GENTILELLO LM, 1995, JAMA-J AM MED ASSOC, V274, P1043, DOI 10.1001/jama.274.13.1043; GERREIN JR, 1973, ARCH GEN PSYCHIAT, V28, P798; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; GRANT BF, 1993, ADDICTION, V88, P413, DOI 10.1111/j.1360-0443.1993.tb00829.x; HANSAGI H, 1995, STROKE, V26, P1768, DOI 10.1161/01.STR.26.10.1768; Hart CL, 1999, BMJ-BRIT MED J, V318, P1725, DOI 10.1136/bmj.318.7200.1725; HAYASHIDA M, 1989, NEW ENGL J MED, V320, P358, DOI 10.1056/NEJM198902093200605; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; HESSELBROCK M, 1983, INT J ADDICT, V18, P593, DOI 10.3109/10826088309027359; HIATT RA, 1988, PREV MED, V17, P683, DOI 10.1016/0091-7435(88)90085-0; HILTON ME, 1987, ALCOHOL CLIN EXP RES, V11, P167, DOI 10.1111/j.1530-0277.1987.tb01283.x; HOFF EC, 1953, AM J PSYCHIAT, V109, P670, DOI 10.1176/ajp.109.9.670; HORGAN C, 1993, SUBSTANCE ABUSE NATI; HORWITZ RI, 1989, ARCH INTERN MED, V149, P1089, DOI 10.1001/archinte.149.5.1089; ISAACSON JH, 1994, J GEN INTERN MED, V9, P550, DOI 10.1007/BF02599279; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; Kantor G K, 1997, Recent Dev Alcohol, V13, P315; Kessler RC, 1996, AM J ORTHOPSYCHIAT, V66, P17, DOI 10.1037/h0080151; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; Kitamura A, 1998, AM J EPIDEMIOL, V147, P59; KIYOHARA Y, 1995, STROKE, V26, P368, DOI 10.1161/01.STR.26.3.368; KLATSKY AL, 1989, STROKE, V20, P741, DOI 10.1161/01.STR.20.6.741; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KOSKINEN P, 1990, AM J CARDIOL, V66, P954, DOI 10.1016/0002-9149(90)90932-Q; KOSKINEN P, 1987, BRIT HEART J, V57, P468, DOI 10.1136/hrt.57.5.468; Kranzler HR, 1997, ADDICT BEHAV, V22, P431, DOI 10.1016/S0306-4603(96)00064-0; Kupari M, 1998, NOVART FDN SYMP, V216, P68; LANG T, 1987, J CHRON DIS, V40, P713, DOI 10.1016/0021-9681(87)90108-1; Leon AC, 1996, J GEN INTERN MED, V11, P426, DOI 10.1007/BF02600191; Leonard KE, 1999, J STUD ALCOHOL, V60, P537, DOI 10.15288/jsa.1999.60.537; Leppala JM, 1999, CIRCULATION, V100, P1209, DOI 10.1161/01.CIR.100.11.1209; LHUINTRE JP, 1990, ALCOHOL ALCOHOLISM, V25, P613, DOI 10.1093/oxfordjournals.alcalc.a045057; LIEBER CS, 1995, NEW ENGL J MED, V333, P1058, DOI 10.1056/NEJM199510193331607; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MANN RE, 1994, J STUD ALCOHOL, V55, P372, DOI 10.15288/jsa.1994.55.372; MARMOT MG, 1994, BRIT MED J, V308, P1263, DOI 10.1136/bmj.308.6939.1263; MayoSmith MF, 1997, JAMA-J AM MED ASSOC, V278, P144, DOI 10.1001/jama.278.2.144; McCrady BS, 1996, J STUD ALCOHOL, V57, P604, DOI 10.15288/jsa.1996.57.604; MCCRADY BS, 1995, HDB ALCOHOLISM TREAT, P307; McElduff P, 1997, BRIT MED J, V314, P1159, DOI 10.1136/bmj.314.7088.1159; McKenna CJ, 1998, AM HEART J, V135, P833, DOI 10.1016/S0002-8703(98)70042-0; MIDANIK LT, 1989, BRIT J ADDICT, V84, P1419; Miller B A, 1995, Recent Dev Alcohol, V12, P81; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; MONTGOMERY HA, 1993, J STUD ALCOHOL, V54, P502, DOI 10.15288/jsa.1993.54.502; Morton JL, 1996, AM J MED, V101, P153, DOI 10.1016/S0002-9343(96)80069-6; National Institute on Alcohol Abuse and Alcoholism, 1995, PHYS GUID HELP PAT A; NOWINSKI J, 1992, 12 STOP FACILITATION; O'Connor PG, 1997, AM J MED, V103, P477, DOI 10.1016/S0002-9343(97)00271-4; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; OMalley SS, 1996, ARCH GEN PSYCHIAT, V53, P217; OMALLEY SS, 1995, PSYCHIAT ANN, V25, P681, DOI 10.3928/0048-5713-19951101-11; PAILLE FM, 1995, ALCOHOL ALCOHOLISM, V30, P239; Philbrick JT, 1996, J GEN INTERN MED, V11, P9, DOI 10.1007/BF02603478; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Reid MC, 1998, J GEN INTERN MED, V13, P729, DOI 10.1046/j.1525-1497.1998.00223.x; RICH EC, 1985, ARCH INTERN MED, V145, P830, DOI 10.1001/archinte.145.5.830; RIVARA FP, 1993, JAMA-J AM MED ASSOC, V270, P1962, DOI 10.1001/jama.270.16.1962; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rumpf HJ, 1997, ALCOHOL CLIN EXP RES, V21, P894; Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; Saitz R, 1997, MED CLIN N AM, V81, P881, DOI 10.1016/S0025-7125(05)70554-X; Samet JH, 1998, AM J MED, V105, P302, DOI 10.1016/S0002-9343(98)00258-7; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P673; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SCHATZKIN A, 1989, J NATL CANCER I, V81, P31, DOI 10.1093/jnci/81.1.31; SCHMIDT A, 1995, SOUTHERN MED J, V88, P52, DOI 10.1097/00007611-199501000-00007; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Seppa K, 1996, ALCOHOL CLIN EXP RES, V20, P47, DOI 10.1111/j.1530-0277.1996.tb01042.x; SERDULA MK, 1995, J STUD ALCOHOL, V56, P233, DOI 10.15288/jsa.1995.56.233; Sillanaukee P, 1998, ALCOHOL CLIN EXP RES, V22, P892, DOI 10.1111/j.1530-0277.1998.tb03885.x; SIMON MS, 1991, J CLIN EPIDEMIOL, V44, P755, DOI 10.1016/0895-4356(91)90127-U; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; Soyka M, 1994, Alcohol Alcohol Suppl, V2, P531; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Steinbauer JR, 1998, ANN INTERN MED, V129, P353, DOI 10.7326/0003-4819-129-5-199809010-00002; STEINWEG DL, 1993, AM J MED, V94, P520, DOI 10.1016/0002-9343(93)90088-7; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Tonigan JS, 1996, J STUD ALCOHOL, V57, P65, DOI 10.15288/jsa.1996.57.65; Truelsen T, 1998, STROKE, V29, P2467, DOI 10.1161/01.STR.29.12.2467; URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149; VANDENBRANDT PA, 1995, AM J EPIDEMIOL, V141, P907, DOI 10.1093/oxfordjournals.aje.a117357; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; Volk RJ, 1997, J GEN INTERN MED, V12, P763, DOI 10.1046/j.1525-1497.1997.07162.x; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; WANNAMETHEE G, 1992, BRIT HEART J, V68, P443; WEISNER C, 1995, AM J PUBLIC HEALTH, V85, P55, DOI 10.2105/AJPH.85.1.55; Weiss HA, 1996, BRIT J CANCER, V73, P1298, DOI 10.1038/bjc.1996.248; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409; Wilk AI, 1997, J GEN INTERN MED, V12, P274; William W, 1994, Am J Psychiatry, V151, P259; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18; Zhang YQ, 1999, AM J EPIDEMIOL, V149, P93, DOI 10.1093/oxfordjournals.aje.a009791; [No title captured]	157	39	41	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					815	827		10.7326/0003-4819-133-10-200011210-00015	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00015			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	374AA	11085845				2022-12-28	WOS:000165321200008
J	Earn, DJD; Levin, SA; Rohani, P				Earn, DJD; Levin, SA; Rohani, P			Coherence and conservation	SCIENCE			English	Article							CHAOS; DYNAMICS; ECOLOGY; EXTINCTION; PERSISTENCE; IMMIGRATION; SYNCHRONY; DISPERSAL; RATES	A principal aim of current conservation policy is to reduce the impact of habitat fragmentation. Conservation corridors may achieve this goal by facilitating movement among isolated patches, but there is a risk that increased connectivity could synchronize Local population fluctuations (causing coherent oscillations) and thereby increase the danger of global extinction, We identify general conditions under which populations can or cannot undergo coherent oscillations, and we relate these conditions to Local and global extinction probabilities. We suggest a simple method to explore the potential success of conservation corridors and, more generally, any manipulations of dispersal patterns that aim to protect threatened species or control pests.	McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	McMaster University; Princeton University; University of Cambridge	Earn, DJD (corresponding author), McMaster Univ, Dept Math & Stat, Hamilton, ON L8S 4K1, Canada.	earn@math.mcmaster.ca	Levin, Simon A/J-1218-2014	Levin, Simon A/0000-0002-8216-5639; rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341				ALLEN JC, 1993, NATURE, V364, P229, DOI 10.1038/364229a0; ANDERSON R M, 1991; Beier P, 1998, CONSERV BIOL, V12, P1241, DOI 10.1046/j.1523-1739.1998.98036.x; Blasius B, 1999, NATURE, V399, P354, DOI 10.1038/20676; Bohr T., 1998, DYNAMICAL SYSTEMS AP; BROWN JH, 1977, ECOLOGY, V58, P445, DOI 10.2307/1935620; Courchamp F, 1999, TRENDS ECOL EVOL, V14, P405, DOI 10.1016/S0169-5347(99)01683-3; Earn DJD, 2000, SCIENCE, V287, P667, DOI 10.1126/science.287.5453.667; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; Gonzalez A, 1998, SCIENCE, V281, P2045, DOI 10.1126/science.281.5385.2045; Guckenheimer J., 1983, J APPL MECH, DOI DOI 10.1115/1.3167759; Hanski I, 2000, NATURE, V404, P755, DOI 10.1038/35008063; HANSKI I, 1997, METAPOPULATION BIOL; HASTINGS A, 1993, ECOLOGY, V74, P1362, DOI 10.2307/1940066; HASTINGS A, 1993, ANNU REV ECOL SYST, V24, P1, DOI 10.1146/annurev.es.24.110193.000245; HASTINGS A, 1994, SCIENCE, V263, P1133, DOI 10.1126/science.263.5150.1133; Heino M, 1997, P ROY SOC B-BIOL SCI, V264, P481, DOI 10.1098/rspb.1997.0069; KANEKO K, 1989, PHYS REV LETT, V63, P219, DOI 10.1103/PhysRevLett.63.219; Laurance W.F., 1997, TROPICAL FOREST REMN, V1st; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; METZ JAJ, 1992, TRENDS ECOL EVOL, V7, P198, DOI 10.1016/0169-5347(92)90073-K; Pimm SL, 1998, NATURE, V393, P23, DOI 10.1038/29892; Rohani P, 1999, SCIENCE, V286, P968, DOI 10.1126/science.286.5441.968; RUXTON GD, 1994, P ROY SOC B-BIOL SCI, V256, P189, DOI 10.1098/rspb.1994.0069; Silva JAL, 2000, B MATH BIOL, V62, P337, DOI 10.1006/bulm.1999.0157; Sole RV, 1998, J THEOR BIOL, V193, P539, DOI 10.1006/jtbi.1998.0716; Stephens PA, 1999, TRENDS ECOL EVOL, V14, P401, DOI 10.1016/S0169-5347(99)01684-5; STONE L, 1993, NATURE, V365, P617, DOI 10.1038/365617a0; [No title captured]	32	231	242	0	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1360	1364		10.1126/science.290.5495.1360	http://dx.doi.org/10.1126/science.290.5495.1360			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082064				2022-12-28	WOS:000165379800050
J	Davis, KJ; Dove, PM; De Yoreo, JJ				Davis, KJ; Dove, PM; De Yoreo, JJ			The role of Mg2+ as an impurity in calcite growth	SCIENCE			English	Article							CRYSTAL-GROWTH; MAGNESIUM; CARBONATE; KINETICS; CRYSTALLIZATION; THERMODYNAMICS; 25-DEGREES-C; ARAGONITE; WATER	Magnesium is a key determinant in CaCO3 mineralization; however, macroscopic observations have failed to provide a clear physical understanding of how magnesium modifies carbonate growth. Atomic force microscopy was used to resolve the mechanism of calcite inhibition by magnesium through molecular-scale determination of the thermodynamic and kinetic controls of magnesium on calcite formation. Comparison of directly measured step velocities to standard impurity models demonstrated that enhanced mineral solubility through magnesium incorporation inhibited calcite growth. Terrace width measurements on calcite growth spirals were consistent with a decrease in effective supersaturation due to magnesium incorporation. Ca1-xMgxCO3 solubilities determined from microscopic observations of step dynamics can thus be Linked to macroscopic measurements.	Virginia Polytech Inst & State Univ, Dept Geol Sci, Blacksburg, VA 24061 USA; Lawrence Livermore Natl Lab, Dept Chem & Mat Sci, Livermore, CA 94550 USA	Virginia Polytechnic Institute & State University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Dove, PM (corresponding author), Virginia Polytech Inst & State Univ, Dept Geol Sci, Blacksburg, VA 24061 USA.	dove@vt.edu	Dove, Patricia M/A-7911-2010					BERNER RA, 1975, GEOCHIM COSMOCHIM AC, V39, P489, DOI 10.1016/0016-7037(75)90102-7; BISCHOFF WD, 1987, GEOCHIM COSMOCHIM AC, V51, P1413, DOI 10.1016/0016-7037(87)90325-5; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; BUSENBERG E, 1989, GEOCHIM COSMOCHIM AC, V53, P1189, DOI 10.1016/0016-7037(89)90056-2; Cabrera N., 1958, GROWTH PERFECTION CR, V393-425; Chernov A.A., 1961, SOV PHYS USPEKHI, V4, P116, DOI [10.1070/PU1961v004n01ABEH003328., DOI 10.1070/PU1961V004N01ABEH003328]; DEGROOT K, 1966, NATURE, V212, P183, DOI 10.1038/212183a0; DWYER GS, 1995, SCIENCE, V270, P1347, DOI 10.1126/science.270.5240.1347; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; FOLK RL, 1974, J SEDIMENT PETROL, V44, P40; Gutjahr A, 1996, J CRYST GROWTH, V158, P310, DOI 10.1016/0022-0248(95)00447-5; LAHANN RW, 1978, J SEDIMENT PETROL, V48, P337; Land TA, 1997, SURF SCI, V384, P136, DOI 10.1016/S0039-6028(97)00187-8; Lear CH, 2000, SCIENCE, V287, P269, DOI 10.1126/science.287.5451.269; Mitsuguchi T, 1996, SCIENCE, V274, P961, DOI 10.1126/science.274.5289.961; MUCCI A, 1983, GEOCHIM COSMOCHIM AC, V47, P217, DOI 10.1016/0016-7037(83)90135-7; Papelis C., 1988, 306 STANF U DEP CIV; PAQUETTE J, 1995, GEOCHIM COSMOCHIM AC, V59, P735, DOI 10.1016/0016-7037(95)00004-J; Purton LMA, 1999, GEOLOGY, V27, P1083, DOI 10.1130/0091-7613(1999)027<1083:MCSCRI>2.3.CO;2; Reddy M., 1986, USGS B, V1578, P169; REDDY MM, 1980, J CRYST GROWTH, V50, P470, DOI 10.1016/0022-0248(80)90095-0; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; Stanley SM, 1999, GSA TODAY, V9, P1, DOI 10.1130/GSAT-1999-10-01-science; Teng HH, 1999, GEOCHIM COSMOCHIM AC, V63, P2507, DOI 10.1016/S0016-7037(99)00103-9; Teng HH, 1998, SCIENCE, V282, P724, DOI 10.1126/science.282.5389.724; van Enckevort WJP, 1998, J CRYST GROWTH, V183, P441, DOI 10.1016/S0022-0248(97)00432-6; Voronkov V. V., 1992, Soviet Physics - Crystallography, V37, P289	27	558	581	14	361	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1134	1137		10.1126/science.290.5494.1134	http://dx.doi.org/10.1126/science.290.5494.1134			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073446				2022-12-28	WOS:000165228200039
J	Engstrom, DR; Fritz, SC; Almendinger, JE; Juggins, S				Engstrom, DR; Fritz, SC; Almendinger, JE; Juggins, S			Chemical and biological trends during lake evolution in recently deglaciated terrain	NATURE			English	Article							SOUTHEASTERN ALASKA; GLACIER BAY; ACIDIFICATION; HISTORY; WATER; PARK	As newly formed landscapes evolve, physical and biological changes occur that are collectively known as primary succession. Although succession is a fundamental concept in ecology, it is poorly understood in the context of aquatic environments. The prevailing view is that lakes become more enriched in nutrients as they age, leading to increased biological production. Here we report the opposite pattern of lake development, observed from the water chemistry of lakes that formed at various times within the past 10,000 years during glacial retreat at Glacier Bay, Alaska. The lakes have grown more dilute and acidic with time, accumulated dissolved organic carbon and undergone a transient rise in nitrogen concentration, all as a result of successional changes in surrounding vegetation and soils. Similar trends are evident from fossil diatom stratigraphy of lake sediment cores. These results demonstrate a tight hydrologic coupling between terrestrial and aquatic environments during the colonization of newly deglaciated landscapes, and provide a conceptual basis for mechanisms of primary succession in boreal lake ecosystems.	Sci Museum Minnesota, St Croix Watershed Res Stn, Marine On St Croix, MN 55047 USA; Univ Nebraska, Dept Geosci, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Newcastle Upon Tyne, Dept Geog, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Newcastle University - UK	Engstrom, DR (corresponding author), Sci Museum Minnesota, St Croix Watershed Res Stn, Marine On St Croix, MN 55047 USA.		Juggins, Stephen/D-1653-2010	Juggins, Stephen/0000-0003-4466-424X; Engstrom, Daniel/0000-0002-8066-029X				ALMENDINGER JE, 1990, P 2 GLAC BAY SCI S, P133; Battarbee Richard W., 1999, P85; Birks HH, 2000, J PALEOLIMNOL, V23, P91, DOI 10.1023/A:1008079725596; BIRKS HJB, 1990, PHILOS T R SOC B, V327, P263, DOI 10.1098/rstb.1990.0062; BORMANN BT, 1990, J ECOL, V78, P561, DOI 10.2307/2260884; BREW DA, 1978, 78494 US GEOL SURV, P1; BROWER WA, 1977, CLIMATIC ATLAS OUTER, V1; Carpenter S. R., 1998, NONPOINT POLLUTION S; CHAPIN FS, 1994, J ECOL, V64, P149; CHAPIN FS, 1995, P 3 GLAC BAY SCI S 1, P96; Cooper WS, 1931, ECOLOGY, V12, P61, DOI 10.2307/1932934; Cooper WS, 1923, ECOLOGY, V4, P223, DOI 10.2307/1929047; CROCKER RL, 1955, J ECOL, V43, P427, DOI 10.2307/2257005; CRONAN CS, 1985, GEOCHIM COSMOCHIM AC, V49, P1697, DOI 10.1016/0016-7037(85)90140-1; ENGSTROM DR, 1990, SCIENCE, V250, P1383, DOI 10.1126/science.250.4986.1383; ENGSTROM DR, 1987, CAN J FISH AQUAT SCI, V44, P1306, DOI 10.1139/f87-154; ENGSTROM DR, 1990, P 2 GLAC BAY SCI S, P127; FASTIE CL, 1995, ECOLOGY, V76, P1899, DOI 10.2307/1940722; FORD MSJ, 1990, ECOL MONOGR, V60, P57, DOI 10.2307/1943026; GOLDMAN CR, 1961, ECOLOGY, V42, P282, DOI 10.2307/1932080; Hunter L. E., 1995, P 3 GLAC BAY SCI S 1, P46; Juggins S, 1996, FRESHWATER BIOL, V36, P203, DOI 10.1046/j.1365-2427.1996.00079.x; KORHOLA AA, 1991, BOREAS, V20, P333, DOI 10.1111/j.1502-3885.1991.tb00284.x; Lawrence D. B., 1951, Yearbook, American Philosophical Society, Philadelphia 1950, P175; LAWRENCE DB, 1958, AM SCI, V46, P89; MANN DH, 1985, CAN J EARTH SCI, V22, P913, DOI 10.1139/e85-095; Matthews JA., 1992, ECOLOGY RECENTLY DEG; MCBRIDE MS, 1975, J RES US GEOL SURV, V3, P505; NAUMANN E, 1932, BINNENGEWASSER, V11, P1; NOBLE MG, 1984, BRYOLOGIST, V87, P119, DOI 10.2307/3243117; Olson O. G., 1995, P 3 GLAC BAY SCI S N, P154; OLSON OG, 1998, THESIS LEHIGH U; Pearsall WH, 1921, P R SOC LOND B-CONTA, V92, P259, DOI 10.1098/rspb.1921.0024; RASMUSSEN JB, 1989, LIMNOL OCEANOGR, V34, P1336, DOI 10.4319/lo.1989.34.7.1336; REINERS W A, 1971, Ecology (Washington D C), V52, P55, DOI 10.2307/1934737; RENBERG I, 1993, AMBIO, V22, P264; RODHE W, 1969, EUTROPHICATION CAUSE, P50; Taylor J. K, 1966, AUSTR ENV, P29; TERBRAAK CJF, 1986, ECOLOGY, V67, P1167; Thienemann A., 1931, Archiv fuer Hydrobiologie Stuttgart Suppl, V9, P205; UGOLINI FC, 1979, NATURE, V281, P366, DOI 10.1038/281366a0; WHITEHEAD D R, 1989, Journal of Paleolimnology, V2, P185; WILLIAMSON CE, IN PRESS ECOLOGY; WINTER TC, 1988, LIMNOL OCEANOGR, V33, P1209, DOI 10.4319/lo.1988.33.5.1209	44	247	252	3	88	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					161	166		10.1038/35041500	http://dx.doi.org/10.1038/35041500			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089963	Green Published			2022-12-28	WOS:000165180400035
J	Decatur, AL; Portnoy, DA				Decatur, AL; Portnoy, DA			A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity	SCIENCE			English	Article							INFECTED CELLS; GROWTH; DETERMINANTS; PATHOGENESIS; PHAGOSOME	Establishment and maintenance of an intracellular niche are critical to the success of an intracellular pathogen, Here, the pore-forming protein listeriolysin O (LLO), secreted by Listeria monocytogenes, was shown to contain a PEST-like sequence (P, Pro; E, Glu; S, Ser; T, Thr) that is essential for the virulence and intracellular compartmentalization of this pathogen. Mutants lacking the PEST-like sequence entered the host cytosol but subsequently permeabilized and killed the host cell. LLO lacking the PEST-like sequence accumulated in the host-cell cytosol, suggesting that this sequence targets LLO for degradation. Transfer of the sequence to perfringolysin O transformed this toxic cytolysin into a nontoxic derivative that facilitated intracellular growth.	Univ Calif Berkeley, Sch Publ Hlth, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Portnoy, DA (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010283, R29AI027655, R01AI027655, R37AI029619] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI027655, AI27655, AI10283, R37 AI029619] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; Clemens DL, 1996, TRENDS MICROBIOL, V4, P113, DOI 10.1016/0966-842X(96)81528-9; DECATUR AL, UNPUB; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FREITAG NE, 2000, GRAM POSITIVE PATHOG, pCH51; GEDDE M, UNPUB; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; HO SN, 1989, GENE, V77, pS1; Jones S, 1996, MOL MICROBIOL, V21, P1219, DOI 10.1046/j.1365-2958.1996.00074.x; JONES S, 1994, METHOD ENZYMOL, V236, P463; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; Moors MA, 1999, INFECT IMMUN, V67, P131, DOI 10.1128/IAI.67.1.131-139.1999; PORTNOY DA, 1992, INFECT IMMUN, V60, P1263, DOI 10.1128/IAI.60.4.1263-1267.1992; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227	19	181	221	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					992	995		10.1126/science.290.5493.992	http://dx.doi.org/10.1126/science.290.5493.992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062133				2022-12-28	WOS:000165103200052
J	Spicuzza, L; Gabutti, A; Porta, C; Montano, N; Bernardi, L				Spicuzza, L; Gabutti, A; Porta, C; Montano, N; Bernardi, L			Yoga and chemoreflex response to hypoxia and hypercapnia	LANCET			English	Article							HEART-FAILURE	We tested whether chemoreflex sensitivity could be affected by the practice of yoga, and whether this is specifically because of a slow breathing rate obtained during yoga or as a general consequence of yoga. We found that slow breathing rate per se substantially reduced chemoreflex sensitivity, but long-term yoga practice was responsible for a generalised reduction in chemoreflex.	Univ Pavia, Osped S Matteo, IRCCS, Med Clin 1, I-27100 Pavia, Italy; Univ Pavia, Dept Internal Med, I-27100 Pavia, Italy; Univ Catania, Inst Resp Dis, I-95124 Catania, Italy; Univ Milan, Osped Sacco, Ctr Nazl Ric Med Interna 2, Ctr Ric Cardiovasc, I-20122 Milan, Italy	University of Pavia; University of Pavia; University of Catania; University of Milan; Luigi Sacco Hospital	Bernardi, L (corresponding author), Univ Pavia, Osped S Matteo, IRCCS, Med Clin 1, Via Palestro 3, I-27100 Pavia, Italy.		Spicuzza, Lucia/AAC-5892-2022	Spicuzza, Lucia/0000-0002-8246-8357; Montano, Nicola/0000-0001-9206-0075				Bernardi L, 1998, LANCET, V351, P1308, DOI 10.1016/S0140-6736(97)10341-5; BERNARDI L, 1999, 11 BIENN INT S HYP M; Coats AJS, 1997, CARDIOVASC DRUG THER, V11, P265, DOI 10.1023/A:1007739830030; HEWITT J, 1983, YOGA BREATHING POSTU, P89; MILICEMILI J, 1975, NEW ENGL J MED, V10, P864	5	95	99	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1495	1496		10.1016/S0140-6736(00)02881-6	http://dx.doi.org/10.1016/S0140-6736(00)02881-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081541				2022-12-28	WOS:000090067300022
J	Galan, JE				Galan, JE			Alternative strategies for becoming an insider: Lessons from the bacterial world	CELL			English	Review							LISTERIA-MONOCYTOGENES; PHOSPHOINOSITIDE 3-KINASE; E-CADHERIN; ENTRY; CELLS		Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.							Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; Gaillard JL, 1996, J EXP MED, V183, P359, DOI 10.1084/jem.183.2.359; Galan JE, 2000, P NATL ACAD SCI USA, V97, P8754, DOI 10.1073/pnas.97.16.8754; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Isberg RR, 2000, MICROBES INFECT, V2, P793, DOI 10.1016/S1286-4579(00)90364-2; Lecuit M, 2000, P NATL ACAD SCI USA, V97, P10008, DOI 10.1073/pnas.97.18.10008; Lecuit M, 1999, EMBO J, V18, P3956, DOI 10.1093/emboj/18.14.3956; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Shen Y, 2000, CELL, V103, P501, DOI 10.1016/S0092-8674(00)00141-0	12	12	14	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					363	366		10.1016/S0092-8674(00)00127-6	http://dx.doi.org/10.1016/S0092-8674(00)00127-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081622	Bronze			2022-12-28	WOS:000090144100001
J	Groisman, I; Huang, YS; Mendez, R; Cao, QP; Theurkauf, W; Richter, JD				Groisman, I; Huang, YS; Mendez, R; Cao, QP; Theurkauf, W; Richter, JD			CPEB, maskin, and cyclin B1 mRNA at the mitotic apparatus: Implications for local translational control of cell division	CELL			English	Article							MATERNAL MESSENGER-RNA; XENOPUS OOCYTE MATURATION; ELEMENT-BINDING PROTEIN; CYTOPLASMIC POLYADENYLATION; C-MOS; REGULATED POLYADENYLATION; RIBOSE METHYLATION; SPECIFICITY FACTOR; COILED-COIL; CENTROSOME	In Xenopus development, the expression of several maternal mRNAs is regulated by cytoplasmic polyadenylation. CPEB and maskin, two factors that control polyadenylation-induced translation are present on the mitotic apparatus of animal pole blastomeres in embryos. Cyclin B1 protein and mRNA, whose translation is regulated by polyadenylation, are colocalized with CPEB and maskin. CPEB interacts with microtubules and is involved in the localization of cyclin B1 mRNA to the mitotic apparatus. Agents that disrupt polyadenylation-induced translation inhibit cell division and promote spindle and centrosome defects in injected embryos. Two of these agents inhibit the synthesis of cyclin B1 protein and one, which has little effect on this process, disrupts the localization of cyclin B1 mRNA and protein. These data suggest that CPEB-regulated mRNA translation is important for the integrity of the mitotic apparatus and for cell division.	Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA.		Huang, Yi-Shuian/P-2824-2018	Huang, Yi-Shuian/0000-0001-9000-7748; Groisman, Irina/0000-0001-8909-678X; Mendez, Raul/0000-0002-1952-6905; Groisman, Sonia/0000-0003-1153-3841; Theurkauf, William/0000-0001-7342-1912	NIGMS NIH HHS [GM46779, GM50898] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046779, R01GM050898] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bally-Cuif L, 1998, MECH DEVELOP, V77, P31, DOI 10.1016/S0925-4773(98)00109-9; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; DAVIS CA, 1993, METHOD ENZYMOL, V225, P502; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; Dickson KS, 1999, MOL CELL BIOL, V19, P5707; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; Gebauer F, 1996, P NATL ACAD SCI USA, V93, P14602, DOI 10.1073/pnas.93.25.14602; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Goto T, 1999, DNA CELL BIOL, V18, P227, DOI 10.1089/104454999315448; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1998, MOL CELL BIOL, V18, P685, DOI 10.1128/MCB.18.2.685; HIROKAWA N, 1985, J CELL BIOL, V101, P1858, DOI 10.1083/jcb.101.5.1858; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; KLOC M, 1999, ANAL LOCALIZED RNAS; Kuge H, 1998, NUCLEIC ACIDS RES, V26, P3208, DOI 10.1093/nar/26.13.3208; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LANTZ V, 1992, DEVELOPMENT, V115, P75; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; MENDEZ R, 2000, IN PRESS MOL CELL; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; Niessing D, 1999, EMBO J, V18, P1966, DOI 10.1093/emboj/18.7.1966; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; RAFF JW, 1990, DEVELOPMENT, V110, P1249; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; RICHTER JD, 2000, TRANSLATIONAL CONTRO; Roghi C, 1998, J CELL SCI, V111, P557; Schnapp BJ, 1997, SEMIN CELL DEV BIOL, V8, P529, DOI 10.1006/scdb.1997.0178; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Stutz A, 1998, GENE DEV, V12, P2535, DOI 10.1101/gad.12.16.2535; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; Tatsuka M, 1998, CANCER RES, V58, P4811; Walker J, 1999, RNA, V5, P14, DOI 10.1017/S1355838299981219; WICKENS M, 1996, TRANSLATIONAL CONTRO; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	58	220	225	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					435	447		10.1016/S0092-8674(00)00135-5	http://dx.doi.org/10.1016/S0092-8674(00)00135-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081630	Bronze			2022-12-28	WOS:000090144100009
J	Somers, WS; Tang, J; Shaw, GD; Camphausen, RT				Somers, WS; Tang, J; Shaw, GD; Camphausen, RT			Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1	CELL			English	Article							GLYCOPROTEIN LIGAND-1; TYROSINE SULFATION; AMINO-TERMINUS; BINDING-SITES; RECOGNITION; ADHESION; DOMAINS; OLIGOSACCHARIDE; REPLACEMENT; ANTIBODIES	P-, E- and L-selectin constitute a family of cell adhesion receptors that mediate the initial tethering and rolling of leukocytes on inflamed endothelium as a prelude to their firm attachment and extravasation into tissues. The selectins bind weakly to sialyl Lewis(X) (SLe(X))-like glycans, but with high-affinity to specific glycoprotein counterreceptors, including PSGL-1. Here, we report crystal structures of human P- and E-selectin constructs containing the lectin and EGF (LE) domains co-complexed with SLe(X). We also present the crystal structure of P-selectin LE co-complexed with the N-terminal domain of human PSGL-1 modified by both tyrosine sulfation and SLe(X). These structures reveal differences in how E- and P-selectin bind SLe(X) and the molecular basis of the high-affinity interaction between P-selectin and PSGL-1.	Genet Inst Inc, Wyeth Res, Cambridge, MA 02140 USA	Pfizer	Camphausen, RT (corresponding author), Genet Inst Inc, Wyeth Res, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	rcamphausen@genetics.com						Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ASA D, 1992, GLYCOBIOLOGY, V2, P395, DOI 10.1093/glycob/2.5.395; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; BERTOZZI CR, 1995, CHEM BIOL, V2, P703, DOI 10.1016/1074-5521(95)90096-9; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Croce K, 1998, BIOCHEMISTRY-US, V37, P16472, DOI 10.1021/bi981341g; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; McEver RP, 1997, J CLIN INVEST, V100, pS97; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Poppe L, 1997, J AM CHEM SOC, V119, P1727, DOI 10.1021/ja9610702; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Varki A, 1997, J CLIN INVEST, V100, pS31; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	45	601	627	2	84	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					467	479		10.1016/S0092-8674(00)00138-0	http://dx.doi.org/10.1016/S0092-8674(00)00138-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081633	Bronze			2022-12-28	WOS:000090144100012
J	Blatchford, O; Murray, WR; Blatchford, M				Blatchford, O; Murray, WR; Blatchford, M			A risk score to predict need for treatment for upper-gastrointestinal haemorrhage	LANCET			English	Article							PROGNOSTIC FACTORS; OUTPATIENT CARE; HEMORRHAGE; ISOLEUCINE; MORTALITY; SYSTEM; RATIO	Background Current risk-stratification systems for patients with acute upper-gastrointestinal bleeding discriminate between patients at high or low risks of dying or rebleeding. We therefore developed and prospectively validated a risk score to identify a patient's need for treatment. Methods Our first study used data from 1748 patients admitted for upper-gastrointestinal haemorrhage. By logistic regression, we derived a risk score that predicts patients' risks of needing blood transfusion or intervention to control bleeding, rebleeding, or dying. From this score, we developed a simplified fast-track screen for use at initial presentation. In a second study, we prospectively Validated this score using receiver operating characteristic (ROC) curves-a measure of the validity of a scoring system-and chi(2) goodness-of-fit testing with data from 197 patients. We also validated the quicker screening tool. Findings We calculated risk scores from patients' admission haemoglobin, blood urea, purse, and systolic brood pressure, as well as presentation with syncope or melaena, and evidence of hepatic disease or cardiac failure. The score discriminated well with a ROC curve area of 0.92 (95% CI 0.88-0.95). The score was well calibrated for patients needing treatment (p-=0.84). Interpretation Our score identified patients at low or high risk of needing treatment to manage their bleeding. This score should assist the clinical management of patients presenting with upper-gastrointestinal haemorrhage, but requires external validation.	Univ Glasgow, Dept Publ Hlth, Glasgow, Lanark, Scotland; Univ Glasgow, Dept Gen Practice, Glasgow, Lanark, Scotland; Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Blatchford, O (corresponding author), Argyll & Clyde Hlth Board, Paisley PA2 7BN, Renfrew, Scotland.							Bhatti N, 1998, CHEST, V114, P1137, DOI 10.1378/chest.114.4.1137; Blatchford O, 1997, BMJ-BRIT MED J, V315, P510, DOI 10.1136/bmj.315.7107.510; BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; Christiansen T, 1935, ACTA MED SCAND, V85, P0333; CLASON AE, 1986, BRIT J SURG, V73, P985, DOI 10.1002/bjs.1800731213; Dejong CHC, 1996, GUT, V39, P13, DOI 10.1136/gut.39.1.13; Elisaf M. S., 1997, EUR J INTERN MED, V8, P127; FELBER S, 1988, J PEDIATR GASTR NUTR, V7, P685, DOI 10.1097/00005176-198809000-00011; Gunning K, 1999, BRIT MED J, V319, P241, DOI 10.1136/bmj.319.7204.241; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KATSCHINSKI B, 1994, DIGEST DIS SCI, V39, P706, DOI 10.1007/BF02087411; Longstreth GF, 1998, GASTROINTEST ENDOSC, V47, P219, DOI 10.1016/S0016-5107(98)70316-5; LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; MAILER C, 1965, BRIT MED J, V2, P784, DOI 10.1136/bmj.2.5465.784; MEYER L, 1935, ACTA MED SCAND, V87, P313; MOSS G, 1975, AM J SURG, V130, P269, DOI 10.1016/0002-9610(75)90382-7; OLSEN LH, 1991, BRIT J SURG, V78, P71, DOI 10.1002/bjs.1800780122; PIMPL W, 1987, ENDOSCOPY, V19, P101, DOI 10.1055/s-2007-1013010; PUMPHREY CW, 1980, BRIT MED J, V280, P527, DOI 10.1136/bmj.280.6213.527-a; Rockall TA, 1996, LANCET, V347, P1138, DOI 10.1016/S0140-6736(96)90607-8; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; SAEED ZA, 1993, AM J GASTROENTEROL, V88, P1842; Schiff L., 1939, AM J DIG DIS, V6, P597; SILVERSTEIN FE, 1981, GASTROINTEST ENDOSC, V27, P80, DOI 10.1016/S0016-5107(81)73156-0; SNOOK JA, 1986, LANCET, V1, P1064; STELLATO T, 1980, AM J GASTROENTEROL, V73, P486; VANBERLO CLH, 1989, HEPATOLOGY, V10, P315, DOI 10.1002/hep.1840100311; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331	28	611	664	0	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1318	1321		10.1016/S0140-6736(00)02816-6	http://dx.doi.org/10.1016/S0140-6736(00)02816-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073021				2022-12-28	WOS:000089858300013
J	Smith, G; Dempsey, M; Falk, G				Smith, G; Dempsey, M; Falk, G			Constipation and hiatus hernia	LANCET			English	Article									Concord Repatriat Gen Hosp, Dept Endosurg, Sydney, NSW, Australia; Strathfield Private Hosp, Sydney, NSW, Australia	Concord Repatriation General Hospital	Smith, G (corresponding author), Concord Repatriat Gen Hosp, Dept Endosurg, Sydney, NSW, Australia.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1306	1306		10.1016/S0140-6736(05)74238-0	http://dx.doi.org/10.1016/S0140-6736(05)74238-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073018				2022-12-28	WOS:000089858300010
J	Mouradian, WE; Wehr, E; Crall, JJ				Mouradian, WE; Wehr, E; Crall, JJ			Disparities in children's oral health and access to dental care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAID; CARIES	Dental caries can be prevented by a combination of community, professional, and individual measures including water fluoridation, professional ly applied topical fluorides and dental sealants, and use of fluoride toothpastes. Yet, tooth decay is the most common chronic disease of childhood. Dental cave is the most prevalent un met health need in US children with wide disparities existing in oral health and access to care. Only 1 in 5 children covered by Medicaid received preventive oral care for which they ave eligible. Children from low income and minority families have poorer oral health outcomes, fewer dental visits, and fewer protective sealants. Water fluoridation is the most effective measure in preventing caries, but only 62% of water supplies are fluoridated, and lack of fluoridation may disproportionately affect poor and minority children. Childhood oral disease has significant medical and financial consequences that may not be appreciated because of the separation of medicine and dentistry. The infectious nature of dental caries, its early onset, and the potential of early interventions require an emphasis on preventive oral care in primary pediatric care to complement existing dental services. However, many pediatricians lack critical knowledge to promote oral health. We recommend financial incentives for prioritizing Medicaid Early and Periodic Screening, Diagnostic, and Treatment dental services; managed care accountability; integration of medical and dental professional training, clinical cave, and research; and national leadership.	Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Pediat Dent, Seattle, WA 98195 USA; Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; George Washington Univ, Sch Publ Hlth & Hlth Serv, Ctr Hlth Serv & Policy Res, Washington, DC USA; Univ Connecticut, Ctr Hlth, Dept Pediat Dent, Storrs, CT USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; George Washington University; University of Connecticut	Mouradian, WE (corresponding author), Childrens Hosp & Reg Med Ctr, 4800 Sand Point Way NE,POB 5371,CH-47, Seattle, WA 98105 USA.		Ackland, Julie/C-8607-2012		PHS HHS [952336, 98R402816] Funding Source: Medline; ATSDR CDC HHS [TS 291-14/15] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); ATSDR CDC HHS		Acs George, 1999, Pediatric Dentistry, V21, P109; Allukian M, 2000, AM J PUBLIC HEALTH, V90, P843, DOI 10.2105/AJPH.90.6.843; *AM AC PED, 1998, AN COSTS PROV HLTH C; *AM DENT ASS SURV, 1998, 1997 SURV DENT PRACT; BARSLEY R, 1999, MMWR-MORBID MORTAL W, V48, P753; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BERKOWITZ RJ, 1985, ARCH ORAL BIOL, V30, P377, DOI 10.1016/0003-9969(85)90014-7; BLOOM B, 1992, DHHS PUBLICATION; Carrasquillo O, 1998, AM J PUBLIC HEALTH, V88, P464, DOI 10.2105/AJPH.88.3.464; *CDCP, 1993, FLUOR CENS 1992 SUMM; *CHSRP REP, 2000, NEG NEW HLTH SYST NA; *CHSRP REP, 2000, SAMPL SAMPL PURCH SP; Crall J J, 1997, J Dent Educ, V61, P776; Crall JJ, 1999, J PUBLIC HEALTH DENT, V59, P136, DOI 10.1111/j.1752-7325.1999.tb03262.x; *DEP HLTH HUM SERV, 2000, MAT CHILD HLTH BUR; *DEP HLTH HUM SERV, 2000, OR HLTH AM REP SURG; Edelstein B L, 1999, J Dent Educ, V63, P644; Edelstein Burton L., 2000, Pediatric Dentistry, V22, P17; *FAC CHILD, 2000, SURG GEN C CHILDR OR; Feldman CA, 1997, J AM DENT ASSOC, V128, P1687, DOI 10.14219/jada.archive.1997.0131; FIELD MJ, 1995, DENT ED CROSSROADS C, P3; Formicola A J, 1999, J Dent Educ, V63, P331; GIFT HC, 1992, AM J PUBLIC HEALTH, V82, P1663, DOI 10.2105/AJPH.82.12.1663; GREENWELL A L, 1990, Pediatric Dentistry, V12, P278; Griffin SO, 2000, J PUBLIC HEALTH DENT, V60, P21, DOI 10.1111/j.1752-7325.2000.tb03287.x; Hanson K L, 1998, Matern Child Health J, V2, P5, DOI 10.1023/A:1021837407789; *HLTH CAR FIN ADM, 2000, INN MAN DENT DEC YOU; Hollister M C, 1993, J Dent Educ, V57, P901; Kanellis MJ, 2000, J PUBLIC HEALTH DENT, V60, P28; Kaste LM, 1996, J DENT RES, V75, P631, DOI 10.1177/002203459607502S03; LEWIS C, IN PRESS PEDIATRICS; Milgrom P, 1998, J AM DENT ASSOC, V129, P753, DOI 10.14219/jada.archive.1998.0318; Milgrom P, 1997, J AM DENT ASSOC, V128, P1440, DOI 10.14219/jada.archive.1997.0066; NASH DA, 1995, J DENT EDUC, V59, P586; *NAT I DENT RES, 1989, DHHS PUBL; NELSON WE, 1996, TXB PEDIAT, P628; Newacheck PW, 2000, PEDIATRICS, V105, P989; Newacheck PW, 2000, PEDIATRICS, V105, P760, DOI 10.1542/peds.105.4.760; NOWAK A, 1999, HANDBOOK; NOWAK AJ, 1976, DENTISTRY HANDICAPPE; Oppel Jr. R. A., 2000, NY TIMES        0922, pA14; Romer M, 1999, J DENT CHILD, V66, P132; Schlenker T, 1990, Wis Med J, V89, P403; Sheller B, 1997, Pediatr Dent, V19, P470; Slavkin HC, 2000, JAMA-J AM MED ASSOC, V284, P1215, DOI 10.1001/jama.284.10.1215; Tinanoff Norman, 1997, Pediatric Dentistry, V19, P12; TOBLER L, 1999, NAT C STAT LEG; U. S. Department of Health and Human Services, 1999, CHILD MALTR 1997 REP; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 C ED; US General Accounting Offices, 2000, OR HLTH DENT DIS CHR; *US INSP GEN, 1996, PUBL OEI; *US PHS, 1995, HLTH PEOPL 2000 PROG; *US PHS, 2000, HLTH PEOPL 2000 REV, P131; Vargas CM, 1998, J AM DENT ASSOC, V129, P1229, DOI 10.14219/jada.archive.1998.0420; Wehr E, 1994, Future Child, V4, P115, DOI 10.2307/1602437; YUDOWSKY BK, 1997, MEDICAID STATE REPOR	56	224	241	1	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2625	2631		10.1001/jama.284.20.2625	http://dx.doi.org/10.1001/jama.284.20.2625			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086371				2022-12-28	WOS:000165296200038
J	Schoning, KU; Scholz, P; Guntha, S; Wu, X; Krishnamurthy, R; Eschenmoser, A				Schoning, KU; Scholz, P; Guntha, S; Wu, X; Krishnamurthy, R; Eschenmoser, A			Chemical etiology of nucleic acid structure: The alpha-threofuranosyl-(3 '-> 2 ') oligonucleotide system	SCIENCE			English	Article							BASE-PAIRING PROPERTIES; RNA P-RNA; PYRANOSYL-RNA; HOMO-DNA; HYBRID DUPLEXES; BUILDING-BLOCKS; PENTOSE; OLIGOMERIZATION; STABILITY; GUANIDINE	TNAs [(L)-alpha -threofuranosyl oligonucleotides] containing vicinally connected (3'-->2') phosphodiester bridges undergo informational base pairing in antiparallel strand orientation and are capable of cross-pairing with RNA and DNA. Being derived from a sugar containing only four carbons, TNA is structurally the simplest of all potentially natural oligonucleotide-type nucleic acid alternatives studied thus far. This, along with the base-pairing properties of TNA, warrants close scrutiny of the system in the context of the problem of RNA's origin.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland	Scripps Research Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich	Eschenmoser, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	aeschen@scripps.edu	Krishnamurthy, Ramanarayanan/AAO-6030-2020	Krishnamurthy, Ramanarayanan/0000-0001-5238-610X				Beier M, 1999, SCIENCE, V283, P699, DOI 10.1126/science.283.5402.699; BOHRINGER M, 1992, HELV CHIM ACTA, V75, P1416, DOI 10.1002/hlca.19920750503; Bolli M, 1997, CHEM BIOL, V4, P309, DOI 10.1016/S1074-5521(97)90074-0; Bolli M, 1997, HELV CHIM ACTA, V80, P1901, DOI 10.1002/hlca.19970800613; Breslauer K.J., 1986, THERMODYNAMIC DATA B, P402; Cantor CR, 1980, BIOPHYSICAL CHEM 3, P1135; Damha MJ, 1998, J AM CHEM SOC, V120, P12976, DOI 10.1021/ja982325+; DEMPCY RO, 1994, P NATL ACAD SCI USA, V91, P7864, DOI 10.1073/pnas.91.17.7864; DIEDRICHSEN U, 1993, THESIS ETH ZURICH; Egger A, 1999, SYNLETT, P913; ESCHENMOSER A, 1992, HELV CHIM ACTA, V75, P218, DOI 10.1002/hlca.19920750120; Eschenmoser A, 1996, NATO ADV SCI INST SE, V320, P293; Eschenmoser A, 1999, SCIENCE, V284, P2118, DOI 10.1126/science.284.5423.2118; FISCHER RW, 1992, THESIS ETH ZURICH; Garner P, 2000, J AM CHEM SOC, V122, P2405, DOI 10.1021/ja993216d; Gatzi K, 1938, HELV CHIM ACTA, V21, P195, DOI 10.1002/hlca.19380210132; Groebke K, 1998, HELV CHIM ACTA, V81, P375, DOI 10.1002/hlca.19980810302; GROEBKE K, 1993, THESIS ETH ZURICH; GRYAZNOV SM, 1995, P NATL ACAD SCI USA, V92, P5798, DOI 10.1073/pnas.92.13.5798; HELG AG, 1994, THESIS ETH ZURICH; Herdewijn P, 1996, LIEBIGS ANN CHEM, V9, P1337; HUNZIKER J, 1993, HELV CHIM ACTA, V76, P259, DOI 10.1002/hlca.19930760119; HUNZIKER J, 1995, MODERN SYNTHETIC MET, V7, P331; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; Jungmann O, 1999, ORG LETT, V1, P1527, DOI 10.1021/ol990183y; Kojima N, 2000, ORG LETT, V2, P81, DOI 10.1021/ol9912478; Kozlov IA, 2000, CHEM-EUR J, V6, P151, DOI 10.1002/(SICI)1521-3765(20000103)6:1<151::AID-CHEM151>3.3.CO;2-8; Kozlov IA, 1999, J AM CHEM SOC, V121, P5856, DOI 10.1021/ja990440u; KRISHNAMURTHY R, 1994, THESIS ETH ZURICH; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; LOPEZ MG, 1992, J CARBOHYD CHEM, V11, P799, DOI 10.1080/07328309208020093; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MULLER T, 1998, THESIS; MURRAY DH, 1967, J PHARM SCI, V56, P865, DOI 10.1002/jps.2600560716; Nelson KE, 2000, P NATL ACAD SCI USA, V97, P3868, DOI 10.1073/pnas.97.8.3868; OTTING G, 1993, HELV CHIM ACTA, V76, P2701, DOI 10.1002/hlca.19930760802; PITSCH S, 1995, HELV CHIM ACTA, V78, P1621, DOI 10.1002/hlca.19950780702; PITSCH S, 1993, HELV CHIM ACTA, V76, P2161, DOI 10.1002/hlca.19930760602; RAO AVR, 1994, J CHEM SOC CHEM COMM, P1255, DOI 10.1039/c39940001255; Reck F, 1999, ORG LETT, V1, P1531, DOI 10.1021/ol990184q; Robins MJ, 1996, J ORG CHEM, V61, P9207, DOI 10.1021/jo9617023; SCHMIDT JG, 1998, J AM CHEM SOC, V120, P4563; SCHWEIZER B, UNPUB; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Tereshko V, 1998, J AM CHEM SOC, V120, P269, DOI 10.1021/ja971962h; VORBRUGGEN H, 1981, CHEM BER-RECL, V114, P1279, DOI 10.1002/cber.19811140407; ZELINSKY WS, 1987, NUCLEIC ACIDS RES, V15, P1699	47	428	457	2	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1347	1351		10.1126/science.290.5495.1347	http://dx.doi.org/10.1126/science.290.5495.1347			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082060				2022-12-28	WOS:000165379800046
J	Hayflick, L				Hayflick, L			The future of ageing	NATURE			English	Editorial Material							TELOMERASE	Advances in our knowledge of age-associated diseases have far outpaced advances in our understanding of the fundamental ageing processes that underlie the vulnerability to these pathologies. If we are to increase human life expectancy beyond the fifteen-year limit that would result if today's leading causes of death were resolved, more attention must be paid to basic research on ageing. Determination of longevity must be distinguished from ageing to take us from the common question of why we age to a more revealing question that is rarely posed: why do we live as long as we do? But if the ability to intervene in ageing ever becomes a reality, it will be rife with unintended and undesirable consequences.	Univ Calif San Francisco, Sch Med, Dept Anat, Sea Ranch, CA 95497 USA	University of California System; University of California San Francisco	Hayflick, L (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, POB 89, Sea Ranch, CA 95497 USA.		Hayflick, Leonard/AAW-2460-2020					Anderson MA, 1999, CLAY CLAY MINER, V47, P28, DOI 10.1346/CCMN.1999.0470103; Anderson RN, 1999, US DECENNIAL LIFE TA, V1, P7; ANDESON RN, 1999, NATL VITAL STAT REPO, V47, P32; ANERSON RN, 1999, US DECENNIAL LIFE TA, V1; CRIMMINS EM, 1994, DEMOGRAPHY, V31, P159, DOI 10.2307/2061913; Hayflick L, 2000, BRIT J CANCER, V83, P841, DOI 10.1054/bjoc.2000.1296; Hayflick L, 1998, EXP GERONTOL, V33, P639, DOI 10.1016/S0531-5565(98)00023-0; Hayflick L, 2000, NATURE, V403, P365, DOI 10.1038/35000303; HAYFLICK L, 1996, WHY WE AGE; HOBBS FB, 1996, US BUREAU CEN P23190, P3; Klapper W, 1998, FEBS LETT, V439, P143, DOI 10.1016/S0014-5793(98)01357-X; Klapper W, 1998, FEBS LETT, V434, P409, DOI 10.1016/S0014-5793(98)01020-5; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; Tuljapurkar S, 2000, NATURE, V405, P789, DOI 10.1038/35015561; *US BUR CENS, 1996, CURR POP REP P251130; WADE A, 1991, SOCIAL SECURITY MORT	16	199	207	1	32	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					267	269		10.1038/35041709	http://dx.doi.org/10.1038/35041709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	371LL	11089985				2022-12-28	WOS:000165180400058
J	Martin, GM; Oshima, J				Martin, GM; Oshima, J			Lessons from human progeroid syndromes	NATURE			English	Review							CONGENITAL GENERALIZED LIPODYSTROPHY; WERNER-SYNDROME PROTEIN; DNA HELICASE; ATAXIA-TELANGIECTASIA; COCKAYNE-SYNDROME; SYNDROME GENE; CELLS; MUTATIONS; REPEAT; REPAIR	A number of human genes have been identified in which mutations can lead to the accelerated emergence of features of senescence. Studies of these genes, and of the functions of their protein products, may lead to a clearer understanding of the nature of senescence, and could provide clues for ways in which ageing might be retarded.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Martin, GM (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; BROWN WT, 1992, AM J CLIN NUTR, V55, P1222; Castro E, 1999, AM J MED GENET, V82, P399, DOI 10.1002/(SICI)1096-8628(19990219)82:5<399::AID-AJMG8>3.3.CO;2-I; Cooper MP, 2000, GENE DEV, V14, P907; Crow JF, 1999, MUTAT RES-REV MUTAT, V437, P5, DOI 10.1016/S1383-5742(99)00063-0; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P7994; GARG A, 1992, J CLIN ENDOCR METAB, V75, P358, DOI 10.1210/jc.75.2.358; Garg A, 1996, DIABETES CARE, V19, P28, DOI 10.2337/diacare.19.1.28; Garg A, 1999, J CLIN ENDOCR METAB, V84, P3390, DOI 10.1210/jc.84.9.3390; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; GRIST SA, 1992, MUTAT RES, V266, P189, DOI 10.1016/0027-5107(92)90186-6; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; HARNSHERE MG, 1999, J MED GENET, V36, P59; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Klesert TR, 2000, NAT GENET, V25, P105, DOI 10.1038/75490; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; LEE AT, 1992, ANN NY ACAD SCI, V663, P63, DOI 10.1111/j.1749-6632.1992.tb38649.x; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Martin GM, 1997, NATURE, V390, P18, DOI 10.1038/36210; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Martin GM, 1996, HUM MOL GENET, V5, P215, DOI 10.1093/hmg/5.2.215; MARTIN GM, 1970, LAB INVEST, V23, P86; MARTIN GM, 1998, HDB AGING BRAIN, P126; MARTIN GM, 1990, GENETIC EFFECTS AGIN, V2, P493; McKusick V.A., 1998, MENDELIAN INHERITANC; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Oshima J, 1996, LANCET, V348, P1106, DOI 10.1016/S0140-6736(05)64456-X; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Tiscornia G, 2000, MOL CELL, V5, P959, DOI 10.1016/S1097-2765(00)80261-0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; vanderBurgt I, 1996, J MED GENET, V33, P153, DOI 10.1136/jmg.33.2.153; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; VENNOS EM, 1992, J AM ACAD DERMATOL, V27, P750, DOI 10.1016/0190-9622(92)70249-F; WANG SM, 1991, MUTAT RES, V256, P59, DOI 10.1016/0921-8734(91)90034-9; Westvik J, 1996, ACTA PAEDIATR, V85, P44, DOI 10.1111/j.1651-2227.1996.tb14265.x; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Ye L, 1997, AM J MED GENET, V70, P103; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	58	160	165	0	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					263	266		10.1038/35041705	http://dx.doi.org/10.1038/35041705			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089984				2022-12-28	WOS:000165180400057
J	Moore, PS				Moore, PS			The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFECTION		Columbia Univ, New York, NY 10032 USA	Columbia University	Moore, PS (corresponding author), Columbia Univ, New York, NY 10032 USA.		Moore, Patrick S./F-3960-2011; Moore, Patrick/GVR-8294-2022	Moore, Patrick S./0000-0002-8132-858X; 				Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Desrosiers RC, 1997, J VIROL, V71, P9764, DOI 10.1128/JVI.71.12.9764-9769.1997; Dukers NHTM, 2000, AM J EPIDEMIOL, V151, P213, DOI 10.1093/oxfordjournals.aje.a010195; Greensill J, 2000, J VIROL, V74, P1572, DOI 10.1128/JVI.74.3.1572-1577.2000; Luppi M, 2000, NEW ENGL J MED, V343, P1378, DOI 10.1056/NEJM200011093431905; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; MOORE PS, IN PRESS FIELDS VIRO; Parravicini C, 1997, AM J PATHOL, V151, P1517; Pauk J, 2000, NEW ENGL J MED, V343, P1369, DOI 10.1056/NEJM200011093431904; Rose TM, 1997, J VIROL, V71, P4138, DOI 10.1128/JVI.71.5.4138-4144.1997; Schultz ER, 2000, J VIROL, V74, P4919, DOI 10.1128/JVI.74.10.4919-4928.2000	12	54	57	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1411	1413		10.1056/NEJM200011093431912	http://dx.doi.org/10.1056/NEJM200011093431912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070109				2022-12-28	WOS:000165152800012
J	Beyth, RJ; Quinn, L; Landefeld, CS				Beyth, RJ; Quinn, L; Landefeld, CS			A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	20th Annual Meeting of the Society-of-General-Internal-Medicine	MAY 01-03, 1997	WASHINGTON, D.C.	Soc Gen Internal Med			ORAL ANTICOAGULANT-THERAPY; NONRHEUMATIC ATRIAL-FIBRILLATION; PROTHROMBIN TIME; SELF-MANAGEMENT; DIFFERENT INTENSITIES; ELDERLY PATIENTS; MEDICAL-CARE; RISK-FACTORS; OUTPATIENTS; ATTITUDES	Background: warfarin is effective in the treatment and prevention of many venous thromboembolic disorders, but it often leads to bleeding, Objective: To develop a multicomponent program of management of warfarin therapy and to determine its effect on the frequency of warfarin-related major bleeding in older patients. Design: Randomized, controlled trial. Setting: University hospital in Cleveland, Ohio. Patients: 325 patients 65 years of age or older who started warfarin therapy during hospitalization. Interventions: Patients were stratified according to baseline risk for major bleeding and were randomly assigned to receive the intervention (n = 163) or usual care (n = 162) by their primary physicians for 6 months. The intervention consisted of patient education about warfarin, training to increase patient participation, self-monitoring of prothrombin time, and guideline-based management of warfarin dosing, Measurements: Major bleeding, death, recurrent venous thromboembolism, and therapeutic control of anticoagulant therapy at 6 months. Results: In an intention-to-treat analysis, major bleeding was more common at 6 months in the usual care group than in the intervention group (cumulative incidence, 12% vs. 5.6%; P = 0.0498, log-rank test). The most frequent site of major bleeding in both groups was the gastrointestinal tract. Death and recurrent venous thromboembolism occurred with similar frequency in both groups at 6 months. Throughout 6 months, the proportion of total treatment time during which the international normalized ratio was within the therapeutic range was higher in the intervention group than in the usual care group (56% vs. 32%; P < 0.001). After 6 months, major bleeding occurred with similar frequencies in the intervention and usual care groups. Conclusions: A multicomponent comprehensive program of warfarin management reduced the frequency of major bleeding in older patients. Although the generalizability and cost-effectiveness of this program remain to be demonstrated, these findings support the premise that efforts to reduce the likelihood of major bleeding will lead to safe and effective use of warfarin therapy in older patients.	Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Cleveland, OH 44106 USA; Cleveland Vet Affairs Med Ctr, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	Beyth, RJ (corresponding author), Baylor Coll Med, Houston Ctr Qual Care & Utilizat Studies, Sect Hlth Serv Res, Vet Affairs Med Ctr, 152,bldg 110T,2002 Holcombe Blvd, Houston, TX 77030 USA.	rbeyth@bcm.tmc.edu			NIA NIH HHS [AG-09657, AG-00712, AG-10418091] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009657] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON DR, 1993, ARCH INTERN MED, V153, P1441, DOI 10.1001/archinte.153.12.1441; [Anonymous], 1974, Health Education Monograph, V2, P324; ANSELL J, 1989, ARCH INTERN MED, V149, P2509, DOI 10.1001/archinte.149.11.2509; Ansell JE, 1996, AM HEART J, V132, P1095, DOI 10.1016/S0002-8703(96)90040-X; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BECKER DM, 1993, ARCH PATHOL LAB MED, V117, P602; BECKER MH, 1985, MED CARE, V23, P539, DOI 10.1097/00005650-198505000-00014; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; Beyth RJ, 1998, AM J MED, V105, P91, DOI 10.1016/S0002-9343(98)00198-3; BEYTH RJ, 1995, DRUG AGING, V6, P45, DOI 10.2165/00002512-199506010-00004; Brodsky MA, 1996, ARCH INTERN MED, V156, P2553, DOI 10.1001/archinte.156.22.2553; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CHARNEY R, 1988, INT J CARDIOL, V18, P197, DOI 10.1016/0167-5273(88)90165-9; Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COON WW, 1974, ARCH INTERN MED, V133, P386, DOI 10.1001/archinte.133.3.386; DAVIS FB, 1977, ARCH INTERN MED, V137, P197, DOI 10.1001/archinte.137.2.197; DUNBAR JM, 1979, COMPLIANCE HLTH CARE, P174; ERRICHETTI AM, 1984, ARCH INTERN MED, V144, P1966, DOI 10.1001/archinte.144.10.1966; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FORFAR JC, 1979, BRIT HEART J, V42, P128; GITTER MJ, 1995, MAYO CLIN PROC, V70, P725, DOI 10.4065/70.8.725; Green LW, 1979, COMPLIANCE HLTH CARE, P157; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDEFELD CS, 1992, ANN INTERN MED, V116, P829, DOI 10.7326/0003-4819-116-10-829; LANDEFELD CS, 1990, AM J MED, V89, P569, DOI 10.1016/0002-9343(90)90174-C; LANDEFELD CS, 1987, AM J MED, V82, P703, DOI 10.1016/0002-9343(87)90004-0; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LANDEFELD CS, 1989, J CLIN EPIDEMIOL, V42, P711, DOI 10.1016/0895-4356(89)90066-8; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V54, P515; LUCAS FV, 1987, AM J CLIN PATHOL, V88, P442, DOI 10.1093/ajcp/88.4.442; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; MCCURDY SA, 1992, ARCH INTERN MED, V152, P589, DOI 10.1001/archinte.152.3.589; McMahan DA, 1998, J GEN INTERN MED, V13, P311, DOI 10.1046/j.1525-1497.1998.00096.x; Mendelson G, 1998, J AM GERIATR SOC, V46, P1423, DOI 10.1111/j.1532-5415.1998.tb06011.x; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PETERSEN P, 1989, LANCET, V1, P175; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WEIBERT RT, 1989, CLIN PHARMACY, V8, P864; White RH, 1996, ARCH INTERN MED, V156, P1197, DOI 10.1001/archinte.156.11.1197; WHITE RH, 1989, ANN INTERN MED, V111, P730, DOI 10.7326/0003-4819-111-9-730; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	60	277	288	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					687	695		10.7326/0003-4819-133-9-200011070-00010	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	369PC	11074901				2022-12-28	WOS:000165075300003
J	Shadick, NA; Lew, RA; Liang, MH				Shadick, NA; Lew, RA; Liang, MH			Outcomes of Lyme disease - Response	ANNALS OF INTERNAL MEDICINE			English	Letter									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Shadick, NA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.							KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; Mosteller F., 1968, HDB SOC PSYCHOL, V2, P80; SELVIN S, 1991, STAT ANAL EPIDEMIOLO	3	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					746	747		10.7326/0003-4819-133-9-200011070-00023	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00023			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074914				2022-12-28	WOS:000165075300013
J	Kareiva, P; Marvier, M; McClure, M				Kareiva, P; Marvier, M; McClure, M			Recovery and management options for spring/summer chinook salmon in the Columbia River Basin	SCIENCE			English	Article								Construction of four dams on the lower Snake River (in northwestern United States) between 1961 and 1975 altered salmon spawning habitat, elevated smolt and adult migration mortality, and contributed to severe declines of Snake River salmon populations. By applying a matrix model to long-term population data, we found that (i) dam passage improvements have dramatically mitigated direct mortality associated with dams; (ii) even if main stem survival were elevated to 100%, Snake River spring/summer chinook salmon (Oncorhynchus tshawytscha) would probably continue to decline toward extinction; and (iii) modest reductions in first-year mortality or estuarine mortality would reverse current population declines.	NOAA, Natl Marine Fisheries Serv, NW Fisheries Sci Ctr, Seattle, WA 98112 USA; Santa Clara Univ, Dept Biol, Santa Clara, CA 95053 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Santa Clara University	McClure, M (corresponding author), NOAA, Natl Marine Fisheries Serv, NW Fisheries Sci Ctr, 2725 Montlake Blvd E, Seattle, WA 98112 USA.		Ebersole, Joseph L/A-8371-2009; McClure, Michelle M/O-7853-2015	McClure, Michelle M/0000-0003-4791-8719; Marvier, Michelle/0000-0001-8360-9265				BEAMESDERFER RCP, 1998, PLAN ANAL TESTING HY, pCH1; Caswell H, 1989, MATRIX POPULATION MO; ELMSCOCKROM TJ, 1998, SALMON SPAWNING GROU; HALLGRISWOLD J, 1988, SALMON SPAWNING GROU; MARMOREK DR, 1998, PLAN ANAL TESTING HY; *NAT MAR FISH SERV, 2000, DRAFT BIOL OP OP FED; *NAT MAR FISH SERV, 2000, SUMM RES REL TRANSP; National Research Council, 1996, UPSTR SALM SOC PAC N; Northwest Power Planning Council, 1986, COMP INF SALM STEELH; *NW POW PLANN COUN, 1989, PREL INF REP SALM ST; PETROSKY CE, 1998, PATH WEIGHT EVIDENCE; Ratner S, 1997, CONSERV BIOL, V11, P879, DOI 10.1046/j.1523-1739.1997.95457.x; RICKER WE, 1976, J FISH RES BOARD CAN, V33, P1483, DOI 10.1139/f76-191; *US ARM CORPS ENG, 1999, LOW SNAK RIV JUV SAL; Waples RS, 1995, AM FISH S S, V17, P8; WHITE M, 1989, SALMON SPAWNING GROU; WILLIAMS J, IN PRESS N AM J FISH	17	244	249	5	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					977	979		10.1126/science.290.5493.977	http://dx.doi.org/10.1126/science.290.5493.977			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062128				2022-12-28	WOS:000165103200047
J	Buonomo, SBC; Clyne, RK; Fuchs, J; Loidl, J; Uhlmann, F; Nasmyth, K				Buonomo, SBC; Clyne, RK; Fuchs, J; Loidl, J; Uhlmann, F; Nasmyth, K			Disjunction of homologous chromosomes in meiosis I depends on proteolytic cleavage of the meiotic cohesin Rec8 by separin	CELL			English	Article							SISTER-CHROMATID COHESION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; SCHIZOSACCHAROMYCES-POMBE; CONSERVED PROTEIN; SHUTTLE VECTORS; YEAST MEIOSIS; FISSION YEAST; RECOMBINATION	It has been proposed but never proven that cohesion between sister chromatids distal to chiasmata is responsible for holding homologous chromosomes together while spindles attempt to pull them toward opposite poles during metaphase of meiosis I. Meanwhile, the mechanism by which disjunction of homologs is triggered at the onset of anaphase I has remained a complete mystery. In yeast, cohesion between sister chromatid arms during meiosis depends on a meiosis-specific cohesin subunit called Rec8, whose mitotic equivalent, Scc1, is cleaved at the metaphase to anaphase transition by an endopeptidase called separin. We show here that cleavage of Rec8 by separin at one of two different sites is necessary for the resolution of chiasmata and the disjunction of homologous chromosomes during meiosis.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Vienna	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at		Fuchs, Joerg/0000-0003-4171-5371; Uhlmann, Frank/0000-0002-3527-6619; Nasmyth, Kim/0000-0001-7030-4403; , Josef/0000-0002-2519-4484; Buonomo, Sara/0000-0002-0177-2884				Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Cha RS, 2000, GENE DEV, V14, P493; Dong HJ, 2000, J CELL BIOL, V148, P417, DOI 10.1083/jcb.148.3.417; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIROUX CN, 1989, GENOME, V31, P88, DOI 10.1139/g89-017; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P281; JIN QW, 2000, IN PRESS J CELL SCI; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KLAPHOLZ S, 1985, GENETICS, V110, P187; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Krawchuk MD, 1999, GENETICS, V153, P57; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; LOIDL J, 1998, GENETIC MORPHOLOGICA, P257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Orr-Weaver TL, 1999, CELL, V99, P1, DOI 10.1016/S0092-8674(00)80055-0; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PONTICELLI AS, 1989, GENETICS, V123, P45; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RIEDER CL, 1992, J CELL SCI, V102, P387; Rieder CL, 1999, J CELL SCI, V112, P2607; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; ROCKMILL B, 1995, GENETICS, V141, P49; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Sambrook J, 1989, MOL CLONING, V3; SIKORSKI RS, 1989, GENETICS, V122, P19; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; THIERRY A, 1995, YEAST, V11, P121, DOI 10.1002/yea.320110204; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619	52	343	351	2	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					387	398		10.1016/S0092-8674(00)00131-8	http://dx.doi.org/10.1016/S0092-8674(00)00131-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081626	Bronze			2022-12-28	WOS:000090144100005
J	Cockayne, DA; Hamilton, SG; Zhu, QM; Dunn, PM; Zhong, Y; Novakovic, S; Malmberg, AB; Cain, G; Berson, A; Kassotakis, L; Hedley, L; Lachnit, WG; Burnstock, G; McMahon, SB; Ford, APDW				Cockayne, DA; Hamilton, SG; Zhu, QM; Dunn, PM; Zhong, Y; Novakovic, S; Malmberg, AB; Cain, G; Berson, A; Kassotakis, L; Hedley, L; Lachnit, WG; Burnstock, G; McMahon, SB; Ford, APDW			Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X(3)-deficient mice	NATURE			English	Article							ROOT GANGLION NEURONS; P2X RECEPTORS; SENSORY NEURONS; RAT; ATP; INFLAMMATION; MICTURITION; RESPONSES	Extracellular ATP is implicated in numerous sensory processes ranging from the response to pain to the regulation of motility in visceral organs(1). The ATP receptor P2X(3) is selectively expressed on small diameter sensory neurons(2-4), supporting this hypothesis. Here we show that mice deficient in P2X(3) lose the rapidly desensitizing ATP-induced currents in dorsal root ganglion neurons. P2X(3) deficiency also causes a reduction in the sustained ATP-induced currents in nodose ganglion neurons. P2X(3)-null mice have reduced pain-related behaviour in response to injection of ATP and formalin. Significantly, P2X(3)-null mice exhibit a marked urinary bladder hyporeflexia, characterized by decreased voiding frequency and increased bladder capacity, but normal bladder pressures. Immunohistochemical studies localize P2X(3) to nerve fibres innervating the urinary bladder of wild-type mice, and show that loss of P2X(3) does not alter sensory neuron innervation density. Thus, P2X(3) is critical for peripheral pain responses and afferent pathways controlling urinary bladder volume reflexes. Antagonists to P2X(3) may therefore have therapeutic potential in the treatment of disorders of urine storage and voiding such as overactive bladder.	Roche Biosci, Neurobiol Unit, Palo Alto, CA 94304 USA; Kings Coll London, Neurosci Res Ctr, London SE1 9RT, England; UCL Royal Free & Univ Coll Med Sch, Autonom Neurosci Inst, London NW3 2PF, England	Roche Holding; University of London; King's College London; University of London; University College London; UCL Medical School	Cockayne, DA (corresponding author), Roche Biosci, Neurobiol Unit, 3401 Hillview Ave, Palo Alto, CA 94304 USA.	debra.cockayne@roche.com		McMahon, Stephen/0000-0003-4656-5536				BlandWard PA, 1997, BRIT J PHARMACOL, V122, P365, DOI 10.1038/sj.bjp.0701371; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; Bradbury EJ, 1998, MOL CELL NEUROSCI, V12, P256, DOI 10.1006/mcne.1998.0719; Burgard EC, 1999, J NEUROPHYSIOL, V82, P1590, DOI 10.1152/jn.1999.82.3.1590; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Burnstock G, 2000, PROG PAIN RES MANAG, V16, P63; Burnstock G, 2000, BRIT J ANAESTH, V84, P476, DOI 10.1093/oxfordjournals.bja.a013473; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; de Groat WC, 1998, BEHAV BRAIN RES, V92, P127, DOI 10.1016/S0166-4328(97)00185-X; Dmitrieva N, 1997, NEUROSCIENCE, V78, P449, DOI 10.1016/S0306-4522(96)00575-1; Elneil S., 1999, Neurourology and Urodynamics, V18, P339; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; FITZGERALD JM, 1995, BLADDER; Grubb BD, 1999, EUR J NEUROSCI, V11, P149, DOI 10.1046/j.1460-9568.1999.00426.x; Hamilton SG, 2000, BRAIN, V123, P1238, DOI 10.1093/brain/123.6.1238; Hamilton SG, 1999, BRIT J PHARMACOL, V126, P326, DOI 10.1038/sj.bjp.0702258; Ishizuka O, 1996, J UROLOGY, V156, P1853, DOI 10.1016/S0022-5347(01)65552-6; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MCMAHON SB, 1986, PROG BRAIN RES, V67, P245; Namasivayam S, 1999, BJU INT, V84, P854; Rae MG, 1998, BRIT J PHARMACOL, V124, P176, DOI 10.1038/sj.bjp.0701803; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robertson SJ, 1996, BRIT J PHARMACOL, V118, P951, DOI 10.1111/j.1476-5381.1996.tb15491.x; Thomas S, 1998, J PHYSIOL-LONDON, V509, P411, DOI 10.1111/j.1469-7793.1998.411bn.x; Tsuda M, 1999, BRIT J PHARMACOL, V128, P1497, DOI 10.1038/sj.bjp.0702960; Ueno S, 1999, BRIT J PHARMACOL, V126, P429, DOI 10.1038/sj.bjp.0702319; Vulchanova L, 1998, EUR J NEUROSCI, V10, P3470, DOI 10.1046/j.1460-9568.1998.00355.x; Zhong Y, 1998, BRIT J PHARMACOL, V125, P771, DOI 10.1038/sj.bjp.0702118	28	796	827	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1011	1015		10.1038/35039519	http://dx.doi.org/10.1038/35039519			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069181				2022-12-28	WOS:000090032500045
J	Tapson, VF				Tapson, VF			Risk of venous thromboembolism with use of antipsychotic drugs	LANCET			English	Editorial Material									Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC 27710 USA	Duke University	Tapson, VF (corresponding author), Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC 27710 USA.							GRAHMANN H, 1959, Nervenarzt, V30, P224; HAFNER H, 1965, COMPR PSYCHIAT, V6, P25, DOI 10.1016/S0010-440X(65)80005-0; Hagg S, 2000, LANCET, V355, P1155, DOI 10.1016/S0140-6736(00)02066-3; Maynes D, 2000, CAN J PSYCHIAT, V45, P296; MIELKE F A, 1956, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V194, P263, DOI 10.1007/BF00352726; TAPSON V, 2000, CECIL TXB MED; VARIA I, 1983, PSYCHOSOMATICS, V24, P1097, DOI 10.1016/S0033-3182(83)73114-2	7	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1206	1206		10.1016/S0140-6736(00)02776-8	http://dx.doi.org/10.1016/S0140-6736(00)02776-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072931				2022-12-28	WOS:000089724900002
J	Hasdai, D; Topol, EJ; Califf, RM; Berger, PB; Holmes, DR				Hasdai, D; Topol, EJ; Califf, RM; Berger, PB; Holmes, DR			Cardiogenic shock complicating acute coronary syndromes	LANCET			English	Review							ACUTE MYOCARDIAL-INFARCTION; GUSTO-I TRIAL; INTRAAORTIC BALLOON COUNTERPULSATION; EARLY REVASCULARIZATION; PLASMINOGEN-ACTIVATOR; REPERFUSION; PROGNOSIS; MORTALITY; SURVIVAL; SURGERY	Cardiogenic shock remains the major cause of death among patients with all types of acute coronary syndromes. Thus, there Is a growing interest in the identification of patients who are at risk for developing cardiogenic shock, in the exploration of different therapeutic approaches to preventing its development, and in the improvement of outcome when it occurs. This article reviews the aetiology and pathophysiology of cardiogenic shock, its epidemiology, its treatment (including pharmaceutical agents, counterpulsation, and revascularisation), and its outcome. Algorithms are presented that predict Its occurrence in both ST-segment-elevation myocardial infarction and unstable angina or non-ST-elevation myocardial infarction, and that predict its mortality in patients with ST-segment-elevation acute myocardial infarction. such new areas as metabolic therapy and glycoprotein IIb/IIIa inhibitors are discussed, as are the economic implications of shock.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Rabin Med Ctr, Petah Tiqwa, Israel; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Duke Clin Res Inst, Durham, NC USA	Mayo Clinic; Rabin Medical Center; Cleveland Clinic Foundation; Duke University	Holmes, DR (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.	holmes.david@mayo.edu		Topol, Eric/0000-0002-1478-4729				ABDELFATTAH AS, 1990, CIRCULATION, V82, P341; *AIMS TRIAL STUD G, 1988, LANCET, V2, P545; ALONSO DR, 1973, CIRCULATION, V48, P588, DOI 10.1161/01.CIR.48.3.588; Anderson RD, 1997, J AM COLL CARDIOL, V30, P708, DOI 10.1016/S0735-1097(97)00227-1; ANTMAN EM, 1997, HEART DIS TXB CARDIO, P1184; BARDET J, 1977, AM HEART J, V93, P280, DOI 10.1016/S0002-8703(77)80245-7; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; Berger PB, 1997, CIRCULATION, V96, P122; Berger PB, 1999, CIRCULATION, V99, P873, DOI 10.1161/01.CIR.99.7.873; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Brookes C, 1999, CIRCULATION, V100, P761, DOI 10.1161/01.CIR.100.7.761; BUCKESFELD RP, 1973, BMJ-BRIT MED J, V2, P365, DOI 10.1136/bmj.2.5862.365-a; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; CORBUCCI GG, 1993, INT J CLIN PHARM RES, V13, P87; DEWOOD MA, 1980, CIRCULATION, V61, P1105, DOI 10.1161/01.CIR.61.6.1105; DUNKMAN WB, 1972, CIRCULATION, V46, P465, DOI 10.1161/01.CIR.46.3.465; ELTCHANINOFF H, 1995, AM HEART J, V130, P459, DOI 10.1016/0002-8703(95)90352-6; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; Goldberg RJ, 1999, NEW ENGL J MED, V340, P1162, DOI 10.1056/NEJM199904153401504; GURWITZ JH, 1994, ARCH INTERN MED, V154, P2202; Hasdai D, 1999, EUR HEART J, V20, P128, DOI 10.1053/euhj.1999.1282; Hasdai D, 2000, J AM COLL CARDIOL, V35, P136, DOI 10.1016/S0735-1097(99)00508-2; Hasdai D, 1999, AM HEART J, V138, P21, DOI 10.1016/S0002-8703(99)70241-3; HASDAI D, IN PRESS J AM COLL C; Herrick JB, 1912, J AMER MED ASSOC, V59, P2015; HIROSE S, 1986, LANCET, V2, P397; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; HOCHMAN JS, 1995, CIRCULATION, V91, P873, DOI 10.1161/01.CIR.91.3.873; Hochman JS, 1999, CIRCULATION, V100, P369; HOLMES DR, 1995, J AM COLL CARDIOL, V26, P668, DOI 10.1016/0735-1097(95)00215-P; Holmes DR, 1999, CIRCULATION, V100, P2067, DOI 10.1161/01.CIR.100.20.2067; Holmes DR, 1997, LANCET, V349, P75, DOI 10.1016/S0140-6736(96)03031-0; KILLIP T, 1989, J AM COLL CARDIOL, V14, P47, DOI 10.1016/0735-1097(89)90052-1; Kline JA, 1997, CARDIOVASC RES, V34, P289, DOI 10.1016/S0008-6363(97)00022-9; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; Mehta RH, 1999, AM HEART J, V138, P688, DOI 10.1016/S0002-8703(99)70184-5; Menon V, 2000, AM J MED, V108, P374, DOI 10.1016/S0002-9343(00)00310-7; Noble S, 1996, DRUGS, V52, P589, DOI 10.2165/00003495-199652040-00012; PREWITT RM, 1992, J AM COLL CARDIOL, V20, P1626, DOI 10.1016/0735-1097(92)90459-Z; PREWITT RM, 1994, J AM COLL CARDIOL, V23, P794, DOI 10.1016/0735-1097(94)90770-6; QUIGLEY RL, 1993, CIRCULATION, V88, P65; STOMEL RJ, 1994, CHEST, V105, P997, DOI 10.1378/chest.105.4.997; SUBRAMANIAN VA, 1980, NEW YORK STATE J MED, V80, P947; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Urban P, 1999, EUR HEART J, V20, P1030, DOI 10.1053/euhj.1998.1353; Webb JG, 1997, AM J CARDIOL, V79, P81, DOI 10.1016/S0002-9149(96)00683-2; WILCOX RG, 1988, LANCET, V2, P525; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	48	102	110	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	2000	356	9231					749	756		10.1016/S0140-6736(00)02640-4	http://dx.doi.org/10.1016/S0140-6736(00)02640-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085707				2022-12-28	WOS:000088948200039
J	Young, CJ; Gaston, RS				Young, CJ; Gaston, RS			Renal transplantation in black Americans.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RACIAL-DIFFERENCES; KIDNEY-TRANSPLANT; ALLOGRAFT SURVIVAL; AFRICAN-AMERICAN; UNITED-NETWORK; IMMUNOSUPPRESSIVE THERAPY; GRAFT-SURVIVAL; BLOOD-PRESSURE; RACE; HLA		Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Div Transplantat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Gaston, RS (corresponding author), Univ Alabama Birmingham, Dept Med, Div Nephrol, 625 THT,1530 3rd Ave S, Birmingham, AL 35294 USA.	rgaston@nrtc.dom.uab.edu	Gaston, Robert/AAR-2932-2020					[Anonymous], 1999, Am J Kidney Dis, V34, pS1; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; BARGER B, 1992, TRANSPLANTATION, V53, P770, DOI 10.1097/00007890-199204000-00013; Barger B O, 1987, Clin Transpl, P217; Barley J, 1996, J HUM HYPERTENS, V10, P31; BEATTY PG, 1995, TRANSPLANTATION, V60, P778, DOI 10.1097/00007890-199510270-00003; Bergman S, 1996, AM J KIDNEY DIS, V27, P341, DOI 10.1016/S0272-6386(96)90356-X; Bloem LJ, 1996, HYPERTENSION, V27, P62, DOI 10.1161/01.HYP.27.1.62; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; Callender C, 1997, TRANSPL P, V29, P1482, DOI 10.1016/S0041-1345(96)00697-5; Cecka J M, 1998, Clin Transpl, P1; CHERTOW GM, 1995, KIDNEY INT, V48, pS48; Cosio FG, 1997, AM J KIDNEY DIS, V29, P419, DOI 10.1016/S0272-6386(97)90204-3; COSIO FG, 1995, KIDNEY INT, V47, P1136, DOI 10.1038/ki.1995.162; Curtis JJ, 1999, AM J KIDNEY DIS, V34, P756, DOI 10.1016/S0272-6386(99)70404-X; Curtis JJ, 1998, J AM SOC NEPHROL, V9, P1293; Danoff TM, 1999, TRANSPLANTATION, V67, pS8, DOI 10.1097/00007890-199904150-00036; DEGEEST S, 1995, TRANSPLANTATION, V59, P340; Delmonico FL, 1999, TRANSPLANTATION, V68, P1875, DOI 10.1097/00007890-199912270-00010; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Epstein R., 1997, MORTAL PERIL OUR INA; Feldman HI, 1997, TRANSPLANTATION, V64, P80, DOI 10.1097/00007890-199707150-00015; Feucht HE, 1998, TRANSPLANTATION, V65, P757, DOI 10.1097/00007890-199803150-00029; First MR, 1996, CLIN TRANSPLANT, V10, P55; FRIEDMAN EA, 1978, NEW ENGL J MED, V298, P368, DOI 10.1056/NEJM197802162980704; Gaston RS, 1999, TRANSPLANT P, V31, p21S, DOI 10.1016/S0041-1345(99)00118-9; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; GASTON RS, 1992, TRANSPLANTATION, V53, P103, DOI 10.1097/00007890-199201000-00020; GASTON RS, 2000, EXTENDING MEDICARE C, P310; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; Gjertson D W, 1989, Clin Transpl, P353; GJERTSON DW, 1994, CLIN TRANSPLANTS 199, P445; GJERTSON DW, 1996, CLIN TRANS, P433; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GRIM CE, 1995, HYPERTENSION PATHOPH, V1, P171; Hall WD, 1997, AM J KIDNEY DIS, V29, P720, DOI 10.1016/S0272-6386(97)90125-6; Halloran PF, 1999, J AM SOC NEPHROL, V10, P167; HARPER AM, 1999, CLIN TRANSPLANTS 199, P73; HATA Y, 1997, CLIN TRANSPLANTS 199, P381; HELD PJ, 1994, NEW ENGL J MED, V331, P765, DOI 10.1056/NEJM199409223311203; HRICIK DE, 1992, TRANSPLANTATION, V53, P41, DOI 10.1097/00007890-199201000-00007; Hutchings A, 1999, TRANSPLANTATION, V67, pS40, DOI 10.1097/00007890-199904150-00163; Isaacs RB, 1999, AM J KIDNEY DIS, V34, P706, DOI 10.1016/S0272-6386(99)70397-5; JAKLITSCH MT, 1989, TRANSPLANT P, V21, P1274; Jones DS, 1999, CLIN PHARMACOL THER, V65, P408, DOI 10.1016/S0009-9236(99)70135-9; KALIL RSN, 1992, AM J KIDNEY DIS, V20, P63, DOI 10.1016/S0272-6386(12)80318-0; KALLICH JD, 1993, ACCESS CADAVERIC KID; Kasiske BL, 2000, JAMA-J AM MED ASSOC, V283, P2445, DOI 10.1001/jama.283.18.2445; Kasiske BL, 1998, J AM SOC NEPHROL, V9, P2142; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; Katznelson S, 1996, CLIN TRANS, P379; KERMAN RH, 1992, TRANSPLANTATION, V53, P64, DOI 10.1097/00007890-199201000-00012; KERMAN RH, 1991, TRANSPLANTATION, V51, P338, DOI 10.1097/00007890-199102000-00013; Korbet SM, 1999, AM J KIDNEY DIS, V34, P713, DOI 10.1016/S0272-6386(99)70398-7; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; LAZDA VA, 1992, TRANSPLANTATION, V53, P352, DOI 10.1097/00007890-199202010-00017; LAZDA VA, 1989, TRANSPLANT P, V21, P1415; LEFFELL MS, 1994, TRANSPLANTATION, V58, P1119, DOI 10.1097/00007890-199411270-00011; LINDHOLM A, 1992, CLIN PHARMACOL THER, V52, P359, DOI 10.1038/clpt.1992.156; Matas A, 1999, TRANSPLANTATION, V67, pS269, DOI 10.1097/00007890-199904150-01074; *NAT I DIAB DIG KI, 1996, REN DAT SYST USRDS 1; Nevins T, 1999, TRANSPLANTATION, V67, pS115, DOI 10.1097/00007890-199904150-00463; Neylan JF, 1998, TRANSPLANTATION, V65, P515, DOI 10.1097/00007890-199802270-00011; Neylan JF, 1997, TRANSPLANTATION, V64, P1277, DOI 10.1097/00007890-199711150-00008; NORMAN DJ, 1995, TRANSPLANT P, V27, P800; OJO A, 1993, AM J KIDNEY DIS, V22, P835, DOI 10.1016/S0272-6386(12)70343-8; OJO AO, 1995, KIDNEY INT, V48, P1592, DOI 10.1038/ki.1995.452; OJO AO, 1994, AM J KIDNEY DIS, V24, P59, DOI 10.1016/S0272-6386(12)80160-0; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; Oliver J. D. III, 1999, Journal of the American Society of Nephrology, V10, p741A; OPELZ G, 1977, TRANSPLANT P, V9, P137; OPELZ G, 1989, TRANSPLANT P, V21, P3918; ORIOL R, 1982, TRANSPLANTATION, V33, P22, DOI 10.1097/00007890-198201000-00005; PERDUE ST, 1982, TRANSPLANTATION, V34, P75, DOI 10.1097/00007890-198208000-00002; POSNER MP, 1986, TRANSPLANTATION, V41, P474, DOI 10.1097/00007890-198604000-00012; QUALHEIM RE, 1991, AM J KIDNEY DIS, V18, P336, DOI 10.1016/S0272-6386(12)80092-8; RATNER LE, 1995, TRANSPLANTATION, V60, P1047; Rettig RA, 1991, KIDNEY FAILURE FEDER; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; ROSTAND SG, 1992, AM J KIDNEY DIS, V19, P411, DOI 10.1016/S0272-6386(12)80946-2; SAND W, 1993, BIOHYDROMETALLURGICA, V1, P15; Sanders CE, 1996, AM J KIDNEY DIS, V28, P572, DOI 10.1016/S0272-6386(96)90469-2; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; Scaife ER, 1997, TRANSPLANT P, V29, P3441, DOI 10.1016/S0041-1345(97)00971-8; Scantlebury V, 1998, TRANSPLANTATION, V65, P586, DOI 10.1097/00007890-199802270-00025; SCHLIEF R, 1994, ADV ECHO CONTRAST, V3, P60; Schweitzer EJ, 1997, AM J KIDNEY DIS, V29, P739, DOI 10.1016/S0272-6386(97)90128-1; SCHWEIZER RT, 1990, TRANSPLANTATION, V49, P374, DOI 10.1097/00007890-199002000-00029; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; Starzl TE, 1997, TRANSPLANTATION, V64, P983, DOI 10.1097/00007890-199710150-00009; SUMMERSON JH, 1995, AM J KIDNEY DIS, V26, P577, DOI 10.1016/0272-6386(95)90591-X; Suthanthiran R, 1998, KIDNEY INT, V53, P639, DOI 10.1046/j.1523-1755.1998.00858.x; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; Tankersley MR, 1997, TRANSPLANT P, V29, P3722, DOI 10.1016/S0041-1345(97)01086-5; TERASAKI PI, 1997, CLIN TRANSPLANTS 199, P443; *UN NETW ORG SHAR, 1994, UNOS UPD, V10, P18; *UN NETW ORG SHAR, 1999, 1998 ANN REP US SCI; Warnock DG, 2000, SEMIN NEPHROL, V20, P40; WELLER JM, 1987, AM J KIDNEY DIS, V9, P191, DOI 10.1016/S0272-6386(87)80054-9; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Woodward Robert S., 1999, Journal of the American Society of Nephrology, V10, p751A; Yuge J, 1989, Clin Transpl, P407; ZACHARY AA, 1994, TRANSPLANTATION, V57, P1115; ZHOU YC, 1991, CLIN TRANSPLANTS 199, P447; 1993, ECONOMIST        OCT, P93	107	226	228	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1545	1552		10.1056/NEJM200011233432107	http://dx.doi.org/10.1056/NEJM200011233432107			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087885				2022-12-28	WOS:000165410900007
J	Grinspoon, S; Thomas, E; Pitts, S; Gross, E; Mickley, D; Miller, K; Herzog, D; Klibanski, A				Grinspoon, S; Thomas, E; Pitts, S; Gross, E; Mickley, D; Miller, K; Herzog, D; Klibanski, A			Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa	ANNALS OF INTERNAL MEDICINE			English	Article							BONE TURNOVER; OSTEOPOROSIS; DENSITY	Background: Anorexia nervosa is highly prevalent among young women. Objective: To determine prevalence and predictive factors for regional bone loss. Design: Prospective cohort analysis. Setting: University hospital. Patients: 130 women with anorexia nervosa. Measurements: Dual-energy x-ray absorptiometry. Results: The prevalence of osteopenia (-1.0 SD greater than or equal to T-score > -2.5 SD) and osteoporosis (T-score less than or equal to -2.5 SD) was 50% and 13% for the anterior-posterior spine, 57% and 24% for the lateral spine, and 47% and 16% for the total hip, respectively. Bone mineral density (BMD) was reduced by at least 1.0 SD at one or more skeletal sites in 92% of patients and by at least 2.5 SD in 38% of patients. Weight was the most consistent predictor of BMD at all skeletal sites. Twenty-three percent of patients were current estrogen users, and 58% were previous estrogen users. Bone mineral density did not differ by history of estrogen use at any site. Conclusions: Bone mineral density is reduced at several skeletal sites in most women with anorexia nervosa. Weight, but not estrogen use, is a significant predictor of BMD in this population at all skeletal sites.	Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Wilkins Ctr, Greenwich, CT USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Grinspoon, S (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052625, P30DK040561, T32DK007028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038333] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR001066, MO1-RR01066] Funding Source: Medline; NIDDK NIH HHS [R01-DK52625, P30 DK040561, T32 DK007028, R01 DK052625, P30 DK040561-06] Funding Source: Medline; NIMH NIH HHS [R01-MH38333, R01 MH038333] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BILLER BMK, 1989, J CLIN ENDOCR METAB, V68, P548, DOI 10.1210/jcem-68-3-548; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; FINKELSTEIN JS, 1994, J CLIN ENDOCR METAB, V78, P724, DOI 10.1210/jc.78.3.724; FRISANCHO AR, 1983, AM J CLIN NUTR, V37, P311, DOI 10.1093/ajcn/37.2.311; Frisancho AR, 1990, ANTHROPOMETRIC STAND; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3864, DOI 10.1210/jc.81.11.3864; Grinspoon S, 1999, J CLIN ENDOCR METAB, V84, P2049, DOI 10.1210/jc.84.6.2049; HERZOG W, 1993, J BONE MINER RES, V8, P597; Hotta M, 2000, J CLIN ENDOCR METAB, V85, P200, DOI 10.1210/jc.85.1.200; KLIBANSKI A, 1995, J CLIN ENDOCR METAB, V80, P898, DOI 10.1210/jc.80.3.898; LUCAS AR, 1991, AM J PSYCHIAT, V148, P917; POPE HG, 1984, INT J EAT DISORDER, V3, P45, DOI 10.1002/1098-108X(198421)3:3<45::AID-EAT2260030304>3.0.CO;2-G; RIGOTTI NA, 1984, NEW ENGL J MED, V311, P1601, DOI 10.1056/NEJM198412203112503; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V265, P1133, DOI 10.1001/jama.265.9.1133; SEEMAN E, 1992, J BONE MINER RES, V7, P1467; Soyka LA, 1999, J CLIN ENDOCR METAB, V84, P4489, DOI 10.1210/jc.84.12.4489; 1959, STAT B METROPOL INSU, V40, P1	18	261	268	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					790	794		10.7326/0003-4819-133-10-200011210-00011	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085841	Green Accepted			2022-12-28	WOS:000165321200004
J	Kimmelstiel, C; Pandian, N				Kimmelstiel, C; Pandian, N			Mitral stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Kimmelstiel, C (corresponding author), New England Med Ctr, 750 Washington St, Boston, MA 02111 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1387	1387		10.1056/NEJM200011093431907	http://dx.doi.org/10.1056/NEJM200011093431907			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070104				2022-12-28	WOS:000165152800007
J	Giasson, BI; Duda, JE; Murray, IVJ; Chen, QP; Souza, JM; Hurtig, HI; Ischiropoulos, H; Trojanowski, JQ; Lee, VMY				Giasson, BI; Duda, JE; Murray, IVJ; Chen, QP; Souza, JM; Hurtig, HI; Ischiropoulos, H; Trojanowski, JQ; Lee, VMY			Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions	SCIENCE			English	Article							MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; NITRIC-OXIDE; TYROSINE NITRATION; PEROXYNITRITE; DEMENTIA; INCLUSIONS; STRESS	Aggregated alpha -synuclein proteins form brain Lesions that are hallmarks of neurodegenerative synucleinopathies, and oxidative stress has been implicated in the pathogenesis of some of these disorders. Using antibodies to specific nitrated tyrosine residues in alpha -synuclein, we demonstrate extensive and widespread accumulations of nitrated alpha -synuclein in the signature inclusions of Parkinson's disease, dementia with Lewy bodies, the Lewy body variant of Alzheimer's disease, and multiple system atrophy brains. We also show that nitrated alpha -synuclein is present in the major filamentous building blocks of these inclusions, as well as in the insoluble fractions of affected brain regions of synucleinopathies. The selective and specific nitration of alpha -synuclein in these disorders provides evidence to directly link oxidative and nitrative damage to the onset and progression of neurodegenerative synucleinopathies.	Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Stokes Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Giasson, BI (corresponding author), Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu	Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360				Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; Browne SE, 1999, BRAIN PATHOL, V9, P147; Cookson MR, 1999, BRAIN PATHOL, V9, P165; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, AM J PATHOL, V157, P1439, DOI 10.1016/S0002-9440(10)64781-5; DUDA JE, UNPUB; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; GIASSON BI, UNPUB; Good PF, 1996, AM J PATHOL, V149, P21; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Lyras L, 1998, J NEUROCHEM, V71, P302; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; RODRIGUEZ EM, 1984, HISTOCHEMISTRY, V81, P253, DOI 10.1007/BF00495636; SCHMIDT ML, 1991, AM J PATHOL, V139, P53; Smith MA, 1997, J NEUROSCI, V17, P2653; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; White CR, 1999, METHOD ENZYMOL, V301, P288; Ye YZ, 1996, METHOD ENZYMOL, V269, P201	36	1270	1309	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					985	989		10.1126/science.290.5493.985	http://dx.doi.org/10.1126/science.290.5493.985			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062131				2022-12-28	WOS:000165103200050
J	Goss, DA				Goss, DA			Nearwork and myopia	LANCET			English	Editorial Material									Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Goss, DA (corresponding author), Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.							Bear JC, 1991, REFRACTIVE ANOMALIES, P57; CURTIN BJ, 1985, MYOPIAS BASIC SCI CL, P120; Fulk GW, 2000, OPTOMETRY VISION SCI, V77, P395, DOI 10.1097/00006324-200008000-00006; GROSVENOR T, 1999, CLIN MANAGEMENT MYOP, P113; JIANG BC, 2000, MYOPIA 2000, P291; Kroger RHH, 2000, BRIT J OPHTHALMOL, V84, P890, DOI 10.1136/bjo.84.8.890; Leung JTM, 1999, OPTOMETRY VISION SCI, V76, P346, DOI 10.1097/00006324-199906000-00013; Rosenfield M, 1998, MYOPIA NEARWORK, P91; SCHAEFFEL F, 1990, VISUAL NEUROSCI, V4, P177, DOI 10.1017/S0952523800002327; Smith EL, 1998, MYOPIA NEARWORK, P57; *WORK GROUP MYOP P, 1989, MYOP PREV PROGR, P1; Zadnik K., 1998, BORISHS CLIN REFRACT, P30	12	60	65	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1456	1457		10.1016/S0140-6736(00)02864-6	http://dx.doi.org/10.1016/S0140-6736(00)02864-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081523				2022-12-28	WOS:000090067300004
J	Horner, PJ; Gage, FH				Horner, PJ; Gage, FH			Regenerating the damaged central nervous system	NATURE			English	Review							SPINAL-CORD INJURY; PARTIAL FUNCTIONAL RECOVERY; SCHWANN-CELL GRAFTS; ADULT-MOUSE BRAIN; AXONAL REGENERATION; STEM-CELLS; REACTIVE ASTROCYTES; NEURITE OUTGROWTH; GROWTH-FACTOR; PROMOTES REGENERATION	It is self-evident that the adult mammalian brain and spinal cord do not regenerate after injury, but recent discoveries have forced a reconsideration of this accepted principle. Advances in our understanding of how the brain develops have provided a rough blueprint for how we may bring about regeneration in the damaged brain. Studies in developmental neurobiology, intracellular signalling and neuroimmunology are bringing the regeneration field closer to success. Notwithstanding these advances, clear and indisputable evidence for adult functional regeneration remains to be shown.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu	Horner, Philip J./AAF-7012-2021					Aubert I, 1998, J COMP NEUROL, V399, P1; Bahr M, 1997, ADV NEUROL, V73, P83; BARTLETT PF, 1982, P NATL ACAD SCI-BIOL, V79, P2722, DOI 10.1073/pnas.79.8.2722; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bernhardt RR, 1999, EXP NEUROL, V157, P223, DOI 10.1006/exnr.1999.7059; BISBY MA, 1992, MOL NEUROBIOL, V6, P107, DOI 10.1007/BF02780547; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal RS., 1928, DEGENERATION REGENER; CARONI P, 1988, PROG BRAIN RES, V78, P363; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Franklin RJM, 1997, J NEUROSCI RES, V50, P337, DOI 10.1002/(SICI)1097-4547(19971015)50:2<337::AID-JNR21>3.0.CO;2-3; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gaiano N, 1998, J NEUROBIOL, V36, P152, DOI 10.1002/(SICI)1097-4695(199808)36:2<152::AID-NEU4>3.0.CO;2-0; Gautier SE, 1998, J BIOMED MATER RES, V42, P642, DOI 10.1002/(SICI)1097-4636(19981215)42:4<642::AID-JBM22>3.3.CO;2-B; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; Gould E, 1999, BIOL PSYCHIAT, V46, P1472, DOI 10.1016/S0006-3223(99)00247-4; Grill R, 1997, J NEUROSCI, V17, P5560; Haas CA, 1999, J NEUROSCI, V19, P9953; Harvey N L, 1998, Adv Biochem Eng Biotechnol, V62, P107; Hopker VH, 1999, NATURE, V401, P69, DOI 10.1038/43441; Horner PJ, 2000, J NEUROSCI, V20, P2218; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Jakeman LB, 1998, EXP NEUROL, V154, P170, DOI 10.1006/exnr.1998.6924; Jaworski DM, 1999, EXP NEUROL, V157, P327, DOI 10.1006/exnr.1999.7062; KAWAJA MD, 1991, NEURON, V7, P1019, DOI 10.1016/0896-6273(91)90346-2; Keirstead HS, 1999, EXP NEUROL, V159, P225, DOI 10.1006/exnr.1999.7100; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KORDOWER JH, 1999, CNS REGENERATION BAS, P159; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Matyszak MK, 1998, PROG NEUROBIOL, V56, P19, DOI 10.1016/S0301-0082(98)00014-8; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Ono K, 1999, BIOCHEM BIOPH RES CO, V262, P610, DOI 10.1006/bbrc.1999.1223; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pettigrew DB, 1999, J NEUROSCI, V19, P8358; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.0.CO;2-G; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Stichel CC, 1999, GLIA, V28, P156, DOI 10.1002/(SICI)1098-1136(199911)28:2<156::AID-GLIA7>3.0.CO;2-Z; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Weidner N, 1999, J COMP NEUROL, V413, P495, DOI 10.1002/(SICI)1096-9861(19991101)413:4<495::AID-CNE1>3.0.CO;2-Z; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951	90	622	666	6	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					963	970		10.1038/35039559	http://dx.doi.org/10.1038/35039559			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069169				2022-12-28	WOS:000090032500033
J	Armstrong, K; Kirkby-Bott, J; Johnson, DW				Armstrong, K; Kirkby-Bott, J; Johnson, DW			Chest pain, syncope, and puddings	LANCET			English	Article									Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld 4102, Australia		Johnson, DW (corresponding author), Princess Alexandra Hosp, Dept Renal Med, Ipswich Rd, Brisbane, Qld 4102, Australia.		Johnson, David/F-2897-2011	Johnson, David/0000-0001-5491-3460				Capps R, 1934, AM J MED SCI, V188, P800, DOI 10.1097/00000441-193412000-00007; Gomelsky A, 1997, Md Med J, V46, P83; MACDONALD RG, 1975, ANAESTHESIA, V30, P50, DOI 10.1111/j.1365-2044.1975.tb00794.x; SANDOR F, 1964, BRIT J SURG, V51, P682, DOI 10.1002/bjs.1800510909; STILWELL ME, 1981, J CAN ASSOC RADIOL, V32, P60	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1322	1322		10.1016/S0140-6736(00)02817-8	http://dx.doi.org/10.1016/S0140-6736(00)02817-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073022				2022-12-28	WOS:000089858300014
J	Capasso, L				Capasso, L			Herculaneum victims of the volcanic eruptions of Vesuvius in 79 AD	LANCET			English	Review									Minist Cultural Heritage Italian Govt, Natl Survey Anthropol, I-66100 Chieti, Italy		Capasso, L (corresponding author), Minist Cultural Heritage Italian Govt, Natl Survey Anthropol, Via Arniense 162, I-66100 Chieti, Italy.							Baby R.S., 1954, OHIO HIST SOC PAPERS, P1; BAXTER PJ, 1990, B VOLCANOL, V52, P532, DOI 10.1007/BF00301534; BONUCCI E, 1975, RENDICONTI ACCADEM 8, V49, P517; BUDETTA T, 1993, NUOVI SCAVI NELLAREA, P677; Capasso L, 1998, LANCET, V351, P992, DOI 10.1016/S0140-6736(00)80058-6; HAGLUND W, 1997, FORENSISC TAPHONOMY; Heglar R., 1984, HUMAN IDENTIFICATION, P148; HERMANN B, 1977, J HUM EVOL, V6, P101; KENT DV, 1981, NATURE, V290, P393, DOI 10.1038/290393a0; MAURY RC, 1976, B CTR RES PAU, V10, P289; SHERIDAN MF, 1981, NATURE, V289, P282, DOI 10.1038/289282a0; SHIPMAN P, 1984, J ARCHEOL SCI, V11, P302; SIGURDSSON H, 1982, AM J ARCHAEOL, V86, P39, DOI 10.2307/504292; TAMARIT LV, 1992, P 9 EUR M PAL ASS BA, P395	14	17	18	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1344	1346		10.1016/S0140-6736(00)02827-0	http://dx.doi.org/10.1016/S0140-6736(00)02827-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073037				2022-12-28	WOS:000089858300040
J	Benecke, P; Krug, F; Wohlschlager, C; Psathakis, D				Benecke, P; Krug, F; Wohlschlager, C; Psathakis, D			A rare cause of rupture of the quadriceps tendon	LANCET			English	Article									Med Univ Lubeck, Univ Klinikum, Dept Surg, D-23538 Lubeck, Germany; Med Univ Lubeck, Inst Pathol, D-23538 Lubeck, Germany	University of Lubeck; University of Lubeck	Krug, F (corresponding author), Sottor Falle 23, D-22529 Hamburg, Germany.							JOZSA L, 1989, MATRIX, V9, P140, DOI 10.1016/S0934-8832(89)80032-0; KANNUS P, 1991, J BONE JOINT SURG AM, V73A, P1507, DOI 10.2106/00004623-199173100-00009; MOHR W, 1988, PATHOLOGIE BANDAPPAR; Petersen W, 1999, UNFALLCHIRURG, V102, P543, DOI 10.1007/s001130050448	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1236	1236		10.1016/S0140-6736(00)02788-4	http://dx.doi.org/10.1016/S0140-6736(00)02788-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072944				2022-12-28	WOS:000089724900015
J	Frankel, D				Frankel, D			Adverse drug reactions	LANCET			English	Editorial Material									The Lancet, New York, NY 10010 USA		Frankel, D (corresponding author), The Lancet, New York, NY 10010 USA.								0	0	0	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1212	1212		10.1016/S0140-6736(00)02781-1	http://dx.doi.org/10.1016/S0140-6736(00)02781-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072936				2022-12-28	WOS:000089724900007
J	Stewart, PM				Stewart, PM			Dexamethasone-suppressible hypertension	LANCET			English	Editorial Material							APPARENT MINERALOCORTICOID EXCESS; GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; GENE; PHENOTYPE		Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							AGARWAL AK, IN PRESS HYPERTENSIO; Davies E, 1999, HYPERTENSION, V33, P703, DOI 10.1161/01.HYP.33.2.703; DLUHY RG, 1995, STEROIDS, V60, P48, DOI 10.1016/0039-128X(94)00010-A; Funder JW, 2000, J CLIN ENDOCR METAB, V85, P2158, DOI 10.1210/jc.85.6.2158; Geller DS, 2000, SCIENCE, V289, P119, DOI 10.1126/science.289.5476.119; HAMILTON BP, 1979, J CLIN ENDOCR METAB, V48, P848, DOI 10.1210/jcem-48-5-848; JAMIESON A, 1995, CLIN SCI, V88, P563, DOI 10.1042/cs0880563; Li A, 1998, AM J HUM GENET, V63, P370, DOI 10.1086/301955; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Litchfield WR, 1998, HYPERTENSION, V31, P445, DOI 10.1161/01.HYP.31.1.445; Nunez BS, 1999, HYPERTENSION, V34, P638, DOI 10.1161/01.HYP.34.4.638; RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; Stowasser M, 2000, J CLIN ENDOCR METAB, V85, P2160, DOI 10.1210/jc.85.6.2160; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135	15	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					697	699		10.1016/S0140-6736(00)02624-6	http://dx.doi.org/10.1016/S0140-6736(00)02624-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085685				2022-12-28	WOS:000088948200005
J	Odom, TW; Huang, JL; Cheung, CL; Lieber, CM				Odom, TW; Huang, JL; Cheung, CL; Lieber, CM			Magnetic clusters on single-walled carbon nanotubes: The Kondo effect in a one-dimensional host	SCIENCE			English	Article							ELECTRONIC-PROPERTIES; STATES; SPECTROSCOPY	Single-walled carbon nanotubes are ideal systems for investigating fundamental properties and applications of one-dimensional electronic systems. The interaction of magnetic impurities with electrons confined in one dimension has been studied by spatially resolving the local electronic density of states of small cobalt clusters on metallic single-walled nanotubes with a low-temperature scanning tunneling microscope. Spectroscopic measurements performed on and near these clusters exhibit a narrow peak near the Fermi level that has been identified as a Kondo resonance. Using the scanning tunneling microscope to fabricate ultrasmall magnetic nanostructures consisting of small cobalt clusters on short nanotube pieces, spectroscopic studies of this quantum box structure exhibited features characteristic of the bulk Kondo resonance, but also new features due to finite size.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	cml@cmliris.harvard.edu	Chu, Yung-Ming/C-6318-2009; Cheung, Chin Li/B-8270-2013	Cheung, Chin Li/0000-0001-8210-2833; Odom, Teri/0000-0002-8490-292X				ANDERSON PW, 1961, PHYS REV, V124, P41, DOI 10.1103/PhysRev.124.41; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Duffy DM, 1998, PHYS REV B, V58, P7443, DOI 10.1103/PhysRevB.58.7443; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Grigorian L, 1999, PHYS REV B, V60, pR11309, DOI 10.1103/PhysRevB.60.R11309; Gueron S, 1999, PHYS REV LETT, V83, P4148, DOI 10.1103/PhysRevLett.83.4148; Gurevich L, 2000, APPL PHYS LETT, V76, P384, DOI 10.1063/1.125761; Hewson A C, 1993, KONDO PROBLEM HEAVY; Kim P, 1999, PHYS REV LETT, V82, P1225, DOI 10.1103/PhysRevLett.82.1225; KONDO J, 1964, PROG THEOR PHYS, V32, P37, DOI 10.1143/PTP.32.37; Li JT, 1998, PHYS REV LETT, V80, P2893, DOI 10.1103/PhysRevLett.80.2893; Madhavan V, 1998, SCIENCE, V280, P567, DOI 10.1126/science.280.5363.567; Manoharan HC, 2000, NATURE, V403, P512, DOI 10.1038/35000508; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; Odom TW, 1998, NATURE, V391, P62, DOI 10.1038/34145; Odom TW, 2000, J PHYS CHEM B, V104, P2794, DOI 10.1021/jp993592k; Saito R., 1998, PHYS PROPERTIES CARB; Schiller A, 2000, PHYS REV B, V61, P9036, DOI 10.1103/PhysRevB.61.9036; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Venema LC, 1999, SCIENCE, V283, P52, DOI 10.1126/science.283.5398.52; Wildoer JWG, 1998, NATURE, V391, P59, DOI 10.1038/34139; WOLFGANG B, 1999, PHYS REV LETT, V82, P2143; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241	26	111	123	0	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1549	1552		10.1126/science.290.5496.1549	http://dx.doi.org/10.1126/science.290.5496.1549			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090347	Green Published			2022-12-28	WOS:000165446200042
J	Verveer, PJ; Wouters, FS; Reynolds, AR; Bastiaens, PIH				Verveer, PJ; Wouters, FS; Reynolds, AR; Bastiaens, PIH			Quantitative imaging of lateral ErbB1 receptor signal propagation in the plasma membrane	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; SPATIAL-RESOLUTION; DIMERIZATION; ACTIVATION; PHOSPHORYLATION; CELLS; TRANSDUCTION; AGGREGATION; MICROSCOPY	Evidence for a new signaling mechanism consisting of ligand-independent lateral propagation of receptor activation in the plasma membrane is presented. We visualized the phosphorylation of green fluorescent protein (GFP)-tagged ErbB1 (ErbB1-GFP) receptors in cells focally stimulated with epidermal growth factor (EGF) covalently attached to beads. This was achieved by quantitative imaging of protein reaction states in cells by fluorescence resonance energy transfer (FRET) with global analysis of fluorescence lifetime imaging microscopy (FLIM) data. The rapid and extensive propagation of receptor phosphorylation over the entire cell after focal stimulation demonstrates a signaling wave at the plasma membrane resulting in full activation of all receptors.	European Mol Biol Lab, Cell Biol & Cell Biophys Program, D-69117 Heidelberg, Germany; Imperial Canc Res Fund, Cell Biophys Lab, London WC2A 3PX, England	European Molecular Biology Laboratory (EMBL); Cancer Research UK	Verveer, PJ (corresponding author), European Mol Biol Lab, Cell Biol & Cell Biophys Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.							Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; COCHET C, 1988, J BIOL CHEM, V263, P3290; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LAKOWICZ JR, 1991, REV SCI INSTRUM, V62, P1727, DOI 10.1063/1.1142413; Marques MM, 1999, EXP CELL RES, V252, P432, DOI 10.1006/excr.1999.4634; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Nagai Y, 2000, NAT BIOTECHNOL, V18, P313, DOI 10.1038/73767; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; PAWSON T, 1988, ONCOGENE, V3, P491; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SOUMPASIS DM, 1983, BIOPHYS J, V41, P95, DOI 10.1016/S0006-3495(83)84410-5; Squire A, 1999, J MICROSC-OXFORD, V193, P36, DOI 10.1046/j.1365-2818.1999.00427.x; Verveer PJ, 2000, BIOPHYS J, V78, P2127, DOI 10.1016/S0006-3495(00)76759-2; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Wouters FS, 1999, CURR BIOL, V9, P1127, DOI 10.1016/S0960-9822(99)80484-9; WOUTERS FS, 2000, CURRENT PROTOCOLS CE, V17; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	30	284	298	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1567	1570		10.1126/science.290.5496.1567	http://dx.doi.org/10.1126/science.290.5496.1567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090353				2022-12-28	WOS:000165446200048
J	Bombardier, C; Laine, L; Reicin, A; Shapiro, D; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Schnitzer, TJ; Weaver, A				Bombardier, C; Laine, L; Reicin, A; Shapiro, D; Burgos-Vargas, R; Davis, B; Day, R; Ferraz, MB; Hawkey, CJ; Hochberg, MC; Kvien, TK; Schnitzer, TJ; Weaver, A		VIGOR Study Grp	Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; DOUBLE-BLIND; CONTROLLED TRIAL; CYCLOOXYGENASE; OSTEOARTHRITIS; COMPLICATIONS; INHIBITION; CELECOXIB	Background: Each year, clinical upper gastrointestinal events occur in 2 to 4 percent of patients who are taking nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We assessed whether rofecoxib, a selective inhibitor of cyclooxygenase-2, would be associated with a lower incidence of clinically important upper gastrointestinal events than is the nonselective NSAID naproxen among patients with rheumatoid arthritis. Methods: We randomly assigned 8076 patients who were at least 50 years of age (or at least 40 years of age and receiving long-term glucocorticoid therapy) and who had rheumatoid arthritis to receive either 50 mg of rofecoxib daily or 500 mg of naproxen twice daily. The primary end point was confirmed clinical upper gastrointestinal events (gastroduodenal perforation or obstruction, upper gastrointestinal bleeding, and symptomatic gastroduodenal ulcers). Results: Rofecoxib and naproxen had similar efficacy against rheumatoid arthritis. During a median follow-up of 9.0 months, 2.1 confirmed gastrointestinal events per 100 patient-years occurred with rofecoxib, as compared with 4.5 per 100 patient-years with naproxen (relative risk, 0.5; 95 percent confidence interval, 0.3 to 0.6; P<0.001). The respective rates of complicated confirmed events (perforation, obstruction, and severe upper gastrointestinal bleeding) were 0.6 per 100 patient-years and 1.4 per 100 patient-years (relative risk, 0.4; 95 percent confidence interval, 0.2 to 0.8; P=0.005). The incidence of myocardial infarction was lower among patients in the naproxen group than among those in the rofecoxib group (0.1 percent vs. 0.4 percent; relative risk, 0.2; 95 percent confidence interval, 0.1 to 0.7); the overall mortality rate and the rate of death from cardiovascular causes were similar in the two groups. Conclusions: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor. (N Engl J Med 2000;343:1520-8.) (C) 2000, Massachusetts Medical Society.	Mt Sinai Hosp, Inst Work & Hlth, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Toronto, ON, Canada; Univ So Calif, Sch Med, Dept Med, Gastrointestinal Div, Los Angeles, CA 90033 USA; Univ Nacl Autonoma Mexico, Fac Med, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Div Res, Mexico City 04510, DF, Mexico; Merck & Co Inc, Rahway, NJ 07065 USA; Hosp Gen Mexico City, Mexico City, DF, Mexico; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ New S Wales, Dept Clin Pharmacol, Sydney, NSW, Australia; St Vincents Hosp, Sydney, NSW 2010, Australia; Univ Fed Sao Paulo, Escola Paulista Med, Dept Med, Div Rheumatol, Sao Paulo, Brazil; Univ Nottingham Hosp, Sch Med & Surg Sci, Div Gastroenterol, Nottingham NG7 2UH, England; Univ Maryland, Div Clin Immunol & Rheumatol, Baltimore, MD 21201 USA; Oslo City Dept Rheumatol, Oslo, Norway; Diakonhjemmet Hosp, Oslo, Norway; Northwestern Univ, Sch Med, Off Clin Res & Training, Chicago, IL USA	Institute for Work & Health; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Southern California; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Merck & Company; Hospital General de Mexico; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of New South Wales Sydney; St Vincents Hospital Sydney; Universidade Federal de Sao Paulo (UNIFESP); University of Nottingham; University System of Maryland; University of Maryland Baltimore; Diakonhjemmet Hospital; Northwestern University	Bombardier, C (corresponding author), Inst Work & Hlth, 250 Bloor St E,Suite 702, Toronto, ON M4W 1E6, Canada.	claire.bombardier@utoronto.ca	Burgos-Vargas, Ruben/AAZ-1295-2020; emery, paul/B-3560-2013; Day, Richard/D-8699-2011	Burgos-Vargas, Ruben/0000-0003-1058-8955; Day, Richard/0000-0002-6045-6937				[Anonymous], 1990, DRUG THER B, V28, P25; BROCHIER ML, 1993, EUR HEART J, V14, P951, DOI 10.1093/eurheartj/14.7.951; Cannon GW, 2000, ARTHRITIS RHEUM-US, V43, P978, DOI 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0; COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.2307/2335362; COX DR, 1972, J R STAT SOC B, V34, P187; CRYER B, 1998, SLEISENGER FORDTRANS, P343; Daniels B, 1999, ARTHRITIS RHEUM, V42, pS143; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Ehrich EW, 1999, J RHEUMATOL, V26, P2438; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67; Hawkey C, 2000, ARTHRITIS RHEUM-US, V43, P370, DOI 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D; Laine L, 1999, GASTROENTEROLOGY, V117, P776, DOI 10.1016/S0016-5085(99)70334-3; Laine L, 1996, Gastrointest Endosc Clin N Am, V6, P489; Langman MJ, 1999, JAMA-J AM MED ASSOC, V282, P1929, DOI 10.1001/jama.282.20.1929; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; Schnitzer TJ, 1999, CLIN THER, V21, P1688, DOI 10.1016/S0149-2918(99)80048-4; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Singh G, 1998, J RHEUMATOL, V25, P8; Singh G, 1996, ARCH INTERN MED, V156, P1530, DOI 10.1001/archinte.156.14.1530; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; Wolfe MM, 1999, NEW ENGL J MED, V341, P548	27	2943	3052	3	197	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1520	1528		10.1056/NEJM200011233432103	http://dx.doi.org/10.1056/NEJM200011233432103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087881				2022-12-28	WOS:000165410900003
J	Deinum, J; Derkx, FHM				Deinum, J; Derkx, FHM			Cystatin for estimation of glomerular filtration rate?	LANCET			English	Editorial Material							SERUM CREATININE; RENAL-FUNCTION		Univ Hosp Dijkzigt, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands; Univ Hosp Dijkzigt, Dept Pharm, NL-3015 GD Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Derkx, FHM (corresponding author), Univ Hosp Dijkzigt, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands.							COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; Keevil BG, 1998, CLIN CHEM, V44, P1535; PERRONE RD, 1992, CLIN CHEM, V38, P1933; Randers E, 1999, CLIN CHEM LAB MED, V37, P389, DOI 10.1515/CCLM.1999.064; SIMONSEN O, 1985, SCAND J CLIN LAB INV, V45, P97, DOI 10.3109/00365518509160980; ZIETSE R, 1995, CLIN NEPHROL, V43, P29	7	41	46	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1624	1625		10.1016/S0140-6736(00)03152-4	http://dx.doi.org/10.1016/S0140-6736(00)03152-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089817				2022-12-28	WOS:000165249200006
J	Caspersen, JP; Pacala, SW; Jenkins, JC; Hurtt, GC; Moorcroft, PR; Birdsey, RA				Caspersen, JP; Pacala, SW; Jenkins, JC; Hurtt, GC; Moorcroft, PR; Birdsey, RA			Contributions of land-use history to carbon accumulation in US forests	SCIENCE			English	Article								Carbon accumulation in forests has been attributed to historical changes in Land use and the enhancement of tree growth by CO2 fertilization, N deposition, and climate change. The relative contribution of land use and growth enhancement is estimated by using inventory data from five states spanning a latitudinal gradient in the eastern United States, Land use is the dominant factor governing the rate of carbon accumulation in these states, with growth enhancement contributing far Less than previously reported. The estimated fraction of aboveground net ecosystem production due to growth enhancement is 2.0 +/- 4.4%, with the remainder due to Land use.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08540 USA; US Forest Serv, NE Res Stn, USDA, Burlington, VT 05402 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Complex Syst Res Ctr, Durham, NH 03824 USA; US Forest Serv, NE Res Stn, USDA, Newtown Sq, PA 19073 USA	Princeton University; United States Department of Agriculture (USDA); United States Forest Service; University System Of New Hampshire; University of New Hampshire; United States Department of Agriculture (USDA); United States Forest Service	Caspersen, JP (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08540 USA.	jpc@eno.princeton.edu	Hurtt, George/A-8450-2012; Gutierrez, Emilia/O-7568-2014	Hurtt, George/0000-0001-7278-202X; Gutierrez, Emilia/0000-0002-6085-5700				BIRDSEY RA, 1992, RM214 USDA FERS SERV; BIRDSEY RA, 1995, PRODUCTIVITY AM FORE, P56; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; HANSEN MH, 1992, NC151 USDA FOR SERV; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Mooney H.A., 1999, TERRESTRIAL BIOSPHER, P141; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Spiecker H., 1996, GROWTH TRENDS EUROPE; Steffen W, 1998, SCIENCE, V280, P1393	9	386	434	4	120	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1148	1151		10.1126/science.290.5494.1148	http://dx.doi.org/10.1126/science.290.5494.1148			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073451				2022-12-28	WOS:000165228200044
J	Scully, KM; Jacobson, EM; Jepsen, K; Lunyak, V; Viadiu, H; Carriere, C; Rose, DW; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG				Scully, KM; Jacobson, EM; Jepsen, K; Lunyak, V; Viadiu, H; Carriere, C; Rose, DW; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG			Allosteric effects of Pit-1 DNA sites on long-term repression in cell type specification	SCIENCE			English	Article							GROWTH-HORMONE GENE; LOCUS-CONTROL REGION; CRYSTAL-STRUCTURE; TRANSGENIC MICE; PROMOTER ACTIVITY; THYROID-HORMONE; CO-REPRESSOR; OCA-B; BINDING; DOMAIN	Reciprocal gene activation and restriction during cell type differentiation from a common Lineage is a hallmark of mammalian organogenesis. A key question, then, is whether a critical transcriptional activator of cell type-specific gene targets can also restrict expression of the same genes in other cell types. Here, we show that whereas the pituitary-specific POU domain factor Pit-1 activates growth hormone gene expression in one cell type, the somatotrope, it restricts its expression from a second cell type, the lactotrope. This distinction depends on a two-base pair spacing in accommodation of the bipartite POU domains on a conserved growth hormone promoter site. The allosteric effect on Pit-1, in combination with other DNA binding factors, results in the recruitment of a corepressor complex. including nuclear receptor corepressor N-CoR, which, unexpectedly, is required for active Long-term repression of the growth hormone gene in lactotropes.	Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Transgen Res Unit, La Jolla, CA 92093 USA	Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Aggarwal, AK (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA.	aggarwal@inka.mssm.edu; mrosenfeld@ucsd.edu	Viadiu, Hector/E-7785-2013; lunyak, victoria/R-3765-2017	lunyak, victoria/0000-0001-9093-2714	NIDDK NIH HHS [R01 DK54802, R01 DK18477] Funding Source: Medline; NIGMS NIH HHS [R01 GM49327] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054802, R01DK018477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049327] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Chasman D, 1999, GENE DEV, V13, P2650, DOI 10.1101/gad.13.20.2650; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; Dasen JS, 1999, CURR OPIN GENET DEV, V9, P566, DOI 10.1016/S0959-437X(99)00015-5; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Glass CK, 2000, GENE DEV, V14, P121; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Jin Y, 1999, MOL ENDOCRINOL, V13, P1249, DOI 10.1210/me.13.8.1249; JONES BK, 1995, MOL CELL BIOL, V15, P7010; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; LIRA SA, 1988, P NATL ACAD SCI USA, V85, P4755, DOI 10.1073/pnas.85.13.4755; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; LUO Y, 1995, MOL CELL BIOL, V15, P4115; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCULLY KM, UNPUB; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	33	208	210	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1127	1131		10.1126/science.290.5494.1127	http://dx.doi.org/10.1126/science.290.5494.1127			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073444				2022-12-28	WOS:000165228200037
J	Maron, BJ				Maron, BJ			The paradox of exercise	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; TIME PHYSICAL-ACTIVITY; PRIMARY CARDIAC-ARREST; VIGOROUS EXERCISE; DEATH; PREVENTION; RISK; ASSOCIATION; EXERTION		Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA	Minneapolis Heart Institute Foundation	Maron, BJ (corresponding author), Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA.							Albert CM, 2000, NEW ENGL J MED, V343, P1355, DOI 10.1056/NEJM200011093431902; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Jouven X, 2000, NEW ENGL J MED, V343, P826, DOI 10.1056/NEJM200009213431201; Lemaitre RN, 1999, ARCH INTERN MED, V159, P686, DOI 10.1001/archinte.159.7.686; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, 1994, MED SCI SPORTS EXERC, V26; MARON BJ, IN PRESS CIRCULATION; Maron BJ, 1994, J AM COLL CARDIOL, V24, P845; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; WANNAMETHEE G, 1995, CIRCULATION, V91, P1749, DOI 10.1161/01.CIR.91.6.1749; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302	18	100	104	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1409	1411		10.1056/NEJM200011093431911	http://dx.doi.org/10.1056/NEJM200011093431911			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070108				2022-12-28	WOS:000165152800011
J	Girou, E; Schortgen, F; Delclaux, C; Brun-Buisson, C; Blot, F; Lefort, Y; Lemaire, F; Brochard, L				Girou, E; Schortgen, F; Delclaux, C; Brun-Buisson, C; Blot, F; Lefort, Y; Lemaire, F; Brochard, L			Association of noninvasive ventilation with nosocomial infections and survival in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	International Conference of the American-Thoracic-Society	APR 23-28, 1999	SAN DIEGO, CALIFORNIA	Amer Thoracic Soc			ACUTE RESPIRATORY-FAILURE; POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE PULMONARY-DISEASE; INTENSIVE-CARE UNIT; MECHANICAL VENTILATION; FACE MASK; AIRWAY PRESSURE; ATTRIBUTABLE MORTALITY; SUPPORT VENTILATION; ACUTE EXACERBATIONS	Context Invasive life-support techniques are a major risk factor for nosocomial infection. Noninvasive ventilation (NIV) can be used to avoid endotracheal intubation and may reduce morbidity among patients in intensive care units (ICUs). Objective To determine whether the use of NIV is associated with decreased risk of nosocomial infections and improved survival in everyday clinical practice among patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) or hypercapnic cardiogenic pulmonary edema (CPE). Design and setting Matched case-control study conducted in the medical ICU of a French university hospital from January 1996 through March 1998, Patients fifty patients with acute exacerbation of COPD or severe CPE who were treated with NIV for at least 2 hours and 50 patients treated with mechanical ventilation between 1993 and 1998 (controls), matched on diagnosis, Simplified Acute Physiology Score II, Logistic Organ Dysfunction score, age, and no contraindication to NIV. Main Outcome Measures Rates of nosocomial infections, antibiotic use, lengths of ventilatory support and of ICU stay, ICU mortality, compared between cases and controls, Results Rates of nosocomial infections and of nosocomial pneumonia were significantly lower in patients who received NIV than those treated with mechanical ventilation (18% vs 60% and 8% vs 22%; P<.001 and P=.04, respectively). Similarly, the daily risk of acquiring an infection (19 vs 39 episodes per 1000 patient-days; P=.05), proportion of patients receiving antibiotics for nosocomial infection (8% vs 26%, P=.01), mean (SD) duration of ventilation (6 [6] vs 10 [12] days; P=.01), mean (SD) length of ICU stay (9 [7] vs 15 [14] days; P=.02), and crude mortality (4% vs 26%; P=.002) were all lower among patients who received NIV than those treated with mechanical ventilation, Conclusions Use of NIV instead of mechanical ventilation is associated with a lower risk of nosocomial infections, less antibiotic use, shorter length of ICU stay, and lower mortality.	Assistance Publ Hop Paris, Hop Henri Mondor, Unite Hyg & Prevent Infect, F-94010 Creteil, France; Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, F-94010 Creteil, France; Assistance Publ Hop Paris, Hop Henri Mondor, INSERM, U492, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Girou, E (corresponding author), Assistance Publ Hop Paris, Hop Henri Mondor, Unite Hyg & Prevent Infect, F-94010 Creteil, France.			Schortgen, Frederique/0000-0003-1756-7508				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; Antonelli M, 2000, JAMA-J AM MED ASSOC, V283, P235, DOI 10.1001/jama.283.2.235; Barbe F, 1996, EUR RESPIR J, V9, P1240, DOI 10.1183/09031936.96.09061240; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRUNBUISSON C, 1987, ARCH INTERN MED, V147, P873, DOI 10.1001/archinte.147.5.873; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; Confalonieri M., 1998, European Respiratory Journal, V12, p128S; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Girou E, 1998, AM J RESP CRIT CARE, V157, P1151, DOI 10.1164/ajrccm.157.4.9701129; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; Guerin C, 1998, INTENS CARE MED, V24, P27, DOI 10.1007/s001340050510; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; Kollef MH, 1999, NEW ENGL J MED, V340, P627, DOI 10.1056/NEJM199902253400807; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; MAKI DG, 1989, ARCH INTERN MED, V149, P30, DOI 10.1001/archinte.149.1.30; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; Nava S, 1997, CHEST, V111, P1631, DOI 10.1378/chest.111.6.1631; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Nourdine K, 1999, INTENS CARE MED, V25, P567, DOI 10.1007/s001340050904; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Rusterholtz T, 1999, INTENS CARE MED, V25, P21, DOI 10.1007/s001340050782; Sznajder M, 1998, INTENS CARE MED, V24, P582, DOI 10.1007/s001340050619; TEASDALE G, 1974, LANCET, V2, P81; Wood KA, 1998, CHEST, V113, P1339, DOI 10.1378/chest.113.5.1339; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	37	267	288	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2361	2367		10.1001/jama.284.18.2361	http://dx.doi.org/10.1001/jama.284.18.2361			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066187	Bronze			2022-12-28	WOS:000165074500031
J	Schenk, P; Madl, C; Rezaie-Majd, S; Lehr, S; Muller, C				Schenk, P; Madl, C; Rezaie-Majd, S; Lehr, S; Muller, C			Methylene blue improves the hepatopulmonary syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							NITRIC-OXIDE SYNTHESIS; HYPERDYNAMIC CIRCULATION; SEPTIC SHOCK; EXHALED AIR; CIRRHOSIS; INHIBITION; RATS	Background: The hypoxemia of the hepatopulmonary syndrome, seen in patients with severe chronic liver dysfunction, results from widespread pulmonary vasodilation. No established drug therapy is available for this condition. Objective: To study the effect of methylene blue, a potent inhibitor of guanylate cyclase, in patients with severe hepatopulmonary syndrome, Design: Open, uncontrolled trial, Setting: Medical intensive care unit at the university hospital in Vienna, Austria. Patients: 7 patients with advanced cirrhosis and severe hepatopulmonary syndrome with Pao(2) of 60 mm Hg br less, Intervention: Insertion of a pulmonary artery catheter and an arterial indwelling catheter; intravenous administration of methylene blue, 3 mg/kg of body weight, over a 15-minute period. Measurements: Serial measurements of gas exchange and hemodynamic variables, Results: After methylene blue administration, Pao(2) increased in all patients (from a baseline mean +/- SD of 58 +/- 2.5 mm Hg to 74 +/- 11.5 mm Hg 5 hours after infusion; P = 0.006) and the alveolar-arterial difference for partial pressure of oxygen (PAO(2)-Pao(2)) decreased in all patients, with a maximum effect achieved after 5 hours (from 49 +/- 3.3 mm Hg to 30 +/- 10.4 mm Hg; P = 0.003); even after 10 hours, PAO(2)-Pao(2) was still significantly reduced compared with baseline (P = 0.041), Oxygenation improved because of reduction in shunt fraction (from 41% +/- 3.1% to 25% +/- 4.5%; P < 0.001). Mean pulmonary artery pressure increased (from 20 <plus/minus> 5.2 mm Hg to 23 +/- 3.6 mm Hg; P = 0.028), as did pulmonary vascular resistance (from 58 +/- 23 dyne/sec.cm(-5) to 115 +/- 56 dyne/sec.cm(-5); P = 0.012), Arterial blood pressure did not change significantly. Cardiac output decreased (from 10.6 +/- 2.2 L/min to 8.6 +/- 2.7 L/min; P = 0.008) and systemic vascular resistance increased (from 527 +/- 144 dyne/sec.cm(-5) to 729 +/- 222 dyne/sec.cm(-5); P = 0.037), Heart rate, central venous pressure, and pulmonary capillary wedge pressure remained unchanged. Conclusion: Intravenous methylene blue improved hypoxemia and hyperdynamic circulation in patients with liver cirrhosis and severe hepatopulmonary syndrome.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Schenk, P (corresponding author), Univ Vienna, Allgemeines Krankenhaus Wien, Dept Internal Med 4, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	peter.schenk@akh-wien.ac.at						CALVER A, 1994, CLIN SCI, V86, P203, DOI 10.1042/cs0860203; CAMPILLO B, 1995, HEPATOLOGY, V22, P1423, DOI 10.1016/0270-9139(95)90147-7; Castro M, 1996, CLIN CHEST MED, V17, P35, DOI 10.1016/S0272-5231(05)70297-5; CREMONA G, 1995, EUR RESPIR J, V8, P1883, DOI 10.1183/09031936.95.08111883; Gachot B, 1995, INTENS CARE MED, V21, P1027, DOI 10.1007/BF01700666; Hori N, 1996, CLIN EXP PHARMACOL P, V23, P30; KROWKA MJ, 1994, CHEST, V105, P1528, DOI 10.1378/chest.105.5.1528; MARCZIN N, 1992, J PHARMACOL EXP THER, V263, P170; MATSUMOTO A, 1995, ANN INTERN MED, V123, P110, DOI 10.7326/0003-4819-123-2-199507150-00005; NIEDERBERGER M, 1995, GASTROENTEROLOGY, V109, P1624, DOI 10.1016/0016-5085(95)90652-5; Pilette C, 1996, J GASTROEN HEPATOL, V11, P1, DOI 10.1111/j.1440-1746.1996.tb00002.x; PREISER JC, 1995, CRIT CARE MED, V23, P259, DOI 10.1097/00003246-199502000-00010; RODRIGUEZROISIN R, 1992, THORAX, V47, P897, DOI 10.1136/thx.47.11.897; ROLLA G, 1994, NEW ENGL J MED, V331, P1098, DOI 10.1056/NEJM199410203311617; Rolla G, 1997, HEPATOLOGY, V26, P842, DOI 10.1002/hep.510260406; SOGNI P, 1995, J HEPATOL, V23, P471, DOI 10.1016/0168-8278(95)80207-X; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; West JB, 1977, BIOENGINEERING ASPEC, P361; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; ZHANG HB, 1995, CRIT CARE MED, V23, P1711, DOI 10.1097/00003246-199510000-00016	20	145	157	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					701	706		10.7326/0003-4819-133-9-200011070-00012	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074903				2022-12-28	WOS:000165075300005
J	Shen, Y; Naujokas, K; Park, M; Ireton, K				Shen, Y; Naujokas, K; Park, M; Ireton, K			InlB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; EPITHELIAL MORPHOGENESIS; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; MAMMALIAN-CELLS; SURFACE PROTEIN; L-MONOCYTOGENES; NK1 FRAGMENT; ENTRY	The Listeria monocytogenes surface protein InlB promotes bacterial entry into mammalian cells. Here, we identify a cellular surface receptor required for InlB-mediated entry. Treatment of mammalian cells with InlB protein or infection with L. monocytogenes induces rapid tyrosine phosphorylation of Met, a receptor tyrosine kinase (RTK) for which the only known ligand is Hepatocyte Growth Factor (HGF). Like HGF, InlB binds to the extracellular domain of Met and induces "scattering" of epithelial cells. Experiments with Met-positive and Met-deficient cell lines demonstrate that Met is required for InlB-dependent entry of L. monocytogenes. InlB is a novel Met agonist that induces bacterial entry through exploitation of a host RTK pathway.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Mol Oncol Grp, Royal Victoria Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada	University of Toronto; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Ireton, K (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 100 Coll St, Toronto, ON M5S 1A8, Canada.							Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Braun L, 1999, MOL MICROBIOL, V34, P10, DOI 10.1046/j.1365-2958.1999.01560.x; Braun L, 1997, MOL MICROBIOL, V25, P285, DOI 10.1046/j.1365-2958.1997.4621825.x; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Cossart P, 1998, EMBO J, V17, P3797, DOI 10.1093/emboj/17.14.3797; DRAMSI S, 1995, MOL MICROBIOL, V16, P251, DOI 10.1111/j.1365-2958.1995.tb02297.x; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; Greiffenberg L, 1998, INFECT IMMUN, V66, P5260, DOI 10.1128/IAI.66.11.5260-5267.1998; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Ireton K, 1999, J BIOL CHEM, V274, P17025, DOI 10.1074/jbc.274.24.17025; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; Kilby MD, 1996, GROWTH FACTORS, V13, P133, DOI 10.3109/08977199609034573; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; MARK MR, 1992, J BIOL CHEM, V267, P26166; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; NGUYEN LM, 1997, J BIOL CHEM, V27, P20811; Parida SK, 1998, MOL MICROBIOL, V28, P81, DOI 10.1046/j.1365-2958.1998.00776.x; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; Virji M, 1996, MICROBIOL-SGM, V142, P3319, DOI 10.1099/13500872-142-12-3319; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHU H, 1994, CELL GROWTH DIFFER, V5, P359	32	388	414	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					501	510		10.1016/S0092-8674(00)00141-0	http://dx.doi.org/10.1016/S0092-8674(00)00141-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081636	Bronze			2022-12-28	WOS:000090144100015
J	Weetman, AP				Weetman, AP			Medical progress: Graves' disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							AUTOIMMUNE THYROID-DISEASE; QUALITY-OF-LIFE; THYROTROPIN RECEPTOR; ANTITHYROID DRUGS; CIGARETTE-SMOKING; RADIOIODINE TREATMENT; ANTIGEN PRESENTATION; HUMAN AUTOANTIBODIES; MONOCLONAL-ANTIBODY; LINKAGE ANALYSIS		Univ Sheffield, No Gen Hosp, Div Clin Sci, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Weetman, AP (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England.							Adams D., 1956, P U OTAGO MED SCH, V34, P11; Aizawa Y, 1997, CLIN ENDOCRINOL, V46, P1, DOI 10.1046/j.1365-2265.1997.d01-1737.x; BAHN RS, 1993, NEW ENGL J MED, V329, P1468; Bahn RS, 1998, J CLIN ENDOCR METAB, V83, P998, DOI 10.1210/jc.83.3.998; Barbesino G, 1998, J CLIN ENDOCR METAB, V83, P3290, DOI 10.1210/jc.83.9.3290; BARCLAY ML, 1994, CLIN ENDOCRINOL, V40, P759, DOI 10.1111/j.1365-2265.1994.tb02509.x; Bartalena L, 1998, ANN INTERN MED, V129, P632, DOI 10.7326/0003-4819-129-8-199810150-00010; BARTALENA L, 1995, EUR J ENDOCRINOL, V133, P507, DOI 10.1530/eje.0.1330507; Bartalena L, 1997, BAILLIERE CLIN ENDOC, V11, P521, DOI 10.1016/S0950-351X(97)80738-0; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BOTTAZZO GF, 1983, LANCET, V2, P1115; Brix TH, 1998, THYROID, V8, P627, DOI 10.1089/thy.1998.8.627; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; Carnell NE, 1998, THYROID, V8, P647, DOI 10.1089/thy.1998.8.647; Carnell NE, 1998, THYROID, V8, P1079; Chazenbalk GD, 1999, J CLIN ENDOCR METAB, V84, P702, DOI 10.1210/jc.84.2.702; Chen QY, 1999, J CLIN ENDOCR METAB, V84, P3182, DOI 10.1210/jc.84.9.3182; Chiovato L, 1996, EUR J ENDOCRINOL, V134, P680, DOI 10.1530/eje.0.1340680; Chiovato L, 1998, J CLIN ENDOCR METAB, V83, P2155; Chiovato L, 1998, J CLIN ENDOCR METAB, V83, P40, DOI 10.1210/jc.83.1.40; Chou FF, 1999, THYROID, V9, P253, DOI 10.1089/thy.1999.9.253; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Costagliola S, 1999, J CLIN ENDOCR METAB, V84, P90, DOI 10.1210/jc.84.1.90; Davies TF, 1998, J CLIN ENDOCR METAB, V83, P3777, DOI 10.1210/jc.83.11.3777; DiPaola R, 1997, J CLIN ENDOCR METAB, V82, P670, DOI 10.1210/jc.82.2.670; FARRAR JJ, 1991, CLIN ENDOCRINOL, V35, P207, DOI 10.1111/j.1365-2265.1991.tb03523.x; FATOURECHI V, 1994, MEDICINE, V73, P1; FRANKLYN JA, 1994, NEW ENGL J MED, V331, P559; Franklyn JA, 1999, LANCET, V353, P2111, DOI 10.1016/S0140-6736(98)12295-X; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; Fukata S, 1999, THYROID, V9, P29, DOI 10.1089/thy.1999.9.29; GARRITY JA, 1993, AM J OPHTHALMOL, V116, P533, DOI 10.1016/S0002-9394(14)73194-0; Gerding MN, 1997, THYROID, V7, P885, DOI 10.1089/thy.1997.7.885; Gilquin J, 1998, LANCET, V352, P1907, DOI 10.1016/S0140-6736(05)60398-4; Gunji K, 1998, THYROID, V8, P1079; HALL P, 1993, ACTA ENDOCRINOL-COP, V128, P230, DOI 10.1530/acta.0.1280230; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; HEUFELDER AE, 1995, EUR J ENDOCRINOL, V132, P532, DOI 10.1530/eje.0.1320532; Heward JM, 1998, J CLIN ENDOCR METAB, V83, P3394, DOI 10.1210/jc.83.10.3394; Imseis RE, 1998, J CLIN ENDOCR METAB, V83, P685, DOI 10.1210/jc.83.2.685; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; JARLOV AE, 1995, CLIN ENDOCRINOL, V43, P325, DOI 10.1111/j.1365-2265.1995.tb02039.x; KAUFMAN DW, 1988, BRIT MED J, V297, P262; KENDALLTAYLOR P, 1998, CLIN ENDOCRINOL, P328; KOSUGI S, 1993, J CLIN ENDOCR METAB, V77, P19, DOI 10.1210/jc.77.1.19; Krassas GE, 1999, EUR J ENDOCRINOL, V140, P373, DOI 10.1530/eje.0.1400373; KRISS JP, 1964, J CLIN ENDOCR METAB, V24, P1005, DOI 10.1210/jcem-24-10-1005; Kung AWC, 1998, J CLIN ENDOCR METAB, V83, P514, DOI 10.1210/jc.83.2.514; Laurberg P, 1998, EUR J ENDOCRINOL, V139, P584, DOI 10.1530/eje.0.1390584; Levy EG, 1997, BAILLIERE CLIN ENDOC, V11, P585, DOI 10.1016/S0950-351X(97)80798-7; LiVolsi VA, 2000, WERNER INGBARS THYRO, P488; Ljunggren JG, 1998, THYROID, V8, P653, DOI 10.1089/thy.1998.8.653; MANDEL SJ, 1994, THYROID, V4, P129, DOI 10.1089/thy.1994.4.129; Many MC, 1999, J IMMUNOL, V162, P4966; Marcocci C, 1999, CLIN ENDOCRINOL, V51, P503; Marelli-Berg FM, 1997, J IMMUNOL, V159, P5853; Martin A, 1997, J CLIN ENDOCR METAB, V82, P3361, DOI 10.1210/jc.82.10.3361; Maugendre D, 1999, CLIN ENDOCRINOL, V50, P127, DOI 10.1046/j.1365-2265.1999.00629.x; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; McLachlan SM, 1996, J CLIN ENDOCR METAB, V81, P3152, DOI 10.1210/jc.81.9.3152; Momotani N, 1997, J CLIN ENDOCR METAB, V82, P3633, DOI 10.1210/jc.82.11.3633; Mourits MP, 1997, CLIN ENDOCRINOL, V47, P632; *NAPS, 05570 NAPS; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Peacey SR, 1996, THYROID, V6, P41, DOI 10.1089/thy.1996.6.41; PERROS P, 1993, CLIN ENDOCRINOL, V38, P367, DOI 10.1111/j.1365-2265.1993.tb00516.x; PERROS P, 1995, CLIN ENDOCRINOL, V42, P45, DOI 10.1111/j.1365-2265.1995.tb02597.x; Prummel MF, 1998, THYROID, V8, P545, DOI 10.1089/thy.1998.8.545; PRUMMEL MF, 1990, ARCH INTERN MED, V150, P1098, DOI 10.1001/archinte.150.5.1098; Rapoport B, 1999, ENDOCR REV, V20, P100; Rivkees SA, 1998, J CLIN ENDOCR METAB, V83, P3767, DOI 10.1210/jc.83.11.3767; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; SINGER PA, 1995, JAMA-J AM MED ASSOC, V273, P808, DOI 10.1001/jama.273.10.808; SMALL RG, 1989, OPHTHALMOLOGY, V96, P424; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; SOLOMON B, 1990, J CLIN ENDOCR METAB, V70, P1518, DOI 10.1210/jcem-70-6-1518; TAKATA I, 1980, ACTA ENDOCRINOL-COP, V94, P46, DOI 10.1530/acta.0.0940046; TAMAI H, 1989, J CLIN ENDOCR METAB, V69, P49, DOI 10.1210/jcem-69-1-49; TELLEZ M, 1992, CLIN ENDOCRINOL, V36, P291, DOI 10.1111/j.1365-2265.1992.tb01445.x; Toft AD, 1998, CLIN ENDOCRINOL, V49, P271, DOI 10.1046/j.1365-2265.1998.00583.x; TOMER Y, 1993, ENDOCR REV, V14, P107, DOI 10.1210/er.14.1.107; Tomer Y, 1998, J CLIN ENDOCR METAB, V83, P4321, DOI 10.1210/jc.83.12.4321; Tomer Y, 1998, AM J HUM GENET, V63, P1749, DOI 10.1086/302146; UTECH CI, 1995, THYROID, V5, P185, DOI 10.1089/thy.1995.5.185; Vanderpump MPJ, 1999, CONT ENDOCRINOL, V15, P141; VILLADOLID MC, 1995, J CLIN ENDOCR METAB, V80, P2830, DOI 10.1210/jc.80.9.2830; Vitti P, 1997, THYROID, V7, P369, DOI 10.1089/thy.1997.7.369; VITTI P, 1993, J CLIN ENDOCR METAB, V76, P499, DOI 10.1210/jc.76.2.499; WEETMAN AP, 1984, CLIN EXP IMMUNOL, V56, P330; WEETMAN AP, 1994, Q J MED, V87, P337; Weetman AP, 1998, CLIN ENDOCRINOL, V49, P21, DOI 10.1046/j.1365-2265.1998.00487.x; WEETMAN AP, 1999, THYROID DIS MANAGER; Williams KV, 1997, J CLIN ENDOCR METAB, V82, P1727, DOI 10.1210/jc.82.6.1727; WING DA, 1994, AM J OBSTET GYNECOL, V170, P90; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jc.80.1.41; YOUNG RJ, 1976, J CLIN PATHOL, V29, P398, DOI 10.1136/jcp.29.5.398	98	710	764	0	89	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1236	1248		10.1056/NEJM200010263431707	http://dx.doi.org/10.1056/NEJM200010263431707			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071676				2022-12-28	WOS:000090014100007
J	Jourdan, S; Rossi, ML; Goulding, J				Jourdan, S; Rossi, ML; Goulding, J			Italy: medical negligence as a crime	LANCET			English	Article									Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England; Medicolegal Dept, Turin, Italy; Bury Metropolitan Bortough Council, Personal Serv, Bury, Lancs, England; Bury Metropolitan Bortough Council, Community Serv, Bury, Lancs, England	Walton Centre	Rossi, ML (corresponding author), Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England.							WOOLF LJ, 1999, CIVIL PROCEDURE REFO	1	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1267	1268		10.1016/S0140-6736(00)02802-6	http://dx.doi.org/10.1016/S0140-6736(00)02802-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072963				2022-12-28	WOS:000089724900044
J	Shapiro, E; Krivit, W; Lockman, L; Jambaque, I; Peters, C; Cowan, M; Harris, R; Blanche, S; Bordigoni, P; Loes, D; Ziegler, R; Crittenden, M; Ris, D; Berg, B; Cox, C; Moser, H; Fischer, A; Aubourg, P				Shapiro, E; Krivit, W; Lockman, L; Jambaque, I; Peters, C; Cowan, M; Harris, R; Blanche, S; Bordigoni, P; Loes, D; Ziegler, R; Crittenden, M; Ris, D; Berg, B; Cox, C; Moser, H; Fischer, A; Aubourg, P			Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy	LANCET			English	Article							BRAIN MR OBSERVATIONS; FATTY-ACIDS; GENE; MUTATIONS; THERAPY; PROGRESSION; PHENOTYPES; ADRENOMYELONEUROPATHY; IMMUNOSUPPRESSION; PROTEIN	Background The childhood-onset cerebral form of X-linked adrenoleukodystrophy, a demyelinating disorder of the central nervous system, leads to a vegetative state and death within 3-5 years once clinical symptoms are detectable. The hypothesis to be tested was whether bone-marrow transplantation can over an extended period of time halt the inexorable progressive demyelination and neurological deterioration. Methods 12 patients with childhood onset of cerebral X-linked adrenoleukodystrophy have been followed for 5-10 years after bone-marrow transplantation. Magnetic resonance imaging (MRI), neurological, neuropsychological, electrophysiological, and plasma very-long-chain fatty acid (VLCFA) measurements were used to evaluate the effect of this treatment. Findings MRI showed complete reversal of abnormalities in two patients and improvement in one. One patient showed no change from baseline to last follow-up. All eight patients who showed an initial period of continued demyelination stabilised and remained unchanged thereafter. Motor function remained normal or improved after bone-marrow transplantation in ten patients. Verbal intelligence remained within the normal range for 11 patients. Performance (non-verbal) abilities were improved or were stable in seven patients. Decline in performance abilities followed by stability occurred in five patients. Plasma VLCFA concentrations decreased by 55% and remained slightly above the upper limits of normal. Interpretation 5-10-year follow-up of 12 patients with childhood-onset cerebral X-linked adrenoleukodystrophy shows the long-term beneficial effect of bone marrow transplantation when the procedure is done at an early stage of the disease.	Univ Minnesota, Div Paediat Neurol, Minneapolis, MN 55455 USA; Hop St Vincent de Paul, INSERM, F-75674 Paris, France; Univ Calif San Francisco, San Francisco, CA 94143 USA; Cincinnati Childrens Hosp, Cincinnati, OH USA; Hop Brabois, Nancy, France; Johns Hopkins Hosp, Kennedy Krieger Inst, Baltimore, MD 21287 USA; Hop Necker Enfants Malad, Paris, France	University of Minnesota System; University of Minnesota Twin Cities; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; Cincinnati Children's Hospital Medical Center; CHU de Nancy; Johns Hopkins University; Johns Hopkins Medicine; Kennedy Krieger Institute; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Shapiro, E (corresponding author), Univ Minnesota, Div Paediat Neurol, Mayo Mail Code 486,420 Delaware St SE, Minneapolis, MN 55455 USA.				NINDS NIH HHS [NS29099] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029099] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUBOURG P, 1993, NEW ENGL J MED, V329, P745, DOI 10.1056/NEJM199309093291101; AUBOURG P, 1990, NEW ENGL J MED, V322, P1860, DOI 10.1056/NEJM199006283222607; AUBOURG P, 1985, J LIPID RES, V26, P263; AUBOURG P, 1997, HDB CLIN NEUROLOGY N, P447; Bezman L, 1998, AM J MED GENET, V76, P415, DOI 10.1002/(SICI)1096-8628(19980413)76:5<415::AID-AJMG9>3.0.CO;2-L; BRAUN A, 1995, AM J HUM GENET, V56, P854; Doerflinger N, 1998, HUM GENE THER, V9, P1025, DOI 10.1089/hum.1998.9.7-1025; FANEN P, 1994, J CLIN INVEST, V94, P516, DOI 10.1172/JCI117363; Feigenbaum V, 1996, AM J HUM GENET, V58, P1135; FUCHS S, 1994, HUM MOL GENET, V3, P1903, DOI 10.1093/hmg/3.10.1903; Kemp S, 1998, NAT MED, V4, P1261, DOI 10.1038/3242; KOK F, 1995, HUM MUTAT, V6, P104, DOI 10.1002/humu.1380060203; Korenke GC, 1997, J INHERIT METAB DIS, V20, P59, DOI 10.1023/A:1005361607523; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; KRIVIT W, 1996, CORRECTION CERTAIN G, P48; LIGTENBERG MJL, 1995, AM J HUM GENET, V56, P44; LOES DJ, 1994, AM J NEURORADIOL, V15, P1761; LOES DJ, 1994, AM J NEURORADIOL, V15, P1767; Moser AB, 1999, ANN NEUROL, V45, P100, DOI 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U; Moser HW, 2000, J INHERIT METAB DIS, V23, P273, DOI 10.1023/A:1005688130338; MOSER HW, 1984, NEUROLOGY, V34, P1410, DOI 10.1212/WNL.34.11.1410; Moser HW, 1997, BRAIN, V120, P1485, DOI 10.1093/brain/120.8.1485; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NAIDU S, 1988, ARCH NEUROL-CHICAGO, V45, P846, DOI 10.1001/archneur.1988.00520320032011; PETERS C, CORRECTION GENETIC D, V5; RIZZO WB, 1989, NEUROLOGY, V39, P1415, DOI 10.1212/WNL.39.11.1415; SHAPIRO EG, 1995, J INHERIT METAB DIS, V18, P413, DOI 10.1007/BF00710053; Singh I, 1998, NEW ENGL J MED, V339, P702, DOI 10.1056/NEJM199809033391012; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; STUMPF DA, 1981, ARCH NEUROL-CHICAGO, V38, P48, DOI 10.1001/archneur.1981.00510010074014; UZIEL G, 1991, DEV NEUROSCI-BASEL, V13, P274, DOI 10.1159/000112173; Wechsler D., 2014, WECHSLER PRESCHOOL P; Wechsler D., 1991, WISC 3 WECHSLER INTE	34	202	217	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					713	718		10.1016/S0140-6736(00)02629-5	http://dx.doi.org/10.1016/S0140-6736(00)02629-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085690				2022-12-28	WOS:000088948200010
J	Anand, SS; Yusuf, S; Vuksan, V; Devanesen, S; Teo, KK; Montague, PA; Kelemen, L; Yi, CL; Lonn, E; Gerstein, H; Hegele, RA; McQueen, M				Anand, SS; Yusuf, S; Vuksan, V; Devanesen, S; Teo, KK; Montague, PA; Kelemen, L; Yi, CL; Lonn, E; Gerstein, H; Hegele, RA; McQueen, M		SHARE Investigators	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)	LANCET			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; BASE-LINE CHARACTERISTICS; INTIMA-MEDIA THICKNESS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; DESIGN; PREVALENCE; MECHANISMS; RATIONALE; STROKE	Background Cardiovascular disease rates vary greatly between ethnic groups in Canada. To establish whether this variation can be explained by differences in disease risk factors and subclinical atherosclerosis, we undertook a population-based study of three ethnic groups in Canada: South Asians, Chinese, and Europeans. Methods 985 participants were recruited from three cities (Hamilton, Toronto, and Edmonton) by stratified random sampling. Clinical cardiovascular disease was defined by history or electrocardiographic findings. Carotid atherosclerosis was measured with B-mode ultrasonography. Conventional (smoking, hypertension, diabetes, raised cholesterol) and novel risk factors (markers of a prothrombotic state) were measured. Findings Within each ethnic group and overall, the degree of carotid atherosclerosis was associated with a higher prevalence of cardiovascular disease. South Asians had the highest prevalence of this condition compared with Europeans and Chinese (11%, 5%, and 2%, respectively, p=0.0004): Despite this finding, Europeans had more atherosclerosis (mean of the maximum intimal medial thickness 0.75 [0.16] mm) than South Asians (0.72 [0.15] mm), and Chinese (0.69 [0.16] mm). South Asians had an increased prevalence of glucose intolerance, higher total and LDL cholesterol, higher triglycerides, and lower HDL cholesterol, and much greater abnormalities in novel risk factors including higher concentrations of fibrinogen, homocysteine, lipoprotein (a), and plasminogen activator homocysteine, inhibitor-1. Interpretation Although there are differences in conventional and novel risk factors between ethnic groups, this variation and the degree of atherosclerosis only partly explains the higher rates of cardiovascular disease among South Asians compared with Europeans and Chinese. The increased risk of cardiovascular events could be due to factors affecting plaque rupture, the interaction between prothrombotic factors and atherosclerosis, or as yet undiscovered risk factors.	McMaster Univ, HGH McMaster Clin, Prevent Cardiol & Therapeut Res Program, Dept Med, Hamilton, ON L8L 2X2, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2M7, Canada; Univ Western Ontario, John P Robarts Res Inst, London, ON N6A 3K7, Canada	McMaster University; McMaster University; University of Toronto; University of Alberta; Western University (University of Western Ontario)	Anand, SS (corresponding author), McMaster Univ, HGH McMaster Clin, Prevent Cardiol & Therapeut Res Program, Dept Med, Hamilton, ON L8L 2X2, Canada.		Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020; Gerstein, Hertzel C/B-1235-2013; Gerstein, Hertzel/ABB-8781-2020	Hegele, Robert/0000-0003-2861-5325; Gerstein, Hertzel C/0000-0001-8072-2836; Gerstein, Hertzel/0000-0001-8072-2836				ALLAIN CC, 1974, CLIN CHEM, V20, P470; Anand SS, 1998, CAN J CARDIOL, V14, P1349; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Armitage P., 2001, STAT METHODS MED RES; BHOPAL R, 1999, BRIT MED J, P319; BLACKBURN H, 1982, MINNESOTA CODE MANUA; Bots ML, 1997, CIRCULATION, V96, P1432, DOI 10.1161/01.CIR.96.5.1432; Byington RP, 1997, AM J CARDIOL, V80, P1087, DOI 10.1016/S0002-9149(97)00611-5; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CROUSE JR, 1995, AM J CARDIOL, V75, P455, DOI 10.1016/S0002-9149(99)80580-3; ERIKSSON E, 1988, THROMB RES, V50, P91, DOI 10.1016/0049-3848(88)90177-6; FORTIN LJ, 1995, CLIN BIOCHEM, V28, P155, DOI 10.1016/0009-9120(94)00073-5; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Harland JO, 1997, PUBLIC HEALTH, V111, P331, DOI 10.1016/S0033-3506(97)00064-4; Harland JO, 1997, J EPIDEMIOL COMMUN H, V51, P636, DOI 10.1136/jech.51.6.636; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Libby P, 1998, Vasc Med, V3, P225, DOI 10.1177/1358836X9800300309; Lonn EM, 1996, AM J CARDIOL, V78, P914, DOI 10.1016/S0002-9149(96)00467-5; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; NEELEY WE, 1972, CLIN CHEM, V18, P509; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; Reddy KS, 1998, CIRCULATION, V97, P596; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sheth T, 1999, CAN MED ASSOC J, V161, P132; Sheth T, 1997, Ethn Health, V2, P287; WARNICK GR, 1985, CLIN CHEM, V31, P217; Woo KS, 1997, INT J CARDIOL S1, V62, P639	33	621	630	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					279	284		10.1016/S0140-6736(00)02502-2	http://dx.doi.org/10.1016/S0140-6736(00)02502-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071182				2022-12-28	WOS:000088305900008
J	Cohen, MS; Shugars, DC; Fiscus, SA				Cohen, MS; Shugars, DC; Fiscus, SA			Limits on oral transmission of HIV-1	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-FREE SIV; INFECTION		Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Dent Ecol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cohen, MS (corresponding author), Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27599 USA.		Abrams, William R/A-5782-2008					BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Baron S, 2000, J INFECT DIS, V181, P498, DOI 10.1086/315251; DILLON B, 2000, 7 C RETR OPP INF SAN; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shugars DC, 2000, ORAL SURG ORAL MED O, V89, P432, DOI 10.1016/S1079-2104(00)70124-7; Shugars DC, 1998, J AM DENT ASSOC, V129, P851, DOI 10.14219/jada.archive.1998.0349; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261	13	27	29	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					272	272		10.1016/S0140-6736(00)02500-9	http://dx.doi.org/10.1016/S0140-6736(00)02500-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071180				2022-12-28	WOS:000088305900006
J	Bystricky, M; Kunze, K; Burlini, L; Burg, JP				Bystricky, M; Kunze, K; Burlini, L; Burg, JP			High shear strain of olivine aggregates: Rheological and seismic consequences	SCIENCE			English	Article							LATTICE PREFERRED ORIENTATION; UPPER-MANTLE; DEFORMATION; ANISOTROPY; LITHOSPHERE; LITHOPROBE; TECTONICS; FABRICS; PROGRAM; DUNITE	High-pressure and high-temperature torsion experiments on olivine aggregates in dislocation creep show about 15 to 20% strain weakening before steady-state behavior, characterized by subgrain-rotation recrystallization and a strong lattice preferred orientation. Such weakening may provide a way to focus flow in the upper mantle without a change in deformation mechanism. Flow laws derived from low strain data may not be appropriate for use in modeling high strain regions. In such areas, seismic wave propagation will be anisotropic with an axis of approximate rotational symmetry about the shear direction. In contrast to current thinking, the anisotropy will not indicate the orientation of the shear plane in highly strained, recrystallized olivine-rich rocks.	ETH Zentrum, Inst Geol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bystricky, M (corresponding author), ETH Zentrum, Inst Geol, CH-8092 Zurich, Switzerland.		Kunze, Karsten/B-8561-2013; Bystricky, Misha/A-8149-2010; Burg, Jean-Pierre/A-7640-2008	Kunze, Karsten/0000-0003-4682-8017; Bystricky, Misha/0000-0002-7433-9758; Burg, Jean-Pierre/0000-0002-4927-4729				BABUSKA V, 1991, SEISMIC ANISOTROPY E; BAILEY JA, 1985, METALS HDB, V8, P139; Ben Ismail W, 1998, TECTONOPHYSICS, V296, P145; BOILLOT G, 1989, NATURE, V341, P523, DOI 10.1038/341523a0; Boullier A.M., 1975, PHYS CHEM EARTH, DOI [10.1016/B978-0-08-018017-5.50037-7, DOI 10.1016/B978-0-08-018017-5.50037-7]; Canova G. R., 1982, ASTM STP, V753, P189; CHOPRA PN, 1981, TECTONOPHYSICS, V78, P453, DOI 10.1016/0040-1951(81)90024-X; CHOPRA PN, 1984, J GEOPHYS RES, V89, P7861, DOI 10.1029/JB089iB09p07861; CHRISTENSEN NI, 1984, GEOPHYS J ROY ASTR S, V76, P89, DOI 10.1111/j.1365-246X.1984.tb05025.x; Cook FA, 1998, GEOLOGY, V26, P839, DOI 10.1130/0091-7613(1998)026<0839:TDASIO>2.3.CO;2; Cook FA, 1999, TECTONICS, V18, P1, DOI 10.1029/1998TC900016; Fischer KM, 2000, J GEOPHYS RES-SOL EA, V105, P16181, DOI 10.1029/1999JB900441; HESS HH, 1964, NATURE, V203, P629, DOI 10.1038/203629a0; KARATO S, 1993, SCIENCE, V260, P771, DOI 10.1126/science.260.5109.771; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; LALLEMANT HGA, 1970, GEOL SOC AM BULL, V81, P2203, DOI DOI 10.1130/0016-7606(1970)81[2203:SROOAM]2.0.CO;2.; MAINPRICE D, 1993, PHYS EARTH PLANET IN, V78, P257, DOI 10.1016/0031-9201(93)90160-B; MAINPRICE D, 1990, COMPUT GEOSCI, V16, P385, DOI 10.1016/0098-3004(90)90072-2; NICOLAS A, 1986, REV GEOPHYS, V24, P875, DOI 10.1029/RG024i004p00875; NICOLAS A, 1987, COMPOSITION STRUCTUR, V16, P111, DOI DOI 10.1029/GD016P0111; Paterson MS, 2000, J STRUCT GEOL, V22, P1341, DOI 10.1016/S0191-8141(00)00042-0; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; Tommasi A, 1999, EARTH PLANET SC LETT, V168, P173, DOI 10.1016/S0012-821X(99)00046-1; Tullis T., 1986, AM GEOPHYS UN MONOGR, V36, P297; Wenk HR, 1999, J GEOPHYS RES-SOL EA, V104, P25513, DOI 10.1029/1999JB900261; Wenk HR, 1998, J APPL CRYSTALLOGR, V31, P262, DOI 10.1107/S002188989700811X; WERNICKE B, 1982, J STRUCT GEOL, V4, P105, DOI 10.1016/0191-8141(82)90021-9; Zhang SQ, 2000, TECTONOPHYSICS, V316, P133, DOI 10.1016/S0040-1951(99)00229-2; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	29	232	242	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1564	1567		10.1126/science.290.5496.1564	http://dx.doi.org/10.1126/science.290.5496.1564			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090352				2022-12-28	WOS:000165446200047
J	Harrison, C; Adamson, DH; Cheng, ZD; Sebastian, JM; Sethuraman, S; Huse, DA; Register, RA; Chaikin, PM				Harrison, C; Adamson, DH; Cheng, ZD; Sebastian, JM; Sethuraman, S; Huse, DA; Register, RA; Chaikin, PM			Mechanisms of ordering in striped patterns	SCIENCE			English	Article							BLOCK-COPOLYMER MICROSTRUCTURE; SWIFT-HOHENBERG EQUATION; DIBLOCK COPOLYMERS; DYNAMICS; ANNIHILATION; LITHOGRAPHY	We have studied the ordering dynamics of the striped patterns of a single layer of cylindrical block copolymer microdomains in a thin film. By tracking disclinations during annealing with time-lapse atomic force microscopy, we observe a dominant mechanism of disclination annihilation involving three or four disclinations (quadrupoles). Pairwise disclination annihilation events are suppressed as a result of the topological constraints in this system. The kinetic scaling laws with exponents observed here are consistent with topologically allowed annihilation events involving multiple disclinations. The results provide insight into two-dimensional pattern formation and may lead to the successful application of block copolymer lithography.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem Engn, Princeton, NJ 08544 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Princeton University; Princeton University; Princeton University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Harrison, C (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.		Adamson, Douglas H/C-8721-2009; Register, Richard/AAW-2042-2021	Cheng, Zhengdong/0000-0001-7720-1909; Register, Richard/0000-0002-5223-4306				Adams JL, 1998, MACROMOLECULES, V31, P201, DOI 10.1021/ma9710500; AMUNDSON K, 1993, MACROMOLECULES, V26, P1324, DOI 10.1021/ma00058a022; AMUNDSON K, 1994, MACROMOLECULES, V27, P6559, DOI 10.1021/ma00100a047; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; Bowman C, 1998, REV MOD PHYS, V70, P289, DOI 10.1103/RevModPhys.70.289; Christensen JJ, 1998, PHYS REV E, V58, P5364, DOI 10.1103/PhysRevE.58.5364; CROSS MC, 1995, PHYS REV LETT, V75, P2152, DOI 10.1103/PhysRevLett.75.2152; Dai HJ, 1996, PHYS REV LETT, V77, P3677, DOI 10.1103/PhysRevLett.77.3677; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; ELDER KR, 1992, PHYS REV LETT, V68, P3024, DOI 10.1103/PhysRevLett.68.3024; Hahm J, 1998, J CHEM PHYS, V109, P10111, DOI 10.1063/1.477702; Harrison C, 2000, MACROMOLECULES, V33, P857, DOI 10.1021/ma991551g; Harrison C, 1998, MACROMOLECULES, V31, P2185, DOI 10.1021/ma9716037; Harrison C, 1998, J VAC SCI TECHNOL B, V16, P544, DOI 10.1116/1.589860; Harrison C, 1998, POLYMER, V39, P2733, DOI 10.1016/S0032-3861(97)00613-7; Hou Q, 1997, PHYSICA A, V239, P219, DOI 10.1016/S0378-4371(96)00480-3; Kleman M., 1983, POINTS LINES WALLS; Li RR, 2000, APPL PHYS LETT, V76, P1689, DOI 10.1063/1.126137; Liu C, 1997, J CHEM PHYS, V106, P7822, DOI 10.1063/1.473740; LOPES WA, 1999, B AM PHYS SOC, V44, P1473; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Park M. H., UNPUB; SEUL M, 1995, SCIENCE, V267, P476, DOI 10.1126/science.267.5197.476; STRANDBURG KJ, 1988, REV MOD PHYS, V60, P161, DOI 10.1103/RevModPhys.60.161; SZE SM, 1988, VLSI TECHNOLOGY, P184; TONER J, 1981, PHYS REV B, V23, P316, DOI 10.1103/PhysRevB.23.316; YURKE B, 1993, PHYS REV E, V47, P1525, DOI 10.1103/PhysRevE.47.1525	27	321	324	2	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1558	1560		10.1126/science.290.5496.1558	http://dx.doi.org/10.1126/science.290.5496.1558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090350				2022-12-28	WOS:000165446200045
J	Jager, EWH; Smela, E; Inganas, O				Jager, EWH; Smela, E; Inganas, O			Microfabricating conjugated polymer actuators	SCIENCE			English	Review							INDUCED VOLUME CHANGES; BENDING BEAM METHOD; ELECTROCHEMICAL APPLICATIONS; POLYPYRROLE; MUSCLES; DEPOSITION	Conjugated polymer actuators can be operated in aqueous media, which makes them attractive for laboratories-on-a-chip and applications under physiological conditions. One of the most stable conjugated polymers under these conditions is polypyrrole, which can be patterned by means of standard photolithography. Polypyrrole-gold bilayer actuators that bend out of the plane of the wafer have been microfabricated in our laboratory. These can be used to move and position other microcomponents. Here we review the current status of these microactuators, outlining the methods used to fabricate them. We describe the devices that have been demonstrated as well as some potential future applications.	Linkoping Univ, Dept Phys & Measurement Technol, S-58183 Linkoping, Sweden; Univ Maryland, Dept Mech Engn, College Pk, MD 20742 USA	Linkoping University; University System of Maryland; University of Maryland College Park	Jager, EWH (corresponding author), Linkoping Univ, Dept Phys & Measurement Technol, S-58183 Linkoping, Sweden.	edjag@ifm.liu.se	Jager, Edwin/F-1481-2013; Smela, Elisabeth/B-9911-2011	Jager, Edwin/0000-0002-2071-7768; Smela, Elisabeth/0000-0003-3921-2265; Inganas, Olle/0000-0002-6243-1450				ANGELOPOULOS M, 1998, HDB CONDUCTING POLYM, P921; Bao ZN, 1999, J MATER CHEM, V9, P1895, DOI 10.1039/a902652e; Baughman RH, 1996, SYNTHETIC MET, V78, P339, DOI 10.1016/0379-6779(96)80158-5; Baughman RH, 1991, MOL ELECT, P267; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; Chang SC, 1998, APPL PHYS LETT, V73, P2561, DOI 10.1063/1.122533; Chen XW, 1996, CHEM MATER, V8, P2439, DOI 10.1021/cm9600034; CHEN XW, 1995, SYNTHETIC MET, V74, P159, DOI 10.1016/0379-6779(95)03355-6; Chiu DT, 2000, P NATL ACAD SCI USA, V97, P2408, DOI 10.1073/pnas.040562297; CHOU SY, 1995, APPL PHYS LETT, V67, P3114, DOI 10.1063/1.114851; DellaSanta A, 1997, SYNTHETIC MET, V90, P93, DOI 10.1016/S0379-6779(97)81256-8; Ekstrand G, 2000, MESA MG, P311; Ekstrom S, 2000, ANAL CHEM, V72, P286, DOI 10.1021/ac990731l; GANDHI MR, 1995, SYNTHETIC MET, V73, P247, DOI 10.1016/0379-6779(95)80022-0; Granlund T, 2000, ADV MATER, V12, P269, DOI 10.1002/(SICI)1521-4095(200002)12:4<269::AID-ADMA269>3.0.CO;2-5; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; Hebner TR, 1998, APPL PHYS LETT, V72, P519, DOI 10.1063/1.120807; HEINZE J, 1991, SYNTHETIC MET, V43, P2805, DOI 10.1016/0379-6779(91)91183-B; Hutchison AS, 2000, SYNTHETIC MET, V113, P121, DOI 10.1016/S0379-6779(00)00190-9; Idla K, 2000, ELECTROCHIM ACTA, V45, P2121, DOI 10.1016/S0013-4686(99)00433-8; Jager EWH, 1999, SENSOR ACTUAT B-CHEM, V56, P73, DOI 10.1016/S0925-4005(99)00159-8; Jager EWH, 1999, P SOC PHOTO-OPT INS, V3669, P377, DOI 10.1117/12.349696; Jager EWH, 2000, SCIENCE, V288, P2335, DOI 10.1126/science.288.5475.2335; JAGER EWH, IN PRESS ADV MAT; KANETO K, 1995, SYNTHETIC MET, V71, P2211, DOI 10.1016/0379-6779(94)03226-V; Kranz C, 1996, ADV MATER, V8, P634, DOI 10.1002/adma.19960080805; Lewis T.W., 1997, POLYM PREP-ACS, V38, P520; Lewis TW, 1997, SYNTHETIC MET, V85, P1419, DOI 10.1016/S0379-6779(97)80301-3; Lin G, 2000, J MICROELECTROMECH S, V9, P9, DOI 10.1109/84.825771; Madden JD, 1999, SYNTHETIC MET, V105, P61, DOI 10.1016/S0379-6779(99)00034-X; Madden JD, 2000, SYNTHETIC MET, V113, P185, DOI 10.1016/S0379-6779(00)00195-8; Madou MJ, 2000, MESA MG, P565; OTERO TF, 1995, BIOELECTROCH BIOENER, V38, P411, DOI 10.1016/0302-4598(95)01802-L; PEI QB, 1992, ADV MATER, V4, P277, DOI 10.1002/adma.19920040406; PEI QB, 1992, J PHYS CHEM-US, V96, P10507, DOI 10.1021/j100204a071; PEI QB, 1993, P SOC PHOTO-OPT INS, V1916, P28, DOI 10.1117/12.148490; PEI QB, 1993, SYNTHETIC MET, V57, P3724, DOI 10.1016/0379-6779(93)90504-P; PEI QB, 1993, SYNTHETIC MET, V57, P3730, DOI 10.1016/0379-6779(93)90505-Q; PEI QB, 1993, J PHYS CHEM-US, V97, P6034, DOI 10.1021/j100124a041; Pettersson PF, 2000, 1ST ANNUAL INTERNATIONAL IEEE-EMBS SPECIAL TOPIC CONFERENCE ON MICROTECHNOLOGIES IN MEDICINE & BIOLOGY, PROCEEDINGS, P334, DOI 10.1109/MMB.2000.893799; Qibing Pei, 1993, Smart Materials and Structures, V2, P1, DOI 10.1088/0964-1726/2/1/001; Sager C, 2000, 1ST ANNUAL INTERNATIONAL IEEE-EMBS SPECIAL TOPIC CONFERENCE ON MICROTECHNOLOGIES IN MEDICINE & BIOLOGY, PROCEEDINGS, P76, DOI 10.1109/MMB.2000.893745; Sansinena JM, 1997, CHEM COMMUN, P2217, DOI 10.1039/a705341j; Schultze JW, 1999, ELECTROCHIM ACTA, V44, P1847, DOI 10.1016/S0013-4686(98)00326-0; Shimoda S, 1998, ELECTROCHIM ACTA, V44, P219, DOI 10.1016/S0013-4686(98)00048-6; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Smela E, 1999, ADV MATER, V11, P1343, DOI 10.1002/(SICI)1521-4095(199911)11:16<1343::AID-ADMA1343>3.0.CO;2-V; Smela E, 1998, LANGMUIR, V14, P2996, DOI 10.1021/la970863e; Smela E, 1999, J MICROMECH MICROENG, V9, P1, DOI 10.1088/0960-1317/9/1/001; SMELA E, 1993, ADV MATER, V5, P630, DOI 10.1002/adma.19930050905; Smela E, 1999, ADV MATER, V11, P953; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; Smela E, 1999, J MICROELECTROMECH S, V8, P373, DOI 10.1109/84.809051; SMELA E, 1995, 8 INT C SOL STAT SEN, V9, P218; TERRY SC, 1979, IEEE T ELECTRON DEV, V26, P1880, DOI 10.1109/T-ED.1979.19791; VANDERBERG A, 2000, MICRO TOTAL ANAL SYS; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	57	780	836	14	418	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1540	1545		10.1126/science.290.5496.1540	http://dx.doi.org/10.1126/science.290.5496.1540			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090345				2022-12-28	WOS:000165446200040
J	Zhou, CW; Kong, J; Yenilmez, E; Dai, HJ				Zhou, CW; Kong, J; Yenilmez, E; Dai, HJ			Modulated chemical doping of individual carbon nanotubes	SCIENCE			English	Article							TRANSPORT-PROPERTIES; SINGLE	Modulation doping of a semiconducting single-walled carbon nanotube along its length leads to an intramolecular wire electronic device. The nanotube is doped n-type for half of Its length and p-type for the other half. Electrostatic gating can tune the system into p-n junctions, causing it to exhibit rectifying characteristics or negative differential conductance. The system can also be tuned into n-type, exhibiting single-electron charging and negative differential conductance at low temperatures. The low-temperature behavior is manifested by a quantum dot formed by chemical inhomogeneity along the tube.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Dai, HJ (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	hdai@chem.stanford.edu	Zhou, Chongwu/F-7483-2010; Dai, Hongjie/ABC-4574-2021					Antonov RD, 1999, PHYS REV LETT, V83, P3274, DOI 10.1103/PhysRevLett.83.3274; Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; Bezryadin A, 1998, PHYS REV LETT, V80, P4036, DOI 10.1103/PhysRevLett.80.4036; Bockrath M, 2000, PHYS REV B, V61, P10606, DOI 10.1103/PhysRevB.61.R10606; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; CHANG LL, 1974, APPL PHYS LETT, V24, P593, DOI 10.1063/1.1655067; Chico L, 1996, PHYS REV LETT, V76, P971, DOI 10.1103/PhysRevLett.76.971; Collins PG, 2000, SCIENCE, V287, P1801, DOI 10.1126/science.287.5459.1801; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; ESAKI L, 1976, IEEE T ELECTRON DEV, V23, P644, DOI 10.1109/T-ED.1976.18466; Esfarjani K, 1999, APPL PHYS LETT, V74, P79, DOI 10.1063/1.122957; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Hu JT, 1999, NATURE, V399, P48, DOI 10.1038/19941; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; KONG J, IN PRESS APPL PHYS L; Lee RS, 2000, PHYS REV B, V61, P4526, DOI 10.1103/PhysRevB.61.4526; Leonard F, 1999, PHYS REV LETT, V83, P5174, DOI 10.1103/PhysRevLett.83.5174; Martel R, 1998, APPL PHYS LETT, V73, P2447, DOI 10.1063/1.122477; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; Nygard J, 1999, APPL PHYS A-MATER, V69, P297, DOI 10.1007/s003390051004; SHOCKLEY W, 1976, IEEE T ELECTRON DEV, V23, P597, DOI 10.1109/T-ED.1976.18463; Streetman B.G., 2006, SOLID STATE ELECT DE; Tans SJ, 2000, NATURE, V404, P834, DOI 10.1038/35009026; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241; Zhou CW, 2000, APPL PHYS LETT, V76, P1597, DOI 10.1063/1.126107	29	591	648	3	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1552	1555		10.1126/science.290.5496.1552	http://dx.doi.org/10.1126/science.290.5496.1552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090348				2022-12-28	WOS:000165446200043
J	Domart, Y; Garet, E				Domart, Y; Garet, E			Lichtenberg figures due to a lightning strike.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Compiegne Gen Hosp, F-60200 Compiegne, France		Domart, Y (corresponding author), Compiegne Gen Hosp, F-60200 Compiegne, France.								0	17	17	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1536	1536		10.1056/NEJM200011233432105	http://dx.doi.org/10.1056/NEJM200011233432105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087883				2022-12-28	WOS:000165410900005
J	Campion, EW; Curfman, GD; Drazen, JM				Campion, EW; Curfman, GD; Drazen, JM			Tracking the peer-review process.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890					0	22	23	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1485	1486		10.1056/NEJM200011163432009	http://dx.doi.org/10.1056/NEJM200011163432009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078775				2022-12-28	WOS:000165271300009
J	Derry, S; Loke, YK				Derry, S; Loke, YK			Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-DOSE ASPIRIN; ACETYLSALICYLIC-ACID; SECONDARY PREVENTION; CONTROLLED-TRIAL; MYOCARDIAL-INFARCTION; EUROPEAN STROKE; ADVERSE EVENTS; PLACEBO; PROGRESSION; MORTALITY	Objectives To assess the incidence of gastrointestinal haemorrhage associated with long term aspirin therapy and to determine the effect of dose reduction and formulation on the incidence of such haemorrhage. Design Meta-analysis of 24 randomised controlled trials (almost 66 000 participants). Intervention Aspirin compared with placebo or no treatment, for a minimum of one year, Main outcome measures Incidence of gastrointestinal haemorrhage. Results Gastrointestinal haemorrhage occurred in 2.47% of patients taking aspirin compared with 1.42% taking placebo (odds ratio 1.68; 95% confidence interval 1.51 to 1.88); the number needed to harm was 106 (82 to 140) based on an average of 28 months' therapy. At doses below 163 mg/day, gastrointestinal haemorrhage occurred in 2.30% of patients taking aspirin compared with 1.45% taking placebo (1.59; 1.40 to 1.81). Meta-regression showed no relation between gastrointestinal haemorrhage and dose. For modified release formulations of aspirin the odds ratio was 1.93 (1.15 to 3.23). Conclusions Long term therapy with aspirin is associated with a significant increase in the incidence of gastrointestinal haemorrhage. No evidence exists that reducing the dose or using modified release formulations would reduce the incidence of gastrointestinal haemorrhage.	Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Loke, YK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.	yoon.loke@clinpharm.ox.ac.uk						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1976, J CHRON DIS, V29, P625; [Anonymous], 1991, Lancet, V338, P1345; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; BRITTON M C H, 1987, Stroke, V18, P325; *CAN COOP STUD GRO, 1978, NEW ENGL J MED, V299, P53; CLARKE M, 1999, REV MANAGER REVMAN C; DEEKS JJ, 2000, P 2 S SYST REV BAS O; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Diener HC, 1997, J NEUROL SCI, V151, pS1, DOI 10.1016/S0022-510X(97)86566-5; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; EHRESMANN U, 1977, MED WELT, V28, P1157; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; EYPASCH E, 1995, BRIT MED J, V311, P619, DOI 10.1136/bmj.311.7005.619; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; GAVAGHAN TP, 1991, CIRCULATION, V83, P1526, DOI 10.1161/01.CIR.83.5.1526; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HESS H, 1985, LANCET, V1, P415; Kelly JP, 1996, LANCET, V348, P1413, DOI 10.1016/S0140-6736(96)01254-8; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; KROL WF, 1980, CIRCULATION, V62, P449; LOKE YK, 2000, P 7 COCHR C ROM 1999; Meade TW, 1998, LANCET, V351, P233; Olivotto IA, 1996, RADIOTHER ONCOL, V41, P1; PETERSEN P, 1989, LANCET, V1, P175; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); SILAGY CA, 1993, CLIN PHARMACOL THER, V54, P84, DOI 10.1038/clpt.1993.115; The Aspirin Myocardial Infarction Study Research Group, 1980, CIRCULATION, V62, pV79; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN LC, 1991, J AM COLL CARDIOL, V18, P1587, DOI 10.1016/0735-1097(91)90489-V; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; Zanchetti A, 1999, LANCET, V353, P149, DOI 10.1016/S0140-6736(05)76187-0	38	503	538	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2000	321	7270					1183	+		10.1136/bmj.321.7270.1183	http://dx.doi.org/10.1136/bmj.321.7270.1183			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073508	Bronze, Green Published			2022-12-28	WOS:000165357100025
J	Ferner, RE				Ferner, RE			Medication errors that have led to manslaughter charges	BRITISH MEDICAL JOURNAL			English	Article									City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React Reporting, Birmingham B18 7QH, W Midlands, England.			Ferner, Robin/0000-0003-3769-1346				[Anonymous], 2000, ORG MEMORY REPORT EX; CLOUGH S, 1999, COMMUNICATION   0106; DYER C, 1975, BRIT MED J, V3, P108; Fenn P, 2000, BRIT MED J, V320, P1567, DOI 10.1136/bmj.320.7249.1567; HALLE M, 1994, OBSERVER        0213, P7; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, VVolume 600; NELSONJONES R, 1995, MED NEGLIGENCE CASE, pA511; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; STOKES P, 1998, COMMUNICATION   1128; STOKES P, 1999, COMMUNICATION   1005; TAYLOR JL, 1970, DOCTOR LAW; 1925, BMJ, V1, P1022; 1978, TIMES           0428, P4; 1982, TIMES           0707, P3; 1995, GUARDIAN        0307, P2; 1986, TIMES           1205, P2; 1994, GUARDIAN        0304, P3; 1990, GUARDIAN        0731, P6; 1994, GUARDIAN        0507, P8; 1978, TIMES           1031, P4; 1982, TIMES           0715, P4	21	40	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1212	1216		10.1136/bmj.321.7270.1212	http://dx.doi.org/10.1136/bmj.321.7270.1212			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073516	Green Published			2022-12-28	WOS:000165357100033
J	Gardner, JA				Gardner, JA			Ars longa, vita brevis - Last remaining astronomy department disbanded.	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					143	143						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089951				2022-12-28	WOS:000165180400021
J	Kleemann, R; Hausser, A; Geiger, G; Mischke, R; Burger-Kentischer, A; Flieger, O; Johannes, FJ; Roger, T; Calandra, T; Kapurniotu, A; Grell, M; Finkelmeier, D; Brunner, H; Bernhagen, J				Kleemann, R; Hausser, A; Geiger, G; Mischke, R; Burger-Kentischer, A; Flieger, O; Johannes, FJ; Roger, T; Calandra, T; Kapurniotu, A; Grell, M; Finkelmeier, D; Brunner, H; Bernhagen, J			Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1	NATURE			English	Article							MIGRATION-INHIBITORY FACTOR; PROTEIN; GENES; EXPRESSION; SUBUNITS; BINDING; REVEALS	Cytokines are multifunctional mediators that classically modulate immune activity by receptor-mediated pathways. Macrophage migration inhibitory factor (MIF) is a cytokine that has a critical role in several inflammatory conditions(1-3) but that also has endocrine(4,5) and enzymatic functions(6,7). The molecular targets of MIF action have so far remained unclear. Here we show that MIF specifically interacts with an intracellular protein, Jab1, which is a coactivator of AP-1 transcription(8,9) that also promotes degradation of the cyclin-dependent kinase inhibitor p27(Kip1) (ref. 10). MIF colocalizes with Jab1 in the cytosol, and both endogenous and exogenously added MIF following endocytosis bind Jab1. MIF inhibits Jab1- and stimulus-enhanced AP-1 activity, but does not interfere with the induction of the transcription factor NF kappaB. Jab1 activates c-Jun amino-terminal kinase (JNK) activity and enhances endogenous phospho-c-Jun levels, and MIF inhibits these effects. MIF also antagonizes Jab1-dependent cell-cycle regulation by increasing p27(Kip1) expression through stabilization of p27(Kip1) protein. Consequently, Jab1-mediated rescue of fibroblasts from growth arrest is blocked by MIF. Amino acids 50-65 and Cys 60 of MIF are important for Jab1 binding and modulation. We conclude that MIF may act broadly to negatively regulate Jab1-controlled pathways and that the MIF-Jab1 interaction may provide a molecular basis for key activities of MIF.	Univ Stuttgart, Biochem Lab, Inst Interfacial Engn, D-70569 Stuttgart, Germany; Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Fraunhofer IGB, D-70569 Stuttgart, Germany; CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland; Univ Tubingen, Inst Physiol Chem, D-72076 Tubingen, Germany	University of Stuttgart; University of Stuttgart; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Eberhard Karls University of Tubingen	Bernhagen, J (corresponding author), Univ Stuttgart, Biochem Lab, Inst Interfacial Engn, Nobelstr 12, D-70569 Stuttgart, Germany.		Calandra, Thierry/D-9017-2015; Hausser, Angelika/AAC-4531-2021; Roger, Thierry/G-2007-2012	Calandra, Thierry/0000-0003-3051-1285; Roger, Thierry/0000-0002-9358-0109				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bacher M, 1998, MOL MED, V4, P217, DOI 10.1007/BF03401919; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Dedio J, 1998, J IMMUNOL, V160, P3534; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KARIN M, 1995, J BIOL CHEM, V270; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Roger T, 1998, BIOCHEM J, V330, P429, DOI 10.1042/bj3300429; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Waeber G, 1997, P NATL ACAD SCI USA, V94, P4782, DOI 10.1073/pnas.94.9.4782; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1271	30	486	519	0	21	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					211	216		10.1038/35041591	http://dx.doi.org/10.1038/35041591			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089976				2022-12-28	WOS:000165180400048
J	Asch, SM; Sloss, EEM; Hogan, C; Brook, RH; Kravitz, RL				Asch, SM; Sloss, EEM; Hogan, C; Brook, RH; Kravitz, RL			Measuring underuse of necessary care among elderly Medicare beneficiaries using inpatient and outpatient claims	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; ADMINISTRATIVE DATA; MEASURING QUALITY; EPIDEMIOLOGY; INFORMATION; INSURANCE; SYSTEM; RATES	Context Continuing changes in the health care delivery system make it essential to monitor underuse of needed care, even for relatively well-insured populations. Traditional approaches to measuring underuse have relied on patient surveys and chart reviews, which are expensive, or simple single-condition claims-based indicators, which are not clinically convincing. Objective To develop a comprehensive, low-cost system for measuring underuse of necessary care among elderly patients using inpatient and outpatient Medicare claims. Design A 7-member, multispecialty expert physician panel was assembled and used a modified Delphi method to develop clinically detailed underuse indicators likely to be associated with avoidable poor outcomes for 15 common acute and chronic medical and surgical conditions. An automated system was developed to calculate the indicators using administrative data. Setting and Subjects A total of 345253 randomly selected elderly US Medicare beneficiaries in 1994-1996, Main Outcome Measures Proportion of beneficiaries receiving care, stratified by indicators of necessary care (n=40, including 3 for preventive care), and avoidable outcomes (n=6). Results For 16 of 40 necessary care indicators (including preventive care indicators), beneficiaries received the indicated care less than two thirds of the time. Of all indicators, African Americans scored significantly worse than whites on 16 and better on 2; residents of poverty areas scored significantly lower than nonresidents on 17 and higher on 1; residents of federally defined Health Professional Shortage Areas scored significantly lower than nonresidents on 16 and higher on none (P<.05 for all). Conclusions This claims-based method detected substantial underuse problems likely to result in negative outcomes in elderly populations. Significantly more underuse problems were detected in populations known to receive less-than-average medical care, The method can serve as a reliable, valid tool for monitoring trends in underuse of needed care for older patients and for comparing care across health care plans and geographic areas based on claims data.	RAND Corp, Santa Monica, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA; Direct Res, Vienna, VA USA; Univ Calif Davis, Ctr Hlth Serv Res Primary Care, Davis, CA 95616 USA	RAND Corporation; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Davis	Asch, SM (corresponding author), 1700 Main St,POB 2138, Santa Monica, CA 90407 USA.		Kravitz, Richard/AAF-7425-2021	Kravitz, Richard/0000-0001-5575-529X				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ASCH S, 1995, RAND PUBL; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; Bishop W, 1998, J Healthc Qual, V20, P10; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; FINK A, 1987, JAMA-J AM MED ASSOC, V258, P1905, DOI 10.1001/jama.258.14.1905; GARNICK DW, 1994, JOINT COMM J QUAL IM, V20, P679, DOI 10.1016/S1070-3241(16)30117-1; Goldfield N, 1996, Am J Med Qual, V11, pS35; Gray DT, 1997, AM J EPIDEMIOL, V145, P1123; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; Hannan EL, 1997, HEALTH SERV RES, V31, P659; *HLTH CAR FIN ADM, 2000, RES AN SUPP IMPL PER; *HLTH CAR FIN ADM, 2000, DIAB NAT PROJ; *HLTH CAR FIN ADM, 2000, BREAST CANC NAT PROJ; *I MED COMM MON AC, 1993, ACC HLTH CAR AM; Iezzoni L I, 1992, QRB Qual Rev Bull, V18, P361; IEZZONI LI, 1994, INQUIRY-J HEALTH CAR, V31, P40; Johantgen M, 1998, Jt Comm J Qual Improv, V24, P88; Kahan JP, 1996, MED CARE, V34, P512, DOI 10.1097/00005650-199606000-00002; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KRITCHEVSKY SB, 1995, INFECT CONT HOSP EP, V16, P33; LEAPE LL, 1991, ARTERY BYPASS GRAFT; Leatherman S, 1991, QRB Qual Rev Bull, V17, P349; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; McClish DK, 1997, AM J EPIDEMIOL, V145, P227; *MED PAYM ADV COMM, 1999, MEDPAC COMM HCFAS RI; Merrell K, 1997, HEALTH AFFAIR, V16, P175, DOI 10.1377/hlthaff.16.1.175; Miller ME, 1997, MED CARE, V35, P114, DOI 10.1097/00005650-199702000-00002; MITCHELL JB, 1994, MED CARE, V32, pJS39; Palmer H, 1996, Qual Manag Health Care, V4, P1; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; *PHYS PAYM REV COM, 1994, ANN REP C 1993, pCH5; *PHYS PAYM REV COM, 1994, ANN REP C 1994, pCH17; *PHYS PAYM REV COM, 1992, 92578 PHYS PAYM REV; *PRES ADV COMM CON, 1998, QUAL 1 BETT HLTH CAR, P21; ROMANO PS, 1994, J CLIN EPIDEMIOL, V47, P249, DOI 10.1016/0895-4356(94)90006-X; ROOS LL, 1991, J CLIN EPIDEMIOL, V44, P881, DOI 10.1016/0895-4356(91)90050-J; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; Samsa GP, 1999, STROKE, V30, P338, DOI 10.1161/01.STR.30.2.338; Schneider EC, 1999, JAMA-J AM MED ASSOC, V282, P1184, DOI 10.1001/jama.282.12.1184; SIU AL, 1991, HEALTH AFFAIR, V10, P62, DOI 10.1377/hlthaff.10.1.62; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; 1999, CRITERIA DESIGNATION	45	139	140	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2325	2333		10.1001/jama.284.18.2325	http://dx.doi.org/10.1001/jama.284.18.2325			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369NU	11066182	Bronze			2022-12-28	WOS:000165074500026
J	Schon, JH; Dodabalapur, A; Kloc, C; Batlogg, B				Schon, JH; Dodabalapur, A; Kloc, C; Batlogg, B			RETRACTED: A light-emitting field-effect transistor (Retracted Article. See vol 298, pg 961, 2002)	SCIENCE			English	Article; Retracted Publication							STIMULATED-EMISSION; SINGLE-CRYSTAL; SEXITHIOPHENE	We report here on the structure and operating characteristics of an ambipolar Light-emitting field-effect transistor based on single crystals of the organic semiconductor alpha -sexithiophene, Electrons and holes are injected from the source and drain electrodes, respectively. Their concentrations are controlled by the applied gate and drain-source voltages. Excitons are generated, Leading to radiative recombination. Moreover, above a remarkably Low threshold current, coherent light is emitted through amplified spontaneous emission. Hence, this three-terminal device is the basis of a very promising architecture for electrically driven laser action in organic semiconductors.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Schon, JH (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	hendrik@lucent.com; ananth@lucent.com	Dodabalapur, Ananth/H-3043-2012; Kloc, Christian/A-2255-2011					Berggren M, 1997, NATURE, V389, P466; CASPERSON LW, 1972, IEEE J QUANTUM ELECT, VQE 8, P80, DOI 10.1109/JQE.1972.1076944; DODABALAPUR A, 1995, SCIENCE, V269, P1560, DOI 10.1126/science.269.5230.1560; Dodabalapur A, 1996, APPL PHYS LETT, V68, P1108, DOI 10.1063/1.115728; DODABALAPUR A, 1996, ADV MATER, V10, P853; Fichou D, 1997, ADV MATER, V9, P1178, DOI 10.1002/adma.19970091512; Garnier F, 1998, APPL PHYS LETT, V72, P2087, DOI 10.1063/1.121284; HOROWITZ G, 1994, ADV MATER, V6, P752, DOI 10.1002/adma.19940061007; Kloc C, 1997, J CRYST GROWTH, V182, P416, DOI 10.1016/S0022-0248(97)00370-9; Mekis A, 2000, OPT LETT, V25, P942, DOI 10.1364/OL.25.000942; Muccini M, 1998, J CHEM PHYS, V108, P7327, DOI 10.1063/1.476151; NEUDECK GW, 1987, IEEE T ELECTRON DEV, V34, P344, DOI 10.1109/T-ED.1987.22928; PFLEIDERER H, 1986, IEEE T ELECTRON DEV, V33, P145, DOI 10.1109/T-ED.1986.22451; Rogers JA, 1999, APPL PHYS LETT, V74, P3257, DOI 10.1063/1.123312; Schon JH, 2000, SCIENCE, V289, P599, DOI 10.1126/science.289.5479.599; Schon JH, 2000, SCIENCE, V287, P1022, DOI 10.1126/science.287.5455.1022; SCHON JH, 2000, IN PRESS P EUR MAT R; Zou Z, 2000, IEEE PHOTONIC TECH L, V12, P1, DOI 10.1109/68.817427	18	116	125	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					963	965		10.1126/science.290.5493.963	http://dx.doi.org/10.1126/science.290.5493.963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062124				2022-12-28	WOS:000165103200043
J	McKinsey, TA; Zhang, CL; Lu, JR; Olson, EN				McKinsey, TA; Zhang, CL; Lu, JR; Olson, EN			Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation	NATURE			English	Article							TRANSCRIPTION FACTOR MEF2C; PROTEIN-KINASE; GENE-EXPRESSION; ACTIVATION; PHOSPHORYLATION; CALCINEURIN; SURVIVAL; DOMAIN; CRM1	Members of the myocyte enhancer factor-2 (MEF2) family of transcription factors associate with myogenic basic helix-loop-helix transcription factors such as MyoD to activate skeletal myogenesis(1). MEF2 proteins also interact with the class II histone deacetylases HDAC4 and HDAC5, resulting in repression of MEF2-dependent genes(2-4). Execution of the muscle differentiation program requires release of MEF2 from repression by HDACs, which are expressed constitutively in myoblasts and myotubes(5). Here we show that HDAC5 shuttles from the nucleus to the cytoplasm when myoblasts are triggered to differentiate. Calcium/calmodulin-dependent protein kinase (CaMK) signalling, which stimulates myogenesis(5) and prevents formation of MEF2-HDAC complexes(4), also induces nuclear export of HDAC4 and HDAC5 by phosphorylation of these transcriptional repressors. An HDAC5 mutant lacking two CaMK phosphorylation sites is resistant to CaMK-mediated nuclear export and acts as a dominant inhibitor of skeletal myogenesis, whereas a cytoplasmic HDAC5 mutant is unable to block efficiently the muscle differentiation program. Our results highlight a mechanism for transcriptional regulation through signal- and differentiation-dependent nuclear export of a chromatin-remodelling enzyme, and suggest that nucleo-cytoplasmic trafficking of HDACs is involved in the control of cellular differentiation.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	eolson@hamon.swmed.edu	Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	NHLBI NIH HHS [R01 HL053351] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963	30	836	876	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					106	111		10.1038/35040593	http://dx.doi.org/10.1038/35040593			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081517	Green Accepted			2022-12-28	WOS:000165050400061
J	Mer, G; Bochkarev, A; Gupta, R; Bochkareva, E; Frappier, L; Ingles, CJ; Edwards, AM; Chazin, WJ				Mer, G; Bochkarev, A; Gupta, R; Bochkareva, E; Frappier, L; Ingles, CJ; Edwards, AM; Chazin, WJ			Structural basis for the recognition of DNA repair proteins UNG2, XPA, and RAD52 by replication factor RPA	CELL			English	Article							SINGLE-STRANDED-DNA; NUCLEOTIDE EXCISION-REPAIR; A COMPLEMENTING PROTEIN; BINDING DOMAIN; CRYSTAL-STRUCTURE; NMR; COMPLEX; RECOMBINATION; GLYCOSYLASE; MECHANISM	Replication protein A (RPA), the nuclear ssDNA-binding protein in eukaryotes, is essential to DNA replication, recombination, and repair. We have shown that a globular domain at the C terminus of subunit RPA32 contains a specific surface that interacts in a similar manner with the DNA repair enzyme UNG2 and repair factors XPA and RAD52, each of which functions in a different repair pathway. NMR structures of the RPA32 domain, free and in complex with the minimal interaction domain of UNG2, were determined, defining a common structural basis for linking RPA to the nucleotide excision, base excision, and recombinational pathways of repairing damaged DNA. Our findings support a hand-off model for the assembly and coordination of different components of the DNA repair machinery.	Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Scripps Research Institute; University of Toronto; University of Toronto; University of Oklahoma System; University of Oklahoma Health Sciences Center; Vanderbilt University	Edwards, AM (corresponding author), Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	aled.edwards@utoronto.ca; walter.chazin@vanderbilt.edu	Mer, Georges/AAT-4946-2021	Mer, Georges/0000-0002-1900-1578; Edwards, Aled/0000-0002-4782-6016				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Buchko GW, 1999, BIOCHEMISTRY-US, V38, P15116, DOI 10.1021/bi991755p; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Ikegami T, 1998, NAT STRUCT BIOL, V5, P701, DOI 10.1038/1400; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee BE, 1999, MOL CELLS, V9, P185; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Macke TJ, 1998, ACS SYM SER, V682, P379; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mer G, 2000, J BIOMOL NMR, V17, P179, DOI 10.1023/A:1008306832408; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; PEARLMAN DA, 1995, AMBER 4 1; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Saijo M, 1996, NUCLEIC ACIDS RES, V24, P4719, DOI 10.1093/nar/24.23.4719; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stigger E, 1998, J BIOL CHEM, V273, P9337, DOI 10.1074/jbc.273.15.9337; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; ZWALEN C, 1997, J AM CHEM SOC, V119, P6711; [No title captured]	43	193	197	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					449	456		10.1016/S0092-8674(00)00136-7	http://dx.doi.org/10.1016/S0092-8674(00)00136-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081631	Bronze			2022-12-28	WOS:000090144100010
J	Pittet, D; Hugonnet, S; Harbarth, S; Mourouga, P; Sauvan, V; Touveneau, S; Perneger, TV				Pittet, D; Hugonnet, S; Harbarth, S; Mourouga, P; Sauvan, V; Touveneau, S; Perneger, TV		Infection Control Programme	Effectiveness of a hospital-wide programme to improve compliance with hand hygiene	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; NOSOCOMIAL INFECTIONS; CARE; STAFF	Background Hand hygiene prevents cross infection in hospitals, but compliance with recommended instructions is commonly poor. We attempted to promote hand hygiene by implementing a hospital-wide programme, with special emphasis on bedside, alcohol-based hand disinfection. We measured nosocomial infections in parallel. Methods We monitored the overall compliance with hand hygiene during routine patient care in a teaching hospital in Geneva, Switzerland, before and during implementation of a hand-hygiene campaign. Seven hospital-wide observational surveys were done twice yearly from December, 1994, to December, 1997. Secondary outcome measures were nosocomial infection rates, attack rates of meticillin-resistant Staphylococcus aureus (MRSA), and consumption of handrub disinfectant. Findings We observed more than 20 000 opportunities for hand hygiene. Compliance improved progressively from 48% in 1994, to 66% in 1997 (p<0.001). Although recourse to handwashing with soap and water remained stable, frequency of hand disinfection substantially increased during the study period (p<0.001). This result was unchanged after adjustment for known risk factors of poor adherence. Hand hygiene improved significantly among nurses and nursing assistants, but remained poor among doctors. During the same period, overall nosocomial infection decreased (prevalence of 16.9% in 1994 to 9.9% in 1998; p=0.04), MRSA transmission rates decreased (2.16 to 0.93 episodes per 10 000 patient-days; p<0.001), and the consumption of alcohol-based handrub solution increased from 3.5 to 15.4 L per 1000 patient-days between 1993 and 1998 (p<0.001). Interpretation The campaign produced a sustained improvement in compliance with hand hygiene, coinciding with a reduction of nosocomial infections and MRSA transmission. The promotion of bedside, antiseptic handrubs largely contributed to the increase in compliance.	Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Qual Care Programme, CH-1211 Geneva 14, Switzerland; Univ Geneva, Inst Social & Prevent Med, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland.	didier.pittet@hcuge.ch		Pittet, Didier/0000-0002-3667-7131				ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; AubryDamon H, 1997, CLIN INFECT DIS, V25, P647, DOI 10.1086/513749; Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6; Cookson B, 1999, BRIT MED J, V318, P686; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; EHRENKRANZ NJ, 1991, INFECT CONT HOSP EP, V12, P654, DOI 10.2307/30146898; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GUIGUET M, 1990, INFECT CONT HOSP EP, V11, P23, DOI 10.1086/646074; HALEY RW, 1981, AM J MED, V70, P51, DOI 10.1016/0002-9343(81)90411-3; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; Kretzer EK, 1998, AM J INFECT CONTROL, V26, P245, DOI 10.1016/S0196-6553(98)80008-4; Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468; LARSON E, 1995, J HOSP INFECT, V30, P88, DOI 10.1016/0195-6701(95)90010-1; Larson EL, 1997, AM J INFECT CONTROL, V25, P3, DOI 10.1016/S0196-6553(97)90046-8; LARSON EL, 1995, AM J INFECT CONTROL, V23, P251, DOI 10.1016/0196-6553(95)90070-5; Monnet DL, 1998, INFECT CONT HOSP EP, V19, P552; Pittet D, 2000, INFECT CONT HOSP EP, V21, P381, DOI 10.1086/501777; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Pittet D, 1999, INFECT CONT HOSP EP, V20, P37, DOI 10.1086/501554; Pittet D, 1996, INFECT CONT HOSP EP, V17, P496; Pittet D, 1999, ARCH INTERN MED, V159, P821, DOI 10.1001/archinte.159.8.821; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Rotter LM, 1996, HOSP EPIDEMIOLOGY IN, P1052; Scheckler WE, 1998, INFECT CONT HOSP EP, V19, P114; Solomon DH, 1998, JAMA-J AM MED ASSOC, V280, P2020, DOI 10.1001/jama.280.23.2020; Teare EL, 1999, J HOSP INFECT, V43, P1, DOI 10.1053/jhin.1999.0251; Thompson BL, 1997, INFECT CONT HOSP EP, V18, P97; Voss A, 1997, INFECT CONT HOSP EP, V18, P205; WEBSTER J, 1992, J HOSP INFECT, V21, P137, DOI 10.1016/0195-6701(92)90033-I; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	31	1502	1563	2	151	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1307	1312		10.1016/S0140-6736(00)02814-2	http://dx.doi.org/10.1016/S0140-6736(00)02814-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073019				2022-12-28	WOS:000089858300011
J	Dale, S; Shaw, J				Dale, S; Shaw, J			Eosinophilic pustular folliculitis	LANCET			English	Article									Univ Chicago Hosp, Dermatol Sect, Chicago, IL 60637 USA	University of Chicago; University of Illinois System	Dale, S (corresponding author), Univ Chicago Hosp, Dermatol Sect, Chicago, IL 60637 USA.								0	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1235	1235		10.1016/S0140-6736(05)73849-6	http://dx.doi.org/10.1016/S0140-6736(05)73849-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072943				2022-12-28	WOS:000089724900014
J	Speed, CA; Shapiro, LM				Speed, CA; Shapiro, LM			Exercise prescription in cardiac disease	LANCET			English	Editorial Material							SUDDEN STRENUOUS EXERCISE; CORONARY-ARTERY DISEASE		Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England; Addenbrookes Hosp, Dept Rheumatol & Sports & Exercise Med, Cambridge, England	Papworth Hospital; Addenbrooke's Hospital; University of Cambridge	Shapiro, LM (corresponding author), Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England.							BARNARD RJ, 1973, CIRCULATION, V48, P936, DOI 10.1161/01.CIR.48.5.936; BARNARD RJ, 1973, J APPL PHYSIOL, V34, P833, DOI 10.1152/jappl.1973.34.6.833; BETHELL HJN, 1999, BENEFITS HAZARDS EXE, P339; Burrows S, 1999, BRIT J SPORT MED, V33, P287; FLETCHER GF, 1990, CIRCULATION, V82, P2286, DOI 10.1161/01.CIR.82.6.2286; FOSTER C, 1981, CIRCULATION, V63, P592, DOI 10.1161/01.CIR.63.3.592; FRANKLIN BA, 1992, AM J CARDIOL, V69, P1426, DOI 10.1016/0002-9149(92)90895-6; OBERMAN A, 1995, AM J CARDIOL, V76, P643, DOI 10.1016/S0002-9149(99)80189-1; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POLLOCK ML, 1975, ARCH PHYS MED REHAB, V56, P141; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; POLLOCK ML, 1996, US PRESIDENTS COUNCI, V2; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; SIRE S, 1987, EUR HEART J, V8, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062195; SULLIVAN MJ, 1988, CIRCULATION, V78, P506, DOI 10.1161/01.CIR.78.3.506; Swan L, 2000, HEART, V83, P685, DOI 10.1136/heart.83.6.685	16	9	10	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1208	1210		10.1016/S0140-6736(00)02778-1	http://dx.doi.org/10.1016/S0140-6736(00)02778-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072933				2022-12-28	WOS:000089724900004
J	Brodie, MJ; French, JA				Brodie, MJ; French, JA			Management of epilepsy in adolescents and adults	LANCET			English	Article							FRONTAL-LOBE EPILEPSY; COMPLEX PARTIAL SEIZURES; TONIC CLONIC SEIZURES; ANTIEPILEPTIC DRUGS; GENERALIZED EPILEPSY; DOUBLE-BLIND; NERVE-STIMULATION; FEBRILE SEIZURES; CARBAMAZEPINE; VALPROATE	Epilepsy is the most common serious neurological disorder affecting an estimated 50 million people worldwide. Particular focus should be placed on a safe diagnosis, seizure and syndrome classification, and choice of pharmacological and surgical options for a range of patient populations with different health-care requirements. Eight new antiepileptic drugs were licensed in the 1990s with more to come. These new drugs along with earlier resective surgery have led to a better outcome for many more people with this condition.	Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurol, Penn Epilesy Ctr, Philadelphia, PA 19104 USA	University of Glasgow; University of Pennsylvania; Pennsylvania Medicine	Brodie, MJ (corresponding author), Univ Glasgow, Western Infirm, Dept Med & Therapeut, Epilepsy Unit, Glasgow G11 6NT, Lanark, Scotland.	Martin.J.Brodie@clinmed.gla.ac.uk	French, Jacqueline A/G-6795-2013	French, Jacqueline A/0000-0003-2242-8027				[Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Brodie MJ, 1997, EPILEPSIA, V38, P1245, DOI 10.1111/j.1528-1157.1997.tb01224.x; Brodie MJ, 1999, EPILEPSY RES, V37, P81, DOI 10.1016/S0920-1211(99)00039-X; Brodie MJ, 1999, EPILEPSY RES, V34, P199, DOI 10.1016/S0920-1211(98)00110-7; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; Brodie MJ, 1997, EPILEPSY RES, V26, P423, DOI 10.1016/S0920-1211(96)01007-8; BRODIE MJ, 1999, EPILIPSIA, V40, P17; CHADWICK D, 1994, CNS DRUGS, V2, P423, DOI 10.2165/00023210-199402060-00003; Cramer JA, 1999, EPILEPSIA, V40, P590, DOI 10.1111/j.1528-1157.1999.tb05561.x; Crawford P, 1999, SEIZURE-EUR J EPILEP, V8, P201, DOI 10.1053/seiz.1999.0295; Delanty N, 1998, LANCET, V352, P383, DOI 10.1016/S0140-6736(98)02158-8; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Duncan JS, 1997, BRAIN, V120, P339, DOI 10.1093/brain/120.2.339; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; FEELY M, 1984, J NEUROL NEUROSUR PS, V47, P1279, DOI 10.1136/jnnp.47.12.1279; FRENCH J, 1994, ANN INTERN MED, V120, P411, DOI 10.7326/0003-4819-120-5-199403010-00010; FRENCH J, 1995, CURR OPIN NEUROL, V8, P117, DOI 10.1097/00019052-199504000-00005; French JA, 1996, NEUROLOGY, V46, P54, DOI 10.1212/WNL.46.1.54; FRENCH JA, 1997, CURRENT THERAPY NEUR, P61; Hannah JA, 1998, SEIZURE-EUR J EPILEP, V7, P3, DOI 10.1016/S1059-1311(98)90002-4; Isojarvi JIT, 1996, ANN NEUROL, V39, P579, DOI 10.1002/ana.410390506; Koch S, 1999, EPILEPSIA, V40, P1237, DOI 10.1111/j.1528-1157.1999.tb00852.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Labar D, 1999, NEUROLOGY, V52, P1510, DOI 10.1212/WNL.52.7.1510; Leestma JE, 1997, EPILEPSIA, V38, P47, DOI 10.1111/j.1528-1157.1997.tb01076.x; Marson AG, 1997, EPILEPSIA, V38, P859, DOI 10.1111/j.1528-1157.1997.tb01251.x; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Pellock JM, 1997, EPILEPSIA, V38, P1261, DOI 10.1111/j.1528-1157.1997.tb00061.x; Perucca E, 1998, EPILEPSIA, V39, P5, DOI 10.1111/j.1528-1157.1998.tb01268.x; Picard F, 1999, EPILEPSIA, V40, P1198, DOI 10.1111/j.1528-1157.1999.tb00848.x; Radhakrishnan K, 1998, NEUROLOGY, V51, P465, DOI 10.1212/WNL.51.2.465; Ramsey RE, 1997, EPILEPSY COMPREHENSI, P1455; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Scheepers B, 1998, SEIZURE-EUR J EPILEP, V7, P403, DOI 10.1016/S1059-1311(05)80010-X; Scheffer IE, 1997, BRAIN, V120, P479, DOI 10.1093/brain/120.3.479; SCHEFFER IE, 1995, BRAIN, V118, P61, DOI 10.1093/brain/118.1.61; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Smith D, 1999, QJM-INT J MED, V92, P15, DOI 10.1093/qjmed/92.1.15; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Stephen LJ, 1999, SEIZURE-EUR J EPILEP, V8, P339, DOI 10.1053/seiz.1999.0301; Stephen LJ, 2000, LANCET, V355, P1441, DOI 10.1016/S0140-6736(00)02149-8; Stephen LJ, 1998, LANCET, V351, P958; VICKREY BG, 1994, EPILEPSIA, V35, P597, DOI 10.1111/j.1528-1157.1994.tb02480.x; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; YERBY MS, 1996, MODERN MANAGEMENT EP, P887; Zahn CA, 1998, NEUROLOGY, V51, P949, DOI 10.1212/WNL.51.4.949	50	135	138	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					323	329		10.1016/S0140-6736(00)02515-0	http://dx.doi.org/10.1016/S0140-6736(00)02515-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071202				2022-12-28	WOS:000088305900037
J	Davies, L; Wilkinson, M; Bonner, S; Calverley, PMA; Angus, RM				Davies, L; Wilkinson, M; Bonner, S; Calverley, PMA; Angus, RM			"Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							OUTCOMES	Objectives To compare "hospital at home" and hospital care as an inpatient in acute exacerbations of chronic obstructive pulmonary disease. Design Prospective randomised controlled trial with three months' follow up. Setting University teaching hospital offering secondary care service to 350 000 patients. Patients Selected patients with an exacerbation of chronic obstructive pulmonary disease where hospital admission had been recommended after medical assessment. Interventions Nurse administered home care was provided as an alternative to inpatient admission. Main outcome measures Readmission rates at two weeks and three months, changes in forced expiratory volume in one second (FEV1) from baseline at these times and mortality. Results 583 patients with chronic obstructive pulmonary disease referred for admission were assessed. 192 met the criteria for home care, and 42 refused to enter the trial. 100 were randomised to home care and 50 to hospital care. On admission, FEV1 after use of a bronchodilator was 36.1% (95% confidence interval 2.4% to 69.8%) predicted in home care and 35.1% (6.3% to 63.9%) predicted in hospital care. No significant difference was found in FEV1 after se of a bronchodilator at two weeks (42.6%, 3.4% to 81.8% versus 42.1%, 5.1% to 79.1%) or three months (41.5%, 8.2% to 74.8% versus 41.9%, 6.2% to 77.6%) between the groups. 37% of patients receiving home care and 34% receiving hospital care were readmitted at three months. No significant difference was found in mortality between the groups at three months (9% versus 8%). Conclusions Hospital at home care is a practical alternative to emergency admission in selected patients with exacerbations of chronic obstructive pulmonary disease.	Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England; Univ Hosp Aintree, Dept Accid & Emergency, ACTRITF Team, Liverpool L9 7AL, Merseyside, England; Univ Hosp Aintree, Dept Med, Liverpool L9 7AL, Merseyside, England	University of Liverpool	Angus, RM (corresponding author), Univ Hosp Aintree, Aintree Chest Ctr, Liverpool L9 7AL, Merseyside, England.							ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; *BRIT THOR SOC, 1998, THORAX, V53, pA70; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; DAVIES L, 1998, THORAX S4, V53, pA71; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; HAGGERTY MC, 1991, CHEST, V100, P607, DOI 10.1378/chest.100.3.607; JEFFREY AA, 1992, THORAX, V47, P37; National Health Service Executive, 1996, BURD DIS DISC DOC; Osman LM, 1997, THORAX, V52, P67; ROBERTS CM, 2000, IN PRESS EUR RESP J; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	13	129	129	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1265	1268		10.1136/bmj.321.7271.1265	http://dx.doi.org/10.1136/bmj.321.7271.1265			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082090	Green Published, Bronze			2022-12-28	WOS:000165445800028
J	Guadagnoli, E; Landrum, MB; Peterson, EA; Gahart, MT; Ryan, TJ; McNeil, BJ				Guadagnoli, E; Landrum, MB; Peterson, EA; Gahart, MT; Ryan, TJ; McNeil, BJ			Appropriateness of coronary angiography after myocardial infarction among medicare beneficiaries: Managed care versus fee for service.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC PROCEDURES; ELDERLY PATIENTS; ASSOCIATION; REVASCULARIZATION; EXPENDITURES	Background: Previous studies have documented that cardiac procedures are performed less frequently in patients enrolled in managed-care plans than in those with fee-for-service coverage. However, it is not known whether this difference is due to less frequent use of cardiac procedures when they are indicated or to less frequent use when they are not indicated. Methods: We compared the use of coronary angiography after acute myocardial infarction among Medicare beneficiaries who had traditional fee-for-service coverage with the use among Medicare beneficiaries enrolled in managed-care plans. The analysis was adjusted for differences in demographic and clinical characteristics of the patients and for characteristics of the hospitals to which they were admitted. We studied more than 50,000 beneficiaries in seven states and evaluated their care according to guidelines proposed by the American College of Cardiology and the American Heart Association (ACC-AHA). Results: Among the 44 percent of patients in both groups who had ACC-AHA class I indications (those for which angiography is useful and effective), more fee-for-service beneficiaries than managed-care enrollees underwent angiography (46 percent vs. 37 percent, P<0.001). The rate of angiography was very low among patients with class I indications who were admitted to hospitals without angiography facilities (31 percent in the fee-for-service group and 15 percent in the managed-care group, P<0.001). Among patients with class III indications (those for which angiography is not effective), the rate of use was low in both groups (approximately 13 percent). Conclusions: In situations in which angiography is thought to be useful, it is used less often among Medicare beneficiaries enrolled in managed-care plans than among those with fee-for-service coverage. Moreover, rates of use among patients with class I indications are fairly low in both groups, suggesting that there is room for improving the care of elderly patients with myocardial infarction, especially those admitted to hospitals without angiography facilities. (N Engl J Med 2000;343:1460-6.) (C) 2000, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; US Gen Accounting Off, Hlth Educ & Human Serv Div, Washington, DC 20548 USA; Boston Univ, Sch Med, Dept Med, Cardiol Sect, Boston, MA 02118 USA; Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Boston University; Harvard University; Brigham & Women's Hospital	Guadagnoli, E (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008071] Funding Source: NIH RePORTER; AHRQ HHS [HS-08071] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM HOSP ASS, 1995, AHA GUID HLTH CAR FI; [Anonymous], DHHS PUBLICATION; Baker LC, 1999, JAMA-J AM MED ASSOC, V281, P432, DOI 10.1001/jama.281.5.432; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Canto JG, 2000, NEW ENGL J MED, V342, P1094, DOI 10.1056/NEJM200004133421505; Christensen S, 1998, HEALTH AFFAIR, V17, P224, DOI 10.1377/hlthaff.17.4.224; Cooper M. M., 1996, DARTMOUTH ATLAS HLTH; Cutler DM, 1998, NBER FR HLTH POL RES, V1, P77; Daniels MJ, 1999, J AM STAT ASSOC, V94, P29, DOI 10.2307/2669675; Every NR, 1998, J AM COLL CARDIOL, V32, P387, DOI 10.1016/S0735-1097(98)00254-X; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; EVERY NR, 1995, J AM COLL CARDIOL, V26, P401, DOI 10.1016/0735-1097(95)80013-7; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; *GEN ACC OFF, 1999, GAOHEHS99144; GILKS WR, 1994, STATISTICIAN, V43, P169, DOI 10.2307/2348941; Krumholz HM, 1999, JAMA-J AM MED ASSOC, V281, P37; KUYKENDALL DH, 1995, MED CARE, V33, P715, DOI 10.1097/00005650-199507000-00007; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; Leape LL, 1999, ANN INTERN MED, V130, P183, DOI 10.7326/0003-4819-130-3-199902020-00003; LITTLE RJA, 1982, AM STAT, V36, P38, DOI 10.2307/2684091; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Mirvis DM, 1999, AM HEART J, V137, P706, DOI 10.1016/S0002-8703(99)70227-9; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Sada MJ, 1998, J AM COLL CARDIOL, V31, P1474, DOI 10.1016/S0735-1097(98)00137-5; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Wennberg D, 1997, J Health Serv Res Policy, V2, P75; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; Zwanziger J, 1996, HEALTH AFFAIR, V15, P185, DOI 10.1377/hlthaff.15.2.185	28	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1460	1466		10.1056/NEJM200011163432006	http://dx.doi.org/10.1056/NEJM200011163432006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078772				2022-12-28	WOS:000165271300006
J	Jick, H; Zornberg, GL; Jick, SS; Seshadri, S; Drachman, DA				Jick, H; Zornberg, GL; Jick, SS; Seshadri, S; Drachman, DA			Statins and the risk of dementia	LANCET			English	Article							ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; FRONTOTEMPORAL DEMENTIA; INTERNATIONAL WORKSHOP; VASCULAR DEMENTIA; TOTAL CHOLESTEROL; DIAGNOSIS; ASSOCIATION; PREVALENCE; EPSILON-4	Background Dementia affects an estimated 10% of the population older than 65 years. Because vascular and lipid-related mechanisms are thought to have a role in the pathogenesis of Alzheimer's disease and vascular dementia, we did an epidemiological study of the potential effect of HMGCoA (3 hydroxy-3 methylglutaryl-coenzyme A) reductase inhibitors (statins) and other lipid-lowering agents on dementia, Methods We used a nested case-control design with information derived from 368 practices which contribute to the UK-based General Practice Research Database. The base study population included three groups of patients age 50 years and older: all individuals who had received lipid-lowering agents (LLAs); all individuals with a clinical diagnosis of untreated hyperlipidaemia: and a randomly selected group of other individuals. From this base population, all cases with a computer-recorded clinical diagnosis of dementia were identified. Each case was matched with up to four controls derived from the base population on age, sex, practice, and index date of case. Findings The study encompassed 284 cases with dementia and 1 080 controls. Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure. The relative risk estimates of dementia adjusted for ape, sex, history of coronary-artery disease, hypertension, coronary-bypass surgery and cerebral ischaemia, smoking and body mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% CI 0.45-1.14]), or treated with non-statin LLAs (0.96 [0.47-1.97], was close to 1.0 and not significant compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drugs. The adjusted relative risk for those prescribed statins was 0.29 (0.13-0.63; p=0.002). Interpretation Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to non-statin LLAs. The available data do not distinguish between Alzheimer's disease and other forms of dementia.	Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA; Boston Univ, Sch Med, Framingham Heart Study, Framingham, MA 01702 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; Boston University; Boston University; Framingham Heart Study; Harvard University; Harvard T.H. Chan School of Public Health	Drachman, DA (corresponding author), Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA.	david.drachman@umassmed.edu		Seshadri, Sudha/0000-0001-6135-2622; Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992	NINDS NIH HHS [R01 NS017950] Funding Source: Medline; PHS HHS [AC05134] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRAYNE C, 1995, BRIT J PSYCHIAT, V167, P255, DOI 10.1192/bjp.167.2.255; Buee L, 1997, ANN NY ACAD SCI, V826, P7, DOI 10.1111/j.1749-6632.1997.tb48457.x; Chow TW, 1999, ARCH NEUROL-CHICAGO, V56, P817, DOI 10.1001/archneur.56.7.817; Chun MR, 1998, NEUROBIOLOGY OF PRIMARY DEMENTIA, P1; Dahiyat M, 1999, ANN NEUROL, V46, P664, DOI 10.1002/1531-8249(199910)46:4<664::AID-ANA18>3.0.CO;2-J; Davignon J, 1999, CURR OPIN LIPIDOL, V10, P543, DOI 10.1097/00041433-199912000-00010; de la Monte SM, 2000, NEUROBIOL AGING, V21, P309, DOI 10.1016/S0197-4580(99)00108-6; DRACHMAN D, 1998, TXB NEUROLOGY, P389; DRACHMAN DA, 1993, NEUROLOGY, V43, P243, DOI 10.1212/WNL.43.2.243; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; Hachinski V, 1997, ANN NY ACAD SCI, V826, P1, DOI 10.1111/j.1749-6632.1997.tb48456.x; Hess DC, 2000, NEUROLOGY, V54, P790, DOI 10.1212/WNL.54.4.790; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Hyman BT, 2000, ARCH NEUROL-CHICAGO, V57, P646, DOI 10.1001/archneur.57.5.646; Jagust WJ, 1997, ANN NY ACAD SCI, V826, P254, DOI 10.1111/j.1749-6632.1997.tb48477.x; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 1998, LANCET, V352, P1767, DOI 10.1016/S0140-6736(98)04350-5; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Kaesemeyer WH, 1999, J AM COLL CARDIOL, V33, P234, DOI 10.1016/S0735-1097(98)00514-2; Knopp RH, 1999, NEW ENGL J MED, V341, P498, DOI 10.1056/NEJM199908123410707; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Neary D, 1996, BRAIN COGNITION, V31, P176, DOI 10.1006/brcg.1996.0041; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; *PROGR BCDS, 1974, BRIT MED J, V1, P440; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Sackett D. L., 1997, EVIDENCE BASED MED P; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SESHADRI S, 2000, IN PRESS ARCH NEUROL; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; St George-Hyslop P, 1995, Prog Clin Biol Res, V393, P139; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439	34	1328	1383	2	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1627	1631		10.1016/S0140-6736(00)03155-X	http://dx.doi.org/10.1016/S0140-6736(00)03155-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089820				2022-12-28	WOS:000165249200009
J	Nunn, CL; Gittleman, JL; Antonovics, J				Nunn, CL; Gittleman, JL; Antonovics, J			Promiscuity and the primate immune system	SCIENCE			English	Article							POPULATION-DYNAMICS; MATING SYSTEMS; EVOLUTION; TRANSMISSION; PHYLOGENY; PARASITES; SEASON; SIZE	The behavioral and ecological factors involved in immune system evolution remain poorly explored. We present a phylogenetic analysis of white blood cell counts in primates to test three hypotheses related to disease risk: increases in risk are expected with group size or population density, exposure to soilborne pathogens, and mating promiscuity. White blood cell counts were significantly greater in species where females have more mating partners, indicating that the risk of sexually transmitted disease is likely to be a major factor Leading to systematic differences in the primate immune system.	Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA	University of Virginia	Nunn, CL (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22904 USA.				NIGMS NIH HHS [GM60766-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerly DD, 1998, AM NAT, V152, P767, DOI 10.1086/286208; Alexander R.D., 1974, Annual Rev Ecol Syst, V5, P325, DOI 10.1146/annurev.es.05.110174.001545; ANTIA R, 1994, AM NAT, V144, P457, DOI 10.1086/285686; BORER WZ, 2000, CONNS CURRENT THERAP, P1205; CLUTTONBROCK TH, 1977, J ZOOL, V183, P1, DOI 10.1111/j.1469-7998.1977.tb04171.x; Dobson A, 1996, ECOLOGY, V77, P1026, DOI 10.2307/2265573; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; FREELAND W J, 1976, Biotropica, V8, P12, DOI 10.2307/2387816; GOLDIZEN AW, 1988, TRENDS ECOL EVOL, V3, P36, DOI 10.1016/0169-5347(88)90045-6; HARCOURT AH, 1981, NATURE, V293, P55, DOI 10.1038/293055a0; HARCOURT AH, 1995, FUNCT ECOL, V9, P468, DOI 10.2307/2390011; HART BL, 1990, NEUROSCI BIOBEHAV R, V14, P273, DOI 10.1016/S0149-7634(05)80038-7; Harvey P.H., 1991, COMP METHOD EVOLUTIO; HARVEY PH, 1985, EVOLUTION, V39, P559, DOI 10.1111/j.1558-5646.1985.tb00395.x; HAUSFATER G, 1982, Primates, V23, P287, DOI 10.1007/BF02381167; HOLMES KK, 1994, SEXUALLY TRANSMITTED; Hrdy S.B., 1987, P370; Lockhart AB, 1996, BIOL REV, V71, P415, DOI 10.1111/j.1469-185X.1996.tb01281.x; LOEHLE C, 1995, ECOLOGY, V76, P326, DOI 10.2307/1941192; *MIN ZOOL GARD, 1999, INT SPEC INF SYST PH; MOLLER AP, 1993, ADV STUD BEHAV, V22, P65, DOI 10.1016/S0065-3454(08)60405-2; Nunn CL, 2000, AM NAT, V156, P519, DOI 10.1086/303405; NUNN CL, IN PRESS RECONSTRUCT; PURVIS A, 1995, PHILOS T ROY SOC B, V348, P405, DOI 10.1098/rstb.1995.0078; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Roitt I., 1998, IMMUNOLOGY; Smith RJ, 1997, J HUM EVOL, V32, P523, DOI 10.1006/jhev.1996.0122; TAUB DM, 1980, STUDIES ECOLOGY BEHA, P287; Thrall PH, 2000, P ROY SOC B-BIOL SCI, V267, P1555, DOI 10.1098/rspb.2000.1178; Thrall PH, 1997, AM NAT, V149, P485, DOI 10.1086/286001; van Schaik Carel P., 1999, P204, DOI 10.1017/CBO9780511542466.011; [No title captured]	32	184	186	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1168	1170		10.1126/science.290.5494.1168	http://dx.doi.org/10.1126/science.290.5494.1168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073457				2022-12-28	WOS:000165228200050
J	Guarente, L; Kenyon, C				Guarente, L; Kenyon, C			Genetic pathways that regulate ageing in model organisms	NATURE			English	Review							YEAST SACCHAROMYCES-CEREVISIAE; FORKHEAD TRANSCRIPTION FACTOR; EXTENDED LIFE-SPAN; AGE-1 PI3 KINASE; CAENORHABDITIS-ELEGANS; C-ELEGANS; OXIDATIVE STRESS; SIGNALING PATHWAY; DAUER FORMATION; PROTEIN-KINASE	Searches for genes involved in the ageing process have been made in genetically tractable model organisms such as yeast, the nematode Caenorhabditis elegans, Drosophila melanogaster fruitflies and mice. These genetic studies have established that ageing is indeed regulated by specific genes, and have allowed an analysis of the pathways involved, linking physiology, signal transduction and gene regulation. Intriguing similarities in the phenotypes of many of these mutants indicate that the mutations may also perturb regulatory systems that control ageing in higher organisms.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Ailion M, 1999, P NATL ACAD SCI USA, V96, P7394, DOI 10.1073/pnas.96.13.7394; Antebi A, 2000, GENE DEV, V14, P1512; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; Ashrafi K, 2000, GENE DEV, V14, P1872; Ashrafi K, 1999, P NATL ACAD SCI USA, V96, P9100, DOI 10.1073/pnas.96.16.9100; AVERY L, 1993, GENETICS, V133, P897; Bartke A, 1998, EXP GERONTOL, V33, P675, DOI 10.1016/S0531-5565(98)00032-1; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; DORMAN JB, 1995, GENETICS, V141, P1399; EGILMEZ NK, 1989, J BACTERIOL, V171, P37, DOI 10.1128/jb.171.1.37-42.1989; Finch CE, 1990, LONGEVITY SENESCENCE; Friedman D.B., 1988, Journals of Gerontology, V43, P102; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gems D, 1998, GENETICS, V150, P129; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hauck SJ, 2000, FREE RADICAL BIO MED, V28, P970, DOI 10.1016/S0891-5849(00)00186-6; Heo SJ, 1999, GENES CELLS, V4, P619, DOI 10.1046/j.1365-2443.1999.00288.x; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hunter WS, 1999, PHYSIOL BEHAV, V67, P433, DOI 10.1016/S0031-9384(99)00098-0; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; JAZWINSKI SM, 1993, GENETICA, V91, P35, DOI 10.1007/BF01435986; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kawano T, 2000, BIOCHEM BIOPH RES CO, V273, P431, DOI 10.1006/bbrc.2000.2971; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim S, 1999, MOL BIOL CELL, V10, P3125, DOI 10.1091/mbc.10.10.3125; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirchman PA, 1999, GENETICS, V152, P179; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Kopchick JJ, 1999, MOL GENET METAB, V68, P232, DOI 10.1006/mgme.1999.2890; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Murakami S, 1996, GENETICS, V143, P1207; Murakami S, 1998, CURR BIOL, V8, P1091, DOI 10.1016/S0960-9822(98)70448-8; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Riddle DL, 1997, C ELEGANS, P739; RINE J, 1987, GENETICS, V116, P9; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Sgro CM, 1999, SCIENCE, V286, P2521, DOI 10.1126/science.286.5449.2521; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sun JT, 1999, MOL CELL BIOL, V19, P216; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Tissenbaum HA, 1998, GENETICS, V148, P703; Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VOWELS JJ, 1992, GENETICS, V130, P105; WAREHAM KA, 1987, NATURE, V327, P725, DOI 10.1038/327725a0; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147	97	1025	1088	6	242	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					255	262		10.1038/35041700	http://dx.doi.org/10.1038/35041700			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089983				2022-12-28	WOS:000165180400056
J	Finnell, RH; Burn, J				Finnell, RH; Burn, J			Effect of anti-epileptic drugs on intrauterine growth	LANCET			English	Editorial Material							ANTIEPILEPTIC DRUGS		Univ Nebraska, Med Ctr, Ctr Human Mol Genet, Omaha, NE 68198 USA; Univ Newcastle Upon Tyne, No Reg Genet Serv, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Nebraska System; University of Nebraska Medical Center; Newcastle University - UK	Finnell, RH (corresponding author), Univ Nebraska, Med Ctr, Ctr Human Mol Genet, 600 S 42nd St, Omaha, NE 68198 USA.		Finnell, Richard/D-8174-2018	Finnell, Richard/0000-0002-5962-8754				Fairgrieve SD, 2000, BRIT MED J, V321, P674, DOI 10.1136/bmj.321.7262.674; Finnell RH, 1997, DRUG TOXICITY EMBRYO, P121; James F, 2000, J MED GENET, V37, pS67; Janz D.J.G.M.M., 1964, GER MED MON, V9, P20; KANEKO S, 1992, NEUROLOGY, V42, P68; LINDHOUT D, 1992, NEUROLOGY, V42, P94; Lundberg YW, 2000, AM J HUM GENET, V67, P20; Wide K, 2000, EPILEPSIA, V41, P854, DOI 10.1111/j.1528-1157.2000.tb00253.x	8	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1537	1538		10.1016/S0140-6736(00)03118-4	http://dx.doi.org/10.1016/S0140-6736(00)03118-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075761				2022-12-28	WOS:000165134500003
J	Blackburn, EH				Blackburn, EH			Telomere states and cell fates	NATURE			English	Article							TO-END FUSIONS; SACCHAROMYCES-CEREVISIAE; LACKING TELOMERASE; HUMAN FIBROBLASTS; MOUSE TELOMERASE; LIFE-SPAN; IN-VITRO; LENGTH; YEAST; RNA	Telomere length has frequently been used as a means to predict the future life of cells. But by itself it can be a poor indicator of ageing or cell viability. What, then, is the important property of a telomere? Here recent findings are integrated into a new, probabilistic view of the telomere to explain how and when it can signal not only its own fate but also that of a cell.	Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA.	telomer@itsa.ucsf.edu						Ahmed S, 2000, NATURE, V403, P159, DOI 10.1038/35003120; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bassham S, 1998, MOL CELL BIOL, V18, P269, DOI 10.1128/MCB.18.1.269; Bertuch A, 1998, TRENDS CELL BIOL, V8, P339, DOI 10.1016/S0962-8924(98)01331-2; Blackburn E, 1999, MT SINAI J MED, V66, P292; BLACKBURN EH, IN PRESS COLD SPRING; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; di Fagagna FD, 1999, NAT GENET, V23, P76; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Frenck RW, 1998, P NATL ACAD SCI USA, V95, P5607, DOI 10.1073/pnas.95.10.5607; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harley CB, 1997, CIBA F SYMP, V211, P129; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Holliday R, 1996, BIOESSAYS, V18, P3, DOI 10.1002/bies.950180103; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; JONES RB, 1985, MECH AGEING DEV, V29, P143, DOI 10.1016/0047-6374(85)90014-4; KARATZA C, 1984, J CELL SCI, V65, P163; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kirschner M, 2000, CELL, V100, P79, DOI 10.1016/S0092-8674(00)81685-2; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; Krauskopf A, 1998, P NATL ACAD SCI USA, V95, P12486, DOI 10.1073/pnas.95.21.12486; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PONTEN J, 1983, J CELL PHYSIOL, V117, P342, DOI 10.1002/jcp.1041170309; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Roy J, 1998, GENE DEV, V12, P3286, DOI 10.1101/gad.12.20.3286; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Sprung CN, 1997, MUTAT RES-FUND MOL M, V379, P177, DOI 10.1016/S0027-5107(97)00119-X; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	48	1026	1084	3	133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					53	56		10.1038/35040500	http://dx.doi.org/10.1038/35040500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081503				2022-12-28	WOS:000165050400047
J	Bracht, H; Nicols, SP; Walukiewicz, W; Silveira, JP; Briones, F; Haller, EE				Bracht, H; Nicols, SP; Walukiewicz, W; Silveira, JP; Briones, F; Haller, EE			Large disparity between gallium and antimony self-diffusion in gallium antimonide	NATURE			English	Article							GAAS ISOTOPE HETEROSTRUCTURES; V COMPOUND SEMICONDUCTORS; ELECTRONIC-STRUCTURE; VACANCIES; GASB	The most fundamental mass transport process in solids is selfdiffusion. The motion of host-lattice (`self-') atoms in solids is mediated by point defects such as vacancies or interstitial atoms, whose formation and migration enthalpies determine the kinetics of this thermally activated process(1,2). Self-diffusion studies also contribute to the understanding of the diffusion of impurities, and a quantitative understanding of self- and foreign-atom diffusion in semiconductors is central to the development of advanced electronic devices. In the past few years, self- diffusion studies have been performed successfully with isotopically controlled semiconductor heterostructures of germanium(3), silicon(4), gallium arsenide(5,6) and gallium phosphide(7). Self- diffusion studies with isotopically controlled GaAs and GaP have been restricted to Ga self- diffusion, as only Ga has two stable isotopes, Ga-69 and Ga-71. Here we report self- diffusion studies with an isotopically controlled multilayer structure of crystalline GaSb. Two stable isotopes exist for both Ga and Sb, allowing the simultaneous study of diffusion on both sublattices. Our experiments show that near the melting temperature, Ga diffuses more rapidly than Sb by over three orders of magnitude. This surprisingly large difference in atomic mobility requires a physical explanation going beyond standard diffusion models. Combining our data for Ga and Sb diffusion with related results for foreign-atom diffusion in GaSb (refs 8, 9), we conclude that the unusually slow Sb diffusion in GaSb is a consequence of reactions between defects on the Ga and Sb sublattices, which suppress the defects that are required for Sb diffusion.	Univ Calif Berkeley, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Berkeley, CA 94720 USA; CSIC, Ctr Nacl Microelect, Inst Microelect Madrid, Madrid 28066, Spain	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Microelectronica (CNM); CSIC - Instituto de Microelectronica de Barcelona (IMB-CNM); CSIC - Instituto de Microelectronica de Madrid (IMM)	Bracht, H (corresponding author), Univ Calif Berkeley, Berkeley, CA 94720 USA.		Walukiewicz, Wladyslaw/N-4525-2018	Walukiewicz, Wladyslaw/0000-0001-9936-5234; Microelectronica de Madrid, Instituto de/0000-0003-4211-9045				BEKE DL, 1998, LANDOLTBORNSTEIN, V33, P13361; Bosker G, 1998, MATER RES SOC SYMP P, V527, P347, DOI 10.1557/PROC-527-347; Bracht H, 1999, SOLID STATE COMMUN, V112, P301, DOI 10.1016/S0038-1098(99)00376-2; Bracht H, 1998, PHYS REV LETT, V81, P393, DOI 10.1103/PhysRevLett.81.393; EDELIN G, 1980, PHILOS MAG B, V42, P95, DOI 10.1080/01418638008225641; FUCHS HD, 1995, PHYS REV B, V51, P16817, DOI 10.1103/PhysRevB.51.16817; Gude A, 1997, PHILOS MAG A, V76, P1, DOI 10.1080/01418619708209959; KUHN W, 1987, PHYS STATUS SOLIDI B, V151, P541; MATHIOT D, 1980, PHILOS MAG A, V41, P447, DOI 10.1080/01418618008239324; MEHRER H, 1990, LANDOLTBORNSTEIN B, V26; Salamon M, 1999, PHILOS MAG A, V79, P2137, DOI 10.1080/01418619908210413; TALWAR DN, 1982, PHYS REV B, V25, P2660, DOI 10.1103/PhysRevB.25.2660; Tang XP, 1999, NATURE, V402, P160, DOI 10.1038/45996; WALUKIEWICZ W, 1988, PHYS REV B, V37, P4760, DOI 10.1103/PhysRevB.37.4760; WALUKIEWICZ W, 1989, APPL PHYS LETT, V54, P2094, DOI 10.1063/1.101174; Wang L, 1996, PHYS REV LETT, V76, P2342, DOI 10.1103/PhysRevLett.76.2342; Wang L, 1997, APPL PHYS LETT, V70, P1831, DOI 10.1063/1.118705; WEILER D, 1984, PHILOS MAG A, V49, P309, DOI 10.1080/01418618408234931; XU HQ, 1990, J APPL PHYS, V68, P4077, DOI 10.1063/1.346246	19	88	94	1	34	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					69	72		10.1038/35040526	http://dx.doi.org/10.1038/35040526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081507				2022-12-28	WOS:000165050400051
J	Dezhina, I; Graham, L				Dezhina, I; Graham, L			Is Russian science recovering?	NATURE			English	Editorial Material									Inst Econ Transit, Moscow 103918, Russia; MIT, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Dezhina, I (corresponding author), Inst Econ Transit, Gazetny Per 5, Moscow 103918, Russia.	dezhina@crdf.ru; lrg@mit.edu	Dezhina, Irina G/F-7485-2014	Dezhina, Irina G/0000-0002-3402-3433				ANTOKHIN M, 2000, A DONDUKOV PROMISES; DEZHINA I, 2000, VESTNIK ROSSIISKOI A, V4, P291; DEZHINA I, 1999, GODU TENDENTSII I PE, V21, P615; Graham LorenR., 1998, WHAT HAVE WE LEARNED; LIBENSON MN, 2000, UNPUB STATEMENT COOR; *STAT COMM STAT RU, 1996, NAUK 5 ROSS 5 1996 G; *STAT COMM STAT RU, 1999, NAUK 5 ROSS 5 TSIFR, V37; WINES M, 2000, NY TIMES        1012, pA3; 2000, NEZAVISIMAYA GA 0310, V13; 1999, PITTSBURGH POST 0531; 2000, NEZAVISIMAYA GA 0604, V4	11	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					19	20		10.1038/35040625	http://dx.doi.org/10.1038/35040625			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081488				2022-12-28	WOS:000165050400020
J	Fernandez-Funez, P; Nino-Rosales, ML; de Gouyon, B; She, WC; Luchak, JM; Martinez, P; Turiegano, E; Benito, J; Capovilla, M; Skinner, PJ; McCall, A; Canal, I; Orr, HT; Zoghbi, HY; Botas, J				Fernandez-Funez, P; Nino-Rosales, ML; de Gouyon, B; She, WC; Luchak, JM; Martinez, P; Turiegano, E; Benito, J; Capovilla, M; Skinner, PJ; McCall, A; Canal, I; Orr, HT; Zoghbi, HY; Botas, J			Identification of genes that modify ataxin-1-induced neurodegeneration	NATURE			English	Article							SCA1 TRANSGENIC MICE; DROSOPHILA-MELANOGASTER; BINDING PROTEIN; POLYGLUTAMINE; DISEASE; HUNTINGTIN; ENCODES	A growing number of human neurodegenerative diseases result from the expansion of a glutamine repeat in the protein that causes the disease(1). Spinocerebellar ataxia type 1 (SCA1) is one such disease-caused by expansion of a polyglutamine tract in the protein ataxin-1. To elucidate the genetic pathways and molecular mechanisms underlying neuronal degeneration in this group of diseases, we have created a model system for SCA1 by expressing the full-length human SCA1 gene in Drosophila. Here we show that high levels of wild-type ataxin-1 can cause degenerative phenotypes similar to those caused by the expanded protein. We conducted genetic screens to identify genes that modify SCA1-induced neurodegeneration. Several modifiers highlight the role of protein folding and protein clearance in the development of SCA1. Furthermore, new mechanisms of polyglutamine pathogenesis were revealed by the discovery of modifiers that are involved in RNA processing, transcriptional regulation and cellular detoxification. These findings may be relevant to the treatment of polyglutamine diseases and, perhaps, to other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Autonoma Madrid, Dept Biol, Madrid, Spain; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Autonomous University of Madrid; University of Minnesota System; University of Minnesota Twin Cities	Botas, J (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Turiegano, Enrique/M-8679-2013; Capovilla, Maria/O-8483-2016	Turiegano, Enrique/0000-0003-4620-7894; Orr, Harry/0000-0001-6118-741X; Capovilla, Maria/0000-0002-1308-7964; Zoghbi, Huda/0000-0002-0700-3349; Skinner, Pamela/0000-0003-3388-1687				Bodoor K, 1999, BIOCHEM CELL BIOL, V77, P321, DOI 10.1139/bcb-77-4-321; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Chai YH, 1999, J NEUROSCI, V19, P10338; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Grams R, 1998, GENE, V215, P191, DOI 10.1016/S0378-1119(98)00251-0; HAREL A, 1989, J CELL SCI, V94, P463; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Lin X, 1999, NEURON, V24, P499, DOI 10.1016/S0896-6273(00)81104-6; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Rorth P, 1998, DEVELOPMENT, V125, P1049; Salinas AE, 1999, CURR MED CHEM, V6, P279; Waragai M, 1999, HUM MOL GENET, V8, P977, DOI 10.1093/hmg/8.6.977; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532	21	500	531	0	16	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					101	106		10.1038/35040584	http://dx.doi.org/10.1038/35040584			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081516				2022-12-28	WOS:000165050400060
J	Urban, FE; Cole, JE; Overpeck, JT				Urban, FE; Cole, JE; Overpeck, JT			Influence of mean climate change on climate variability from a 155-year tropical Pacific coral record	NATURE			English	Article							SOUTHERN-OSCILLATION; GALAPAGOS CORALS; ENSO; TEMPERATURE; OCCURRENCES; CENTURIES; INDEX	Today, the El Nino/Southern Oscillation (ENSO) system is the primary driver of interannual variability in global climate, but its long-term behaviour is poorly understood. Instrumental observations reveal a shift in 1976 towards warmer and wetter conditions in the tropical Pacific, with widespread climatic and ecological consequences(1-3). This shift, unique over the past century(4), has prompted debate over the influence of increasing atmospheric concentrations of greenhouse gases on ENSO variability(5-7). Here we present a 155-year ENSO reconstruction from a central tropical Pacific coral that provides new evidence for long-term changes in the regional mean climate and its variability. A gradual transition in the early twentieth century and the abrupt change in 1976, both towards warmer and wetter conditions, co-occur with changes in variability. In the mid-late nineteenth century, cooler and drier background conditions coincided with prominent decadal variability; in the early twentieth century, shorter-period (similar to2.9 years) variability intensified. After 1920, variability weakens and becomes focused at interannual timescales; with the shift in 1976, variability with a period of about 4 years becomes prominent. Our results suggest that variability in the tropical Pacific is linked to the region's mean climate, and that changes in both have occurred during periods of natural as well as anthropogenic climate forcing.	Univ Colorado, PAOS, INSTAAR, Dept Geol Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Cole, JE (corresponding author), Univ Colorado, PAOS, INSTAAR, Dept Geol Sci, Box 450, Boulder, CO 80309 USA.	jcole@geo.arizona.edu	Cole, Julia/ABA-5759-2020	Cole, Julia/0000-0002-3389-7809				ALLAN R., 1997, NINO SO OSCILLATION; Cole JE, 2000, SCIENCE, V287, P617, DOI 10.1126/science.287.5453.617; COLE JE, 1993, SCIENCE, V260, P1790, DOI 10.1126/science.260.5115.1790; Cole JE, 1990, PALEOCEANOGRAPHY, V5, P669, DOI 10.1029/PA005i005p00669; DUNBAR RB, 1994, PALEOCEANOGRAPHY, V9, P291, DOI 10.1029/93PA03501; EBBESMEYER CC, 1991, P 7 ANN PAC CLIM PAC, P120; Evans MN, 1998, NATURE, V394, P732, DOI 10.1038/29424; Fairbanks RG, 1997, CORAL REEFS, V16, pS93, DOI 10.1007/s003380050245; GAGAN MK, 1994, EARTH PLANET SC LETT, V121, P549, DOI 10.1016/0012-821X(94)90090-6; GRAHAM NE, 1995, SCIENCE, V267, P666, DOI 10.1126/science.267.5198.666; Guilderson TP, 1999, PALEOCEANOGRAPHY, V14, P457, DOI 10.1029/1999PA900024; Hughen KA, 1999, GEOPHYS RES LETT, V26, P3129, DOI 10.1029/1999GL006062; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; KENNEDY JA, 1992, NATURE, V357, P62, DOI 10.1038/357062a0; Mann ME, 1996, CLIMATIC CHANGE, V33, P409, DOI 10.1007/BF00142586; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; MANN ME, NINO SO OSCILLATION, P321; Picaut J, 1996, SCIENCE, V274, P1486, DOI 10.1126/science.274.5292.1486; QUINN WH, 1987, J GEOPHYS RES-OCEANS, V92, P14449, DOI 10.1029/JC092iC13p14449; Rajagopalan B, 1997, J CLIMATE, V10, P2351, DOI 10.1175/1520-0442(1997)010<2351:AEOAAV>2.0.CO;2; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P2161, DOI 10.1175/1520-0493(1987)115<2161:AEOTTS>2.0.CO;2; Stahle DW, 1998, B AM METEOROL SOC, V79, P2137, DOI 10.1175/1520-0477(1998)079<2137:EDROTS>2.0.CO;2; TRENBERTH KE, 1987, MON WEATHER REV, V115, P3078, DOI 10.1175/1520-0493(1987)115<3078:OTEOTS>2.0.CO;2; Trenberth KE, 1996, GEOPHYS RES LETT, V23, P57, DOI 10.1029/95GL03602; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; Tudhope AW, 1995, EARTH PLANET SC LETT, V136, P575, DOI 10.1016/0012-821X(95)00156-7; Wellington GM, 1996, PALEOCEANOGRAPHY, V11, P467, DOI 10.1029/96PA01023; Wolter K, 1993, PROC 17 CLIMATE DIAG, V52; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	30	233	239	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					989	993		10.1038/35039597	http://dx.doi.org/10.1038/35039597			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069175				2022-12-28	WOS:000090032500039
J	Trilla, A; Bruguera, M				Trilla, A; Bruguera, M			Spain: avoiding lawsuits	LANCET			English	Article									Univ Barcelona, Hosp Clin & Prov Barcelona, E-08036 Barcelona, Spain; Barcelona Coll Phys, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona	Trilla, A (corresponding author), Univ Barcelona, Hosp Clin & Prov Barcelona, E-08036 Barcelona, Spain.		Trilla, Antoni/G-2446-2018						0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1266	1267		10.1016/S0140-6736(00)02801-4	http://dx.doi.org/10.1016/S0140-6736(00)02801-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072962				2022-12-28	WOS:000089724900043
J	Lasser, K; Boyd, JW; Woolhandler, S; Himmelstein, DU; McCormick, D; Bor, DH				Lasser, K; Boyd, JW; Woolhandler, S; Himmelstein, DU; McCormick, D; Bor, DH			Smoking and mental illness - A population-based prevalence study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; TARDIVE-DYSKINESIA; TOBACCO SMOKING; SCHIZOPHRENIA; DISORDERS; ADOLESCENCE; COMORBIDITY; CALIFORNIA; CESSATION; CHILDHOOD	Context Studies of selected groups of persons with mental illness, such as those who are institutionalized or seen in mental health clinics, have reported rates of smoking to be higher than in persons without mental illness. However, recent population-based, nationally representative data are lacking. Objective To assess rates of smoking and tobacco cessation in adults, with and without mental illness. Design, Setting, and Participants Analysis of data on 4411 respondents aged 15 to 54 years from the National Comorbidity Survey, a nationally representative multistage probability survey conducted from 1991 to 1992. Main Outcome Measures Rates of smoking and tobacco cessation according to the number and type of psychiatric diagnoses, assessed by a modified version of the Composite International Diagnostic interview, Results Current smoking rates for respondents with no mental illness, lifetime mental illness, and past-month mental illness were 22.5%, 34.8%, and 41.0%, respectively. Lifetime smoking rates were 39.1%, 55.3%, and 59.0%, respectively (P<.001 for all comparisons). Smokers with any history of mental illness had a self-reported quit rate of 37.1% (P=.04), and smokers with past-month mental illness had a self-reported quit rate of 30.5% (P<.001) compared with smokers without mental illness (42.5%). Odds ratios for current and lifetime smoking in respondents with mental illness in the past month vs respondents without mental illness, adjusted for age, sex, and region of the country, were 2.7 (95% confidence interval [CI], 2.3-3.1) and 2.7 (95% CI, 2.4-3.2), respectively. Persons with a mental disorder in the past month consumed approximately 44.3% of cigarettes smoked by this nationally representative sample. Conclusions Persons with mental illness are about twice as likely to smoke as other persons but have substantial quit rates.	Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Cambridge Hosp, Dept Psychiat, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Smith Coll, Dept Relig, Northampton, MA 01063 USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Smith College	Lasser, K (corresponding author), Cambridge Hosp, Dept Med, Macht Bldg,1493 Cambridge St, Cambridge, MA 02139 USA.	klasser@massmed.org		Lasser, Karen/0000-0003-3777-6075	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER; BHP HRSA HHS [5T32PE11001-12] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); BHP HRSA HHS		Addington J, 1998, AM J PSYCHIAT, V155, P974, DOI 10.1176/ajp.155.7.974; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Anda RF, 1999, JAMA-J AM MED ASSOC, V282, P1652, DOI 10.1001/jama.282.17.1652; Biener L, 1998, AM J PUBLIC HEALTH, V88, P1389, DOI 10.2105/AJPH.88.9.1389; BINDER RL, 1987, BIOL PSYCHIAT, V22, P1280, DOI 10.1016/0006-3223(87)90038-2; Breslau N, 1996, AM J PUBLIC HEALTH, V86, P985, DOI 10.2105/AJPH.86.7.985; Breslau N, 1999, ARCH GEN PSYCHIAT, V56, P1141, DOI 10.1001/archpsyc.56.12.1141; BRESLAU N, 1995, BEHAV GENET, V25, P95, DOI 10.1007/BF02196920; BRUCE ML, 1994, AM J PSYCHIAT, V151, P716; CARMODY TP, 1992, J PSYCHOACTIVE DRUGS, V24, P111, DOI 10.1080/02791072.1992.10471632; *CDCP, 2000, CIG SMOK AD US 1997; CHILES JA, 1993, AM J ADDICTION, V2, P315; DECINA P, 1990, BIOL PSYCHIAT, V28, P502, DOI 10.1016/0006-3223(90)90483-I; DELEON J, 1995, AM J PSYCHIAT, V152, P453; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; GLASSMAN AH, 1993, AM J PSYCHIAT, V150, P546; GOFF DC, 1992, AM J PSYCHIAT, V149, P1189; Gonzalez-Pinto A, 1998, J CLIN PSYCHIAT, V59, P225, DOI 10.4088/JCP.v59n0503; HU TW, 1995, AM J PUBLIC HEALTH, V85, P1218, DOI 10.2105/AJPH.85.9.1218; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; HUGHES JR, 1993, J CLIN PSYCHIAT, V54, P109; Johnson JG, 2000, JAMA-J AM MED ASSOC, V284, P2348, DOI 10.1001/jama.284.18.2348; Kelly C, 1999, AM J PSYCHIAT, V156, P1751; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KESSLER RC, 2000, INT U CONS POL SOC R; LOHR JB, 1992, SCHIZOPHR RES, V8, P93, DOI 10.1016/0920-9964(92)90024-Y; MENZA MA, 1991, BIOL PSYCHIAT, V30, P109, DOI 10.1016/0006-3223(91)90163-G; NORDINE R, 2000, SEGMENTATION STUDY O; Pierce JP, 1998, JAMA-J AM MED ASSOC, V280, P893, DOI 10.1001/jama.280.10.893; ROBIN LN, 1981, PSYCHIAT DISORERS AM; Siegel M, 1998, ANN INTERN MED, V129, P128, DOI 10.7326/0003-4819-129-2-199807150-00013; STYRON W, 1990, DARKNESS VISIBLE MEM, P84; U.S. Department of Health and Human Services, 1994, HLTH CONS SMOK CESS, P124; WHO, COMP INT DIAGN INT C; Wu LT, 1999, AM J PUBLIC HEALTH, V89, P1837, DOI 10.2105/AJPH.89.12.1837; YASSA R, 1987, Biological Psychiatry, V22, P67, DOI 10.1016/0006-3223(87)90131-4; Ziedonis DM, 1997, SCHIZOPHRENIA BULL, V23, P247, DOI 10.1093/schbul/23.2.247	38	1888	1916	6	100	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2606	2610		10.1001/jama.284.20.2606	http://dx.doi.org/10.1001/jama.284.20.2606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	373NU	11086367	Bronze			2022-12-28	WOS:000165296200034
J	Klein, J				Klein, J			The HLA system - 2 (vol 343, pg 782, 2000)	NEW ENGLAND JOURNAL OF MEDICINE			English	Correction																		Klein J, 2000, NEW ENGL J MED, V343, P782, DOI 10.1056/NEJM200009143431106	1	7	7	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1504	1504						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078779				2022-12-28	WOS:000165271300031
J	Schoenberg, R; Safran, C				Schoenberg, R; Safran, C			Internet based repository of medical records that retains patient confidentiality	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SECURITY; COMMUNICATION; AVAILABILITY; ERROR		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Clin Comp, Boston, MA 02155 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Schoenberg, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Clin Comp, 21 Autumn St, Boston, MA 02155 USA.	rschoenb@caregroup.harvard.edu						Annas GJ, 1998, NEW ENGL J MED, V338, P695, DOI 10.1056/NEJM199803053381020; Bakker A, 1998, INT J MED INFORM, V49, P31, DOI 10.1016/S1386-5056(98)00007-0; Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; CIMINO JJ, 1998, P AMIA S, P21; Dudeck J, 1998, INT J MED INFORM, V48, P163, DOI 10.1016/S1386-5056(97)00122-6; Epstein MA, 1998, J DIGIT IMAGING, V11, P33, DOI 10.1007/BF03168723; Espinosa AL, 1998, INT J MED INFORM, V49, P97, DOI 10.1016/S1386-5056(98)00016-1; Gibby GL, 1998, J CLIN MONITOR COMP, V14, P385, DOI 10.1023/A:1009971521520; Kuilboer MM, 1997, J AM MED INFORM ASSN, P749; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; Leape LL, 1998, JAMA-J AM MED ASSOC, V280, P1444, DOI 10.1001/jama.280.16.1444; Luxenberg S N, 1997, Proc AMIA Annu Fall Symp, P804; Mandl KD, 1998, ANN INTERN MED, V129, P495, DOI 10.7326/0003-4819-129-6-199809150-00012; Masys DR, 1997, J AM MED INFORM ASSN, P340; *NAT LAB MED, 1996, 9510 CBM NAT LIB MED; Neame R, 1997, BRIT MED J, V314, P573, DOI 10.1136/bmj.314.7080.573; Rind DM, 1997, ANN INTERN MED, V127, P138, DOI 10.7326/0003-4819-127-2-199707150-00008; Slack WV, 1999, INT J MED INFORM, V54, P183, DOI 10.1016/S1386-5056(99)00006-4; Stanberry B, 1997, J Telemed Telecare, V3, P179, DOI 10.1258/1357633971931101; Toyoda K, 1998, INT J MED INFORM, V48, P57, DOI 10.1016/S1386-5056(97)00110-X; WOODWARD B, 1995, NEW ENGL J MED, V333, P1419, DOI 10.1056/NEJM199511233332112	21	26	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2000	321	7270					1199	+		10.1136/bmj.321.7270.1199	http://dx.doi.org/10.1136/bmj.321.7270.1199			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073513	Bronze, Green Published			2022-12-28	WOS:000165357100030
J	van der Vleuten, C				van der Vleuten, C			Validity of final examinations in undergraduate medical training	BRITISH MEDICAL JOURNAL			English	Article							GLOBAL RATING-SCALES; PERFORMANCE; OSCE		Univ Maastricht, Dept Educ Dev & Res, NL-6200 MD Maastricht, Netherlands	Maastricht University	van der Vleuten, C (corresponding author), Univ Maastricht, Dept Educ Dev & Res, POB 616, NL-6200 MD Maastricht, Netherlands.							Gray JD, 1996, ACAD MED, V71, pS55, DOI 10.1097/00001888-199601000-00043; HARDEN RM, 1979, MED EDUC, V13, P41; Hays R. B., 1995, TEACH LEARN MED, V7, P43; JOLLY BC, 1994, BEDSIDE MANNERS TEAC; MILLER GE, 1990, ACAD MED, V65, pS63, DOI 10.1097/00001888-199009000-00045; Regehr G, 1998, ACAD MED, V73, P993, DOI 10.1097/00001888-199809000-00020; Remmen R, 1998, MED TEACH, V20, P428; ROTHMAN AI, 1997, ADV HEALTH SCI EDUC, V1, P215; SEMB GB, 1994, REV EDUC RES, V64, P253, DOI 10.3102/00346543064002253; STREINER C, 1995, EVALUATION METHODS R, P29; SWANSON D, 1987, ASSESS EVAL HIGH EDU, V12, P220, DOI DOI 10.1080/0260293870120307	11	111	117	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1217	+		10.1136/bmj.321.7270.1217	http://dx.doi.org/10.1136/bmj.321.7270.1217			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073517	Green Published			2022-12-28	WOS:000165357100034
J	Wagner, M				Wagner, M			Choosing caesarean section	LANCET			English	Editorial Material							CESAREAN-DELIVERY				Wagner, M (corresponding author), 2950 Van Ness St NW,Apartment 911, Washington, DC 20008 USA.							AlMufti R, 1997, EUR J OBSTET GYN R B, V73, P1, DOI 10.1016/S0301-2115(96)02692-9; [Anonymous], 1985, LANCET, V2, P436; Birchard K, 1999, LANCET, V354, P1710, DOI 10.1016/S0140-6736(05)76701-5; Enkin M., 1995, GUIDE EFFECTIVE CARE; Goer H., 1999, THINKING WOMANS GUID; Goodstein D, 1996, ANN NY ACAD SCI, V775, P31, DOI 10.1111/j.1749-6632.1996.tb23124.x; Hall MH, 1999, LANCET, V354, P776, DOI 10.1016/S0140-6736(05)76016-5; HARER W, 2000, AM COLL OBSTET GYNEC, V5, P2; LOMAS J, 1999, EFFECTIVE CARE PREGN; NOTZON FC, 1990, JAMA-J AM MED ASSOC, V263, P3286, DOI 10.1001/jama.263.24.3286; Olatunbosun OA, 1998, BRIT MED J, V316, P365, DOI 10.1136/bmj.316.7128.365; Plaut MM, 1999, AM J OBSTET GYNECOL, V180, P1535, DOI 10.1016/S0002-9378(99)70049-9; Rattner D, 1996, REV SAUDE PUBL, V30, P19, DOI 10.1590/S0034-89101996000100004; Sachs BP, 1999, NEW ENGL J MED, V340, P54, DOI 10.1056/NEJM199901073400112; Schenker JG, 1999, INT J GYNECOL OBSTET, V64, P317; SHOWALTER E, 1999, BRIT MED J, V319, P1397; Smith JF, 1997, OBSTET GYNECOL, V90, P344, DOI 10.1016/S0029-7844(97)00284-6; STEPHENSON P, 1992, INT DIFFERENCES USE; WAGNER M, 1995, LANCET, V346, P1020, DOI 10.1016/S0140-6736(95)91696-2; Wagner M, 1998, J SOC OBSTET GYNECOL, V13, P1225; WAGNER M, 1994, PURSUING BIRTH MACH; Wagner M., 1988, J PUBLIC HLTH POLICY, V19, P25; 1998, BMJ, V317, P463	23	161	164	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1677	1680		10.1016/S0140-6736(00)03169-X	http://dx.doi.org/10.1016/S0140-6736(00)03169-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089840				2022-12-28	WOS:000165249200038
J	Zuckerman, B; Sharfstein, J; Wise, P				Zuckerman, B; Sharfstein, J; Wise, P			Child health initiatives and journal narrow-mindedness	LANCET			English	Editorial Material									Boston Univ, Sch Med, Dept Pediat, Boston Med Ctr, Boston, MA 02118 USA	Boston Medical Center; Boston University	Zuckerman, B (corresponding author), Boston Univ, Sch Med, Dept Pediat, Boston Med Ctr, Boston, MA 02118 USA.			Zuckerman, Barry/0000-0002-0044-2592				Harrison H, 2000, ARCH DIS CHILD, V82, P283, DOI 10.1136/adc.82.4.283	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1626	1626		10.1016/S0140-6736(00)03154-8	http://dx.doi.org/10.1016/S0140-6736(00)03154-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089819				2022-12-28	WOS:000165249200008
J	Kaneko, A; Taleo, G; Kalkoa, M; Yamar, S; Kobayakawa, T; Bjorkman, A				Kaneko, A; Taleo, G; Kalkoa, M; Yamar, S; Kobayakawa, T; Bjorkman, A			Malaria eradication on islands	LANCET			English	Article							VANUATU ARCHIPELAGO; FALCIPARUM-MALARIA; MADAGASCAR	Background To be successful. a malaria control programme needs to be tailored to the local epidemiological characteristics. Vanuatu consists of 80 inhabited islands in the Southwest Pacific, with hypoendemic and mesoendemic malaria and suitable conditions for sustained parasite elimination. We aimed to assess whether malaria can be eliminated on isolated islands. Methods Weekly mass drug administration of chloroquine, pyrimethamine/sulfadoxine (Fansidar), and primaquine was carried out on the entire population of 718 inhabitants of Aneityum island for 9 weeks in 1991 before the onset of the rainy season. Simultaneously with the administration of drugs, permethrin-impregnated bednets were distributed to the entire population. Larvivorous fish were also introduced into several identified breeding sites of Anopheles farauti. Periodic malariometric monitoring has continued for the past 9 years. Two additional islands of Vanuatu, one with and one without malaria transmission, have been monitored for comparison. Findings High community involvement as measured by drug compliance (88.3%) and bednet provision (0.94 nets per villager) has resulted in sustained interruption of malaria transmission in Aneityum. The surveys showed complete absence of Plasmodium falciparum after mass drug administration, and P vivax disappeared from 1996 onwards, with the exception of two instances of imported infections (one mixed infection in 1993 and one P vivax infection in 1999). Interpretation Malaria can be eliminated on isolated islands with well-adapted short-term mass drug administration and sustained vector control if there is a high degree of community participation.	Tokyo Womens Med Univ, Sch Med, Dept Int Affairs & Trop Med, Shinjuku Ku, Tokyo 1628666, Japan; Dept Hlth, Malaria Sect, Port Vila, Vanuatu; Karolinska Inst, Karolinska Hosp, Infect Dis Unit, S-10401 Stockholm, Sweden	Tokyo Women's Medical University; Karolinska Institutet; Karolinska University Hospital	Kaneko, A (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Int Affairs & Trop Med, Shinjuku Ku, Tokyo 1628666, Japan.	akirak@research.twmu.ac.jp		, Akira/0000-0003-2411-3352				Arez AP, 1999, PARASITOLOGY, V118, P347, DOI 10.1017/S0031182099003972; ARNOLD J, 1954, J LAB CLIN MED, V44, P429; BELKIN JN, 1945, J PARASITOL, V31, P241, DOI 10.2307/3273001; Bruce-Chwatt L. J., 1988, Malaria: principles and practice of malariology. Volume 1., P1; Buxton P, 1927, RES POLYNESIA MELANE; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; COATNEY G. ROBERT., 1950, JOUR NATL MALARIA SOC, V9, P381; FONTENILLE D, 1990, AM J TROP MED HYG, V43, P107, DOI 10.4269/ajtmh.1990.43.107; GANCZAKOWSKI M, 1995, AM J HUM GENET, V56, P294; GARFIELD RM, 1983, LANCET, V2, P500; HII JLK, 1987, MED VET ENTOMOL, V1, P397, DOI 10.1111/j.1365-2915.1987.tb00370.x; Ishikawa H., 1996, Japanese Journal of Tropical Medicine and Hygiene, V24, P11; Kaneko A, 1998, ACTA TROP, V70, P285, DOI 10.1016/S0001-706X(98)00035-7; Laveran A, 1902, CR SOC BIOL, V54, P908; LEPERS JP, 1988, LANCET, V1, P586; Loureiro LF, 1996, ANN TROP MED PARASIT, V90, P223, DOI 10.1080/00034983.1996.11813048; MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743; MILLS A R, 1954, J Trop Med Hyg, V57, P99; Molineaux L, 2020, GARKI PROJECT RES EP, V8; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; ONORI E, 1972, B WORLD HEALTH ORGAN, V47, P718; Peters W, 1987, CHEMOTHERAPY DRUG RE; REEVE PA, 1994, PAPUA NEW GUINEA MED, V37, P181; Rishikesh N., 1988, P1227; WERNSDORFER W, 1992, SE ASIAN J TROP M S4, V23, pS123; WHO, 1963, TERM MAL MAL ER	26	170	172	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1560	1564		10.1016/S0140-6736(00)03127-5	http://dx.doi.org/10.1016/S0140-6736(00)03127-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075770				2022-12-28	WOS:000165134500012
J	Parrish-Novak, J; Dillon, SR; Nelson, A; Hammond, A; Sprecher, C; Gross, JA; Johnston, J; Madden, K; Xu, WF; West, J; Schrader, S; Burkhead, S; Heipel, M; Brandt, C; Kuijper, JL; Kramer, J; Conklin, D; Presnell, SR; Berry, J; Shiota, F; Bort, S; Hambly, K; Mudri, S; Clegg, C; Moore, M; Grant, FJ; Lofton-Day, C; Gilbert, T; Raymond, F; Ching, A; Yao, L; Smith, D; Webster, P; Whitmore, T; Maurer, M; Kaushansky, K; Holly, RD; Foster, D				Parrish-Novak, J; Dillon, SR; Nelson, A; Hammond, A; Sprecher, C; Gross, JA; Johnston, J; Madden, K; Xu, WF; West, J; Schrader, S; Burkhead, S; Heipel, M; Brandt, C; Kuijper, JL; Kramer, J; Conklin, D; Presnell, SR; Berry, J; Shiota, F; Bort, S; Hambly, K; Mudri, S; Clegg, C; Moore, M; Grant, FJ; Lofton-Day, C; Gilbert, T; Raymond, F; Ching, A; Yao, L; Smith, D; Webster, P; Whitmore, T; Maurer, M; Kaushansky, K; Holly, RD; Foster, D			Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function	NATURE			English	Article							NATURAL-KILLER-CELLS; MPL CYTOPLASMIC DOMAIN; C-MPL; SIGNAL; SUPERFAMILY; LIGAND; CD40; PROGENITOR; CYTOKINES; LOCATION	Cytokines are important in the regulation of haematopoiesis and immune responses, and can influence lymphocyte development. Here we have identified a class I cytokine receptor that is selectively expressed in lymphoid tissues and is capable of signal transduction. The full-length receptor was expressed in BaF3 cells, which created a functional assay for ligand detection and cloning. Conditioned media from activated human CD3(+) T cells supported proliferation of the assay cell line. We constructed a complementary DNA expression library from activated human CD3+ T cells, and identified a cytokine with a four-helix-bundle structure using functional cloning. This cytokine is most closely related to IL2 and IL15, and has been designated IL21 with the receptor designated IL21R. In vitro assays suggest that IL21 has a role in the proliferation and maturation of natural killer (NK) cell populations from bone marrow, in the proliferation of mature B-cell populations co-stimulated with anti-CD40, and in the proliferation of T cells co-stimulated with anti-CD3.	Zymogenet Inc, Dept Funct Cloning, Seattle, WA 98102 USA; Zymogenet Inc, Dept Immunol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Prot Biochem, Seattle, WA 98102 USA; Zymogenet Inc, Dept Biol Informat, Seattle, WA 98102 USA; Zymogenet Inc, Dept Genet, Seattle, WA 98102 USA; Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.; University of Washington; University of Washington Seattle	Foster, D (corresponding author), Zymogenet Inc, Dept Funct Cloning, 1201 Eastlake Ave E, Seattle, WA 98102 USA.							BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; DZAKI K, 2000, P NATL ACAD SCI USA, V97, P14439; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; GONG JH, 1994, LEUKEMIA, V8, P652; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HAGEKULL B, 1981, INFANT BEHAV DEV, V4, P97, DOI 10.1016/S0163-6383(81)80012-4; Kammer W, 1996, J BIOL CHEM, V271, P23634, DOI 10.1074/jbc.271.39.23634; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Morris AE, 1997, ANIMAL CELL TECHNOLOGY, P529; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; ROBERTSON MJ, 1990, BLOOD, V76, P2421; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; VIGON I, 1993, ONCOGENE, V8, P2607; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Whiteside TL, 1998, CURR TOP MICROBIOL, V230, P221; Williams NS, 1998, IMMUNOL REV, V165, P47, DOI 10.1111/j.1600-065X.1998.tb01229.x; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; Yu HX, 1998, BLOOD, V92, P3647, DOI 10.1182/blood.V92.10.3647.422k43_3647_3657; ZURAWSKI SM, 1993, EMBO J, V12, P5113, DOI 10.1002/j.1460-2075.1993.tb06206.x	29	934	1068	2	58	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					57	63		10.1038/35040504	http://dx.doi.org/10.1038/35040504			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081504				2022-12-28	WOS:000165050400048
J	Uhlmann, F; Wernic, D; Poupart, MA; Koonin, EV; Nasmyth, K				Uhlmann, F; Wernic, D; Poupart, MA; Koonin, EV; Nasmyth, K			Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast	CELL			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; SECONDARY STRUCTURE; CUT2 PROTEOLYSIS; FISSION YEAST; BUDDING YEAST; IDENTIFICATION; INHIBITOR; CELLS	In eukaryotic cells, replicated DNA strands remain physically connected until their segregation to opposite poles of the cell during anaphase. This "sister chromatid cohesion" is essential for the alignment of chromosomes on the mitotic spindle during metaphase. Cohesion depends on the multisubunit cohesin complex, which possibly forms the physical bridges connecting sisters. Proteolytic cleavage of cohesin's Scc1 subunit at the metaphase to anaphase transition is essential for sister chromatid separation and depends on a conserved protein called separin. We show here that separin is a cysteine protease related to caspases that alone can cleave Scc1 in vitro. Cleavage of Scc1 in metaphase arrested cells is sufficient to trigger the separation of sister chromatids and their segregation to opposite cell poles.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Boehringer Ingelheim Canada Ltd, Laval, PQ H7S 2G5, Canada; NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim; National Institutes of Health (NIH) - USA	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at		Nasmyth, Kim/0000-0001-7030-4403; Uhlmann, Frank/0000-0002-3527-6619				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APLIN RT, 1983, INT J PEPT PROT RES, V21, P555; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DOUGHERTY WG, 1989, VIROLOGY, V171, P356, DOI 10.1016/0042-6822(89)90603-X; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Griffin DK, 1996, INT REV CYTOL, V167, P263, DOI 10.1016/S0074-7696(08)61349-2; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; KRANTZ A, 1994, METHOD ENZYMOL, V244, P656; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAZIA D, 1961, MITOSIS PHYSL CELL D, V3; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOLEBAJER J, 1958, CHROMOSOMA, V9, P332, DOI 10.1007/BF02568085; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; NEUWALD AF, 1995, PROTEIN SCI, V4, P1618, DOI 10.1002/pro.5560040820; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OSTERGREN G, 1973, PLANT CHROMOSOMES, V23; PARKS TD, 1995, VIROLOGY, V210, P194, DOI 10.1006/viro.1995.1331; Rose M, 1990, LAB COURSE MANUAL ME; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YAIMA H, 1981, J AM CHEM SOC, V103, P5867; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986	52	640	658	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					375	386		10.1016/S0092-8674(00)00130-6	http://dx.doi.org/10.1016/S0092-8674(00)00130-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081625	Bronze			2022-12-28	WOS:000090144100004
J	Greene, E; Lyon, BE; Muehter, VR; Ratcliffe, L; Oliver, SJ; Boag, PT				Greene, E; Lyon, BE; Muehter, VR; Ratcliffe, L; Oliver, SJ; Boag, PT			Disruptive sexual selection for plumage coloration in a passerine bird	NATURE			English	Article							LAZULI BUNTINGS; MATURATION; EVOLUTION; MALES; SIZE	The theory of sexual selection was developed to explain the evolution of highly exaggerated sexual ornaments(1). Now supported by vast empirical evidence(2), sexual selection is generally considered to favour individuals with the most extreme trait expression(2-4). Here we describe disruptive selection on a sexual ornament, plumage coloration, in yearling male lazuli buntings (Passerina amoena). In habitats with limited good-quality nesting cover, the dullest and the brightest yearlings were more successful in obtaining high-quality territories, pairing with females and siring offspring, than yearlings with intermediate plumage. This pattern reflects the way that territorial adult males vary levels of aggression to influence the structure of their social neighbourhood. Adult males showed less aggression towards dull yearlings than intermediate and bright ones, permitting the dull yearlings to settle on good territories nearby. Fitness comparisons based on paternity analyses showed that both the adults and dull yearlings benefited genetically from this arrangement, revealing a rare example of sexually selected male-male cooperation(5,6).	Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Boston Univ, Marine Program, Woods Hole, MA 02543 USA	University of Montana System; University of Montana; University of California System; University of California Santa Cruz; Queens University - Canada; Boston University	Greene, E (corresponding author), Univ Montana, Div Biol Sci, Missoula, MT 59812 USA.	egreene@selway.umt.edu	Boag, Peter T/B-2907-2014; Lyon, Bruce E/E-8491-2011	Boag, Peter T/0000-0003-0050-2089; 				Andersson Malte, 1994; Birkhead TR, 1992, SPERM COMPETITON BIR; DARWIN C, 1881, DESCENT MAN SELECTIO; DAVIES NB, 1989, ANIM BEHAV, V38, P226, DOI 10.1016/S0003-3472(89)80085-5; DUGATKIN LA, 1994, BEHAV ECOL SOCIOBIOL, V35, P141, DOI 10.1007/BF00171504; EMLEN ST, 1977, SCIENCE, V197, P215, DOI 10.1126/science.327542; Endler J.A., 1986, Monographs in Population Biology, pviii; GIBBS HL, 1990, SCIENCE, V250, P1394, DOI 10.1126/science.250.4986.1394; GREENE E, 1996, BIRDS N AM; GROSS MR, 1985, NATURE, V313, P47, DOI 10.1038/313047a0; Hunt S, 1998, P ROY SOC B-BIOL SCI, V265, P451, DOI 10.1098/rspb.1998.0316; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LESSELLS CM, 1987, AUK, V104, P116, DOI 10.2307/4087240; LYON BE, 1986, EVOLUTION, V40, P605, DOI 10.1111/j.1558-5646.1986.tb00511.x; MCDONALD DB, 1994, SCIENCE, V266, P1030, DOI 10.1126/science.7973654; MOLLER AP, 1994, EVOLUTION, V48, P1089, DOI 10.1111/j.1558-5646.1994.tb05296.x; MORTON ES, 1990, AUK, V107, P275, DOI 10.2307/4087610; Muehter VR, 1997, BEHAV ECOL SOCIOBIOL, V41, P281, DOI 10.1007/s002650050389; NOE R, 1994, BEHAV ECOL SOCIOBIOL, V35, P1; ORIANS GH, 1969, AM NAT, V103, P589, DOI 10.1086/282628; Otter K, 1998, BEHAV ECOL SOCIOBIOL, V43, P25, DOI 10.1007/s002650050463; PRICE TD, 1984, EVOLUTION, V38, P327, DOI 10.1111/j.1558-5646.1984.tb00291.x; ROHWER S, 1988, AM NAT, V131, P556, DOI 10.1086/284806; ROHWER S, 1980, AM NAT, V115, P400, DOI 10.1086/283569; SAPPINGTON TW, 1990, P NATL ACAD SCI USA, V87, P6132, DOI 10.1073/pnas.87.16.6132; SCHLUTER D, 1988, EVOLUTION, V42, P849, DOI [10.2307/2408904, 10.1111/j.1558-5646.1988.tb02507.x]; SMITH TB, 1993, NATURE, V363, P618, DOI 10.1038/363618a0; WAGNER RH, 1993, J THEOR BIOL, V163, P333, DOI 10.1006/jtbi.1993.1123; Yezerinac SM, 1997, P ROY SOC B-BIOL SCI, V264, P527, DOI 10.1098/rspb.1997.0075; YOUNG BE, 1991, CONDOR, V93, P236, DOI 10.2307/1368939	30	99	99	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					1000	1003		10.1038/35039500	http://dx.doi.org/10.1038/35039500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069178				2022-12-28	WOS:000090032500042
J	Pellegrini, L; Burke, DF; von Delft, F; Mulloy, B; Blundell, TL				Pellegrini, L; Burke, DF; von Delft, F; Mulloy, B; Blundell, TL			Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin	NATURE			English	Article							BINDING DOMAIN; FGF; IDENTIFICATION; DIMERIZATION; MITOGENESIS; ACTIVATION; SULFATE; NMR	Fibroblast growth factors (FGFs) are a large family of structurally related proteins with a wide range of physiological and pathological activities(1). Signal transduction requires association of FGF with its receptor tyrosine kinase (FGFR)(2) and heparan sulphate proteoglycan in a specific complex on the cell surface. Direct involvement of the heparan sulphate glycosaminoglycan polysaccharide in the molecular association between FGF and its receptor is essential for biological activity(3-5). Although crystal structures of binary complexes of FGF-heparin(6,7) and FGF-FGFR(8,9) have been described, the molecular architecture of the FGF signalling complex has not been elucidated. Here we report the crystal structure of the FGFR2 ectodomain in a dimeric form that is induced by simultaneous binding to FGF1 and a heparin decasaccharide. The complex is assembled around a central heparin molecule linking two FGF1 ligands into a dimer that bridges between two receptor chains. The asymmetric heparin binding involves contacts with both FGF1 molecules but only one receptor chain. The structure of the FGF1-FGFR2-heparin ternary complex provides a structural basis for the essential role of heparan sulphate in FGF signalling.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	University of Cambridge; National Institute for Biological Standards & Control	Pellegrini, L (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.		Burke, David F/C-2091-2013; Pellegrini, Luca/AAE-2312-2022	Burke, David F/0000-0001-8830-3951; Pellegrini, Luca/0000-0002-9300-497X; von Delft, Frank/0000-0003-0378-0017				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GALZIE Z, 1997, CELL BIOL, V75, P669; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lin XH, 1999, DEVELOPMENT, V126, P3715; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Oldridge M, 1997, HUM MOL GENET, V6, P137, DOI 10.1093/hmg/6.1.137; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; SUDHALTER J, 1989, J BIOL CHEM, V264, P6892; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	30	586	641	1	65	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1029	1034		10.1038/35039551	http://dx.doi.org/10.1038/35039551			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069186				2022-12-28	WOS:000090032500050
J	Angus, JA; Wright, CE; Xi, Q				Angus, JA; Wright, CE; Xi, Q			Targetting voltage-gated calcium channels in cardiovascular therapy	LANCET			English	Editorial Material							N-TYPE; CA2+ CHANNELS		Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia	University of Melbourne	Angus, JA (corresponding author), Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia.		Tuluc, Petronel/C-2527-2011; Angus, James/F-6666-2014; Wright, Christine/B-2509-2012	Angus, James/0000-0002-0605-9682; Wright, Christine/0000-0002-3339-040X				BEZPROZVANNY L, 1995, MOL PHARMACOL, V48, P540; Brose WG, 1997, CLIN J PAIN, V13, P256, DOI 10.1097/00002508-199709000-00012; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Furukawa T, 1997, BRIT J PHARMACOL, V121, P1136, DOI 10.1038/sj.bjp.0701226; MISHRA SK, 1994, CIRC RES, V75, P144, DOI 10.1161/01.RES.75.1.144; Molderings GJ, 2000, CIRCULATION, V101, P403, DOI 10.1161/01.CIR.101.4.403; Sarsero D, 1998, BRIT J PHARMACOL, V125, P109, DOI 10.1038/sj.bjp.0702045; Whorlow SL, 1996, CLIN EXP PHARMACOL P, V23, P16; WRIGHT CE, 1995, J CARDIOVASC PHARM, V25, P459, DOI 10.1097/00005344-199503000-00017; Wright CE, 2000, J HYPERTENS, V18, P65, DOI 10.1097/00004872-200018010-00010; XI Q, 2000, P AUST SOC EXP PHARM, V7, P98	11	15	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1287	1289		10.1016/S0140-6736(00)02807-5	http://dx.doi.org/10.1016/S0140-6736(00)02807-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073011				2022-12-28	WOS:000089858300003
J	Tierney, MC				Tierney, MC			Oestradiol concentrations in prediction of cognitive decline In women	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ALZHEIMERS-DISEASE; DOUBLE-BLIND; ESTROGEN; MEMORY; RISK		Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Family & Community Med, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Tierney, MC (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Family & Community Med, Toronto, ON M4N 3M5, Canada.							Asthana S, 1999, PSYCHONEUROENDOCRINO, V24, P657, DOI 10.1016/S0306-4530(99)00020-7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gibbs RB, 2000, NEUROBIOL AGING, V21, P107, DOI 10.1016/S0197-4580(00)00103-2; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; Tierney MC, 2000, ARCH FAM MED, V9, P527, DOI 10.1001/archfami.9.6.527; Yaffe K, 1998, J AM GERIATR SOC, V46, P816, DOI 10.1111/j.1532-5415.1998.tb02713.x	10	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					694	695		10.1016/S0140-6736(00)02621-0	http://dx.doi.org/10.1016/S0140-6736(00)02621-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	347UU	11085682				2022-12-28	WOS:000088948200002
J	Javaheri, S; Cohen, V; Libman, I; Sandor, V				Javaheri, S; Cohen, V; Libman, I; Sandor, V			Life-threatening tinnitus	LANCET			English	Article									McGill Univ, Jewish Gen Hosp, Dept Internal Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Dept Neurol, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University	Javaheri, S (corresponding author), McGill Univ, Jewish Gen Hosp, Dept Internal Med, Pavil G,Room G-050,3755 Chemin Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.							CLOUSTON PD, 1992, ANN NEUROL, V31, P268, DOI 10.1002/ana.410310307; Dalmau JO, 1999, ARCH NEUROL-CHICAGO, V56, P405, DOI 10.1001/archneur.56.4.405; DIRR LY, 1990, NEUROLOGY, V40, P1304, DOI 10.1212/WNL.40.8.1304	3	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					308	308		10.1016/S0140-6736(00)02507-1	http://dx.doi.org/10.1016/S0140-6736(00)02507-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071187				2022-12-28	WOS:000088305900013
J	Kannus, P; Parkkari, J; Niemi, S; Pasanen, M; Palvanen, M; Jarvinen, M; Vuori, I				Kannus, P; Parkkari, J; Niemi, S; Pasanen, M; Palvanen, M; Jarvinen, M; Vuori, I			Prevention of hip fracture in elderly people with use of a hip protector.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; RISK-FACTORS; FALLING CONDITIONS; IMPACT; MORTALITY; INTERVENTION; EPIDEMIOLOGY; ALENDRONATE; EXERCISE; CALCIUM	Background: Hip fractures are common in frail elderly adults worldwide. We investigated the effect of an anatomically designed external hip protector on the risk of these age-related fractures. Methods: We randomly assigned 1801 ambulatory but frail elderly adults (1409 women and 392 men; mean age, 82 years), in a 1:2 ratio, either to a group that wore a hip protector or to a control group. Fractures of the hip and all other fractures were recorded until the end of the first full month after 62 hip fractures had occurred in the control group. The risk of fracture in the two groups was compared, and in the hip-protector group the risk of fracture was also analyzed according to whether the protector had been in use at the time of a fall. Results: During follow-up, 13 subjects in the hip-protector group had a hip fracture, as compared with 67 subjects in the control group. The respective rates of hip fracture were 21.3 and 46.0 per 1000 person-years (relative hazard in the hip-protector group, 0.4; 95 percent confidence interval, 0.2 to 0.8; P=0.008). The risk of pelvic fracture was slightly but not significantly lower in the hip-protector group than in the control group (2 subjects and 12 subjects, respectively, had pelvic fracture) (relative hazard, 0.4; 95 percent confidence interval, 0.1 to 1.8; P greater than or equal to 0.05). The risk of other fractures was similar in the two groups. In the hip-protector group, four subjects had a hip fracture (among 1034 falls) while wearing the protector, and nine subjects had a hip fracture (among 370 falls) while not wearing the protector (relative hazard, 0.2; 95 percent confidence interval, 0.05 to 0.5; P=0.002). Conclusions: The risk of hip fracture can be reduced in frail elderly adults by the use of an anatomically designed external hip protector. (N Engl J Med 2000;343:1506-13.) (C) 2000, Massachusetts Medical Society.	President Urho Kaleva Kekkonen Inst Hlth Promot R, Accid & Trauma Res Ctr, FIN-33500 Tampere, Finland; President Urho Kaleva Kekkonen Inst Hlth Promot R, Res Ctr Sports Med, FIN-33500 Tampere, Finland; Tampere Univ, Med Sch & Univ Hosp, Dept Surg, FIN-33101 Tampere, Finland	Tampere University	Kannus, P (corresponding author), President Urho Kaleva Kekkonen Inst Hlth Promot R, Accid & Trauma Res Ctr, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.	klpeka@uta.fi						Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOK RJ, 1995, BRIT MED J, V310, P1056; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS S, 1993, OSTEOPOROS INT S1, V3, P67; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Diggle PJ, 1995, J AM STAT ASSOC; Feussner JR, 1996, J BONE MINER RES, V11, P877; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; Greenspan SL, 1998, AM J MED, V104, P539, DOI 10.1016/S0002-9343(98)00115-6; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; Heinonen A, 1996, LANCET, V348, P1343, DOI 10.1016/S0140-6736(96)04214-6; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 1999, LANCET, V353, P802, DOI 10.1016/S0140-6736(98)04235-4; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; LAWTON MP, 1971, J AM GERIATR SOC, V19, P465, DOI 10.1111/j.1532-5415.1971.tb01206.x; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; McColl A, 1998, J PUBLIC HEALTH MED, V20, P196, DOI 10.1093/oxfordjournals.pubmed.a024743; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; PARKKARI J, 1995, J BONE MINER RES, V10, P1437; Parkkari J, 1997, CALCIFIED TISSUE INT, V60, P354, DOI 10.1007/s002239900242; Parkkari J, 1998, AGE AGEING, V27, P225, DOI 10.1093/ageing/27.2.225; PARKKARI J, 1994, J BONE MINER RES, V9, P1391; Parkkari J, 1999, CALCIFIED TISSUE INT, V65, P183; Paspati I, 1998, CALCIFIED TISSUE INT, V62, P542, DOI 10.1007/s002239900476; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.273.17.1341; Schwartz AV, 1998, OSTEOPOROSIS INT, V8, P240, DOI 10.1007/s001980050060; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Wolinsky FD, 1997, AM J PUBLIC HEALTH, V87, P398, DOI 10.2105/AJPH.87.3.398	34	360	374	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1506	1513		10.1056/NEJM200011233432101	http://dx.doi.org/10.1056/NEJM200011233432101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087879	Bronze			2022-12-28	WOS:000165410900001
J	Bousquet, P; Peylin, P; Ciais, P; Le Quere, C; Friedlingstein, P; Tans, PP				Bousquet, P; Peylin, P; Ciais, P; Le Quere, C; Friedlingstein, P; Tans, PP			Regional changes in carbon dioxide fluxes of land and oceans since 1980	SCIENCE			English	Article							ATMOSPHERIC CO2; EL-NINO; EQUATORIAL PACIFIC; SINK; VARIABILITY; CYCLE	We have applied an inverse model to 20 years of atmospheric carbon dioxide measurements to infer yearly changes in the regional carbon balance of oceans and continents. The model indicates that global terrestrial carbon fluxes were approximately twice as variable as ocean fluxes between 1980 and 1998, Tropical Land ecosystems contributed most of the interannual changes in Earth's carbon balance over the 1980s, whereas northern mid- and high-latitude Land ecosystems dominated from 1990 to 1995, Strongly enhanced uptake of carbon was found over North America during the 1992-1993 period compared to 1989-1990.	Lab Sci Climat Environm, F-91198 Gif Sur Yvette, France; Univ Versailles St Quentin Yvelines, F-78035 Versailles, France; NOAA, Climate Monitoring & Diagnost Lab, Boulder, CO 80303 USA	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; National Oceanic Atmospheric Admin (NOAA) - USA	Bousquet, P (corresponding author), Lab Sci Climat Environm, F-91198 Gif Sur Yvette, France.		Tans, Pieter/AAG-8273-2019; Ciais, Philippe/A-6840-2011; Friedlingstein, Pierre/H-2700-2014; Le Quere, Corinne/C-2631-2017	Tans, Pieter/0000-0002-9883-0787; Ciais, Philippe/0000-0001-8560-4943; Friedlingstein, Pierre/0000-0003-3309-4739; Le Quere, Corinne/0000-0003-2319-0452; Peylin, Philippe/0000-0001-9335-6994; Bousquet, Philippe/0000-0002-4444-2703				Andres RJ, 1996, GLOBAL BIOGEOCHEM CY, V10, P419, DOI 10.1029/96GB01523; Bousquet P, 1999, J GEOPHYS RES-ATMOS, V104, P26161, DOI 10.1029/1999JD900342; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; CONWAY TJ, 1994, J GEOPHYS RES-ATMOS, V99, P22831, DOI 10.1029/94JD01951; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Feely RA, 1997, DEEP-SEA RES PT II, V44, P1851, DOI 10.1016/S0967-0645(97)00061-1; Feely RA, 1999, NATURE, V398, P597, DOI 10.1038/19273; FEELY RA, 1998, COMMUNICATION; FEELY RA, 1997, COMMUNICATION; FRANCEY RJ, 1995, NATURE, V373, P326, DOI 10.1038/373326a0; FRIEDLINGSTEIN P, 1995, GLOBAL BIOGEOCHEM CY, V9, P541, DOI 10.1029/95GB02381; Goyet C, 1997, DEEP-SEA RES PT I, V44, P859, DOI 10.1016/S0967-0637(96)00111-2; GOYET C, 2000, NDP076 ORNL; Hansen J, 1996, GEOPHYS RES LETT, V23, P1665, DOI 10.1029/96GL01040; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Law RM, 1996, GLOBAL BIOGEOCHEM CY, V10, P783, DOI 10.1029/96GB01892; Lee K, 1998, NATURE, V396, P155, DOI 10.1038/24139; LEQUERE C, IN PRESS GLOBAL BIOG; LEVITUS S, 1993, PROG OCEANOGR, V31, P245, DOI 10.1016/0079-6611(93)90003-V; MASARIE KA, 1995, J GEOPHYS RES-ATMOS, V100, P11593, DOI 10.1029/95JD00859; PARTON WJ, 1993, GLOBAL BIOGEOCHEM CY, V7, P785, DOI 10.1029/93GB02042; PEYLIN P, 1999, INVERSE METHODS GLOB, P295; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; WINGUTH AME, 1994, GLOBAL BIOGEOCHEM CY, V8, P39, DOI 10.1029/93GB03134; WONG CS, 1993, TELLUS B, V45, P64, DOI 10.1034/j.1600-0889.1993.00006.x	26	554	599	10	122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1342	1346		10.1126/science.290.5495.1342	http://dx.doi.org/10.1126/science.290.5495.1342			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082059	Green Submitted			2022-12-28	WOS:000165379800045
J	Brill-Edwards, P; Ginsberg, JS; Gent, M; Hirsh, J; Burrows, R; Kearon, C; Geerts, W; Kovacs, M; Weitz, JI; Robinson, KS; Whittom, R; Couture, G				Brill-Edwards, P; Ginsberg, JS; Gent, M; Hirsh, J; Burrows, R; Kearon, C; Geerts, W; Kovacs, M; Weitz, JI; Robinson, KS; Whittom, R; Couture, G		Recurrence Clot Pregnancy Study Gr	Safety of withholding heparin in pregnant women with a history of venous thromboembolism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; ORAL ANTICOAGULANT-THERAPY; PROTEIN-C; RECURRENT THROMBOEMBOLISM; PULMONARY-EMBOLISM; MATERNAL MORTALITY; ASSAY; THROMBOPROPHYLAXIS; PROPHYLAXIS; PUERPERIUM	Background: Women with a history of venous thromboembolism may be at increased risk for venous thromboembolic events during pregnancy. In these women, the decision to give or withhold heparin in the antepartum period is controversial, because accurate estimates of the frequency of recurrent thromboembolic events if antepartum heparin is withheld are not available. Methods: We prospectively studied 125 pregnant women with a single previous episode of venous thromboembolism. Antepartum heparin was withheld, but anticoagulant therapy was given for four to six weeks post partum. Our primary objective was to determine the rate of antepartum recurrence of venous thromboembolism. Laboratory studies were performed to identify thrombophilia in 95 women. Results: Three of the 125 women (2.4 percent) had an antepartum recurrence of venous thromboembolism (95 percent confidence interval, 0.2 to 6.9 percent). There were no recurrences in the 44 women who had no evidence of thrombophilia and who also had a previous episode of thrombosis that was associated with a temporary risk factor. Among the 51 women with abnormal laboratory results or a previous episode of idiopathic thrombosis, or both, 3 (5.9 percent) had an antepartum recurrence of venous thromboembolism (95 percent confidence interval, 1.2 to 16.2 percent). Conclusions: The risk of recurrent antepartum venous thromboembolism in women with a history of venous thromboembolism is low, and therefore routine antepartum prophylaxis with heparin is not warranted. (N Engl J Med 2000;343:1439-44.) (C) 2000, Massachusetts Medical Society.	McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; Monash Med Ctr, Clayton, Vic 3168, Australia; Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; London Hlth Sci Ctr, London, ON, Canada; Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada; Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; Univ Quebec St Francois dAssise, Ctr Hosp, Quebec City, PQ, Canada	McMaster University; Monash University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Universite de Montreal; Laval University; University of Quebec	Ginsberg, JS (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,HSC-3X28, Hamilton, ON L8N 3Z5, Canada.		ginsberg, jeffrey s/ABC-1065-2020; Kovacs, Michael/G-3315-2011; Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; ANDERSSON NE, 1991, THROMB HAEMOSTASIS, V65, P912; BADARACC.MA, 1974, BRIT MED J, V1, P215, DOI 10.1136/bmj.1.5901.215; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; COLVIN BT, 1993, J CLIN PATHOL, V46, P97, DOI 10.1136/jcp.46.2.97; DAHLMAN T, 1990, BRIT J OBSTET GYNAEC, V97, P221, DOI 10.1111/j.1471-0528.1990.tb01785.x; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; DESWIET M, 1987, BRIT J HOSP MED, V38, P264; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; FAUGHT W, 1995, AM J OBSTET GYNECOL, V172, P147, DOI 10.1016/0002-9378(95)90104-3; Ginsberg JS, 1998, CHEST, V114, p524S, DOI 10.1378/chest.114.5_Supplement.524S; HOWELL R, 1983, BRIT J OBSTET GYNAEC, V90, P1124, DOI 10.1111/j.1471-0528.1983.tb06458.x; KAUNITZ AM, 1985, OBSTET GYNECOL, V65, P605; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; LAO TT, 1985, BRIT J OBSTET GYNAEC, V92, P202, DOI 10.1111/j.1471-0528.1985.tb01082.x; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; MATERNAL A, 1993, J CLIN PATHOL, V46, P489; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; TENGBORN L, 1989, AM J OBSTET GYNECOL, V160, P90, DOI 10.1016/0002-9378(89)90095-1; THIAGARAJAN P, 1986, BLOOD, V68, P869; TRIPLETT DA, 1993, THROMB HAEMOSTASIS, V70, P787; WARWICK R, 1989, J ROY SOC MED, V82, P591, DOI 10.1177/014107688908201008	30	303	311	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1439	1444		10.1056/NEJM200011163432002	http://dx.doi.org/10.1056/NEJM200011163432002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078768				2022-12-28	WOS:000165271300002
J	Haider, R; Ashworth, A; Kabir, I; Huttly, SRA				Haider, R; Ashworth, A; Kabir, I; Huttly, SRA			Effect of community-based peer counsellors on exclusive breastfeeding practices in Dhaka, Bangladesh: a randomised controlled trial	LANCET			English	Article								Background Most mothers breastfeed in Bangladesh, but they rarely practise exclusive breastfeeding. Hospital-based strategies for breastfeeding promotion cannot reach them because about 95% have home deliveries. We postulated that with the intervention of trained peer counsellors, mothers could be enabled to breastfeed exclusively for the recommended duration of 5 months. Methods 40 adjacent zones in Dhaka were randomised to intervention or control groups. Women were enrolled during the last trimester of pregnancy between February and December, 1996. In the intervention group, 15 home-based counselling visits were scheduled, with two visits in the last trimester, three early postpartum (within 48 h, on day 5, between days 10 and 14), and fortnightly thereafter until the infant was 5 months old. Peer counsellors were local mothers who received 10 days' training. Findings 363 women were enrolled in each group. Peer counselling significantly improved breastfeeding practices. For the primary outcome, the prevalence of exclusive breastfeeding at 5 months was 202/228 (70%) for the intervention group and 17/285 (6%) for the control group (difference=64%; 95% CI 57%-71%, p>0.0001). For the secondary outcomes, mothers in the intervention group initiated breastfeeding earlier than control mothers and were less likely to give prelacteal and postlacteal foods. At day 4, significantly more mothers in the intervention group breastfed exclusively than controls. Interpretation Peer counsellors can effectively increase the initiation and duration of exclusive breastfeeding. We recommend incorporation of peer counsellors in mother and child health programmes in developing countries.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Dhaka 1000, Bangladesh; London Sch Hyg & Trop Med, London WC1, England	International Centre for Diarrhoeal Disease Research (ICDDR); University of London; London School of Hygiene & Tropical Medicine	Haider, R (corresponding author), Urban Family Hlth Partnership & John Snow Inc, Level 2 Progress Tower,Rd 23, Dhaka 1212, Bangladesh.	rhaider@ufhp.bdmail.net						AKHTER HH, 1998, NATL BASELINE SUVEY; Alvarado-M. Reynaldo, 1996, Food and Nutrition Bulletin, V17, P49; [Anonymous], 1995, Wkly Epidemiol Rec, V70, P117; Haider R, 1999, J TROP PEDIATRICS, V45, P315, DOI 10.1093/tropej/45.5.315; King F S, 1992, HELPING MOTHERS BREA; KIRKWOOD B, 1990, ESSENTIALS MED STAT; Kistin N, 1994, J Hum Lact, V10, P11, DOI 10.1177/089033449401000121; LEITE AJM, 1998, J CLIN EPIDEMIOL, V51, pS10; MITRA S, 1997, BANGLADESH DEMOGRAPH; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; TALUKDER MQ, 1997, STATE BREASTFEEDING; *UNICEF, 1991, TAK BAB FRIENDL IN; *WHO, 1993, UICEFNUT93 WHO; *WHO, 1993, WHOCDR9336; WHO UNICEF, 1989, PROT PROM SUPP BREAS	15	279	289	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1643	1647		10.1016/S0140-6736(00)03159-7	http://dx.doi.org/10.1016/S0140-6736(00)03159-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089824				2022-12-28	WOS:000165249200013
J	Hashizume, K; Chaussidon, M; Marty, B; Robert, F				Hashizume, K; Chaussidon, M; Marty, B; Robert, F			Solar wind record on the moon: Deciphering presolar from planetary nitrogen	SCIENCE			English	Article							ISOTOPIC COMPOSITION; CORPUSCULAR RADIATION; ENERGETIC PARTICLES; ORDINARY CHONDRITES; LUNAR ILMENITES; FRACTIONATION; GRAINS; AR; NUCLEOSYNTHESIS; ABUNDANCES	Ion microprobe analyses show that solar wind nitrogen associated with solar wind hydrogen implanted in the first tens of nanometers of Lunar regolith grains is depleted in N-15 by at least 24% relative to terrestrial atmosphere, whereas a nonsolar component associated with deuterium-rich hydrogen, detected in silicon-bearing coatings at the surface of some ilmenite grains, is enriched in N-15. Systematic enrichment of N-15 in terrestrial planets and bulk meteorites relative to the protosolar gas cannot be explained by isotopic fractionation in nebular or planetary environments but requires the contribution of N-15-rich compounds to the total nitrogen in planetary materials. Most of these compounds are possibly of an interstellar origin and never equilibrated with the N-15-depleted protosolar nebula.	Ctr Rech Petrog & Geochim, F-54501 Vandoeuvre Nancy, France; Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Osaka 5600043, Japan; INPL, Ecole Natl Super Geol, F-54501 Vandoeuvre Nancy, France; Museum Natl Hist Nat, Lab Mineral, F-75005 Paris, France	Universite de Lorraine; Osaka University; Universite de Lorraine; Museum National d'Histoire Naturelle (MNHN)	Hashizume, K (corresponding author), Ctr Rech Petrog & Geochim, BP 20, F-54501 Vandoeuvre Nancy, France.		Chaussidon, Marc/E-7067-2017					ADAMS NG, 1981, ASTROPHYS J, V247, pL123, DOI 10.1086/183604; BECKER RH, 1989, GEOCHIM COSMOCHIM AC, V53, P1135, DOI 10.1016/0016-7037(89)90219-6; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; BOCHSLER P, 1994, METEORITICS, V29, P653, DOI 10.1111/j.1945-5100.1994.tb00780.x; Chaussidon M, 1999, NATURE, V402, P270, DOI 10.1038/46235; Fouchet T, 2000, ICARUS, V143, P223, DOI 10.1006/icar.1999.6255; Frick U., 1988, P LUNAR PLANET SCI, P87; GEISS J, 1994, PHILOS T R SOC A, V349, P213, DOI 10.1098/rsta.1994.0126; Geiss J., 1991, SUN TIME, P98; GRADY MM, 1993, EARTH PLANET SC LETT, V116, P165, DOI 10.1016/0012-821X(93)90052-B; GRADY MM, 1986, GEOCHIM COSMOCHIM AC, V50, P2799, DOI 10.1016/0016-7037(86)90228-0; HASHIZUME K, 1995, GEOCHIM COSMOCHIM AC, V59, P4057, DOI 10.1016/0016-7037(95)00236-S; HASHIZUME K, 1999, LUNAR PLANET SCI, V30; Humbert F., 1998, THESIS U H POINCARE; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; Kallenbach R, 1998, ASTROPHYS J, V507, pL185, DOI 10.1086/311702; Keller LP, 1997, GEOCHIM COSMOCHIM AC, V61, P2331, DOI 10.1016/S0016-7037(97)00085-9; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; Marty B, 1999, GEOCHIM COSMOCHIM AC, V63, P3619, DOI 10.1016/S0016-7037(99)00169-6; MCELROY MB, 1976, SCIENCE, V194, P70, DOI 10.1126/science.194.4260.70; MESSENGER S, 1997, AIP C P, V402, P545; PROMBO CA, 1993, GEOCHIM COSMOCHIM AC, V57, P3749, DOI 10.1016/0016-7037(93)90153-N; SUGIURA N, 1992, EARTH PLANET SC LETT, V111, P441, DOI 10.1016/0012-821X(92)90195-2; WIELER R, 1995, ASTROPHYS J, V453, P987, DOI 10.1086/176458; Wieler R, 1999, EARTH PLANET SC LETT, V167, P47, DOI 10.1016/S0012-821X(99)00012-6; Wieler R, 1996, NATURE, V384, P46, DOI 10.1038/384046a0; Ziegler J.F, 1985, STOPPING RANGE IONS; Zinner E, 1998, ANNU REV EARTH PL SC, V26, P147, DOI 10.1146/annurev.earth.26.1.147	29	130	131	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1142	1145		10.1126/science.290.5494.1142	http://dx.doi.org/10.1126/science.290.5494.1142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073449				2022-12-28	WOS:000165228200042
J	Yudkovsky, N; Ranish, JA; Hahn, S				Yudkovsky, N; Ranish, JA; Hahn, S			A transcription reinitiation intermediate that is stabilized by activator	NATURE			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; FACTOR TFIIA; IN-VITRO; RECRUITMENT; HOLOENZYME; INITIATION; YEAST; PROMOTER	High levels of gene transcription by RNA polymerase II depend on high rates of transcription initiation and reinitiation. Initiation requires recruitment of the complete transcription machinery to a promoter, a process facilitated by activators and chromatin remodelling factors. Reinitiation probably occurs through a different pathway(1). After initiation, a subset of the transcription machinery remains at the promoter, forming a platform for assembly of a second transcription complex(2-4). Here we describe the isolation of a reinitiation intermediate that includes transcription factors TFIID, TFIIA, TFIIH, TFIIE and Mediator. This intermediate can act as a scaffold for formation of a functional reinitiation complex. Formation of this scaffold is dependent on ATP and TFIIH. The scaffold is stabilized in the presence of the activator Gal4-VP16, but not Gal4-AH, suggesting a new role for some activators and Mediator in promoting high levels of transcription.	Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute	Hahn, S (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.			Hahn, Steven/0000-0001-7240-2533				CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; Hahn S, 1998, COLD SPRING HARB SYM, V63, P181, DOI 10.1101/sqb.1998.63.181; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lee YC, 1999, MOL CELL BIOL, V19, P2967; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; RANISH JA, 1991, J BIOL CHEM, V266, P19320; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; Sandaltzopoulos R, 1998, MOL CELL BIOL, V18, P361, DOI 10.1128/MCB.18.1.361; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	27	286	290	2	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					225	229		10.1038/35041603	http://dx.doi.org/10.1038/35041603			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089979				2022-12-28	WOS:000165180400051
J	Zhang, ZG; Shibahara, K; Stillman, B				Zhang, ZG; Shibahara, K; Stillman, B			PCNA connects DNA replication to epigenetic inheritance in yeast	NATURE			English	Article							ASSEMBLY FACTOR-I; ORIGIN RECOGNITION COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL STATES; POLYMERASE-EPSILON; CELL-CYCLE; CHROMATIN; REPRESSION; MUTATIONS; PROTEINS	Formation of a heterochromatin-like structure results in transcriptional silencing at the HM mating-type loci and telomeres in Saccharomyces cerevisiae(1-3). Once formed, such epigenetically determined structures are inherited for many mitotic divisions(4). Here we show that mutations in the proliferating cell nuclear antigen (PCNA), an essential component at the DNA replication fork(5), reduced repression of genes near a telomere and at the silent mating-type locus, HMR. The pol30-8 mutant displayed coexistence of both repressed (pink) and de-repressed (white) cells within a single colony when assayed with the ADE2 gene inserted at HMR. Unlike pol30-8, the pol30-6 and pol30-79 mutants partially reduced gene silencing at telomeres and the HMR and synergistically decreased silencing in cells lacking chromatin assembly factor 1 (CAF-1). All silencing defective mutants showed reduced binding to CAF-1 in vitro and altered chromatin association of the CAF-1 large subunit in vivo. Thus, PCNA participates in inheritance of both DNA and epigenetic chromatin structures during the S phase of the cell cycle, the latter by at least two mechanisms.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091				AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; Ehrenhofer-Murray AE, 1999, GENETICS, V153, P1171; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Moggs JG, 2000, MOL CELL BIOL, V20, P1206, DOI 10.1128/MCB.20.4.1206-1218.2000; Murzina N, 1999, MOL CELL, V4, P529, DOI 10.1016/S1097-2765(00)80204-X; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; Scott MP, 2000, CELL, V100, P27, DOI 10.1016/S0092-8674(00)81681-5; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Verreault A, 2000, GENE DEV, V14, P1430; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721	30	239	243	5	34	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					221	225		10.1038/35041601	http://dx.doi.org/10.1038/35041601			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089978				2022-12-28	WOS:000165180400050
J	Yamashita, J; Itoh, H; Hirashima, M; Ogawa, M; Nishikawa, S; Yurugi, T; Naito, M; Nakao, K; Nishikawa, S				Yamashita, J; Itoh, H; Hirashima, M; Ogawa, M; Nishikawa, S; Yurugi, T; Naito, M; Nakao, K; Nishikawa, S			Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL FORMATION; SMOOTH-MUSCLE CELLS; PDGF-B; HEMATOPOIETIC LINEAGES; MESODERMAL CELLS; IN-VITRO; RECEPTOR; BETA; VASCULOGENESIS	Interaction between endothelial cells and mural cells (pericytes and vascular smooth muscle) is essential for vascular development and maintenance(1-4). Endothelial cells arise from Flk1-expressing (Flk1(+)) mesoderm cells(5), whereas mural cells are believed to derive from mesoderm, neural crest or epicardial cells and migrate to form the vessel wall(6-8). Difficulty in preparing pure populations of these lineages has hampered dissection of the mechanisms underlying vascular formation. Here we show that Flk1(+) cells derived from embryonic stem cells can differentiate into both endothelial and mural cells and can reproduce the vascular organization process. Vascular endothelial growth factor promotes endothelial cell differentiation, whereas mural cells are induced by platelet-derived growth factor-BB. Vascular cells derived from Flk1(+) cells can organize into vessel-like structures consisting of endothelial tubes supported by mural cells in three-dimensional culture. Injection of Flk1(+) cells into chick embryos showed that they can incorporate as endothelial and mural cells and contribute to the developing vasculature in vivo. Our findings indicate that Flk1(+) cells can act as `vascular progenitor cells' to form mature vessels and thus offer potential for tissue engineering of the vascular system.	Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 6068509, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068509, Japan; Niigata Univ, Sch Med, Dept Pathol 2, Niigata 9518510, Japan	Kyoto University; Kyoto University; Niigata University	Yamashita, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068509, Japan.		Hirashima, Masanori/ABC-9204-2021	Hirashima, Masanori/0000-0002-0190-4381				Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Choi K, 1998, DEVELOPMENT, V125, P725; CUEVAS P, 1984, ANAT EMBRYOL, V170, P155, DOI 10.1007/BF00319000; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hirashima M, 1999, BLOOD, V93, P1253, DOI 10.1182/blood.V93.4.1253.404k31_1253_1263; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; Jiang XB, 2000, DEVELOPMENT, V127, P1607; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Matsuyoshi N, 1997, P ASSOC AM PHYSICIAN, V109, P362; Mikawa T, 1996, DEV BIOL, V174, P221, DOI 10.1006/dbio.1996.0068; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; Ogawa M, 1999, BLOOD, V93, P1168, DOI 10.1182/blood.V93.4.1168.404k12_1168_1177; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takakura N, 1996, J EXP MED, V184, P2301, DOI 10.1084/jem.184.6.2301; Topouzis S, 1996, DEV BIOL, V178, P430, DOI 10.1006/dbio.1996.0229; UEDA M, 1995, CORONARY ARTERY DIS, V6, P71, DOI 10.1097/00019501-199501000-00011; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yamamoto T, 1996, AM J PATHOL, V149, P1271; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643	30	1026	1129	1	48	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					92	96		10.1038/35040568	http://dx.doi.org/10.1038/35040568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081514				2022-12-28	WOS:000165050400058
J	Vance, JC				Vance, JC			A degree of vision	LANCET			English	Editorial Material							OPHTHALMOLOGISTS		Mater Childrens Hosp, Dept Paediat & Child Hlth, S Brisbane, Qld 4101, Australia		Vance, JC (corresponding author), Mater Childrens Hosp, Dept Paediat & Child Hlth, S Brisbane, Qld 4101, Australia.							ADAMS GL, 1970, PSYCHIAT MED, V1, P233, DOI 10.2190/R0G9-95LE-8NK7-YBHE; Burgoon J. K., 1985, HDB INTERPERSONAL CO, P344; CARPENTER JO, 1974, ARCH PHYS MED REHAB, V55, P272; DAVIS L, 1996, NAT FED BLIND CIT AU, P20; FITZGERALD RG, 1970, ARCH GEN PSYCHIAT, V22, P370; FRIEDMAN DB, 1994, PRINCIPLES PRACTICE, P3722; GOLDBERG MF, 1994, OPHTHALMIC GENET, V15, P47, DOI 10.3109/13816819409098863; GREENBLATT SL, 1988, SOC SCI MED, V26, P393, DOI 10.1016/0277-9536(88)90307-3; HALLAHAN D, 1997, EXCEPT CHILDREN, P343; HERSHBERGER PJ, 1992, PERCEPT MOTOR SKILL, V74, P509, DOI 10.2466/PMS.74.2.509-510; HUBER A, 1994, CURR OPIN NEUROL, V7, P65, DOI 10.1097/00019052-199402000-00012; Keeffe JE, 1996, AUST NZ J OPHTHALMOL, V24, P207, DOI 10.1111/j.1442-9071.1996.tb01582.x; Kubler-Ross E., 1970, DEATH DYING; LAMPERT J, 1995, AM J OCCUP THER, V49, P885, DOI 10.5014/ajot.49.9.885; Lindsay S, 1992, CURR OPIN GENET DEV, V2, P459, DOI 10.1016/S0959-437X(05)80158-3; Lovie-Kitchin JE., 1996, CLIN EXP OPTOM, V79, P227; NEMSHICK LA, 1986, J VISUAL IMPAIR BLIN, V80, P859; PARRISH RK, 1988, ARCH OPHTHALMOL-CHIC, V106, P31; SHIPSEY SM, 1994, PRINCIPLES PRACTICE, P3717; STETTEN D, 1981, NEW ENGL J MED, V305, P458, DOI 10.1056/NEJM198108203050811	20	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1517	1519		10.1016/S0140-6736(00)02888-9	http://dx.doi.org/10.1016/S0140-6736(00)02888-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	367NA	11081552				2022-12-28	WOS:000090067300043
J	Hankey, GJ				Hankey, GJ			Clopidogrel and thrombotic thrombocytopenic purpura	LANCET			English	Editorial Material							TICLOPIDINE		Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia	Royal Perth Hospital; University of Western Australia	Hankey, GJ (corresponding author), Royal Perth Hosp, Dept Neurol, Perth, WA 6001, Australia.		Hankey, Graeme J/H-4968-2014	Hankey, Graeme J/0000-0002-6044-7328				Bennett CL, 1999, ARCH INTERN MED, V159, P2524, DOI 10.1001/archinte.159.21.2524; Bennett CL, 2000, NEW ENGL J MED, V342, P1773, DOI 10.1056/NEJM200006153422402; Bennett CL, 1998, ANN INTERN MED, V128, P541, DOI 10.7326/0003-4819-128-7-199804010-00004; Bennett CL, 1998, LANCET, V352, P1036, DOI 10.1016/S0140-6736(05)60079-7; Bertrand ME, 1999, CIRCULATION, V100, P620; CARWILE JM, 1999, BLOOD S, V94, P78; Connors JM, 1999, TRANSFUSION, V39, p56S; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gordon LI, 1997, SEMIN HEMATOL, V34, P140; McCarthy LJ, 1998, LANCET, V352, P1284, DOI 10.1016/S0140-6736(05)70492-X; Moussa I, 1999, CIRCULATION, V99, P2364, DOI 10.1161/01.CIR.99.18.2364; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Steinhubl SR, 1999, JAMA-J AM MED ASSOC, V281, P806, DOI 10.1001/jama.281.9.806; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Tsai HM, 1998, NEW ENGL J MED, V339, P1585, DOI 10.1056/NEJM199811263392203	15	30	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					269	270		10.1016/S0140-6736(00)02498-3	http://dx.doi.org/10.1016/S0140-6736(00)02498-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071178				2022-12-28	WOS:000088305900004
J	Smith, AG				Smith, AG			How toxic is DDT?	LANCET			English	Editorial Material							MALARIA CONTROL; BREAST-CANCER; RISK		Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Smith, AG (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.							BOUMAN H, 1991, S AFR MED J, V79, P326; BOUWMAN H, 1992, B WORLD HEALTH ORGAN, V70, P241; BOUWMAN H, 1991, J TOXICOL ENV HEALTH, V33, P141, DOI 10.1080/15287399109531514; Cocco P, 1997, ARCH ENVIRON HEALTH, V52, P299, DOI 10.1080/00039899709602202; ERIKSSON P, 1992, BRAIN RES, V582, P277, DOI 10.1016/0006-8993(92)90144-X; GARABRANT DH, 1992, J NATL CANCER I, V84, P764, DOI 10.1093/jnci/84.10.764; Hayes Jr W. J., 1991, HDB PESTICIDE TOXICO, P1; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KEY T, 1994, BMJ-BRIT MED J, V308, P1520, DOI 10.1136/bmj.308.6943.1520; Schecter A, 1997, ARCH ENVIRON CON TOX, V33, P453, DOI 10.1007/s002449900276; SMITH AG, 1991, HDB PESTICIDE TOXICO, P731; WEST TF, 1946, DDT SYNTHETIC INSECT	12	30	32	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					267	268		10.1016/S0140-6736(00)02497-1	http://dx.doi.org/10.1016/S0140-6736(00)02497-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071177				2022-12-28	WOS:000088305900003
J	Quake, SR; Scherer, A				Quake, SR; Scherer, A			From micro- to nanofabrication with soft materials	SCIENCE			English	Review							DNA-MOLECULES; LITHOGRAPHY; FABRICATION; SILICON; COMPLEX	Soft materials are finding applications in areas ranging from microfluidic device technology to nanofabrication. We review recent work in these areas, discuss the motivation for device fabrication with soft materials, and describe applications of soft materials. In particular. we discuss active microfluidic devices for cell sorting and biochemical assays, replication-molded optics with subdiffraction limit features, and nanometer-scale resonators and wires formed from single-molecule DNA templates as examples of how the special properties of soft materials address outstanding problems in device fabrication.	CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	California Institute of Technology	Quake, SR (corresponding author), CALTECH, Dept Appl Phys, MS 128-95, Pasadena, CA 91125 USA.							Anderson JR, 2000, ANAL CHEM, V72, P3158, DOI 10.1021/ac9912294; Beebe DJ, 2000, NATURE, V404, P588, DOI 10.1038/35007047; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; Bousse L, 2000, ANNU REV BIOPH BIOM, V29, P155, DOI 10.1146/annurev.biophys.29.1.155; Braun E, 1998, NATURE, V391, P775, DOI 10.1038/35826; BROERS AN, 1988, IBM J RES DEV, V32, P502, DOI 10.1147/rd.324.0502; Chou H.-P., 2000, P SOL STAT SENS ACT, P111; CHOU HL, UNPUB; Chou HP, 1999, P NATL ACAD SCI USA, V96, P11, DOI 10.1073/pnas.96.1.11; CHOU HP, 2000, THESIS CALTECH PASAD; Delamarche E, 1997, SCIENCE, V276, P779, DOI 10.1126/science.276.5313.779; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Effenhauser CS, 1997, ANAL CHEM, V69, P3451, DOI 10.1021/ac9703919; Fritzsche W, 1999, APPL PHYS LETT, V75, P2854, DOI 10.1063/1.125172; Fu AY, 1999, NAT BIOTECHNOL, V17, P1109, DOI 10.1038/15095; Guo LJ, 1997, APPL PHYS LETT, V71, P1881, DOI 10.1063/1.119426; Jackman RJ, 1998, SCIENCE, V280, P2089, DOI 10.1126/science.280.5372.2089; Li MT, 2000, APPL PHYS LETT, V76, P673, DOI 10.1063/1.125896; MACKIE S, 1985, SOLID STATE TECHNOL, V28, P117; MAHL H, 1940, Z TECH PHYS, V21, P17; MAHL H, 1940, METALLWIRTSCHAFT, V19, P488; Mait JN, 2000, OPT LETT, V25, P381, DOI 10.1364/OL.25.000381; PETERSEN KE, 1982, P IEEE, V70, P420, DOI 10.1109/PROC.1982.12331; Richter J, 2000, ADV MATER, V12, P507, DOI 10.1002/(SICI)1521-4095(200004)12:7<507::AID-ADMA507>3.0.CO;2-G; Rogers JA, 1997, J MICROELECTROMECH S, V6, P184, DOI 10.1109/84.623106; Schaefer VJ, 1942, J APPL PHYS, V13, P427, DOI 10.1063/1.1714890; THOMAS G, 1962, TRANSMISSION ELECTRO, P134; TUTTLE E, UNPUB; UNGER M, UNPUB; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; VANDERGAAG BP, 1990, APPL PHYS LETT, V56, P481, DOI 10.1063/1.102772; Xia YN, 1996, SCIENCE, V273, P347, DOI 10.1126/science.273.5273.347; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yang PD, 2000, SCIENCE, V287, P465, DOI 10.1126/science.287.5452.465; Zhao XM, 1996, ADV MATER, V8, P420, DOI 10.1002/adma.19960080511	35	950	1146	14	517	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1536	1540		10.1126/science.290.5496.1536	http://dx.doi.org/10.1126/science.290.5496.1536			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090344				2022-12-28	WOS:000165446200039
J	Colhoun, HM; Rubens, MB; Underwood, SR; Fuller, JH				Colhoun, HM; Rubens, MB; Underwood, SR; Fuller, JH			Cross sectional study of differences in coronary artery calcification by socioeconomic status	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UCL, Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; Royal Brompton & Harefield NHS Hosp Trust, London SW3 6NP, England	University of London; University College London; Royal Brompton & Harefield NHS Foundation Trust	Colhoun, HM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	helen@public-health.ucl.ac.uk		Colhoun, Helen/0000-0002-8345-3288				Brunner E, 1999, J EPIDEMIOL COMMUN H, V53, P757, DOI 10.1136/jech.53.12.757; COLHOUN HM, IN PRESS J AM COLL C; Frankel S, 1999, AM J EPIDEMIOL, V150, P1081, DOI 10.1093/oxfordjournals.aje.a009932; Leeson CPM, 2000, CIRCULATION, V101, P1533, DOI 10.1161/01.CIR.101.13.1533; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175	5	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2000	321	7271					1262	1263		10.1136/bmj.321.7271.1262	http://dx.doi.org/10.1136/bmj.321.7271.1262			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082087	Green Published, Bronze			2022-12-28	WOS:000165445800026
J	Griffiths, RE; Ptak, A; Feigelson, ED; Garmire, G; Townsley, L; Brandt, WN; Sambruna, R; Bregman, JN				Griffiths, RE; Ptak, A; Feigelson, ED; Garmire, G; Townsley, L; Brandt, WN; Sambruna, R; Bregman, JN			Hot plasma and black hole binaries in starburst galaxy M82	SCIENCE			English	Article							RESOLUTION; EMISSION; SPECTRA	High-resolution x-ray observations of the prototype starburst galaxy Messier 82 (M82) obtained with the advanced CCD (charge-coupled device) imaging spectrometer on board the Chandra X-ray Observatory provide a detailed view of hot plasma and energetic processes. Plasma with temperature of about 40,000,000 kelvin fills the inner 1 kiloparsec, which is much hotter than the 1,000,000 to 2,000,000 kelvin interstellar medium component in the Milky Way Galaxy. Produced by many supernova explosions, this central region is overpressurized and drives M82's prominent galactic wind into the intergalactic medium. We also resolved about 20 compact x-ray sources, many of which could be high-mass x-ray binary star systems containing black holes.	Carnegie Mellon Univ, Dept Phys, Pittsburgh, PA 15213 USA; Penn State Univ, Dept Astron & Astrophys, Davey Lab 525, University Pk, PA 16802 USA; Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA	Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Michigan System; University of Michigan	Griffiths, RE (corresponding author), Carnegie Mellon Univ, Dept Phys, Pittsburgh, PA 15213 USA.	griffith@astro.phys.cmu.edu	Ptak, Andrew/D-3574-2012; Brandt, William N/N-2844-2015	Brandt, William N/0000-0002-0167-2453; Bregman, Joel/0000-0001-6276-9526				BARNES JE, 1999, IAU S, V196; Barret D, 1996, ASTROPHYS J, V473, P963, DOI 10.1086/178206; BRADT HVD, 1983, ANNU REV ASTRON ASTR, V21, P13, DOI 10.1146/annurev.aa.21.090183.000305; BREGMAN JN, 1995, ASTROPHYS J, V439, P155, DOI 10.1086/175160; COLLURA A, 1994, ASTROPHYS J, V420, pL63, DOI 10.1086/187163; COWLEY AP, 1999, IAU S, V192, P100; de Grijs R, 2000, ASTRON J, V119, P681, DOI 10.1086/301235; EBELING H, IN PRESS MON NOT R A; FREEDMAN WL, 1994, ASTROPHYS J, V427, P628, DOI 10.1086/174172; FREEMAN PG, UNPUB; GARMIRE G, UNPUB; GRIFFITHS RE, 1979, ASTROPHYS J, V230, pL21, DOI 10.1086/182954; HOLT S, 1999, DARK AGES GALAXIES W; HUANG ZP, 1994, ASTROPHYS J, V424, P114, DOI 10.1086/173876; Kaneda H, 1997, ASTROPHYS J, V491, P638, DOI 10.1086/304965; KRONBERG PP, 1988, GALACTIC EXTRAGALACT, P391; Moran EC, 1997, ASTROPHYS J, V478, P172, DOI 10.1086/303795; OCONNELL RW, 1978, ASTROPHYS J, V221, P62, DOI 10.1086/156005; OCONNELL RW, 1995, ASTROPHYS J, V446, pL1, DOI 10.1086/187916; Ptak A, 1999, ASTROPHYS J, V517, pL85, DOI 10.1086/312032; RIEKE GH, 1980, ASTROPHYS J, V238, P24, DOI 10.1086/157954; Satyapal S, 1997, ASTROPHYS J, V483, P148, DOI 10.1086/304214; SOFUE Y, 1998, IAU S, V184; Stevens IR, 1999, MON NOT R ASTRON SOC, V308, pL23, DOI 10.1046/j.1365-8711.1999.02958.x; TOWNSLEY L, UNPUB; Townsley LK, 2000, ASTROPHYS J, V534, pL139, DOI 10.1086/312672; Tsuru TG, 1997, PUBL ASTRON SOC JPN, V49, P619, DOI 10.1093/pasj/49.6.619; VANDERHUCHT KA, 1999, IAU S, V193; WATSON MG, 1984, ASTROPHYS J, V286, P144, DOI 10.1086/162583; WEEDMAN DW, 1981, ASTROPHYS J, V248, P105, DOI 10.1086/159133; Weisskopf MC, 1996, PROC SPIE, V2805, P2, DOI 10.1117/12.245079; Williams F, 1999, ILLINOIS J MATH, V43, P633, DOI 10.1215/ijm/1256060683	32	120	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1325	1328		10.1126/science.290.5495.1325	http://dx.doi.org/10.1126/science.290.5495.1325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082054				2022-12-28	WOS:000165379800040
J	Beller, GA				Beller, GA			Noninvasive assessment of myocardial viability.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR DYSFUNCTION; VIABLE MYOCARDIUM; HEART-FAILURE; REVASCULARIZATION; ECHOCARDIOGRAPHY; CARDIOMYOPATHY; IMPROVEMENT; SURVIVAL; SURGERY		Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA	University of Virginia	Beller, GA (corresponding author), Univ Virginia Hlth Syst, Charlottesville, VA 22908 USA.							Afridi I, 1998, J AM COLL CARDIOL, V32, P921, DOI 10.1016/S0735-1097(98)00321-0; Bart BA, 1997, J AM COLL CARDIOL, V30, P1002, DOI 10.1016/S0735-1097(97)00235-0; Bax JJ, 1997, J AM COLL CARDIOL, V30, P1451, DOI 10.1016/S0735-1097(97)00352-5; Bax JJ, 1999, J AM COLL CARDIOL, V34, P163, DOI 10.1016/S0735-1097(99)00157-6; Beller GA, 1997, J NUCL CARDIOL, V4, pS152; Chaudhry FA, 1999, J AM COLL CARDIOL, V34, P730, DOI 10.1016/S0735-1097(99)00252-1; Dakik HA, 1997, CIRCULATION, V96, P2892, DOI 10.1161/01.CIR.96.9.2892; Haas F, 1997, J AM COLL CARDIOL, V30, P1693, DOI 10.1016/S0735-1097(97)00375-6; Hillenbrand HB, 2000, CIRCULATION, V102, P1678, DOI 10.1161/01.CIR.102.14.1678; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; Kim RJ, 2000, NEW ENGL J MED, V343, P1445, DOI 10.1056/NEJM200011163432003; Meluzin J, 1998, J AM COLL CARDIOL, V32, P912, DOI 10.1016/S0735-1097(98)00324-6; Pagley PR, 1997, CIRCULATION, V96, P793; RAHIMTOOLA SH, 1989, AM HEART J, V117, P211, DOI 10.1016/0002-8703(89)90685-6; Senior R, 1999, J AM COLL CARDIOL, V33, P1848, DOI 10.1016/S0735-1097(99)00102-3	15	33	34	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1488	1490		10.1056/NEJM200011163432011	http://dx.doi.org/10.1056/NEJM200011163432011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078777				2022-12-28	WOS:000165271300011
J	Berger, A				Berger, A			BAX gene needed for NSAIDs chemoprotection	BRITISH MEDICAL JOURNAL			English	News Item																		Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1173	1173						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073498				2022-12-28	WOS:000165357100008
J	Wu-Scharf, D; Jeong, BR; Zhang, CM; Cerutti, H				Wu-Scharf, D; Jeong, BR; Zhang, CM; Cerutti, H			Transgene and transposon silencing in Chlamydomonas reinhardtii by a DEAH-Box RNA helicase	SCIENCE			English	Article							ANTISENSE TRANSCRIPTS; C-ELEGANS; GENE; PLANTS; INTERFERENCE; COMPLEXES; SENSE	The molecular mechanism(s) responsible for posttranscriptional gene silencing and RNA interference remain poorly understood. We have cloned a gene (Mut6) from the unicellular green alga Chlamydomonas reinhardtii that is required for the silencing of a transgene and two transposon families, Mut6 encodes a protein that is highly homologous to RNA helicases of the DEAH-box family, This protein is necessary for the degradation of certain aberrant RNAs, such as improperly processed transcripts, which are often produced by transposons and some transgenes.	Univ Nebraska, Sch Biol Sci & Plant Sci Initiat, Beadle Ctr E211, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Cerutti, H (corresponding author), Univ Nebraska, Sch Biol Sci & Plant Sci Initiat, Beadle Ctr E211, POB 880666, Lincoln, NE 68588 USA.		Jeong, Byeong-ryool/N-1661-2019	Jeong, Byeong-ryool/0000-0003-0642-1650				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Cerutti H, 1997, PLANT CELL, V9, P925, DOI 10.1105/tpc.9.6.925; Cerutti H, 1997, GENETICS, V145, P97; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DAY A, 1991, J MOL BIOL, V218, P273, DOI 10.1016/0022-2836(91)90712-F; FERRIS PJ, 1989, GENETICS, V122, P363; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; Hilleren P, 1999, ANNU REV GENET, V33, P229, DOI 10.1146/annurev.genet.33.1.229; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jorgensen RA, 1999, TRENDS GENET, V15, P11, DOI 10.1016/S0168-9525(98)01651-5; Ketting RF, 2000, NATURE, V404, P296, DOI 10.1038/35005113; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Kimura RH, 1999, NUCLEIC ACIDS RES, V27, P3380, DOI 10.1093/nar/27.16.3380; Kooter JM, 1999, TRENDS PLANT SCI, V4, P340, DOI 10.1016/S1360-1385(99)01467-3; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Metzlaff M, 2000, PLANT J, V23, P63, DOI 10.1046/j.1365-313x.2000.00793.x; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Puoti A, 1999, MOL CELL BIOL, V19, P2189; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; WUSCHARF D, UNPUB; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	29	226	255	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1159	1162		10.1126/science.290.5494.1159	http://dx.doi.org/10.1126/science.290.5494.1159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073454	Green Submitted			2022-12-28	WOS:000165228200047
J	Marqusee, E; Benson, CB; Frates, MC; Doubilet, PM; Larsen, PR; Cibas, ES; Mandel, SJ				Marqusee, E; Benson, CB; Frates, MC; Doubilet, PM; Larsen, PR; Cibas, ES; Mandel, SJ			Usefulness of ultrasonography in the management of nodular thyroid disease	ANNALS OF INTERNAL MEDICINE			English	Article							NEEDLE ASPIRATION BIOPSY; ULTRASOUND; SONOGRAPHY; PALPATION; CYTOLOGY; GLAND	Background: Fine-needle aspiration biopsy is the standard diagnostic test for evaluating possible malignancy in a thyroid nodule Objective: To evaluate the role of routine ultrasonography in the management of nodular thyroid disease. Design: Retrospective chart review. S etting: Multidisciplinary thyroid nodule clinic (endocrinology and radiology). Patients: Patients with suspected nodular thyroid disease or suspected recurrent thyroid cancer referred between October 1995 and March 1997. All patients had thyroid ultrasonography and ultrasonography-guided fine-needle aspiration biopsy of nodules at least 1 cm in maximum diameter. Measurements: Medical records, ultrasonography findings, cytology reports, and histologic reports were reviewed. Ultrasonography findings were compared with the referring physician's findings on physical examination. Results: 223 patients were seen in the clinic. A total of 209 fine-needle aspiration biopsies were performed on 156 patients. Among 50 of 114 patients referred for a solitary nodule, ultrasonography detected additional nonpalpable nodules at least 1 cm in diameter in 27 and determined that no nodules required aspiration in 23. Of 59 patients referred for a diffuse goiter or a multinodular gland, ultrasonography detected discrete nodules at least 1 cm in diameter that required aspiration in 39 and determined that aspiration was unnecessary in 20, Conclusions: Ultrasonography altered the clinical management for 63% of the patients (109 of 173) referred to the thyroid nodule clinic after abnormal results on thyroid physical examination.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Inst Med, Div Thyroid, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Marqusee, E (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Inst Med, Div Thyroid, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	emarqusee@bics.bwh.harvard.edu	Doubilet, Peter/AAY-7351-2021		NHLBI NIH HHS [5-T32-HL07609] Funding Source: Medline; NIDDK NIH HHS [K08-DK02221] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002221] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELFIORE A, 1992, AM J MED, V93, P363, DOI 10.1016/0002-9343(92)90164-7; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BRANDER A, 1991, RADIOLOGY, V181, P683, DOI 10.1148/radiology.181.3.1947082; Carmeci C, 1998, THYROID, V8, P283, DOI 10.1089/thy.1998.8.283; CLARK KJ, 1995, J CLIN ULTRASOUND, V23, P215, DOI 10.1002/jcu.1870230403; COCHANDPRIOLLET B, 1994, AM J MED, V97, P152, DOI 10.1016/0002-9343(94)90025-6; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; EZZAT S, 1994, ARCH INTERN MED, V154, P1838; Hagag P, 1998, THYROID, V8, P989, DOI 10.1089/thy.1998.8.989; Hatada T, 1998, AM J SURG, V175, P133, DOI 10.1016/S0002-9610(97)00274-2; HOPKINS CR, 1995, SEMIN ULTRASOUND CT, V16, P279, DOI 10.1016/0887-2171(95)90033-0; Kafaja S, 1999, J INVEST MED, V47, p22A; Kumar H, 1999, THYROID, V9, P1105, DOI 10.1089/thy.1999.9.1105; Leenhardt L, 1999, J CLIN ENDOCR METAB, V84, P24, DOI 10.1210/jc.84.1.24; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MCCALL A, 1986, SURGERY, V100, P1128; ROSEN IB, 1993, AM J SURG, V166, P346, DOI 10.1016/S0002-9610(05)80329-0; Schneider AB, 1997, J CLIN ENDOCR METAB, V82, P4020, DOI 10.1210/jc.82.12.4020; Tollin SR, 2000, THYROID, V10, P235, DOI 10.1089/thy.2000.10.235; Woeber KA, 1999, ANN INTERN MED, V131, P959, DOI 10.7326/0003-4819-131-12-199912210-00009	20	252	273	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					696	700		10.7326/0003-4819-133-9-200011070-00011	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074902				2022-12-28	WOS:000165075300004
J	Miller, OI; Tang, SF; Keech, A; Pigott, NB; Beller, N; Celermajer, DS				Miller, OI; Tang, SF; Keech, A; Pigott, NB; Beller, N; Celermajer, DS			Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study	LANCET			English	Article							RESPIRATORY-DISTRESS SYNDROME; CARDIOPULMONARY BYPASS; ENDOTHELIAL-CELLS; DOWNS-SYNDROME; L-ARGININE; DISEASE; CHILDREN; WITHDRAWAL; ACETYLCHOLINE; MANAGEMENT	Background Pulmonary hypertensive crises (PHTC) are a major cause of morbidity and mortality after congenital heart surgery. inhaled nitric oxide is frequently used as rescue therapy. We did a randomised double-blind study to investigate the role of routinely administered inhaled nitric oxide to prevent pulmonary hypertension in infants at high risk. Methods We enrolled 124 infants (64 male, 60 female; median age 3 months [IQR 1-5]), 76% with large ventricular or atrioventricular septal defects, who had high pulmonary flow, pressure, or both. and were undergoing corrective surgery for congenital heart disease. They were randomly assigned continuous low-dose inhaled nitric oxide (n=63) or placebo (n=61) from surgery until just before extubation. We measured the numbers of PHTC, time on study gas, and hours spent in intensive care. Analysis was done by intention to treat. Findings Compared with placebo, infants receiving inhaled nitric oxide had fewer PHTC (median four [IQR 0-12] vs seven [1-19]; relative risk, unadjusted 0.66, p<0.001, adjusted for dispersion 0.65, p=0.045) and shorter times until criteria for extubation were met (80 [38-121] vs 112 h [63-164], p=0.019). Time taken to wean infants off study gas was 35% longer in the nitric oxide group than in the placebo group (p=0.19), but the total time on the study gas was still 30 h shorter for the nitric oxide group (87 [43-125] vs 117 h [67-168], p=0.023). No important toxic effects arose. Interpretation In infants at high risk of pulmonary hypertension, routine use of inhaled nitric oxide after congenital heart surgery can lessen the risk of pulmonary hypertensive crises and shorten the postoperative course, with no toxic effects.	Royal Alexandra Hosp Children, Paediat Intens Care Unit, Sydney, NSW, Australia; Royal Alexandra Hosp Children, Adolph Basser Cardiac Inst, Sydney, NSW, Australia; Natl Hlth & Med Res Council, Clin Trials Ctr, Sydney, NSW, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Miller, OI (corresponding author), Prince Wales Hosp, Cardiac Program, Randwick, NSW 2031, Australia.		Beller, Elaine M/E-1615-2013	Beller, Elaine M/0000-0002-3241-2611				[Anonymous], 1980, Pediatrics, V65, P375; Atz AM, 1999, ANESTHESIOLOGY, V91, P307, DOI 10.1097/00000542-199907000-00041; Beghetti M, 1998, ANN THORAC SURG, V66, P532, DOI 10.1016/S0003-4975(98)00447-0; BURROWS FA, 1986, CAN ANAESTH SOC J, V33, P606, DOI 10.1007/BF03014268; CASTANEDA AR, 1992, NADAS PEDIAT CARDIOL; CELERMAJER DS, 1993, CIRCULATION, V87, P440, DOI 10.1161/01.CIR.87.2.440; Clancy RR, 2000, J THORAC CARDIOV SUR, V119, P347, DOI 10.1016/S0022-5223(00)70191-7; Day RW, 1996, CRIT CARE MED, V24, P215, DOI 10.1097/00003246-199602000-00006; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; FOUBERT L, 1992, LANCET, V339, P1615, DOI 10.1016/0140-6736(92)91886-D; FRIEDMAN WF, 1982, AM J CARDIOL, V50, P631, DOI 10.1016/0002-9149(82)90332-0; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HALS J, 1993, ACTA PAEDIATR, V82, P595, DOI 10.1111/j.1651-2227.1993.tb12763.x; HAYDAR A, 1992, LANCET, V340, P1545, DOI 10.1016/0140-6736(92)92796-I; Hoehn T, 1998, CRIT CARE MED, V26, P1857, DOI 10.1097/00003246-199811000-00028; HOPKINS RA, 1991, EUR J CARDIO-THORAC, V5, P628, DOI 10.1016/1010-7940(91)90118-4; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ivy DD, 1998, J THORAC CARDIOV SUR, V115, P875, DOI 10.1016/S0022-5223(98)70369-1; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MILLER OI, 1994, J THORAC CARDIOV SUR, V108, P487, DOI 10.1016/S0022-5223(12)70258-1; MILLER OI, 1995, LANCET, V346, P51, DOI 10.1016/S0140-6736(95)92681-X; MILLER OI, 1994, ARCH DIS CHILD-FETAL, V70, pF47, DOI 10.1136/fn.70.1.F47; MORRAY JP, 1986, ANESTHESIOLOGY, V65, P221, DOI 10.1097/00000542-198608000-00020; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS JD, 1993, CIRCULATION, V87, P447, DOI 10.1161/01.CIR.87.2.447; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Russell IAM, 1998, ANESTH ANALG, V87, P46, DOI 10.1097/00000539-199807000-00011; Schulze-Neick I, 1999, CIRCULATION, V100, P749, DOI 10.1161/01.CIR.100.7.749; Stork E, 1997, NEW ENGL J MED, V336, P597; Tang SF, 1996, ANAESTH INTENS CARE, V24, P127; WESSEL DL, 1993, CIRCULATION, V88, P2128, DOI 10.1161/01.CIR.88.5.2128; WHELLER J, 1979, CIRCULATION, V60, P1640, DOI 10.1161/01.CIR.60.7.1640	33	151	163	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1464	1469		10.1016/S0140-6736(00)02869-5	http://dx.doi.org/10.1016/S0140-6736(00)02869-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081528				2022-12-28	WOS:000090067300009
J	Souslova, V; Cesare, P; Ding, YN; Akopian, AN; Stanfa, L; Suzuki, R; Carpenter, K; Dickenson, A; Boyce, S; Hill, R; Nebenius-Oosthuizen, D; Smith, AJH; Kidd, EJ; Wood, JN				Souslova, V; Cesare, P; Ding, YN; Akopian, AN; Stanfa, L; Suzuki, R; Carpenter, K; Dickenson, A; Boyce, S; Hill, R; Nebenius-Oosthuizen, D; Smith, AJH; Kidd, EJ; Wood, JN			Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X(3) receptors	NATURE			English	Article							DORSAL HORN NEURONS; SYNAPTIC TRANSMISSION; ATP; RAT; RESPONSES; NOCICEPTION; ACTIVATION	ATP activates damage-sensing neurons (nociceptors) and can evoke a sensation of pain(1). The ATP receptor P2X(3) is selectively expressed by nociceptors(2,3) and is one of seven ATP-gated, cation-selective ion channels(4-6). Here we demonstrate that ablation of the P2X(3) gene results in the loss of rapidly desensitizing ATP-gated cation currents in dorsal root ganglion neurons, and that the responses of nodose ganglion neurons to ATP show altered kinetics and pharmacology resulting from the loss of expression of P2X(2/3) heteromultimers. Null mutants have normal sensorimotor function. Behavioural responses to noxious mechanical and thermal stimuli are also normal, although formalin-induced pain behaviour is reduced. In contrast, deletion of the P2X(3) receptor causes enhanced thermal hyperalgesia in chronic inflammation. Notably, although dorsal-horn neuronal responses to mechanical and noxious heat application are normal, P2X(3)-null mice are unable to code the intensity of non-noxious 'warming' stimuli.	UCL, Dept Biol, London WC1E 6BT, England; UCL, Dept Pharmacol, London WC1E 6BT, England; Merck Sharp & Dohme Res Labs, Terlings Pk CM20 2QR, Essex, England; Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Cardiff Univ, Welsh Sch Pharm, Cardiff CF1 3XF, S Glam, Wales	University of London; University College London; University of London; University College London; Merck & Company; University of Edinburgh; Cardiff University	Wood, JN (corresponding author), UCL, Dept Biol, Mortimer St, London WC1E 6BT, England.	J.Wood@ucl.ac.uk	; Kidd, Emma/N-6201-2014	Cesare, Paolo/0000-0003-1324-5974; Kidd, Emma/0000-0001-5507-1170				Akopian AN, 1999, NAT NEUROSCI, V2, P541, DOI 10.1038/9195; BlandWard PA, 1997, BRIT J PHARMACOL, V122, P365, DOI 10.1038/sj.bjp.0701371; BLEEHEN T, 1977, PAIN, V3, P367, DOI 10.1016/0304-3959(77)90066-5; Cesare P, 1997, CURR OPIN NEUROBIOL, V7, P493, DOI 10.1016/S0959-4388(97)80028-1; CESARE P, 2000, P PHYSL SOC P, V523; Chapman V, 1998, PAIN, V77, P289, DOI 10.1016/S0304-3959(98)00106-7; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Grubb BD, 1999, EUR J NEUROSCI, V11, P149, DOI 10.1046/j.1460-9568.1999.00426.x; Gu JGG, 1998, NEUROSCI LETT, V253, P167, DOI 10.1016/S0304-3940(98)00632-6; Gu JGG, 1997, NATURE, V389, P749, DOI 10.1038/39639; Kidd EJ, 1998, NEUROSCIENCE, V87, P533, DOI 10.1016/S0306-4522(98)00294-2; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LI J, 1995, J NEUROSCI, V15, P3357; Li P, 1998, J NEUROPHYSIOL, V80, P3356, DOI 10.1152/jn.1998.80.6.3356; MacKenzie AB, 1999, ANN NY ACAD SCI, V868, P716, DOI 10.1111/j.1749-6632.1999.tb11351.x; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Nakamura F, 1996, P NATL ACAD SCI USA, V93, P10465, DOI 10.1073/pnas.93.19.10465; Stanfa LC, 2000, BRIT J PHARMACOL, V129, P351, DOI 10.1038/sj.bjp.0703047; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tsuda M, 1999, BRIT J PHARMACOL, V128, P1497, DOI 10.1038/sj.bjp.0702960; Ueno S, 1999, BRIT J PHARMACOL, V126, P429, DOI 10.1038/sj.bjp.0702319	21	350	373	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1015	1017		10.1038/35039526	http://dx.doi.org/10.1038/35039526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069182				2022-12-28	WOS:000090032500046
J	Greenberg, DS				Greenberg, DS			Bush and Gore: a shared enthusiasm for medical research	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1251	1251		10.1016/S0140-6736(05)73857-5	http://dx.doi.org/10.1016/S0140-6736(05)73857-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072957				2022-12-28	WOS:000089724900031
J	Vernia, P; Fracasso, PL; Casale, V; Villotti, G; Marcheggiano, A; Stigliano, V; Pinnaro, P; Bagnardi, V; Caprilli, R				Vernia, P; Fracasso, PL; Casale, V; Villotti, G; Marcheggiano, A; Stigliano, V; Pinnaro, P; Bagnardi, V; Caprilli, R			Topical butyrate for acute radiation proctitis: randomised, crossover trial	LANCET			English	Article							CHAIN FATTY-ACIDS; ULCERATIVE-COLITIS; INJURY; MUCOSA; BOWEL; RAT	Background No available therapy has, as yet, proven effective to treat acute radiation proctitis (ARP) following radiation therapy for malignant pelvic disease. We assessed whether sodium butyrate enemas, at a dose of 80 mmol/L (80 mL/24 h), might offer effective treatment for this condition. Methods 20 patients presenting with ARP after completing a cycle of 35-52 Gy external-beam radiation therapy for pelvic malignant disease, were treated for 3 weeks with topical sodium butyrate and saline enemas according to a randomised, double-blind, crossover protocol. Clinical, endoscopic, and histological findings were assessed at enrolment, at week 3, and then at the end of the study. Data were analysed by two-tailed t test for paired data (continuous variables) and a logistic-regression model with variable multiple response for ordered categorical data. Findings Topical butyrate, but not saline, led to remission of symptoms (clinical score from 8.2 [SE 1.6] to 1.5 [0.7] vs 7.9 [1.8] to 8.1 [3.4]). When the treatment regimen was switched, eight out of nine of the previously placebo-treated patients went into remission, whereas three patients relapsed when switched to saline. The advantage of butyrate over placebo, expressed as CI, odds ratio, and p value was significant for almost all the clinical, endoscopic and histological factors taken into consideration. Interpretation Topical sodium butyrate, unlike other therapeutic regimens used so far, proved effective in the treatment of ARP.	Univ Rome La Sapienza, Dipartimento Sci Clin, Cattedra Gastroenterol 1, I-00161 Rome, Italy; Ist Regina Elena, I-00161 Rome, Italy; Univ Milan, Dipartimento Stat, I-20122 Milan, Italy	Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Milan	Vernia, P (corresponding author), Univ Rome La Sapienza, Dipartimento Sci Clin, Cattedra Gastroenterol 1, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Vernia, Piero/AAM-4267-2020; Pinnarò, Paola/H-8862-2017; Fracasso, Pierluigi/ABD-9575-2021	Pinnarò, Paola/0000-0003-3049-7380; Fracasso, Pierluigi/0000-0003-4265-9981				AlSabbagh R, 1996, AM J GASTROENTEROL, V91, P1814; Babb RR, 1996, AM J GASTROENTEROL, V91, P1309; Baughan C A, 1993, Clin Oncol (R Coll Radiol), V5, P19, DOI 10.1016/S0936-6555(05)80689-2; CASALE V, 1993, ITAL J GASTROENTEROL, V25, P41; DARGENIO G, 1994, GASTROENTEROLOGY, V106, P399, DOI 10.1016/0016-5085(94)90598-3; DELANEY JP, 1994, RADIAT RES, V137, P405, DOI 10.2307/3578717; DUBRAY BM, 1994, RADIOTHER ONCOL, V33, P41, DOI 10.1016/0167-8140(94)90084-1; Kim YI, 1998, NUTR REV, V56, P17; Kochhar R, 1999, DIGEST DIS SCI, V44, P973, DOI 10.1023/A:1026612731210; KVIETYS PR, 1981, GASTROENTEROLOGY, V80, P962; MCKENNA KJ, 1994, SURGERY, V115, P626; Miller AR, 1999, INT J RADIAT ONCOL, V43, P817, DOI 10.1016/S0360-3016(98)00485-4; MORTENSEN FV, 1990, GUT, V31, P1391, DOI 10.1136/gut.31.12.1391; NUSSBAUM ML, 1993, CLIN PLAST SURG, V20, P573; SAKATA T, 1991, SHORT CHAIN FATTY AC, P63; SENN S, 1993, CROSS OVER TRIALS CL; VERNIA P, 1995, ALIMENT PHARM THERAP, V9, P309; Wang CJ, 1998, INT J RADIAT ONCOL, V40, P85, DOI 10.1016/S0360-3016(97)00560-9; Zimmermann FB, 1998, STRAHLENTHER ONKOL, V174, P85	19	77	80	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1232	1235		10.1016/S0140-6736(00)02787-2	http://dx.doi.org/10.1016/S0140-6736(00)02787-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072942				2022-12-28	WOS:000089724900013
J	Young, A; Rea, D				Young, A; Rea, D			ABC of colorectal cancer - Treatment of advanced disease	BRITISH MEDICAL JOURNAL			English	Review									Univ Birmingham, Sch Hlth Sci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Young, A (corresponding author), Univ Birmingham, Sch Hlth Sci, Birmingham B15 2TT, W Midlands, England.							CADY B, 1991, SEMIN ONCOL, V18, P399; *CLIN OUTC GROUP, 1997, GUID COMM CANC SERV; *DEP HLTH, 1994, POL FRAM COMM CANC S; GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904; GLIMELIUS B, 1995, ANN ONCOL, V6, P267, DOI 10.1093/oxfordjournals.annonc.a059157	5	31	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1278	1281		10.1136/bmj.321.7271.1278	http://dx.doi.org/10.1136/bmj.321.7271.1278			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082094	Green Published			2022-12-28	WOS:000165445800031
J	Jousson, O; Pawlowski, J; Zaninetti, L; Zechman, FW; Dini, F; Di Guiseppe, G; Woodfield, R; Millar, A; Meinesz, A				Jousson, O; Pawlowski, J; Zaninetti, L; Zechman, FW; Dini, F; Di Guiseppe, G; Woodfield, R; Millar, A; Meinesz, A			Invasive alga reaches California - The alga has been identified that threatens to smother Californian coastal ecosystems.	NATURE			English	Article							CAULERPA-TAXIFOLIA; MEDITERRANEAN-SEA; ORIGIN		Univ Geneva, Dept Zool & Biol Anim, CH-1224 Chene Bougeries, Switzerland; Calif State Univ Fresno, Dept Biol, Fresno, CA 93740 USA; Univ Pisa, Dipartimento Etol Ecol & Evoluz, I-56126 Pisa, Italy; Merkel & Associates, San Diego, CA 92123 USA; Royal Bot Gardens, Sydney, NSW 2000, Australia; Univ Nice, Lab Environm Marin Littoral, F-06108 Nice, France	University of Geneva; California State University System; California State University Fresno; University of Pisa; UDICE-French Research Universities; Universite Cote d'Azur	Jousson, O (corresponding author), Univ Geneva, Dept Zool & Biol Anim, CH-1224 Chene Bougeries, Switzerland.		Jousson, Olivier/S-4397-2019; Jousson, Olivier/N-7000-2013	Jousson, Olivier/0000-0003-3344-7194; Di Giuseppe, Graziano/0000-0002-9999-7650				Dalton R, 2000, NATURE, V406, P447, DOI 10.1038/35020226; Jousson O, 1998, MAR ECOL PROG SER, V172, P275, DOI 10.3354/meps172275; Kaiser J, 2000, SCIENCE, V289, P222; Komatsu T, 1997, MAR ECOL PROG SER, V146, P145, DOI 10.3354/meps146145; Meinesz A, 1995, BOT MAR, V38, P499, DOI 10.1515/botm.1995.38.1-6.499; Meinesz A, 1996, CR ACAD SCI III-VIE, V319, P603; MEINESZ A, 1991, OCEANOL ACTA, V14, P415; Olsen JL, 1998, J PHYCOL, V34, P850, DOI 10.1046/j.1529-8817.1998.340850.x; PIGHINI M, 1999, 4 INT WORKSH CAUL TA	9	166	175	0	41	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					157	158		10.1038/35041623	http://dx.doi.org/10.1038/35041623			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089959				2022-12-28	WOS:000165180400030
J	Juodkazis, S; Mukai, N; Wakaki, R; Yamaguchi, A; Matsuo, S; Misawa, H				Juodkazis, S; Mukai, N; Wakaki, R; Yamaguchi, A; Matsuo, S; Misawa, H			Reversible phase transitions in polymer gels induced by radiation forces	NATURE			English	Article							N-ISOPROPYLACRYLAMIDE; PRESSURE; POLY(N-ISOPROPYLACRYLAMIDE)	Many polymer gels undergo reversible, discontinuous volume changes in response to changes in the balance between repulsive intermolecular forces that act to expand the polymer network and attractive forces that act to shrink it. Repulsive forces are usually electrostatic or hydrophobic in nature, whereas attraction is mediated by hydrogen bonding or van der Waals interactions. The competition between these counteracting forces, and hence the gel volume(1-3), can thus be controlled by subtle changes in parameters such as pH (ref. 4), temperature(5), solvent composition(6) or gel composition(7). Here we describe a more direct influence on this balance of forces, by showing that the radiation force generated by a focused laser beam induces reversible shrinkage in polymer gels. Control experiments confirm that the laser-induced volume phase transitions are due to radiation forces, rather than local heating, modifying the weak interactions in the gels, in agreement with previous observations of light-induced chain association in polymer solutions(8,9). We rnd that, owing to shear-relaxation processes(10), gel shrinkage occurs up to several tens of micrometres away from the irradiation spot, raising the prospect that the combination of stimuli-responsive polymer gels and laser light might lead to new gel-based systems for applications such as actuating or sensing.	Univ Tokushima, Grad Sch Engn, Dept Ecosyst Engn, Tokushima 7708506, Japan; Univ Tokushima, Satellite Venture Business Lab Photon Nanomat, Tokushima 7708506, Japan	Tokushima University; Tokushima University	Misawa, H (corresponding author), Univ Tokushima, Grad Sch Engn, Dept Ecosyst Engn, 2-1 Minamijyosanjima, Tokushima 7708506, Japan.	misawa@eco.tokushima-u.ac.jp	Juodkazis, Saulius/Q-6943-2019; Juodkazis, Saulius/D-7615-2011; Yamaguchi, Akira/A-5308-2012; Misawa, Hiroaki/A-4312-2012	Juodkazis, Saulius/0000-0003-3542-3874; Juodkazis, Saulius/0000-0003-3542-3874; Yamaguchi, Akira/0000-0003-3029-3775; Misawa, Hiroaki/0000-0003-1070-387X; , Saulius/0000-0003-3897-2844				ANNAKA M, 1992, NATURE, V355, P430, DOI 10.1038/355430a0; ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156; Fritze M, 1998, OPT LETT, V23, P141, DOI 10.1364/OL.23.000141; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; Hofkens J, 1997, LANGMUIR, V13, P414, DOI 10.1021/la9606308; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; ILMAIN F, 1991, NATURE, V349, P400, DOI 10.1038/349400a0; Ishikawa M, 1996, B CHEM SOC JPN, V69, P59, DOI 10.1246/bcsj.69.59; Juodkazis S, 1999, APPL PHYS LETT, V74, P3627, DOI 10.1063/1.123203; Misawa H, 1999, PROG POLYM SCI, V24, P665, DOI 10.1016/S0079-6700(99)00009-X; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; SCHILD HG, 1990, J PHYS CHEM-US, V94, P4352, DOI 10.1021/j100373a088; Shen Y. R., 1984, PRINCIPLES NONLINEAR, P366; SHIBAYAMA M, 1993, ADV POLYM SCI, V109, P1; Smith TA, 1999, J PHYS CHEM B, V103, P1660, DOI 10.1021/jp983691i; Strobl G R, 1997, PHYS POLYM, P63; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; Takeoka Y, 1999, PHYS REV LETT, V82, P4863, DOI 10.1103/PhysRevLett.82.4863	20	275	284	1	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					178	181		10.1038/35041522	http://dx.doi.org/10.1038/35041522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089966				2022-12-28	WOS:000165180400038
J	El-Gabalawy, HS; Duray, P; Goldbach-Mansky, R				El-Gabalawy, HS; Duray, P; Goldbach-Mansky, R			Evaluating patients with arthritis of recent onset - Studies in pathogenesis and prognosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY RHEUMATOID-ARTHRITIS; REACTIVE ARTHRITIS; INFLAMMATORY ARTHRITIS; COMBINATION THERAPY; HLA-DRB1 ALLELES; DOUBLE-BLIND; CLASSIFICATION; ASSOCIATION; PROGRESSION; SYNOVITIS	Inflammatory synovitis of recent onset poses a diagnostic and prognostic challenge to primary care physicians and rheumatologists, A lack of understanding of the underlying etiologic and pathogenic processes limits the ability to distinguish forms of arthritis that follow a benign, self-limiting course from forms that proceed to an aggressive, erosive disease requiring intensive immunosuppressive therapy. It is estimated that between 30% and 40% of patients presenting with early synovitis have disease that remains unclassified. Using data from a cohort of patients with early synovitis and reviewing current literature, we discuss investigational approaches toward a new classification of patients with early synovitis. Although a lack of understanding of this heterogeneous clinical syndrome has led clinicians to take a largely empirical approach to treatment thus far, the evolving awareness of disease predisposition at a genetic level and the expanding ability to specifically manipulate biological pathways may ultimately change the approach to this clinical problem.	NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	El-Gabalawy, HS (corresponding author), NIH, Bldg 10,Room 9S205, Bethesda, MD 20892 USA.	elgabala@exchange.nih.gov	Goldbach-Mansky, Raphaela/N-5917-2017	El-Gabalawy, Hani/0000-0002-0796-4422	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041111] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; AMOR B, 1994, J RHEUMATOL, V21, P1883; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; DOUGADOS M, 1991, ARTHRITIS RHEUM, V34, P1218, DOI 10.1002/art.1780341003; El-Gabalawy HS, 1999, ARTHRITIS RHEUM-US, V42, P1696, DOI 10.1002/1529-0131(199908)42:8<1696::AID-ANR19>3.0.CO;2-K; EMERY P, 1995, ANN RHEUM DIS, V54, P944, DOI 10.1136/ard.54.12.944; Fleischmann RM, 1999, CLIN THER, V21, P1429, DOI 10.1016/S0149-2918(00)80002-8; Gaydos CA, 1998, NEW ENGL J MED, V339, P739, DOI 10.1056/NEJM199809103391105; Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P145, DOI 10.1186/ar79; Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P236, DOI 10.1186/ar93; Harrison B, 1999, ARTHRITIS RHEUM, V42, P2174, DOI 10.1002/1529-0131(199910)42:10<2174::AID-ANR19>3.0.CO;2-G; HULSEMANN JL, 1995, CLIN EXP RHEUMATOL, V13, P37; JAWAHEER D, 1994, ARTHRITIS RHEUM, V37, P681, DOI 10.1002/art.1780370511; LAUHIO A, 1991, ARTHRITIS RHEUM-US, V34, P6, DOI 10.1002/art.1780340103; MakiIkola O, 1997, RHEUMATOL INT, V16, P227, DOI 10.1007/BF01375653; McGonagle D, 1998, LANCET, V352, P1137, DOI 10.1016/S0140-6736(97)12004-9; McQueen FM, 1998, ANN RHEUM DIS, V57, P350, DOI 10.1136/ard.57.6.350; Mottonen T, 1998, ANN RHEUM DIS, V57, P533, DOI 10.1136/ard.57.9.533; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; Schumacher HR, 1998, RHEUM DIS CLIN N AM, V24, P261, DOI 10.1016/S0889-857X(05)70008-9; Schumacher HR, 1999, ARTHRITIS RHEUM-US, V42, P1281, DOI 10.1002/1529-0131(199906)42:6<1281::AID-ANR27>3.0.CO;2-8; Sieper J, 1999, ARTHRITIS RHEUM-US, V42, P1386, DOI 10.1002/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E; Stenger AAME, 1998, BRIT J RHEUMATOL, V37, P1157; Taurog JD, 1998, AM J MED SCI, V316, P250, DOI 10.1097/00000441-199810000-00005; Toussirot E, 1999, J RHEUMATOL, V26, P1446; VANDERHEIDE A, 1995, ARTHRITIS RHEUM, V38, P1466; VANDERLINDEN S, 1995, BAILLIERE CLIN RHEUM, V9, P355, DOI 10.1016/S1521-6942(06)80008-2; Verhoeven AC, 1998, BRIT J RHEUMATOL, V37, P1102; Wiles N, 1999, ARTHRITIS RHEUM, V42, P1339, DOI 10.1002/1529-0131(199907)42:7<1339::AID-ANR6>3.0.CO;2-Y; Wilkinson NZ, 1999, RHEUMATOLOGY, V38, P260, DOI 10.1093/rheumatology/38.3.260; Wollenhaupt J, 1998, BAILLIERE CLIN RHEUM, V12, P627, DOI 10.1016/S0950-3579(98)80041-1; Wollenhaupt Juergen, 1998, Current Opinion in Rheumatology, V10, P306	32	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2368	2373		10.1001/jama.284.18.2368	http://dx.doi.org/10.1001/jama.284.18.2368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066188				2022-12-28	WOS:000165074500032
J	Whitby, FG; Masters, EI; Kramer, L; Knowlton, JR; Yao, Y; Wang, CC; Hill, CP				Whitby, FG; Masters, EI; Kramer, L; Knowlton, JR; Yao, Y; Wang, CC; Hill, CP			Structural basis for the activation of 20S proteasomes by 11S regulators	NATURE			English	Article							REG-ALPHA; ANTIGEN PRESENTATION; CLASS-I; PROTEIN; PA28; IDENTIFICATION; SUBUNIT; BETA; PURIFICATION; PA28-ALPHA	Most of the non-lysosomal proteolysis that occurs in eukaryotic cells is performed by a nonspecific and abundant barrel-shaped complex called the 20S proteasome(1). Substrates access the active sites, which are sequestered in an internal chamber, by traversing a narrow opening(2) (alpha -annulus) that is blocked in the unliganded 20S proteasome by amino-terminal sequences of alpha -subunits(3). Peptide products probably exit the 20S proteasome through the same opening. 11S regulators (also called PA26 (ref. 4), PA28 (ref. 5) and REG(6,7)) are heptamers(4,8,9) that stimulate 20S proteasome peptidase activity in vitro and may facilitate product release in vivo. Here we report the co-crystal structure of yeast 20S proteasome with the 11S regulator from Trypanosoma brucei 4 (PA26). PA26 carboxy-terminal tails provide binding affinity by inserting into pockets on the 20S proteasome, and PA26 activation loops induce conformational changes in alpha -subunits that open the gate separating the proteasome interior from the intracellular environment. The reduction in processivity expected for an open conformation of the exit gate may explain the role of 11S regulators in the production of ligands for major histocompatibility complex class I molecules(10,11).	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Utah System of Higher Education; University of Utah; University of California System; University of California San Francisco	Hill, CP (corresponding author), Univ Utah, Dept Biochem, 50 N Med Dr, Salt Lake City, UT 84132 USA.	chris@biochem.utah.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRUNGER AT, 1996, XPLOR VERSION 3 843; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Knowlton JR, 1997, NATURE, V390, P639, DOI 10.1038/37670; Li J, 2000, J MOL BIOL, V299, P641, DOI 10.1006/jmbi.2000.3800; MA CP, 1992, J BIOL CHEM, V267, P10515; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Song XL, 1997, J BIOL CHEM, V272, P27994, DOI 10.1074/jbc.272.44.27994; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; Zhang ZG, 1998, P NATL ACAD SCI USA, V95, P2807, DOI 10.1073/pnas.95.6.2807; Zhang ZG, 1999, BIOCHEMISTRY-US, V38, P5651, DOI 10.1021/bi990056+	30	390	414	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					115	120		10.1038/35040607	http://dx.doi.org/10.1038/35040607			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081519				2022-12-28	WOS:000165050400063
J	Reynen, K; Daniel, WG				Reynen, K; Daniel, WG			Idiopathic clubbing.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Dresden, D-01307 Dresden, Germany	Technische Universitat Dresden	Reynen, K (corresponding author), Univ Dresden, D-01307 Dresden, Germany.								0	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1235	1235		10.1056/NEJM200010263431706	http://dx.doi.org/10.1056/NEJM200010263431706			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071675				2022-12-28	WOS:000090014100006
J	Tegler, SC; Romanishin, W				Tegler, SC; Romanishin, W			Extremely red Kuiper-belt objects in near-circular orbits beyond 40 AU	NATURE			English	Article							PHOTOMETRY; 1993-SC	Kuiper-belt objects (KBOs) are an ancient reservoir of comets beyond Neptune's orbit(1,2). Some of these objects were recently found to have the reddest optical colours in the Solar System(3), but the number of objects for which accurate colours were available was too small for any correlation to be discerned between colour and physical or dynamical properties, which might shed light on the origin of these objects. Here we report that all nine of the KBOs in our survey on near-circular (low-eccentricity) orbits with perihelion distances larger than 40 AU have extremely red surfaces, thereby connecting an observable property with a dynamical class. Of the objects with orbital eccentricities greater than 0.1, about half are also very red, while the rest have colours similar to the Sun, meaning that reflected sunlight is not strongly modified by the objects' surface properties. In addition, of the 13 'classical' KBOs (those with semimajor axis a approximate to 45 AU and eccentricity e < 0.15), the ten that are very red are in orbits with small angles of inclination to the ecliptic, whereas the three with solar colours are all in high-inclination orbits. We suggest that these three 'grey' classical KBOs may be part of a dynamical group that is separate from the 'red' classical KBOs.	No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA; Univ Oklahoma, Dept Phys & Astron, Norman, OK 73019 USA	Northern Arizona University; University of Oklahoma System; University of Oklahoma - Norman	Tegler, SC (corresponding author), No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86011 USA.							JEWITT D, 1993, NATURE, V362, P730, DOI 10.1038/362730a0; LANDOLT AU, 1992, ASTRON J, V104, P340, DOI 10.1086/116242; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; MARSDEN BG, 2000, LIST TRANSNEPTUNIAN; OKE JB, 1995, PUBL ASTRON SOC PAC, V107, P375, DOI 10.1086/133562; Romanishin W, 1997, ASTRON J, V113, P1893, DOI 10.1086/118402; Tegler SC, 1997, ICARUS, V126, P212, DOI 10.1006/icar.1996.5646; Tegler SC, 1997, ASTRON J, V114, P1230, DOI 10.1086/118556; Tegler SC, 1998, NATURE, V392, P49, DOI 10.1038/32108	9	146	146	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					979	981		10.1038/35039572	http://dx.doi.org/10.1038/35039572			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069171				2022-12-28	WOS:000090032500035
J	Bonithon-Kopp, C; Kronborg, O; Giacosa, A; Rath, U; Faivre, J				Bonithon-Kopp, C; Kronborg, O; Giacosa, A; Rath, U; Faivre, J		European Canc Prevention Org Study	Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial	LANCET			English	Article							COLON-CANCER; DIETARY FIBER; EPIDEMIOLOGIC EVIDENCE; LARGE-BOWEL; RISK; POLYPS; FAT; CARCINOGENESIS; WOMEN; MEN	Background Some epidemiological studies have suggested that high dietary intake of calcium and fibre reduces colorectal carcinogenesis. Available data are not sufficient to serve as a basis for firm dietary advice. We undertook a multicentre randomised trial to test the effect of diet supplementation with calcium and fibre on adenoma recurrence. Methods We randomly assigned 665 patients with a history of colorectal adenomas to three treatment groups, in a parallel design: calcium gluconolactate and carbonate (2 g elemental calcium daily), fibre (3.5 g ispaghula husk), or placebo. Participants had colonoscopy after 3 years of followup. The primary endpoint was adenoma recurrence. Analyses were by intention to treat. Findings 23 patients died, 15 were lost to follow-up, 45 refused repeat colonoscopy, and five developed severe contraindications to colonoscopy. Among the 552 participants who completed the follow-up examination, 94 slopped treatment early. At least one adenoma developed in 28 (15.9%) of 176 patients in the calcium group, 58 (29.3%) of 198 in the fibre group, and 36 (20.2%) of 178 in the placebo group. The adjusted odds ratio for recurrence was 0.66 (95% CI 0.38-1.17. p=0.16) for calcium treatment and 1.67 (1.01-2.76, p=0.042) for the fibre treatment. The odds ratio associated with the fibre treatment was significantly higher in participants with baseline dietary calcium intake above the median than in those with intake below the median (interaction test, p=0.028) Interpretation Supplementation with fibre as ispaghula husk may have adverse effects on colorectal adenoma recurrence, especially in patients with high dietary calcium intake. Calcium supplementation was associated with a modest but not significant reduction in the risk of adenoma recurrence.	Fac Med Dijon, Registre Bourguignon Tumeurs Digest, F-21079 Dijon, France; Odense Univ Hosp, Dept Surg Gastroenterol, DK-5000 Odense, Denmark; Ist Nazl Ric Canc, Serv Nutr, I-16132 Genoa, Italy; Heidelberg Univ, Med Klin, D-6900 Heidelberg, Germany	Universite de Bourgogne; University of Southern Denmark; Odense University Hospital; University of Genoa; IRCCS AOU San Martino IST; Ruprecht Karls University Heidelberg	Faivre, J (corresponding author), Fac Med Dijon, Registre Bourguignon Tumeurs Digest, BP 87900, F-21079 Dijon, France.	jean.faivre@u-bourgogne.fr						Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Alberts DS, 1996, JNCI-J NATL CANCER I, V88, P81, DOI 10.1093/jnci/88.2.81; ALDER RJ, 1993, AM J EPIDEMIOL, V138, P804, DOI 10.1093/oxfordjournals.aje.a116784; Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; BEDENNE L, 1992, CANCER, V69, P883, DOI 10.1002/1097-0142(19920215)69:4<883::AID-CNCR2820690408>3.0.CO;2-B; BergsmaKadijk JA, 1996, EPIDEMIOLOGY, V7, P590, DOI 10.1097/00001648-199611000-00005; Bostick RM, 1997, CANCER EPIDEM BIOMAR, V6, P971; BOUTRON MC, 1989, NUTR CANCER, V12, P83, DOI 10.1080/01635588909514005; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; Faivre J, 1997, EUR J CANCER PREV, V6, P132; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Gaard M, 1996, EUR J CANCER PREV, V5, P445; Hofstad B, 1998, DIGESTION, V59, P148, DOI 10.1159/000007480; HOWE GR, 1992, J NATL CANCER I, V84, P1887, DOI 10.1093/jnci/84.24.1887; JACOBS LR, 1990, DIETARY FIBER /, P389; MACLENNAN R, 1995, J NATL CANCER I, V87, P1760, DOI 10.1093/jnci/87.23.1760; Martinez ME, 1998, CANCER EPIDEM BIOMAR, V7, P163; MCKEOWNEYSSEN GE, 1994, J CLIN EPIDEMIOL, V47, P525, DOI 10.1016/0895-4356(94)90299-2; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; Moore MA, 1998, CRIT REV ONCOL HEMAT, V27, P229, DOI 10.1016/S1040-8428(98)00006-7; NEWMARK HL, 1984, J NATL CANCER I, V72, P1323; PEIPINS LA, 1994, EPIDEMIOL REV, V16, P273, DOI 10.1093/oxfordjournals.epirev.a036154; Platz EA, 1997, CANCER EPIDEM BIOMAR, V6, P661; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; STERN HS, 1990, SURGERY, V108, P528; TROCK B, 1990, JNCI-J NATL CANCER I, V82, P650, DOI 10.1093/jnci/82.8.650; Wasan HS, 1996, LANCET, V348, P319, DOI 10.1016/S0140-6736(96)01401-8; WILPART M, 1987, Nutrition and Cancer, V10, P39	29	331	347	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1300	1306		10.1016/S0140-6736(00)02813-0	http://dx.doi.org/10.1016/S0140-6736(00)02813-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073017				2022-12-28	WOS:000089858300009
J	Mocroft, A; Katlama, C; Johnson, AM; Pradier, C; Antunes, F; Mulcahy, F; Chiesi, A; Phillips, AN; Kirk, O; Lundgren, JD				Mocroft, A; Katlama, C; Johnson, AM; Pradier, C; Antunes, F; Mulcahy, F; Chiesi, A; Phillips, AN; Kirk, O; Lundgren, JD		EuroSIDA Study Grp	AIDS across Europe, 1994-98: the EuroSIDA study	LANCET			English	Article							HIV-INFECTED PATIENTS; IMMUNODEFICIENCY-VIRUS INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; DEFINING ILLNESSES; CONTROLLED TRIAL; CELL COUNTS; SURVIVAL; COHORT; COMBINATION; PROPHYLAXIS	Background The clinical presentation of HIV-1 related diseases could have changed after the introduction of highly active antiretroviral treatment (HAART). We aimed to assess changes over time in the incidence of ADIs overall and within CD4 lymphocyte count strata, the relationship with treatment and degree of immunodeficiency at diagnosis of ADIs. Methods We did a prospective observational multicentre study of over 7300 patients in 52 European HIV-1 outpatient clinics. Incidence rates per 100 patient-years of observation were calculated. Findings In total, we recorded 1667 new ADIs; the incidence of ADIs declined from 30.7 per 100 patient-years of observation during 1994 (95% CI 28.0-33.4) to 2.5 per 100 patient-years of observation during 1998 (95% CI 2.0-3.0, p<0.0001, test for trend). Median CD4 lymphocyte count at diagnosis of a new ADI increased from 28 cells/mu L to 125 cells/mu L between 1994 and 1998 (p<0.0001), yet a steep decline in the rate of ADIs was seen after stratification by latest CD4 lymphocyte count within each year (less than or equal to 50, 51-200, and >200 cells/mu L). Patients on HAART had a lower rate of ADIs than patients not on this treatment within each CD4 lymphocyte count strata. The proportion of ADIs attributable to cytomegalovirus retinitis and Mycobacterium avium complex declined over time (p=0.0058 and 0.0022, respectively), whereas the proportion of diagnoses attributable to non-Hodgkin lymphoma has increased (p<0.0001). In 1994, less than 4% of ADIs were non-Hodgkin lymphoma, in 1998 the proportion was almost 16%. This condition has become one of the most common ADIs in patients on HAART. Interpretation Our findings lend support to the idea that treatment regimens can lower the incidence of ADIs. The immediate risk of an ADI for a given CD4 lymphocyte count has declined over time and is lower among patients on HAART. Long-term follow-up of patients on combination treatment is essential to monitor the incidence of new and emerging diagnoses.	Hvidovre Univ Hosp, Dept Infect Dis, EuroSIDA Coordinating Ctr, Hvidovre, Denmark; UCL Royal Free & UCL Med Sch, Mortimer Market Ctr, London, England; Hop La Pitie Salpetriere, Paris, France; Hop Archet, Nice, France; Hosp Santa Maria, Lisbon, Portugal; St James Hosp, Dublin 8, Ireland; Ist Super Sanita, I-00161 Rome, Italy	University of Copenhagen; University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Nice; Universidade de Lisboa; Hospital Santa Maria; Trinity College Dublin; Istituto Superiore di Sanita (ISS)	Lundgren, JD (corresponding author), Hvidovre Univ Hosp, Dept Infect Dis, EuroSIDA Coordinating Ctr, Hvidovre, Denmark.	eurosida@inet.uni2.dk	Lundgren, Jens/AAE-6876-2019; Pradier, Christian/AFE-8255-2022; Mocroft, Amanda/G-8748-2011; Pradier, Christian/AAE-9669-2022; Phillips, Andrew N/B-4427-2008; Mocroft, Amanda/C-1527-2008; kirk, ole/ABB-4746-2021; VALLET, Yannick/F-9979-2011	Mocroft, Amanda/0000-0001-8316-1122; Phillips, Andrew N/0000-0003-2384-4807; Antunes, Francisco/0000-0001-7932-1154; Lundgren, Jens/0000-0001-8901-7850; Johnson, Anne/0000-0003-1330-7100; Chiesi, Antonio/0000-0002-6892-8142				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; BACELLAR H, 1994, J INFECT DIS, V170, P1284, DOI 10.1093/infdis/170.5.1284; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Cameron DW, 1998, LANCET, V351, P543, DOI 10.1016/S0140-6736(97)04161-5; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; EGGER M, 1998, 12 WORLD AIDS C GEN; Forrest DM, 1998, CLIN INFECT DIS, V27, P1379, DOI 10.1086/515030; Gaidano G, 1998, AM J PATHOL, V152, P623; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; HANSON DL, 1993, J ACQ IMMUN DEF SYND, V6, P624; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; JONES J, 1999, 6 C RETR OPP INF CHI; Jones JL, 1999, J ACQ IMMUN DEF SYND, V21, pS11; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Law MG, 1999, AIDS, V13, P263, DOI 10.1097/00002030-199902040-00015; Ledergerber B, 1999, BRIT MED J, V319, P23, DOI 10.1136/bmj.319.7201.23; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; Miller V, 1999, LANCET, V353, P463, DOI 10.1016/S0140-6736(98)04954-X; MITCHELET C, 1998, AIDS, V12, P1815; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V21, P401; Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491; MOCROFT AJ, 1995, LANCET, V346, P12, DOI 10.1016/S0140-6736(95)92649-6; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pezzotti P, 1999, J ACQ IMMUN DEF SYND, V20, P515, DOI 10.1097/00042560-199904150-00017; PHILLIPS AN, 1991, LANCET, V337, P389; Phillips AN, 1998, J ACQ IMMUN DEF SYND, V17, P239, DOI 10.1097/00042560-199803010-00009; Spira R, 1998, J ACQ IMMUN DEF SYND, V18, P358, DOI 10.1097/00042560-199808010-00007; TURNER BJ, 1991, J ACQ IMMUN DEF SYND, V4, P1059; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	35	337	343	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					291	296		10.1016/S0140-6736(00)02504-6	http://dx.doi.org/10.1016/S0140-6736(00)02504-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071184				2022-12-28	WOS:000088305900010
J	Tu, BP; Ho-Schleyer, SC; Travers, KJ; Weissman, JS				Tu, BP; Ho-Schleyer, SC; Travers, KJ; Weissman, JS			Biochemical basis of oxidative protein folding in the endoplasmic reticulum	SCIENCE			English	Article							DISULFIDE-BOND FORMATION; SACCHAROMYCES-CEREVISIAE; GLUTATHIONE; ISOMERASE; YEAST; GENE; PATHWAY; TRANSPORT; SYSTEM; ERO1P	The endoplasmic reticulum (ER) supports disulfide bond formation by a poorly understood mechanism requiring protein disulfide isomerase (PDI) and ERO1. In yeast, Ero1p-mediated oxidative folding was shown to depend on cellular flavin adenine dinucleotide (FAD) levels but not on ubiquinone or heme and Ero1p was shown to be a FAD-binding protein. We reconstituted efficient oxidative folding in vitro using FAD, PDI, and Ero1p. Disulfide formation proceeded by direct delivery of oxidizing equivalents from Ero1p to folding substrates via PDI. This kinetic shuttling of oxidizing equivalents could allow the ER to support rapid disulfide formation while maintaining the ability to reduce and rearrange incorrect disulfide bonds.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94143 USA.			Weissman, Jonathan/0000-0003-2445-670X				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ASTIN AM, 1977, BIOCHEM J, V166, P275, DOI 10.1042/bj1660275; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Poon WW, 1997, MOL ASPECTS MED, V18, pS121; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TU BP, UNPUB; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; ZIEGLER DM, 1977, TRENDS BIOCHEM SCI, V2, P79, DOI 10.1016/0968-0004(77)90042-1	25	345	355	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1571	1574		10.1126/science.290.5496.1571	http://dx.doi.org/10.1126/science.290.5496.1571			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090354	Green Published			2022-12-28	WOS:000165446200049
J	Vigolo, B; Penicaud, A; Coulon, C; Sauder, C; Pailler, R; Journet, C; Bernier, P; Poulin, P				Vigolo, B; Penicaud, A; Coulon, C; Sauder, C; Pailler, R; Journet, C; Bernier, P; Poulin, P			Macroscopic fibers and ribbons of oriented carbon nanotubes	SCIENCE			English	Article							PURIFICATION; TUBULES	A simple method was used to assemble single-walled carbon nanotubes into indefinitely long ribbons and fibers. The processing consists of dispersing the nanotubes in surfactant solutions, recondensing the nanotubes in the flow of a polymer solution to form a nanotube mesh, and then collating this mesh to a nanotube fiber. Flow-induced alignment may Lead to a preferential orientation of the nanotubes in the mesh that has the form of a ribbon. Unlike classical carbon fibers, the nanotube fibers can be strongly bent without breaking. Their obtained elastic modulus is 10 times higher than the modulus of high-quality bucky paper.	Univ Bordeaux 1, Ctr Rech Paul Pascal, CNRS, F-33600 Pessac, France; Lab Composites Thermostruct, F-33600 Pessac, France; Univ Montpellier 2, Dynam Phases Condensees Grp, F-34095 Montpellier, France	Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier	Poulin, P (corresponding author), Univ Bordeaux 1, Ctr Rech Paul Pascal, CNRS, Ave Schweitzer, F-33600 Pessac, France.	poulin@crpp.u-bordeaux.fr	penicaud, alain/K-4567-2013; Vigolo, Brigitte/F-4870-2016; Han, Jinhua/F-9464-2010; Journet, Catherine/AAE-4068-2021	penicaud, alain/0000-0001-8614-2867; Vigolo, Brigitte/0000-0002-1463-0121; Journet, Catherine/0000-0002-3328-317X; Poulin, Philippe/0000-0001-7748-8671				ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Bonard JM, 1997, ADV MATER, V9, P827, DOI 10.1002/adma.19970091014; Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95; Clarke SM, 1996, EUROPHYS LETT, V35, P233, DOI 10.1209/epl/i1996-00560-3; Dai HJ, 1996, SCIENCE, V272, P523, DOI 10.1126/science.272.5261.523; Doi M., 1988, THEORY POLYM DYNAMIC; DONALD IW, 1987, J MATER SCI, V22, P2661, DOI 10.1007/BF01086455; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; FISHER JE, 1997, PHYS REV B, V55, P4921; Gommans HH, 2000, J APPL PHYS, V88, P2509, DOI 10.1063/1.1287128; Hone J, 2000, APPL PHYS LETT, V77, P666, DOI 10.1063/1.127079; Hunter R.J., 1989, FDN COLLOID SCI, V1; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; Kane CL, 1998, EUROPHYS LETT, V41, P683, DOI 10.1209/epl/i1998-00214-6; OVERNEY G, 1993, Z PHYS D ATOM MOL CL, V27, P93, DOI 10.1007/BF01436769; POULIN P, 2000, Patent No. 0002272; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; ROBERTSON DH, 1992, PHYS REV B, V45, P12592, DOI 10.1103/PhysRevB.45.12592; Salvetat JP, 1999, PHYS REV LETT, V82, P944, DOI 10.1103/PhysRevLett.82.944; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0	23	1552	1640	24	747	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1331	1334		10.1126/science.290.5495.1331	http://dx.doi.org/10.1126/science.290.5495.1331			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082056				2022-12-28	WOS:000165379800042
J	Quill, TE				Quill, TE			Initiating end-of-life discussions with seriously ill patients - Addressing the "elephant in the room"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARDIOPULMONARY RESUSCITATION; PATIENTS PERSPECTIVES; PALLIATIVE CARE; DECISION-MAKING; FAMILY MEMBERS; DYING PATIENTS; DEATH; PHYSICIANS; DIFFERENCE; HOSPICE	Discussions about end-of-life issues are difficult for clinicians to initiate. Patients, their families, and clinicians frequently collude to avoid mentioning death or dying, even when the patient's suffering is severe and prognosis is poor. In addition to determining from observational research when and where communication problems exist, much can be learned from in-depth discussions with patients, family members, and physicians who are facing these issues together. Using segments of interviews with a patient with advanced pulmonary fibrosis, his son, and his primary cave physician, this article illustrates and explores some of these communication issues, including the who, what, when, why, and how of end-of-life discussions. Studies from the medical literature, the patient's and physician's particular experience together, and the author's clinical experience provide practical insights into how to address these issues. Initiating end-of-life discussions earlier and more systematically could allow patients to make more informed choices, achieve better palliation of symptoms, and have more opportunity to work on issues of life closure.	Univ Rochester, Dept Med, Rochester, NY USA; Genesee Hosp, Rochester, NY USA	University of Rochester	Quill, TE (corresponding author), Univ Rochester, Genesee Hosp, Dept Med, 224 Alexander St, Rochester, NY 14607 USA.	timothy.quill@viahealth.org						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Ariu┐s P., 1991, HOUR OUR DEATH; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; BYOCK I, DYING WELL PROSPECT; CHRISTAKIS NA, 1994, J GEN INTERN MED, V9, P314, DOI 10.1007/BF02599178; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; FADEN R, 1994, CLIN GERIATR MED, V10, P541, DOI 10.1016/S0749-0690(18)30339-2; Field MJ, 1997, APPROACHING DEATH IM; FRANKEL R, 1997, ADV DIRECTIVES END L; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hern HE, 1998, CAMB Q HEALTHC ETHIC, V7, P27, DOI 10.1017/S0963180198701045; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KOENIG BA, 1995, WESTERN J MED, V163, P244; Kuczewski MG, 1996, HASTINGS CENT REP, V26, P30, DOI 10.2307/3528574; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LAZARE A, 1989, OUTPATIENT PSYCHIAT, P157; LENTZNER HR, 1992, AM J PUBLIC HEALTH, V82, P1093, DOI 10.2105/AJPH.82.8.1093; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lynn J, 1996, NEW ENGL J MED, V335, P201, DOI 10.1056/NEJM199607183350311; LYNN J, 1995, WESTERN J MED, V163, P250; MCCORMICK TR, 1995, WESTERN J MED, V163, P236; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; Pantilat SZ, 1999, JAMA-J AM MED ASSOC, V282, P171, DOI 10.1001/jama.282.2.171; Quill T, 1996, MIDWIFE DYING PROCES; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SEALE CF, 1989, SOC SCI MED, V28, P551, DOI 10.1016/0277-9536(89)90249-9; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; WAISEL DB, 1995, ANN INTERN MED, V122, P304, DOI 10.7326/0003-4819-122-4-199502150-00011; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709	42	288	290	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2502	2507		10.1001/jama.284.19.2502	http://dx.doi.org/10.1001/jama.284.19.2502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074781	Green Published			2022-12-28	WOS:000165183800025
J	Sachs, GA				Sachs, GA			Sometimes dying still stings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2423	2423		10.1001/jama.284.19.2423	http://dx.doi.org/10.1001/jama.284.19.2423			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371MY	11074757				2022-12-28	WOS:000165183800001
J	Erickson, CL				Erickson, CL			An artificial landscape-scale fishery in the Bolivian Amazon	NATURE			English	Article							AMERICA	Historical ecologists working in the Neotropics argue that the present natural environment is an historical product of human intentionality and ingenuity, a creation that is imposed, built, managed and maintained by the collective multigenerational knowledge and experience of Native Americans(1,2). In the past 12,000 years, indigenous peoples transformed the environment, creating what we now recognize as the rich ecological mosaic of the Neotropics(3-6). The prehispanic savanna peoples of the Bolivian Amazon built an anthropogenic landscape through the construction of raised fields, large settlement mounds, and earthen causeways(7,8). I have studied a complex artificial network of hydraulic earthworks covering 525 km(2) in the Baures region of Bolivia. Here I identify a particular form of earthwork, the zigzag structure, as a fish weir, on the basis of form, orientation, location, association with other hydraulic works and ethnographic analogy.	Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA	University of Pennsylvania	Erickson, CL (corresponding author), Univ Penn, Dept Anthropol, 33rd & Spruce St, Philadelphia, PA 19104 USA.	cerickso@sas.upenn.edu						Balee W., 1998, ADV HIST ECOLOGY; BECKERMAN S, 1979, AM ANTHROPOL, V81, P533, DOI 10.1525/aa.1979.81.3.02a00020; BECKERMAN S, 1994, AMAZONIAN INDIANS PR, P177; Chernela Janet, 1993, WANANO INDIANS BRAZI; CLEMENT CR, 1993, MAN BIOSPH, V13, P139; DECASTILLO J, 1906, DOCUMENTOS HIST GEOG, V1, P308; DENEVAN WM, 1992, ANN ASSOC AM GEOGR, V82, P369, DOI 10.1111/j.1467-8306.1992.tb01965.x; Denevan WM, 1966, ABORIGINAL CULTURAL; Dougherty B., 1984, RELACIONES SOC ARGEN, VXVI, P37; Eder Francisco, 1985, BREVE DESCRIPCION RE; ERICKSON CL, IN PRESS VIAS PRECOL; ERICKSON CL, 1997, INVESTIGACIONES ARQU; Erickson CL, 1995, ARCHAEOLOGY LOWLAND, P66; GARSON A, 1980, AM ANTIQUITY, V45, P62; HANAGARTH W, 1993, ACERCA GEOECOLOGIA S, P134; JONES J, 1980, CONFLICT WHITES INDI; LEE K, 1995, UNPUB COMPLEJO HIDRA; LEMA EO, 1986, MATACOS NOCTENES BOL; MOHOLYNAGY H, 1978, AM ANTIQUITY, V43, P65, DOI 10.2307/279632; NORDENSKIOLD E, 1924, COMP ETHNOGRAPHICAL, V3, P86; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Posey D, 1989, ADV EC BOT, V7; RIESTER J, 1977, GUARASUGWE CROMICA U; Roosevelt AC, 1996, SCIENCE, V272, P373, DOI 10.1126/science.272.5260.373; SCHMITZ PI, 1998, PESQUISAS ANTROPOLOG, V54; SMITH NJH, 1999, AMAZON RIVER FOREST; Stahl PW, 1996, ANNU REV ANTHROPOL, V25, P105, DOI 10.1146/annurev.anthro.25.1.105; SWING CK, 1987, ECOLOGIA BOLIVIA, V10, P19	28	164	171	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					190	193		10.1038/35041555	http://dx.doi.org/10.1038/35041555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	371LL	11089970				2022-12-28	WOS:000165180400042
J	Prins, LJ; De Jong, F; Timmerman, P; Reinhoudt, DN				Prins, LJ; De Jong, F; Timmerman, P; Reinhoudt, DN			An enantiomerically pure hydrogen-bonded assembly	NATURE			English	Article							SUPRAMOLECULAR CHIRALITY; MOLECULAR BOXES; INFORMATION; MEMORY	Chiral molecules have asymmetric arrangements of atoms, forming structures that are non-superposable mirror images of each other. Specific mirror images ('enantiomers') may be obtained either from enantiomerically pure precursor compounds, through enantioselective synthesis, or by resolution of so-called racemic mixtures of opposite enantiomers, provided that racemization (the spontaneous interconversion of enantiomers) is sufficiently slow. Non-covalent assemblies can similarly adopt chiral supramolecular structures(1,2), and if they are held together by relatively strong interactions, such as metal coordination(3), methods analogous to those used to obtain chiral molecules yield enantiomerically pure non-covalent products. But the resolution of assemblies formed through weak interactions, such as hydrogen-bonding, remains challenging, reflecting their lower stability and significantly higher susceptibility to racemization. Here we report the design of supramolecular structures from achiral calix[4]arene dimelamines and cyanurates, which form multiple cooperative hydrogen bonds that together provide sufficient stability to allow the isolation of enantiomerically pure assemblies. Our design strategy is based on a non-covalent 'chiral memory' concept(4,5), whereby we first use chiral barbiturates to induce the supramolecular chirality in a hydrogen-bonded assembly(6), and then substitute them by achiral cyanurates. The stability of the resultant chiral assemblies in benzene, a non-polar solvent not competing for hydrogen bonds, is manifested by a half-life to racemization of more than four days at room temperature.	Univ Twente, MESA Res Inst, Lab Supramol Chem & Technol, NL-7500 AE Enschede, Netherlands	University of Twente	Reinhoudt, DN (corresponding author), Univ Twente, MESA Res Inst, Lab Supramol Chem & Technol, POB 217, NL-7500 AE Enschede, Netherlands.	smct@ct.utwente.nl	Reinhoudt, David N/K-4767-2012					Castellano RK, 1999, J AM CHEM SOC, V121, P11156, DOI 10.1021/ja993165k; Furusho Y, 1997, J AM CHEM SOC, V119, P5267, DOI 10.1021/ja970431q; GREEN MM, 1995, SCIENCE, V268, P1860, DOI 10.1126/science.268.5219.1860; Jolliffe KA, 1998, ANGEW CHEM INT EDIT, V37, P1247, DOI 10.1002/(SICI)1521-3773(19980518)37:9<1247::AID-ANIE1247>3.0.CO;2-7; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; MASCAL M, 1995, J CHEM SOC CHEM COMM, P805, DOI 10.1039/c39950000805; Palmans ARA, 1997, ANGEW CHEM INT EDIT, V36, P2648, DOI 10.1002/anie.199726481; Piguet C, 1997, CHEM REV, V97, P2005, DOI 10.1021/cr960053s; Prins LJ, 2000, J AM CHEM SOC, V122, P3617, DOI 10.1021/ja9936262; Prins LJ, 1999, NATURE, V398, P498, DOI 10.1038/19053; Rivera JM, 1998, SCIENCE, V279, P1021, DOI 10.1126/science.279.5353.1021; SHIEH HS, 1976, ACTA CRYSTALLOGR B, V32, P2354, DOI 10.1107/S0567740876007759; Simanek EE, 1997, J ORG CHEM, V62, P2619, DOI 10.1021/jo9615460; Suarez M, 1998, HELV CHIM ACTA, V81, P1, DOI 10.1002/hlca.19980810102; Timmerman P, 1997, CHEM-EUR J, V3, P1823, DOI 10.1002/chem.19970031115; Vreekamp RH, 1996, ANGEW CHEM INT EDIT, V35, P1215, DOI 10.1002/anie.199612151; WHITESIDES GM, 1995, ACCOUNTS CHEM RES, V28, P37, DOI 10.1021/ar00049a006; Yashima E, 1997, J AM CHEM SOC, V119, P6345, DOI 10.1021/ja964470y; Yashima E, 1999, NATURE, V399, P449, DOI 10.1038/20900	19	274	275	5	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					181	184		10.1038/35041530	http://dx.doi.org/10.1038/35041530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089967				2022-12-28	WOS:000165180400039
J	Heath, PT; Booy, R; Azzopardi, HJ; Slack, MPE; Bowen-Morris, J; Griffiths, H; Ramsay, ME; Deeks, JJ; Moxon, ER				Heath, PT; Booy, R; Azzopardi, HJ; Slack, MPE; Bowen-Morris, J; Griffiths, H; Ramsay, ME; Deeks, JJ; Moxon, ER			Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE; PRP-T; ACCELERATED IMMUNIZATION; CAPSULAR POLYSACCHARIDE; INFANT IMMUNIZATION; PROTEIN CONJUGATE; SERUM ANTIBODIES; RANDOMIZED TRIAL; DISEASE	Context The schedule for Haemophilus influenzae type b (Hib) vaccination of infants in the United Kingdom consists of 3 doses given at 2, 3, and 4 months of age. Many countries include a fourth dose (booster) of Hib vaccine in the second year of life on the basis of declining Hib antibody concentrations after the primary series. Few data are available to show that this fourth dose is actually necessary. Objective To evaluate long-term clinical protection against Hib disease and Hib antibody concentrations following primary Hib vaccination without a booster dose. Design, Setting, and Subjects Clinical protection study conducted between October 1992 and March 1999 in the United Kingdom, in which children developing invasive Hib disease despite vaccination in infancy with 3 doses of Hib conjugate vaccine were reported by pediatricians through an active, prospective, national survey. Separate antibody studies were conducted among 2 cohorts of children (n=153 and n=107) vaccinated at 2, 3, and 4 months of age with Hib conjugate vaccine and followed up to 43 and 72 months of age. Main Outcome Measures Age-specific vaccine effectiveness, derived from the observed number of true vaccine failures after 3 Hib vaccine doses compared with the number of cases expected based on the age-specific rates of invasive Hib disease obtained prior to the introduction of Hib vaccines; and proportion of children in the 2 cohorts with Hib antibody concentrations of less than 0.15 and less than 1.0 mug/mL. Results Ninety-six true vaccine failures occurring after 3 vaccine doses were detected. During the study period, an estimated 4368200 infants in the United Kingdom received 3 doses of vaccine; therefore, the vaccine failure rate was 2.2 per 100000 vaccinees (95% confidence interval, 1.8-2.7 per 100000). Although vaccine effectiveness declined significantly after the first year of life (P<.001), it remained high until the sixth year of life (99.4% in children aged 5-11 months vs 97.3% in those aged 12-71 months). The proportion of cohorts 1 and 2 with anti-PRP antibody levels of less than 0.15 <mu>g/mL increased between 12 and 72 months of age (6% at 12 months, 8% at 43 months, and 32% at 72 months; chi (2)(1)=18.25; P<.001 for trend). Conclusions Our results suggest that anti-PRP antibody levels and clinical protection against Hib disease wane over time after Hib vaccination at 2, 3, and 4 months of age without a booster dose at 2 years of age. The decline in clinical protection is minimal, however, suggesting that a booster dose of Hib vaccine following infant vaccination is not essential.	John Radcliffe Hosp, Oxford Vaccine Grp, Oxford OX3 9DU, England; John Radcliffe Hosp, Publ Hlth Lab Serv, Haemophilus Reference Lab, Oxford OX3 9DU, England; St Bartholomews & Royal London Sch Med & Dent, Dept Child Hlth, London, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England; Inst Hlth Sci, Ctr Stat Med, Oxford, England	University of Oxford; University of Oxford; University of London; Queen Mary University London; Public Health England; University of Oxford	Heath, PT (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Child Hlth, Cranmer Terrace, London SW17 0RE, England.	pheath@sghms.ac.uk	Deeks, Jon/AAV-5745-2020; Ramsay, Mary Elizabeth/S-8281-2016	Deeks, Jon/0000-0002-8850-1971; Heath, Paul/0000-0002-7540-7433; Ramsay, Mary Elizabeth/0000-0002-7156-7640				Adegbola RA, 1999, LANCET, V354, P1091, DOI 10.1016/S0140-6736(99)03010-X; BOOY R, 1993, BRIT MED J, V306, P971, DOI 10.1136/bmj.306.6883.971; Booy R, 1997, LANCET, V349, P1197, DOI 10.1016/S0140-6736(96)06392-1; BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1993, ARCH DIS CHILD, V69, P225, DOI 10.1136/adc.69.2.225; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; Booy R, 1998, LANCET, V351, P1446, DOI 10.1016/S0140-6736(98)22020-4; *BRIT PAED SURV UN, 1998, 12 ROYAL COLL PAED C, P20; CLAESSON BA, 1991, PEDIATR INFECT DIS J, V10, P560, DOI 10.1097/00006454-199108000-00002; Coen PG, 1998, EPIDEMIOL INFECT, V120, P281, DOI 10.1017/S0950268898008784; Eskola J., 1996, Reviews in Medical Microbiology, V7, P231; Eskola J, 1999, LANCET, V354, P2063, DOI 10.1016/S0140-6736(99)04377-9; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FALLA TJ, 1994, J CLIN MICROBIOL, V32, P2382, DOI 10.1128/JCM.32.10.2382-2386.1994; Galil K, 1999, J INFECT DIS, V179, P101, DOI 10.1086/314569; Goldblatt D, 1998, BMJ-BRIT MED J, V316, P1570, DOI 10.1136/bmj.316.7144.1569; Goldblatt D, 1998, J INFECT DIS, V177, P1112, DOI 10.1086/517407; Hargreaves RM, 1996, BRIT MED J, V312, P160; Heath PT, 1997, ARCH DIS CHILD, V77, P488, DOI 10.1136/adc.77.6.488; HEATH PT, IN PRESS CLIN INFECT; Herceg A, 1997, Commun Dis Intell, V21, P173; JONSDOTTIR KE, 1996, ICELANDIC MED J, V82, P32; KAYHTY H, 1983, J INFECT DIS, V147, P1100; Lagos R, 1996, PEDIATR INFECT DIS J, V15, P216, DOI 10.1097/00006454-199603000-00008; Lagos R, 1998, LANCET, V351, P1472, DOI 10.1016/S0140-6736(97)07456-4; MOHLEBOETANI JC, 1993, PEDIATR INFECT DIS J, V12, P589, DOI 10.1097/00006454-199307000-00009; Mulholland EK, 1998, PEDIATR INFECT DIS J, V17, pS123, DOI 10.1097/00006454-199809001-00006; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Peltola H, 1999, J INFECT DIS, V179, P223, DOI 10.1086/314535; Rothman K, 1986, MODERN EPIDEMIOLOGY; Scheifele DW, 1999, VACCINE, V17, P543, DOI 10.1016/S0264-410X(98)00232-1; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1041; *STAT CORP, 1999, STAT STAT SOFTW REL; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; van Alphen L, 1997, J PEDIATR-US, V131, P869, DOI 10.1016/S0022-3476(97)70035-0; WEINBERG GA, 1987, J PEDIATR-US, V111, P22, DOI 10.1016/S0022-3476(87)80336-0; WENGER JD, 1997, NEW GENERATION VACCI, P489; 1998, MMWR MORB MORTAL WKL, V47, P993	38	105	107	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2334	2340		10.1001/jama.284.18.2334	http://dx.doi.org/10.1001/jama.284.18.2334			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066183	Bronze			2022-12-28	WOS:000165074500027
J	Rossi, GP; Vendraminelli, R; Cesari, M; Pessina, AC				Rossi, GP; Vendraminelli, R; Cesari, M; Pessina, AC			A thoracic mass with hypertension and hypokalaemia	LANCET			English	Article							PRIMARY ALDOSTERONISM		Univ Padua, Dept Clin & Expt Med, I-35128 Padua, Italy; Univ Padua, Dept Cytopathol, I-35128 Padua, Italy	University of Padua; University of Padua	Rossi, GP (corresponding author), Univ Padua, Dept Clin & Expt Med, Via Giustiniani 2, I-35128 Padua, Italy.							BOERS GHJ, 1981, NETH J MED, V24, P185; CONN JW, 1964, AM J SURG, V107, P159, DOI 10.1016/0002-9610(64)90252-1; GORDON RD, 1994, CLIN EXP PHARMACOL P, V21, P315, DOI 10.1111/j.1440-1681.1994.tb02519.x; LACK EE, 1997, TUMORS ADRENAL GLAND, P123; YOUNG WF, 1990, MAYO CLIN PROC, V65, P96, DOI 10.1016/S0025-6196(12)62114-4	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1570	1570		10.1016/S0140-6736(00)03129-9	http://dx.doi.org/10.1016/S0140-6736(00)03129-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075772				2022-12-28	WOS:000165134500014
J	Ramsay, M				Ramsay, M			Time to review policy on contraindications to vaccination	LANCET			English	Editorial Material							HYPOTONIC-HYPORESPONSIVE EPISODES; PERTUSSIS-VACCINE; COLLAPSE		Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England	Public Health England	Ramsay, M (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England.		Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				*AUSTR COLL PAED P, 1994, J PAEDIATR CHILD H, V30, P310; Baraff L J, 1985, Dev Biol Stand, V61, P423; BARAFF LJ, 1988, PEDIATRICS, V81, P789; Gold M, 2000, ARCH DIS CHILD, V83, P128, DOI 10.1136/adc.83.2.128; Heijbel H, 1997, DEV BIOL STAND, V89, P101; HMSO, 1996, IMM INF DIS; Miller E, 1998, BRIT MED J, V316, P876, DOI 10.1136/bmj.316.7135.876; Tatochenko V, 2000, J INFECT DIS, V181, pS228, DOI 10.1086/315567; Tozzi AE, 1998, BRIT MED J, V317, P604, DOI 10.1136/bmj.317.7158.604a; Vermeer-de Bondt PE, 1998, BRIT MED J, V316, P902, DOI 10.1136/bmj.316.7135.902; *WHO, 1988, WHO WKLY EPIDEM RECO, V37, P2; 2000, COMMUNICABLE DIS REP, V10, P109	12	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1459	1460						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081525				2022-12-28	WOS:000090067300006
J	Goldmark, JP; Fazzio, TG; Estep, PW; Church, GM; Tsukiyama, T				Goldmark, JP; Fazzio, TG; Estep, PW; Church, GM; Tsukiyama, T			The Isw2 chromatin remodeling complex represses early meiotic genes upon recruitment by Ume6p	CELL			English	Article							HISTONE DEACETYLASE ACTIVITY; SWI-SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REPRESSION; IN-VIVO; NEGATIVE REGULATOR; ACTIVATOR-BINDING; YEAST; EXPRESSION; NUCLEOSOME	The ISWI class of chromatin remodeling factors exhibits potent chromatin remodeling activities in vitro. However, the in vivo functions of this class of factors are unknown at a molecular level. We have found that S. cerevisiae Isw2 complex represses transcription of early meiotic genes during mitotic growth in a parallel pathway to Rpd3-Sin3 histone deacetylase complex. This repressor function of lsw2 complex is largely dependent upon Ume6p, which recruits the complex to target genes. Nuclease digestion analyses revealed that Isw2 complex establishes nuclease-inaccessible chromatin structure near the Ume6p binding site in vivo. Based on these findings, we propose a model for the mechanism of transcriptional repression by two distinct chromatin remodeling complexes.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Univ Washington, Seattle, WA 98109 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Harvard University; Harvard Medical School	Tsukiyama, T (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.	ttsukiya@fhcrc.org		church, george/0000-0001-6232-9969	NIGMS NIH HHS [GM58465-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058465] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aach J, 2000, GENOME RES, V10, P431, DOI 10.1101/gr.10.4.431; ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ANDERSON SF, 1995, PROTEIN SCI, V4, P1832, DOI 10.1002/pro.5560040918; Belotserkovskaya R, 1999, CRIT REV EUKAR GENE, V9, P221, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.70; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; DEURING R, 2000, IN PRESS MOL CELL; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Roberts SM, 1997, GENETICS, V147, P451; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RubinBejerano I, 1996, MOL CELL BIOL, V16, P2518; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; SMITH HE, 1990, MOL CELL BIOL, V10, P6103, DOI 10.1128/MCB.10.12.6103; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Steber CM, 1995, P NATL ACAD SCI USA, V92, P12490, DOI 10.1073/pnas.92.26.12490; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; STRICH R, 1994, GENE DEV, V8, P796, DOI 10.1101/gad.8.7.796; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Suka N, 1998, COLD SPRING HARB SYM, V63, P391, DOI 10.1101/sqb.1998.63.391; Sweet DH, 1997, MOL CELL BIOL, V17, P6223, DOI 10.1128/MCB.17.11.6223; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Trachtulcova P, 2000, YEAST, V16, P35, DOI 10.1002/(SICI)1097-0061(20000115)16:1<35::AID-YEA504>3.0.CO;2-0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1999, CURR BIOL, V9, pR221, DOI 10.1016/S0960-9822(99)80134-1; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	72	203	211	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					423	433		10.1016/S0092-8674(00)00134-3	http://dx.doi.org/10.1016/S0092-8674(00)00134-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081629	Bronze			2022-12-28	WOS:000090144100008
J	Waizenegger, IC; Hauf, S; Meinke, A; Peters, JM				Waizenegger, IC; Hauf, S; Meinke, A; Peters, JM			Two distinct pathways remove mammalian cohesin from chromosome arms in prophase and from centromeres in anaphase	CELL			English	Article							SISTER-CHROMATID SEPARATION; MATURATION-PROMOTING FACTOR; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; CYCLIN-B; MITOSIS; COMPLEX; PROTEIN; DEGRADATION	In yeast, anaphase depends on cohesin cleavage. How anaphase is controlled in vertebrates is unknown because their cohesins dissociate from chromosomes before anaphase. We show that residual amounts of the cohesin SCC1 remain associated with human centromeres until the onset of anaphase when a similarly small amount of SCC1 is cleaved. In Xenopus extracts, SCC1 cleavage depends on the anaphase-promoting complex and separin. Separin immunoprecipitates are sufficient to cleave SCC1, indicating that separin is associated with a protease activity. Separin activation coincides with securin destruction and partial separin cleavage, suggesting that several mechanisms regulate separin activity. We propose that in vertebrates, a cleavage-independent pathway removes cohesin from chromosome arms during prophase, whereas a separin-dependent pathway cleaves centromeric cohesin at the metaphase-anaphase transition.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Vienna, Dept Genet & Microbiol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Vienna	Peters, JM (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	peters@nt.imp.univie.ac.at	Hauf, Silke/H-7321-2012	Hauf, Silke/0000-0001-5938-721X				Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Dej KJ, 2000, TRENDS CELL BIOL, V10, P392, DOI 10.1016/S0962-8924(00)01821-3; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Leismann O, 2000, GENE DEV, V14, P2192, DOI 10.1101/gad.176700; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAY GS, 1992, J BIOL CHEM, V267, P15737; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nagase T, 1996, DNA Res, V3, P43, DOI 10.1093/dnares/3.1.43; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; OSTERGREN G, 1973, STAINING KINETOCHORE, V23, P159; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Pidoux AL, 2000, CURR OPIN CELL BIOL, V12, P308, DOI 10.1016/S0955-0674(00)00094-6; Rieder CL, 1999, J CELL SCI, V112, P2607; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUMARA I, 2000, IN PRESS J CELL BIOL; SUMNER AT, 1992, J CELL SCI, V103, P105; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; TOMONOGA T, 2000, IN PRESS GENES DEV; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	44	563	576	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					399	410		10.1016/S0092-8674(00)00132-X	http://dx.doi.org/10.1016/S0092-8674(00)00132-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081627	Bronze			2022-12-28	WOS:000090144100006
J	McCarroll, L; Paton, MG; Karunaratne, SHPP; Jayasuryia, HTR; Kalpage, KSP; Hemingway, J				McCarroll, L; Paton, MG; Karunaratne, SHPP; Jayasuryia, HTR; Kalpage, KSP; Hemingway, J			Insecticides and mosquito-borne disease	NATURE			English	Article							RESISTANT CULEX-QUINQUEFASCIATUS; WUCHERERIA-BANCROFTI; SRI-LANKA; GENES		Cardiff Univ, Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; Univ Peradeniya, Dept Zool, Peradeniya, Sri Lanka; Open Univ, Dept Zool, Nugegoda, Sri Lanka; Anti Filariasis Campaign, Colombo, Sri Lanka	Cardiff University; University of Peradeniya; Open University Sri Lanka	McCarroll, L (corresponding author), Cardiff Univ, Sch Biosci, Cardiff CF10 3TL, S Glam, Wales.	Hemingway@cardiff.ac.uk		Hemingway, Janet/0000-0002-3200-7173				BROGDON WG, 1990, PESTIC BIOCHEM PHYS, V37, P130, DOI 10.1016/0048-3575(90)90118-L; Hemingway J, 2000, INSECT BIOCHEM MOLEC, V30, P1009, DOI 10.1016/S0965-1748(00)00079-5; Hemingway J, 2000, INSECT MOL BIOL, V9, P93, DOI 10.1046/j.1365-2583.2000.00160.x; Hemingway J, 1998, MED VET ENTOMOL, V12, P1, DOI 10.1046/j.1365-2915.1998.00082.x; Hemingway J, 2000, ANNU REV ENTOMOL, V45, P371, DOI 10.1146/annurev.ento.45.1.371; JAYASEKERA N, 1991, T ROY SOC TROP MED H, V85, P250, DOI 10.1016/0035-9203(91)90044-Y; Nicolas L, 1997, PARASITE, V4, P253, DOI 10.1051/parasite/1997043253; Parakrama Karunaratne S.H.P., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P460; Paton MG, 2000, BIOCHEM J, V346, P17, DOI 10.1042/0264-6021:3460017; Peiris HTR, 1996, MED VET ENTOMOL, V10, P283, DOI 10.1111/j.1365-2915.1996.tb00744.x; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; Salazar C. E., 1994, Insect Molecular Biology, V3, P1, DOI 10.1111/j.1365-2583.1994.tb00145.x; Vaughan A, 1997, BIOCHEM J, V325, P359, DOI 10.1042/bj3250359	13	67	71	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					961	962		10.1038/35039671	http://dx.doi.org/10.1038/35039671			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069167				2022-12-28	WOS:000090032500031
J	Levy, D; Kannel, WB				Levy, D; Kannel, WB			Searching for answers to ethnic disparities in cardiovascular risk	LANCET			English	Editorial Material							CORONARY HEART-DISEASE		NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Sch Med, Framingham, MA USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University	Levy, D (corresponding author), NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.		Gerstein, Hertzel/ABB-8781-2020	Gerstein, Hertzel/0000-0001-8072-2836				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Arad Y, 1996, CIRCULATION, V93, P1951, DOI 10.1161/01.CIR.93.11.1951; Botnar RM, 1999, CIRCULATION, V99, P3139, DOI 10.1161/01.CIR.99.24.3139; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Fayad ZA, 2000, CIRCULATION, V101, P2503, DOI 10.1161/01.CIR.101.21.2503; *NIH, 2000, MORB MORT 2000 CHART, P34; Tenenbaum A, 1998, RADIOLOGY, V208, P153, DOI 10.1148/radiology.208.1.9646807; van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101; YANO K, 1988, AM J EPIDEMIOL, V127, P476, DOI 10.1093/oxfordjournals.aje.a114824	9	23	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					266	267		10.1016/S0140-6736(00)02496-X	http://dx.doi.org/10.1016/S0140-6736(00)02496-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071176				2022-12-28	WOS:000088305900002
J	Roberts, DR; Manguin, S; Mouchet, J				Roberts, DR; Manguin, S; Mouchet, J			DDT house spraying and re-emerging malaria	LANCET			English	Editorial Material							RESISTANCE; PREDICTIONS		Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Roberts, DR (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	droberts@usuhs.mil	Manguin, Sylvie/G-1787-2015; Manguin, Sylvie/GOE-5338-2022	Manguin, Sylvie/0000-0002-5925-7164; Manguin, Sylvie/0000-0002-5925-7164				BROWN AWA, 1976, J MED ENTOMOL, V13, P1, DOI 10.1093/jmedent/13.1.1; Casas M, 1998, J AM MOSQUITO CONTR, V14, P410; CAVALIE P., 1962, Medecine Tropicale, V22, P95; *COMM ENV COOP, 1995, N AM REG ACT PLAN DD; Curtis CF, 2000, PARASITOL TODAY, V16, P119, DOI 10.1016/S0169-4758(99)01605-1; FARID M A, 1991, Kaohsiung Journal of Medical Sciences, V7, P243; Feighner BH, 1998, EMERG INFECT DIS, V4, P295, DOI 10.3201/eid0402.980219; Gilles HM, 1993, BRUCECHWATTS ESSENTI, V340; Litsios S., 1996, The tomorrow of malaria.; MOUCHET J, 1991, ANN SOC BELG MED TR, V71, P259; MOUCHET J, 1988, INSECT SCI APPL, V9, P297, DOI 10.1017/S1742758400006238; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; MOUCHET J, 1994, CAHIERS SANTE, V4, P257; NABARRO D, 1998, UNPUB ROLL BACK MALA; NEWSOME S, 1999, MODERN MALARIA CONTR, P100; *PAN AM HLTH ORG, 1998, 46 PAN AM HLTH ORG, P28; *PAN AM HLTH ORG, 1997, 45 PAN AM HLTH ORG, P25; *PAN AM HLTH ORG, 1994, 12 PAN AM HLTH ORG, P112; *PAN AM HLTH ORG, 1993, PEST HLTH AM, P109; REJMANKOVA E, 1995, AM J TROP MED HYG, V53, P482, DOI 10.4269/ajtmh.1995.53.482; Roberts D R, 1991, Bull Pan Am Health Organ, V25, P210; Roberts DR, 1999, EMERG INFECT DIS, V5, P310, DOI 10.3201/eid0502.990230; Roberts DR, 1996, AM J TROP MED HYG, V54, P304, DOI 10.4269/ajtmh.1996.54.304; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; ROBERTS DR, 1994, AM J TROP MED HYG, V50, P21, DOI 10.4269/ajtmh.1994.50.21; ROBERTS DR, 1999, USE REMOTE SENSORING; Rozendaal J A, 1991, Bull Pan Am Health Organ, V25, P336; STOLBERG SG, 1999, NY TIMES        0828; SUAREZ MF, 1990, J AM MOSQUITO CONTR, V6, P72; Taverne J, 1999, PARASITOL TODAY, V15, P180, DOI 10.1016/S0169-4758(99)01446-5; *WHO, 1992, WORLD HLTH STAT ANN, P349; *WHO, 1999, STRAT ROLL BACK MAL, V15; *WHO, 1994, MED VET ENTOMOL, V8, P113; *WHO, 1979, TECHN REP SER WHO, V640; *WHO, 1993, TECHN REP SER WHO, V839; *WHO, 1984, CHEM METH CONTR ARTH; *WORLD WILDL FUND, 1998, RES DDT DIL PROT BIO, P52	37	101	110	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					330	332		10.1016/S0140-6736(00)02516-2	http://dx.doi.org/10.1016/S0140-6736(00)02516-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071203				2022-12-28	WOS:000088305900038
J	Proshlyakov, DA; Pressler, MA; DeMaso, C; Leykam, JF; DeWitt, DL; Babcock, GT				Proshlyakov, DA; Pressler, MA; DeMaso, C; Leykam, JF; DeWitt, DL; Babcock, GT			Oxygen activation and reduction in respiration: Involvement of redox-active tyrosine 244	SCIENCE			English	Article							CYTOCHROME-C-OXIDASE; HYDROGEN-PEROXIDE; PROTON TRANSLOCATION; MECHANISM; IODINATION; IDENTIFICATION; RADICALS; SITE	Cytochrome oxidase activates and reduces O-2 to water to sustain respiration and uses the energy released to drive proton translocation and adenosine 5'-triphosphate synthesis. A key intermediate in this process, P, lies at the junction of the O-2-reducing and proton-pumping functions. We used radioactive iodide labeling followed by peptide mapping to gain insight into the structure of P. We show that the cross-linked histidine 240-tyrosine 244 (His(240)-Tyr(244) species is redox active in P formation, which establishes its structure as Fe-IV=O/(CuB2+H240)-Y-244. Thus, energy transfer from O-2 to the protein moiety is used as a strategy to avoid toxic intermediates and to control energy utilization in subsequent proton-pumping events.	Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Babcock, GT (corresponding author), Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA.	babcock@cem.msu.edu			NIGMS NIH HHS [GM57323, GM25480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Babcock GT, 1999, P NATL ACAD SCI USA, V96, P12971, DOI 10.1073/pnas.96.23.12971; BLOMBERG MR, IN PRESS J AM CHEM S; Blomberg MRA, 2000, J INORG BIOCHEM, V80, P261, DOI 10.1016/S0162-0134(00)00080-5; Buse G, 1999, PROTEIN SCI, V8, P985, DOI 10.1110/ps.8.5.985; Chen YR, 1999, J BIOL CHEM, V274, P3308, DOI 10.1074/jbc.274.6.3308; CLORE GM, 1980, BIOCHEM J, V185, P155, DOI 10.1042/bj1850155; DEME D, 1985, ARCH BIOCHEM BIOPHYS, V236, P559, DOI 10.1016/0003-9861(85)90659-9; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; HENSEL S, 1990, BIOL CHEM H-S, V371, P411, DOI 10.1515/bchm3.1990.371.1.411; Himo F, 2000, INT J QUANTUM CHEM, V76, P714, DOI 10.1002/(SICI)1097-461X(2000)76:6<714::AID-QUA4>3.0.CO;2-F; Kitagawa T, 1997, PROG INORG CHEM, V45, P431; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; Libby RD, 1996, J BIOL CHEM, V271, P21820, DOI 10.1074/jbc.271.36.21820; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; McCauley KM, 2000, J AM CHEM SOC, V122, P2403, DOI 10.1021/ja993774s; Michel H, 1999, NATURE, V402, P602, DOI 10.1038/45133; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; MOODY AJ, 1994, EUR J BIOCHEM, V226, P731, DOI 10.1111/j.1432-1033.1994.tb20102.x; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Rigby SEJ, 2000, BIOCHEMISTRY-US, V39, P5921, DOI 10.1021/bi992614q; ROMAN R, 1972, BIOCHEMISTRY-US, V11, P2076, DOI 10.1021/bi00761a013; SUN WM, 1993, BIOCHEMISTRY-US, V32, P1324, DOI 10.1021/bi00056a018; TAKAHASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V973, P138, DOI 10.1016/S0005-2728(89)80414-1; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Wikstrom M, 2000, BIOCHEMISTRY-US, V39, P3515, DOI 10.1021/bi9925322; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	30	259	266	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1588	1591		10.1126/science.290.5496.1588	http://dx.doi.org/10.1126/science.290.5496.1588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090359				2022-12-28	WOS:000165446200054
J	Crowley, JC; Katz, LC				Crowley, JC; Katz, LC			Early development of ocular dominance columns	SCIENCE			English	Article							FERRET VISUAL-CORTEX; MONKEY STRIATE CORTEX; BINOCULAR IMPULSE BLOCKADE; SUBPLATE NEURONS; THALAMOCORTICAL CONNECTIONS; OPTIC CHIASM; CAT; ORIENTATION; PLASTICITY; ORGANIZATION	The segregation of Lateral geniculate nucleus (LGN) axons into ocular dominance columns is believed to involve a prolonged, activity-dependent sorting process. However, visualization of early postnatal ferret LGN axons by direct LGN tracer injections revealed segregated ocular dominance columns <7 days after innervation of Layer 4. These early columns were unaffected by experimentally induced imbalances in retinal activity, implying that different mechanisms govern initial column formation and their modification during the subsequent critical period. Instead of activity-dependent plasticity, we propose that ocular dominance column formation relies on the targeting of distinct axonal populations to defined Locales in cortical Layer 4.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Crowley, JC (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012359] Funding Source: NIH RePORTER; NEI NIH HHS [EY07690] Funding Source: Medline; NIMH NIH HHS [MH12359] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANTONINI A, 1993, J NEUROSCI, V13, P3549; Antonini A, 1996, J COMP NEUROL, V369, P64; BARTFELD E, 1992, P NATL ACAD SCI USA, V89, P11905, DOI 10.1073/pnas.89.24.11905; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; CHAPMAN B, 1986, NATURE, V324, P154, DOI 10.1038/324154a0; Chapman B, 2000, SCIENCE, V287, P2479, DOI 10.1126/science.287.5462.2479; Crair MC, 1997, J NEUROPHYSIOL, V77, P3381, DOI 10.1152/jn.1997.77.6.3381; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; CROWLEY JC, UNPUB; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; Durack JC, 1996, CEREB CORTEX, V6, P178, DOI 10.1093/cercor/6.2.178; Erwin E, 1998, J NEUROSCI, V18, P9870; Finney EM, 1998, J NEUROSCI, V18, P8826; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GUILLERY RW, 1995, J NEUROSCI, V15, P4727; HERRMANN K, 1994, EUR J NEUROSCI, V6, P1729, DOI 10.1111/j.1460-9568.1994.tb00565.x; Horton JC, 1996, J NEUROSCI, V16, P1791; Horton JC, 1998, VISUAL NEUROSCI, V15, P289, DOI 10.1017/S0952523898152124; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; HUBEL DH, 1972, J COMP NEUROL, V146, P421, DOI 10.1002/cne.901460402; HUBEL DH, 1969, NATURE, V221, P747, DOI 10.1038/221747a0; Hubener M, 1997, J NEUROSCI, V17, P9270; Issa NP, 1999, J NEUROSCI, V19, P6965, DOI 10.1523/JNEUROSCI.19-16-06965.1999; JACKSON CA, 1989, J NEUROSCI, V9, P1242; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LeVay S., 1979, SOC NEUROSCI S, V4, P83; Mason CA, 1997, CURR OPIN NEUROBIOL, V7, P647, DOI 10.1016/S0959-4388(97)80084-0; Meissirel C, 1997, P NATL ACAD SCI USA, V94, P5900, DOI 10.1073/pnas.94.11.5900; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; NELSON DA, 1995, NEURON, V15, P23, DOI 10.1016/0896-6273(95)90061-6; OBERMAYER K, 1993, J NEUROSCI, V13, P4114; PURVES D, 1988, BODY BRAIN; RAKIC P, 1981, SCIENCE, V214, P928, DOI 10.1126/science.7302569; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; Rathjen S, 2000, NEUROREPORT, V11, P2363, DOI 10.1097/00001756-200008030-00006; REDIES C, 1990, J NEUROSCI, V10, P2791; Ruthazer ES, 1999, J COMP NEUROL, V407, P151; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; STRYKER MP, 1986, J NEUROSCI, V6, P2117; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; Weliky M, 1999, SCIENCE, V285, P599, DOI 10.1126/science.285.5427.599; White LE, 1999, J NEUROSCI, V19, P7089, DOI 10.1523/JNEUROSCI.19-16-07089.1999; WIESEL TN, 1974, BRAIN RES, V79, P273, DOI 10.1016/0006-8993(74)90416-8; ZAHS KR, 1988, J NEUROPHYSIOL, V59, P1410, DOI 10.1152/jn.1988.59.5.1410	48	213	217	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1321	1324		10.1126/science.290.5495.1321	http://dx.doi.org/10.1126/science.290.5495.1321			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082053				2022-12-28	WOS:000165379800039
J	Confavreux, C; Vukusic, S; Moreau, T; Adeleine, P				Confavreux, C; Vukusic, S; Moreau, T; Adeleine, P			Relapses and progression of disability in multiple sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; CLINICAL COURSE; PROGNOSIS	Background: The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of irreversible disability is controversial. Methods: In 1844 patients who had had multiple sclerosis for a mean (+/-SD) of 11+/-10 years, we determined the time of the clinical onset of the disease, the initial course (relapsing-remitting or progressive) and the subsequent course (relapsing-remitting, secondary progressive, or primary progressive), the times of relapses, the time to the onset of irreversible disability, and the time course of progressive, irreversible disability. We used three scores on the Kurtzke Disability Status Scale (range, 0 to 10, with higher scores indicating more severe disability) as measures of the severity and progression of disability: a score of 4 (limited walking ability but able to walk more than 500 m without aid or rest), a score of 6 (ability to walk with unilateral support no more than 100 m without rest), and a score of 7 (ability to walk no more than 10 m without rest while leaning against a wall or holding onto furniture for support). We used Kaplan-Meier analyses to determine the influence of relapses on the time to the onset of irreversible disability. Results: The median times from the onset of multiple sclerosis to the assignment of a score of 4, a score of 6, and a score of 7 on the disability scale were longer among the 1562 patients with a relapsing-remitting onset of disease (11.4, 23.1, and 33.1 years, respectively) than among the 282 patients who had progressive disease from the onset (0.0, 7.1, and 13.4 years, respectively; P<0.001 for all comparisons). In contrast, the times from the assignment of a score of 4 to a score of 6 were similar in the two groups (5.7 and 5.4 years, P=0.74). The time course of progressive, irreversible disease among patients with the primary progressive type of multiple sclerosis was not affected by the presence or absence of superimposed relapses. Conclusions: Among patients with multiple sclerosis, relapses do not significantly influence the progression of irreversible disability. (N Engl J Med 2000; 343:1430-8.) (C) 2000, Massachusetts Medical Society.	Hop Neurol, EDMUS Coordinating Ctr, F-69394 Lyon 03, France; Hop Neurol, Serv Neurol A, F-69394 Lyon 03, France; Hospices Civils Lyon, Unite Biostat & Informat Med, Lyon, France	CHU Lyon; CHU Lyon; CHU Lyon	Confavreux, C (corresponding author), Hop Neurol, EDMUS Coordinating Ctr, 59 Pinel Bvd, F-69394 Lyon 03, France.							Andersson PB, 1999, ARCH NEUROL-CHICAGO, V56, P1138, DOI 10.1001/archneur.56.9.1138; BERGER JR, 1989, NEUROLOGY, V39, P324, DOI 10.1212/WNL.39.3.324; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; CONFAVREUX C, 1992, J NEUROL NEUROSUR PS, V55, P671, DOI 10.1136/jnnp.55.8.671; CONFAVREUX C, 1980, BRAIN, V103, P281, DOI 10.1093/brain/103.2.281; Cottrell DA, 1999, BRAIN, V122, P625, DOI 10.1093/brain/122.4.625; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Ebers GC, 1999, LANCET, V353, P678; Jacobs LD, 1996, ANN NEUROL, V40, P480; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kremenchutzky M, 1999, BRAIN, V122, P1941, DOI 10.1093/brain/122.10.1941; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; PHADKE JG, 1990, BRAIN, V113, P1597, DOI 10.1093/brain/113.6.1597; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rudick RA, 1997, NEW ENGL J MED, V337, P1604, DOI 10.1056/NEJM199711273372207; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; SPSS, 1999, STAT PACK SOC SCI RE; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133	25	905	930	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1430	1438		10.1056/NEJM200011163432001	http://dx.doi.org/10.1056/NEJM200011163432001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078767				2022-12-28	WOS:000165271300001
J	Earhart, KC; Power, MH				Earhart, KC; Power, MH			Bartonella neuroretinitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									USN, Med Ctr, San Diego, CA 92134 USA	United States Department of Defense; United States Navy	Earhart, KC (corresponding author), USN, Med Ctr, San Diego, CA 92134 USA.								0	5	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1459	1459		10.1056/NEJM200011163432005	http://dx.doi.org/10.1056/NEJM200011163432005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078771				2022-12-28	WOS:000165271300005
J	Emanuel, EJ; Fairclough, DL; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Emanuel, LL			Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ONCOLOGY PATIENTS; CARE GIVERS; FAMILIES; HEALTH; BURDEN; DEATH	Context Euthanasia and physician-assisted suicide (PAS) are highly controversial is' sues. While there are studies of seriously ill patients' interest in euthanasia and PAS, there are no data on the attitudes and desires of terminally ill patients regarding these issues. Objective To determine the attitudes of terminally ill patients toward euthanasia and PAS, whether they seriously were considering euthanasia and PAS for themselves, the stability of their desires, factors associated with their desires, and the proportion of patients who die from these interventions. Design Prospective cohort of terminally ill patients and their primary caregivers surveyed twice between March 1996 and July 1997. Setting Outpatient settings in 5 randomly selected metropolitan statistical areas and 1 rural county. Participants A total of 988 patients identified by their physicians to be terminally ill with any disease except for human immunodeficiency virus infection (response ratel 87.4%) and 893 patient-designated primary caregivers (response rate, 97.6%). Main Outcome Measures Support for euthanasia or PAS in standard scenarios; patient-expressed considerations and discussions of their desire for euthanasia or PAS; hoarding of drugs for suicide; patient death by euthanasia or PAS; and patient-reported sociodemographic factors and symptoms related to these outcomes. Results Of the 988 terminally ill patients, a total of 60.2% supported euthanasia or PAS in a hypothetical situation, but only 10.6% reported seriously considering euthanasia or PAS for themselves. Factors associated with being less likely to consider euthanasia or PAS were feeling appreciated (odds ratio [OR], 0.65; 95% confidence interval [CI], 0.52-0.82), being aged 65 years or older (OR, 0.52; 95% CI, 0.34-0.82), and being African American (OR, 0.39; 95 % CI, 0.18-0.84). Factors associated with being more likely to consider euthanasia or PAS were depressive symptoms (OR, 1.25; 95 % Clr 1.05-1.49), substantial caregiving needs (OR, 1.09; 95 % CI, 1.01 - 1.17), and pain (OR, 1.26; 95% CI, 1.02-1.56). At the follow-up interview, half of the terminally ill patients who had considered euthanasia or PAS for themselves changed their minds, while an almost equal number began considering these interventions. Patients with depressive symptoms (OR, 5.29; 95% CI, 1.21-23.2) and dyspnea (OR, 1.68; 95% CI, 1.26-2.22) were more likely to change their minds to consider euthanasia or PAS. According to the caregivers of the 256 decedents, 14 patients (5.6%) had discussed asking the physician for euthanasia or PAS and 6 (2.5%) had hoarded drugs. Ultimately, of the 256 decedents 1 (0.4%) died by euthanasia or PAS, 1 unsuccessfully attempted suicide, and 1 repeatedly requested for her life to be ended but the family and physicians refused. Conclusions In this survey, a small proportion of terminally ill patients seriously considered euthanasia or PAS for themselves. Over a few months, half the patients changed their minds. Patients with depressive symptoms were more likely to change their minds;about desiring euthanasia or PAS.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Northwestern Univ, Sch Med, Interdisciplinary Program Professionalism & Human, Chicago, IL USA	National Institutes of Health (NIH) - USA; Northwestern University	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; Brown J, 1995, AM J PSYCHIAT, V152, P1185; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Emanuel EJ, 1999, ETHICS, V109, P629, DOI 10.1086/233925; EMANUEL L, IN PRESS J PALLIAT M; EPSTEIN AM, 1995, INQUIRY-J HEALTH CAR, V32, P211; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Kissane DW, 1998, LANCET, V352, P1097, DOI 10.1016/S0140-6736(98)05406-3; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Koenig HG, 1996, ARCH INTERN MED, V156, P2240, DOI 10.1001/archinte.156.19.2240; Nuland SB, 2000, NEW ENGL J MED, V342, P583, DOI 10.1056/NEJM200002243420811; Owen C., 1992, PSYCHO-ONCOLOGY, V1, P79, DOI [10.1002/pon.2960010205, DOI 10.1002/PON.2960010205]; Quill TE, 1993, DEATH DIGNITY MAKING; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; Rosenfeld B, 1999, AM J PSYCHIAT, V156, P94, DOI 10.1176/ajp.156.1.94; SHERBOURNE CD, 1993, SOC SCI MED, V12, P164; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; SuarezAlmazor ME, 1997, J CLIN ONCOL, V15, P418, DOI 10.1200/JCO.1997.15.2.418; SUBROD C, 1960, J CHRON DIS, V11, P7; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; Ware J. E., 1993, SF36 HLTH SURVEY MAN; Willems DL, 2000, ARCH INTERN MED, V160, P63, DOI 10.1001/archinte.160.1.63; Wolfe J, 1999, J CLIN ONCOL, V17, P1274, DOI 10.1200/JCO.1999.17.4.1274; [No title captured]	38	235	236	1	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2460	2468		10.1001/jama.284.19.2460	http://dx.doi.org/10.1001/jama.284.19.2460			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074775	Bronze			2022-12-28	WOS:000165183800019
J	Steinhauser, AE; Christakis, NA; Clipp, EC; McNeilly, M; McIntyre, L; Tulsky, JA				Steinhauser, AE; Christakis, NA; Clipp, EC; McNeilly, M; McIntyre, L; Tulsky, JA			Factors considered important at the end of life by patients, family, physicians, and other care providers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUSTAINING TREATMENTS; PREFERENCES; SAMPLE; PEOPLE; DEATH	Context A clear understanding of what patients, families, and health care practitioners view as important at the end of life is integral to the success of improving care of dying patients. Empirical evidence de fining such factors, however, is lacking. Objective To determine the factors considered important at the end of life by patients, their families, physicians, and other care providers. Design and Setting Cross-sectional, stratified random national survey conducted in March-August 1999. Participants Seriously ill patients (n = 340), recently bereaved family (n = 332), physicians (n = 361), and other care providers (nurses, social workers, chaplains, and hospice volunteers; n = 429). Main Outcome Measures Importance of 44 attributes of quality at the end of life (5-point scale) and rankings of 9 major attributes, compared in the 4 groups. Results Twenty-six items consistently were rated as being important (>70% responding that item is important) across all 4 groups, including pain and symptom management, preparation for death, achieving a sense of completion, decisions about treatment preferences, and being treated as a "whole person." Eight items received strong importance ratings from patients but less from physicians (P<.001), including being mentally aware, having funeral arrangements planned, not being a burden, helping others, and coming to peace with Clod. Ten items had broad variation within as well as among the 4 groups, including decisions about life-sustaining treatments, dying at home, and talking about the meaning of death. Participants ranked freedom from pain most important and dying at home least important among 9 major attributes. Conclusions Although pain and symptom management, communication with;one's physician, preparation for death, and the opportunity to achieve a sense of completion are important to most, other factors important to quality at the end of life differ by role and by individual. Efforts to evaluate and improve patients' and families' experiences at the end of life must account for diverse perceptions of quality.	Program Med Encounter & Palliat Care, Durham, NC USA; Vet Adm Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA; Durham Vet Affairs Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Ctr Study Aging & Human Dev, Durham, NC 27710 USA; Duke Univ, Inst Care End Life, Durham, NC USA; Inst Multiculturalism, Durham, NC USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Sociol, Chicago, IL 60637 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University; University of Chicago; University of Chicago	Steinhauser, AE (corresponding author), Vet Affairs Med Ctr 152, 508 Fulton St, Durham, NC 27705 USA.	karensteinhauser@mindspring.com	Christakis, Nicholas A/B-6690-2008; Christakis, Nicholas A/C-3205-2009	McIntyre, Lauren/0000-0002-0077-3359				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; [Anonymous], 1997, APPROACHING DEATH, DOI [10.17226/5801, DOI 10.17226/5801]; CHILDERS TL, 1979, J MARKETING RES, V16, P429, DOI 10.2307/3150720; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis Nicholas, 1999, DEATH FORETOLD PROPH; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Erikson E.H., 1982, LIFE CYCLE COMPLETED; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; GARRETT JM, 1993, J GEN INTERN MED, V8, P361, DOI 10.1007/BF02600073; GARVIN J, 1995, W J MED, V163, P268; GIBSON R, 1998, J PALLIAT MED, V1, P415; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HENDRICK C, 1972, PSYCHON SCI, V26, P349; KING DE, 1994, J FAM PRACTICE, V39, P349; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; *NAT HOSP ORG, 1996, NEW FINDINGS ADDRESS; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; SCHMIDT TA, 1995, ACAD EMERG MED, V2, P513, DOI 10.1111/j.1553-2712.1995.tb03250.x; SEALE C, 1991, SOC SCI MED, V32, P943, DOI 10.1016/0277-9536(91)90249-C; SEALE C, 1995, SOC SCI MED, V40, P589, DOI 10.1016/0277-9536(94)E0119-D; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Solomon MZ, 1995, HASTINGS CENT REP, V25, pS28, DOI 10.2307/3527856; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; TULSKY J, 1997, J CLIN ETHIC, V126, P381; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306	27	1608	1628	11	107	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2476	2482		10.1001/jama.284.19.2476	http://dx.doi.org/10.1001/jama.284.19.2476			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074777	Green Published			2022-12-28	WOS:000165183800021
J	Lynch, M; Conery, JS				Lynch, M; Conery, JS			The evolutionary fate and consequences of duplicate genes	SCIENCE			English	Article							GENOME DUPLICATION; SPECIATION; ORIGIN; VERTEBRATES; DIVERGENCE; PROTEINS	Gene duplication has generally been viewed as a necessary source of material for the origin of evolutionary novelties, but it is unclear how often gene duplicates arise and how frequently they evolve new functions. Observations from the genomic databases for several eukaryotic species suggest that duplicate genes arise at a very high rate, on average 0.01 per gene per million years. Most duplicated genes experience a brief period of relaxed selection early in their history, with a moderate fraction of them evolving in an effectively neutral manner during this period. However, the vast majority of gene duplicates are silenced within a few million years, with the few survivors subsequently experiencing strong purifying selection. Although duplicate genes may only rarely evolve new functions, the stochastic silencing of such genes may play a significant role in the passive origin of new species.	Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Comp & Informat Sci, Eugene, OR 97403 USA	University of Oregon; University of Oregon	Lynch, M (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036827] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM36827] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; AHLBERG PE, 1994, NATURE, V368, P507, DOI 10.1038/368507a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Coyne JA, 1997, EVOLUTION, V51, P295, DOI [10.1111/j.1558-5646.1997.tb02412.x, 10.2307/2410984]; EASTEAL S, 1994, MOL BIOL EVOL, V11, P643; FERRIS SD, 1979, J MOL EVOL, V12, P267, DOI 10.1007/BF01732026; Fischer G, 2000, NATURE, V405, P451, DOI 10.1038/35013058; Force A, 1999, GENETICS, V151, P1531; Gaut BS, 1997, P NATL ACAD SCI USA, V94, P6809, DOI 10.1073/pnas.94.13.6809; Grant D, 2000, P NATL ACAD SCI USA, V97, P4168, DOI 10.1073/pnas.070430597; Haldane JBS, 1933, AM NAT, V67, P5, DOI 10.1086/280465; HOLLAND PWH, 1994, DEVELOPMENT, P125; HUGHES AL, 1994, P ROY SOC B-BIOL SCI, V256, P119, DOI 10.1098/rspb.1994.0058; Hughes AL, 1999, J MOL EVOL, V48, P565, DOI 10.1007/PL00006499; HUGHES MK, 1993, MOL BIOL EVOL, V10, P1360; LI WH, 1985, POPULATION GENETICS, P333; Li WH, 1999, MOL EVOLUTION; Lynch M, 1997, MOL BIOL EVOL, V14, P914, DOI 10.1093/oxfordjournals.molbev.a025834; Lynch M, 2000, GENETICS, V154, P459; Lynch M., 1998, GENETICS ANAL QUANTI; LYNCH M, IN PRESS AM NAT; Martin AP, 1999, AM NAT, V154, P111, DOI 10.1086/303231; MULLER H. J., 1935, GENETICA, V17, P237, DOI 10.1007/BF01985012; Nadeau JH, 1997, GENETICS, V147, P1259; Ohno S., 1970, EVOLUTION GENE DUPLI; OHTA T, 1995, J MOL EVOL, V40, P6; Orr HA, 1996, GENETICS, V144, P1331; PARKER HR, 1985, J EXP ZOOL, V233, P451, DOI 10.1002/jez.1402330314; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Semple C, 1999, J MOL EVOL, V48, P555, DOI 10.1007/PL00006498; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Skrabanek L, 1998, CURR OPIN GENET DEV, V8, P694, DOI 10.1016/S0959-437X(98)80039-7; Stoltzfus A, 1999, J MOL EVOL, V49, P169, DOI 10.1007/PL00006540; WALSH JB, 1985, GENETICS, V110, P345; WATTERSON GA, 1983, GENETICS, V105, P745; Wendel JF, 2000, PLANT MOL BIOL, V42, P225, DOI 10.1023/A:1006392424384; WERTH CR, 1991, AM NAT, V137, P515, DOI 10.1086/285180; White M.J.D., 1978, MODES SPECIATION; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	40	3201	3316	16	457	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1151	1155		10.1126/science.290.5494.1151	http://dx.doi.org/10.1126/science.290.5494.1151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073452				2022-12-28	WOS:000165228200045
J	Weichenrieder, O; Wild, K; Strub, K; Cusack, S				Weichenrieder, O; Wild, K; Strub, K; Cusack, S			Structure and assembly of the Alu domain of the mammalian signal recognition particle	NATURE			English	Article							SRP-RNA; PROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; ENDOPLASMIC-RETICULUM; HAMMERHEAD RIBOZYME; ELONGATION ARREST; SRP9/14 SUBUNIT; BINDING-SITES; 7SL RNA; ELEMENTS	The Alu domain of the mammalian signal recognition particle (SRP) comprises the heterodimer of proteins SRP9 and SRP14 bound to the 5' and 3' terminal sequences of SRP RNA. It retards the ribosomal elongation of signal-peptide-containing proteins before their engagement with the translocation machinery in the endoplasmic reticulum. Here we report two crystal structures of the heterodimer SRP9/14 bound either to the 5' domain or to a construct containing both 5' and 3' domains. We present a model of the complete Alu domain that is consistent with extensive biochemical data. SRP9/14 binds strongly to the conserved core of the 5' domain, which forms a U-turn connecting two helical stacks. Reversible docking of the more weakly bound 3' domain might be functionally important in the mechanism of translational regulation. The Alu domain structure is probably conserved in other cytoplasmic ribonucleoprotein particles and retroposition intermediates containing SRP9/14-bound RNAs transcribed from Alu repeats or related elements in genomic DNA.	European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France; Univ Geneva, Dept Biol Cellulaire, CH-1211 Geneva, Switzerland	European Molecular Biology Laboratory (EMBL); University of Geneva	Cusack, S (corresponding author), European Mol Biol Lab, Grenoble Outstn, BP 156X, F-38042 Grenoble 9, France.			Weichenrieder, Oliver/0000-0001-5818-6248; Cusack, Stephen/0000-0002-9324-0796				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; Birse DEA, 1997, EMBO J, V16, P3757, DOI 10.1093/emboj/16.13.3757; Bovia F, 1997, NUCLEIC ACIDS RES, V25, P318, DOI 10.1093/nar/25.2.318; BOVIA F, 1995, MOL BIOL CELL, V6, P471, DOI 10.1091/mbc.6.4.471; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chang DY, 1997, NUCLEIC ACIDS RES, V25, P1117, DOI 10.1093/nar/25.6.1117; Chang DY, 1996, NUCLEIC ACIDS RES, V24, P4165, DOI 10.1093/nar/24.21.4165; Chen YH, 1998, J BIOL CHEM, V273, P35023, DOI 10.1074/jbc.273.52.35023; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Cusack S, 1998, NAT STRUCT BIOL, V5, P634, DOI 10.1038/1325; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Emde G, 1997, RNA, V3, P538; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; GUNDELFINGER ED, 1983, NUCLEIC ACIDS RES, V11, P7363, DOI 10.1093/nar/11.21.7363; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; Kremerskothen J, 1998, NEUROSCI LETT, V245, P123, DOI 10.1016/S0304-3940(98)00215-8; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Nakamura K, 1999, J BIOL CHEM, V274, P13569, DOI 10.1074/jbc.274.19.13569; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RAPOPORT TA, 1987, J MOL BIOL, V195, P621, DOI 10.1016/0022-2836(87)90186-0; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1986, NATURE, V320, P81, DOI 10.1038/320081a0; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; STRUB K, 1990, MOL CELL BIOL, V10, P777, DOI 10.1128/MCB.10.2.777; STRUB K, 1989, P NATL ACAD SCI USA, V86, P9747, DOI 10.1073/pnas.86.24.9747; Strub K, 1999, RNA, V5, P1333, DOI 10.1017/S1355838299991045; STRUB K, 1991, MOL CELL BIOL, V11, P3949, DOI 10.1128/MCB.11.8.3949; Thomas Y, 1997, NUCLEIC ACIDS RES, V25, P1920, DOI 10.1093/nar/25.10.1920; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; Weichenrieder O, 1997, RNA, V3, P1262; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Zwieb C, 1996, FOLD DES, V1, P315, DOI 10.1016/S1359-0278(96)00044-2	47	138	144	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					167	173		10.1038/35041507	http://dx.doi.org/10.1038/35041507			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089964	Green Published			2022-12-28	WOS:000165180400036
J	Hauer, KE; Winawer, N				Hauer, KE; Winawer, N			Update in hospital medicine	ANNALS OF INTERNAL MEDICINE			English	Review							ELDERLY PATIENTS; CARE; QUALITY		Univ Calif San Francisco, San Francisco, CA 94143 USA; Emory Univ, Atlanta, GA 30322 USA	University of California System; University of California San Francisco; Emory University	Hauer, KE (corresponding author), Univ Calif San Francisco, Box 0320,400 Parnassus Ave, San Francisco, CA 94143 USA.	karenha@itsa.ucsf.edu						CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Ely EW, 1999, ANN INTERN MED, V131, P96, DOI 10.7326/0003-4819-131-2-199907200-00004; Jensen AG, 1999, ARCH INTERN MED, V159, P1437, DOI 10.1001/archinte.159.13.1437; Lurie JD, 1999, AM J MED, V106, P441, DOI 10.1016/S0002-9343(99)00045-5; Navasa M, 1997, Semin Gastrointest Dis, V8, P200; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; RUNYON BA, 1994, NEW ENGL J MED, V330, P337, DOI 10.1056/NEJM199402033300508; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713	12	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					707	713		10.7326/0003-4819-133-9-200011070-00013	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074904				2022-12-28	WOS:000165075300006
J	Calverley, PMA				Calverley, PMA			Oxygen-induced hypercapnia revisited	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; ACUTE RESPIRATORY-FAILURE; VENTILATION		Aintree Univ Hosp NHS Fdn Trust, Dept Med, Liverpool L9 7AL, Merseyside, England	Aintree University Hospitals NHS Foundation Trust; University of Liverpool	Calverley, PMA (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Dept Med, Liverpool L9 7AL, Merseyside, England.							AUBIER M, 1980, AM REV RESPIR DIS, V122, P747, DOI 10.1164/arrd.1980.122.5.747; BAZUAYE EA, 1992, THORAX, V47, P609, DOI 10.1136/thx.47.8.609; BONE RC, 1978, AM J MED, V65, P896, DOI 10.1016/0002-9343(78)90740-4; CAMPBELL EJ, 1967, AM REV RESPIR DIS, V96, P626; COSTELLO RW, 1995, THORAX, V50, P405, DOI 10.1136/thx.50.4.405; Dick CR, 1997, AM J RESP CRIT CARE, V155, P609, DOI 10.1164/ajrccm.155.2.9032202; DONALD K, 1949, LANCET, V257, P1056; DUNN WF, 1991, AM REV RESPIR DIS, V144, P526, DOI 10.1164/ajrccm/144.3_Pt_1.526; Gorini M, 1996, THORAX, V51, P677, DOI 10.1136/thx.51.7.677; LOPEZMAJ.V, 1973, AM REV RESPIR DIS, V108, P232; MCNICOL MW, 1965, LANCET, V1, P336; Plant PK, 2000, THORAX, V55, P550, DOI 10.1136/thorax.55.7.550; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Robinson TD, 2000, AM J RESP CRIT CARE, V161, P1524, DOI 10.1164/ajrccm.161.5.9904119	14	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1538	1539		10.1016/S0140-6736(00)03119-6	http://dx.doi.org/10.1016/S0140-6736(00)03119-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075762				2022-12-28	WOS:000165134500004
J	Gittins, DI; Bethell, D; Schiffrin, DJ; Nichols, RJ				Gittins, DI; Bethell, D; Schiffrin, DJ; Nichols, RJ			A nanometre-scale electronic switch consisting of a metal cluster and redox-addressable groups	NATURE			English	Article							SCANNING-TUNNELING-MICROSCOPY; MONOLAYERS; CONDUCTION; ENSEMBLES; MOLECULES	So-called bottom-up fabrication methods aim to assemble and integrate molecular components exhibiting specific functions into electronic devices that are orders of magnitude smaller than can be fabricated by lithographic techniques. Fundamental to the success of the bottom-up approach is the ability to control electron transport across molecular components. Organic molecules containing redox centres-chemical species whose oxidation number, and hence electronic structure, can be changed reversibly-support resonant tunnelling(1,2) and display promising functional behaviour when sandwiched as molecular layers between electrical contacts(3,4), but their integration into more complex assemblies remains challenging. For this reason, functionalized metal nanoparticles have attracted much interest(5-7): they exhibit single-electron characteristics(8-10) (such as quantized capacitance charging) and can be organized(11-13) through simple self-assembly methods into well ordered structures, with the nanoparticles at controlled locations. Here we report scanning tunnelling microscopy measurements showing that organic molecules containing redox centres can be used to attach metal nanoparticles to electrode surfaces and so control the electron transport between them. Our system consists of gold nanoclusters a few nanometres across and functionalized with polymethylene chains that carry a central, reversibly reducible bipyridinium moiety(14,15). We expect that the ability to electronically contact metal nanoparticles via redox-active molecules, and to alter profoundly their tunnelling properties by charge injection into these molecules, can form the basis for a range of nanoscale electronic switches.	Univ Liverpool, Dept Chem, Ctr Nanoscale Sci, Liverpool L69 7ZD, Merseyside, England	University of Liverpool	Nichols, RJ (corresponding author), Univ Liverpool, Dept Chem, Ctr Nanoscale Sci, Liverpool L69 7ZD, Merseyside, England.		Nichols, Richard/H-2157-2015	Nichols, Richard/0000-0002-1446-8275				Andres RP, 1996, SCIENCE, V272, P1323, DOI 10.1126/science.272.5266.1323; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Bethell D, 1996, J ELECTROANAL CHEM, V409, P137, DOI 10.1016/0022-0728(96)04533-0; BRUST M, 1995, ADV MATER, V7, P795, DOI 10.1002/adma.19950070907; Chen C. J., 1993, INTRO SCANNING TUNNE; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Chen SW, 1999, J PHYS CHEM B, V103, P9996, DOI 10.1021/jp992681u; Collier CP, 1997, SCIENCE, V277, P1978, DOI 10.1126/science.277.5334.1978; DELONG HC, 1992, LANGMUIR, V8, P2491, DOI 10.1021/la00046a023; Feldheim DL, 1998, CHEM SOC REV, V27, P1; Friis EP, 1999, P NATL ACAD SCI USA, V96, P1379, DOI 10.1073/pnas.96.4.1379; Gittins DI, 1999, ADV MATER, V11, P737, DOI 10.1002/(SICI)1521-4095(199906)11:9<737::AID-ADMA737>3.0.CO;2-1; Gittins DI, 2000, J MATER CHEM, V10, P79, DOI 10.1039/a902960e; Han WH, 1997, J PHYS CHEM B, V101, P10719, DOI 10.1021/jp972510u; Ingram RS, 1997, J AM CHEM SOC, V119, P9279, DOI 10.1021/ja972319y; JOACHIM C, 1995, PHYS REV LETT, V74, P2102, DOI 10.1103/PhysRevLett.74.2102; Kiely CJ, 1998, NATURE, V396, P444, DOI 10.1038/24808; Oosterkamp TH, 1998, NATURE, V395, P873, DOI 10.1038/27617; Schmid G., 1994, CLUSTERS COLLOIDS; Tao NJ, 1996, PHYS REV LETT, V76, P4066, DOI 10.1103/PhysRevLett.76.4066; Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664; Ulman A., 1991, INTRO ULTRATHIN ORGA; VAUGHT A, 1995, CHEM PHYS LETT, V236, P306, DOI 10.1016/0009-2614(95)00223-Q; Yazdani A, 1996, SCIENCE, V272, P1921, DOI 10.1126/science.272.5270.1921	24	703	724	1	160	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					67	69		10.1038/35040518	http://dx.doi.org/10.1038/35040518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081506				2022-12-28	WOS:000165050400050
J	Becker, KM; Moe, CL; Southwick, KL; MacCormack, JN				Becker, KM; Moe, CL; Southwick, KL; MacCormack, JN			Transmission of norwalk virus during a football game.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVERSE TRANSCRIPTION-PCR; VIRAL GASTROENTERITIS; OUTBREAKS; SPECIMENS	Background: During a college football game in Florida, diarrhea and vomiting developed in many of the members of a North Carolina team. The next day, similar symptoms developed in some of the players on the opposing team. Methods: We interviewed those who ate the five meals served to the North Carolina team before the game and some of the players on the opposing team who became ill. Patients with primary cases were members or staff of the team who had vomiting or diarrhea at least 10 hours after but no more than 50 hours after eating a box lunch served the day before the game. Patients with secondary cases had a later onset of symptoms or had symptoms without having eaten the box lunch. Stool samples were examined by electron microscopy and by a reverse-transcription-polymerase-chain-reaction (RT-PCR) assay. Results: The two football teams shared no food or beverages and had no contact off the playing field. Of five meals served to the North Carolina team before the game, only the box lunch was associated with a significant risk of illness (relative risk of illness, 4.1; 95 percent confidence interval, 1.6 to 10.0). The rate of attack among those who ate the box lunch was 62 percent. There were 11 secondary cases among the members and staff of the North Carolina team and 11 such cases among the Florida players. All four stool samples obtained from North Carolina patients were positive for Norwalk-like virus on electron microscopy. All four samples as well as one of two stool samples from players on the Florida team were positive for a Norwalk-like virus of genogroup I on RT-PCR assay; the RT-PCR products had identical sequences. Conclusions: This investigation documents person-to-person transmission of Norwalk virus among players during a football game. Persons with acute gastroenteritis should be excluded from playing contact sports.	Dept Hlth & Human Serv, Off Int & Refugee Hlth, Rockville, MD 20857 USA; Ctr Dis Control & Prevent, Epidemiol Intelligence Serv, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; Univ N Carolina, Chapel Hill, NC USA; N Carolina Dept Hlth & Human Serv, Raleigh, NC USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill	Becker, KM (corresponding author), Dept Hlth & Human Serv, Off Int & Refugee Hlth, Rm 18-105,Parklawn Bldg,5600 Fischers Ln, Rockville, MD 20857 USA.	kbecker@osophs.dhhs.gov	Moe, Christine L/G-6118-2012					ANDO T, 1995, J CLIN MICROBIOL, V33, P64, DOI 10.1128/JCM.33.1.64-71.1995; [Anonymous], 1995, CONTROL COMMUNICABLE; Daniels NA, 2000, J INFECT DIS, V181, P1467, DOI 10.1086/315365; DEAN A, 1995, EPI INFO VERSION 6 W; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; GELLERT GA, 1990, INFECT CONT HOSP EP, V11, P459; GOODMAN RA, 1994, JAMA-J AM MED ASSOC, V271, P862, DOI 10.1001/jama.271.11.862; GREENBERG HB, 1979, LANCET, V1, P55; GRIFFIN MR, 1982, AM J EPIDEMIOL, V115, P178, DOI 10.1093/oxfordjournals.aje.a113289; HO MS, 1989, LANCET, V2, P961; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V1, P783; MILLER SE, 1986, J ELECTRON MICR TECH, V4, P265, DOI 10.1002/jemt.1060040305; MOE C, 1998, 98 ANN M AM SOC MICR, P15; MOE CL, 1994, J CLIN MICROBIOL, V32, P642, DOI 10.1128/JCM.32.3.642-648.1994; MONROE SS, 1993, J CLIN MICROBIOL, V31, P2866, DOI 10.1128/JCM.31.11.2866-2872.1993; REMINGTON JS, 1981, NEW ENGL J MED, V304, P433, DOI 10.1056/NEJM198102123040730; Schwab KJ, 1997, J CLIN MICROBIOL, V35, P511, DOI 10.1128/JCM.35.2.511-514.1997; TAYLOR JW, 1981, AM J EPIDEMIOL, V114, P584, DOI 10.1093/oxfordjournals.aje.a113224; XI J, 1992, J CLIN MICROBIOL, V30, P2529, DOI 10.1128/JCM.30.10.2529-2534.1992; XI JA, 1990, SCIENCE, V250, P1580, DOI 10.1126/science.2177224; 1987, MMWR MORB MORTAL WKL, V36, P709	22	81	87	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1223	1227		10.1056/NEJM200010263431704	http://dx.doi.org/10.1056/NEJM200010263431704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071673	Bronze			2022-12-28	WOS:000090014100004
J	Cheetham, MJ; Mortensen, NJM; Nystrom, PO; Kamm, MA; Phillips, RKS				Cheetham, MJ; Mortensen, NJM; Nystrom, PO; Kamm, MA; Phillips, RKS			Persistent pain and faecal urgency after stapled haemorrhoidectomy	LANCET			English	Article							DAY-CASE HEMORRHOIDECTOMY; RANDOMIZED CONTROLLED TRIAL	Introduction Haemorrhoidectomy usually cures haemorrhoids. Day surgery is feasible, and is associated with high patients' satisfaction and few complications, but patients take an average of 2 weeks off work after surgery. Stapled haemorrhoidectomy has the potential to decrease postoperative pain and time off work. However, data on longterm efficacy and function are lacking. Methods 22 patients underwent stapled haemorrhoidectomy: seven in a pilot study, and 15 in a randomised controlled trial to compare the new stapled operation with diathermy haemorrhoidectomy in a day-case setting. All operations were done by one consultant surgeon. Results 16 patients were followed up for longer than 6 months, five of whom (31% [95% CI 8.5-54.0%]) developed symptoms of pain and faecal urgency which persisted for up to 15 months postoperatively. The randomised trial was suspended, and patients were investigated with endoanal ultrasonography, anorectal physiology, and examination under anaesthetic. All five affected patients were reviewed by two independent surgeons experienced in the stapled operation. In one patient, a fibroepithelial polyp was found adjacent to an anodermal ulcer; in the other patients, no abnormality was found. Four of the five affected patients had some muscle incorporated into the doughnut, compared with only one of 11 of the unaffected patients (p=0.012, Fisher's exact test). No other significant differences in operative variables were identified between patients with and without symptoms, Interpretation Persistent severe pain and faecal urgency has been found in a disturbingly high proportion of patients after stapled haemorrhoidectomy. The mechanism behind this phenomenon is unclear, although muscle incorporation in the doughnut may have a role, Other groups who have studied stapled haemorrhoidectomy urgently need to audit their long-term results to assess the frequency of this problem.	St Marks Hosp, Dept Surg, Harrow HA1 3UJ, Middx, England; St Marks Hosp, Dept Physiol, Harrow HA1 3UJ, Middx, England; John Radcliffe Hosp, Dept Colorectal Surg, Oxford OX3 9DU, England; Linkoping Univ Hosp, Dept Surg, S-58185 Linkoping, Sweden	Imperial College London; Imperial College London; University of Oxford; Linkoping University	Phillips, RKS (corresponding author), St Marks Hosp, Dept Surg, Harrow HA1 3UJ, Middx, England.	gun@icrf.icnet.uk	Cheetham, Mark/H-9923-2019	Cheetham, Mark/0000-0003-2302-7014				Carapeti EA, 1998, LANCET, V351, P169, DOI 10.1016/S0140-6736(97)09003-X; Carapeti EA, 1999, BRIT J SURG, V86, P612, DOI 10.1046/j.1365-2168.1999.01127.x; Ho YH, 1998, AUST NZ J SURG, V68, P334, DOI 10.1111/j.1445-2197.1998.tb04766.x; Hunt L, 1999, BRIT J SURG, V86, P255, DOI 10.1046/j.1365-2168.1999.01024.x; LONDON NJM, 1987, BRIT MED J, V295, P363, DOI 10.1136/bmj.295.6594.363; Longo A, 1998, 6TH WORLD CONGRESS OF ENDOSCOPIC SURGERY, PTS 1 AND 2, P777; MACRAE HM, 1995, DIS COLON RECTUM, V38, P687, DOI 10.1007/BF02048023; Mehigan BJ, 2000, LANCET, V355, P782, DOI 10.1016/S0140-6736(99)08362-2; Rowsell M, 2000, LANCET, V355, P779, DOI 10.1016/S0140-6736(99)06122-X; SPEAKMAN CTM, 1991, BRIT J SURG, V78, P1429, DOI 10.1002/bjs.1800781206	10	241	253	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	2000	356	9231					730	733		10.1016/S0140-6736(00)02632-5	http://dx.doi.org/10.1016/S0140-6736(00)02632-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085693				2022-12-28	WOS:000088948200013
J	Su, Y; Swift, M				Su, Y; Swift, M			Mortality rates among carriers of ataxia-telangiectasia mutant alleles	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER-SUSCEPTIBILITY; ATM GENE; EARLY-ONSET; CELL-CYCLE; MUTATIONS; HETEROZYGOTES; FAMILIES; RISK; PHENOTYPES; DEATH	Background: Mutations at the ataxia-telangiectasia locus cause a distinctive autosomal recessive syndrome in homozygotes and predispose heterozygotes to cancer and ischemic heart disease. Objective: To examine mortality rates among persons carrying a mutated ataxia-telangiectasia gene. Design: Retrospective cohort study. Setting: The United States and Canada. Participants: 405 grandparents of patients with ataxia-telangiectasia. Measurements: Ages at death and risk for death (from all causes, cancer, ischemic heart disease, and other causes) among carriers and noncarriers of ataxia-telangiectasia mutations. Results: Compared with noncarriers, carriers of a mutated ataxia-telangiectasia allele had a significantly increased risk for death at 20 through 79 years of age (relative risk, 1.9 [95% CI, 1.3 to 2.8]) (P < 0.001). On average, carriers died 7 to 8 years earlier than noncarriers. Cancer caused most of the excess deaths, and ischemic heart disease caused the remainder. Among carriers, relative risk for death from cancer and ischemic heart disease before 80 years of age was 2.6 (CI, 1.4 to 4.7; P = 0.002) and 2.0 (CI, 1.0 to 4.0; P = 0.062), respectively. Compared with noncarriers, carriers who died of cancer were a mean of 4 years younger (P > 0.2) and carriers who died of ischemic heart disease were a mean of 11 years younger (P = 0.006). Conclusion: Carriers of mutations at the ataxia-telangiectasia locus, who make up 1.4% to 2% of the general population, have a higher mortality rate and an earlier age at death from cancer and ischemic heart disease than noncarriers.	New York Med Coll, Inst Genet Anal Common Dis, Hawthorne, NY 10532 USA	New York Medical College	Su, Y (corresponding author), New York Med Coll, Inst Genet Anal Common Dis, 4 Skyline Dr, Hawthorne, NY 10532 USA.				NCI NIH HHS [CA 14235] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014235] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON PD, 1995, SURVIVAL ANAL USING, P192; Allison PD, 1995, SURVIVAL ANAL USING, P155; Athma P, 1996, CANCER GENET CYTOGEN, V92, P130, DOI 10.1016/S0165-4608(96)00328-7; Bebb DG, 1999, BRIT J CANCER, V80, P1979, DOI 10.1038/sj.bjc.6690630; Bishop DT, 1997, NAT GENET, V15, P226, DOI 10.1038/ng0397-226; BORRESEN AL, 1990, GENE CHROMOSOME CANC, V2, P339, DOI 10.1002/gcc.2870020412; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Buzin CH, 2000, BIOTECHNIQUES, V28, P746, DOI 10.2144/00284rr04; Chen JD, 1998, CANCER RES, V58, P1376; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; CONCANNON P, 2000, ATAXIA TELANGIECTASI; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COX DR, 1972, J R STAT SOC B, V34, P187; DORK T, 1999, AM J HUM GENET, V65, pA14; DORK T, 1999, 8 INT WORKSH AT TEL; Ederer F, 1999, J CLIN EPIDEMIOL, V52, P447, DOI 10.1016/S0895-4356(99)00016-5; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; HANSEN ES, 1990, MUTAT RES, V239, P163, DOI 10.1016/0165-1110(90)90004-U; Inskip HM, 1999, BRIT J CANCER, V79, P1304, DOI 10.1038/sj.bjc.6690209; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Janin N, 1999, BRIT J CANCER, V80, P1042, DOI 10.1038/sj.bjc.6690460; Kalbfleisch J, 1980, STAT ANAL FAILURE TI, P168; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P122; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P189; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEY JL, 1986, METHODS OBSERVATIONA; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Klopper Karin, 2000, European Journal of Human Genetics, V8, P109; Larson GP, 1997, GENET TEST, V1, P165, DOI 10.1089/gte.1997.1.165; Li AR, 2000, AM J MED GENET, V92, P170, DOI 10.1002/(SICI)1096-8628(20000529)92:3<170::AID-AJMG3>3.0.CO;2-#; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; McConville CM, 1996, AM J HUM GENET, V59, P320; MEHTA CR, 1994, BIOMETRICS, V50, P1042, DOI 10.2307/2533442; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MORRELL D, 1990, CANCER GENET CYTOGEN, V50, P119, DOI 10.1016/0165-4608(90)90245-6; MORRELL D, 1986, J NATL CANCER I, V77, P89; NAKAMURA T, 1992, BIOMETRICS, V48, P829, DOI 10.2307/2532348; Nakamura Y, 1998, NAT MED, V4, P1231, DOI 10.1038/3207; Nasrin N, 1997, ARTERIOSCL THROM VAS, V17, P947, DOI 10.1161/01.ATV.17.5.947; PIPPARD EC, 1988, CANCER RES, V48, P2929; Sambrook J, 1989, MOL CLONING LABORATO, p1 25; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1983, LANCET, V1, P1049; SWIFT M, 1993, ADV NEUROL, V61, P115; SWIFT M, 1990, CANCER GENET CYTOGEN, V46, P21, DOI 10.1016/0165-4608(90)90004-T; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Telatar M, 1998, AM J HUM GENET, V62, P86, DOI 10.1086/301673; TERAOKA SN, 1999, 8 INT WORKSH AT TEL; Vorechovsky I, 1996, CANCER RES, V56, P2726	57	114	116	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					770	778		10.7326/0003-4819-133-10-200011210-00009	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085839				2022-12-28	WOS:000165321200002
J	Whitcomb, ME; Walter, DL				Whitcomb, ME; Walter, DL			Research training in six selected internal medicine fellowship programs	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Effective July 1997, the American Board of Internal Medicine (ABIM) established a research pathway to certification to encourage research training of general intemists and subspecialists. Objective: To document the current status of research training in six selected subspecialty programs, to examine opportunities available for trainees to undertake formal course work, and to report the percentage of subspecialty programs that might accept research pathway fellows. Design: National Study of Graduate Education in Internal Medicine questionnaires from 1996-1997 and 1997-1998. Setting: Programs in internal medicine subspecialties accredited by the Accreditation Council for Graduate Medical Education. Participants: 1163 (84%) and 1094 (79%) directors of internal medicine subspecialty programs in 1996-1997 and 1997-1998, respectively. Measurements: survey questions on the amount of time fellows usually spend conducting research and available opportunities to pursue course work leading to an advanced degree. Results: On average, during their last year of training, fellows enrolled in infectious disease, nephrology, endocrinology, and rheumatology programs spent 40% to 50% of their time conducting research, whereas fellows in gastroenterology and cardiology spent 25% to 30% of their time conducting research. Compared with programs sponsored by major teaching hospitals, a greater percentage of programs sponsored by academic medical center hospitals planned to accept persons interested in pursuing the new ABIM Research Pathway (28% vs. 8%) and to provide opportunities for fellows to obtain an advanced degree (60% vs. 14%). Conclusions: Few internal medicine subspecialty programs are currently designed to provide adequate research training as defined by the Institute of Medicine and the ABIM.	Medicare Payment Advisory Commiss, Washington, DC 20006 USA; Assoc Amer Med Coll, Washington, DC USA	Association of American Medical Colleges	Walter, DL (corresponding author), Medicare Payment Advisory Commiss, 1730 K St NW,Suite 800, Washington, DC 20006 USA.	dwalter@medpac.gov						*ABIM RES PATHW, 1997, GUID INT MED SUBSP P; Langdon LO, 1996, ANN INTERN MED, V124, P686, DOI 10.7326/0003-4819-124-7-199604010-00011; LEVEY GS, 1988, ANN INTERN MED, V109, P414, DOI 10.7326/0003-4819-109-5-414; Neilson EG, 1995, J INVEST MED, V43, P534; *NIH OFF SCI POL O, 1996, MED SCH FAC LAB FORC; [No title captured]	6	22	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					800	807		10.7326/0003-4819-133-10-200011210-00013	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085843				2022-12-28	WOS:000165321200006
J	Tlusty, T; Safran, SA				Tlusty, T; Safran, SA			Defect-induced phase separation in dipolar fluids	SCIENCE			English	Article							HARD-SPHERES; ELECTRORHEOLOGICAL FLUIDS; MAGNETIC FLUIDS; LIQUID; COEXISTENCE; NETWORKS	A defect-induced, critical phase separation in dipolar fluids is predicted, which replaces the usual Liquid-gas transition that is driven by the isotropic aggregation of particles and is absent in dipolar fluids due to strong chaining. The coexisting phases are a dilute gas of chain ends that coexists with a high-density Liquid of chain branching points. Our model provides a unified explanation for the branched structures, the unusually Low critical temperature and density, and the consequent two-phase coexistence "islands" that were recently observed in experiment and simulation.	Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Tlusty, T (corresponding author), Weizmann Inst Sci, Dept Mat & Interfaces, IL-76100 Rehovot, Israel.		Tlusty, Tsvi/A-9880-2008; Safran, Samuel/K-1504-2012	Tlusty, Tsvi/0000-0002-9662-3725; Safran, Samuel/0000-0002-0798-1492				Banerjee S, 1998, J STAT PHYS, V93, P109, DOI 10.1023/B:JOSS.0000026729.83187.79; Bernheim-Groswasser A, 1999, LANGMUIR, V15, P5448, DOI 10.1021/la990301q; Camp PJ, 2000, PHYS REV LETT, V84, P115, DOI 10.1103/PhysRevLett.84.115; de Gennes P.-G., 1979, SCALING CONCEPTS POL; DEGENNES PG, 1970, PHYS KONDENS MATER, V11, P189; DRYE TJ, 1992, J CHEM PHYS, V96, P1367, DOI 10.1063/1.462172; Dubois E, 1999, J CHEM PHYS, V111, P7147, DOI 10.1063/1.480007; GAST AP, 1989, ADV COLLOID INTERFAC, V30, P153, DOI 10.1016/0001-8686(89)80006-5; HALSEY TC, 1992, SCIENCE, V258, P761, DOI 10.1126/science.258.5083.761; LEVESQUE D, 1994, PHYS REV E, V49, P5131, DOI 10.1103/PhysRevE.49.5131; Levin Y, 1999, PHYS REV LETT, V83, P1159, DOI 10.1103/PhysRevLett.83.1159; McGrother SC, 1996, PHYS REV LETT, V76, P4183, DOI 10.1103/PhysRevLett.76.4183; Rosensweig RE, 1996, SCIENCE, V271, P614, DOI 10.1126/science.271.5249.614; SANO K, 1983, J PHYS SOC JPN, V52, P2810, DOI 10.1143/JPSJ.52.2810; Sear RP, 1996, PHYS REV LETT, V76, P2310, DOI 10.1103/PhysRevLett.76.2310; Shelley JC, 1999, PHYS REV E, V59, P3065, DOI 10.1103/PhysRevE.59.3065; STEVENS MJ, 1994, PHYS REV LETT, V72, P3686, DOI 10.1103/PhysRevLett.72.3686; Tavares JM, 1999, PHYS REV E, V59, P4388, DOI 10.1103/PhysRevE.59.4388; Tlusty T, 1997, PHYS REV LETT, V78, P2616, DOI 10.1103/PhysRevLett.78.2616; Tlusty T, 2000, PHYS REV LETT, V84, P1244, DOI 10.1103/PhysRevLett.84.1244; VANLEEUWEN ME, 1993, PHYS REV LETT, V71, P3991, DOI 10.1103/PhysRevLett.71.3991; vanRoij R, 1996, PHYS REV LETT, V76, P3348, DOI 10.1103/PhysRevLett.76.3348; WHEELER JC, 1981, J CHEM PHYS, V74, P6415, DOI 10.1063/1.440980	23	277	281	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1328	1331		10.1126/science.290.5495.1328	http://dx.doi.org/10.1126/science.290.5495.1328			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082055				2022-12-28	WOS:000165379800041
J	Lawlor, PG; Fainsinger, RL; Bruera, ED				Lawlor, PG; Fainsinger, RL; Bruera, ED			Delirium at the end of life - Critical issues in clinical practice and research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ELDERLY HOSPITALIZED-PATIENTS; ILL CANCER-PATIENTS; COGNITIVE FAILURE; PREDICTIVE MODEL; MEDICAL PATIENTS; DIAGNOSIS; SUBTYPES; PAIN		Grey Nuns Community Hlth Ctr & Hosp, Edmonton Reg Palliat Care Program, Edmonton, AB T6L 5X8, Canada; Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Texas, Dept Symptom Control & Palliat Care, Houston, TX 77030 USA	University of Alberta; University of Texas System; UTMD Anderson Cancer Center; University of Texas System	Lawlor, PG (corresponding author), Grey Nuns Community Hlth Ctr & Hosp, Edmonton Reg Palliat Care Program, Room 5211,1100 Youville Dr W, Edmonton, AB T6L 5X8, Canada.	plawlor@gpu.srv.ualberta.ca	Bruera, Eduardo/AAA-1550-2022					AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P123; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Breitbart W., 1998, OXFORD TXB PALLIATIV, P933; Bruera E, 1990, J Pain Symptom Manage, V5, P218, DOI 10.1016/0885-3924(90)90014-B; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P192, DOI 10.1016/0885-3924(92)90074-R; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P267, DOI 10.1016/0885-3924(92)90060-U; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P348, DOI 10.1016/0885-3924(95)00052-Z; Cole MG, 1998, J GERIATR PSYCH NEUR, V11, P126, DOI 10.1177/089198879801100303; Fainsinger R, 1991, J Palliat Care, V7, P5; Fainsinger R L, 1993, J Palliat Care, V9, P4; FAINSINGER RL, 2000, TOPICS PALLIATIVE CA, V4, P261; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1994, AM J MED, V97, P278, DOI 10.1016/0002-9343(94)90011-6; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Lawlor PG, 2000, CANCER, V88, P2859, DOI 10.1002/1097-0142(20000615)88:12<2859::AID-CNCR29>3.3.CO;2-K; Lawlor PG, 2000, ARCH INTERN MED, V160, P786, DOI 10.1001/archinte.160.6.786; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LEVKOFF SE, 1988, J AM GERIATR SOC, V36, P1099, DOI 10.1111/j.1532-5415.1988.tb04396.x; LIPOWSKI ZJ, 1987, JAMA-J AM MED ASSOC, V258, P1789, DOI 10.1001/jama.258.13.1789; LIPTZIN B, 1992, BRIT J PSYCHIAT, V161, P843, DOI 10.1192/bjp.161.6.843; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; Meagher DJ, 1996, BRIT J PSYCHIAT, V168, P512, DOI 10.1192/bjp.168.4.512; Minagawa H, 1996, CANCER, V78, P1131, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1131::AID-CNCR26>3.0.CO;2-2; Morrison RS, 2000, JAMA-J AM MED ASSOC, V284, P47, DOI 10.1001/jama.284.1.47; O'Keeffe ST, 1999, AGE AGEING, V28, P115, DOI 10.1093/ageing/28.2.115; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; Walker P, 1997, ANN ONCOL, V8, P915, DOI 10.1023/A:1008274608267	32	53	53	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2427	2429		10.1001/jama.284.19.2427	http://dx.doi.org/10.1001/jama.284.19.2427			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074759				2022-12-28	WOS:000165183800002
J	Rebagliato, M; Cuttini, M; Broggin, L; Berbik, I; de Vonderweid, U; Hansen, G; Kaminski, M; Kollee, LAA; Kucinskas, A; Lenoir, S; Levin, A; Persson, J; Reid, M; Saracci, R				Rebagliato, M; Cuttini, M; Broggin, L; Berbik, I; de Vonderweid, U; Hansen, G; Kaminski, M; Kollee, LAA; Kucinskas, A; Lenoir, S; Levin, A; Persson, J; Reid, M; Saracci, R		EURONIC Study Grp	Neonatal end-of-life decision making - Physicians' attitudes and relationship with self-reported practices in 10 European countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTREMELY PREMATURE NEWBORNS; INTENSIVE-CARE; ETHICAL DECISIONS; DANISH PHYSICIANS; MORTALITY; SUPPORT; NURSERY; UNITS	Context The ethical issues surrounding end-of-life decision making for infants with adverse prognoses are controversial. Little empirical evidence is available on the attitudes and values that underlie such decisions in different countries and cultures. Objective To explore the variability of neonatal physicians' attitudes among 10 European countries and the relationship between such attitudes and self-reported practice of end-of-life decisions. Design and Setting Survey conducted during 1996-1997 in 10 European countries (France, Germany, Italy, the Netherlands, Spain, Sweden, the United Kingdom, Estonia, Hungary, and Lithuania). Participants A total of 1391 physicians (response rate, 89%) regularly employed in 142 neonatal intensive care units (NICUs). Main Outcome Measures Scores on an attitude scale, which measured views regarding absolute value of life (score of 0) vs value of quality of life (score of 10); self-report of having ever set limits to intensive neonatal interventions in cases of poor neurological prognosis. Results Physicians more likely to agree with statements consistent with preserving life at any cost were from Hungary (mean attitude scores, 5.2 [95% confidence interval {CI}, 4.9-5.5]), Estonia (4.9 [95% CI, 4.3-5.5]), Lithuania (5.5 [95% CI, 4.8-6.1]), and Italy (5.7 [95% CI, 5.3-6.0]), while physicians more likely to agree with the idea that quality of life must be taken into account were from the United Kingdom (attitude scores, 7.4 [95% CI, 7.1-7.7]), the Netherlands (7.3 [95% CI, 7.1-7.5]), and Sweden (6.8 [95% CI, 6.4-7.3]). Other factors associated with having a pro-quality-of-life view were being female, having had no children, being Protestant or having no religious background, considering religion as not important, and working in an NICU with a high number of very low-birth-weight newborns. Physicians with scores reflecting a more quality-of-life view were more likely to report that in their practice, they had set limits to intensive interventions in cases of poor neurological prognosis, with an adjusted odds ratio of 1.5 (95% CI, 1.3-1.7) per unit change in attitude score. Conclusions In our study, physicians' likelihood of reporting setting limits to intensive neonatal interventions in cases of poor neurological prognosis is related to their attitudes. After adjusting for potential confounders, country remained the most important predictor of physicians' attitudes and practices.	Miguel Hernandez Univ, Dept Publ Hlth, Alicante 03550, Spain; Burlo Garofolo Childrens Hosp, Epidemiol Unit, Trieste, Italy; Burlo Garofolo Childrens Hosp, Neonatal Intens Care Unit, Trieste, Italy; Natl Res Council, IFC, Div Epidemiol, Pisa, Italy; Vaszary Kolos Hosp, Dept Obstet & Gynaecol, Tergoti, Hungary; Univ Halle Wittenberg, Dept Pediat, Halle, Germany; Inst Gustave Roussy, INSERM, U149, Epidemiol Res Unit Perinatal & Womens Hlth, F-94805 Villejuif, France; Fac Med Toulouse, INSERM, Unit Res Reprod, F-31073 Toulouse, France; Univ Nijmegen Hosp, Dept Neonatol, NL-6500 HB Nijmegen, Netherlands; Vilnius State Univ, Neonatal Clin, Vilnius, Lithuania; Tallinn Hosp, Newborn & Premature Childrens Dept, Tallinn, Estonia; Linkoping Univ, Ctr Med Technol Assessment, Linkoping, Sweden; Univ Glasgow, Dept Publ Hlth, Glasgow, Lanark, Scotland	Universidad Miguel Hernandez de Elche; IRCCS Burlo Garofolo; IRCCS Burlo Garofolo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Martin Luther University Halle Wittenberg; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Radboud University Nijmegen; Vilnius University; Linkoping University; University of Glasgow	Rebagliato, M (corresponding author), Miguel Hernandez Univ, Dept Publ Hlth, Campus San Juan,Ctra Valencia,Km 87, Alicante 03550, Spain.		Cuttini, Marina/AAI-1987-2019; Kollee, L.A.A./L-4443-2015; Rebagliato, Marisa/L-6116-2018	Cuttini, Marina/0000-0002-3284-6874; Rebagliato, Marisa/0000-0001-5825-0190				CANDEE D, 1982, PEDIATR RES, V16, P846, DOI 10.1203/00006450-198210000-00009; CHRISTAKIS NA, 1995, AM J PUBLIC HEALTH, V85, P367, DOI 10.2105/AJPH.85.3.367; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; Cuttini M, 1999, ARCH DIS CHILD-FETAL, V81, pF84, DOI 10.1136/fn.81.2.F84; Cuttini M, 1997, PAEDIATR PERINAT EP, V11, P461, DOI 10.1046/j.1365-3016.1997.d01-29.x; Davis Alison, 1994, P629; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; Garel M, 1997, ARCH PEDIATRIE, V4, P662, DOI 10.1016/S0929-693X(97)83370-2; GREELY HT, 1995, ETHICS PERINATOLOGY, P296; KOHRMAN A, 1994, PEDIATRICS, V93, P532; KOPELMAN LM, 1988, NEW ENGL J MED, V318, P677, DOI 10.1056/NEJM198803173181105; Kuhse H., 1985, SHOULD BABY LIVE PRO; LANTOS JD, 1994, ARCH DIS CHILD-FETAL, V71, pF218, DOI 10.1136/fn.71.3.F218; Lemeshow S, 1998, AM J EPIDEMIOL, V148, P298; LEVIN BW, 1990, SOC SCI MED, V30, P901, DOI 10.1016/0277-9536(90)90218-H; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; MCHAFFIE HE, 1996, LIFE DEATH DECISIONS; Norup M, 1998, ACTA PAEDIATR, V87, P896, DOI 10.1080/080352598750013707; Norup M, 1999, ACTA PAEDIATR, V88, P438, DOI 10.1080/08035259950169846; O'Shea TM, 1998, PEDIATRICS, V101, P642, DOI 10.1542/peds.101.4.642; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN; Payer L., 1988, MED CULTURE VARIETIE; PHILIP AGS, 1995, J PEDIATR-US, V126, P427, DOI 10.1016/S0022-3476(95)70463-9; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; RHODEN NK, 1986, HASTINGS CENT REP, V34, P42; RYAN CA, 1993, J PEDIATR-US, V123, P534, DOI 10.1016/S0022-3476(05)80946-1; Sanders M R, 1995, J Perinatol, V15, P494; SHELP EE, 1986, BORN DIE DECIDING FA; SILVERMAN WA, 1992, PEDIATRICS, V90, P971; *STAT CORP, 1999, STAT STAT SOFTW COMP; TODRES ID, 1977, PEDIATRICS, V60, P197; Tough SC, 2000, J PEDIATR-US, V136, P618, DOI 10.1067/mpd.2000.105132; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; 1999, CORRIERE SERA   0316; 2000, LANCET, V355, P79	39	168	169	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2451	2459		10.1001/jama.284.19.2451	http://dx.doi.org/10.1001/jama.284.19.2451			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074774	Bronze			2022-12-28	WOS:000165183800018
J	De Maeseneer, J; Blokland, I; Willems, S; Vander Stichele, R; Meersschaut, F				De Maeseneer, J; Blokland, I; Willems, S; Vander Stichele, R; Meersschaut, F			Wet combing versus traditional scalp inspection to detect head lice in schoolchildren: observational study	BRITISH MEDICAL JOURNAL			English	Article									Community Hlth Ctr Ledeberg, B-9050 Ledeberg, Belgium; State Univ Ghent Hosp, Heymans Inst Pharmacol, B-9000 Ghent, Belgium; State Univ Ghent, Dept Gen Practice & Primary Hlth Care, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	De Maeseneer, J (corresponding author), State Univ Ghent, Dept Gen Practice & Primary Hlth Care, 1K3 UZ, B-9000 Ghent, Belgium.		Stichele, Robert Vander/K-7203-2015; Willems, Sara/AAI-4851-2021; Willems, Sara/AFU-7707-2022	Stichele, Robert Vander/0000-0001-9118-9651; Willems, Sara/0000-0002-6349-7785				Abramson JH, 1988, MAKING SENSE DATA SE; BINGHAM P, 2000, IN PRESS PUBLIC HLTH; IBARRA J, 1994, ESTABLISHMENT BUG BU; Sackett DL, 1985, CLIN EPIDEMIOLOGY BA	4	41	44	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1187	1188		10.1136/bmj.321.7270.1187	http://dx.doi.org/10.1136/bmj.321.7270.1187			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073509	Green Published, Bronze			2022-12-28	WOS:000165357100026
J	Wong, JB; Koff, RS				Wong, JB; Koff, RS		Int Hepatitis Interventional Thera	Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C - A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							INTERFERON-ALPHA THERAPY; QUALITY-OF-LIFE; TERM FOLLOW-UP; PREVENT HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; COMPENSATED CIRRHOSIS; SAMPLING VARIABILITY; FIBROSIS PROGRESSION; PROGNOSTIC FACTORS; RANDOMIZED TRIAL	Background: Not all patients with histologically mild chronic hepatitis C progress to cirrhosis. Objective: To compare no antiviral treatment, periodic liver biopsy with subsequent antiviral treatment for moderate hepatitis or cirrhosis, and immediate antiviral therapy. Design: Cost-effectiveness analysis. Data Sources: Clinical trial data and published studies. Target Population: Hepatitis C virus-infected patients with histologically mild hepatitis. Time Horizon: Lifetime. Perspective: Societal. Intervention: Immediate combination antiviral treatment or biopsy every 3 years plus combination antiviral therapy for moderate hepatitis or cirrhosis, Outcome Measures: Life expectancy, quality-adjusted life expectancy, and costs. Results of Base-Case Analysis: Over 20 years, biopsy every 3 years with treatment of moderate hepatitis would avoid treatment in 50% of the cohort and would result in an 18% likelihood of cirrhosis compared with 16% for immediate treatment and 27% for no antiviral therapy. Immediate antiviral treatment should increase life expectancy by 1.0 quality-adjusted life-year compared with biopsy management. Over an average lifetime, biopsy management would lead to six liver biopsies costing $6200; immediate antiviral treatment would cost $5100 less than biopsy management because of savings related to biopsy and prevention of future hepatitis C-related morbidity. Immediate therapy was cost-effective compared with biopsy management and had a cost-effectiveness ratio of $7000 compared with no antiviral therapy. Results of Sensitivity Analysis: When age, sex, genotype, and estimates of histologic progression or compliance with follow-up are varied, immediate therapy should result in an increase of at least 0.8 quality-adjusted life-year compared with biopsy management. Conclusion: For histologically mild chronic hepatitis C, initial combination treatment compared with periodic liver biopsy should reduce the future risk for cirrhosis, prolong life, and be cost-effective.	Tufts Univ, Sch Med, New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA; Univ Massachusetts, Sch Med, UMass Mem Hlth Care, Worcester, MA USA	Tufts Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Worcester	Wong, JB (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Tupper Res Inst, 750 Washington St,Box 302, Boston, MA 02111 USA.	jwong@lifespan.org		Wong, John/0000-0003-4203-9010				ABDI W, 1979, ARCH INTERN MED, V139, P667, DOI 10.1001/archinte.139.6.667; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 1997, HEPATOLOGY, V26, pS2; ASCHER NL, 1994, HEPATOLOGY, V20, pS24; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bennett WG, 1997, ANN INTERN MED, V127, P855, DOI 10.7326/0003-4819-127-10-199711150-00001; Benvegnu L, 1998, CANCER-AM CANCER SOC, V83, P901, DOI 10.1002/(SICI)1097-0142(19980901)83:5<901::AID-CNCR15>3.0.CO;2-Z; Bonis PAL, 1997, HEPATOLOGY, V26, P1035, DOI 10.1053/jhep.1997.v26.pm0009328332; Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; Brunetto MR, 1998, LANCET, V351, P1535; Camma C, 1997, J HEPATOL, V26, P1187, DOI 10.1016/S0168-8278(97)80451-5; CHRISTENSEN E, 1989, SCAND J GASTROENTERO, V24, P999, DOI 10.3109/00365528909089247; COLCHER MD, 1994, HEPATOLOGY, V20, P618; DETRE KM, 1996, VIRAL HEPATITIS REV, V2, P219; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Foster GR, 1997, BRIT MED J, V315, P453, DOI 10.1136/bmj.315.7106.453; Foster GR, 1998, HEPATOLOGY, V27, P209, DOI 10.1002/hep.510270132; Gold MR, 1996, COST EFFECTIVENESS H; Grimm I, 1996, Gastroenterology, V110, P2019, DOI 10.1053/gast.1996.v110.agast962019; Harper SE, 1996, HEPATOLOGY, V23, P930; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; KILPE VE, 1993, TRANSPLANTATION, V56, P554, DOI 10.1097/00007890-199309000-00012; Kim WR, 1997, ANN INTERN MED, V127, P866, DOI 10.7326/0003-4819-127-10-199711150-00002; Koretz RL, 1996, LANCET, V347, P194, DOI 10.1016/S0140-6736(96)90379-7; KUMARANAYAKE P, 2000, CAN J GASTROENTEROL, V14, pA23; Kuwana K, 1997, J GASTROEN HEPATOL, V12, P149, DOI 10.1111/j.1440-1746.1997.tb00398.x; Lau DTY, 1998, HEPATOLOGY, V28, P1121, DOI 10.1002/hep.510280430; Levine RA, 1998, ANN INTERN MED, V129, P323, DOI 10.7326/0003-4819-129-4-199808150-00010; Liu G, 1997, J CLIN ONCOL, V15, P110, DOI 10.1200/JCO.1997.15.1.110; MAHARAJ B, 1986, LANCET, V1, P523; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; MATTSSON L, 1988, LIVER, V8, P184; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; *MED EC, 1999, 1999 DRUG TOP RED BO; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Pagliaro L, 1999, ITAL J GASTROENTEROL, V31, P28; Pasta DJ, 1999, MED DECIS MAKING, V19, P353, DOI 10.1177/0272989X9901900314; Poynard T, 1998, HEPATOLOGY, V27, P1443, DOI 10.1002/hep.510270537; Poynard T, 1998, ACTA GASTRO-ENT BELG, V61, P431; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 2000, HEPATOLOGY, V31, P211, DOI 10.1002/hep.510310131; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reichard O, 1999, J HEPATOL, V30, P783, DOI 10.1016/S0168-8278(99)80129-9; Ryder SD, 1999, HEPATOLOGY, V30, p316A; SALERNO F, 1993, AM J GASTROENTEROL, V88, P514; Schalm SW, 1997, HEPATOLOGY, V26, pS128, DOI 10.1002/hep.510260722; SCHLICHTING P, 1983, SCAND J GASTROENTERO, V18, P27, DOI 10.3109/00365528309181554; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seeff LB, 1997, HEPATOLOGY, V26, pS21, DOI 10.1002/hep.510260704; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiell A, 1999, MED J AUSTRALIA, V171, P189, DOI 10.5694/j.1326-5377.1999.tb123595.x; Shindo M, 1999, CANCER, V85, P1943, DOI 10.1002/(SICI)1097-0142(19990501)85:9<1943::AID-CNCR10>3.0.CO;2-F; Sobesky R, 1999, GASTROENTEROLOGY, V116, P378, DOI 10.1016/S0016-5085(99)70135-6; TAKAHASHI M, 1993, AM J GASTROENTEROL, V88, P240; Teramura K, 1997, J CLIN GASTROENTEROL, V25, P346, DOI 10.1097/00004836-199707000-00011; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Ware JE, 1999, HEPATOLOGY, V30, P550, DOI 10.1002/hep.510300203; WASSERMAN Y, 1995, PHYSICIANS FEE REFER; Weinstein MC, 1980, CLIN DECISION ANAL; Wong JB, 2000, AM J GASTROENTEROL, V95, P1524; Wong JB, 1998, JAMA-J AM MED ASSOC, V280, P2088, DOI 10.1001/jama.280.24.2088; YOUSUF M, 1992, SCAND J GASTROENTERO, V27, P812, DOI 10.3109/00365529209011189	70	127	129	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					665	675		10.7326/0003-4819-133-9-200011070-00008	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074899				2022-12-28	WOS:000165075300001
J	Yoshida, H; Horie, H; Matsuura, K; Miyamura, T				Yoshida, H; Horie, H; Matsuura, K; Miyamura, T			Characterisation of vaccine-derived polioviruses isolated from sewage and river water in Japan	LANCET			English	Article							MONKEY KIDNEY-CELLS; NUCLEOTIDE-SEQUENCE; NONCODING REGION; POLIO VACCINE; SABIN TYPE-3; VERO CELLS; NEUROVIRULENCE; POLIOMYELITIS; POLIOVACCINE; MUTATIONS	Background A nucleotide change from U to C at position 472 in the 5' non-coding region of the type 3 poliovirus is associated with increased neurovirulence. Moreover, the proportion of type 3 polioviruses containing this mutation (472-C revertants) correlates with the neurovirulence of a particular sample. We used mutant analysis by PCR and restriction-enzyme cleavage (MAPREC) to estimate the neurovirulence of environmental samples obtained from Toyama prefecture, Japan. Methods Sewage and river water were collected between October, 1993, and September, 1995, and concentrated samples were inoculated into three different cell types. Isolated type 3 viruses were analysed to determine whether they were derived from the live oral poliovirus vaccine strain; they were then tested for neurovirulence by MAPREC. Results 29 type 3 strains were isolated-all of which were vaccine-derived. 16 (55%) comprised between 2% and 91% 472-C revertants by MAPREC and were expected to have high neurovirulence. The remaining strains included less than 0.25% revertants, and were regarded as attenuated viruses. Both types were isolated about 3 months after routine oral poliovirus vaccine administrations in May and October. Three strains isolated from river water were of the virulent type. Interpretation Our results emphasise that there is an environmental risk of vaccine-associated paralytic poliomyelitis as long as live oral poliovirus vaccine is not replaced by inactivated polio vaccine.	Natl Inst Infect Dis, Dept Virol 2, Tokyo 2080011, Japan; Japan Poliomyelitis Res Inst, Tokyo, Japan; Toyama Inst Hlth, Dept Virol, Toyama, Japan	National Institute of Infectious Diseases (NIID)	Yoshida, H (corresponding author), Natl Inst Infect Dis, Dept Virol 2, Gakuen 4-7-1, Tokyo 2080011, Japan.			Yoshida, Hiromu/0000-0002-1488-8309				ABRAHAM R, 1993, J INFECT DIS, V168, P1105, DOI 10.1093/infdis/168.5.1105; Alexander JP, 1997, J INFECT DIS, V175, pS176, DOI 10.1093/infdis/175.Supplement_1.S176; [Anonymous], 2000, JAMA, V283, P1414; BENYESHM.M, 1967, AM J EPIDEMIOL, V86, P112, DOI 10.1093/oxfordjournals.aje.a120717; Chezzi C, 1998, VACCINE, V16, P2031, DOI 10.1016/S0264-410X(98)00079-6; Chiba Y, 2000, JPN J INFECT DIS, V53, P135; Chumakov K M, 1999, Dev Biol Stand, V100, P67; CHUMAKOV KM, 1991, P NATL ACAD SCI USA, V88, P199, DOI 10.1073/pnas.88.1.199; CHUMAKOV KM, 1992, J VIROL, V66, P966, DOI 10.1128/JVI.66.2.966-970.1992; CHUMAKOV KM, 1994, J MED VIROL, V42, P79, DOI 10.1002/jmv.1890420115; Divizia M, 1999, APPL ENVIRON MICROB, V65, P3534; Dorsam V, 2000, VACCINE, V18, P2435, DOI 10.1016/S0264-410X(99)00531-9; Dragunsky E, 1996, BIOLOGICALS, V24, P77, DOI 10.1006/biol.1996.0010; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; EVANS DMA, 1985, NATURE, V314, P548, DOI 10.1038/314548a0; Hagiwara A, 1999, JPN J INFECT DIS, V52, P146; Halsey NA, 1999, PEDIATRICS, V103, P171, DOI 10.1542/peds.103.1.171; Horie H, 1998, BIOLOGICALS, V26, P289, DOI 10.1006/biol.1998.0159; Horie H, 1996, VACCINE, V14, P35, DOI 10.1016/0264-410X(95)00159-X; KAWAMURA N, 1989, J VIROL, V63, P1302, DOI 10.1128/JVI.63.3.1302-1309.1989; Lu ZB, 1996, VIROLOGY, V220, P285, DOI 10.1006/viro.1996.0316; Mallet L, 1997, J MED VIROL, V52, P50; Marker Test Subcommittee. The Japan Live Poliovaccine Research Commission, 1967, JPN J MED SCI BIOL, V20, P167; MATSUURA K, IN PRESS APPL ENV MI; POLLARD SR, 1989, J VIROL, V63, P4949, DOI 10.1128/JVI.63.11.4949-4951.1989; POYRY T, 1988, APPL ENVIRON MICROB, V54, P371; Sutter RW, 2000, PEDIATR CLIN N AM, V47, P287, DOI 10.1016/S0031-3955(05)70208-X; TAMBINI G, 1993, J INFECT DIS, V168, P1510, DOI 10.1093/infdis/168.6.1510; TATEM JM, 1991, J MED VIROL, V35, P101, DOI 10.1002/jmv.1890350206; Wood DJ, 1997, BIOLOGICALS, V25, P3, DOI 10.1006/biol.1997.0055; Wood DJ, 2000, B WORLD HEALTH ORGAN, V78, P347; Yoshida H, 1997, J INFECT DIS, V175, P1233, DOI 10.1086/593677	32	36	38	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1461	1463		10.1016/S0140-6736(00)02868-3	http://dx.doi.org/10.1016/S0140-6736(00)02868-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081527				2022-12-28	WOS:000090067300008
J	Kaufman, DW; Shapiro, S				Kaufman, DW; Shapiro, S			Epidemiological assessment of drug-induced disease	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; 3RD-GENERATION ORAL-CONTRACEPTIVES; INTERNATIONAL CASE-CONTROL; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; APLASTIC-ANEMIA; RISK; ANALGESICS	Adverse reactions are a potential concern for physicians when they prescribe or recommend drugs. Epidemiological principles, when combined with clinical judgment, can be of help in this situation, starting with an appreciation of the strengths and weaknesses of different sources of information on adverse reactions-clinical trials, case reports, and formal epidemiological studies. The latter studies generally provide the most comprehensive information on the risks of serious adverse drug reactions. An understanding of the different types of risk estimates, relative and absolute, is also needed-we stress the value of the absolute risk as the best measure of the impact of an adverse reaction. Rare serious reactions, although striking, have little impact on individual risk, whereas more common reactions, even with much lower fatality rates, are more likely to lead to adverse outcomes for patients. The importance of balancing risks and benefits, taking into account all the information about an individual patient's risk profile, is also highlighted.	Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA	Boston University	Kaufman, DW (corresponding author), Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA.			Kaufman, David/0000-0002-2150-5070				Andrade SE, 1998, J CLIN EPIDEMIOL, V51, P1357, DOI 10.1016/S0895-4356(98)00076-6; Berkel HJ, 1996, EPIDEMIOL REV, V18, P205, DOI 10.1093/oxfordjournals.epirev.a017926; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; DAVIES DM, 1998, DAVIESS TXB ADVERSE; FARMER RDT, 1999, PHARMACOEPIDEMIOL S2, V8, pS187; FUNG M, 1999, PHARMACOEPIDEM DR S, V8, pS105; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, P8; Hennekens CH, 1999, AM HEART J, V137, pS9, DOI 10.1016/S0002-8703(99)70391-1; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; IARC, 1999, IARC MON EV CARC RIS, V72, P49; *IARC WORK GROUP E, 1977, SOM MISC PHARM SUBST, V13, P131; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Kaufman DW, 1996, EUR J HAEMATOL, V57, P23; Kaufman DW, 1997, EPILEPSIA, V38, P1265, DOI 10.1111/j.1528-1157.1997.tb00062.x; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; Lewis MA, 1996, BRIT MED J, V312, P88; POULTER NR, 1995, LANCET, V346, P1575; Rosenberg L, 1997, AM J OBSTET GYNECOL, V177, P707, DOI 10.1016/S0002-9378(97)70168-6; Rothman K., 1998, MODERN EPIDEMIOLOGY; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Rzany B, 1999, LANCET, V353, P2190, DOI 10.1016/S0140-6736(98)05418-X; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; Sidney S, 1996, OBSTET GYNECOL, V88, P939, DOI 10.1016/S0029-7844(96)00351-1; Spitzer WO, 1996, BRIT MED J, V312, P83; SPRIETPOURRA C, 1988, DRUG WITHDRAWAL SALE; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; VanDerKlauw MM, 1996, CLIN EXP ALLERGY, V26, P1355, DOI 10.1046/j.1365-2222.1996.d01-300.x	31	47	47	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1339	1343		10.1016/S0140-6736(00)02826-9	http://dx.doi.org/10.1016/S0140-6736(00)02826-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073036				2022-12-28	WOS:000089858300039
J	Syse, A				Syse, A			Norway: valid (as opposed to informed) consent	LANCET			English	Article								The traditional concept of "informed" consent may be too restrictive; "valid" consent may be a more manageable criterion. Norway's 1999 Patients' Rights Act comes into force on Jan 1, 2001. This essay asks if this new legislation is compatible with this concept of valid consent-and concludes that it is.	Univ Oslo, Dept Publ & Int Law, N-0130 Oslo, Norway	University of Oslo	Syse, A (corresponding author), Univ Oslo, Dept Publ & Int Law, POB 6706, N-0130 Oslo, Norway.							DRANE JF, 1985, HASTINGS CENT REP, V15, P17, DOI 10.2307/3560639; Syse A, 1999, RES COMM ME, V10, P81	2	24	26	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1347	1348		10.1016/S0140-6736(00)02828-2	http://dx.doi.org/10.1016/S0140-6736(00)02828-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073038				2022-12-28	WOS:000089858300041
J	Dohle, GR; Schroder, FH				Dohle, GR; Schroder, FH			Ultrasonographic assessment of the scrotum	LANCET			English	Editorial Material							TESTICULAR MICROLITHIASIS; ULTRASOUND		Univ Rotterdam Hosp, Dept Urol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Dohle, GR (corresponding author), Univ Rotterdam Hosp, Dept Urol, NL-3000 CA Rotterdam, Netherlands.							Adeyoju AB, 2000, BJU INT, V86, P87, DOI 10.1046/j.1464-410x.2000.00704.x; Furness PD, 1998, J UROLOGY, V160, P1151, DOI 10.1016/S0022-5347(01)62723-X; HOBARTH K, 1992, UROLOGY, V40, P464, DOI 10.1016/0090-4295(92)90467-B; Horstman WG, 1997, UROL CLIN N AM, V24, P653, DOI 10.1016/S0094-0143(05)70406-7; Lau MWM, 1999, BRIT J RADIOL, V72, P833, DOI 10.1259/bjr.72.861.10645188; MOLLER H, 1993, EUR UROL, V23, P8; Pierik FH, 1999, J UROLOGY, V162, P1618, DOI 10.1016/S0022-5347(05)68180-3	7	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1625	1626		10.1016/S0140-6736(00)03153-6	http://dx.doi.org/10.1016/S0140-6736(00)03153-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089818				2022-12-28	WOS:000165249200007
J	King, SD; Ritsema, J				King, SD; Ritsema, J			African hot spot volcanism: Small-scale convection in the upper mantle beneath cratons	SCIENCE			English	Article							CONTINENTAL TECTOSPHERE; HEAT-FLOW; DIAMONDS; THICK; LITHOSPHERE; VISCOSITY; OVERTONE	Numerical models demonstrate that small-scale convection develops in the upper mantle beneath the transition of thick cratonic lithosphere and thin oceanic lithosphere. These models explain the Location and geochemical characteristics of intraplate Volcanos on the African and South American plates. They also explain the presence of relatively high seismic shear wave velocities (cold downwellings) in the mantle transition zone beneath the western margin of African cratons and the eastern margin of South American cratons, Small-scale, edge-driven convection is an alternative to plumes for explaining intraplate African and South American hot spot volcanism, and small-scale convection is consistent with mantle downwellings beneath the African and South American Lithosphere.	Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; California Institute of Technology	King, SD (corresponding author), Purdue Univ, Dept Earth & Atmospher Sci, W Lafayette, IN 47907 USA.	sking@purdue.edu	King, Scott D/B-1220-2008	King, Scott D/0000-0002-9564-5164				Anderson DL, 1998, GEODYNAMICS, V28, P255; BINA CR, 1994, J GEOPHYS RES-SOL EA, V99, P15853, DOI 10.1029/94JB00462; BOYD FR, 1985, NATURE, V315, P387, DOI 10.1038/315387a0; BURKE K, 1972, NATURE, V239, P387, DOI 10.1038/239387b0; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Elder J., 1976, BOWELS EARTH; Forte AM, 1996, GEOPHYS RES LETT, V23, P1147, DOI 10.1029/96GL00964; HAGER BH, 1989, PHILOS T R SOC A, V328, P309, DOI 10.1098/rsta.1989.0038; HOLBROOK WS, 1993, NATURE, V364, P433, DOI 10.1038/364433a0; ITA J, 1994, J GEOPHYS RES-SOL EA, V99, P15919, DOI 10.1029/94JB00852; JORDAN TH, 1978, NATURE, V274, P544, DOI 10.1038/274544a0; KARATO S, 1993, SCIENCE, V260, P771, DOI 10.1126/science.260.5109.771; KEEN CE, 1995, NATO ADV SCI INST SE, V463, P17; King SD, 1995, EARTH PLANET SC LETT, V136, P269, DOI 10.1016/0012-821X(95)00205-Q; KING SD, 1990, PHYS EARTH PLANET IN, V59, P195, DOI 10.1016/0031-9201(90)90225-M; King SD, 1998, EARTH PLANET SC LETT, V160, P289, DOI 10.1016/S0012-821X(98)00089-2; KING SD, 1995, REV GEOPHYS, V33, P11, DOI 10.1029/95RG00279; KRAMERS JD, 1979, EARTH PLANET SC LETT, V42, P58, DOI 10.1016/0012-821X(79)90190-0; LEEDS AR, 1974, SCIENCE, V186, P141, DOI 10.1126/science.186.4159.141; LERNERLAM AL, 1987, J GEOPHYS RES-SOLID, V92, P14007, DOI 10.1029/JB092iB13p14007; Mitrovica JX, 1996, J GEOPHYS RES-SOL EA, V101, P555, DOI 10.1029/95JB03208; MUTTER JC, 1988, J GEOPHYS RES-SOLID, V93, P1031, DOI 10.1029/JB093iB02p01031; NYBLADE AA, 1993, J GEOPHYS RES-SOL EA, V98, P12207, DOI 10.1029/93JB00521; POLET J, 1995, GEOLOGY, V23, P205, DOI 10.1130/0091-7613(1995)023<0205:DEOCAI>2.3.CO;2; POLLACK HN, 1993, REV GEOPHYS, V31, P267, DOI 10.1029/93RG01249; Resovsky JS, 1999, J GEOPHYS RES-SOL EA, V104, P993, DOI 10.1029/1998JB900025; Richardson SH, 1997, EARTH PLANET SC LETT, V151, P271, DOI 10.1016/S0012-821X(97)81853-5; RICHARDSON SH, 1984, NATURE, V310, P198, DOI 10.1038/310198a0; Ritsema J, 2000, GEOLOGY, V28, P63, DOI 10.1130/0091-7613(2000)028<0063:NSMOTU>2.3.CO;2; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; RITSEMA J, IN PRESS SCI PROG; RITSEMA J, 1999, EOS S, V80, pS221; Shapiro SS, 1999, LITHOS, V48, P115, DOI 10.1016/S0024-4937(99)00025-0; SLEEP NH, 1992, ANNU REV EARTH PL SC, V20, P19, DOI 10.1146/annurev.ea.20.050192.000315; Tackley PJ, 1996, GEOPHYS RES LETT, V23, P1985, DOI 10.1029/96GL01980; THIESSEN R, 1979, GEOLOGY, V7, P263, DOI 10.1130/0091-7613(1979)7<263:AHATRT>2.0.CO;2; Van Heijst HJ, 1999, GEOPHYS J INT, V137, P601, DOI 10.1046/j.1365-246x.1999.00825.x; vanderLee S, 1997, J GEOPHYS RES-SOL EA, V102, P22815, DOI 10.1029/97JB01168; vanHeijst HJ, 1997, GEOPHYS J INT, V131, P209, DOI 10.1111/j.1365-246X.1997.tb01217.x; VOGT PR, 1991, GEOLOGY, V19, P41, DOI 10.1130/0091-7613(1991)019<0041:BAALRC>2.3.CO;2	40	292	300	5	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1137	1140		10.1126/science.290.5494.1137	http://dx.doi.org/10.1126/science.290.5494.1137			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073447				2022-12-28	WOS:000165228200040
J	Ims, RA; Andreassen, HP				Ims, RA; Andreassen, HP			Spatial synchronization of vole population dynamics by predatory birds	NATURE			English	Article							MICROTUS-OECONOMUS; MUSTELID PREDATORS; TRAVELING WAVES; CYCLES; HYPOTHESIS; MORTALITY; PATTERNS; MAMMALS; PHASE	Northern vole populations exhibit large-scale, spatially synchronous population dynamics(1,2). Such cases of population synchrony provide excellent opportunities for distinguishing between local intrinsic and regional extrinsic mechanisms of population regulation(3). Analyses of large-scale survey data and theoretical modelling(4-6) have indicated several plausible synchronizing mechanisms. It is difficult, however, to determine the most important one without detailed data on local demographic processes(3,7). Here we combine results from two field studies in southeastern Norway-one identifies local demographic mechanisms and landscape-level annual synchrony among 28 enclosed experimental populations and the other examines region-level multi-annual synchrony in open natural populations. Despite fences eliminating predatory mammals and vole dispersal, the growth rates of the experimental populations were synchronized and moreover, perfectly linked with vole abundance in the region. The fates of 481 radio-marked voles showed that bird predation was the synchronizing mechanism. A higher frequency of risky dispersal movements in slowly growing populations appeared to accelerate predation rate. Thus, dispersal may induce a feedback-loop between predation and population growth that enhances synchrony.	Univ Oslo, Dept Biol, Div Zool, N-0316 Oslo, Norway	University of Oslo	Ims, RA (corresponding author), NINA, Polar Environm Ctr, N-9005 Tromso, Norway.							Aars J, 1999, OIKOS, V85, P204, DOI 10.2307/3546487; Andreassen HP, 1998, J ANIM ECOL, V67, P941, DOI 10.1046/j.1365-2656.1998.6760941.x; Bjornstad ON, 1999, ECOLOGY, V80, P622, DOI 10.2307/176640; Bjornstad ON, 1999, TRENDS ECOL EVOL, V14, P427, DOI 10.1016/S0169-5347(99)01677-8; Blasius B, 1999, NATURE, V399, P354, DOI 10.1038/20676; CLOBERT J, IN PRESS CAUSES CONS; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; HANSSON L, 1988, TRENDS ECOL EVOL, V3, P195, DOI 10.1016/0169-5347(88)90006-7; HEIKKILA J, 1994, OIKOS, V70, P245, DOI 10.2307/3545635; Ims RA, 1999, J ANIM ECOL, V68, P839, DOI 10.1046/j.1365-2656.1999.00336.x; IMS RA, 1990, OIKOS, V57, P381, DOI 10.2307/3565968; JOHANNESEN E, 1996, J MAMMAL, V78, P638; Korpimaki E, 1996, BIOSCIENCE, V46, P754, DOI 10.2307/1312851; Korpimaki E, 1998, ECOLOGY, V79, P2448, DOI 10.2307/176834; Krebs CJ, 1996, J MAMMAL, V77, P8, DOI 10.2307/1382705; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; May RM, 1999, NATURE, V398, P371, DOI 10.1038/18769; NORRDAHL K, 1995, P ROY SOC B-BIOL SCI, V261, P49, DOI 10.1098/rspb.1995.0116; Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621; Ranta E, 1997, NATURE, V390, P456, DOI 10.1038/37261; REID DG, 1995, OIKOS, V73, P387, DOI 10.2307/3545963; STEEN H, 1994, ANN ZOOL FENN, V31, P271; STEEN H, 1995, OIKOS, V73, P65, DOI 10.2307/3545726; Steen H, 1996, ECOLOGY, V77, P2365, DOI 10.2307/2265738; Turchin P, 1997, AM NAT, V149, P842, DOI 10.1086/286027; VIITALA J, 1995, NATURE, V373, P425, DOI 10.1038/373425a0; Wolff JO, 1997, J ANIM ECOL, V66, P1, DOI 10.2307/5959	29	181	189	0	54	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					194	196		10.1038/35041562	http://dx.doi.org/10.1038/35041562			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089971				2022-12-28	WOS:000165180400043
J	Baldauf, SL; Roger, AJ; Wenk-Siefert, I; Doolittle, WF				Baldauf, SL; Roger, AJ; Wenk-Siefert, I; Doolittle, WF			A kingdom-level phylogeny of eukaryotes based on combined protein data	SCIENCE			English	Article							SITE RATE VARIATION; EVOLUTIONARY RELATIONSHIPS; RIBOSOMAL-RNA; ORIGINS; SUBUNIT; FAMILY; ACANTHAMOEBA; DIVERSITY; SEQUENCES; ACCURACY	Current understanding of the higher order systematics of eukaryotes relies largely on analyses of the small ribosomal subunit RNA (SSU rRNA). Independent testing of these results is still limited. We have combined the sequences of four of the most broadly taxonomically sampled proteins available to create a roughly parallel data set to that of SSU rRNA. The resulting phylogenetic tree shows a number of striking differences from SSU rRNA phylogeny, including strong support for most major groups and several major supergroups.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England; Dalhousie Univ, Canadian Inst Adv Res, Program Evolutionary Biol, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada; Univ Zurich, Inst Pflanzenbiol, CH-8008 Zurich, Switzerland	University of York - UK; Canadian Institute for Advanced Research (CIFAR); Dalhousie University; University of Zurich	Baldauf, SL (corresponding author), Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England.	slb14@york.ac.uk		Baldauf, Sandra/0000-0003-4485-6671; Doolittle, W. Ford/0000-0002-4675-8832				Adachi J., 1996, COMPUT SCI MONOGR, V28, P1; Baldauf SL, 1997, P NATL ACAD SCI USA, V94, P12007, DOI 10.1073/pnas.94.22.12007; Baldauf SL, 1999, AM NAT, V154, pS178, DOI 10.1086/303292; BALDAUF SL, UNPUB; BHATTACHARYA D, 1995, ARCH PROTISTENKD, V145, P155, DOI 10.1016/S0003-9365(11)80312-X; Cavalier-Smith T, 1998, BIOL REV, V73, P203, DOI 10.1017/S0006323198005167; Cavalier-Smith T, 1999, J EUKARYOT MICROBIOL, V46, P347, DOI 10.1111/j.1550-7408.1999.tb04614.x; Cavalier-Smith T., 1987, EVOLUTIONARY BIOL FU, P339; CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103; DEQUEIROZ A, 1995, ANNU REV ECOL SYST, V26, P657, DOI 10.1146/annurev.es.26.110195.003301; DERIJK P, 1995, J MOL EVOL, V41, P366, DOI 10.1007/BF01215184; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Douglas SE, 1998, CURR OPIN GENET DEV, V8, P655, DOI 10.1016/S0959-437X(98)80033-6; Drouin G, 1995, J MOL EVOL, V41, P841, DOI 10.1007/BF00173163; Embley TM, 1998, CURR OPIN GENET DEV, V8, P624, DOI 10.1016/S0959-437X(98)80029-4; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; *GENB, AF2769427 GENB; *GENB, AF1907712 GENB; Germot A, 1999, J EUKARYOT MICROBIOL, V46, P116, DOI 10.1111/j.1550-7408.1999.tb04594.x; Hausmann K., 1996, PROTOZOOLOGY; Hilario E, 1998, J MOL EVOL, V46, P703, DOI 10.1007/PL00006351; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; Hillis DM, 1998, SYST BIOL, V47, P3, DOI 10.1080/106351598260987; Hirt RP, 1999, P NATL ACAD SCI USA, V96, P580, DOI 10.1073/pnas.96.2.580; Iwamoto M, 1998, CURR GENET, V33, P304, DOI 10.1007/s002940050341; Keeling PJ, 1996, MOL BIOL EVOL, V13, P1297, DOI 10.1093/oxfordjournals.molbev.a025576; Keeling PJ, 1998, J EUKARYOT MICROBIOL, V45, P561, DOI 10.1111/j.1550-7408.1998.tb05117.x; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Kumar S, 1996, J MOL EVOL, V42, P183, DOI 10.1007/BF02198844; Lang BF, 1999, J EUKARYOT MICROBIOL, V46, P320, DOI 10.1111/j.1550-7408.1999.tb04611.x; MACKAY R, COMMUNICATION; MADDISON WP, 1992, MMACCLADE ANAL PHYLO; Moreira D, 1999, MOL BIOL EVOL, V16, P234, DOI 10.1093/oxfordjournals.molbev.a026105; Moreira D, 2000, NATURE, V405, P69, DOI 10.1038/35011054; O'Kelly CJ, 1999, J EUKARYOT MICROBIOL, V46, P522, DOI 10.1111/j.1550-7408.1999.tb06070.x; Patterson DJ, 1999, AM NAT, V154, pS96, DOI 10.1086/303287; Philippe H, 2000, P ROY SOC B-BIOL SCI, V267, P1213, DOI 10.1098/rspb.2000.1130; ROGER AJ, 1996, THESIS DALHOUSIE U H; Sogin ML, 1997, CURR OPIN GENET DEV, V7, P792, DOI 10.1016/S0959-437X(97)80042-1; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Sullivan J, 1996, SYST BIOL, V45, P375, DOI 10.2307/2413571; SWOFFORD DL, IN PRESS PAUP PHYLOG; Van de Peer Y, 2000, GENE, V246, P1, DOI 10.1016/S0378-1119(00)00063-9; Van de Peer Y, 1997, J MOL EVOL, V45, P619, DOI 10.1007/PL00006266; Van der Auwera G, 1998, MOL PHYLOGENET EVOL, V10, P333, DOI 10.1006/mpev.1998.0544; WENKSIEFERT I, 1994, THESIS U ZURICH ZURI; Wiens JJ, 1998, SYST BIOL, V47, P625, DOI 10.1080/106351598260635	50	899	958	2	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					972	977		10.1126/science.290.5493.972	http://dx.doi.org/10.1126/science.290.5493.972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062127				2022-12-28	WOS:000165103200046
J	Ruiz, GM; Rawlings, TK; Dobbs, FC; Drake, LA; Mullady, T; Huq, A; Colwell, RR				Ruiz, GM; Rawlings, TK; Dobbs, FC; Drake, LA; Mullady, T; Huq, A; Colwell, RR			Global spread of microorganisms by ships - Ballast water discharged from vessels harbours a cocktail of potential pathogens.	NATURE			English	Article							MARINE ORGANISMS; TRANSPORT; CLIMATE; DISEASE; ECOLOGY	Ballast water discharged from vessels harbours a cocktail of potential pathogens.	Smithsonian Environm Res Ctr, Edgewater, MD 21037 USA; Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Baltimore, MD 21202 USA; Univ Maryland, Dept Cell & Mol Biol, College Pk, MD 20742 USA; Old Dominion Univ, Dept Ocean Earth & Atmospher Sci, Norfolk, VA 23529 USA	Smithsonian Institution; Smithsonian Environmental Research Center; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park; Old Dominion University	Ruiz, GM (corresponding author), Smithsonian Environm Res Ctr, POB 28, Edgewater, MD 21037 USA.			Ruiz, Gregory/0000-0003-2499-441X				BROCK TD, 1993, BIOL MICROORGANISMS; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; CARLTON JT, 1985, OCEANOGR MAR BIOL, V23, P313; Carlton JT, 1995, CGD1195; Colwell Rita R., 1994, P117; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Daszak P, 2000, SCIENCE, V287, P443, DOI 10.1126/science.287.5452.443; Galil BS, 1997, EUR J PROTISTOL, V33, P244, DOI 10.1016/S0932-4739(97)80002-8; GRIMES DJ, 1991, ESTUARIES, V14, P345, DOI 10.2307/1352260; Hallegraeff GM, 1998, MAR ECOL PROG SER, V168, P297, DOI 10.3354/meps168297; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; MCCARTHY SA, 1994, APPL ENVIRON MICROB, V60, P2597, DOI 10.1128/AEM.60.7.2597-2601.1994; RUIZ GM, IN PRESS ANN REV ECO; Williamson M., 1996, BIOL INVASIONS	14	435	478	16	130	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					49	50		10.1038/35040695	http://dx.doi.org/10.1038/35040695			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081499				2022-12-28	WOS:000165050400043
J	Gandhi, D; Sharma, R; Kotwal, PP; Hatimota, P				Gandhi, D; Sharma, R; Kotwal, PP; Hatimota, P			Migrating lumbar vertebra	LANCET			English	Article									All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, India; All India Inst Med Sci, Dept Orthopaed, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi	Gandhi, D (corresponding author), All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, India.								0	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1485	1485		10.1016/S0140-6736(00)03145-7	http://dx.doi.org/10.1016/S0140-6736(00)03145-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081532	Bronze			2022-12-28	WOS:000090067300013
J	Kunishima, N; Shimada, Y; Tsuji, Y; Sato, T; Yamamoto, M; Kumasaka, T; Nakanishi, S; Jingami, H; Morikawa, K				Kunishima, N; Shimada, Y; Tsuji, Y; Sato, T; Yamamoto, M; Kumasaka, T; Nakanishi, S; Jingami, H; Morikawa, K			Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor	NATURE			English	Article							PUTATIVE PHEROMONE RECEPTORS; LIGAND-BINDING DOMAIN; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; CALCIUM RECEPTOR; ESCHERICHIA-COLI; MGLUR4 SUBTYPE	The metabotropic glutamate receptors (mGluRs) are key receptors in the modulation of excitatory synaptic transmission in the central nervous system. Here we have determined three different crystal structures of the extracellular ligand-binding region of mGluR1-in a complex with glutamate and in two unliganded forms. They all showed disulphide-linked homodimers, whose 'active' and 'resting' conformations are modulated through the dimeric interface by a packed alpha -helical structure. The bi-lobed protomer architectures flexibly change their domain arrangements to form an 'open' or 'closed' conformation. The structures imply that glutamate binding stabilizes both the 'active' dimer and the 'closed' protomer in dynamic equilibrium. Movements of the four domains in the dimer are likely to affect the separation of the transmembrane and intracellular regions, and thereby activate the receptor. This scheme in the initial receptor activation could be applied generally to G-protein-coupled neurotransmitter receptors that possess extracellular ligand-binding sites.	Biomol Engn Res Inst, Dept Biol Struct, Osaka 5650874, Japan; Biomol Engn Res Inst, Dept Mol Biol, Osaka 5650874, Japan; RIKEN, Harima Inst, Struct Biophys Lab, Sayo, Hyogo 6795148, Japan; Kyoto Univ, Fac Med, Dept Biol Sci, Sakyo Ku, Kyoto 6068501, Japan	RIKEN; Kyoto University	Morikawa, K (corresponding author), Biomol Engn Res Inst, Dept Biol Struct, 6-2-3 Furuedai, Osaka 5650874, Japan.		Yamamoto, Masaki/B-7844-2015; Kumasaka, Takashi/D-7428-2018; Kunishima, Naoki/N-7464-2015; Centeno, Patricia Pacios/O-8368-2016	Yamamoto, Masaki/0000-0002-1311-1768; Kumasaka, Takashi/0000-0001-9289-1557; Kunishima, Naoki/0000-0001-9826-9902				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; Costantino G, 1999, J MED CHEM, V42, P5390, DOI 10.1021/jm990353c; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deller MC, 2000, CURR OPIN STRUC BIOL, V10, P213, DOI 10.1016/S0959-440X(00)00072-5; FLOR PJ, 1995, EUR J NEUROSCI, V7, P622, DOI 10.1111/j.1460-9568.1995.tb00666.x; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Hampson DR, 1999, J BIOL CHEM, V274, P33488, DOI 10.1074/jbc.274.47.33488; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hashimoto T, 1997, EUR J NEUROSCI, V9, P1226, DOI 10.1111/j.1460-9568.1997.tb01477.x; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; KHORANA HG, 1992, J BIOL CHEM, V267, P1; Kubo Y, 1998, SCIENCE, V279, P1722, DOI 10.1126/science.279.5357.1722; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MINAKAMI R, 1994, BIOCHEM BIOPH RES CO, V199, P1136, DOI 10.1006/bbrc.1994.1349; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sugiyama S, 1996, J BIOL CHEM, V271, P9519, DOI 10.1074/jbc.271.16.9519; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Vassylyev DG, 1998, J BIOL CHEM, V273, P17604, DOI 10.1074/jbc.273.28.17604; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354	46	1020	1066	7	118	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					971	977		10.1038/35039564	http://dx.doi.org/10.1038/35039564			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069170				2022-12-28	WOS:000090032500034
J	Doyle, P; Maconochie, N; Roman, E; Davies, G; Smith, PG; Beral, V				Doyle, P; Maconochie, N; Roman, E; Davies, G; Smith, PG; Beral, V			Fetal death and congenital malformation in babies born to nuclear industry employees: report from the nuclear industry family study	LANCET			English	Article							LEVEL IONIZING-RADIATION; SPONTANEOUS-ABORTIONS; UNITED-KINGDOM; CHILDREN; REPRODUCTION; EXPOSURE; CANCER; HEALTH; STILLBIRTHS; MORTALITY	Background There is some concern about the genetic effects of exposure to low-level ionising radiation, but the evidence is sparse and conflicting. Most work has concentrated on cancer in offspring and little has been done on adverse reproductive outcome. We aimed to assess whether the offspring of men and women who are occupationally exposed to ionising radiation are at increased risk of fetal death and congenital malformation. Methods We analysed pregnancies reported by an occupational cohort of nuclear industry workers in the UK, employed at establishments operated by the Atomic Energy Authority, Atomic Weapons Establishment, and British Nuclear Fuels. Employment and radiation monitoring data supplied by employers was linked to each pregnancy. Findings 11 697 men and 1903 women reported one or more singleton pregnancy conceived after first employment within the nuclear industry, the men reporting a total of 23 676 singleton pregnancies and the women 3585. The risks of fetal death and congenital malformation were not related to whether the father had been monitored before conception or to the dose of radiation received. Among pregnancies reported by women, the risk of early (<13 weeks of gestation) miscarriage was higher if the mother had been monitored before conception (odds ratio [OR] 1.3, 95% CI 1.0-1.6), but there was no trend with dose, The risk of stillbirth was also higher if the mother had been monitored before conception (OR 2.2, 95% CI 1.0-4.6), but the finding was based on only 29 cases (13 exposed). The risk of any major malformation, or of specific groups of malformations, was not associated with maternal monitoring, or dose received, before conception. Interpretation We found no evidence of a link between exposure to low-level ionising radiation before conception and increased risk of adverse reproductive outcome in men working in the nuclear industry. Similarly for women there was no evidence of an association between monitoring before conception and malformation in offspring, The findings relating maternal preconceptual monitoring to increased risk of fetal death are equivocal and require further investigation.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Epidemiol Unit, London WC1E 7HT, England; Univ Leeds, Leukaemia Res Fund, Inst Epidemiol, Leeds LS2 9JT, W Yorkshire, England; Univ Oxford, Radcliffe Infirm, Imperial Canc Res Fund, Oxford OX2 6HE, England	University of London; London School of Hygiene & Tropical Medicine; University of Leeds; Radcliffe Infirmary; University of Oxford	Doyle, P (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Epidemiol Unit, Keppel St, London WC1E 7HT, England.		smith, peter/ABH-9627-2020	smith, peter/0000-0003-0080-7560; Roman, Eve/0000-0001-7603-3704				ALBERMAN E, 1972, ANN HUM GENET, V36, P185, DOI 10.1111/j.1469-1809.1972.tb00768.x; [Anonymous], 1992, MAN INT STAT CLASS D; Bobrow M, 1993, CHILDHOOD CANC NUCL; BOUE J, 1975, TERATOLOGY, V12, P11, DOI 10.1002/tera.1420120103; Byrne J, 1999, TERATOLOGY, V59, P210, DOI 10.1002/(SICI)1096-9926(199904)59:4<210::AID-TERA4>3.0.CO;2-X; CARPENTER L, 1994, RADIAT RES, V138, P224, DOI 10.2307/3578592; *COMM BIOL EFF ION, 1990, BEIR, V5; CREASY MR, 1976, HUM GENET, V31, P177, DOI 10.1007/BF00296145; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; *EUR REG CONG AN E, 1997, 7 SCI I PUBL HLTH L; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; Goldberg MS, 1998, EPIDEMIOLOGY, V9, P271, DOI 10.1097/00001648-199805000-00010; Green LM, 1997, OCCUP ENVIRON MED, V54, P629, DOI 10.1136/oem.54.9.629; Kallen B, 1998, RADIAT RES, V149, P202, DOI 10.2307/3579931; Kline J, 1998, EPIDEMIOLOGY, V9, P231; KLINE J, 1989, CONCEPTION BIRTH; Maconochie N, 1999, OCCUP ENVIRON MED, V56, P793, DOI 10.1136/oem.56.12.793; Muirhead CR, 1999, NRPBR307; NEEL JV, 1956, EFFECTS EXPOSURE ATO; OTAKE M, 1990, RADIAT RES, V122, P1, DOI 10.2307/3577576; Parker L, 1999, LANCET, V354, P1407, DOI 10.1016/S0140-6736(99)04138-0; Roman E, 1999, BRIT MED J, V318, P1443, DOI 10.1136/bmj.318.7196.1443; Roman E, 1996, OCCUP ENVIRON MED, V53, P73, DOI 10.1136/oem.53.2.73; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sanchez JM, 1999, PRENATAL DIAG, V19, P601, DOI 10.1002/(SICI)1097-0223(199907)19:7<601::AID-PD564>3.3.CO;2-S; SEVER LE, 1991, OCCUP MED, V6, P613; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226, DOI 10.1093/oxfordjournals.aje.a114799	27	52	53	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1293	1299		10.1016/S0140-6736(00)02812-9	http://dx.doi.org/10.1016/S0140-6736(00)02812-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073016				2022-12-28	WOS:000089858300008
J	Catlin, DH; Leder, BZ; Ahrens, B; Starcevic, B; Hatton, CK; Green, GA; Finkelstein, JS				Catlin, DH; Leder, BZ; Ahrens, B; Starcevic, B; Hatton, CK; Green, GA; Finkelstein, JS			Trace contamination of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; 19-NORANDROSTERONE; EXCRETION	Context Several anabolic steroids are sold over-the-counter (OTC) in the United States, and their production is not regulated by the US Food and Drug Administration. Reports have suggested that use of these supplements can cause positive urine test results for metabolites of the prohibited steroid nandrolone. Objectives To assess the content and purity of OTC androstenedione and to determine if androstenedione and 19-norandrostenedione administration causes positive urine test results for 19-norandrosterone, a nandrolone metabolite. Design Randomized controlled trial of androstenedione, open-label trial of 19-norandrostenedione, and mass spectrometry of androstenedione preparations, conducted between October 1998 and April 2000. Setting Outpatient facility of a university hospital. Participants A total of 41 healthy men aged 20 to 44 years. Intervention Participants were randomly assigned to receive oral androstenedione, 100 mg/d (n = 13) or 300 mg/d (n = 11) for 7 days, or no androstenedione (n = 13); in addition, 4 patients received 10 mug of 19-norandrostenedione. Main Outcome Measures Content of OTC androstenedione preparations; level of 19-norandrosterone in urine samples, determined by mass spectrometry, compared among the 3 randomized groups at day 1 and day 7, and among the participants who received 19-norandrostenedione from October 1998 to April 2000, Results All urine samples from participants treated with androstenedione contained 19-norandrosterone, while no samples from the no-androstenedione group did, Urinary concentrations were averaged for day 1 vs day 7 measurements; mean (SD) 19-norandrosterone concentrations in the 100-mg/d and 300-mg/d groups were 3.8 (2.5) ng/mL and 10,2 (6.9) ng/mL, respectively (P = .006),The 19-norandrosterone content exceeded the cut-off for reporting positive cases (>2.0 ng/mL) in 20 of 24. The androstenedione preparation used was pure at a sensitivity of 0.1%, but at 0.001% 19-norandrostenedione was found. For the 4 participants to whom 10 mug of 19-norandrostenedione was administered, 19-norandrosterone was found in all urine samples. Of 7 brands of androstenedione analyzed at the 1% level, 1 contained no androstenedione, 1 contained 10 mg of testosterone, and 4 more contained 90% or less of the amount stated on the label, Conclusion Our study suggests that trace contamination of androstenedione with 19-norandrostenedione is sufficient to cause urine test results positive for 19-norandrosterone, the standard marker for nandrolone use. Oral steroid doses as small as 10 mug are absorbed and excreted in urine. Some brands of androstenedione are grossly mislabeled. Careful analysis of androstenedione preparations is recommended in all studies of its biological effects.	Univ Calif Los Angeles, Olymp Analyt Lab, Dept Mol & Med Pharmacol, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90025 USA; Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90025 USA; Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital	Catlin, DH (corresponding author), Univ Calif Los Angeles, Olymp Analyt Lab, Dept Mol & Med Pharmacol, 2122 Granville Ave, Los Angeles, CA 90025 USA.		Finkelstein, Joel/M-6463-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002759] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [DK02759] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Catlin DH, 1996, JAMA-J AM MED ASSOC, V276, P231, DOI 10.1001/jama.276.3.231; CATLIN DH, 1987, CLIN CHEM, V33, P319; CIARDI M, 1999, RECENT ADV DOPING AN, P97; COPPEN JJW, 1979, TROP SCI, V21, P125; DEHENNIN L, 1987, J STEROID BIOCHEM, V26, P399, DOI 10.1016/0022-4731(87)90107-5; Dehennin L, 1999, J CHROMATOGR B, V721, P301, DOI 10.1016/S0378-4347(98)00480-0; FISHMAN J, 1982, CANC RES B, V42; Le Bizec B, 1999, J CHROMATOGR B, V723, P157, DOI 10.1016/S0378-4347(98)00541-6; Leder BZ, 2000, JAMA-J AM MED ASSOC, V283, P779, DOI 10.1001/jama.283.6.779; Merkli A, 1997, PLANT CELL REP, V16, P632, DOI [10.1007/s002990050292, 10.1007/BF01275505]; REZNIK Y, 1987, J CLIN ENDOCR METAB, V64, P1086, DOI 10.1210/jcem-64-5-1086; Uralets VP, 1999, J ANAL TOXICOL, V23, P357, DOI 10.1093/jat/23.5.357; US Department of Health and Human Services, 1999, GUID IND ANDAS IMP D; *US PHARM DI 2000, 1998, MICROMEDEX, V3; ZORPETTE G, 1999, SCI AM PRESENTS, V10, P52; 1999, CONSUMER REPORTS, V64, P44	17	97	99	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2618	2621		10.1001/jama.284.20.2618	http://dx.doi.org/10.1001/jama.284.20.2618			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086369				2022-12-28	WOS:000165296200036
J	Usami, T; Koyama, K; Takeuchi, O; Morozumi, K; Kimura, G				Usami, T; Koyama, K; Takeuchi, O; Morozumi, K; Kimura, G			Regional variations in the incidence of end-stage renal failure in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; HYPERTENSION; MORTALITY; SALT	Context Despite recent medical advances, the number of patients beginning dialysis annually is increasing in both the United States and Japan. The ethnically homogeneous population of Japan presents an opportunity to study the presence of factors other than race/ethnicity that might contribute to incidence of end-stage renal disease (ESRD), Objective To determine if and where regional differences exist in ESRD in Japan. Design, Setting, and Subjects Analysis of data reported by the Japanese Society for Dialysis Therapy based on the annual number of patients with ESRD beginning maintenance dialysis therapy in all 47 prefectures of Japan from 1982 to 1998. Main Outcome Measures Mean annual ESRD incidence and increasing rate of ESRD in each of 11 predefined areas making up the entire country. Results Incidence of ESRD increased approximately 3-fold in Japan during the study years, from 81.3 per 1 million in 1982 to 237.6 per 1 million in 1998. Significant regional differences were found in both measures. The mean (SEM) annual ESRD incidence (P<.01) and increasing rate of ESRD (P<.01), respectively, were significantly different across Japan. Koshinetsu (140 [11] per 1 million and 9.1 [0.6] per 1 million/y) and Hokuriku (141 [12] per 1 million and 9.7 [0.5] per 1 million/y) were the areas with the lowest incidence and increasing rate of incidence, while Okinawa (188 [17] per 1 million and 13.4 [0.6] per 1 million/y) and Kyushu (179 [15] per 1 million and 12.0 [0.6] per 1 million/y) were the areas with the highest incidence and increasing rate of incidence. Conclusions We found definite and significant regional differences in incidence and increasing rate of incidence of ESRD in Japan. Further analyses are needed to identify factors that contribute to these regional differences and thereby improve strategies for treatment of renal disease.	Nagoya City Univ, Sch Med, Dept Internal Med & Pathophysiol, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Usami, T (corresponding author), Nagoya City Univ, Sch Med, Dept Internal Med & Pathophysiol, Mizuho Ku, Nagoya, Aichi 4678601, Japan.							ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; Black HR, 1997, ARCH INTERN MED, V157, P2413; DAHL LK, 1961, AM J CARDIOL, V8, P571, DOI 10.1016/0002-9149(61)90137-0; *JAP SOC DIAL THER, 1997, I MEMB DIR JAP SOC I; *JAP SOC DIAL THER, 1999, OV REG DIAL TREATM; *JAP SOC NEPHR, 1997, JAP SOC NEPHR MEMB D; JOOSSENS JV, 1983, PREV MED, V12, P53, DOI 10.1016/0091-7435(83)90171-8; Kawamura M, 1997, Hypertens Res, V20, P287, DOI 10.1291/hypres.20.287; Klag MJ, 1997, JAMA-J AM MED ASSOC, V277, P1293, DOI 10.1001/jama.277.16.1293; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MacGregor GA, 1997, AM J HYPERTENS, V10, pS37; *MAN COORD AG JAP, 1998, STAT BUR STAT CTR AN; *MIN HLTH WELF, 1995, MAP NAT HLTH INS HLT; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; SASAKI N, 1962, JPN HEART J, V3, P312; Stamler Jeremiah, 1997, American Journal of Clinical Nutrition, V65, p626S, DOI 10.1093/ajcn/65.2.626S; TANAKA H, 1982, STROKE, V13, P574, DOI 10.1161/01.STR.13.5.574; *US DEP HHS, 1999, US REN DAT SYST USRD; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521	20	66	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2622	2624		10.1001/jama.284.20.2622	http://dx.doi.org/10.1001/jama.284.20.2622			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086370	Bronze			2022-12-28	WOS:000165296200037
J	Pignone, M; Harris, R; Kinsinger, L				Pignone, M; Harris, R; Kinsinger, L			Videotape-based decision aid for colon cancer screening - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							IMPROVING PREVENTIVE CARE; SOCIETY GUIDELINES; PATIENT REMINDERS; PHYSICIAN; PERFORMANCE; ADHERENCE; SERVICES	Background: Rates of colon cancer screening in the United States are low, in part because of poor communication between patients and providers about the availability of effective screening options. Objective: To test whether a decision aid consisting of an educational video, targeted brochure, and chart marker increased performance of colon cancer screening in primary care practices. Design: Randomized, controlled trial. Setting: Three community primary care practices in central North Carolina. Patients: 1657 consecutive adult patients 50 to 75 years of age were contacted. Of these, 651 (39%) agreed to participate; 249 of the 651 participants (38%) were eligible. Eligible patients had no personal or family history of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoidoscopy, colonoscopy, or barium enema in the past 5 years. Intervention: The 249 participants were randomly assigned to view an 11-minute video about colon cancer screening (intervention group) or a video about automobile safety (control group). After viewing the video, intervention group participants chose a color-coded educational brochure (based on stages of change) to indicate their degree of interest in screening. A chart marker of the same color was attached to their charts. Controls received a generic brochure on automobile safety, and no chart marker was attached. Measurements: Frequency of screening test ordering as reported by participants and frequency of completion of screening tests as verified by chart review. Results: Fecal occult blood testing or flexible sigmoidoscopy was ordered for 47.2% of intervention participants and 26.4% of controls (difference, 20.8 percentage points [95% CI, 8.6 to 32.9 percentage points]). Screening tests were completed by 36.8% of the intervention group and 22.6% of the control group (difference, 14.2 percentage points [CI, 3.0 to 25.4 percentage points]). Conclusion: A decision aid consisting of an educational video, brochure, and chart marker increased ordering and performance of colon cancer screening tests.	Univ N Carolina, Div Gen Internal Med & Clin Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Pignone, M (corresponding author), Univ N Carolina, Div Gen Internal Med & Clin Epidemiol, CB 7110,5039 Old Clin Bldg, Chapel Hill, NC 27599 USA.			Pignone, Michael/0000-0002-6657-7342				Balas EA, 2000, ARCH INTERN MED, V160, P301, DOI 10.1001/archinte.160.3.301; BECKER DM, 1989, AM J PREV MED, V5, P353, DOI 10.1016/S0749-3797(18)31056-0; BELCHER DW, 1990, ARCH INTERN MED, V150, P2533, DOI 10.1001/archinte.150.12.2533; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; DAVIDSON RA, 1984, ARCH INTERN MED, V144, P2167, DOI 10.1001/archinte.144.11.2167; DICKEY LL, 1992, J FAM PRACTICE, V34, P457; Dietrich A J, 1989, Fam Med, V21, P195; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; MCPHEE SJ, 1986, J GEN INTERN MED, V1, P275, DOI 10.1007/BF02596202; MEADE CD, 1994, AM J PUBLIC HEALTH, V84, P119, DOI 10.2105/AJPH.84.1.119; MYERS RE, 1991, MED CARE, V29, P1039, DOI 10.1097/00005650-199110000-00009; ORNSTEIN SM, 1991, J FAM PRACTICE, V32, P82; PETRAVAGE J, 1988, J FAM PRACTICE, V27, P387; Pignone M, 1999, J GEN INTERN MED, V14, P432, DOI 10.1046/j.1525-1497.1999.00018.x; PROCHASKA JO, 1992, BRIT J ADDICT, V87, P825; ROBIE PW, 1988, SOUTHERN MED J, V81, P902, DOI 10.1097/00007611-198807000-00022; *STAT CORP, 1997, STAT 5 0 COLL STAT; THOMPSON RS, 1986, MED CARE, V24, P904, DOI 10.1097/00005650-198610000-00004; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; TURNER BJ, 1989, J GEN INTERN MED, V4, P403, DOI 10.1007/BF02599691; *US PREV HLTH SERV, 1996, GUID CLIN PREV SERV; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; 1996, MMWR MORB MORTAL WKL, V45, P107	25	180	178	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					761	769		10.7326/0003-4819-133-10-200011210-00008	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085838				2022-12-28	WOS:000165321200001
J	Rainer, TH; Jacobs, P; Ng, YC; Cheung, NK; Tam, M; Lam, PKW; Wong, R; Cocks, RA				Rainer, TH; Jacobs, P; Ng, YC; Cheung, NK; Tam, M; Lam, PKW; Wong, R; Cocks, RA			Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; ECONOMICS NOTES; TOTAL HIP; TROMETHAMINE; MEPERIDINE; MANAGEMENT; EFFICACY; THERAPY; SULFATE	Objectives To investigate the cost effectiveness of intravenous ketorolac compared with intravenous morphine in relieving pain after blunt limb injury in an accident and emergency department. Design Double blind, randomised, controlled study and cost consequences analysis. Setting Emergency department of a university hospital in the New Territories of Hong Kong. Participants 148 adult patients with painful isolated limb injuries (limb injuries without other injuries). Main outcome measures Primary outcome measure was a cost consequences analysis comparing the use of ketorolac with morphines; secondary outcome measures were pain relief at rest and with limb movement, adverse events, patients' satisfaction, and time spent in the emergency department. Results No difference was found in the median time taken to achieve pain relief at rest between the group receiving ketorolac and the group receiving morphine, but with movement the median reduction in pain score in the ketorolac group was 1.09 per hour (95% confidence interval 1.05 to 2.02) compared with 0.87 (0.89 to 1.06) in the morphine group (P = 0.003). The odds of experiencing adverse events was 144.2 (41.5 to 501.6) times more likely with morphine than with ketorolac. The median time from the initial delivery of analgesia to the participant leaving the department was 20 (4.0 to 39.0) minutes shorter in the ketorolac group, than in the morphine group (P = 0.02). The mean cost per person was $HK44 (pound4; $5.6) in the ketorolac group and $HK229 in the morphine group (P < 9.0001). The median score for patients' satisfaction was 6.0 for ketorolac and 5.0 for morphine (P < 0.0001). Conclusion Intravenous ketorolac is a more cost effective analgesic than intravenous morphine in the management of isolated limb injury in all emergency department in Hong Kong, and its use may be considered as the dominant strategy.	Hong Kong Baptist Univ, Dept Econ, Kowloon, Hong Kong, Peoples R China; Prince Wales Hosp, Ctr Clin Trials & Epidemiol Res, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Finance, Shatin, Hong Kong, Peoples R China; Univ Alberta, Fac Med & Oral Hlth Sci, Dept Publ Hlth Sci, Edmonton, AB T6G 2G3, Canada; Chinese Univ Hong Kong, Prince Wales Hosp, Accid & Emergency Med Unit, Ctr Canc, Shatin, Hong Kong, Peoples R China	Hong Kong Baptist University; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; University of Alberta; Chinese University of Hong Kong; Prince of Wales Hospital	Rainer, TH (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Accid & Emergency Med Unit, Ctr Canc, Roome G05-06, Shatin, Hong Kong, Peoples R China.	rainer1091@cuhk.edu.hk	Rainer, Timothy/I-2591-2013; Wong, Randolph/AAE-3489-2020	Rainer, Timothy/0000-0003-3355-3237; Wong, Randolph/0000-0003-0027-459X				BAKKER C, 1994, J RHEUMATOL, V21, P264; Bartfield J M, 1994, Acad Emerg Med, V1, P532; Beattie WS, 1997, ANESTH ANALG, V84, P715, DOI 10.1097/00000539-199704000-00003; Benedetti C, 1990, MANAGEMENT PAIN, P1640; BLAND M, 1995, INTRO MED STAT; BOSEK V, 1994, CLIN J PAIN, V10, P314, DOI 10.1097/00002508-199412000-00012; *BRIT MED ASS ROYA, 1997, BRIT NAT FORM; BROWN CR, 1990, PHARMACOTHERAPY, V10, pS116; BROWN CR, 1999, PHARMACOTHERAPY, V10, P116; Burke JP, 1996, CLIN THER, V18, P197, DOI 10.1016/S0149-2918(96)80190-1; Byford S, 1998, BRIT MED J, V316, P1529, DOI 10.1136/bmj.316.7143.1529; CEPEDA MS, 1995, ANESTH ANALG, V80, P1150, DOI 10.1097/00000539-199506000-00014; Cordell WH, 1996, ANN EMERG MED, V28, P151, DOI 10.1016/S0196-0644(96)70055-0; Drummond MF, 2015, METHODS EC EVALUATIO; ETCHES RC, 1995, ANESTH ANALG, V81, P1175, DOI 10.1097/00000539-199512000-00010; FOLSLAND B, 1990, J INT MED RES, V18, P305, DOI 10.1177/030006059001800407; FRICKE JR, 1992, J CLIN PHARMACOL, V32, P376, DOI 10.1002/j.1552-4604.1992.tb03850.x; GADDIS GM, 1992, ANN EMERG MED, V21, P629; Gillis JC, 1997, DRUGS, V53, P139, DOI 10.2165/00003495-199753010-00012; GIN T, 1993, ANAESTH INTENS CARE, V21, P420, DOI 10.1177/0310057X9302100409; Goodacre SW, 1996, J ACCID EMERG MED, V13, P177; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jantos TJ, 1996, ANN EMERG MED, V28, P145, DOI 10.1016/S0196-0644(96)70054-9; Kirkwood BR, 1988, ESSENTIALS MED STAT, P167; Koenig K L, 1994, Acad Emerg Med, V1, P544; Marubini E, 1995, ANAL SURVIVAL DATA C; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MAUNUKSELA EL, 1992, CLIN PHARMACOL THER, V52, P436, DOI 10.1038/clpt.1992.167; Morrow G R, 1992, Qual Life Res, V1, P287, DOI 10.1007/BF00434942; MUNRO HM, 1994, BRIT J ANAESTH, V72, P624, DOI 10.1093/bja/72.6.624; OHARA DA, 1987, CLIN PHARMACOL THER, V41, P556, DOI 10.1038/clpt.1987.71; Palmer S, 1999, BRIT MED J, V318, P1349, DOI 10.1136/bmj.318.7194.1349; PARKE TJ, 1995, J CLIN ANESTH, V7, P465, DOI 10.1016/0952-8180(95)00054-L; PEIRCE RJ, 1990, PHARMACOTHERAPY, V10, pS111; Purday JP, 1996, CAN J ANAESTH, V43, P221, DOI 10.1007/BF03011738; RICE ASC, 1995, EUR J ANAESTH, V12, P313; SEVARINO FB, 1994, J CLIN ANESTH, V6, P23, DOI 10.1016/0952-8180(94)90113-9; STANSKI DR, 1990, PHARMACOTHERAPY, V10, pS40; STOUTEN EM, 1992, ACTA ANAESTH SCAND, V36, P716, DOI 10.1111/j.1399-6576.1992.tb03551.x; Strom BL, 1996, JAMA-J AM MED ASSOC, V275, P376, DOI 10.1001/jama.275.5.376; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Todd KH, 1996, ACAD EMERG MED, V3, P142, DOI 10.1111/j.1553-2712.1996.tb03402.x; Torgerson D, 1999, BMJ-BRIT MED J, V318, P1413, DOI 10.1136/bmj.318.7195.1413; TURNER DM, 1995, J SPINAL DISORD, V8, P206, DOI 10.1097/00002517-199506000-00005; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X; WATCHA MF, 1992, ANESTHESIOLOGY, V76, P368, DOI 10.1097/00000542-199203000-00008; WHIPPLE JK, 1995, PHARMACOTHERAPY, V15, P592, DOI 10.1002/j.1875-9114.1995.tb02868.x; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; YEALY DM, 1992, ANN EMERG MED, V21, P985, DOI 10.1016/S0196-0644(05)82941-5	50	37	45	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2000	321	7271					1247	1251		10.1136/bmj.321.7271.1247	http://dx.doi.org/10.1136/bmj.321.7271.1247			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082083	Bronze, Green Published			2022-12-28	WOS:000165445800022
J	Wyss, M; Wiemer, S				Wyss, M; Wiemer, S			Change in the probability for earthquakes in southern California due to the Landers magnitude 7.3 earthquake	SCIENCE			English	Article							PRECURSORY SEISMIC QUIESCENCE; B-VALUES; MAGMA CHAMBERS; STRESS; SLIP; ASPERITIES; RELEASE; MOMENT; TIME	The Landers earthquake in June 1992 redistributed stress in southern California, shutting off the production of small earthquakes in some regions while increasing the seismicity in neighboring regions, up to the present, This earthquake also changed the ratio of small to large events in favor of more small earthquakes within about 100 kilometers of the epicenter. This implies that the probabilistic estimate for future earthquakes in southern California changed because of the Landers earthquake. The location of the strongest increase in probability for Large earthquakes in southern California was the volume that subsequently produced the largest slip in the magnitude 7.1 Hector Mine earthquake of October 1999.	Univ Alaska, Inst Geophys, Fairbanks, AK 99775 USA; Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland	University of Alaska System; University of Alaska Fairbanks; Swiss Federal Institutes of Technology Domain; ETH Zurich	Wyss, M (corresponding author), Univ Alaska, Inst Geophys, Fairbanks, AK 99775 USA.	max@giseis.alaska.edu; stefan@seismo.ifg.ethz.ch	Wiemer, Stefan/E-5033-2015	Wiemer, Stefan/0000-0002-4919-3283				Aki K., 1965, B EARTHQ RES I TOKYO, V43, P237; Amelung F, 1997, GEOPHYS RES LETT, V24, P507, DOI 10.1029/97GL00287; [Anonymous], 1992, REPORT JOINT RES I S; Behr J., 2000, SEISMOL RES LETT, V71, P11; Boatwright J, 1996, J GEOPHYS RES-SOL EA, V101, P13895, DOI 10.1029/96JB00405; BODIN P, 1994, B SEISMOL SOC AM, V84, P835; Bowman DD, 1998, J GEOPHYS RES-SOL EA, V103, P24359, DOI 10.1029/98JB00792; FROHLICH C, 1993, J GEOPHYS RES-SOL EA, V98, P631, DOI 10.1029/92JB01891; Gross S, 1997, J GEOPHYS RES-SOL EA, V102, P7603, DOI 10.1029/96JB03741; HABERMANN RE, 1983, J GEOPHYS RES, V88, P5056, DOI 10.1029/JB088iB06p05056; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; Jaume SC, 1999, PURE APPL GEOPHYS, V155, P279, DOI 10.1007/s000240050266; Jones LM, 1997, GEOPHYS RES LETT, V24, P469, DOI 10.1029/97GL00188; Kagan YY, 1999, PURE APPL GEOPHYS, V155, P537, DOI 10.1007/s000240050277; Kato N, 1997, PURE APPL GEOPHYS, V150, P249; KEILISBOROK VI, 1988, NATURE, V335, P690, DOI 10.1038/335690a0; KILB D, IN PRESS NATURE; Knopoff L, 1996, J GEOPHYS RES-SOL EA, V101, P5779, DOI 10.1029/95JB03730; MARRIOTT D, 2000, EOS, V81, P5302; Murru M, 1999, GEOPHYS RES LETT, V26, P2553, DOI 10.1029/1999GL900568; OGATA Y, 1993, GEOPHYS J INT, V113, P727, DOI 10.1111/j.1365-246X.1993.tb04663.x; Parsons T, 2000, GEOPHYS RES LETT, V27, P1949, DOI 10.1029/1999GL011272; Parsons T, 1999, J GEOPHYS RES-SOL EA, V104, P20183, DOI 10.1029/1999JB900056; PRESS F, 1995, J GEOPHYS RES-SOL EA, V100, P6421, DOI 10.1029/95JB00316; REASENBERG P, 1985, J GEOPHYS RES-SOLID, V90, P5479, DOI 10.1029/JB090iB07p05479; REASENBERG PA, 1997, US GEOL SURV PROF D, V1550, pD49; Richardson E, 1999, J GEOPHYS RES-SOL EA, V104, P28859, DOI 10.1029/1999JB900320; Sammis CG, 1999, PURE APPL GEOPHYS, V155, P307, DOI 10.1007/s000240050267; SCHOLZ CH, 1968, B SEISMOL SOC AM, V58, P399; STEIN RS, 1992, SCIENCE, V258, P1328, DOI 10.1126/science.258.5086.1328; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; URBANCIC TI, 1992, PURE APPL GEOPHYS, V139, P449, DOI 10.1007/BF00879946; VARNES DJ, 1989, PURE APPL GEOPHYS, V130, P661, DOI 10.1007/BF00881603; WALD DJ, 1994, B SEISMOL SOC AM, V84, P668; Wiemer S, 1997, GEOPHYS RES LETT, V24, P189, DOI 10.1029/96GL03779; WIEMER S, 1994, B SEISMOL SOC AM, V84, P900; Wiemer S, 1998, GEOPHYS J INT, V134, P409, DOI 10.1046/j.1365-246x.1998.00561.x; Wiemer S, 1997, J GEOPHYS RES-SOL EA, V102, P15115, DOI 10.1029/97JB00726; Wiemer S., 1996, THESIS U ALASKA FAIR; WYSS M, 1973, GEOPHYS J ROY ASTR S, V31, P341, DOI 10.1111/j.1365-246X.1973.tb06506.x; Wyss M, 1998, GEOPHYS J INT, V134, P329, DOI 10.1046/j.1365-246x.1998.00543.x; Wyss M, 2000, J GEOPHYS RES-SOL EA, V105, P7829, DOI 10.1029/1999JB900347; Wyss M, 1999, ANN GEOFIS, V42, P851; Wyss M, 1999, PURE APPL GEOPHYS, V155, P259, DOI 10.1007/s000240050265; Wyss M, 1997, J GEOPHYS RES-SOL EA, V102, P20413, DOI 10.1029/97JB01074; Zuniga FR, 1999, PURE APPL GEOPHYS, V155, P713, DOI 10.1007/s000240050285; Zuniga FR, 1995, B SEISMOL SOC AM, V85, P1858	47	123	135	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1334	1338		10.1126/science.290.5495.1334	http://dx.doi.org/10.1126/science.290.5495.1334			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082057				2022-12-28	WOS:000165379800043
J	Silveira, MJ; DiPiero, A; Gerrity, MS; Feudtner, C				Silveira, MJ; DiPiero, A; Gerrity, MS; Feudtner, C			Patients' knowledge of options at the end of life - Ignorance in the face of death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-DETERMINATION ACT; ADVANCE DIRECTIVES; ELDERLY OUTPATIENTS; MEDICAL-CARE; ATTITUDES; PHYSICIANS	Context Effectiveness of legislation promoting advance directives and legalizing physician-assisted suicide depends on patients' understanding their legal options about end-of-life care. However, outpatients' understanding of their legal options at the end of life has not been studied. Objectives To estimate the percentage of outpatients who are informed about 4 areas relevant to end-of-life care: refusal and withdrawal of lifesaving treatments, physician-assisted suicide, active euthanasia, and double effect; and to determine whether authoring advance directives, experiencing illness, acting as a proxy for health care decisions, and caring for an ill loved one are associated with better knowledge in end-of-life care. Design Cross-sectional survey. Setting and Participants One thousand consecutive English-speaking, adult patients attending 1 university-based internal medicine clinic and 3 community-based, university-affiliated, mixed internal medicine and family practice clinics in Oregon during May and June 1999. Main Outcome Measures Percentage of correct responses in the 4 topic areas and total knowledge score, adjusted for demographic (eg, age, race, educational level, income level, marital status) and experiential (eg, health, proxy decision making, advance directives, and death of a loved one) factors. Results Of the 1000 patients invited to participate, 728 (73 %) consented and completed the questionnaire and were included in the analysis. A total of 69% of respondents answered correctly regarding refusal of treatment, 46% for withdrawal of treatment, 23% for assisted suicide, 32% for active euthanasia, and 41% for double effect. Sixty-two percent of respondents did not distinguish between assisted suicide and euthanasia. After adjustment for other covariates, better knowledge was significantly associated with white race (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.3-4.2), having at least a college degree (OR, 3.0; 95% CI, 1.4-6.7), and having been a proxy for health care decisions (OR, 1.8, 95% CI, 1.2-2.6). Personal experience with illness (OR, 1.0; 95% CI, 0.6-1.5), death or illness of a loved one (OR, 1.6; 95% CI; 1.0-2.7), and authoring an advance directive (OR,1,3; 95% CI, 0.9-2.0) were not associated with better knowledge. Conclusions A significant proportion of outpatients at university-affiliated clinics in Oregon appear to misunderstand options in end-of-life care. Our results suggest that greater public knowledge about end-of-life care is needed, and advance care planning must be preceded by education about options in end-of-life care.	Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98195 USA; Oregon Hlth Sci Univ, Dept Gen Internal Med, Portland, OR 97201 USA	University of Washington; University of Washington Seattle; Oregon Health & Science University	Silveira, MJ (corresponding author), Univ Washington, Hlth Sci Ctr H220, Robert Wood Johnson Clin Scholars Program, Box 357183, Seattle, WA 98195 USA.		Silveira, Maria J/E-9802-2013; Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434; Gerrity, Martha/0000-0002-8772-4591; Silveira, Maria/0000-0002-6600-8633				*AMA POLL, 1997, AM MED NEWS     0113, P3; EDINGER W, 1992, J FAM PRACTICE, V35, P650; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL L, 1991, HASTINGS CENT REP, V21, pS6, DOI 10.2307/3562901; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GAMBLE ER, 1991, ARCH INTERN MED, V151, P277, DOI 10.1001/archinte.151.2.277; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Kane R J, 1991, J Health Hosp Law, V24, P373; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P402, DOI 10.1001/jama.266.3.402; MEISEL A, 1995, RIGHT DIE; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; Smucker W D, 1993, J Am Board Fam Pract, V6, P473; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909; WHITE ML, 1991, JAMA-J AM MED ASSOC, V266, P410, DOI 10.1001/jama.1991.03470030110035; 1994, TRENDS HLTH CARE LAW, V9, P29	20	127	127	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2483	2488		10.1001/jama.284.19.2483	http://dx.doi.org/10.1001/jama.284.19.2483			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371MY	11074778	Bronze			2022-12-28	WOS:000165183800022
J	Luppi, M; Barozzi, P; Schulz, TF; Setti, G; Staskus, K; Trovato, R; Narni, F; Donelli, A; Maiorana, A; Marasca, R; Sandrini, S; Torelli, G; Sheldon, J				Luppi, M; Barozzi, P; Schulz, TF; Setti, G; Staskus, K; Trovato, R; Narni, F; Donelli, A; Maiorana, A; Marasca, R; Sandrini, S; Torelli, G; Sheldon, J			Bone marrow failure associated with human herpesvirus 8 infection after transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY-EFFUSION LYMPHOMA; POLYMERASE CHAIN-REACTION; KAPOSIS-SARCOMA; NUCLEAR ANTIGEN; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8; RECIPIENTS; PROTEIN; GENE	Background: Human herpesvirus 8 (HHV-8) infection has been linked to the development of Kaposi's sarcoma and to rare lymphoproliferative disorders. Methods: We used molecular methods, serologic methods, in situ hybridization, and immunohistochemical analyses to study HHV-8 infection in association with nonmalignant illnesses in three patients after transplantation. Results: Primary HHV-8 infections developed in two patients four months after each received a kidney from the same HHV-8-seropositive cadaveric donor. Seroconversion and viremia occurred coincidentally with disseminated Kaposi's sarcoma in one patient and with an acute syndrome of fever, splenomegaly, cytopenia, and marrow failure with plasmacytosis in the other patient. HHV-8 latent nuclear antigen was present in immature progenitor cells from the aplastic marrow of the latter patient. Identification of the highly variable K1 gene sequence of the HHV-8 genome in both the donor's peripheral-blood cells and the recipients' serum confirmed that transmission had occurred. HHV-8 viremia also occurred after autologous peripheral-blood stem-cell transplantation in an HHV-8-seropositive patient with non-Hodgkin's lymphoma. Reactivation of the infection was associated with the development of fever and marrow aplasia with plasmacytosis; there was no evidence of other infections. HHV-8 transcripts and latent nuclear antigen were expressed in the aplastic marrow but not in two normal marrow samples obtained before transplantation. Conclusions: Primary HHV-8 infection and reactivation of infection may be associated with nonneoplastic complications in immunosuppressed patients. (N Engl J Med 2000;343:1378-85.) (C) 2000, Massachusetts Medical Society.	Univ Modena & Reggio Emilia, Policlin, Dept Med Sci, Sect Hematol, I-41100 Modena, Italy; Univ Modena & Reggio Emilia, Dept Pathol, I-41100 Modena, Italy; Univ Liverpool, Dept Med Microbiol & Genitourinary Med, Liverpool L69 3BX, Merseyside, England; Univ Brescia, Div Nephrol, Brescia, Italy; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia; University of Liverpool; University of Brescia; University of Minnesota System; University of Minnesota Twin Cities	Torelli, G (corresponding author), Univ Modena & Reggio Emilia, Policlin, Dept Med Sci, Sect Hematol, Via Pozzo 71, I-41100 Modena, Italy.		Schulz, Thomas/AAA-1634-2019; Comoli, Patrizia/K-2732-2018; Maiorana, Antonino/H-6209-2014; Barozzi, Patrizia/Q-2638-2016; Marasca, Roberto/I-8072-2013; Luppi, Mario/J-3668-2016	Comoli, Patrizia/0000-0001-5964-0553; Maiorana, Antonino/0000-0001-9634-2520; Barozzi, Patrizia/0000-0002-8936-1114; Marasca, Roberto/0000-0002-6431-6878; Luppi, Mario/0000-0002-0373-1154; Schulz, Thomas/0000-0001-8792-5345; NARNI, Franco/0000-0003-3994-9101				ABRAMS DI, 1984, AM J CLIN PATHOL, V81, P13, DOI 10.1093/ajcp/81.1.13; Calabro M L, 1998, J Hum Virol, V1, P207; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cinque P, 1996, AIDS, V10, P951, DOI 10.1097/00002030-199610090-00004; Cook PM, 1999, AIDS, V13, P1165, DOI 10.1097/00002030-199907090-00004; Dotti G, 1999, LEUKEMIA, V13, P664, DOI 10.1038/sj.leu.2401390; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Farci P, 1996, NEW ENGL J MED, V335, P631, DOI 10.1056/NEJM199608293350904; Farge D, 1999, TRANSPLANTATION, V67, P1236, DOI 10.1097/00007890-199905150-00007; Frances C, 1999, NEW ENGL J MED, V340, P1045, DOI 10.1056/NEJM199904013401314; Ganem D, 1997, CELL, V91, P157, DOI 10.1016/S0092-8674(00)80398-0; Ho M, 1998, NEW ENGL J MED, V339, P1391, DOI 10.1056/NEJM199811053391910; Jones D, 1998, NEW ENGL J MED, V339, P444, DOI 10.1056/NEJM199808133390705; Kurtzman G, 1989, Baillieres Clin Haematol, V2, P51, DOI 10.1016/S0950-3536(89)80007-1; KURTZMAN GJ, 1987, NEW ENGL J MED, V317, P287, DOI 10.1056/NEJM198707303170506; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; Matsushima AY, 1999, AM J SURG PATHOL, V23, P1393, DOI 10.1097/00000478-199911000-00010; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Oksenhendler E, 1998, NEW ENGL J MED, V338, P1585, DOI 10.1056/NEJM199805283382204; Parravicini C, 1997, BLOOD, V90, P2826; Penn I, 1997, TRANSPLANTATION, V64, P669, DOI 10.1097/00007890-199709150-00001; Platt GM, 1999, J VIROL, V73, P9789, DOI 10.1128/JVI.73.12.9789-9795.1999; Raab MS, 1998, J VIROL, V72, P6725, DOI 10.1128/JVI.72.8.6725-6731.1998; Rabkin CS, 1999, NEW ENGL J MED, V340, P1045; Rabkin CS, 1998, J INFECT DIS, V178, P304, DOI 10.1086/515649; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Regamey N, 1998, NEW ENGL J MED, V339, P1358, DOI 10.1056/NEJM199811053391903; Rose TM, 1997, J VIROL, V71, P4138, DOI 10.1128/JVI.71.5.4138-4144.1997; Rosenzwajg M, 1999, BONE MARROW TRANSPL, V24, P351, DOI 10.1038/sj.bmt.1701931; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; SECCHIERO P, 1995, J INFECT DIS, V171, P273, DOI 10.1093/infdis/171.2.273; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Singh N, 1996, ANN INTERN MED, V124, P1065, DOI 10.7326/0003-4819-124-12-199606150-00007; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; VERDONCK LF, 1991, BLOOD, V78, P844; Wang FZ, 1996, BLOOD, V88, P3615, DOI 10.1182/blood.V88.9.3615.bloodjournal8893615; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; Zong JC, 1999, J VIROL, V73, P4156, DOI 10.1128/JVI.73.5.4156-4170.1999	39	158	166	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1378	1385		10.1056/NEJM200011093431905	http://dx.doi.org/10.1056/NEJM200011093431905			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070102				2022-12-28	WOS:000165152800005
J	Papavasiliou, FN; Schatz, DG				Papavasiliou, FN; Schatz, DG			Cell-cycle-regulated DNA double-strand breaks in somatic hypermutation of immunoglobulin genes	NATURE			English	Article							HEAVY-CHAIN LOCUS; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; RECOMBINATION; ANTIBODY; TRANSCRIPTION; DELETIONS; SEQUENCES; PATHWAYS; RECEPTOR	Targeted hypermutation of immunoglobulin variable region genes occurs in B cells during an immune response(1), and gives rise to families of related mutant antibodies which are then selected for their binding affinity to the immunizing antigen(2). Somatic hypermutation predominantly generates point mutations, many of which occur at specific residues (hotspots)(3). The reaction has been linked to transcription and requires the presence of immunoglobulin enhancers(4-6), but replacement of the variable gene by heterologous sequences, or the variable region promoter by a heterologous promoter, does not interfere with the mutation process(7,8). Here we show the existence of abundant DNA double-strand breaks (DSBs) in hypermutating sequences. Generation of the DSBs is coupled to transcription, enhancer-dependent, and correlates with the appearance of nearby mutations. Furthermore, the DSBs are cell-cycle restricted, being found almost exclusively in cells that have completed, or nearly completed, DNA replication. We propose a model for somatic hypermutation in which mutations are introduced into the DNA during repair of DSBs by homologous recombination. The finding of DSBs during somatic hypermutation may help to explain the chromosomal translocations found in some B-cell tumours.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University	Schatz, DG (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, Box 208011,310 Cedar St, New Haven, CT 06520 USA.	david.schatz@yale.edu	Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; Holbeck SL, 1997, GENETICS, V147, P1017; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kenter AL, 1999, J EXP MED, V190, P307, DOI 10.1084/jem.190.3.307; Klein U, 1998, IMMUNOL REV, V162, P261; Lo AKF, 1997, ANN NY ACAD SCI, V815, P432, DOI 10.1111/j.1749-6632.1997.tb52095.x; McGill CB, 1998, GENETICS, V148, P1525; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; STRATHERN JN, 1995, GENETICS, V140, P965; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; Vignali DAA, 1996, J EXP MED, V183, P2097, DOI 10.1084/jem.183.5.2097; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; WEISS S, 1987, EMBO J, V6, P927, DOI 10.1002/j.1460-2075.1987.tb04840.x; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; YELAMOS J, 1995, NATURE, V376, P225	30	226	230	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					216	221		10.1038/35041599	http://dx.doi.org/10.1038/35041599			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089977				2022-12-28	WOS:000165180400049
J	Frey, JJ				Frey, JJ			I have always been fascinated ...	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2295	2296		10.1001/jama.284.18.2295	http://dx.doi.org/10.1001/jama.284.18.2295			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066159				2022-12-28	WOS:000165074500001
J	Johnson, JG; Cohen, P; Pine, DS; Klein, DF; Kasen, S; Brook, JS				Johnson, JG; Cohen, P; Pine, DS; Klein, DF; Kasen, S; Brook, JS			Association between cigarette smoking and anxiety disorders during adolescence and early adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PANIC DISORDER; PSYCHIATRIC-DISORDERS; MAJOR DEPRESSION; SUBSTANCE USE; NICOTINE; ATTACKS	Context Cigarette smoking is associated with some anxiety disorders, but the direction of the association between smoking and specific anxiety disorders has not been determined. Objective To investigate the longitudinal association between cigarette smoking and anxiety disorders among adolescents and young adults. Design The Children in the Community Study, a prospective longitudinal investigation. Setting and Participants Community-based sample of 688 youths (51% female) from upstate New York interviewed in the years 1985-1986, at a mean age of 16 years, and in the years 1991-1993, at a mean age of 22 years. Main Outcome Measure Participant cigarette smoking and psychiatric disorders in adolescence and early adulthood, measured by age-appropriate versions of the Diagnostic interview Schedule for Children. Results Heavy cigarette smoking (greater than or equal to 20 cigarettes/d) during adolescence was associated with higher risk of agoraphobia (10.3% vs 1.8%; odds ratio [OR], 6.79; 95% confidence interval [CI], 1.53-30.17), generalized anxiety disorder (20.5% vs 3.71%; OR, 5.53; 95% CI, 1.84-16.66), and panic disorder (7.7% vs 0.6%; OR, 15.58; 95% CI, 2.31-105.14) during early adulthood after controlling for age, sex, difficult childhood temperament; alcohol and drug use, anxiety, and depressive disorders during adolescence; and parental smoking, educational level, and psychopathology. Anxiety disorders during adolescence were not significantly associated with chronic cigarette smoking during early adulthood. Fourteen percent and 15% of participants with and without anxiety during adolescence, respectively, smoked at least 20 cigarettes per day during early adulthood (OR, 0.88; 95% CI, 0.36-2.14). Conclusion Our results suggest that cigarette smoking may increase risk of certain anxiety disorders during late adolescence and early adulthood.	New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY USA; Mt Sinai Med Ctr, Dept Community Med, New York, NY 10029 USA; NIMH, Intramural Res Program, Program Mood & Anxiety Disorders, Bethesda, MD 20892 USA	New York State Psychiatry Institute; Columbia University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Johnson, JG (corresponding author), New York State Psychiat Inst, Dept Psychiat, Box 60,1051 Riverside Dr, New York, NY 10032 USA.		Pine, Daniel/Z-1601-2019		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003188] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-03188] Funding Source: Medline; NIMH NIH HHS [MH-36971, K-20-MH-01391] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Amering M, 1999, COMPR PSYCHIAT, V40, P35, DOI 10.1016/S0010-440X(99)90074-3; Biber B, 1999, AM J PSYCHIAT, V156, P739; Breslau N, 1999, ARCH GEN PSYCHIAT, V56, P1141, DOI 10.1001/archpsyc.56.12.1141; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; Brook JS, 1998, J AM ACAD CHILD PSY, V37, P322, DOI 10.1097/00004583-199803000-00018; Cohen P., 1996, LIFE VALUES ADOLESCE; Costello E. J., 1984, TESTING NIMH DIAGNOS; DILSAVER SC, 1987, AM J PSYCHIAT, V144, P1245; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Himle J., 1988, PHOBIA PRACTICE RES, V1, P25; Kandel DB, 1997, J ABNORM CHILD PSYCH, V25, P121, DOI 10.1023/A:1025779412167; Kassel JD, 1997, HEALTH PSYCHOL, V16, P359, DOI 10.1037/0278-6133.16.4.359; KLEIN DF, 1994, ANXIETY, V1, P144; KOGAN L, 1977, J SOCIAL SERVICE RES, V1, P117, DOI DOI 10.1300/J079V01N02_01; Patton GC, 1998, AM J PUBLIC HEALTH, V88, P1518, DOI 10.2105/AJPH.88.10.1518; PERNA G, 1995, AM J PSYCHIAT, V152, P85; Pine DS, 2000, ARCH GEN PSYCHIAT, V57, P960, DOI 10.1001/archpsyc.57.10.960; Pine DS, 1998, ARCH GEN PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; POHL R, 1992, PSYCHIAT RES, V43, P253, DOI 10.1016/0165-1781(92)90058-B; Sonntag H, 2000, EUR PSYCHIAT, V15, P67, DOI 10.1016/S0924-9338(00)00209-1; SQUIRESWHEELER E, 1985, NEW YORK HIGH RISK S; West R, 1997, AM J PSYCHIAT, V154, P1589, DOI 10.1176/ajp.154.11.1589	22	353	362	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2348	2351		10.1001/jama.284.18.2348	http://dx.doi.org/10.1001/jama.284.18.2348			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369NU	11066185				2022-12-28	WOS:000165074500029
J	Neyt, C; Jagla, K; Thisse, C; Thisse, B; Haines, L; Currie, PD				Neyt, C; Jagla, K; Thisse, C; Thisse, B; Haines, L; Currie, PD			Evolutionary origins of vertebrate appendicular muscle	NATURE			English	Article							PRECURSOR CELLS; ZEBRAFISH; SPECIFICATION; MUSCULATURE; INDUCTION; HEDGEHOG; EMBRYOS; SLOW	The evolution of terrestrial tetrapod species heralded a transition in locomotor strategies. While most fish species use the undulating contractions of the axial musculature to generate propulsive force, tetrapods also rely on the appendicular muscles of the limbs to generate movement(1,2). Despite the fossil record generating an understanding of the way in which the appendicular skeleton has evolved to provide the scaffold for tetrapod limb musculature(3), there is, by contrast, almost no information as to how this musculature arose. Here we examine fin muscle formation within two extant classes of fish. We find that in the teleost, zebrafish, fin muscles arise from migratory mesenchymal precursor cells that possess molecular and morphogenetic identity with the limb muscle precursors of tetrapod species. Chondrichthyan dogfish embryos, however, use the primitive mechanism of direct epithelial somitic extensions to derive the muscles of the fin. We conclude that the genetic mechanism controlling formation of tetrapod limb muscles evolved before the Sarcopterygian radiation.	Western Gen Hosp, MRC, Human Genet Unit, Comparat & Dev Genet Sect, Edinburgh EH4 2XU, Midlothian, Scotland; INSERM, U384, F-63001 Clermont Ferrand, France; ULP, CNRS, INSERM, Inst Genet Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	University of Edinburgh; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Currie, PD (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Comparat & Dev Genet Sect, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	petec@hgu.mrc.ac.uk	Jagla, Krzysztof/E-4144-2016	Jagla, Krzysztof/0000-0003-4965-8818; Currie, Peter/0000-0001-8874-8862; THISSE, Christine/0000-0002-8684-1681				Basden AM, 2000, NATURE, V403, P185, DOI 10.1038/35003183; Blagden CS, 1997, GENE DEV, V11, P2163, DOI 10.1101/gad.11.17.2163; Braus H., 1899, MORPHOL JB, V27, P501; Brohmann H, 2000, DEVELOPMENT, V127, P437; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; Cinnamon Y, 1999, DEVELOPMENT, V126, P4305; COATES MI, 1994, DEVELOPMENT, P169; CORNING HK, 1842, MORPHOLOGISCHES JB, V22, P79; Currie PD, 1996, NATURE, V382, P452, DOI 10.1038/382452a0; Denetclaw WF, 2000, DEVELOPMENT, V127, P893; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Didier Dominique A., 1995, American Museum Novitates, V3119, P1; Dietrich S, 1998, DEVELOPMENT, V125, P2235; Dohrn A., 1884, MITTEILUNGEN ZOOLOGI, V5, P161; Goodrich E.S., 1958, STUDIES STRUCTURE DE, VI; GRIM M, 1973, Folia Morphologica (Prague), V21, P197; Gross MK, 2000, DEVELOPMENT, V127, P413; Harrison RG, 1895, ARCH MIKROSK ANAT, V46, P500; Higashijima S, 1997, DEV BIOL, V192, P289, DOI 10.1006/dbio.1997.8779; Houzelstein D, 1999, DEVELOPMENT, V126, P2689; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; Janvier P, 1999, TRENDS ECOL EVOL, V14, P298, DOI 10.1016/S0169-5347(99)01666-3; Kardong K.V., 1995, VERTEBRADOSANATOMIA; Kozlowski DJ, 1997, BIOCHEM CELL BIOL, V75, P551, DOI 10.1139/bcb-75-5-551; Mankoo BS, 1999, NATURE, V400, P69, DOI 10.1038/21892; Rasmussen AS, 1999, J MOL EVOL, V48, P118, DOI 10.1007/PL00006439; Schafer K, 1999, NAT GENET, V23, P213, DOI 10.1038/13843; Weinberg ES, 1996, DEVELOPMENT, V122, P271	30	140	142	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					82	86		10.1038/35040549	http://dx.doi.org/10.1038/35040549			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081511				2022-12-28	WOS:000165050400055
J	Bourke, U				Bourke, U			Luxembourg: medicine at the European Court of Justice	LANCET			English	Article								The European court of Justice in Luxembourg was created as the legal institution of the European Union. Cases are brought by the European Commission, by member states, and by individuals and cases may be referred from national courts for clarification from the ECJ. Medical Gases are likely to be brought under four Articles of the Treaty of the European Union. 12 cases from 1986 to October, 2000, are used to illustrate the variety of medical cases that have been decided by the ECJ or are still pending.	Lower Farmhouse, Moreton In Marsh GL56 0TN, England		Bourke, U (corresponding author), Lower Farmhouse, Moreton In Marsh GL56 0TN, England.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1514	1516		10.1016/S0140-6736(00)02886-5	http://dx.doi.org/10.1016/S0140-6736(00)02886-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081551				2022-12-28	WOS:000090067300042
J	Gruchalla, RS				Gruchalla, RS			Clinical assessment of drug-induced disease	LANCET			English	Article							MAST-CELL ACTIVATION; HOSPITALIZED-PATIENTS; TRYPTASE; HYPERSENSITIVITY; SULFAMETHOXAZOLE; SULFONAMIDES; MASTOCYTOSIS; METABOLITES; TOXICITY; MARKERS	Physicians are often confronted with patients who state that they are "allergic" to a drug or drugs. Knowing which medications can be prescribed safely is therefore difficult, and care of such patients frustrating. The goal of this review is to help physicians develop management plans for patients who present with drug-induced diseases'. It provides information that allows physicians to differentiate between reactions that are truly allergic in nature and those that are not immunologically mediated. Relevant information on medical history, physical findings, and laboratory tests that may be helpful in the assessment are discussed, and guidance is provided on when and if a drug may be safely readministered. Unfortunately, however, until we are able to better understand the mechanisms responsible for drug-induced reactions, our management tools will remain limited.	Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gruchalla, RS (corresponding author), Univ Texas, SW Med Ctr, Div Allergy & Immunol, Dallas, TX 75390 USA.							ADKINSON N, 1998, ALLERGY PRINCIPLES P, V2, P1212; [Anonymous], 1999, Ann Allergy Asthma Immunol, V83, P665; Araujo O E, 1984, J Emerg Med, V2, P129, DOI 10.1016/0736-4679(84)90332-9; ARKY R, 1999, PHYSICIANS DESK REFE; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; deShazo RD, 1997, JAMA-J AM MED ASSOC, V278, P1895, DOI 10.1001/jama.278.22.1895; EISEN HN, 1959, CELLULAR HUMORAL ASP; Gell PGH., 1975, CLIN ASPECTS IMMUNOL, V3; Gruchalla RS, 1998, J ALLERGY CLIN IMMUN, V101, P371, DOI 10.1016/S0091-6749(98)70250-7; Hess DA, 1997, ANN PHARMACOTHER, V31, P1378, DOI 10.1177/106002809703101116; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEVY J, 1992, ANAPHYLACTIC REACTIO, P83; LEVY M, 1991, CLIN PEDIATR, V30, P42, DOI 10.1177/000992289103000107; LITT J, 1995, DRUG ERUPTION REFERE; MATSSON P, 1991, AGENTS ACTIONS, V33, P218, DOI 10.1007/BF01993172; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; OSAWA J, 1990, Journal of Dermatology (Tokyo), V17, P235; PARK BK, 1992, BRIT J CLIN PHARMACO, V34, P377, DOI 10.1111/j.1365-2125.1992.tb05647.x; Pirmohamed M, 1998, BRIT MED J, V316, P1295, DOI 10.1136/bmj.316.7140.1295; PRIMOHAMED M, 1996, CLIN PHARMACOKINET, V32, P215; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RILEY RJ, 1995, CLIN EXP IMMUNOL, V99, P1; ROMANO A, 1995, ALLERGY, V50, P113; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SHEAR N, 1985, BRIT J DERMATOL, V28, pS112; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1990, ARCH DERMATOL, V126, P94, DOI 10.1001/archderm.126.1.94; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; Solensky R, 2000, ANN ALLERG ASTHMA IM, V84, P329, DOI 10.1016/S1081-1206(10)62782-2; Stitt VJ., 1988, J NATL MED ASSOC, V80, P106; VERVLOET D, 1999, DRUG ALLERGY, P323; Weiss ME, 1998, IMMUNOL ALLERGY CLIN, V18, P731, DOI 10.1016/S0889-8561(05)70035-7; *WHO, 1966, INT DRUG MON ROL HOS	37	61	63	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1505	1511		10.1016/S0140-6736(00)02885-3	http://dx.doi.org/10.1016/S0140-6736(00)02885-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081549				2022-12-28	WOS:000090067300040
J	Mitton, S				Mitton, S			Have physicists glimpsed the particle pinnacle?	LANCET			English	Editorial Material									Univ Cambridge, St Edmunds Coll, Cambridge CB3 0BN, England	University of Cambridge	Mitton, S (corresponding author), Univ Cambridge, St Edmunds Coll, Cambridge CB3 0BN, England.		Mitton, Simon A/A-5899-2012	Mitton, Simon A/0000-0003-3695-9806					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1460	1460						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081526				2022-12-28	WOS:000090067300007
J	van Craaikamp, JCJ; Oosting, ME				van Craaikamp, JCJ; Oosting, ME			Netherlands: IVF for unmarried women, euthanasia	LANCET			English	Article								Most physicians in Europe, if asked what is very different about medicine and the law in the Netherlands, would choose euthanasia. We will discuss recent developments there but begin with a different topic-equality of access to in vitro fertilisation.	CMS Derks Star Busmann Hanotiau, Transnatl Legal Serv, NL-3584 BB Utrecht, Netherlands		Oosting, ME (corresponding author), CMS Derks Star Busmann Hanotiau, Transnatl Legal Serv, Pythagoraslaan 2, NL-3584 BB Utrecht, Netherlands.							BREWAEYS AMA, 1997, THESIS U LEIDEN; ENLERT U, 1994, HUM REPROD, V9, P1969; FORDER CJ, 1998, LEGAL POSITION SPERM; *HLTH COUNC COMM R, 1997, HLTH COUNC PUBL, V103; VERHULST FC, 1998, ADOPTION FOREIGN CHI	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1512	1513		10.1016/S0140-6736(00)02887-7	http://dx.doi.org/10.1016/S0140-6736(00)02887-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081550				2022-12-28	WOS:000090067300041
J	Motyka, B; Korbutt, G; Pinkoski, MJ; Heibein, JA; Caputo, A; Hobman, M; Barry, M; Shostak, I; Sawchuk, T; Holmes, CFB; Gauldie, J; Bleackley, RC				Motyka, B; Korbutt, G; Pinkoski, MJ; Heibein, JA; Caputo, A; Hobman, M; Barry, M; Shostak, I; Sawchuk, T; Holmes, CFB; Gauldie, J; Bleackley, RC			Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis	CELL			English	Article							BREAST-CANCER CELLS; 6-PHOSPHATE RECEPTOR; DNA FRAGMENTATION; TARGET-CELLS; LYTIC GRANULES; MEDIATED CYTOTOXICITY; INITIATES APOPTOSIS; CYTOSOLIC DELIVERY; SERINE PROTEASES; RAPID INDUCTION	The serine proteinase granzyme B is crucial for the rapid induction of target cell apoptosis by cytotoxic T cells. Granzyme B was recently demonstrated to enter cells in a perforin-independent manner, thus predicting the existence of a cell surface receptor(s). We now present evidence that this receptor is the cation-independent mannose 6-phosphate/insulin-like growth factor receptor (CI-MPR). Inhibition of the granzyme B-CI-MPR interaction prevented granzyme B cell surface binding, uptake, and the induction of apoptosis. Significantly, expression of the CI-MPR was essential for cytotoxic T cell-mediated apoptosis of target cells in vitro and for the rejection of allogeneic cells in vivo. These results suggest a novel target for immunotherapy and a potential mechanism used by tumors for immune evasion.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2H7, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	University of Alberta; University of Alberta; McMaster University	Bleackley, RC (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.			Motyka, Bruce/0000-0002-8448-2777				Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; Bagu JR, 1997, J BIOL CHEM, V272, P5087, DOI 10.1074/jbc.272.8.5087; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Browne KA, 1999, MOL CELL BIOL, V19, P8604; BRUNETTI CR, 1994, J BIOL CHEM, V269, P17067; Caputo A, 1999, PROTEINS, V35, P415, DOI 10.1002/(SICI)1097-0134(19990601)35:4<415::AID-PROT5>3.0.CO;2-7; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; Chappell SA, 1997, BRIT J CANCER, V76, P1558, DOI 10.1038/bjc.1997.596; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; CONFORT C, 1995, ENDOCRINOLOGY, V136, P3759, DOI 10.1210/en.136.9.3759; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; Darmon AJ, 1998, CRIT REV IMMUNOL, V18, P255, DOI 10.1615/CritRevImmunol.v18.i3.50; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Diamond AS, 2000, J IMMUNOL, V165, P247, DOI 10.4049/jimmunol.165.1.247; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; EINSTEIN R, 1991, J CELL BIOL, V112, P81, DOI 10.1083/jcb.112.1.81; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; GRIFFITHS G, 1990, J CELL SCI, V95, P441; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Heibein JA, 1999, J IMMUNOL, V163, P4683; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAPLAN A, 1977, J CLIN INVEST, V60, P1088, DOI 10.1172/JCI108860; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAKSHMI S, 1980, BIOCHIM BIOPHYS ACTA, V614, P446, DOI 10.1016/0005-2744(80)90234-X; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MA ZM, 1992, J BIOL CHEM, V267, P19017; MA ZM, 1991, J BIOL CHEM, V266, P10589; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MASSON D, 1987, CELL, V49, P679, DOI 10.1016/0092-8674(87)90544-7; MILLIKIN D, 1991, CANCER RES, V51, P5449; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; MORITA R, 1991, CANCER RES, V51, P5817; MunierLehmann H, 1996, BIOCHEM SOC T, V24, P133, DOI 10.1042/bst0240133; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; Ohashi K, 2000, NAT MED, V6, P327; OKA Y, 1986, J BIOL CHEM, V261, P9090; Page LJ, 1998, BBA-MOL CELL RES, V1401, P146, DOI 10.1016/S0167-4889(97)00138-9; Pinkoski MJ, 1998, BLOOD, V92, P1044; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	65	303	326	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					491	500		10.1016/S0092-8674(00)00140-9	http://dx.doi.org/10.1016/S0092-8674(00)00140-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081635	Bronze			2022-12-28	WOS:000090144100014
J	Farrell, RJ; Alsahli, M; LaMont, JT				Farrell, RJ; Alsahli, M; LaMont, JT			Is successful triage of patients with upper-gastrointestinal bleeding possible without endoscopy?	LANCET			English	Editorial Material							SCORING SYSTEM; HEMORRHAGE; MORTALITY; THERAPY		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Farrell, RJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA.							FRIEDMAN LS, 1993, GASTROENTEROL CLIN N, V22, P717; FULLARTON GM, 1990, ENDOSCOPY, V22, P110, DOI 10.1055/s-2007-1012813; GRIFFITHS WJ, 1979, NEW ENGL J MED, V300, P1411, DOI 10.1056/NEJM197906213002503; KATSCHINSKI B, 1994, DIGEST DIS SCI, V39, P706, DOI 10.1007/BF02087411; Rockall TA, 1996, LANCET, V347, P1138, DOI 10.1016/S0140-6736(96)90607-8; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; SAEED ZA, 1993, AM J GASTROENTEROL, V88, P1842; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331; ZIMMERMAN J, 1995, SCAND J GASTROENTERO, V30, P327, DOI 10.3109/00365529509093285	9	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1289	1290		10.1016/S0140-6736(00)02808-7	http://dx.doi.org/10.1016/S0140-6736(00)02808-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073012				2022-12-28	WOS:000089858300004
J	Leffell, DJ				Leffell, DJ			The other side of the sun	LANCET			English	Editorial Material									Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	Yale University	Leffell, DJ (corresponding author), Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA.							ARMSTRONG BK, 1995, DERMATOL CLIN, V13, P583, DOI 10.1016/S0733-8635(18)30064-0; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Kelly DA, 2000, J EXP MED, V191, P561, DOI 10.1084/jem.191.3.561; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; NISHIGORI C, 1996, J INVEST DERMATOL S, V1, P143; Young AR, 2000, J INVEST DERMATOL, V115, P37, DOI 10.1046/j.1523-1747.2000.00012.x	6	1	2	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					699	699		10.1016/S0140-6736(00)02625-8	http://dx.doi.org/10.1016/S0140-6736(00)02625-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085686				2022-12-28	WOS:000088948200006
J	Amory, JK; Anawalt, BD; Paulsen, CA; Bremner, WJ				Amory, JK; Anawalt, BD; Paulsen, CA; Bremner, WJ			Klinefelter's syndrome	LANCET			English	Article							MEN		Univ Washington, Populat Ctr Res Reprod, Seattle, WA 98195 USA; Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle	Amory, JK (corresponding author), Univ Washington, Populat Ctr Res Reprod, Seattle, WA 98195 USA.		Anawalt, Bradley D./AAW-3316-2020	Anawalt, Bradley D./0000-0003-2652-4032; Amory, John/0000-0002-7419-435X				Anawalt BD, 1996, J CLIN ENDOCR METAB, V81, P3341, DOI 10.1210/jc.81.9.3341; BEIGHTON P, 1986, MAN SYNDROME, P214; Foresta C, 1999, J CLIN ENDOCR METAB, V84, P3807, DOI 10.1210/jc.84.10.3807; GORDON DL, 1972, ARCH INTERN MED, V130, P726, DOI 10.1001/archinte.130.5.726; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Klinefelter HF, 1942, J CLIN ENDOCRINOL, V2, P615, DOI 10.1210/jcem-2-11-615; Palermo GD, 1998, NEW ENGL J MED, V338, P588, DOI 10.1056/NEJM199802263380905; Smyth CM, 1998, ARCH INTERN MED, V158, P1309, DOI 10.1001/archinte.158.12.1309	8	25	28	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					333	335		10.1016/S0140-6736(00)02517-4	http://dx.doi.org/10.1016/S0140-6736(00)02517-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071204				2022-12-28	WOS:000088305900039
J	Lori, F; Lewis, MG; Xu, JQ; Varga, G; Zinn, DE; Crabbs, C; Wagner, W; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Tinelli, C; Lisziewicz, J				Lori, F; Lewis, MG; Xu, JQ; Varga, G; Zinn, DE; Crabbs, C; Wagner, W; Greenhouse, J; Silvera, P; Yalley-Ogunro, J; Tinelli, C; Lisziewicz, J			Control of SIV rebound through structured treatment interruptions during early infection	SCIENCE			English	Article							VIRAL LOAD; HIV-1; DISCONTINUATION; SUPPRESSION; RESPONSES; LYMPHOCYTES; INHIBITOR; VIREMIA; PLASMA	In a randomized controlled trial with acute simian immunodeficiency virus (SIV)-infected macaques, both highly active antiretroviral therapy (HAART) and HAART with fixed-schedule structured treatment interruption (STI-HAART; alternating 3 weeks on and 3 weeks off therapy) suppressed viral load. In the STI-HAART group, T cell virus-specific immune response (VIR) and control of viral rebound increased concurrently during subsequent interruptions. In contrast, VIR did not increase and SIV rebounded after permanent treatment withdrawal in all animals on continuous HAART. Fixed-schedule STI-HAART appears to be an effective alternative to continuous HAART for the early treatment of retroviral infection.	Res Inst Genet & Human therapy, Washington, DC 20007 USA; So Res Inst, Frederick, MD 21701 USA; IRCCS Policlin S Matteo, Pavia, Italy	IRCCS Fondazione San Matteo	Lisziewicz, J (corresponding author), Res Inst Genet & Human therapy, Med Dent Bldg SW307,3900 Reservoir Rd NW, Washington, DC 20007 USA.	right@gunet.georgetown.edu		Tinelli, Carmine/0000-0002-8749-1978; Lisziewicz, Julianna/0000-0002-3349-4495				CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; deJong MD, 1997, AIDS, V11, pF79, DOI 10.1097/00002030-199711000-00002; FAGARD C, 2000, 7 C RETR OPP INF SAN; GAO WY, 1993, P NATL ACAD SCI USA, V90, P8925, DOI 10.1073/pnas.90.19.8925; Hel Z, 2000, NAT MED, V6, P1140, DOI 10.1038/80481; Jubault V, 1998, AIDS, V12, P2358; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lori F, 2000, LANCET, V355, P287, DOI 10.1016/S0140-6736(99)03515-1; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; MALLEY SD, 1994, LANCET, V343, P1292, DOI 10.1016/S0140-6736(94)92182-2; MILLER V, 1999, ROM STAT ART C TREAT; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rosenwirth B, 2000, J VIROL, V74, P1704, DOI 10.1128/JVI.74.4.1704-1711.2000; Staszewski S, 1998, AIDS, V12, P2360; Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197	21	145	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1591	1593		10.1126/science.290.5496.1591	http://dx.doi.org/10.1126/science.290.5496.1591			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090360				2022-12-28	WOS:000165446200055
J	Lipton, RB; Stewart, WF; Stone, FM; Lainez, MJA; Sawyer, JPC				Lipton, RB; Stewart, WF; Stone, FM; Lainez, MJA; Sawyer, JPC			Stratified cave vs step care strategies for migraine - The disability in strategies of care (DISC) study: A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGEMENT; ZOLMITRIPTAN; RELIABILITY; GUIDELINES; SCORE	Context Various guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated. Objective To compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine. Design and Setting Randomized, controlled parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical centers in 13 countries. Patients A total of 835 adult migraine patients with a Migraine Disability Assessment Scale (MIDAS) grade of II, III, or IV were analyzed as the efficacy population; the safety analysis included 930 patients. Interventions Patients were randomly assigned to receive(1) stratified care (n=279), in which patients with MIDAS grade II treated up to 6 attacks with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg, and patients with MIDAS grade III and IV treated up to 6 attacks with zolmitriptan, 2.5 mg; (2) step care across attacks (n = 271), in which initial treatment was with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg. Patients not responding in at least 2 of the first 3 attacks switched to zolmitriptan, 2.5 mg, to treat the remaining 3 attacks; and (3) step care within attacks (n = 285), in which initial treatment for all attacks was with aspirin, 800 to 1000 mg, plus metoclopramide, 20 mg. Patients not responding to treatment after 2 hours in each attack escalated treatment to zolmitriptan, 2.5 mg. Main Outcome Measures Headache response, achieved if pain intensity was reduced from severe or moderate at baseline to mild or no pain at 2 hours; and disability time per treated attack at 4 hours for all 6 attacks, compared among the 3 groups. Results Headache response at 2 hours was significantly greater across 6 attacks in the stratified care treatment group (52.7%) than in either the step care across attacks group (40.6%; P<.001) or the step care within attacks group (36.4%; P<.001). Disability time (6 attacks) was significantly lower in the stratified care group (mean area under the curve [AUC], 185.0 mm.h) than in the step care across attacks group (mean AUG, 209.4 mm.h; P<.001) or the step care within attacks group (mean AUG, 199.7 mm.h; P<.001). The incidence of adverse events was higher in the stratified care group (321 events) vs both step care groups (159 events in across-attack group; 217 in within-attack group), although most events were of mild-to-moderate intensity. Conclusion Our results indicate that as a treatment strategy, stratified care provides significantly better clinical outcomes than step care strategies within or across attacks as measured by headache response and disability time.	Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Social Med, Bronx, NY 10467 USA; Innovat Med Res Inc, Stamford, CT 06905 USA; Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Innovat Med Res Inc, Baltimore, MD USA; AstraZeneca, Macclesfield, Cheshire, England; Univ Valencia, Hosp Clin Univ, Valencia, Spain	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; AstraZeneca; Hospital Clinic Universitari de Valencia; University of Valencia	Lipton, RB (corresponding author), Innovat Med Res Inc, 1200 High Ridge Rd, Stamford, CT 06905 USA.	rlipton@imrinc.com	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011					Diener HC, 1998, DRUGS, V56, P811, DOI 10.2165/00003495-199856050-00006; Georgitis JW, 1999, CHEST, V115, P210, DOI 10.1378/chest.115.1.210; Headache Classification Committee of the International Headache Society, 1998, CEPHALALGIA S7, V8, P19; Lipton RB, 1998, HEADACHE, V38, P87, DOI 10.1046/j.1526-4610.1998.3802087.x; Lipton RB, 1997, CEPHALALGIA, V17, P53, DOI 10.1177/0333102497017S1807; Lipton RB, 1998, CEPHALALGIA, V18, P40, DOI 10.1177/0333102498018S2208; LIPTON RB, 2000, NEUROLOGY S3, V54, pA314; LIPTON RB, 1998, HEADACHE S2, V39, pS20; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; NEWMAN L, 1998, HEADACHE, V38, P395; PrysePhillips WEM, 1997, CAN MED ASSOC J, V156, P1273; Rapoport AM, 1997, NEUROLOGY, V49, P1210, DOI 10.1212/WNL.49.5.1210; Saper J. R., 1993, HDB HEADACHE MANAGEM; Sawyer J, 1998, NEUROLOGY, V50, pA433; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; Solomon GD, 1997, NEUROLOGY, V49, P1219, DOI 10.1212/WNL.49.5.1219; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Stewart WF, 1999, CEPHALALGIA, V19, P107, DOI 10.1046/j.1468-2982.1999.019002107.x; STEWART WF, IN PRESS PAIN; TFETLHANSEN P, 1984, CEPHALALGIA, V4, P107; THOMPSON CJ, 1992, EUR NEUROL, V32, P177; WOLFINGER R, 1993, J STAT COMPUT SIM, V48, P233, DOI 10.1080/00949659308811554; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; 1996, PRINCIPLES GOOD CLIN	24	219	226	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2599	2605		10.1001/jama.284.20.2599	http://dx.doi.org/10.1001/jama.284.20.2599			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086366	Bronze			2022-12-28	WOS:000165296200033
J	Stephansson, O; Dickman, PW; Johansson, A; Cnattingius, S				Stephansson, O; Dickman, PW; Johansson, A; Cnattingius, S			Maternal hemoglobin concentration during pregnancy and risk of stillbirth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT; GESTATIONAL-AGE; PRETERM BIRTH; PLASMA-VOLUME; PRE-ECLAMPSIA; FETAL; DEATH; 2ND-TRIMESTER; HYPERTENSION; ASSOCIATION	Context High and low maternal hemoglobin concentrations during pregnancy have been reported to increase risk of small-for-gestational-age (SGA) birth, which is a predictor of stillbirth. The relationship between hemoglobin concentration during pregnancy and risk of stillbirth is unclear. Objective To study the associations among hemoglobin concentration at first measurement during antenatal care, change in hemoglobin concentration during pregnancy, and risk of stillbirth. Design, Setting, and Participants Population-based, matched case-control study of births from 1987 through 1996 in Sweden including 702 primiparous women with stillbirths occurring at 28 weeks' gestation or later and 702 primiparous women with live births. Main Outcome Measures Risk of stillbirth, classified as malformed or nonmalformed, antepartum or intrapartum, preterm or term, and SGA or non-SGA, compared by maternal hemoglobin concentration at first antenatal measurement and weekly changes in hemoglobin concentration during pregnancy, adjusted for maternal age, body mass index, height, smoking, socioeconomic status, and week of first hemoglobin measurement. Results In multivariate analyses, compared with women with hemoglobin concentrations of 126 to 135 g/L at first antenatal measurement, women with concentrations of 146 g/L or higher were at increased risk of stillbirth (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.0-3.3). This risk was slightly increased when the analysis was restricted to antepartum stillbirths without malformations (OR, 2.0; 95% CI, 1.1-3.8). When we further restricted the analyses to preterm and SCA antepartum nonmalformed stillbirths, the ORs increased to 2.7 (95% Cf, 1.1-6.4) and 4.2 (95% CI, 1.3-13.9), respectively. Excluding women with preeclampsia and eclampsia further increased these risks. Average weekly change in hemoglobin concentration during early or tate pregnancy was not significantly associated with risk of stillbirth, although a larger decrease in concentration tended to be protective. Anemia (hemoglobin concentration <110 g/L) was not significantly associated with risk of stillbirth in multivariate analyses (OR, 1.2; 95% CI, 0.5-2.7). Conclusions High hemoglobin concentration at first measurement during antenatal care appears to be associated with increased risk of stillbirth, especially preterm and SGA antepartum stillbirths.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Stephansson, O (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, SE-17177 Stockholm, Sweden.	olof.stephansson@mep.ki.se	Dickman, Paul W/B-4572-2013	Dickman, Paul W/0000-0002-5788-3380; Johansson, Anna/0000-0002-1191-7231; Stephansson, Olof/0000-0003-1528-4563				[Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; BLEKTA M, 1970, AM J OBSTET GYNECOL, V106, P10, DOI 10.1016/0002-9378(70)90120-1; CDC, 1989, MMWR-MORBID MORTAL W, V38, P400; CHESLEY LC, 1972, AM J OBSTET GYNECOL, V112, P440, DOI 10.1016/0002-9378(72)90493-0; Cnattingius S, 1998, BRIT MED J, V316, P1483, DOI 10.1136/bmj.316.7143.1483; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; GALLERY EDM, 1979, Q J MED, V48, P593; Gardosi J, 1998, BRIT J OBSTET GYNAEC, V105, P524, DOI 10.1111/j.1471-0528.1998.tb10153.x; GARN SM, 1981, SEMIN PERINATOL, V5, P155; HUISMAN A, 1986, ACTA OBSTET GYN SCAN, V65, P605, DOI 10.3109/00016348609158396; KLEBANOFF MA, 1991, AM J OBSTET GYNECOL, V164, P59, DOI 10.1016/0002-9378(91)90626-3; KNOTTNERUS JA, 1990, J CLIN EPIDEMIOL, V43, P461, DOI 10.1016/0895-4356(90)90134-B; LIEBERMAN E, 1988, AM J OBSTET GYNECOL, V159, P107, DOI 10.1016/0002-9378(88)90502-9; MAHOMED K, 1999, IRON SUPPLEMENTATION; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; MURPHY JF, 1986, LANCET, V1, P992; NAEYE RL, 1977, OBSTET GYNECOL, V50, P583; *NAT BOARD HLTH WE, 1997, HLTH CAR PREGN, P7; SAGEN N, 1984, ACTA OBSTET GYN SCAN, V63, P245, DOI 10.3109/00016348409155506; SAGEN N, 1982, BRIT J OBSTET GYNAEC, V89, P802, DOI 10.1111/j.1471-0528.1982.tb05029.x; SAS Institute Inc, 1997, SAS STAT SOFTW CHANG; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; STEER P, 1995, BMJ-BRIT MED J, V310, P489, DOI 10.1136/bmj.310.6978.489; Steer PJ, 2000, AM J CLIN NUTR, V71, p1285S, DOI 10.1093/ajcn/71.5.1285s; *SWED SOC CLASS, 1995, REP STAT COORD; Whittaker PG, 1996, OBSTET GYNECOL, V88, P33, DOI 10.1016/0029-7844(96)00095-6; Winbo IGB, 1997, INT J EPIDEMIOL, V26, P1298, DOI 10.1093/ije/26.6.1298; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V270, P2846	29	95	101	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2611	2617		10.1001/jama.284.20.2611	http://dx.doi.org/10.1001/jama.284.20.2611			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086368	Bronze			2022-12-28	WOS:000165296200035
J	Hobbs, RD				Hobbs, RD			An Amish house call	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Oakwood Hosp, Dearborn, MI 48124 USA	Beaumont Health	Hobbs, RD (corresponding author), 3319 River Pines, Ann Arbor, MI 48103 USA.	rhobbs3945@aol.com							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					834	836		10.7326/0003-4819-133-10-200011210-00018	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085848				2022-12-28	WOS:000165321200011
J	Sebghati, TS; Engle, JT; Goldman, WE				Sebghati, TS; Engle, JT; Goldman, WE			Intracellular parasitism by Histoplasma capsulatum: Fungal virulence and calcium dependence	SCIENCE			English	Article							TELOMERIC SEQUENCES; P388D1 MACROPHAGES; PATHOGENESIS; EXPRESSION; INFECTION; SELECTION; CELLS; GENE; DNA	Histoplasma capsulatum is an effective intracellular parasite of macrophages and causes the most prevalent fungal respiratory disease in the United States. A "dimorphic" fungus, H. capsulatum exists as a saprophytic mold in soil and converts to the parasitic yeast form after inhalation, Only the yeasts secrete a calcium-binding protein (CBP) and can grow in calcium-limiting conditions. To probe the relation between calcium Limitation and intracellular parasitism, we designed a strategy to disrupt CBP1 in H. capsulatum using a telomeric Linear plasmid and a two-step genetic selection, The resulting cbp1 yeasts no Longer grew when deprived of calcium, and they were also unable to destroy macrophages in vitro or proliferate in a mouse model of pulmonary infection.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Goldman, WE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230, St Louis, MO 63110 USA.			Goldman, William/0000-0002-1551-6718	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025584] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07317] Funding Source: Medline; NIAID NIH HHS [AI25584] Funding Source: Medline; PHS HHS [A107172] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Batanghari JW, 1997, INFECT IMMUN, V65, P5257, DOI 10.1128/IAI.65.12.5257-5261.1997; Batanghari JW, 1998, MOL MICROBIOL, V27, P531, DOI 10.1046/j.1365-2958.1998.00697.x; BAUGHMAN RP, 1986, AM REV RESPIR DIS, V134, P771; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; DEEPE GS, 1990, EUR J CLIN MICROBIOL, V9, P567, DOI 10.1007/BF01967211; EISSENBERG LG, 1991, INFECT IMMUN, V59, P1639, DOI 10.1128/IAI.59.5.1639-1646.1991; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; EISSENBERG LG, 1988, J LEUKOCYTE BIOL, V43, P483, DOI 10.1002/jlb.43.6.483; EISSENBERG LG, 1991, CLIN MICROBIOL REV, V4, P411, DOI 10.1128/CMR.4.4.411-421.1991; GARCIAVESCOVI E, 1997, J BIOL CHEM, V272, P1440; Gerasimenko JV, 1998, CURR BIOL, V8, P1335, DOI 10.1016/S0960-9822(07)00565-9; GOODWIN RA, 1980, MEDICINE, V59, P1, DOI 10.1097/00005792-198001000-00001; GRAYBILL JR, 1988, J INFECT DIS, V158, P623, DOI 10.1093/infdis/158.3.623; Hogan LH, 1997, GENE, V186, P219, DOI 10.1016/S0378-1119(96)00713-5; LEVITZ SM, 1985, J INFECT DIS, V152, P938, DOI 10.1093/infdis/152.5.938; PUNT PJ, 1987, GENE, V56, P117, DOI 10.1016/0378-1119(87)90164-8; Retallack DM, 1999, INFECT IMMUN, V67, P624, DOI 10.1128/IAI.67.2.624-629.1999; Rippon JW., 1988, MED MYCOLOGY PATHOGE, P381; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; Smith J.A., 2000, CURRENT PROTOCOLS MO; VARMA A, 1992, INFECT IMMUN, V60, P1101, DOI 10.1128/IAI.60.3.1101-1108.1992; Woods JP, 1998, J BACTERIOL, V180, P5135, DOI 10.1128/JB.180.19.5135-5143.1998; WOODS JP, 1992, MOL MICROBIOL, V6, P3603, DOI 10.1111/j.1365-2958.1992.tb01796.x; Woods JP, 1998, INFECT IMMUN, V66, P1697, DOI 10.1128/IAI.66.4.1697-1707.1998; WOODS JP, 1993, J BACTERIOL, V175, P636, DOI 10.1128/JB.175.3.636-641.1993; WORSHAM PL, 1988, MOL GEN GENET, V214, P348, DOI 10.1007/BF00337734; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137	27	132	137	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1368	1372		10.1126/science.290.5495.1368	http://dx.doi.org/10.1126/science.290.5495.1368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082066				2022-12-28	WOS:000165379800052
J	Feldman, AM; McNamara, D				Feldman, AM; McNamara, D			Myocarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IDIOPATHIC DILATED CARDIOMYOPATHY; POLYMERASE-CHAIN-REACTION; GIANT-CELL MYOCARDITIS; NITRIC-OXIDE SYNTHASE; C VIRUS-INFECTION; COXSACKIEVIRUS B3-INDUCED MYOCARDITIS; CLINICALLY SUSPECTED MYOCARDITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS IMMUNE GLOBULIN; SUDDEN CARDIAC DEATH		Univ Pittsburgh, Sch Med, UPMC Hlth Syst, Cardiovasc Inst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Feldman, AM (corresponding author), Univ Pittsburgh, Sch Med, UPMC Hlth Syst, Cardiovasc Inst, 200 Lothrop St,S-572 Scaife Hall, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [1RO1 HL60032-1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060032] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams KF, 1999, J CARD FAIL, V5, P357; AITKEN K, 1994, CIRCULATION, V90, P139; Anandasabapathy S, 1998, J CLIN PHARMACOL, V38, P295, DOI 10.1002/j.1552-4604.1998.tb04428.x; Andreoletti L, 1997, J MED VIROL, V52, P206, DOI 10.1002/(SICI)1096-9071(199706)52:2<206::AID-JMV15>3.0.CO;2-I; ARCHARD LC, 1991, EUR HEART J, V12, P56, DOI 10.1093/eurheartj/12.suppl_D.56; Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; Baig MK, 1998, J AM COLL CARDIOL, V31, P195, DOI 10.1016/S0735-1097(97)00433-6; Barbaro G, 1998, NEW ENGL J MED, V339, P1093, DOI 10.1056/NEJM199810153391601; Baykurt C, 1999, PEDIATR INT, V41, P389, DOI 10.1046/j.1442-200x.1999.01077.x; Billingham M E, 1985, Heart Vessels Suppl, V1, P278; BLANKENHORN MA, 1956, CIRCULATION, V13, P217, DOI 10.1161/01.CIR.13.2.217; Bowles NE, 1999, J AM COLL CARDIOL, V34, P857, DOI 10.1016/S0735-1097(99)00264-8; BOWLES NE, 1986, LANCET, V1, P1120; Bozkurt B, 1999, J AM COLL CARDIOL, V34, P177, DOI 10.1016/S0735-1097(99)00161-8; BURKE AP, 1991, ARCH PATHOL LAB MED, V115, P764; CAFORIO ALP, 1990, J AUTOIMMUN, V3, P187, DOI 10.1016/0896-8411(90)90140-N; CAFORIO ALP, 1994, LANCET, V344, P773, DOI 10.1016/S0140-6736(94)92339-6; Caforio ALP, 1996, DRUGS, V52, P515, DOI 10.2165/00003495-199652040-00005; Caforio ALP, 1997, HEART, V77, P62, DOI 10.1136/hrt.77.1.62; CAMBRIDGE G, 1979, BRIT HEART J, V41, P692; Chapman NM, 2000, J VIROL, V74, P4047, DOI 10.1128/JVI.74.9.4047-4056.2000; CHOW L H, 1989, Journal of the American College of Cardiology, V13, p253A; COHEN IS, 1986, NEW ENGL J MED, V315, P628, DOI 10.1056/NEJM198609043151007; Cooper LT, 1997, NEW ENGL J MED, V336, P1860, DOI 10.1056/NEJM199706263362603; Davies JM, 1997, IMMUNOL CELL BIOL, V75, P113, DOI 10.1038/icb.1997.16; DAVIES MJ, 1992, BRIT HEART J, V68, P346; de Leeuw N, 1999, CLIN INFECT DIS, V29, P522, DOI 10.1086/598625; DEC GW, 1990, J AM COLL CARDIOL, V16, P97, DOI 10.1016/0735-1097(90)90463-Y; DEC GW, 1992, J AM COLL CARDIOL, V20, P85, DOI 10.1016/0735-1097(92)90141-9; DEC GW, 1985, NEW ENGL J MED, V312, P885, DOI 10.1056/NEJM198504043121404; Dipla K, 1998, CIRCULATION, V97, P2316, DOI 10.1161/01.CIR.97.23.2316; DRORY Y, 1991, AM J CARDIOL, V68, P1388, DOI 10.1016/0002-9149(91)90251-F; DRUCKER NA, 1994, CIRCULATION, V89, P252, DOI 10.1161/01.CIR.89.1.252; Fairweather D, 1998, IMMUNOLOGY, V94, P263, DOI 10.1046/j.1365-2567.1998.00500.x; FENOGLIO JJ, 1981, HUM PATHOL, V12, P900, DOI 10.1016/S0046-8177(81)80195-5; FENOGLIO JJ, 1983, NEW ENGL J MED, V308, P12, DOI 10.1056/NEJM198301063080103; Fohlman J, 1996, CIRCULATION, V94, P2254, DOI 10.1161/01.CIR.94.9.2254; *FOOD DRUG ADM, 1998, ONC DRUGS ADV COMM M; FOWLES RE, 1984, PROG CARDIOVASC DIS, V27, P153, DOI 10.1016/0033-0620(84)90002-1; Friedrich MG, 1998, CIRCULATION, V97, P1802, DOI 10.1161/01.CIR.97.18.1802; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; Fujioka S, 1996, AM HEART J, V131, P760, DOI 10.1016/S0002-8703(96)90284-7; Gebhard JR, 1998, AM J PATHOL, V153, P417, DOI 10.1016/S0002-9440(10)65585-X; GODENY EK, 1987, J IMMUNOL, V139, P913; GORE I, 1947, AM HEART J, V34, P827, DOI 10.1016/0002-8703(47)90147-6; GROGAN M, 1995, J AM COLL CARDIOL, V26, P80, DOI 10.1016/0735-1097(95)00148-S; Grumbach IM, 1999, ACTA CARDIOL, V54, P83; Grumbach IM, 1998, CARDIOLOGY, V90, P75, DOI 10.1159/000006822; *HEART FAIL SOC AM, 2000, J CARD FAIL, V6, P74; Heim A, 1997, ANTIVIR RES, V34, P101, DOI 10.1016/S0166-3542(97)01028-0; HENKE A, 1995, J VIROL, V69, P6720, DOI 10.1128/JVI.69.11.6720-6728.1995; Higuchi MD, 1997, AM J TROP MED HYG, V56, P485; Huber SA, 1997, CLIN IMMUNOL IMMUNOP, V83, P93, DOI 10.1006/clin.1997.4342; Huber SA, 1996, J IMMUNOL, V156, P3528; HUBER SA, 1993, VIRAL INFECT HEART, P82; Hunter P, 1998, VACCINE, V16, P55, DOI 10.1016/S0264-410X(97)00158-8; Iwasaki A, 1999, J AM COLL CARDIOL, V33, P1400, DOI 10.1016/S0735-1097(98)00692-5; Jahns R, 1999, J AM COLL CARDIOL, V34, P1545, DOI 10.1016/S0735-1097(99)00381-2; JIN HK, 1995, J CLIN INVEST, V95, P1947, DOI 10.1172/JCI117877; JIN O, 1990, CIRCULATION, V82, P8, DOI 10.1161/01.CIR.82.1.8; Kao JH, 1998, CIRCULATION, V98, P1044, DOI 10.1161/01.CIR.98.10.1044; KASAHARA H, 1994, J CLIN INVEST, V94, P1026, DOI 10.1172/JCI117416; Kawahito K, 1998, AM J CARDIOL, V82, P910, DOI 10.1016/S0002-9149(98)00503-7; Kawai C, 1999, CIRCULATION, V99, P1091, DOI 10.1161/01.CIR.99.8.1091; KIBRICK S, 1958, PEDIATRICS, V22, P857; KLEIN R, 1984, CLIN EXP IMMUNOL, V58, P283; Kleinert S, 1997, J HEART LUNG TRANSPL, V16, P1248; Knowlton KU, 1999, CIRC RES, V85, P559, DOI 10.1161/01.RES.85.6.559; Kuhl U, 1998, J AM COLL CARDIOL, V32, P1371, DOI 10.1016/S0735-1097(98)00397-0; LATHAM RD, 1989, AM HEART J, V117, P876, DOI 10.1016/0002-8703(89)90626-1; Lauer B, 1997, J AM COLL CARDIOL, V30, P1354, DOI 10.1016/S0735-1097(97)00317-3; Lee JK, 1998, NAT MED, V4, P1383, DOI 10.1038/3973; LERNER A. M., 1965, PROG MED VIROL, V7, P97; Levy NT, 1998, ANN INTERN MED, V128, P648, DOI 10.7326/0003-4819-128-8-199804150-00007; Li YW, 2000, CIRCULATION, V101, P231, DOI 10.1161/01.CIR.101.3.231; LIE JT, 1988, ANN INTERN MED, V109, P525, DOI 10.7326/0003-4819-109-7-525; Lieback E, 1996, EUR HEART J, V17, P135; LIEBERMAN EB, 1991, J AM COLL CARDIOL, V18, P1617, DOI 10.1016/0735-1097(91)90493-S; LIMAS C, 1992, AM HEART J, V124, P1258, DOI 10.1016/0002-8703(92)90409-O; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; Lipshultz SE, 1998, CIRCULATION, V97, P1246, DOI 10.1161/01.CIR.97.13.1246; Litovsky SH, 1996, MODERN PATHOL, V9, P1126; Liu P, 1996, CAN J CARDIOL, V12, P935; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; MAISCH B, 1987, EUR HEART J, V8, P233, DOI 10.1093/eurheartj/8.suppl_J.233; Maisch B, 1995, EUR HEART J, V16, P173, DOI 10.1093/eurheartj/16.suppl_O.173; Maisel A, 1998, CIRC RES, V82, P458, DOI 10.1161/01.RES.82.4.458; MAK TW, 1994, CLIN CHEM, V40, P2128; Marelli D, 1997, J CARDIAC SURG, V12, P55, DOI 10.1111/j.1540-8191.1997.tb00091.x; Martin J, 1997, ANN THORAC SURG, V63, P1145, DOI 10.1016/S0003-4975(97)00067-2; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MASON JW, 1978, AM J CARDIOL, V41, P887, DOI 10.1016/0002-9149(78)90729-4; MATSUMORI A, 1988, AM HEART J, V115, P1229, DOI 10.1016/0002-8703(88)90013-0; MATSUMORI A, 1982, CIRCULATION, V66, P355, DOI 10.1161/01.CIR.66.2.355; Matsumori A, 1999, JPN CIRC J, V63, P934, DOI 10.1253/jcj.63.934; MATSUMORI A, 1995, CIRCULATION, V92, P2519, DOI 10.1161/01.CIR.92.9.2519; MATTINGLY TW, 1965, JAMA-J AM MED ASSOC, V191, P127; MCCAFFREY FM, 1991, AM J DIS CHILD, V145, P177, DOI 10.1001/archpedi.1991.02160020069020; McCarthy RE, 2000, NEW ENGL J MED, V342, P690, DOI 10.1056/NEJM200003093421003; McCormack JG, 1998, CLIN INFECT DIS, V26, P1007, DOI 10.1086/517634; McNamara DM, 1999, CIRCULATION, V100, P21; McNamara DM, 1997, CIRCULATION, V95, P2476, DOI 10.1161/01.CIR.95.11.2476; MICHELS VV, 1994, MAYO CLIN PROC, V69, P24, DOI 10.1016/S0025-6196(12)61607-3; MIDEI MG, 1990, CIRCULATION, V81, P922, DOI 10.1161/01.CIR.81.3.922; Mikami S, 1997, CIRC RES, V81, P504, DOI 10.1161/01.RES.81.4.504; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; Nakamura H, 1996, CIRCULATION, V94, P3348, DOI 10.1161/01.CIR.94.12.3348; NEU N, 1987, J IMMUNOL, V139, P3630; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; OBRADOR D, 1993, J AM COLL CARDIOL, V21, P1667, DOI 10.1016/0735-1097(93)90385-E; OCONNELL JB, 1989, WESTERN J MED, V150, P431; Okabe M, 1997, CIRCULATION, V96, P22; Opavsky MA, 1999, CIRC RES, V85, P551, DOI 10.1161/01.RES.85.6.551; Pankuweit S, 1997, J MOL CELL CARDIOL, V29, P77, DOI 10.1006/jmcc.1996.0253; PARRILLO JE, 1989, NEW ENGL J MED, V321, P1061, DOI 10.1056/NEJM198910193211601; PARRILLO JE, 1984, CIRCULATION, V69, P93, DOI 10.1161/01.CIR.69.1.93; Pauschinger M, 1999, CIRCULATION, V99, P1348, DOI 10.1161/01.CIR.99.10.1348; PHILLIPS M, 1986, JAMA-J AM MED ASSOC, V256, P2696, DOI 10.1001/jama.256.19.2696; Podlowski S, 1998, CIRCULATION, V98, P2470, DOI 10.1161/01.CIR.98.22.2470; *PUBL HLTH LAB SER, 1967, BRIT MED J, V4, P575; Pummerer CL, 1996, LAB INVEST, V74, P845; Rebolledo MA, 1998, CIRC RES, V83, P738, DOI 10.1161/01.RES.83.7.738; Reiss N, 1996, ARTIF ORGANS, V20, P964, DOI 10.1111/j.1525-1594.1996.tb04579.x; RODRIGUEZ ER, 1991, AM J CARDIOL, V68, P1511, DOI 10.1016/0002-9149(91)90288-V; ROSE NR, 1987, CIBA F SYMP, V129, P3; SANDERSON JE, 1985, AM J CARDIOL, V55, P755, DOI 10.1016/0002-9149(85)90151-1; Saphir O, 1941, ARCH PATHOL, V32, P1000; SAPHIR O, 1960, PATHOLOGY HEART, P779; Schofield CJ, 1999, ADV PARASIT, V42, P1, DOI 10.1016/S0065-308X(08)60147-5; SCHULTHEISS HP, 1985, J MOL CELL CARDIOL, V17, P603, DOI 10.1016/S0022-2828(85)80029-8; SCHWAIGER A, 1993, AM HEART J, V126, P406, DOI 10.1016/0002-8703(93)91058-M; SEKO Y, 1990, CIRC RES, V67, P360, DOI 10.1161/01.RES.67.2.360; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; Seko Y, 1998, CIRC RES, V82, P613, DOI 10.1161/01.RES.82.5.613; SHANES JG, 1987, CIRCULATION, V75, P401, DOI 10.1161/01.CIR.75.2.401; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Smith SC, 1997, CIRCULATION, V95, P163, DOI 10.1161/01.CIR.95.1.163; SMITH WG, 1966, BRIT HEART J, V28, P204; TOMIOKA N, 1986, J AM COLL CARDIOL, V7, P868, DOI 10.1016/S0735-1097(86)80349-7; VIGNOLA PA, 1984, J AM COLL CARDIOL, V4, P812, DOI 10.1016/S0735-1097(84)80411-8; Wang WZ, 1997, CIRCULATION, V95, P245, DOI 10.1161/01.CIR.95.1.245; Wesslen L, 1996, EUR HEART J, V17, P902; WHY HJF, 1994, CIRCULATION, V89, P2582, DOI 10.1161/01.CIR.89.6.2582; WILSON FM, 1969, AM J PATHOL, V55, P253; Wojnicz R, 1998, EUR HEART J, V19, P1564, DOI 10.1053/euhj.1998.1085; YAMAMOTO T, 1994, TOHOKU J EXP MED, V174, P59, DOI 10.1620/tjem.174.59; YASUDA T, 1987, CIRCULATION, V76, P306, DOI 10.1161/01.CIR.76.2.306; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656; Zaragoza C, 1998, P NATL ACAD SCI USA, V95, P2469, DOI 10.1073/pnas.95.5.2469	149	795	856	3	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1388	1398		10.1056/NEJM200011093431908	http://dx.doi.org/10.1056/NEJM200011093431908			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070105				2022-12-28	WOS:000165152800008
J	Galgiani, JN; Catanzaro, A; Cloud, GA; Johnson, RH; Williams, PL; Mirels, LF; Nassar, F; Lutz, JE; Stevens, DA; Sharkey, PK; Singh, VR; Larsen, RA; Delgado, KL; Flanigan, C; Rinaldi, MG				Galgiani, JN; Catanzaro, A; Cloud, GA; Johnson, RH; Williams, PL; Mirels, LF; Nassar, F; Lutz, JE; Stevens, DA; Sharkey, PK; Singh, VR; Larsen, RA; Delgado, KL; Flanigan, C; Rinaldi, MG		Nat Inst Allergy Infect Dis-Mycose	Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis - A randomized, double-blind trial	ANNALS OF INTERNAL MEDICINE			English	Article							MURINE COCCIDIOIDOMYCOSIS; CHRONIC PULMONARY; THERAPY; KETOCONAZOLE; MENINGITIS; CHROMATOGRAPHY; SCH39304; MYCOSES; ASSAY	Background: In previous open-label noncomparative clinical trials, bath fluconazole and itraconazole were effective therapy for progressive forms of coccidioidomycosis. Objective: To determine whether fluconazole or itraconazole is superior for treatment of nonmeningeal progressive coccidioidal infections. Design: Randomized, double-blind, placebo-controlled trial. Setting: 7 treatment centers in California, Arizona, and Texas. Patients: 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections. Intervention: Oral fluconazole, 400 mg/d, or itraconazole, 200 mg twice daily. Measurements: After 4, 8, and 12 months, a predefined scoring system was used to assess severity of infection. Findings were compared with those at baseline. Results: Overall, 50% of patients (47 of 94) and 63% of patients (67 of 97) responded to 8 months of treatment with fluconazole and itraconazole, respectively (difference, 13 percentage points [95% CI, -2 to 28 percentage points]; P = 0.08). Patients with skeletal infections responded twice as frequently to itraconazole as to fluconazole. By 12 months, 57% of patients had responded to fluconazole and 72% had responded to itraconazole (difference, 15 percentage points [CI, 0.003 to 30 percentage points]; P = 0.05). Soft tissue disease was associated with increased likelihood of response, as in previous studies. Azole drug was detected in serum specimens from all but 3 patients; however, drug concentrations were not helpful in predicting outcome. Relapse rates after discontinuation of therapy did not differ significantly between groups (28% after fluconazole treatment and 18% after itraconazole treatment). Both drugs were well tolerated. Conclusions: Neither fluconazole nor itraconazole showed statistically superior efficacy in nonmeningeal coccidioidomycosis, although there is a trend toward slightly greater efficacy with itraconazole at the doses studied.	So Arizona Vet Affairs Hlth Care Syst, Valley Fever Ctr Excellence, Tucson, AZ 85723 USA; Univ Arizona, Tucson, AZ USA; Univ Calif San Diego, San Diego, CA 92103 USA; Univ Alabama Birmingham, Birmingham, AL USA; Kern Med Ctr, Bakersfield, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ So Calif, Los Angeles, CA USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, San Jose, CA USA; Visalia Med Clin, Visalia, CA USA; Univ Texas San Antonio, San Antonio, TX 78285 USA; Maricopa Cty Gen Hosp, Phoenix, AZ USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; University of Arizona; University of California System; University of California San Diego; University of Alabama System; University of Alabama Birmingham; University of California System; University of California Los Angeles; University of Southern California; Santa Clara Valley Medical Center; Stanford University; University of Texas System; University of Texas at San Antonio (UTSA); Maricopa County General Hospital	Galgiani, JN (corresponding author), So Arizona Vet Affairs Hlth Care Syst, Valley Fever Ctr Excellence, 3601 S 6th Ave, Tucson, AZ 85723 USA.	spherule@u.arizona.edu	Galgiani, John/GLT-7012-2022		NCRR NIH HHS [MO1-RR00827] Funding Source: Medline; NIAID NIH HHS [N01-AI-15082, N01-AI-65296] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI065296, N01AI015082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRASS C, 1980, REV INFECT DIS, V2, P656; CATANZARO A, 1990, CHEST, V97, P666, DOI 10.1378/chest.97.3.666; CATANZARO A, 1982, ANN INTERN MED, V96, P436, DOI 10.7326/0003-4819-96-4-436; CATANZARO A, 1995, AM J MED, V98, P249, DOI 10.1016/S0002-9343(99)80371-4; CLEMONS KV, 1995, ANTIMICROB AGENTS CH, V39, P1169, DOI 10.1128/AAC.39.5.1169; Clemons KV, 1997, ANTIMICROB AGENTS CH, V41, P200, DOI 10.1128/AAC.41.1.200; CLEMONS KV, 1990, ANTIMICROB AGENTS CH, V34, P928, DOI 10.1128/AAC.34.5.928; Cochran W.G., 1967, STAT METHODS; CRAVEN PC, 1983, ANN INTERN MED, V98, P160, DOI 10.7326/0003-4819-98-2-160; DEFAVERI J, 1990, ANTIMICROB AGENTS CH, V34, P663, DOI 10.1128/AAC.34.4.663; DEFELICE R, 1982, AM J MED, V72, P681, DOI 10.1016/0002-9343(82)90480-6; DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DIAZ M, 1991, CHEST, V100, P682, DOI 10.1378/chest.100.3.682; DRUTZ DJ, 1978, AM REV RESPIR DIS, V117, P727; FIERER J, 1990, ANTIMICROB AGENTS CH, V34, P13, DOI 10.1128/AAC.34.1.13; Galgiani JN, 1999, ANN INTERN MED, V130, P293, DOI 10.7326/0003-4819-130-4-199902160-00015; Galgiani JN, 2000, CLIN INFECT DIS, V30, P658, DOI 10.1086/313747; GALGIANI JN, 1988, AM J MED, V84, P603, DOI 10.1016/0002-9343(88)90143-X; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GRANT SM, 1989, DRUGS, V37, P310, DOI 10.2165/00003495-198937030-00003; GRAYBILL JR, 1980, REV INFECT DIS, V2, P661; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; HARRIS SC, 1989, ANTIMICROB AGENTS CH, V33, P714, DOI 10.1128/AAC.33.5.714; HARRISON HR, 1983, PEDIATR INFECT DIS J, V2, P216, DOI 10.1097/00006454-198305000-00009; HOSMER DW, 1989, APPL LOGISTIC REGRES; HOSTETLER JS, 1993, ANTIMICROB AGENTS CH, V37, P2224, DOI 10.1128/AAC.37.10.2224; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lutz JE, 1997, ANTIMICROB AGENTS CH, V41, P1558, DOI 10.1128/AAC.41.7.1558; PAPPAS PG, 1995, ANN INTERN MED, V123, P354, DOI 10.7326/0003-4819-123-5-199509010-00006; PEREZ JA, 1995, ARCH INTERN MED, V155, P1665, DOI 10.1001/archinte.155.15.1665; ROSS JB, 1982, ANN INTERN MED, V96, P440, DOI 10.7326/0003-4819-96-4-440; Stevens D A, 1983, Am J Med, V74, P58, DOI 10.1016/0002-9343(83)90515-6; STEVENS DA, 1995, NEW ENGL J MED, V332, P1077, DOI 10.1056/NEJM199504203321607; STEVENS DA, 1980, COCCIDIOIDOMYCOSIS T, P1; STILLER RL, 1980, P 5 INT C MYC SUP CU, P375; TUCKER RM, 1990, J AM ACAD DERMATOL, V23, P593, DOI 10.1016/0190-9622(90)70261-F; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; WIEDEN MA, 1983, J CLIN MICROBIOL, V18, P529, DOI 10.1128/JCM.18.3.529-534.1983; WILLIAMS PL, 1996, COCCIDIOIDOMYCOSIS, P423	42	156	161	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					676	686		10.7326/0003-4819-133-9-200011070-00009	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074900				2022-12-28	WOS:000165075300002
J	Ashley, EA; Myers, J; Froelicher, V				Ashley, EA; Myers, J; Froelicher, V			Exercise testing in clinical medicine	LANCET			English	Review							CORONARY-ARTERY DISEASE; BLOOD-PRESSURE RESPONSE; CHRONIC HEART-FAILURE; ALL-CAUSE MORTALITY; OXYGEN-CONSUMPTION; PROGNOSTIC VALUE; RATE RECOVERY; TREADMILL; PROTOCOL; PREDICTOR	Exercise-induced changes in the electrocardiogram have been used to identify coronary artery disease for almost a century. Over the past decade, however, clinicians have increasingly focused on more expensive diagnostic tools believing them to offer improved diagnostic accuracy. In fact, by incorporating historical data, the simple exercise test can in most cases outperform the newer tests, The use of prediction equations and non-staged exercise protocols can improve the test still further, while advances In the use of the test for prognosis, with the discovery of novel risk factors and the addition of gas analysis, may in the future shift the primary emphasis away from diagnosis. Brief, inexpensive, and done in most cases without the presence of a cardiologist, the exercise test offers the highest value for predictive accuracy of any of the non-invasive tests for coronary artery disease.	Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England; Stanford Univ, Div Cardiol, Palo Alto, CA 94304 USA; Palo Alto Vet Adm Hlth Care Syst, Palo Alto, CA USA	University of Oxford; Stanford University	Ashley, EA (corresponding author), Univ Oxford, John Radcliffe Hosp, Dept Cardiovasc Med, Oxford OX3 9DU, England.	euan.ashley@cardiov.ox.ac.uk		Froelicher, Victor/0000-0001-8831-4853				American College of Sports Medicine, 2000, GUID EX TEST PRESCR; Atwood JE, 1998, AM HEART J, V136, P543, DOI 10.1016/S0002-8703(98)70233-9; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; BUCHFUHRER MJ, 1983, J APPL PHYSIOL, V55, P1558, DOI 10.1152/jappl.1983.55.5.1558; Campbell L, 1999, AM J CARDIOL, V84, P1304, DOI 10.1016/S0002-9149(99)00562-7; Chua TP, 1997, J AM COLL CARDIOL, V29, P1585, DOI 10.1016/S0735-1097(97)00078-8; Coats AJS, 1999, CIRCULATION, V99, P1138, DOI 10.1161/01.CIR.99.9.1138; Cole CR, 1999, NEW ENGL J MED, V341, P1351, DOI 10.1056/NEJM199910283411804; Do D, 1997, CHEST, V111, P1742, DOI 10.1378/chest.111.6.1742; Einthoven W, 1908, ARCH GESAMTE PHYSIOL, V122, P517, DOI 10.1007/BF01677829; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; Froelicher VF, 1998, ANN INTERN MED, V128, P965, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00001; Gauri AJ, 1999, CIRCULATION, V100, P505; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1997, CIRCULATION, V96, P345; Goldhammer S, 1932, Z KLIN MED, V122, P134; Goldstein RE, 1999, JAMA-J AM MED ASSOC, V281, P565, DOI 10.1001/jama.281.6.565; Goraya TY, 2000, ANN INTERN MED, V132, P862, DOI 10.7326/0003-4819-132-11-200006060-00003; HAMBRECHT RP, 1992, AM J CARDIOL, V70, P141, DOI 10.1016/0002-9149(92)91265-6; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; Kjeldsen, 1997, Blood Press Monit, V2, P147; Lauer MS, 1999, AM HEART J, V137, P903, DOI 10.1016/S0002-8703(99)70415-1; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; Li DS, 1998, CIRC RES, V82, P957, DOI 10.1161/01.RES.82.9.957; Lipinski MJ, 1999, CIRCULATION, V100, P505; LYNCH A, 1996, THOUGHT CONTAGION BE, V1; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; MARK DB, 1987, ANN INTERN MED, V106, P53, DOI 10.7326/0003-4819-106-1-53; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; McHam SA, 1999, J AM COLL CARDIOL, V34, P754, DOI 10.1016/S0735-1097(99)00269-7; Michaelides AP, 1999, NEW ENGL J MED, V340, P340, DOI 10.1056/NEJM199902043400502; MORRIS CK, 1991, AM HEART J, V122, P1423, DOI 10.1016/0002-8703(91)90586-7; Myers J, 2000, J Cardiopulm Rehabil, V20, P251, DOI 10.1097/00008483-200007000-00007; Myers J, 1998, ANN INTERN MED, V129, P286, DOI 10.7326/0003-4819-129-4-199808150-00004; MYERS J, 1991, J AM COLL CARDIOL, V17, P1334, DOI 10.1016/S0735-1097(10)80144-5; Myers J, 2000, AM HEART J, V139, P78, DOI 10.1016/S0002-8703(00)90312-0; O'Rourke RA, 2000, CIRCULATION, V102, P126, DOI 10.1161/01.CIR.102.1.126; PANZA JA, 1991, J AM COLL CARDIOL, V17, P657, DOI 10.1016/S0735-1097(10)80180-9; REDWOOD DR, 1971, CIRCULATION, V43, P618, DOI 10.1161/01.CIR.43.5.618; Robbins M, 1999, CIRCULATION, V100, P2411, DOI 10.1161/01.CIR.100.24.2411; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; Shaw LJ, 1998, CIRCULATION, V98, P1622, DOI 10.1161/01.CIR.98.16.1622; Singh JP, 1999, CIRCULATION, V99, P1831, DOI 10.1161/01.CIR.99.14.1831; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; TAMESIS B, 1993, AM J CARDIOL, V72, P715, DOI 10.1016/0002-9149(93)90891-F; TOPOL EJ, 1995, CIRCULATION, V92, P2333, DOI 10.1161/01.CIR.92.8.2333; Will PM, 1999, AM HEART J, V138, P1033, DOI 10.1016/S0002-8703(99)70067-0	48	104	113	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1592	1597		10.1016/S0140-6736(00)03138-X	http://dx.doi.org/10.1016/S0140-6736(00)03138-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075788				2022-12-28	WOS:000165134500038
J	Kaye, AH; Andrewes, D				Kaye, AH; Andrewes, D			Glasgow Outcome Scale: research scale or blunt instrument?	LANCET			English	Editorial Material							BRAIN INJURY		Univ Melbourne, Royal Melbourne Hosp, Dept Neurosurg & Surg, Parkville, Vic 3050, Australia; Univ Melbourne, Royal Melbourne Hosp, Dept Psychol, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Kaye, AH (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Neurosurg & Surg, Parkville, Vic 3050, Australia.			Kaye, Andrew Henry/0000-0001-5049-8861				JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P759; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; SBORDONE RJ, 1987, REHABILITATION COGNI; SIEGAL S, 1956, NONPARAMETRIC STAT B, P201; WALSH KW, 1991, UNDERSTANDING BRAIN, P167; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; 1986, LANCET, V1, P1361	12	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1540	1541		10.1016/S0140-6736(00)03121-4	http://dx.doi.org/10.1016/S0140-6736(00)03121-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075764				2022-12-28	WOS:000165134500006
J	Navarro, V				Navarro, V			Assessment of the world health report 2000	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Publ Hlth, Publ Policy Program, Baltimore, MD 21205 USA; Pompeu Fabra Univ, Barcelona, Spain	Johns Hopkins University; Pompeu Fabra University	Navarro, V (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Publ Policy Program, 624 N Broadway,Room 448, Baltimore, MD 21205 USA.		Navarro, Vicente/E-8174-2014	Navarro, Vicente/0000-0002-3310-3984				ALLEYNE AO, 1999, GLOB COUNC 26 ANN C; *AM HOSP ASS, 1997, REAL CHECK PUBL PERC; Banerji D, 1999, INT J HEALTH SERV, V29, P227, DOI 10.2190/RAB4-D873-99AM-ACJR; Berkman L., 2000, SOCIAL EPIDEMIOLOGY; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P216, DOI 10.1377/hlthaff.10.3.216; Navarro V, 2000, POLITICAL EC SOCIAL; NAVARRO V, 2000, SOC SCI MED, V52, P1; NUNEZ M, IN PRESS INEQUALITY; *PAN AM HLTH ORG, 1998, TECHN REP SER PAN AM, V65; Wilkinson R, 1996, UNHEALTHY SOC; World Health Organization, 2000, HLTH SYST IMPR PERF	11	110	120	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1598	1601		10.1016/S0140-6736(00)03139-1	http://dx.doi.org/10.1016/S0140-6736(00)03139-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	370QV	11075789				2022-12-28	WOS:000165134500039
J	Cheben, P; del Monte, F; Worsfold, DJ; Carlsson, DJ; Grover, CP; Mackenzie, JD				Cheben, P; del Monte, F; Worsfold, DJ; Carlsson, DJ; Grover, CP; Mackenzie, JD			A photorefractive organically modified silica glass with high optical gain	NATURE			English	Article							ROOM-TEMPERATURE; POLYMERIC FILMS; EFFICIENCY	Photorefractive materials(1) exhibit a spatial modulation of the refractive index due to redistribution of photogenerated charges in an optically nonlinear medium. As such, they have the ability to manipulate light and are potentially important for optical applications(1) including image processing, optical storage, programmable optical interconnects and simulation of neural networks. Photorefractive materials are generally crystals, polymers and glasses with electro-optic or birefringent properties and noncentrosymmetric structure(2). Here we report the photorefractive effect in both non-centrosymmetric and centrosymmetric azo-dye-doped silica glasses, in which refractive index gratings that are spatially phase-shifted with respect to the incident light intensity pattern are observed. The effect results from a nonlocal response of the material to optical illumination, and enables the transfer of energy between two interfering light beams (asymmetric two-beam coupling). Although the writing time for the present grating is relatively slow, we have achieved a two-beam coupling optical gain of 188 cm(-1) in the centrosymmetric glasses, and a gain of 444 cm(-1) in the non-centrosymmetric structures. The latter are fabricated using a corona discharge process 3 to induce a permanent arrangement of azo-dye chromophores.	Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA; Natl Res Council Canada, Inst Natl Measurement Stand, Ottawa, ON K1A 0R6, Canada; CSIC, Inst Ciencia Mat Madrid, E-28049 Madrid, Spain; Natl Res Council Canada, Inst Chem Proc & Environm Technol, Ottawa, ON K1A 0R6, Canada	University of California System; University of California Los Angeles; National Research Council Canada; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Madrid (ICMM); National Research Council Canada	Cheben, P (corresponding author), Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA.		del Monte, Francisco FdM/A-5643-2011	del Monte, Francisco FdM/0000-0002-2868-0023				[Anonymous], 1986, LASER INDUCED DYNAMI; BOYD RW, 1992, NONLINEAR OPTICS, V413; BRINKER CJ, 1990, PHYSICS CHEM SOL GEL; CHAPUT F, 1993, CHEM MATER, V5, P589, DOI 10.1021/cm00029a001; Darracq B, 1997, APPL PHYS LETT, V70, P292, DOI 10.1063/1.118396; DUCHARME S, 1991, PHYS REV LETT, V66, P1846, DOI 10.1103/PhysRevLett.66.1846; Ebelmen J. J., 1844, CR HEBD ACAD SCI, V19, P398; Enomoto T, 1997, J PHYS CHEM B, V101, P7422, DOI 10.1021/jp964056k; GIBBONS WM, 1991, NATURE, V351, P49, DOI 10.1038/351049a0; KIPPELEN B, 1997, NONLINEAR OPTICS ORG, P465; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; Marder SR, 1997, NATURE, V388, P845, DOI 10.1038/42190; MEERHOLZ K, 1994, NATURE, V371, P497, DOI 10.1038/371497a0; MITCHELL GR, 1997, POLYM PREPRINTS, V38, P510; MOERNER WE, 1994, J OPT SOC AM B, V11, P320, DOI 10.1364/JOSAB.11.000320; Moerner WE, 1997, ANNU REV MATER SCI, V27, P586; Nolte D.D., 1995, PHOTOREFRACTIVE EFFE; Petrov M., 1991, PHOTOREFRACTIVE CRYS; SANDALPHON B, 1994, OPT LETT, V19, P68; SEKKAT Z, 1992, APPL PHYS B-PHOTO, V54, P486, DOI 10.1007/BF00325395; SEKKAT Z, 1991, APPL PHYS B-PHOTO, V53, P121, DOI 10.1007/BF00325543; SOUTHGATE PD, 1976, APPL PHYS LETT, V28, P250, DOI 10.1063/1.88727; TODOROV T, 1984, APPL OPTICS, V23, P4309, DOI 10.1364/AO.23.004309	23	126	131	0	27	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					64	67		10.1038/35040513	http://dx.doi.org/10.1038/35040513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081505				2022-12-28	WOS:000165050400049
J	Qin, LC; Zhao, XL; Hirahara, K; Miyamoto, Y; Ando, Y; Iijima, S				Qin, LC; Zhao, XL; Hirahara, K; Miyamoto, Y; Ando, Y; Iijima, S			Materials science - The smallest carbon nanotube	NATURE			English	Article									NEC Corp Ltd, JST ICORP Nanotubulite Project, Tsukuba, Ibaraki 3058501, Japan; Meijo Univ, Dept Mat Sci & Engn, Tempaku Ku, Nagoya, Aichi 4688502, Japan	NEC Corporation; Meijo University	Qin, LC (corresponding author), NEC Corp Ltd, JST ICORP Nanotubulite Project, 34 Miyukigaoka, Tsukuba, Ibaraki 3058501, Japan.	qin@frl.cl.nec.co.jp	Hirahara, Kaori/C-5286-2014	Hirahara, Kaori/0000-0002-7776-4493; Ando, Yukio/0000-0001-7115-9105				AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; BLASE X, 1994, PHYS REV LETT, V72, P1878, DOI 10.1103/PhysRevLett.72.1878; Heath JR, 1998, NATURE, V393, P730, DOI 10.1038/31579; IIJIMA S, 1992, PHYS REV LETT, V69, P3100, DOI 10.1103/PhysRevLett.69.3100; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Kataura H, 2000, MATER RES SOC SYMP P, V593, P113; Prinzbach H, 2000, NATURE, V407, P60, DOI 10.1038/35024037; Qin LC, 1997, CHEM PHYS LETT, V268, P101, DOI 10.1016/S0009-2614(97)00166-8; SAWADA S, 1992, SOLID STATE COMMUN, V83, P917, DOI 10.1016/0038-1098(92)90911-R; Sun LF, 2000, NATURE, V403, P384, DOI 10.1038/35000290; Zhao X, 1997, CARBON, V35, P775, DOI 10.1016/S0008-6223(97)00033-X	11	368	390	8	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					50	50		10.1038/35040699	http://dx.doi.org/10.1038/35040699			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081500	Bronze			2022-12-28	WOS:000165050400044
J	Wang, N; Tang, ZK; Li, GD; Chen, JS				Wang, N; Tang, ZK; Li, GD; Chen, JS			Materials science - Single-walled 4 angstrom carbon nanotube arrays	NATURE			English	Article							CHANNELS		Hong Kong Univ Sci & Technol, Dept Phys, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Wang, N (corresponding author), Hong Kong Univ Sci & Technol, Dept Phys, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.		Chen, Jie-Sheng/B-1509-2009; Tang, Zikang/G-8164-2011; TANG, Zikang/AAJ-4156-2021; Wang, Ning/B-5436-2011	Chen, Jie-Sheng/0000-0003-1233-7746; Wang, Ning/0000-0002-4902-5589				AJAYAN PM, 1992, NATURE, V358, P23, DOI 10.1038/358023a0; BLAU X, 1994, PHYS REV LETT, V72, P1878; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Meier W.M., 1992, ATLAS ZEOLITE STRUCT; Piskoti C, 1998, NATURE, V393, P771, DOI 10.1038/31668; Prinzbach H, 2000, NATURE, V407, P60, DOI 10.1038/35024037; Rao AM, 2000, PHYS REV LETT, V84, P1820, DOI 10.1103/PhysRevLett.84.1820; Sun HD, 1999, APPL PHYS A-MATER, V69, P381, DOI 10.1007/s003390051018; Sun LF, 2000, NATURE, V403, P384, DOI 10.1038/35000290; Tang ZK, 2000, PHYSICA B, V279, P200, DOI 10.1016/S0921-4526(99)00734-6; Tang ZK, 1998, APPL PHYS LETT, V73, P2287, DOI 10.1063/1.121704	11	513	538	4	181	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					50	51		10.1038/35040702	http://dx.doi.org/10.1038/35040702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081501				2022-12-28	WOS:000165050400045
J	Keller, SM; Adak, S; Wagner, H; Herskovic, A; Komaki, R; Brooks, BJ; Perry, MC; Livingston, RB; Johnson, DH				Keller, SM; Adak, S; Wagner, H; Herskovic, A; Komaki, R; Brooks, BJ; Perry, MC; Livingston, RB; Johnson, DH		Eastern Cooperative Oncology Grp	A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEMOTHERAPY; RADIOTHERAPY; CARCINOMA; CISPLATIN; TABLES	Background: We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non-small-cell lung cancer. Methods: After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per square meter of body-surface area intravenously on day 1) and etoposide (120 mg per square meter intravenously on days 1, 2, and 3) administered concurrently with radiotherapy (a total of 50.4 Gy, given in 28 daily fractions) or radiotherapy alone (a total of 50.4 Gy, given in 28 daily fractions). Results: Of the 488 patients who were enrolled in the study, 242 were assigned to receive radiotherapy alone and 246 were assigned to receive chemotherapy and radiotherapy. The median duration of follow-up was 44 months. Treatment-associated mortality was 1.2 percent in the group given radiotherapy alone and 1.6 percent in the group given chemotherapy and radiotherapy. The median survival was 39 months in the group given radiotherapy and 38 months in the group given chemotherapy and radiotherapy (P= 0.56 by the log-rank test). The relative likelihood of survival among patients assigned to receive chemotherapy and radiotherapy, as compared with those assigned to receive radiotherapy alone, was 0.93 (95 percent confidence interval, 0.74 to 1.18). Intrathoracic disease recurred within the radiation field in 30 of 234 patients (13 percent) in the group given radiotherapy and in 28 of 236 patients (12 percent) in the group given chemotherapy and radiotherapy (P=0.84); data on recurrence were not available for 18 patients. Conclusions: As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non-small-cell lung cancer.	Beth Israel Deaconess Med Ctr, Dept Surg, New York, NY 10003 USA; Dana Farber Canc Inst, Dept Biostat, Boston, MA USA; H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL USA; Oakwood Hosp, Dept Radiat Oncol, Detroit, MI USA; Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; Alton Ochsner Med Fdn & Ochsner Clin, Div Med Oncol, Baton Rouge, LA USA; Univ Missouri, Ellis Fischer Canc Ctr, Div Hematol & Med Oncol, Columbia, MO USA; Univ Washington, Div Med Oncol, Seattle, WA 98195 USA; Vanderbilt Univ, Div Med Oncol, Nashville, TN USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; H Lee Moffitt Cancer Center & Research Institute; Beaumont Health; University of Texas System; UTMD Anderson Cancer Center; Ochsner Health System; University of Missouri System; University of Missouri Columbia; University of Washington; University of Washington Seattle; Vanderbilt University	Keller, SM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Surg, 1st Ave & 16th St, New York, NY 10003 USA.	skeller@bethisraelny.org	Johnson, David H./A-7437-2009		NATIONAL CANCER INSTITUTE [U10CA031946, U10CA023318] Funding Source: NIH RePORTER; NCI NIH HHS [CA31946, CA120046, CA23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTI W, 1995, BRIT MED J, V311, P899; BELANI CP, 1998, P AN M AM SOC CLIN, V17, pA455; Burdett S, 1998, LANCET, V352, P257; COX DR, 1972, J R STAT SOC B, V34, P187; DAUTZENBERG B, 1995, CANCER, V76, P779, DOI 10.1002/1097-0142(19950901)76:5<779::AID-CNCR2820760511>3.0.CO;2-O; DHINGRA HM, 1985, J CLIN ONCOL, V3, P176, DOI 10.1200/JCO.1985.3.2.176; GANDARA DR, 1989, J NATL CANCER I, V81, P790, DOI 10.1093/jnci/81.10.790; HOLMES EC, 1986, J CLIN ONCOL, V4, P710, DOI 10.1200/JCO.1986.4.5.710; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELLER SM, 1988, TECHNIQUE MEDIASTINA; LAD T, 1988, J CLIN ONCOL, V6, P9; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mayer, 1998, CHEST, V113, P564; Mayer R, 1997, CHEST, V112, P954, DOI 10.1378/chest.112.4.954; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; *STUD GROUP ADJ CH, 1995, EUR J SURG ONCOL, V21, P69; TISI GM, 1983, AM REV RESPIR DIS, V127, P659, DOI 10.1164/arrd.1983.127.5.659; Wada H, 1996, J CLIN ONCOL, V14, P1048, DOI 10.1200/JCO.1996.14.4.1048; WEISENBURGER TH, 1986, NEW ENGL J MED, V315, P1377; XU GC, 1998, CHINESE J ONCOL, V20, P228	23	334	352	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1217	1222		10.1056/NEJM200010263431703	http://dx.doi.org/10.1056/NEJM200010263431703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071672				2022-12-28	WOS:000090014100003
J	Rascon, C; Parry, AO				Rascon, C; Parry, AO			Geometry-dominated fluid adsorption on sculpted solid substrates	NATURE			English	Article							CAPILLARY CONDENSATION; SURFACES; WEDGE	The shape(1,2) and chemical composition(3) of solid surfaces can be controlled at a mesoscopic scale. Exposing such structured substrates to a gas that is close to coexistence with its liquid phase can produce quite distinct adsorption characteristics compared to those of planar systems(4), which may be important for technologies such as super-repellent surfaces(5,6) or micro-fluidics(7,8). Recent studies have concentrated on the adsorption of liquids on rough(9-11) and heterogeneous(12) substrates, and the characterization of nanoscopic liquid films(13). But the fundamental effect of geometry on the adsorption of a fluid from the gas phase has hardly been addressed. Here we present a simple theoretical model which shows that varying the shape of the substrate can exert a profound influence on the adsorption isotherms of liquids. The model smoothly connects wetting and capillary condensation through a number of examples of fluid interfacial phenomena, and opens the possibility of tailoring the adsorption properties of solid substrates by sculpting their surface shape.	Univ London Imperial Coll Sci Technol & Med, Dept Math, London SW7 2BZ, England	Imperial College London	Parry, AO (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Math, 180 Queens Gate, London SW7 2BZ, England.		Rascon, Carlos/L-9898-2014	Rascon, Carlos/0000-0003-4999-0343				Bico J, 1999, EUROPHYS LETT, V47, P220, DOI 10.1209/epl/i1999-00548-y; CHRISTENSON HK, 1994, PHYS REV LETT, V73, P1821, DOI 10.1103/PhysRevLett.73.1821; CONCUS P, 1969, P NATL ACAD SCI USA, V63, P292, DOI 10.1073/pnas.63.2.292; Dietrich S., 1988, PHASE TRANSITIONS CR, V12, P1; DIETRICH S, 1999, P NATO ASI NEW APPR, P197; EVANS R, 1986, J CHEM PHYS, V84, P2376, DOI 10.1063/1.450352; Gau H, 1999, SCIENCE, V283, P46, DOI 10.1126/science.283.5398.46; Giugliarelli G, 1996, PHYS REV E, V53, P5035, DOI 10.1103/PhysRevE.53.5035; Gravesen P., 1993, Journal of Micromechanics and Microengineering, V3, P168, DOI 10.1088/0960-1317/3/4/002; HAUGE EH, 1992, PHYS REV A, V46, P4994, DOI 10.1103/PhysRevA.46.4994; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; KARDAR M, 1990, EUROPHYS LETT, V12, P161, DOI 10.1209/0295-5075/12/2/012; KUMAR A, 1995, ACCOUNTS CHEM RES, V28, P219, DOI 10.1021/ar00053a003; Luna M, 1999, J PHYS CHEM B, V103, P9576, DOI 10.1021/jp991256y; MARCONI UMB, 1989, PHYS REV A, V39, P4109, DOI 10.1103/PhysRevA.39.4109; NEIMARK AV, 1981, COLLOID J USSR+, V43, P402; Netz RR, 1997, PHYS REV E, V55, P687, DOI 10.1103/PhysRevE.55.687; Parry AO, 2000, PHYS REV LETT, V85, P345, DOI 10.1103/PhysRevLett.85.345; POMEAU Y, 1986, J COLLOID INTERF SCI, V113, P5, DOI 10.1016/0021-9797(86)90199-2; Rascon C, 2000, J CHEM PHYS, V112, P5175, DOI 10.1063/1.481073; Rejmer K, 1999, PHYS REV E, V60, P4027, DOI 10.1103/PhysRevE.60.4027; Shibuichi S, 1998, J COLLOID INTERF SCI, V208, P287, DOI 10.1006/jcis.1998.5813; Trau M, 1997, NATURE, V390, P674, DOI 10.1038/37764; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	25	168	172	1	43	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					986	989		10.1038/35039590	http://dx.doi.org/10.1038/35039590			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069174	Green Submitted			2022-12-28	WOS:000090032500038
J	Reschke, K; Klose, S; Ridwelski, K; Lehnert, H				Reschke, K; Klose, S; Ridwelski, K; Lehnert, H			Obesity: sometimes more than adipose tissue	LANCET			English	Article									Univ Magdeburg, Sch Med, Dept Endocrinol & Metab, D-39120 Magdeburg, Germany; Univ Magdeburg, Sch Med, Dept Surg, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Lehnert, H (corresponding author), Univ Magdeburg, Sch Med, Dept Endocrinol & Metab, Leipziger Str 44, D-39120 Magdeburg, Germany.							Korbin CD, 1998, RADIOLOGY, V208, P459, DOI 10.1148/radiology.208.2.9680576; Tait D L, 1997, Tex Med, V93, P89; Zanini P, 1996, Minerva Ginecol, V48, P215	3	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					734	734		10.1016/S0140-6736(00)02633-7	http://dx.doi.org/10.1016/S0140-6736(00)02633-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085694				2022-12-28	WOS:000088948200014
J	Mowat, AM				Mowat, AM			Coeliac disease - a future for peptide therapy?	LANCET			English	Editorial Material							CELIAC-DISEASE; T-CELLS; GLIADIN PEPTIDES; ORGAN-CULTURE; ALPHA-GLIADIN; A-GLIADIN; RECOGNIZE; TOXICITY		Univ Glasgow, Western Infirm, Dept Bacteriol & Immunol, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Mowat, AM (corresponding author), Univ Glasgow, Western Infirm, Dept Bacteriol & Immunol, Glasgow G11 6NT, Lanark, Scotland.		Mowat, Allan M/H-7932-2016	Mowat, Allan M/0000-0001-9389-3079				Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; DERITIS G, 1988, GASTROENTEROLOGY, V94, P41, DOI 10.1016/0016-5085(88)90607-5; GJERTSEN HA, 1994, HUM IMMUNOL, V39, P243, DOI 10.1016/0198-8859(94)90267-4; Lock C, 1991, Semin Immunol, V3, P247; MacDonald TT, 1999, IMMUNOL TODAY, V20, P505, DOI 10.1016/S0167-5699(99)01536-4; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; MANTZARIS G, 1991, SCAND J GASTROENTERO, V26, P392, DOI 10.3109/00365529108996500; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; MOWAT AM, 1999, MUCOSAL IMMUNOLOGY, P587; Mowat AMI, 1998, GUT, V43, P599, DOI 10.1136/gut.43.5.599; NILSEN EM, 1995, GUT, V37, P766, DOI 10.1136/gut.37.6.766; SHIDRAWI RG, 1995, SCAND J GASTROENTERO, V30, P758, DOI 10.3109/00365529509096324; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; ten Dam M, 1998, CLIN EXP IMMUNOL, V114, P189; Van de Wal Y, 2000, GUT, V46, P734, DOI 10.1136/gut.46.5.734; van de Wal Y, 1998, P NATL ACAD SCI USA, V95, P10050, DOI 10.1073/pnas.95.17.10050; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120	19	7	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					270	271		10.1016/S0140-6736(00)02499-5	http://dx.doi.org/10.1016/S0140-6736(00)02499-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071179				2022-12-28	WOS:000088305900005
J	Menzies, D; Fanning, A; Yuan, L; FitzGerald, JM				Menzies, D; Fanning, A; Yuan, L; FitzGerald, JM		Canadian Collaborative Grp Nosocom	Hospital ventilation and risk for tuberculous infection in Canadian health care workers	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; CDC TB SURVEY; SKIN-TEST; NOSOCOMIAL TRANSMISSION; PULMONARY TUBERCULOSIS; YOUNG-ADULTS; OCCUPATIONAL TUBERCULOSIS; DIAGNOSTIC-PROCEDURES; RESPIRATORY ISOLATION	Background: The risk for and determinants of transmission of tuberculosis in hospitals caring for moderate numbers of patients with tuberculosis remain uncertain. Objective: To study the association of tuberculin conversion among health care workers with ventilation of patient care areas. Design: Cross-sectional observational survey. Setting: 17 acute-care community or university hospitals. Participants: All personnel who worked at least 2 days per week in the respiratory and physiotherapy departments or in selected nursing units. Measurements: Participating workers underwent tuberculin skin testing and completed self-administered questionnaires. Previous tuberculin tests and bacille Calmette-Guerin vaccinations were verified. Records of patients with tuberculosis who were hospitalized in the 3 years preceding the study were reviewed. Air exchanges per hour in patient care areas were measured by using a tracer gas technique. Multivariate proportional hazards regression was used to estimate the effect of occupational factors on documented tuberculin conversion, after adjustment for nonoccupational factors, among participants with at least one previous negative result on tuberculin skin testing. Results: Tuberculin conversion was associated with ventilation of general or nonisolation patient rooms of less than 2 air exchanges per hour (adjusted hazard ratio, 3.4 [95% Cl, 2.1 to 5.8]); with work in moderate- to high-risk hospitals (adjusted hazard ratio, 2.2 [Cl, 1.3 to 3.5]); and with work in the nursing (adjusted hazard ratio, 4.3 [Cl, 2.7 to 6.91), respiratory therapy (adjusted hazard ratio, 6.1 [Cl, 3.1 to 12.0]), and physiotherapy (adjusted hazard ratio, 3.3 [Cl, 1.5 to 74) departments or housekeeping (adjusted hazard ratio, 4.2 [Cl, 2.3 to 7.6]). Conversion was not associated with inadequate ventilation of respiratory isolation rooms (adjusted hazard ratio, 1.0 [Cl, 0.8 to 1.3). Conclusion: Tuberculin conversion among health care workers was strongly associated with inadequate ventilation in general patient rooms and with type and duration of work, but not with ventilation of respiratory isolation rooms.	McGill Univ, Montreal Chest Inst, Montreal, PQ H2X 2P4, Canada; Univ Alberta, Edmonton, AB, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	McGill University; University of Alberta; University of British Columbia	Menzies, D (corresponding author), McGill Univ, Montreal Chest Inst, 3650 St Urbain St, Montreal, PQ H2X 2P4, Canada.	menzies@meakins.lan.mcgill.ca						ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; *AM STAND TEST MAT, 1988, ANN BOOK ASTM STAND, P568; [Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; Bangsberg DR, 1997, INFECT CONT HOSP EP, V18, P566; Barnhart S, 1997, J OCCUP ENVIRON MED, V39, P849, DOI 10.1097/00043764-199709000-00008; BASS JB, 1981, AM REV RESPIR DIS, V123, P394; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; CAUTHEN CM, 1994, AM J RESP CRIT CARE, V149, P1597, DOI 10.1164/ajrccm.149.6.8004319; COUNSELL SR, 1989, ARCH INTERN MED, V149, P1274, DOI 10.1001/archinte.149.6.1274; COX DR, 1972, J R STAT SOC B, V34, P187; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1; EHRENKRA.NJ, 1972, ANN INTERN MED, V77, P377, DOI 10.7326/0003-4819-77-3-377; Fella P, 1995, AM J INFECT CONTROL, V23, P352, DOI 10.1016/0196-6553(95)90265-1; Fennelly KP, 1998, INFECT CONT HOSP EP, V19, P754; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P118; FITZGERALD JM, 1996, CANADIAN TUBERCULOSI; FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P135; FRIDKIN SK, 1995, INFECT CONT HOSP EP, V16, P129; GORDIN FM, 1988, AM REV RESPIR DIS, V137, P153, DOI 10.1164/ajrccm/137.1.153; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; Holton D, 1997, Can J Infect Dis, V8, P188; JEANES CWL, 1969, CAN MED ASSOC J, V100, P888; KNIGHT RA, 1963, AM REV RESPIR DIS, V88, P119; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; LINGREENBERG A, 1992, AM J INFECT CONTROL, V20, P16, DOI 10.1016/S0196-6553(05)80119-1; Long R, 1999, CAN MED ASSOC J, V160, P1185; MAGNUS K, 1955, LANCET, V2, P643; MALASKY C, 1990, AM REV RESPIR DIS, V142, P505, DOI 10.1164/ajrccm/142.3.505; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; MATHUR P, 1994, ARCH INTERN MED, V154, P306, DOI 10.1001/archinte.154.3.306; Menzies D, 1997, AM J RESP CRIT CARE, V156, P1915, DOI 10.1164/ajrccm.156.6.9704017; MENZIES D, 1995, NEW ENGL J MED, V332, P92, DOI 10.1056/NEJM199501123320206; MENZIES R, 1992, AM REV RESPIR DIS, V145, P621, DOI 10.1164/ajrccm/145.3.621; MENZIES R, 1995, AM J RESP CRIT CARE, V152, P1992, DOI 10.1164/ajrccm.152.6.8520767; MENZIES R, 1992, AM REV RESPIR DIS, V146, P752, DOI 10.1164/ajrccm/146.3.752; MENZIES R, 1994, ANN INTERN MED, V120, P190, DOI 10.7326/0003-4819-120-3-199402010-00003; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; NARDELL EA, 1993, INFECT CONT HOSP EP, V14, P681; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302; Nicas M, 1998, J OCCUP ENVIRON MED, V40, P648, DOI 10.1097/00043764-199807000-00011; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAAD I, 1989, INFECT CONT HOSP EP, V10, P465, DOI 10.1086/645922; Rao VK, 1999, ANN INTERN MED, V130, P404, DOI 10.7326/0003-4819-130-5-199903020-00004; RICHARDS NM, 1979, AM REV RESPIR DIS, V120, P59; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; Rivest P, 1998, CAN MED ASSOC J, V158, P605; SCOTT B, 1994, ARCH INTERN MED, V154, P326, DOI 10.1001/archinte.154.3.326; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SEPULVEDA RL, 1990, AM REV RESPIR DIS, V142, P24, DOI 10.1164/ajrccm/142.1.24; SLUTKIN G, 1986, AM REV RESPIR DIS, V134, P1048, DOI 10.1164/arrd.1986.134.5.1048; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; THOMPSON NJ, 1979, AM REV RESPIR DIS, V119, P587; VANDENBRANDE P, 1992, CHEST, V101, P447, DOI 10.1378/chest.101.2.447; Wells WF, 1955, AIR HYG ECOL STUDY D; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7; Woeltje KF, 1997, INFECT CONT HOSP EP, V18, P548; 1996, CANADIAN COMMUNICABL, P1	65	134	138	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					779	789		10.7326/0003-4819-133-10-200011210-00010	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085840				2022-12-28	WOS:000165321200003
J	Tilg, H; Diehl, AM				Tilg, H; Diehl, AM			Mechanisms of disease: Cytokines in alcoholic and nonalcoholic steatohepatitis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; ADENOSYL-L-METHIONINE; PERIVENOUS RAT HEPATOCYTES; FACTOR-INDUCED APOPTOSIS; INDUCED LIVER-INJURY; FACTOR-ALPHA; INSULIN-RESISTANCE; PLASMA ENDOTOXIN; NITRIC-OXIDE; FATTY LIVER		Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, A-6020 Innsbruck, Austria; Johns Hopkins Univ, Dept Med, Div Gastroenterol, Baltimore, MD USA	Medical University of Innsbruck; Johns Hopkins University	Tilg, H (corresponding author), Univ Innsbruck Hosp, Dept Med, Div Gastroenterol & Hepatol, Anichstr 35, A-6020 Innsbruck, Austria.	herbert.tilg@uibk.ac.at			NIAAA NIH HHS [R01 AA10154] Funding Source: Medline; NIDDK NIH HHS [DK53792] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053792, R55DK053792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010154] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ABDELMALEK M, 1995, J CLIN GASTROENTEROL, V20, P127, DOI 10.1097/00004836-199503000-00011; ADACHI Y, 1995, GASTROENTEROLOGY, V108, P218, DOI 10.1016/0016-5085(95)90027-6; AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Barak AJ, 1997, ALCOHOL CLIN EXP RES, V21, P1100, DOI 10.1097/00000374-199709000-00024; Bellas RE, 1997, AM J PATHOL, V151, P891; BENEDETTI A, 1988, J HEPATOL, V6, P137, DOI 10.1016/S0168-8278(88)80024-2; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; BIRD GLA, 1990, ANN INTERN MED, V112, P917, DOI 10.7326/0003-4819-112-12-917; Bosch J, 2000, J HEPATOL, V32, P141, DOI 10.1016/S0168-8278(00)80422-5; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRUGUERA M, 1977, GASTROENTEROLOGY, V73, P1383; CAPRON JP, 1982, DIGEST DIS SCI, V27, P265, DOI 10.1007/BF01296926; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Cortez-Pinto H, 1999, JAMA-J AM MED ASSOC, V282, P1659, DOI 10.1001/jama.282.17.1659; Crabb D W, 1995, Prog Liver Dis, V13, P151; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; DELAMAZA MP, 1995, J AM COLL NUTR, V14, P192; Diehl AM, 1999, J BIOENERG BIOMEMBR, V31, P493, DOI 10.1023/A:1005452624640; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Faggioni R, 1999, AM J PHYSIOL-REG I, V276, pR136, DOI 10.1152/ajpregu.1999.276.1.R136; FEINGOLD KR, 1988, BIOCHEM BIOPH RES CO, V153, P576, DOI 10.1016/S0006-291X(88)81134-3; FELVER ME, 1990, ALCOHOL CLIN EXP RES, V14, P255, DOI 10.1111/j.1530-0277.1990.tb00482.x; FEO F, 1986, TOXICOL APPL PHARM, V83, P331, DOI 10.1016/0041-008X(86)90310-8; FERENCI P, 1989, J HEPATOL, V9, P105, DOI 10.1016/0168-8278(89)90083-4; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Fromenty B, 1997, J HEPATOL, V26, P43, DOI 10.1016/S0168-8278(97)80496-5; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GARCIARUIZ C, 1995, HEPATOLOGY, V21, P207, DOI 10.1016/0270-9139(95)90430-1; Hanck C, 1998, ALCOHOL ALCOHOLISM, V33, P606, DOI 10.1093/alcalc/33.6.606; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HILL DB, 1992, J LAB CLIN MED, V119, P547; HOUGLUM K, 1994, J CLIN INVEST, V94, P808, DOI 10.1172/JCI117400; Iimuro Y, 1997, HEPATOLOGY, V26, P1530; IMPERIALE TF, 1990, ANN INTERN MED, V113, P299, DOI 10.7326/0003-4819-113-4-299; KATYARE SS, 1978, ARCH BIOCHEM BIOPHYS, V188, P15, DOI 10.1016/0003-9861(78)90349-1; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lee FYJ, 1999, AM J PHYSIOL-CELL PH, V276, pC386, DOI 10.1152/ajpcell.1999.276.2.C386; LEIST M, 1994, J IMMUNOL, V153, P1778; Lieber CS, 2000, J HEPATOL, V32, P113, DOI 10.1016/S0168-8278(00)80420-1; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; MACSWEEN RNM, 1986, SEMIN LIVER DIS, V6, P221, DOI 10.1055/s-2008-1040605; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Marsano LS, 1998, HEPATO-GASTROENTEROL, V45, P331; Martin PY, 1998, NEW ENGL J MED, V339, P533, DOI 10.1056/NEJM199808203390807; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; MCCLAIN C, 1993, SEMIN LIVER DIS, V13, P170, DOI 10.1055/s-2007-1007347; MCCLAIN CJ, 1986, LIFE SCI, V39, P1479, DOI 10.1016/0024-3205(86)90554-0; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; NANJI AA, 1993, AM J PATHOL, V142, P367; Nanji AA, 1996, J PHARMACOL EXP THER, V277, P1694; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; NANJI AA, 1994, P SOC EXP BIOL MED, V205, P243; Orange JS, 1997, J VIROL, V71, P9248, DOI 10.1128/JVI.71.12.9248-9258.1997; ORREGO H, 1987, NEW ENGL J MED, V317, P1421, DOI 10.1056/NEJM198712033172301; PALMER M, 1990, GASTROENTEROLOGY, V99, P1408, DOI 10.1016/0016-5085(90)91169-7; PARES A, 1986, J HEPATOL, V2, P33, DOI 10.1016/S0168-8278(86)80006-X; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Rai RM, 1996, AM J PHYSIOL-GASTR L, V270, pG909, DOI 10.1152/ajpgi.1996.270.6.G909; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; Rai RM, 1997, HEPATOLOGY, V25, P889, DOI 10.1002/hep.510250417; Rashid A, 1999, HEPATOLOGY, V30, p405A; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Sakao Y, 1999, INT IMMUNOL, V11, P471, DOI 10.1093/intimm/11.3.471; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; Sheth SG, 1997, ANN INTERN MED, V127, P658; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shulman GI, 1999, AM J CARDIOL, V84, p3J; Takahashi N, 1999, J EXP MED, V189, P207, DOI 10.1084/jem.189.1.207; Tanaka Y, 1996, INT IMMUNOL, V8, P569, DOI 10.1093/intimm/8.4.569; TILG H, 1993, HEPATOLOGY, V18, P1132; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; TSUKAMOTO H, 1986, HEPATOLOGY, V6, P814, DOI 10.1002/hep.1840060503; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Velussi M, 1997, J HEPATOL, V26, P871, DOI 10.1016/S0168-8278(97)80255-3; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8; Wiest R, 1999, SEMIN LIVER DIS, V19, P411, DOI 10.1055/s-2007-1007129; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Zeldin G, 1996, ALCOHOL CLIN EXP RES, V20, P1639, DOI 10.1111/j.1530-0277.1996.tb01710.x	102	721	757	0	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1467	1476		10.1056/NEJM200011163432007	http://dx.doi.org/10.1056/NEJM200011163432007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078773				2022-12-28	WOS:000165271300007
J	Jick, H; Kaye, JA; Vasilakis-Scaramozza, C; Jick, SS				Jick, H; Kaye, JA; Vasilakis-Scaramozza, C; Jick, SS			Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISEASE; WOMEN	Objective To compare the risk of idiopathic venous thromboembolism among women taking third generation oral contraceptives (with gestodene or desogestrel) with that among women taking oral contraceptives with levonorgestrel. Design Cohort and case-control analyses derived from the General Practice Research Database. Setting UK general practices,January 1993 to December 1999. Participants Women aged 15-39 taking third generation oral contraceptives or oral contraceptives with levonorgestrel. Main outcome measures Relative incidence (cohort study) and odds ratios (case-control study) as measures of the relative risk of venous thromboembolism. Results The adjusted estimates of relative risk for venous thromboembolism associated with third generation oral contraceptives compared with oral contraceptives with levonorgestrel was 1.9 (95% confidence interval 1.3 to 2.8) in the cohort analysis and 2.3 (1.3 to 3.9) in the case-control study. The estimates for the two types of oral contraceptives were similar before and after the warning issued by the Committee on Safety of Medicines in October 1995. A shift away from the use of third generation oral contraceptives after the scare was more pronounced among younger women (who have a lower risk of venous thromboembolism) than among older women. Fewer cases of venous thromboembolism occurred in 1996 and later than would have been expected if the use of oral contraceptives had remained unchanged. Conclusions These findings are consistent with previously reported studies, which found that compared with oral contraceptives with levonorgestrel, third generation oral contraceptives are associated with around twice the risk of venous thromboembolism.	Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Jick, H (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA.	hjick@bu.edu		Jick, Susan/0000-0002-2215-1067; Kaye, James A./0000-0002-9357-4227; Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen BS, 1998, THROMB HAEMOSTASIS, V79, P28, DOI 10.1055/s-0037-1614213; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Farley TMM, 1999, HUM REPROD UPDATE, V5, P721, DOI 10.1093/humupd/5.6.721; FARLEY TMM, 1995, LANCET, V346, P1582; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Farmer RDT, 2000, BMJ-BRIT MED J, V321, P477, DOI 10.1136/bmj.321.7259.477; Farmer RDT, 1997, LANCET, V349, P83, DOI 10.1016/S0140-6736(96)07496-X; Herings RMC, 1999, LANCET, V354, P127, DOI 10.1016/S0140-6736(99)01257-X; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Jick SS, 1998, LANCET, V351, P1404, DOI 10.1016/S0140-6736(05)79443-5; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; Vasilakis C, 1999, LANCET, V354, P1610, DOI 10.1016/S0140-6736(99)04394-9; Vasilakis C, 1999, CONTRACEPTION, V59, P79, DOI 10.1016/S0010-7824(99)00011-6; Walker AM, 1998, CONTRACEPTION, V57, P169, DOI 10.1016/S0010-7824(98)00014-6	17	140	141	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2000	321	7270					1190	1195		10.1136/bmj.321.7270.1190	http://dx.doi.org/10.1136/bmj.321.7270.1190			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073511	Green Published			2022-12-28	WOS:000165357100028
J	Lanyon, P; Muir, K; Doherty, S; Doherty, M				Lanyon, P; Muir, K; Doherty, S; Doherty, M			Assessment of a genetic contribution to osteoarthritis of the hip: sibling study	BRITISH MEDICAL JOURNAL			English	Article							1ST NATIONAL-HEALTH; FARMERS; JOINT; WOMEN	Objectives To study the influence of genetics on the development of hip osteoarthritis as determined by structural change on plain radiographs. Design Sibling study. Setting Nottinghamshire, England. Participants 392 index participants with hip osteoarthritis of sufficient severity to warrant total hip replacement, 604 siblings of the index participants, and 1718 participants who had undergone intravenous urography. Main outcome measure Odds ratios for hip osteoarthritis in siblings. Results The age adjusted odds ratios in siblings were 4.9 (95% confidence interval, 3.9 to 6.4) for probable hip osteoarthritis and 6.4 (4.5 to 9.1) for definite hip osteoarthritis. These values were not significantly altered by adjusting for other risk factors. Conclusion Siblings have a high risk of hip osteoarthritis as shown by structural changes on plain radiographs. One explanation is that hip osteoarthritis is under strong genetic influence.	Queens Med Ctr, Clin Immunol Unit, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; City Hosp Nottingham, Acad Rheumatol, Nottingham NG5 1PB, England	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Lanyon, P (corresponding author), Queens Med Ctr, Clin Immunol Unit, Nottingham NG7 2UH, England.		Lanyon, Peter/K-8100-2019	Lanyon, Peter/0000-0002-9855-6802; Doherty, Michael/0000-0002-5763-8326				ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Chitnavis J, 1997, J BONE JOINT SURG BR, V79B, P660, DOI 10.1302/0301-620X.79B4.7437; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cooper C, 1998, AM J EPIDEMIOL, V147, P516; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CROFT P, 1992, BRIT MED J, V304, P1269, DOI 10.1136/bmj.304.6837.1269; DANIELSSON L, 1984, CLIN ORTHOP RELAT R, P110; DANIELSSON LARS G., 1964, ACTA ORTHOPAED SCAND, V66, P1; Felson DT, 1996, ANN RHEUM DIS, V55, P668, DOI 10.1136/ard.55.9.668; Felson DT, 1998, ARTHRITIS RHEUM, V41, P1064, DOI 10.1002/1529-0131(199806)41:6<1064::AID-ART13>3.0.CO;2-K; Fox KM, 1996, J RHEUMATOL, V23, P693; GABRIEL SE, 1995, J RHEUMATOL, V22, P23; Hirsch R, 1998, ARTHRITIS RHEUM, V41, P1227, DOI 10.1002/1529-0131(199807)41:7<1227::AID-ART13>3.0.CO;2-N; JORRING K, 1980, ACTA ORTHOP SCAND, V51, P253; LINDBERG H, 1986, CLIN ORTHOP RELAT R, P273; O'Reilly S, 1999, OSTEOARTHR CARTILAGE, V7, P461, DOI 10.1053/joca.1999.0240; OBRIEN TM, 1989, IRISH J MED SCI, V158, P63, DOI 10.1007/BF02942144; ROACH KE, 1994, J RHEUMATOL, V21, P2334; SMITH RW, 1995, ANN RHEUM DIS, V54, P179, DOI 10.1136/ard.54.3.179; Spector TD, 1996, BRIT MED J, V312, P940; Stecher RM, 1941, AM J MED SCI, V201, P801, DOI 10.1097/00000441-194106000-00004; TEPPER S, 1993, AM J EPIDEMIOL, V137, P1081, DOI 10.1093/oxfordjournals.aje.a116611; THELIN A, 1990, AM J IND MED, V18, P339, DOI 10.1002/ajim.4700180316	25	90	91	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1179	1183		10.1136/bmj.321.7270.1179	http://dx.doi.org/10.1136/bmj.321.7270.1179			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073507	Bronze, Green Published			2022-12-28	WOS:000165357100024
J	Finkel, T; Holbrook, NJ				Finkel, T; Holbrook, NJ			Oxidants, oxidative stress and the biology of ageing	NATURE			English	Review							AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC DROSOPHILA-MELANOGASTER; MANGANESE SUPEROXIDE-DISMUTASE; ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; EXTENDED LIFE-SPAN; CAENORHABDITIS-ELEGANS; HYDROGEN-PEROXIDE; CONTROLLED TRIAL; VITAMIN-E	Living in an oxygenated environment has required the evolution of effective cellular strategies to detect and detoxify metabolites of molecular oxygen known as reactive oxygen species. Here we review evidence that the appropriate and inappropriate production of oxidants, together with the ability of organisms to respond to oxidative stress, is intricately connected to ageing and life span.	NHLBI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Finkel, T (corresponding author), NHLBI, Mol Biol Lab, NIH, Bldg 10-6N-240,10 Ctr Dr, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005012, Z01HL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Andreassen OA, 2000, NEUROREPORT, V11, P2491, DOI 10.1097/00001756-200008030-00029; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Cypser JR, 1999, NEUROBIOL AGING, V20, P503, DOI 10.1016/S0197-4580(99)00085-8; DUDAS SP, 1995, J GERONTOL A-BIOL, V50, pB117, DOI 10.1093/gerona/50A.3.B117; Dukan S, 2000, P NATL ACAD SCI USA, V97, P5746, DOI 10.1073/pnas.100422497; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Golubev AG, 1996, BIOCHEMISTRY-MOSCOW+, V61, P1443; Goto S, 1999, MECH AGEING DEV, V107, P245, DOI 10.1016/S0047-6374(98)00133-X; Guyton K Z, 1998, J Investig Dermatol Symp Proc, V3, P23; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335; Harman D., 1957, J GERONTOL, V2, P298; Harshman LG, 2000, J GERONTOL A-BIOL, V55, pB415, DOI 10.1093/gerona/55.9.B415; HAYES KC, 1974, INVEST OPHTH VISUAL, V13, P499; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; Huang TT, 2000, J GERONTOL A-BIOL, V55, pB5; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; JOHNSON TE, 1988, J GERONTOL, V43, pB137, DOI 10.1093/geronj/43.5.B137; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kao AW, 1997, ENDOCRINOLOGY, V138, P2474, DOI 10.1210/en.138.6.2474; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Liu YS, 1996, J BIOL CHEM, V271, P3604; LOUWERSE ES, 1995, ARCH NEUROL-CHICAGO, V52, P559, DOI 10.1001/archneur.1995.00540300031009; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P8727, DOI 10.1073/pnas.86.22.8727; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; McCall MR, 1999, FREE RADICAL BIO MED, V26, P1034, DOI 10.1016/S0891-5849(98)00302-5; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Mockett RJ, 1999, FASEB J, V13, P1733, DOI 10.1096/fasebj.13.13.1733; Morimoto RI, 1998, NAT BIOTECHNOL, V16, P833, DOI 10.1038/nbt0998-833; Murakami S, 1996, GENETICS, V143, P1207; Murakami S, 1998, CURR BIOL, V8, P1091, DOI 10.1016/S0960-9822(98)70448-8; Nagano S, 1999, NEUROSCI LETT, V265, P159, DOI 10.1016/S0304-3940(99)00227-X; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; ORR WC, 1993, ARCH BIOCHEM BIOPHYS, V301, P34, DOI 10.1006/abbi.1993.1111; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ponnappan Usha, 1998, Frontiers in Bioscience, V3, pD152; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; RICHARDSON A, 1996, CELLULAR AGING CELL, P67; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Roth GS, 1999, J AM GERIATR SOC, V47, P896, DOI 10.1111/j.1532-5415.1999.tb03851.x; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sun JT, 1999, MOL CELL BIOL, V19, P216; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wang PH, 1998, P NATL ACAD SCI USA, V95, P4556, DOI 10.1073/pnas.95.8.4556; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WHEELER JC, 1995, P NATL ACAD SCI USA, V92, P10408, DOI 10.1073/pnas.92.22.10408; WOJCICKI J, 1991, ATHEROSCLEROSIS, V87, P9, DOI 10.1016/0021-9150(91)90227-T; WONG A, 1995, GENETICS, V139, P1247; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yu BP, 1999, MECH AGEING DEV, V111, P73, DOI 10.1016/S0047-6374(99)00072-X	106	6758	7094	71	2034	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					239	247		10.1038/35041687	http://dx.doi.org/10.1038/35041687			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	371LL	11089981				2022-12-28	WOS:000165180400054
J	Gottlieb, SS; Khatta, M; Fisher, ML				Gottlieb, SS; Khatta, M; Fisher, ML			Coenzyme Q(10) and congestive heart failure - Response	ANNALS OF INTERNAL MEDICINE			English	Letter									Univ Maryland, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gottlieb, SS (corresponding author), Univ Maryland, Baltimore, MD 21201 USA.							Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; Hjalmarson A, 1999, LANCET, V353, P2001; LANGSJOEN PH, 1988, KLIN WOCHENSCHR, V66, P583, DOI 10.1007/BF01720833; Packer M, 1999, CIRCULATION, V100, P2312, DOI 10.1161/01.CIR.100.23.2312	4	5	5	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					745	746		10.7326/0003-4819-133-9-200011070-00021	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074912				2022-12-28	WOS:000165075300011
J	Verity, CM; Nicoll, A; Will, RG; Devereux, G; Stellitano, L				Verity, CM; Nicoll, A; Will, RG; Devereux, G; Stellitano, L			Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study	LANCET			English	Article							SPONGIFORM ENCEPHALOPATHY	Background Variant Creutzfeldt-Jakob Disease (vCJD) was first reported in 1996; the youngest patient developed first reported in 1996; the youngest patient developed symptoms at 16 years of age. We have done 3 years of prospective active surveillance for progressive intellectual and neurological deterioration (PIND) in UK children, and have searched for vCJD among the children who were reported. Methods Since May, 1997, there has been active surveillance for patients younger than 16 years old with FIND by means of a monthly card sent to all UK consultant paediatricians by the British Paediatric Surveillance Unit. Clinical details of cases of FIND are obtained from reporting paediatricians by telephone interview or site visit, and an expert group of paediatric neurologists then classifies the cases. Findings After 3 years, 885 patients with suspected FIND have been reported. Among them were two fatal cases of definite vCJD and one case, of probable vCJD; all were reported in 1999. One girl was age 12 years at onset-the youngest ever case of vCJD. No other children with the clinical features of vCJD were identified. The expert group has discussed 655 cases, of which 360 have a confirmed underlying cause, being categorised into 88 known neurodegenerative diseases. Interpretation That this prospective active surveillance in the UK has found few children with suspected vCJD is relatively reassuring, However, 3 years is a short time to survey a disease with an unknown incubation period. Since one probable and two definite cases of vCJD were reported to the study in 1999, there is concern that more childhood cases may appear.	Addenbrookes Hosp, Child Dev Ctr, PIND Surveillance Grp, Cambridge CB2 2QQ, England; PHLS Communicable Dis Surveillance Ctr, London, England; Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh	Verity, CM (corresponding author), Addenbrookes Hosp, Child Dev Ctr, PIND Surveillance Grp, Box 107, Cambridge CB2 2QQ, England.							Gore SM, 1996, BRIT MED J, V312, P791, DOI 10.1136/bmj.312.7034.791; Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Ironside JW, 2000, LANCET, V355, P1693, DOI 10.1016/S0140-6736(00)02243-1; *NAT CREUTZF JAK D, 1999, 8 NAT CREUTZF JAK DI; *ROYAL COLL PAED C, 1999, BRIT PAED SURV UN AN; *TRAG VAR CREUTZF, 1999, LANCET, V353, P939; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 2000, ANN NEUROL, V47, P575; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; Will RG, 1999, LANCET, V353, P979, DOI 10.1016/S0140-6736(99)01160-5; Zeidler M, 2000, LANCET, V355, P1412, DOI 10.1016/S0140-6736(00)02140-1	14	40	41	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1224	1227		10.1016/S0140-6736(00)02785-9	http://dx.doi.org/10.1016/S0140-6736(00)02785-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072940				2022-12-28	WOS:000089724900011
J	Csibra, G; Davis, G; Spratling, MW; Johnson, MH				Csibra, G; Davis, G; Spratling, MW; Johnson, MH			Gamma oscillations and object processing in the infant brain	SCIENCE			English	Article							RESPONSES; PERCEPTION; ORGANIZATION	An enduring controversy in neuroscience concerns how the brain "binds" together separately coded stimulus features to form unitary representations of objects. Recent evidence has indicated a close link between this binding process and 40-hertz (gamma-band) oscillations generated by localized neural circuits. In a separate line of research, the ability of young infants to perceive objects as unitary and bounded has become a central focus for debates about the mechanisms of perceptual development. Here we demonstrate that binding-related 40-hertz oscillations are evident in the infant brain around 8 months of age, which is the same age at which behavioral and event-related potential evidence indicates the onset of perceptual binding of spatially separated static visual features.	Univ London Birkbeck Coll, Sch Psychol, Ctr Brain & Cognit Dev, London WC1E 7HX, England	University of London; Birkbeck University London	Csibra, G (corresponding author), Univ London Birkbeck Coll, Sch Psychol, Ctr Brain & Cognit Dev, Malet St, London WC1E 7HX, England.	g.csibra@bbk.ac.uk	Csibra, Gergely/C-4345-2008; Spratling, Michael W/G-7689-2011; Davis, Gregory/G-9954-2012	Csibra, Gergely/0000-0002-7044-3056; Spratling, Michael W/0000-0001-9531-2813; Johnson, Mark/0000-0003-4229-2585				BERTENTHAL BI, 1980, CHILD DEV, V51, P1072, DOI 10.2307/1129546; Csibra G, 1998, INT J PSYCHOPHYSIOL, V29, P201, DOI 10.1016/S0167-8760(98)00016-6; Davis G, 1998, J EXP PSYCHOL HUMAN, V24, P169; Elliott MA, 2000, J EXP PSYCHOL LEARN, V26, P703, DOI 10.1037/0278-7393.26.3.703; Ffytche DH, 1996, NEUROIMAGE, V3, P104, DOI 10.1006/nimg.1996.0012; GHIM HR, 1990, INFANT BEHAV DEV, V13, P221, DOI 10.1016/0163-6383(90)90032-4; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Herrmann CS, 1999, CLIN NEUROPHYSIOL, V110, P636, DOI 10.1016/S1388-2457(99)00002-4; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; KAVSEK MJ, 1999, UNPUB BIENN M SOC RE; Kellman P. J., 1998, HDB CHILD PSYCHOL, V2, P103; Muller MM, 1996, EXP BRAIN RES, V112, P96; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SUGAWARA M, 1991, SCAND J PSYCHOL, V32, P352, DOI 10.1111/j.1467-9450.1991.tb00886.x; Tallon-Baudry C, 1998, J NEUROSCI, V18, P4244; TallonBaudry C, 1996, J NEUROSCI, V16, P4240; TallonBaudry C, 1997, NEUROREPORT, V8, P1103, DOI 10.1097/00001756-199703240-00008; TREISMAN A, 1982, COGNITIVE PSYCHOL, V14, P459; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B	19	192	193	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1582	1585		10.1126/science.290.5496.1582	http://dx.doi.org/10.1126/science.290.5496.1582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	376EX	11090357				2022-12-28	WOS:000165446200052
J	Delbanco, T; Hartman, EE				Delbanco, T; Hartman, EE			An 80-year-old man with memory loss, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Larson EB, 2000, JAMA-J AM MED ASSOC, V283, P1046, DOI 10.1001/jama.283.8.1046	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2639	2639		10.1001/jama.284.20.2639	http://dx.doi.org/10.1001/jama.284.20.2639			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086373				2022-12-28	WOS:000165296200040
J	McDonald, WI				McDonald, WI			Relapse, remission, and progression in multiple sclerosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NATURAL-HISTORY; CLINICAL COURSE		Royal Coll Physicians, London NW1 4LE, England	Royal College of Physicians	McDonald, WI (corresponding author), Royal Coll Physicians, London NW1 4LE, England.							Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Confavreux C, 2000, NEW ENGL J MED, V343, P1430, DOI 10.1056/NEJM200011163432001; KAPOOR R, 1998, J NEUROL NEUROSUR PS, V65, P414; Kornek B, 1999, BRAIN PATHOL, V9, P651; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; RUNMARKER B, 1993, BRAIN, V116, P117, DOI 10.1093/brain/116.1.117; Smith KJ, 1999, PHILOS T R SOC B, V354, P1649, DOI 10.1098/rstb.1999.0510; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; Werring DJ, 2000, J NEUROL NEUROSUR PS, V68, P441, DOI 10.1136/jnnp.68.4.441	9	39	42	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1486	1487		10.1056/NEJM200011163432010	http://dx.doi.org/10.1056/NEJM200011163432010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078776				2022-12-28	WOS:000165271300010
J	Semino, O; Passarino, G; Oefner, PJ; Lin, AA; Arbuzova, S; Beckman, LE; De Benedictis, G; Francalacci, P; Kouvatsi, A; Limborska, S; Marcikiae, M; Mika, A; Mika, B; Primorac, D; Santachiara-Benerecetti, AS; Cavalli-Sforza, LL; Underhill, PA				Semino, O; Passarino, G; Oefner, PJ; Lin, AA; Arbuzova, S; Beckman, LE; De Benedictis, G; Francalacci, P; Kouvatsi, A; Limborska, S; Marcikiae, M; Mika, A; Mika, B; Primorac, D; Santachiara-Benerecetti, AS; Cavalli-Sforza, LL; Underhill, PA			The genetic legacy of paleolithic Homo sapiens sapiens in extant Europeans: A Y chromosome perspective	SCIENCE			English	Article							MICROSATELLITE LOCI; NATIVE-AMERICAN; POLYMORPHISMS; DNA; POPULATIONS; MARKERS	A genetic perspective of human history in Europe was derived from 22 binary markers of the nonrecombining Y chromosome (NRY). Ten lineages account for >95% of the 1007 European Y chromosomes studied. Geographic distribution and age estimates of alleles are compatible with two Paleolithic and one Neolithic migratory episode that have contributed to the modern European gene pool. A significant correlation between the NRY haplotype data and principal components based on 95 protein markers was observed, indicating the effectiveness of NRY binary polymorphisms in the characterization of human population composition and history.	Univ Pavia, Dipartimento Genet & Microbiol, I-27100 Pavia, Italy; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Calabria, Dipartimento Biol Cellulare, I-87030 Arcavacata Di Rende, Italy; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Hosp Nol, Int Medicogenet Ctr, UA-340000 Donetsk, Ukraine; Umea Univ, Dept Oncoll Pathol & Med Genet, S-90185 Umea, Sweden; Univ Sassari, Dipartimento Zool & Antropol Biol, I-07100 Sassari, Italy; Aristotle Univ Thessaloniki, Dept Genet Dev & Mol Biol, GR-54006 Thessaloniki, Macedonia, Greece; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia; Clin Hosp Ctr Osijek, Sch Med, Dept Pathol, Osijek 31000, Croatia; Reg Ctr Krwiodawstwa & Krwioleczny Lublinie Oddzi, PL-22400 Zamosc, Poland; Univ Hosp Split, Dept Pediat, Lab Clin & Forens Genet, Split 21000, Croatia; Samodzielny Publ Szpital Wojwodzki Papieza Jona P, PL-22400 Zamosc, Poland	University of Pavia; Stanford University; University of Calabria; Stanford University; Umea University; University of Sassari; Aristotle University of Thessaloniki; Russian Academy of Sciences; University of Split	Semino, O (corresponding author), Univ Pavia, Dipartimento Genet & Microbiol, Via Ferrata 1, I-27100 Pavia, Italy.	semino@ipvgen.univp.it	Primorac, Dragan/ABF-6238-2020; Limborska, Svetlana/A-5633-2016; Limborska, Svetlana/S-2961-2019; Primorac, Dragan/I-6941-2017; Arbuzova, Svetlana/W-5491-2018; Primorac, Dragan/GYJ-1505-2022	Limborska, Svetlana/0000-0002-1697-6820; Arbuzova, Svetlana/0000-0002-5846-1067; SEMINO, Ornella/0000-0002-9675-9403; FRANCALACCI, Paolo/0000-0001-7912-162X	NIGMS NIH HHS [GM 28428, GM 55273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM028428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERMAN AJ, 1984, NEOLITHIC TRANSITION; Bergen AW, 1999, ANN HUM GENET, V63, P63, DOI 10.1046/j.1469-1809.1999.6310063.x; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; Chakraborty R, 1997, P NATL ACAD SCI USA, V94, P1041, DOI 10.1073/pnas.94.3.1041; Chikhi L, 1998, P NATL ACAD SCI USA, V95, P9053, DOI 10.1073/pnas.95.15.9053; Gimbutas M., 1970, INDOEUROPEAN INDOEUR, P155; Goldstein DB, 1996, MOL BIOL EVOL, V13, P1213, DOI 10.1093/oxfordjournals.molbev.a025686; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; Hammer MF, 2000, P NATL ACAD SCI USA, V97, P6769, DOI 10.1073/pnas.100115997; Hammer MF, 1997, GENETICS, V145, P787; Klein R. G., 1992, EVOLUTIONARY ANTHR, V1, P5, DOI DOI 10.1002/evan.1360010105; Lahr MM, 1998, YEARB PHYS ANTHROPOL, V41, P137; Lell JT, 1997, HUM GENET, V100, P536, DOI 10.1007/s004390050548; Macaulay V, 1999, AM J HUM GENET, V64, P232, DOI 10.1086/302204; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; Otte M., 1990, WORLD 18000 BP, P54; Quintana-Murci L, 1999, ANN HUM GENET, V63, P153, DOI 10.1046/j.1469-1809.1999.6320153.x; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; Richards MB, 1998, ANN HUM GENET, V62, P241, DOI 10.1046/j.1469-1809.1998.6230241.x; RUHLEN MA, 1987, GUIDE WORLD LANGUAGE; SANTACHIARABENE.AS, UNPUB; Santos FR, 2000, HUM MOL GENET, V9, P421, DOI 10.1093/hmg/9.3.421; Seielstad MT, 1998, NAT GENET, V20, P278, DOI 10.1038/3088; Semino O, 1996, AM J HUM GENET, V59, P964; Shen PD, 2000, P NATL ACAD SCI USA, V97, P7354, DOI 10.1073/pnas.97.13.7354; Torroni A, 1998, AM J HUM GENET, V62, P1137, DOI 10.1086/301822; Underhill PA, 1997, GENOME RES, V7, P996, DOI 10.1101/gr.7.10.996; Underhill PA, 2000, NAT GENET, V26, P358, DOI 10.1038/81685; WHITFIELD LS, 1995, NATURE, V378, P379, DOI 10.1038/378379a0; Willis KJ, 2000, SCIENCE, V287, P1406, DOI 10.1126/science.287.5457.1406; Zerjal T, 1997, AM J HUM GENET, V60, P1174	32	598	617	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1155	1159		10.1126/science.290.5494.1155	http://dx.doi.org/10.1126/science.290.5494.1155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073453				2022-12-28	WOS:000165228200046
J	Usiello, A; Baik, JH; Rouge-Pont, F; Picetti, R; Dierich, A; LeMeur, M; Piazza, PV; Borrelli, E				Usiello, A; Baik, JH; Rouge-Pont, F; Picetti, R; Dierich, A; LeMeur, M; Piazza, PV; Borrelli, E			Distinct functions of the two isoforms of dopamine D-2 receptors	NATURE			English	Article							DEFICIENT MICE; D2 RECEPTORS; LOCOMOTOR-ACTIVITY; G-PROTEINS; NEURONS; HYPERPLASIA; AGONISTS; RELEASE; GENE	Signalling through dopamine D2 receptors governs physiological functions related to locomotion, hormone production and drug abuse(1-7). D2 receptors are also known targets of antipsychotic drugs that are used to treat neuropsychiatric disorders such as schizophrenia(8). By a mechanism of alternative splicing, the D2 receptor gene encodes two molecularly distinct isoforms(9), D2S and D2L, previously thought to have the same function. Here we show that these receptors have distinct functions in vivo; D2L acts mainly at postsynaptic sites and D2S serves presynaptic autoreceptor functions. The cataleptic effects of the widely used antipsychotic haloperidol(1) are absent in D2L-deficient mice. This suggests that D2L is targeted by haloperidol, with implications for treatment of neuropsychiatric disorders. The absence of D2L reveals that D2S inhibits D1 receptor-mediated functions, uncovering a circuit of signalling interference between dopamine receptors.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Univ Bordeaux 2, INSERM, U259, F-33077 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Borrelli, E (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	eb@igbmc.u-strasbg.fr	Borrelli, Emiliana/M-8994-2018; usiello, alessandro/B-2368-2012; Picetti, Roberto/B-9944-2011	Picetti, Roberto/0000-0003-4756-5271; Usiello, Alessandro/0000-0001-9203-853X				Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Boulay D, 2000, EUR J PHARMACOL, V391, P63, DOI 10.1016/S0014-2999(99)00916-4; Boulay D, 1999, NEUROPHARMACOLOGY, V38, P1389, DOI 10.1016/S0028-3908(99)00064-7; Calabresi P, 1997, J NEUROSCI, V17, P4536; CRENSHAW EB, 1987, CELL, V49, P389, DOI 10.1016/0092-8674(87)90291-1; Egan MF, 1997, CURR OPIN NEUROBIOL, V7, P701, DOI 10.1016/S0959-4388(97)80092-X; EILAM D, 1989, EUR J PHARMACOL, V161, P151, DOI 10.1016/0014-2999(89)90837-6; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; Jung MY, 1999, NEUROSCIENCE, V91, P911, DOI 10.1016/S0306-4522(98)00705-2; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; Kelly MA, 1998, J NEUROSCI, V18, P3470; Khan ZU, 1998, P NATL ACAD SCI USA, V95, P7731, DOI 10.1073/pnas.95.13.7731; L'hirondel M, 1998, BRAIN RES, V792, P253, DOI 10.1016/S0006-8993(98)00146-2; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; Mercuri NB, 1997, NEUROSCIENCE, V79, P323; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; Nisenbaum ES, 1998, SYNAPSE, V29, P213, DOI 10.1002/(SICI)1098-2396(199807)29:3<213::AID-SYN3>3.3.CO;2-3; Picetti R, 1997, CRIT REV NEUROBIOL, V11, P121, DOI 10.1615/CritRevNeurobiol.v11.i2-3.20; PROTAIS P, 1983, PSYCHOPHARMACOLOGY, V81, P126, DOI 10.1007/BF00429006; ROUGEPONT F, 1995, J NEUROSCI, V15, P7189; RUBINSTEIN M, 1988, N-S ARCH PHARMACOL, V337, P115; Ruskin DN, 1998, J PHARMACOL EXP THER, V286, P272; Saiardi A, 1997, NEURON, V19, P115, DOI 10.1016/S0896-6273(00)80352-9; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; WADDINGTON JL, 1993, DOPAMINE RECEPTOR IN, P52; Xu F, 2000, NAT NEUROSCI, V3, P465, DOI 10.1038/74839	30	529	550	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					199	203		10.1038/35041572	http://dx.doi.org/10.1038/35041572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089973				2022-12-28	WOS:000165180400045
J	Cohen, J				Cohen, J			Combination antibiotic therapy for severe peritonitis	LANCET			English	Editorial Material							INFECTIONS; NETILMICIN; GENTAMICIN		Hammersmith Hosp, Imperial Coll Sch Med, Dept Infect Dis & Microbiol, London W12 0NN, England	Imperial College London	Cohen, J (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Dept Infect Dis & Microbiol, London W12 0NN, England.							COMETTA A, 1994, ANTIMICROB AGENTS CH, V38, P1309, DOI 10.1128/AAC.38.6.1309; Del Favero A, 1999, 39 INT C ANT AG CHEM, P722; DONNELLY JP, 1985, J INFECTION, V11, P205, DOI 10.1016/S0163-4453(85)93063-4; Dupont H, 2000, ANTIMICROB AGENTS CH, V44, P2028, DOI 10.1128/AAC.44.8.2028-2033.2000; Falagas ME, 1996, EUR J CLIN MICROBIOL, V15, P913, DOI 10.1007/BF01690508; Johnson CC, 1997, CLIN INFECT DIS, V24, P1035, DOI 10.1086/513658; MARTINO P, 1985, EUR J CANCER CLIN ON, V21, P439, DOI 10.1016/0277-5379(85)90034-3; MOSDELL DM, 1991, ANN SURG, V214, P543, DOI 10.1097/00000658-199111000-00001; ROTSTEIN OD, 1985, REV INFECT DIS, V7, P151; SAUNDERS NJ, 1995, J ANTIMICROB CHEMOTH, V36, P729, DOI 10.1093/jac/36.4.729; VANDERAUWERA P, 1985, J ANTIMICROB CHEMOTH, V16, P581, DOI 10.1093/jac/16.5.581	11	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1539	1540		10.1016/S0140-6736(00)03120-2	http://dx.doi.org/10.1016/S0140-6736(00)03120-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075763				2022-12-28	WOS:000165134500005
J	Willy, PJ; Kobayashi, R; Kadonaga, JT				Willy, PJ; Kobayashi, R; Kadonaga, JT			A basal transcription factor that activates or represses transcription	SCIENCE			English	Article							II GENE-TRANSCRIPTION; CORE PROMOTER ELEMENT; NEGATIVE COFACTOR; IN-VIVO; BINDING; NC2; DROSOPHILA; MECHANISM; TFIIA; DR1	We have identified an activity that is required for transcription of downstream promoter element (DPE)-containing core promoters in vitro. The purified factor was found to be the Drosophila homolog of the transcriptional repressor known as NC2 or Dr1-Drap1. Purified recombinant dNC2 activates DPE-driven promoters and represses TATA-driven promoters. A mutant version of dNC2 can activate DPE promoters but is unable to repress TATA promoters. Thus, the activation and repression functions are distinct. These studies reveal that NC2 (Dr1-Drap1) is a bifunctional basal transcription factor that differentially regulates gene transcription through DPE or TATA box motifs.	Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cold Spring Harbor Laboratory	Kadonaga, JT (corresponding author), Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline; NIGMS NIH HHS [GM41249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Castano E, 2000, P NATL ACAD SCI USA, V97, P7184, DOI 10.1073/pnas.140202297; Gadbois EL, 1997, P NATL ACAD SCI USA, V94, P3145, DOI 10.1073/pnas.94.7.3145; GEISBERG JV, UNPUB; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; INOSTROZA JA, 1992, CELL, V70, P477; Kim J, 1996, J BIOL CHEM, V271, P18405, DOI 10.1074/jbc.271.31.18405; KIM TK, 1995, J BIOL CHEM, V270, P10976, DOI 10.1074/jbc.270.18.10976; Kutach AK, 2000, MOL CELL BIOL, V20, P4754, DOI 10.1128/MCB.20.13.4754-4764.2000; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; WILLY PJ, UNPUB; Yeung K, 1997, MOL CELL BIOL, V17, P36, DOI 10.1128/MCB.17.1.36; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097	20	128	137	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					982	984		10.1126/science.290.5493.982	http://dx.doi.org/10.1126/science.290.5493.982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062130				2022-12-28	WOS:000165103200049
J	Metzger, RA				Metzger, RA			The stars my incarnation - You read it here first, folks.	NATURE			English	Article																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					35	35		10.1038/35040666	http://dx.doi.org/10.1038/35040666			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081490	Bronze			2022-12-28	WOS:000165050400034
J	Xu, YW; Tao, X; Shen, BH; Horng, T; Medzhitov, R; Manley, JL; Tong, L				Xu, YW; Tao, X; Shen, BH; Horng, T; Medzhitov, R; Manley, JL; Tong, L			Structural basis for signal transduction by the Toll/interleukin-1 receptor domains	NATURE			English	Article							DIFFRACTION DATA; ADAPTER PROTEIN; DROSOPHILA TOLL; INNATE IMMUNITY; IL-1 RECEPTOR; FAMILY; MYD88; MACROMOLECULES; MUTATIONS; MODELS	Toll-like receptors (TLRs) and the interleukin-1 receptor superfamily (IL-1Rs) are integral to both innate and adaptive immunity for host defence(1-3). These receptors share a conserved cytoplasmic domain(4,5), known as the TIR domain. A single-point mutation in the TIR domain of murine TLR4 (Pro712His, the Lps(d) mutation) abolishes the host immune response to lipopolysaccharide (LPS)(6), and mutation of the equivalent residue in TLR2, Pro681His, disrupts signal transduction in response to stimulation by yeast and Gram-positive bacteria(7). Here we report the crystal structures of the TIR domains of human TLR1 and TLR2 and of the Pro681His mutant of TLR2. The structures have a large conserved surface patch that also contains the site of the Lps(d) mutation. Mutagenesis and functional studies confirm that residues in this surface patch are crucial for receptor signalling. The Lps(d) mutation does not disturb the structure of the TIR domain itself. Instead, structural and functional studies indicate that the conserved surface patch may mediate interactions with the downstream MyD88 adapter molecule(7-11), and that the Lps(d) mutation may abolish receptor signalling by disrupting this recruitment.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Sch Med, Sect Immunobiol, New Haven, CT 06520 USA	Columbia University; Yale University	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459; Tong, Liang/0000-0002-0563-6468				Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Du X, 1999, BLOOD CELL MOL DIS, V25, P328, DOI 10.1006/bcmd.1999.0262; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORRIS JL, 1992, GENE DEV, V6, P1654, DOI 10.1101/gad.6.9.1654; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; Shen BH, 1998, DEVELOPMENT, V125, P4719; Slack JL, 2000, J BIOL CHEM, V275, P4670, DOI 10.1074/jbc.275.7.4670; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; TONG L, 1998, ACTA CRYSTALLOGR A, V52, P905; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1	29	615	657	2	60	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					111	115		10.1038/35040600	http://dx.doi.org/10.1038/35040600			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081518				2022-12-28	WOS:000165050400062
J	Fitzgerald, DW; Desvarieux, M; Severe, P; Joseph, P; Johnson, WD; Pape, JW				Fitzgerald, DW; Desvarieux, M; Severe, P; Joseph, P; Johnson, WD; Pape, JW			Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; 2-YEAR FOLLOW-UP; PULMONARY TUBERCULOSIS; INFECTED PATIENTS; HIV-INFECTION; MORTALITY; RELAPSE; AFRICA; CHEMOTHERAPY; PROPHYLAXIS	Background Patients with HIV-1 infection respond well to treatment for active tuberculosis, but whether such patients are at increased risk of disease recurrence after complete cure is uncertain. We did a randomised trial in Port au Prince, Haiti, to determine whether recurrent tuberculosis after curative tuberculosis treatment is more common in HIV-1-infected individuals than HIV-1-uninfected individuals, and to determine whether post-treatment isoniazid prophylaxis decreases the risk of recurrent tuberculosis. Methods Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti, and who successfully completed a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1 year of posttreatment isoniazid prophylaxis or placebo. The primary outcome measure was rate of recurrent tuberculosis after at least 24 months. An intention-to-treat analysis was used. Findings Of 354 patients with active pulmonary tuberculosis, 274 successfully completed treatment, and 233 were randomised. Of 142 HIV-1-positive patients, 68 were assigned isoniazid and 74 placebo. Of 91 HIV-1-negative individuals, 51 were assigned isoniazid and 40 placebo. The rate of recurrent tuberculosis was 4.8 per 100 person-years in HIV-1-infected individuals and 0.4 per 100 person-years in uninfected individuals (relative risk 10.7 [95% CI 1.4-81.6]). Among HIV-1-positive patients receiving isoniazid, the tuberculosis recurrence rate was 1.4 per 100 person-years, and among HIV-1-positive patients receiving placebo, it was 7.8 per 100 person-years (0.18 [0.04-0.83]). Among HIV-1-positive individuals, all cases of current tuberculosis occurred in individuals wit a history of HIV-1-related symptoms before initial tuberculosis diagnosis. Interpretation The rate of recurrent tuberculosis is higher in HIV-1-positive individuals than in HIV-1-negative individuals, and is strongly associated with a history of symptomatic HIV-1 disease before initial tuberculosis diagnosis. Posttreatment isoniazid prophylaxis decreases the risk of recurrence in HIV-1-positive individuals, and should be considered for HIV-1-positive individuals with a history of HIV-1-related symptoms at the time of tuberculosis diagnosis.	Cornell Univ, Coll Med, Div Int Med & Infect Dis, New York, NY 10021 USA; Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti; Univ Minnesota, Minneapolis, MN USA	Cornell University; University of Minnesota System; University of Minnesota Twin Cities	Johnson, WD (corresponding author), Cornell Univ, Coll Med, Div Int Med & Infect Dis, New York, NY 10021 USA.	wdjohnso@mail.med.cornell.edu	Desvarieux, Moise/C-4991-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022624] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00018, TW 00002] Funding Source: Medline; NIAID NIH HHS [R37 AI22624] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; *ADV COMM EL TUB, 1998, MMWR-MORBID MORTAL W, V47, P18; [Anonymous], 1992, MMWR-MORBID MORTAL W, V41; BASS JB, 1990, AM REV RESPIR DIS, V142, P725; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; *CDC, 1986, MMWR-MORBID MORTAL W, V35, P334; Chaisson RE, 1996, AM J RESP CRIT CARE, V154, P1034, DOI 10.1164/ajrccm.154.4.8887603; Connolly C, 1999, AIDS, V13, P1543, DOI 10.1097/00002030-199908200-00015; ELLIOTT AM, 1995, J TROP MED HYG, V98, P9; HARRIES AD, 1996, TUBERCULOSIS HIV CLI, P29; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; Johnson JL, 1997, INT J TUBERC LUNG D, V1, P446; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; Kelly PM, 1999, T ROY SOC TROP MED H, V93, P287, DOI 10.1016/S0035-9203(99)90025-1; LANDAY A, 1993, AIDS, V7, P1565, DOI 10.1097/00002030-199312000-00004; MAHER D, 1997, 97220 WHO, P25; MAHER D, 1997, TREATMENT TUBERCULOS, P27; Masur H, 1999, ANN INTERN MED, V131, P873, DOI 10.7326/0003-4819-131-11-199912070-00022; Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Pulido F, 1997, ARCH INTERN MED, V157, P227, DOI 10.1001/archinte.157.2.227; Volmink J, 2000, LANCET, V355, P1345, DOI 10.1016/S0140-6736(00)02124-3; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	27	124	127	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	2000	356	9240					1470	1474		10.1016/S0140-6736(00)02870-1	http://dx.doi.org/10.1016/S0140-6736(00)02870-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081529				2022-12-28	WOS:000090067300010
J	Coussens, LM; Tinkle, CL; Hanahan, D; Werb, Z				Coussens, LM; Tinkle, CL; Hanahan, D; Werb, Z			MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis	CELL			English	Article							CAPILLARY ENDOTHELIAL-CELLS; COLLAGENASE GELATINASE-B; MATRIX METALLOPROTEINASES; TRANSGENIC MICE; EXPRESSION; ANGIOGENESIS; INHIBITORS; SECRETION; TUMORIGENESIS; PROGRESSION	The matrix metalloproteinase MMP-9/gelatinase B is upregulated in angiogenic dysplasias and invasive cancers of the epidermis in a mouse model of multistage tumorigenesis elicited by HPV16 oncogenes. Transgenic mice lacking MMP-9 show reduced keratinocyte hyperproliferation at all neoplastic stages and a decreased incidence of invasive tumors. Yet those carcinomas that do arise in the absence of MMP-9 exhibit a greater loss of keratinocyte differentiation, indicative of a more aggressive and higher grade tumor. Notably, MMP-9 is predominantly expressed in neutrophils, macrophages, and mast cells, rather than in oncogene-positive neoplastic cells. Chimeric mice expressing MMP-9 only in cells of hematopoietic origin, produced by bone marrow transplantation, reconstitute the MMP-9-dependent contributions to squamous carcinogenesis. Thus, inflammatory cells can be coconspirators in carcinogenesis.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Coussens, LM (corresponding author), Univ Calif San Francisco, Canc Res Inst, 513 Parnassus Ave, San Francisco, CA 94143 USA.	coussens@cc.ucsf.edu	Tinkle, Christopher/D-4211-2018; Coussens, Lisa/ABH-9834-2020	Tinkle, Christopher/0000-0001-5552-2664; 	NATIONAL CANCER INSTITUTE [P01CA072006, R01CA047632, R37CA037395] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA072006-020003, CA 47632, R01 CA047632-12, R37 CA037395, R37 CA037395-18, CA72006, P01 CA072006, R37-CA37395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER RR, 1990, DEVELOPMENT, V110, P211; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Broders AC, 1932, NYJ MED, V32, P667; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cockett MI, 1998, BIOCHEM SOC SYMP, P295; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FOSSTIEN E, 2000, ANN CLIN LAB SCI, V1, P3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HERRON GS, 1986, J BIOL CHEM, V261, P2810; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Lane E B, 1990, Semin Cancer Biol, V1, P165; Madlener M, 1998, EXP CELL RES, V242, P201, DOI 10.1006/excr.1998.4049; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Olumi AF, 1999, CANCER RES, V59, P5002; REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091; Smits AJ, 1997, EXP THERM FLUID SCI, V14, P1, DOI 10.1016/S0894-1777(96)00189-6; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; TALHOUK RS, 1991, DEVELOPMENT, V112, P439; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Vu TH, 1998, BIOL EXTRAC, P115; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yu Q, 2000, GENE DEV, V14, P163	37	1071	1112	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					481	490		10.1016/S0092-8674(00)00139-2	http://dx.doi.org/10.1016/S0092-8674(00)00139-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081634	Green Accepted, Bronze			2022-12-28	WOS:000090144100013
J	Reinfelder, JR; Kraepiel, AML; Morel, FMM				Reinfelder, JR; Kraepiel, AML; Morel, FMM			Unicellular C-4 photosynthesis in a marine diatom	NATURE			English	Article							PHOSPHOENOLPYRUVATE CARBOXYLASE; INORGANIC CARBON; PHYTOPLANKTON; LIMITATION	Nearly 50 years ago, inorganic carbon was shown to be fixed in microalgae as the C-3 compound phosphoglyceric acid(1). The enzyme responsible for C-3 carbon fixation, ribulose-1,5-bisphosphate carboxylase (Rubisco), however, requires inorganic carbon in the form of CO2 (ref. 2), and Rubisco enzymes from diatoms have half-saturation constants for CO2 of 30-60 muM (ref. 3). As a result, diatoms growing in seawater that contains about 10 muM CO2 may be CO2 limited(4). Kinetic and growth studies have shown that diatoms can avoid CO2 limitation 5-7, but the biochemistry of the underlying mechanisms remains unknown. Here we present evidence that C-4 photosynthesis supports carbon assimilation in the marine diatom Thalassiosira weissflogii, thus providing a biochemical explanation for CO2-insensitive photosynthesis in marine diatoms. If C-4 photosynthesis is common among marine diatoms, it may account for a significant portion of carbon fixation and export in the ocean, and would explain the greater enrichment of C-13 in diatoms compared with other classes of phytoplankton. Unicellular C-4 carbon assimilation may have predated the appearance of multicellular C-4 plants.	Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA; Univ Strasbourg 1, Ctr Geochim Surface, F-67084 Strasbourg, France; Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA	Rutgers State University New Brunswick; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Princeton University	Reinfelder, JR (corresponding author), Rutgers State Univ, Dept Environm Sci, 14 Coll Farm Rd, New Brunswick, NJ 08901 USA.		Morel, Francois M M/A-8107-2008; Reinfelder, John/C-7214-2016	Reinfelder, John/0000-0002-3737-604X				AUSENHUS SL, 1992, BIOCHEMISTRY-US, V31, P6427, DOI 10.1021/bi00143a010; Badger MR, 1998, CAN J BOT, V76, P1052, DOI 10.1139/b98-074; BERNER RA, 1990, SCIENCE, V249, P1382, DOI 10.1126/science.249.4975.1382; BOYD P, 1995, DEEP-SEA RES PT I, V42, P619, DOI 10.1016/0967-0637(95)00017-Z; CALVIN M, 1951, SYM SOC EXP BIOL, V5, P284; COLMAN B, 1995, PLANT CELL ENVIRON, V18, P919, DOI 10.1111/j.1365-3040.1995.tb00601.x; COOPER TG, 1971, J BIOL CHEM, V246, P5488; COOPER TG, 1969, J BIOL CHEM, V244, P1081; EHLERINGER JR, 1993, ANNU REV ECOL SYST, V24, P411, DOI 10.1146/annurev.es.24.110193.002211; Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES; FRY B, 1991, MAR ECOL PROG SER, V76, P149, DOI 10.3354/meps076149; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; HATCH MD, 1990, PLANT PHYSIOL, V93, P825, DOI 10.1104/pp.93.2.825; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Korb RE, 1997, J PHYCOL, V33, P433, DOI 10.1111/j.0022-3646.1997.00433.x; Lane TW, 2000, PLANT PHYSIOL, V123, P345, DOI 10.1104/pp.123.1.345; Magnin NC, 1997, PLANT PHYSIOL, V115, P1681, DOI 10.1104/pp.115.4.1681; Medlin LK, 1997, NOVA HEDWIGIA, V65, P1; MOREL FMM, 1994, NATURE, V369, P740, DOI 10.1038/369740a0; MORRIS I, 1980, PRIMARY PRODUCTIVITY, P139; MORTAINBERTRAND A, 1987, PHYCOLOGIA, V26, P262, DOI 10.2216/i0031-8884-26-2-262.1; OLEARY MH, 1981, BIOCHEMISTRY-US, V20, P7308, DOI 10.1021/bi00528a040; PRICE N M, 1988, Biological Oceanography, V6, P443; RIEBESELL U, 1993, NATURE, V361, P249, DOI 10.1038/361249a0; SLACK CR, 1969, BIOCHEM J, V114, P489, DOI 10.1042/bj1140489; STREAMER M, 1993, MAR BIOL, V115, P195, DOI 10.1007/BF00346335; Tortell PD, 1997, NATURE, V390, P243, DOI 10.1038/36765; WILBUR KM, 1948, J BIOL CHEM, V176, P147	28	240	261	7	100	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					996	999		10.1038/35039612	http://dx.doi.org/10.1038/35039612			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069177				2022-12-28	WOS:000090032500041
J	West, SA; Peters, AD				West, SA; Peters, AD			Evolution - Paying for sex is not easy	NATURE			English	Article							RECOMBINATION		Univ Edinburgh, Ashworth Labs, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	West, SA (corresponding author), Univ Edinburgh, Ashworth Labs, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.		West, Stuart A/M-3608-2014	West, Stuart A/0000-0003-2152-3153				Begon M., 1996, ECOLOGY; BELL G, 1997, SELECTION MECH EVOLU; BELL G, 1982, MASTERPIECE NATURE E; BURT A, 1987, NATURE, V326, P803, DOI 10.1038/326803a0; Doncaster CP, 2000, NATURE, V404, P281, DOI 10.1038/35005078; Ghiselin M.T., 1974, EC NATURE EVOLUTION; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LIVELY CM, 1987, NATURE, V328, P519, DOI 10.1038/328519a0; MAYNARD SMITH J., 1978, EVOLUTION SEX; West SA, 1999, J EVOLUTION BIOL, V12, P1003	10	9	9	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					962	962		10.1038/35039675	http://dx.doi.org/10.1038/35039675			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069168				2022-12-28	WOS:000090032500032
J	Aufderheide, AC				Aufderheide, AC			Progress in soft tissue paleopathology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MUMMY; VIRUS; DNA; IDENTIFICATION		Univ Minnesota, Sch Med, Dept Pathol & Lab Med, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Aufderheide, AC (corresponding author), Univ Minnesota, Sch Med, Dept Pathol & Lab Med, 10 Univ Dr, Duluth, MN 55812 USA.							APPENZELLER O, 1999, HDB CLIN NEUROLOGY, P181; AUFDERHEIDE AC, 1990, 8 EUR M PAL ASS SEPT; AUFDERHEIDE AC, 1998, CAMBRIDGE ENCY HUMAN, P263; Blackman J., 1991, HUMAN PALEOPATHOLOGY, P291; CARTMELL L, 1991, LAT AM ANTIQ, V23, P260; COCKBURN A, 1978, JAMA-J AM MED ASSOC, V240, P151; DALBY G, 1993, INT J OSTEOARCHAEOL, V3, P207; FORNACIARI G, 1986, LANCET, V2, P625; FORNACIARI G, 1992, LANCET, V339, P128, DOI 10.1016/0140-6736(92)91043-8; GERSZTEN PC, 1995, NEUROSURGERY, V36, P756, DOI 10.1227/00006123-199504000-00017; Guhl F, 1999, AM J PHYS ANTHROPOL, V108, P401, DOI 10.1002/(SICI)1096-8644(199904)108:4&lt;401::AID-AJPA2&gt;3.0.CO;2-P; HORNE PD, 1996, BRIT MED J, V313, P240; *HUMMED U, 1980, HAN DYNASTY CHANGSHA, V1; Kolman CJ, 1999, J INFECT DIS, V180, P2060, DOI 10.1086/315151; Li HC, 1999, NAT MED, V5, P1428; Miller R, 2000, JAMA-J AM MED ASSOC, V284, P831, DOI 10.1001/jama.284.7.831-a; MILLER RL, 1993, BIOL ANTHR STUDY ANC, P54; NISSENBAUM A, 1992, J ARCHAEOL SCI, V19, P1, DOI 10.1016/0305-4403(92)90002-K; NOTMAN DNH, 1986, AM J ROENTGENOL, V146, P93, DOI 10.2214/ajr.146.1.93; Notman DNH, 1986, SCI EGYPTOLOGY, P251; Rafi A, 1994, INT J OSTEOARCHAEOL, V4, P287; SALO WL, 1994, P NATL ACAD SCI USA, V91, P2091, DOI 10.1073/pnas.91.6.2091; Tapp E., 1984, EVIDENCE EMBALMED, P65; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; ZIMMERMAN MR, 1984, ARCTIC ANTHROPOL, V21, P53; Zito R., 1991, HUMAN PALEOPATHOLOGY, P73	26	21	22	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2571	2573		10.1001/jama.284.20.2571	http://dx.doi.org/10.1001/jama.284.20.2571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086346				2022-12-28	WOS:000165296200002
J	Gill, TM; DiPietro, L; Krumholz, HM				Gill, TM; DiPietro, L; Krumholz, HM			Exercise stress testing for older persons starting an exercise program - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HEALTH		Yale Univ, Sch Med, Dept Geriatr, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cardiol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dept Geriatr, 333 Cedar St, New Haven, CT 06510 USA.		, Harlan/AAI-2875-2020					Buchner DM, 1997, J GERONTOL A-BIOL, V52, pM218, DOI 10.1093/gerona/52A.4.M218; Hollenberg M, 1998, J GERONTOL A-BIOL, V53, pB259, DOI 10.1093/gerona/53A.4.B259; KOVAL JJ, 1992, J GERONTOL, V47, pS140, DOI 10.1093/geronj/47.3.S140; Petrella RJ, 1999, PREV MED, V29, P571, DOI 10.1006/pmed.1999.0573; RAUTAHARJU PM, 1995, INT J CARDIOL, V51, P165, DOI 10.1016/0167-5273(95)02414-R	5	2	2	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2591	2592						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086356				2022-12-28	WOS:000165296200017
J	Berger, A				Berger, A			Parkinson's disease linked with pesticide	BRITISH MEDICAL JOURNAL			English	News Item																		Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1175	1175						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073503				2022-12-28	WOS:000165357100012
J	Blaser, E; Pylyshyn, ZW; Holcombe, AO				Blaser, E; Pylyshyn, ZW; Holcombe, AO			Tracking an object through feature space	NATURE			English	Article							VISUAL-SEARCH; ATTENTIONAL MODULATION; TRANSPARENT MOTION; PERCEPTION; COLOR; DISCRIMINATION; INFORMATION; INTEGRATION; SELECTION; CAPACITY	Visual attention allows an observer to select certain visual information for specialized processing. Selection is readily apparent in 'tracking' tasks where even with the eyes fixed, observers can track a target as it moves among identical distractor items(1). In such a case, a target is distinguished by its spatial trajectory. Here we show that one can keep track of a stationary item solely on the basis of its changing appearance-specified by its trajectory along colour, orientation, and spatial frequency dimensions-even when a distractor shares the same spatial location. This ability to track through feature space bears directly on competing theories of attention, that is, on whether attention can select locations in space(2-4), features such as colour or shape(5-7), or particular visual objects composed of constellations of visual features. Our results affirm, consistent with a growing body of psychophysical(8-13) and neurophysiological(14-16) evidence, that attention can indeed select specific visual objects. Furthermore, feature-space tracking extends the definition of visual object(17) to include not only items with well defined spatio-temporal trajectories(18), but also those with well defined featuro-temporal trajectories.	Rutgers State Univ, Rutgers Ctr Cognit Sci, Piscataway, NJ 08854 USA; Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Rutgers State University New Brunswick; Harvard University	Blaser, E (corresponding author), Rutgers State Univ, Rutgers Ctr Cognit Sci, Piscataway, NJ 08854 USA.		Holcombe, Alex/A-2344-2012					BAYLIS GC, 1993, J EXP PSYCHOL HUMAN, V19, P451, DOI 10.1037/0096-1523.19.3.451; Blaser E, 1999, P NATL ACAD SCI USA, V96, P11681, DOI 10.1073/pnas.96.20.11681; Bonnel AM, 1998, PERCEPT PSYCHOPHYS, V60, P113, DOI 10.3758/BF03211922; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; CORBETTA M, 1990, SCIENCE, V248, P1556, DOI 10.1126/science.2360050; DRIVER J, 1992, NATURE, V360, P73, DOI 10.1038/360073a0; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; ERIKSEN CW, 1972, PERCEPT PSYCHOPHYS, V12, P201, DOI 10.3758/BF03212870; He S, 1996, NATURE, V383, P334, DOI 10.1038/383334a0; KAHNEMAN D, 1992, COGNITIVE PSYCHOL, V24, P175, DOI 10.1016/0010-0285(92)90007-O; LAPPIN JS, 1967, J EXP PSYCHOL, V75, P321, DOI 10.1037/h0025044; Lee DK, 1999, PERCEPT PSYCHOPHYS, V61, P1241, DOI 10.3758/BF03206177; Luck SJ, 1997, NATURE, V390, P279, DOI 10.1038/36846; NEISSER U, 1975, COGNITIVE PSYCHOL, V7, P480, DOI 10.1016/0010-0285(75)90019-5; O'Craven KM, 1999, NATURE, V401, P584, DOI 10.1038/44134; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; PYLYSHYN Z W, 1988, Spatial Vision, V3, P179, DOI 10.1163/156856888X00122; QIAN N, 1994, J NEUROSCI, V14, P7357; ROCK I, 1981, J EXP PSYCHOL HUMAN, V7, P275, DOI 10.1037/0096-1523.7.2.275; SAGI D, 1986, NATURE, V321, P693, DOI 10.1038/321693a0; Scholl BJ, 1999, COGNITIVE PSYCHOL, V38, P259, DOI 10.1006/cogp.1998.0698; Shih SI, 1996, J EXP PSYCHOL HUMAN, V22, P758, DOI 10.1037/0096-1523.22.3.758; SPERLING G, 1978, SCIENCE, V202, P315, DOI 10.1126/science.694536; TREISMAN A, 1984, J EXP PSYCHOL HUMAN, V10, P12, DOI 10.1037/0096-1523.10.1.12; Treisman A, 1998, PHILOS T ROY SOC B, V353, P1295, DOI 10.1098/rstb.1998.0284; Valdes-Sosa M, 1998, COGNITION, V66, pB13, DOI 10.1016/S0010-0277(98)00012-2; Valdes-Sosa M, 1998, J COGNITIVE NEUROSCI, V10, P137, DOI 10.1162/089892998563743; VONHOFSTEN C, 1985, J EXP PSYCHOL GEN, V114, P198, DOI 10.1037/0096-3445.114.2.198; WOLFE JM, 1989, J EXP PSYCHOL HUMAN, V15, P419, DOI 10.1037/0096-1523.15.3.419	29	188	192	1	28	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					196	199		10.1038/35041567	http://dx.doi.org/10.1038/35041567			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	371LL	11089972				2022-12-28	WOS:000165180400044
J	DePinho, RA				DePinho, RA			The age of cancer	NATURE			English	Review							COMPARATIVE GENOMIC HYBRIDIZATION; TELOMERASE ACTIVITY; HUMAN FIBROBLASTS; MOUSE TELOMERASE; COLORECTAL-CANCER; REPLICATIVE SENESCENCE; GENETIC ALTERATIONS; IMMORTAL CELLS; LIVER-DISEASES; ONCOGENIC RAS	A striking link exists between advanced age and increased incidence of cancer. Here I review how several of the age-related molecular and physiological changes might act in concert to promote cancer, and in particular epithelial carcinogenesis. Experimental data indicate that the aged, cancer-prone phenotype might represent the combined pathogenetic effects of mutation load, epigenetic regulation, telomere dysfunction and altered stromal milieu. Further verification of the role of these effects should in turn lead to the design of effective therapeutics for the treatment and prevention of cancer in the aged.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X				Al-Mulla F, 1999, GENE CHROMOSOME CANC, V24, P306, DOI 10.1002/(SICI)1098-2264(199904)24:4<306::AID-GCC3>3.0.CO;2-5; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; *AM CANC SOC, 2000, CANC FACTS FIG, P1; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; ATKIN NB, 1989, CANCER GENET CYTOGEN, V40, P3, DOI 10.1016/0165-4608(89)90140-4; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 2000, TRENDS GENET, V16, P147, DOI 10.1016/S0168-9525(99)01968-X; Cormier RT, 2000, CANCER RES, V60, P3965; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUSSENS L, IN PRESS CELL; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Cunha GR, 1996, J MAMMARY GLAND BIOL, V1, P21, DOI 10.1007/BF02096300; CURTIS H, 1963, RADIAT RES, V19, P337, DOI 10.2307/3571455; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Dolle MET, 2000, P NATL ACAD SCI USA, V97, P8403, DOI 10.1073/pnas.97.15.8403; Foley KP, 1999, BBA-REV CANCER, V1423, pM37, DOI 10.1016/S0304-419X(99)00012-8; GELMAN R, 1988, GENETICS, V118, P693; Goukassian D, 2000, FASEB J, V14, P1325, DOI 10.1096/fj.14.10.1325; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Issa JP, 1999, CRIT REV ONCOL HEMAT, V32, P31, DOI 10.1016/S1040-8428(99)00019-0; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jackson AL, 1998, GENETICS, V148, P1483; JACOBS PA, 1963, NATURE, V197, P1080, DOI 10.1038/1971080a0; JAMES CD, 1988, CANCER RES, V48, P5546; JONES A, 1967, ECON BOT, V21, P163, DOI 10.1007/BF02897864; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; Kolodner RD, 1999, CANCER RES, V59, P5068; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LIU SCC, 1982, J INVEST DERMATOL, V79, P330, DOI 10.1111/1523-1747.ep12500087; LOEB LA, 1991, CANCER RES, V51, P3075; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; McClintock B, 1941, GENETICS, V26, P234; MILLIS AJT, 1992, EXP CELL RES, V201, P373, DOI 10.1016/0014-4827(92)90286-H; Minnick DT, 1996, CANCER SURV, V28, P3; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; Olumi AF, 1999, CANCER RES, V59, P5002; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PIANTANELLI L, 1988, ANN NY ACAD SCI, V521, P99, DOI 10.1111/j.1749-6632.1988.tb35268.x; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RABINOVITCH PS, 1989, LAB INVEST, V60, P65; RAMSEY MJ, 1995, MUTAT RES-DNAGING G, V338, P95, DOI 10.1016/0921-8734(95)00015-X; RENAN MJ, 1993, MOL CARCINOGEN, V7, P139; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SCHWARTZ RA, 1988, SKIN CANC RECOGNIGIO; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tang RP, 1998, CANCER RES, V58, P4052; Tucker JD, 1999, MUTAT RES-FUND MOL M, V425, P135, DOI 10.1016/S0027-5107(99)00036-6; Turker MS, 1998, SEMIN CANCER BIOL, V8, P407, DOI 10.1006/scbi.1998.0112; Urabe Y, 1996, LIVER, V16, P293; VIJG J, IN PRESS HDB BIOL AG; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	95	676	706	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					248	254		10.1038/35041694	http://dx.doi.org/10.1038/35041694			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089982				2022-12-28	WOS:000165180400055
J	Berman, DS; Reisz, RR; Scott, D; Henrici, AC; Sumida, SS; Martens, T				Berman, DS; Reisz, RR; Scott, D; Henrici, AC; Sumida, SS; Martens, T			Early Permian bipedal reptile	SCIENCE			English	Article							KINEMATICS; HINDLIMB; SPEED	A 290-million-year-old reptilian skeleton from the Lower Permian (Asselian) of Germany provides evidence of abilities for cursorial bipedal locomotion, employing a parasagittal digitigrade posture. The skeleton is of a small bolosaurid, Eudibamus cursoris, gen. et sp. nov., and confirms the widespread distribution of Bolosauridae across Laurasia during this early stage of amniote evolution. E. cursoris is the oldest known representative of Parareptilia, a major clade of reptiles.	Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada; Carnegie Museum Nat Hist, Sect Vertebrate Paleontol, Pittsburgh, PA 15213 USA; Calif State Univ San Bernardino, Dept Biol, San Bernardino, CA 92407 USA; Museum Nat Gotha, Abt Palaeontol, D-99853 Gotha, Germany	University of Toronto; University Toronto Mississauga; California State University System; California State University San Bernardino	Reisz, RR (corresponding author), Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada.							Berman David S., 1997, P85, DOI 10.1016/B978-012676460-4/50005-6; CARROLL R L, 1969, Journal of Paleontology, V43, P151; CARROLL RL, 1982, J PALEONTOL, V56, P1; CARROLL RL, 1998, VERTEBRATE PALEONTOL; Clark JM, 1998, NATURE, V391, P886, DOI 10.1038/36092; Eberth DA, 2000, PALAIOS, V15, P293, DOI 10.2307/3515538; EWER RF, 1965, PHILOS T ROY SOC B, V248, P379, DOI 10.1098/rstb.1965.0003; Fieler CL, 1998, J EXP BIOL, V201, P609; HEATON M, 1980, J PALEONTOL, V54, P13; HOLMES R, 1977, J MORPHOL, V152, P101, DOI 10.1002/jmor.1051520107; Hotton Nicholas III, 1997, P207; Irschick DJ, 1999, J EXP BIOL, V202, P1047; IVACHNENKO MF, 1987, PALEONTOLOG J, P93; LAURIN M, 1995, ZOOL J LINN SOC-LOND, V113, P165, DOI 10.1111/j.1096-3642.1995.tb00932.x; LI J, 1995, PALASIATICA, V33, P17; Modesto Sean Patrick, 2000, Palaeontologia Africana, V36, P15; Novas FE, 1996, J VERTEBR PALEONTOL, V16, P723, DOI 10.1080/02724634.1996.10011361; Reisz RR, 1997, TRENDS ECOL EVOL, V12, P218, DOI 10.1016/S0169-5347(97)01060-4; REISZ RR, 1981, SPEC PUBL MUS NAT HI, V7, P1; REWCASTLE SC, 1980, J ZOOL, V191, P147; ROMER AS, 1941, SPEC PAP GEOL SOC AM, V28, P1; SNYDER RC, 1952, COPEIA, P64, DOI 10.2307/1438533; SNYDER RC, 1962, AM ZOOL, V2, P191; SNYDER RC, 1949, COPEIA, P129; SNYDER RC, 1954, AM J ANAT, V95, P1, DOI 10.1002/aja.1000950102; WATSON DMS, 1954, B MUS COMP ZOOL HARV, V111, P299	26	76	78	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					969	972		10.1126/science.290.5493.969	http://dx.doi.org/10.1126/science.290.5493.969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062126				2022-12-28	WOS:000165103200045
J	Zhang, L; Yu, J; Park, BH; Kinzler, KW; Vogelstein, B				Zhang, L; Yu, J; Park, BH; Kinzler, KW; Vogelstein, B			Role of BAX in the apoptotic response to anticancer agents	SCIENCE			English	Article							P53; MICE; MITOCHONDRIA; MUTATIONS; PROTEINS; CANCER; DAMAGE; P21	To assess the role of BAX in drug-induced apoptosis in human colorectal cancer cells, we generated cells that Lack functional BAX genes. Such cells were partially resistant to the apoptotic effects of the chemotherapeutic agent 5-fluorouracil, but apoptosis was not abolished. In contrast, the absence of BAX completely abolished the apoptotic response to the chemopreventive agent sulindac and other nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs inhibited the expression of the antiapoptotic protein Bcl-X-L, resulting in an altered ratio of BAX to BcL-X-L and subsequent mitochondria-mediated cell death. These results establish an unambiguous role for BAX in apoptotic processes in human epithelial cancers and may have implications for cancer chemoprevention strategies.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Ctr Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Program Human Genet, Baltimore, MD 21231 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Ctr Oncol, Baltimore, MD 21231 USA.		Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903	NCI NIH HHS [CA 57345, CA 62924, CA 43460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924, R37CA043460, R01CA043460, R01CA057345, R37CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Coopersmith CM, 1997, ONCOGENE, V15, P131, DOI 10.1038/sj.onc.1201176; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Huang TG, 2000, EUR J CANCER, V36, P249, DOI 10.1016/S0959-8049(99)00247-6; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Johnson S C, 2000, Adv Intern Med, V45, P1; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Lynch HT, 1999, J MED GENET, V36, P801; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Schmidt T, 1999, CELL DEATH DIFFER, V6, P873, DOI 10.1038/sj.cdd.4400562; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307	23	765	798	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					989	+		10.1126/science.290.5493.989	http://dx.doi.org/10.1126/science.290.5493.989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062132				2022-12-28	WOS:000165103200051
J	Suresh, E; Cox, R; Morris, I				Suresh, E; Cox, R; Morris, I			A teenager with rash and joint swelling after meningococcal C conjugate vaccine	LANCET			English	Article									Gen Hosp Kettering, Kettering NN16 8UZ, Northants, England		Cox, R (corresponding author), Gen Hosp Kettering, Rothwell Rd, Kettering NN16 8UZ, Northants, England.							Begg N, 1999, J INFECTION, V39, P1, DOI 10.1016/S0163-4453(99)90095-6; Guiver M, 2000, FEMS IMMUNOL MED MIC, V28, P173, DOI 10.1111/j.1574-695X.2000.tb01473.x; Neal KR, 1999, EPIDEMIOL INFECT, V122, P351, DOI 10.1017/S0950268899002368; 2000, COMM DIS REPORT, V10, P136; 2000, COMM DIS REPORT, V10, P133	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1486	1486		10.1016/S0140-6736(00)02873-7	http://dx.doi.org/10.1016/S0140-6736(00)02873-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081533				2022-12-28	WOS:000090067300014
J	Valenzuela, TD; Roe, DJ; Nichol, G; Clark, LL; Spaite, DW; Hardman, RG				Valenzuela, TD; Roe, DJ; Nichol, G; Clark, LL; Spaite, DW; Hardman, RG			Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC-ACCESS DEFIBRILLATION; HEART-ASSOCIATION REPORT; RESUSCITATION; POLICE	Background: The use of automated external defibrillators by persons other than paramedics and emergency medical technicians is advocated by the American Heart Association and other organizations. However, there are few data on the outcomes when the devices are used by nonmedical personnel for out-of-hospital cardiac arrest. Methods: We studied a prospective series of cases of sudden cardiac arrest in casinos. Casino security officers were instructed in the use of automated external defibrillators. The locations where the defibrillators were stored in the casinos were chosen to make possible a target interval of three minutes or less from collapse to the first defibrillation. Our protocol called for a defibrillation first (if feasible), followed by manual cardiopulmonary resuscitation. The primary outcome was survival to discharge from the hospital. Results: Automated external defibrillators were used in 105 patients whose initial cardiac rhythm was ventricular fibrillation. Fifty-six of the patients (53 percent) survived to discharge from the hospital. Among the 90 patients whose collapse was witnessed (86 percent), the clinically relevant time intervals were a mean (+/-SD) of 3.5+/-2.9 minutes from collapse to attachment of the defibrillator, 4.4+/-2.9 minutes from collapse to the delivery of the first defibrillation shock, and 9.8+/-4.3 minutes from collapse to the arrival of the paramedics. The survival rate was 74 percent for those who received their first defibrillation no later than three minutes after a witnessed collapse and 49 percent for those who received their first defibrillation after more than three minutes. Conclusions: Rapid defibrillation by nonmedical personnel using an automated external defibrillator can improve survival after out-of-hospital cardiac arrest due to ventricular fibrillation. Intervals of no more than three minutes from collapse to defibrillation are necessary to achieve the highest survival rates.	Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85724 USA; Univ Arizona, Coll Publ Hlth, Dept Epidemiol & Biostat, Tucson, AZ 85724 USA; Univ Ontario, Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON, Canada; Clark Cty Fire Dept, Las Vegas, NV USA	University of Arizona; University of Arizona; University of Ottawa; Ottawa Hospital Research Institute	Valenzuela, TD (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave,POB 245057, Tucson, AZ 85724 USA.		Nichol, Graham/Z-4996-2019	Spaite, Daniel/0000-0003-2601-6476				Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; Becker L, 1996, CARDIAC ARREST SCI P, P28; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1995, SUDDEN CARDIAC DEATH, P1; ENGELSTEIN ED, 1998, HURSTS HEART ARTERIE, V1, P1081; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Gratton M, 1999, Prehosp Emerg Care, V3, P303, DOI 10.1080/10903129908958958; Mosesso VN, 1998, ANN EMERG MED, V32, P200, DOI 10.1016/S0196-0644(98)70137-4; Myerburg R, 1997, HEART DIS TXB CARDIO; Nichol G, 1998, CIRCULATION, V97, P1309, DOI 10.1161/01.CIR.97.13.1309; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; Page RL, 1998, CIRCULATION, V97, P1429; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Safar PBN, 1988, CARDIOPULMONARY CERE; Valenzuela TD, 1997, CIRCULATION, V96, P3308; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; White RD, 1998, RESUSCITATION, V39, P145, DOI 10.1016/S0300-9572(98)00135-X	19	941	1003	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1206	1209		10.1056/NEJM200010263431701	http://dx.doi.org/10.1056/NEJM200010263431701			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071670	Green Published			2022-12-28	WOS:000090014100001
J	Bosnjak, D; Marusic, A				Bosnjak, D; Marusic, A			Croatia: legal regulation of doctors	LANCET			English	Article								Accompanying changes in the way health services in Croatia are organised has been a significant change in the way the medical profession is regulated. In 1995 the Croatian Medical Chamber was established, with legal powers. The responsibilities of physicians to their patients are spelled out in considerable detail. Most of these responsibilities are matched by provisions in Croatia's criminal law. Croatia has about 10 000 doctors and dentists and since 1998 19 cases have been resolved by the Medical Chamber and its commissions, public health providers offer protection in medical negligence cases but this could change as more market-oriented health-care provision is introduced. In 1997 and 1998 only 60 malpractice claims under the criminal law were brought and most of those were dismissed.	Croatian Med Journal, Editorial Off, Zagreb, Croatia; Univ Zagreb, Sch Med, Zagreb 10000, Croatia	University of Zagreb	Marusic, A (corresponding author), Croatian Med Journal, Editorial Off, Zagreb, Croatia.		Marusic, Ana/E-7683-2013	Marusic, Ana/0000-0001-6272-0917				HEBRANG A, 1994, CROAT MED J, V35, P130; Turek S, 1999, CROAT MED J, V40, P143	2	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1349	1350		10.1016/S0140-6736(00)02829-4	http://dx.doi.org/10.1016/S0140-6736(00)02829-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073039				2022-12-28	WOS:000089858300042
J	Spratt, BG; Greenwood, BM				Spratt, BG; Greenwood, BM			Prevention of pneumococcal disease by vaccination: does serotype replacement matter?	LANCET			English	Editorial Material							STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; CONJUGATE VACCINES; INVASIVE DISEASE; CLONES		Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Spratt, BG (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England.		Spratt, Brian G/A-1676-2009					Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BLACK S, 2000, 2 INT S PNEUM PNEUM; Coffey TJ, 1998, MOL MICROBIOL, V27, P73, DOI 10.1046/j.1365-2958.1998.00658.x; Crook DWM, 1998, BRIT MED BULL, V54, P595; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; DAGAN R, 2000, 2 INT S PNEUM PNEUM; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; Enright MC, 1999, J CLIN MICROBIOL, V37, P3210, DOI 10.1128/JCM.37.10.3210-3216.1999; Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049; Eskola J, 1999, PEDIATR INFECT DIS J, V18, P543, DOI 10.1097/00006454-199906000-00015; KIPLI T, 2000, 2 INT S PNEUM PNEUM; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; Maiden MCJ, 1999, LANCET, V354, P615, DOI 10.1016/S0140-6736(99)00252-4; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Scott JAG, 1996, CLIN INFECT DIS, V22, P973, DOI 10.1093/clinids/22.6.973	17	132	138	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 7	2000	356	9237					1210	1211		10.1016/S0140-6736(00)02779-3	http://dx.doi.org/10.1016/S0140-6736(00)02779-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072934				2022-12-28	WOS:000089724900005
J	McKinlay, J; Marceau, L				McKinlay, J; Marceau, L			US public health and the 21st century: diabetes mellitus	LANCET			English	Article							CORONARY HEART-DISEASE; MORTALITY DIFFERENCES; RISK-FACTORS; INTERVENTION; INEQUALITIES; DETERMINANTS; EPIDEMIOLOGY; BLACKS; WHITES; INCOME	No one can question the remarkable contribution of US public health to understanding the causes and consequences of illness, disability, and death. However, some commentators question the agenda: the endless pursuit of individual risk factors and the cursory attention to social determinants of disease. We attempt to illustrate some limitations of US public health by focusing on type-2 diabetes (adult-onset non-insulin-dependent diabetes)-an increasingly prevalent but still poorly understood medical condition with devastating complications and implications for quality of life. A more theoretically based multilevel approach to diabetes, outlined for the 21st century, has an almost exclusive downstream curative focus, that ranges from midstream preventive programmes to upstream healthy public policy.	New England Res Inst, Watertown, MA 02172 USA	HealthCore, Inc	McKinlay, J (corresponding author), New England Res Inst, 9 Galen St, Watertown, MA 02172 USA.	johnm@neri.org						ASHTON J, 1988, SEYMOUR NEW PUBLIC H; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; BRUNTON R, 1992, HLTH PROMOTION DISCI; CRAWFORD SL, 1994, AM J PUBLIC HEALTH, V84, P957, DOI 10.2105/AJPH.84.6.957; DAVEYSMITH G, 1996, AM J PUBLIC HEALTH, V86, P486; *DEP HHS, 1990, HLTH STAT DIS CHART; DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48, DOI 10.1093/oxfordjournals.aje.a009191; Glasgow RE, 1999, ANN BEHAV MED, V21, P159, DOI 10.1007/BF02908297; Gouldner A.W., 1973, SOCIOLOGY; KRIEGER N, 1993, AM J PREV MED, V9, P82, DOI 10.1016/S0749-3797(18)30666-4; Kuhn T. S., 1996, STRUCTURE SCI REVOLU; LeClere FB, 1998, J HEALTH SOC BEHAV, V39, P91, DOI 10.2307/2676393; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; Marmot M, 2006, SOCIAL DETERMINANTS; MARMOT MG, 1984, LANCET, V1, P1003; MCKINLAY J, 1994, US DHHS PHS NIH; MCKINLAY J, 1975, BEHAV ASPECTS PREVEN; MCKINLAY JB, 1992, CAN J PUBLIC HEALTH, V83, pS11; MCKINLAY JB, 1993, SOC SCI MED, V36, P109, DOI 10.1016/0277-9536(93)90202-F; MCKINLAY JB, 1979, SOC SCI MED-MED SOC, V13, P541, DOI 10.1016/0271-7123(79)90096-8; McKinlay JB, 1999, AM J PUBLIC HEALTH, V89, P295, DOI 10.2105/AJPH.89.3.295; McKinlay JB, 1996, J HEALTH SOC BEHAV, V37, P1, DOI 10.2307/2137228; MONHEIT AC, 1996, MEPS RES FINDING, V2; NAIDOO J, 1994, HLTH PROMOTION; *NAT CTR HLTH STAT, 1998, HLTH US 1998; Nathan DM, 1996, AM J MED, V100, P157, DOI 10.1016/S0002-9343(97)89453-3; NATHAN DM, 1988, MED CLIN N AM, V72, P1365, DOI 10.1016/S0025-7125(16)30712-X; NAVARRO V, 1990, LANCET, V336, P1238, DOI 10.1016/0140-6736(90)92846-A; NAZROO JY, 1998, S ETHN HLTH; ONEILL M, 1989, READINGS NEW PUBLIC; Pamuk E., 1998, SOCIOECONOMIC STATUS; POTTER JD, 1992, JAMA-J AM MED ASSOC, V268, P1573; Robert SA, 1998, J HEALTH SOC BEHAV, V39, P18, DOI 10.2307/2676387; ROGERS RG, 1992, DEMOGRAPHY, V29, P287, DOI 10.2307/2061732; Rose G., 1992, STRATEGY PREVENTIVE; SHELDON TA, 1999, J PUBLIC HEALTH MED, V14, P104; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P497, DOI 10.2105/AJPH.86.4.497; Smith GD, 1998, LANCET, V351, P934, DOI 10.1016/S0140-6736(05)60603-4; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; STERN MP, 1993, AM J EPIDEMIOL, V137, P733, DOI 10.1093/oxfordjournals.aje.a116733; Susser M, 1996, AM J PUBLIC HEALTH, V86, P674, DOI 10.2105/AJPH.86.5.674; Susser M, 1998, J EPIDEMIOL COMMUN H, V52, P608, DOI 10.1136/jech.52.10.608; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; *US BUR CENS, 2000, HLTH INS COV STAT TY; WEINICK RM, 1996, MEPS RES FINDING, V3; *WHO, 1998, DIAB MELL FACT SHEET; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P1369, DOI 10.2105/AJPH.84.9.1369	48	139	142	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 26	2000	356	9231					757	761		10.1016/S0140-6736(00)02641-6	http://dx.doi.org/10.1016/S0140-6736(00)02641-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	347UU	11085708				2022-12-28	WOS:000088948200040
J	Schmid, AK; Bartelt, NC; Hwang, RQ				Schmid, AK; Bartelt, NC; Hwang, RQ			Alloying at surfaces by the migration of reactive two-dimensional islands	SCIENCE			English	Article							BROWNIAN-MOTION; SOLID-SURFACES; DIFFUSION; CLUSTERS; DROPLETS; PHASE	We have studied the formation kinetics of the copper-tin alloy bronze when tin is deposited on the (111) surface of copper at room temperature. Low-energy electron microscopy and atomic-resolution scanning tunneling microscopy reveal that bronze forms on the surface by a complicated, unanticipated cooperative mechanism: Ordered two-dimensional tin islands containing several hundred thousand atoms spontaneously sweep across the surface, leaving bronze alloys in their tracks. We propose that this process, driven by surface free energy, is a version of the "camphor dance" observed on liquid surfaces, and should be a general mechanism of surface alloying when surface diffusion is faster than exchange into the substrate.	Sandia Natl Labs, Livermore, CA 94551 USA	United States Department of Energy (DOE); Sandia National Laboratories	Schmid, AK (corresponding author), Sandia Natl Labs, Livermore, CA 94551 USA.							ADAMSON AW, 1982, PHYSICAL CHEM SURFAC, P97; BAIN CD, 1994, NATURE, V372, P414, DOI 10.1038/372414a0; BARTELT NC, UNPUB; BAUER E, 1994, REP PROG PHYS, V57, P895, DOI 10.1088/0034-4885/57/9/002; Besenbacher F, 1998, SCIENCE, V279, P1913, DOI 10.1126/science.279.5358.1913; BROCHARD F, 1989, LANGMUIR, V5, P432, DOI 10.1021/la00086a025; CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539; Christensen A, 1997, PHYS REV B, V56, P5822, DOI 10.1103/PhysRevB.56.5822; Contini G, 1998, SURF SCI, V405, pL509, DOI 10.1016/S0039-6028(98)00139-3; de Gennes PG, 1998, PHYSICA A, V249, P196, DOI 10.1016/S0378-4371(97)00466-4; DOSSANTOS DF, 1995, PHYS REV LETT, V75, P2972, DOI 10.1103/PhysRevLett.75.2972; ERLEWEIN J, 1977, SURF SCI, V68, P71, DOI 10.1016/0039-6028(77)90191-1; KHARE SV, 1995, PHYS REV LETT, V75, P2148, DOI 10.1103/PhysRevLett.75.2148; MORGENSTERN K, 1995, PHYS REV LETT, V74, P2058, DOI 10.1103/PhysRevLett.74.2058; NIELSEN LP, 1993, PHYS REV LETT, V71, P754, DOI 10.1103/PhysRevLett.71.754; Pai WW, 1997, PHYS REV LETT, V79, P3210, DOI 10.1103/PhysRevLett.79.3210; PARKIN SSP, 1995, ANNU REV MATER SCI, V25, P357, DOI 10.1146/annurev.ms.25.080195.002041; RAYLEIGH, 1890, PHILOS MAG, V30, P386; Schmid AK, 1996, PHYS REV LETT, V77, P2977, DOI 10.1103/PhysRevLett.77.2977; SCRIVEN LE, 1960, NATURE, V187, P186, DOI 10.1038/187186a0; Wang SC, 1997, PHYS REV LETT, V79, P4234, DOI 10.1103/PhysRevLett.79.4234; WEN JM, 1994, PHYS REV LETT, V73, P2591, DOI 10.1103/PhysRevLett.73.2591; Zajonz H, 2000, SURF SCI, V447, pL141, DOI 10.1016/S0039-6028(99)01222-4	23	91	92	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1561	1564		10.1126/science.290.5496.1561	http://dx.doi.org/10.1126/science.290.5496.1561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090351				2022-12-28	WOS:000165446200046
J	Peltola, H; Davidkin, I; Paunio, M; Valle, M; Leinikki, P; Heinonen, OP				Peltola, H; Davidkin, I; Paunio, M; Valle, M; Leinikki, P; Heinonen, OP			Mumps and rubella eliminated from Finland	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATED CHILDREN; CONGENITAL-RUBELLA; FOLLOW-UP; MEASLES; IMMUNITY; PROGRAM; IMMUNIZATION; INFECTION; IMPACT	Many countries use trivalent measles-mumps-rubella (MMR) vaccine for their mumps and rubella immunization programs. In Finland, a national 2-dose MMR vaccination program for children, free of charge and on a voluntary basis, was launched in 1982, Serological confirmation of all suspected cases of mumps and rubella has been required since 1987, Despite intensive surveillance, no persistent sequelae or deaths attributable to vaccination have been detected. Indigenous mumps and rubella were eliminated in 1996, but 4 imported cases of mumps and 2 of rubella occurred from 1997 to 1999, Lack of secondary cases indicates sufficient immunity in the community. Compared with an epidemic year, up to thousands of cases of mumps meningoencephalitis and orchitis and around 50 cases of congenital rubella syndrome are now avoided annually. A 2-dose vaccine regimen in children during the last 17 years (1983-1999) has interrupted circulation of the target viruses entirely. Finland is the first country documented to be free of indigenous mumps and rubella(measles was eliminated in 1996), Despite the ongoing possibility of imported disease, major outbreaks probably can be avoided by maintaining high vaccination coverage and the 2-dose policy.	Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki	Peltola, H (corresponding author), Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, POB 281, FIN-00029 Helsinki, Finland.							Bang HO, 1943, ACTA MED SCAND, V113, P487; BRISS PA, 1994, J INFECT DIS, V169, P77, DOI 10.1093/infdis/169.1.77; CHARNOW JA, 1993, INFECT DIS CHILD, V6, P31; Davidkin I, 2000, VACCINE, V18, P3106, DOI 10.1016/S0264-410X(00)00139-0; DAVIDKIN I, 1995, VACCINE, V13, P1617, DOI 10.1016/0264-410X(95)00064-8; Davidkin I, 1998, J INFECT DIS, V178, P1567, DOI 10.1086/314513; DESMOND MM, 1978, J PEDIATR-US, V93, P584, DOI 10.1016/S0022-3476(78)80892-0; Galazka AM, 1999, B WORLD HEALTH ORGAN, V77, P3; HEDMAN K, 1988, J CLIN IMMUNOL, V8, P214, DOI 10.1007/BF00917569; JOHANSSON CARL - JOHAN, 1957, ACTA OBSTET ET GYNCEOL SCAND, V36, P1; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KNOX EG, 1980, INT J EPIDEMIOL, V9, P13, DOI 10.1093/ije/9.1.13; KOPLAN JP, 1982, AM J DIS CHILD, V136, P362, DOI 10.1001/archpedi.1982.03970400080021; LAITINEN O, 1974, LANCET, V1, P194; LEINEBERG O, 1945, NORD MED, V27, P1901; LEINEBERG O, 1945, ANN MED MILIT FENNIA, V20, P126; MCINTOSH EDG, 1992, LANCET, V340, P414, DOI 10.1016/0140-6736(92)91483-O; NIEMINEN U, 1993, ACTA PAEDIATR, V82, P267, DOI 10.1111/j.1651-2227.1993.tb12657.x; OJALA P, 1973, AM J EPIDEMIOL, V98, P395, DOI 10.1093/oxfordjournals.aje.a121568; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152, DOI 10.1093/oxfordjournals.aje.a115827; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; Paunio M, 1999, J EPIDEMIOL COMMUN H, V53, P173, DOI 10.1136/jech.53.3.173; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PELTOLA H, 1986, LANCET, V1, P137; Peltola H, 1997, LANCET, V350, P1364, DOI 10.1016/S0140-6736(05)65134-3; PELTOLA H, 1986, LANCET, V1, P939; PENTTINEN K, 1968, AM J EPIDEMIOL, V88, P234, DOI 10.1093/oxfordjournals.aje.a120882; PENTTINEN K, 1954, Ann Med Exp Biol Fenn, V32, P248; PHILIP RN, 1959, AM J HYG, V69, P91; Rabo E, 1981, Lakartidningen, V78, P2840; SOSIN DM, 1989, PEDIATRICS, V84, P779; Ukkonen P, 1996, SCAND J INFECT DIS, V28, P31, DOI 10.3109/00365549609027146; UKKONEN P, 1981, J MED VIROL, V8, P131, DOI 10.1002/jmv.1890080207; VAANANEN P, 1979, J MED VIROL, V3, P245, DOI 10.1002/jmv.1890030402; VIRTANEN M, IN PRESS PEDIATRICS; VUORI M, 1962, Acta Otolaryngol, V55, P231, DOI 10.3109/00016486209127357; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2	39	87	92	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2643	2647		10.1001/jama.284.20.2643	http://dx.doi.org/10.1001/jama.284.20.2643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086376				2022-12-28	WOS:000165296200043
J	Blackman, D; Sprigings, DC; Lever, N; Bashir, Y				Blackman, D; Sprigings, DC; Lever, N; Bashir, Y			Left ventricular pseudoaneurysm	LANCET			English	Article									Northampton Gen Hosp, Dept Cardiol, Northampton, England; John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England	University of Oxford	Blackman, D (corresponding author), Northampton Gen Hosp, Dept Cardiol, Northampton, England.			Lever, Nigel/0000-0002-4812-9001					0	0	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1642	1642		10.1016/S0140-6736(00)03158-5	http://dx.doi.org/10.1016/S0140-6736(00)03158-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089823				2022-12-28	WOS:000165249200012
J	Gottlieb, S				Gottlieb, S			Firm tried to block report on failure of AIDS vaccine	BRITISH MEDICAL JOURNAL			English	News Item																		Kahn JO, 2000, JAMA-J AM MED ASSOC, V284, P2193, DOI 10.1001/jama.284.17.2193	1	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1173	1173		10.1136/bmj.321.7270.1173	http://dx.doi.org/10.1136/bmj.321.7270.1173			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073497	Green Published			2022-12-28	WOS:000165357100007
J	Hanevik, K; Kvale, G				Hanevik, K; Kvale, G			Landmine injuries in Eritrea	BRITISH MEDICAL JOURNAL			English	Article							MINES; MOZAMBIQUE		Univ Bergen, Ctr Int Hlth, N-5021 Bergen, Norway	University of Bergen	Hanevik, K (corresponding author), Univ Bergen, Ctr Int Hlth, N-5021 Bergen, Norway.		Hanevik, Kurt/I-1159-2012	Hanevik, Kurt/0000-0002-1466-2326				ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; TAYLOR C, 1994, NGIC116600494	4	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1189	1189		10.1136/bmj.321.7270.1189	http://dx.doi.org/10.1136/bmj.321.7270.1189			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073510	Green Published, Bronze			2022-12-28	WOS:000165357100027
J	Henderson, L; Kitzinger, J; Green, J				Henderson, L; Kitzinger, J; Green, J			Representing infant feeding: content analysis of British media portrayals of bottle feeding and breast feeding	BRITISH MEDICAL JOURNAL			English	Article							RISK	Objective To examine how breast feeding and bottle feeding are represented by the British media. Design Content analysis. Subjects Television programmes and newspaper articles that made reference to infant feeding during March 1999. Setting UK mass media Main outcome measures Visual and verbal references to breast or bottle feeding in newspapers and television programmes. Results Overall, 235 references to infant feeding were identified in the television sample and 38 in the newspaper sample. Bottle feeding was shown more often than breast feeding and was presented as less problematic. Bottle feeding was associated with "ordinary" families whereas breast feeding was associated with middle class or celebrity women. The health risks of formula milk and ale health benefits of breast feeding were rarely mentioned. Conclusions The media rarely present positive information on breast feeding, even though this feeding practice is associated with the most health benefits. Health professionals and policy makers should be aware of patterns in media cover-age and the cultural background within which women make decisions about infant feeding.	Brunel Univ, Dept Human Sci, Ctr Media & Commun Res, Uxbridge UB8 3PH, Middx, England; Univ Leeds, Mother & Infant Res Unit, Leeds LS2 9LN, W Yorkshire, England	Brunel University; University of Leeds	Henderson, L (corresponding author), Brunel Univ, Dept Human Sci, Ctr Media & Commun Res, Uxbridge UB8 3PH, Middx, England.			Kitzinger, Jenny/0000-0002-2593-8033				AMOS A, 1992, BRIT MED J, V304, P99, DOI 10.1136/bmj.304.6819.99; ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; BEGG N, 1999, BRIT MED J, V318, P30; Chapman S. L. D., 1994, FIGHT PUBLIC HLTH; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; GRILLI R, 1999, COCHRANE LIB; Henderson L, 1999, SOCIOL HEALTH ILL, V21, P560, DOI 10.1111/1467-9566.00173; Hoddinott P, 1999, BRIT MED J, V318, P30, DOI 10.1136/bmj.318.7175.30; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; MACLEAN HM, 1989, HLTH PROMOTION, V3, P355; MAYER EJ, 1988, DIABETES, V37, P1625, DOI 10.2337/diabetes.37.12.1625; MILLER D, 1997, CIRCUIT MASS COMMUNI; Philo G., 1996, MEDIA MENTAL DISTRES; PISACANE A, 1990, LANCET, V336, P336	14	84	84	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1196	+		10.1136/bmj.321.7270.1196	http://dx.doi.org/10.1136/bmj.321.7270.1196			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073512	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000165357100029
J	Cox, PM; Betts, RA; Jones, CD; Spall, SA; Totterdell, IJ				Cox, PM; Betts, RA; Jones, CD; Spall, SA; Totterdell, IJ			Acceleration of global warming due to carbon-cycle feedbacks in a coupled climate model	NATURE			English	Article							STOMATAL CONDUCTANCE; DIOXIDE; PHOTOSYNTHESIS; TERRESTRIAL; CIRCULATION; VEGETATION; SCALE; OCEAN	The continued increase in the atmospheric concentration of carbon dioxide due to anthropogenic emissions is predicted to lead to significant changes in climate(1). About half of the current emissions are being absorbed by the ocean and by land ecosystems(2), but this absorption is sensitive to climate(3,4) as well as to atmospheric carbon dioxide concentrations(5), creating a feedback loop. General circulation models have generally excluded the feedback between climate and the biosphere, using static vegetation distributions and CO2 concentrations from simple carbon-cycle models that do not include climate change(6). Here we present results from a fully coupled, three-dimensional carbon-climate model, indicating that carbon-cycle feedbacks could significantly accelerate climate change over the twenty-first century. We rnd that under a 'business as usual' scenario, the terrestrial biosphere acts as an overall carbon sink until about 2050, but turns into a source thereafter. By 2100, the ocean uptake rate of 5 Gt Cyr(-1) is balanced by the terrestrial carbon source, and atmospheric CO2 concentrations are 250 p.p.m.v. higher in our fully coupled simulation than in uncoupled carbon models(2), resulting in a global-mean warming of 5.5 K, as compared to 4 K without the carbon-cycle feedback.	Meteorol Off, Hadley Ctr, Bracknell RG12 2SY, Berks, England; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England	Met Office - UK; Hadley Centre; NERC National Oceanography Centre; University of Southampton	Cox, PM (corresponding author), Meteorol Off, Hadley Ctr, Bracknell RG12 2SY, Berks, England.		Jones, Chris/I-2983-2014; Betts, Richard A/P-8976-2015; Kapitel, Kristina/AAR-5818-2021; Cox, Peter Michae;/B-3299-2012	Jones, Chris/0000-0002-7141-9285; Betts, Richard A/0000-0002-4929-0307; Cox, Peter Michae;/0000-0002-0679-2219				Antoine D, 1996, GLOBAL BIOGEOCHEM CY, V10, P57, DOI 10.1029/95GB02832; Arrow Kenneth J., 1996, CLIMATE CHANGE 1995; Betts RA, 1997, NATURE, V387, P796, DOI 10.1038/42924; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; COLLATZ GJ, 1992, AUST J PLANT PHYSIOL, V19, P519, DOI 10.1071/PP9920519; COLLATZ GJ, 1991, AGR FOREST METEOROL, V54, P107, DOI 10.1016/0168-1923(91)90002-8; Cox PM, 1999, CLIM DYNAM, V15, P183, DOI 10.1007/s003820050276; Cox PM, 1998, J HYDROL, V212, P79, DOI 10.1016/S0022-1694(98)00203-0; CRAMER W, IN PRESS GLOB CHANGE; ENTING IG, 1994, 31 CSIRO DIV ATM RES; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; Giardina CP, 2000, NATURE, V404, P858, DOI 10.1038/35009076; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Houghton J.T., 1992, CLIMATE CHANGE 1992; KEELING CD, 1995, NATURE, V375, P666, DOI 10.1038/375666a0; LONGHURST A, 1995, J PLANKTON RES, V17, P1245, DOI 10.1093/plankt/17.6.1245; McGuire AD, 1992, GLOBAL BIOGEOCHEM CY, V6, P101, DOI 10.1029/92GB00219; MELILLO JM, 1995, GLOBAL BIOGEOCHEM CY, V9, P407; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; NICHOLLS N, 1996, CLIMATE CHANGE 1995, pCH3; ORR JC, 1996, OCEAN STORAGE CARBON, P33; PALMER JR, IN PRESS DEEP SEA RE; RAICH JW, 1992, TELLUS B, V44, P81, DOI 10.1034/j.1600-0889.1992.t01-1-00001.x; Sarmiento JL, 1996, SCIENCE, V274, P1346, DOI 10.1126/science.274.5291.1346; Sarmiento JL, 1998, NATURE, V393, P245, DOI 10.1038/30455; SCHIMEL D, 1995, CLIMATE CHANGE 1995, P65; Tian HQ, 1998, NATURE, V396, P664, DOI 10.1038/25328; WILSON MF, 1985, J CLIMATOL, V5, P119, DOI 10.1002/joc.3370050202; Wood RA, 1999, NATURE, V399, P572, DOI 10.1038/21170; ZINKE PJ, 1986, NDP018 ORNL CARB DIO	30	2678	2892	86	3648	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					184	187		10.1038/35041539	http://dx.doi.org/10.1038/35041539			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089968				2022-12-28	WOS:000165180400040
J	Kirkwood, TBL; Austad, SN				Kirkwood, TBL; Austad, SN			Why do we age?	NATURE			English	Review							LIFE-SPAN; DROSOPHILA-MELANOGASTER; CAENORHABDITIS-ELEGANS; EVOLUTIONARY-THEORIES; DIETARY RESTRICTION; OXIDATIVE STRESS; GENETIC-ANALYSIS; SENESCENCE; LONGEVITY; RESISTANCE		Newcastle Gen Hosp, Inst Hlth Elderly, Dept Gerontol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA	Newcastle General Hospital; Newcastle University - UK; Idaho; University of Idaho	Kirkwood, TBL (corresponding author), Newcastle Gen Hosp, Inst Hlth Elderly, Dept Gerontol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.		Franzeck, Fabian C/B-5055-2011					ANDERSON GL, 1978, CAN J ZOOL, V56, P1786, DOI 10.1139/z78-244; Austad S. N., 1997, WHY WE AGE; AUSTAD SN, 1994, EXP GERONTOL, V29, P255, DOI 10.1016/0531-5565(94)90005-1; AUSTAD SN, 1993, J ZOOL, V229, P695, DOI 10.1111/j.1469-7998.1993.tb02665.x; AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5; Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312; BELL G, 1984, AM NAT, V124, P600, DOI 10.1086/284300; BERRY RJ, 1992, BIOL REV, V67, P519, DOI 10.1111/j.1469-185X.1992.tb01192.x; Buck S, 2000, J GERONTOL A-BIOL, V55, pB292, DOI 10.1093/gerona/55.6.B292; Charlesworth B, 1996, P NATL ACAD SCI USA, V93, P6140, DOI 10.1073/pnas.93.12.6140; Charlesworth B., 1994, EVOLUTION AGE STRUCT, DOI [10.1017/CBO9780511525711, DOI 10.1017/CBO9780511525711]; Cummins JM, 2000, STUD PROFERLIT, V9, P207; Finch CE, 1990, LONGEVITY SENESCENCE; FINCH CE, 2000, CHANCE DEV AING; Gavrilov LA, 1997, REV CLIN GERONTOL, V7, P5, DOI DOI 10.1017/S0959259897000026; GRUBE K, 1992, P NATL ACAD SCI USA, V89, P11759, DOI 10.1073/pnas.89.24.11759; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Hawkes K, 1998, P NATL ACAD SCI USA, V95, P1336, DOI 10.1073/pnas.95.3.1336; Herrero A, 1999, AGING-CLIN EXP RES, V11, P294, DOI 10.1007/BF03339803; Hill K., 1996, ACHE LIFE HIST ECOLO, DOI 10.4324/9781351329248; HUGHES KA, 1994, NATURE, V367, P64, DOI 10.1038/367064a0; JOHNSON TE, 1993, GENETICS, V134, P465; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Keller L, 1997, NATURE, V389, P958, DOI 10.1038/40130; Kirkwood T., 1999, TIME OUR LIVES SCI H; KIRKWOOD T B L, 1986, P1, DOI 10.1017/CBO9780511753350.002; Kirkwood TBL, 1996, BIOESSAYS, V18, P1009, DOI 10.1002/bies.950181211; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KIRKWOOD TBL, 1982, HUM GENET, V60, P101, DOI 10.1007/BF00569695; KIRKWOOD TBL, 1989, MUTAT RES, V219, P1, DOI 10.1016/0921-8734(89)90035-0; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; KU HH, 1993, FREE RADICAL BIO MED, V15, P621, DOI 10.1016/0891-5849(93)90165-Q; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lithgow Gordon J., 1996, P55; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Martinez DE, 1998, EXP GERONTOL, V33, P217, DOI 10.1016/S0531-5565(97)00113-7; Masoro EJ, 1998, J TOXICOL ENV HEAL B, V1, P243, DOI 10.1080/10937409809524554; Medawar P., 1952, UNSOLVED PROBLEM BIO; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Ogburn CE, 1998, J GERONTOL A-BIOL, V53, pB287, DOI 10.1093/gerona/53A.4.B287; Packer C, 1998, NATURE, V392, P807, DOI 10.1038/33910; Partridge L, 1999, P ROY SOC B-BIOL SCI, V266, P255, DOI 10.1098/rspb.1999.0630; Partridge L, 1996, P ROY SOC B-BIOL SCI, V263, P1365, DOI 10.1098/rspb.1996.0200; Peccei JS, 1995, ETHOL SOCIOBIOL, V16, P425, DOI 10.1016/0162-3095(95)00069-0; PHELAN JP, 1989, GROWTH DEVELOP AGING, V53, P4; Promislow DEL, 1996, GENETICS, V143, P839; Ricklefs RE, 1998, AM NAT, V152, P24, DOI 10.1086/286147; RISCH N, 1987, AM J HUM GENET, V41, P218; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; ROSE M. R., 1991, EVOLUTIONARY BIOL AG; Sell DR, 1996, P NATL ACAD SCI USA, V93, P485, DOI 10.1073/pnas.93.1.485; SERVICE PM, 1988, EVOLUTION, V42, P708, DOI 10.1111/j.1558-5646.1988.tb02489.x; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Sgro CM, 1999, SCIENCE, V286, P2521, DOI 10.1126/science.286.5449.2521; Shanley DP, 2000, EVOLUTION, V54, P740, DOI 10.1111/j.0014-3820.2000.tb00076.x; SHANLEY DP, IN PRESS BIOESSAYS; Shaw FH, 1999, GENETICS, V152, P553; SOHAL RS, 1993, BIOCHEM BIOPH RES CO, V196, P7, DOI 10.1006/bbrc.1993.2208; SOHAL RS, 1978, EXP GERONTOL, V13, P335, DOI 10.1016/0531-5565(78)90042-6; Stearns S.C., 1992, pi; Stearns SC, 2000, P NATL ACAD SCI USA, V97, P3309, DOI 10.1073/pnas.060289597; STEARNS SC, IN PRESS HDB BIOL AG; Tatar M, 1999, AM ZOOL, V39, P920; Van Voorhies WA, 1999, P NATL ACAD SCI USA, V96, P11399, DOI 10.1073/pnas.96.20.11399; Vanfleteren JR, 1996, J EXP ZOOL, V274, P93, DOI 10.1002/(SICI)1097-010X(19960201)274:2&lt;93::AID-JEZ2&gt;3.0.CO;2-8; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; Vieira C, 2000, GENETICS, V154, P213; Walford RL, 1997, J GERONTOL A-BIOL, V52, pB179, DOI 10.1093/gerona/52A.4.B179; Walker DW, 2000, NATURE, V405, P296, DOI 10.1038/35012693; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weindruch R., 1988, RETARDATION AGING DI; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; ZWAAN B, 1995, EVOLUTION, V49, P649, DOI 10.2307/2410318	75	1169	1201	9	337	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					233	238		10.1038/35041682	http://dx.doi.org/10.1038/35041682			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	371LL	11089980				2022-12-28	WOS:000165180400053
J	Holder, HD; Gruenewald, PJ; Ponicki, WR; Treno, AJ; Grube, JW; Saltz, RF; Voas, RB; Reynolds, R; Davis, J; Sanchez, L; Gaumont, G; Roeper, P				Holder, HD; Gruenewald, PJ; Ponicki, WR; Treno, AJ; Grube, JW; Saltz, RF; Voas, RB; Reynolds, R; Davis, J; Sanchez, L; Gaumont, G; Roeper, P			Effect of community-based interventions on high-risk drinking and alcohol-related injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY ROOM; AVAILABILITY; VIOLENCE; HEALTH	Context High-risk alcohol consumption patterns, such as binge drinking and drinking before driving, and underage drinking may be lin ked to traffic crashes and violent assaults in community settings. Objectives To determine the effect of community-based environmental interventions in reducing the rate of high-risk drinking and alcohol-related motor vehicle injuries and assaults. Design and Setting A longitudinal multiple time series of 3 matched intervention communities (northern California, southern California, and South Carolina) conducted from April 1992 to December 1996. Outcomes were assessed by 120 general population telephone surveys per month of randomly selected individuals in the intervention and comparison sites, traffic data on motor vehicle crashes, and emergency department surveys in 1 intervention-comparison pair and 1 additional intervention site. Interventions Mobilize the community; encourage responsible beverage service, reduce underage drinking by limiting access to alcohol; increase local enforcement of drinking and driving laws; and limit access to alcohol by using zoning. Main Outcome Measures Self-reported alcohol consumption and driving after drinking; rates of alcohol-related crashes and assault injuries observed in emergency departments and admitted to hospitals. Results Population surveys revealed that the self-reported amount of alcohol consumed per drinking occasion declined 6% from 1.37 to 1.29 drinks. Self-reported rate of "having had too much to drink" declined 49% from 0.43 to 0.22 times per 6-month period. Self-reported driving when "over the legal limit" was 51% lower (0.77 vs 0.38 times) per 6-month period in the intervention communities relative to the comparison communities. Traffic data revealed that, in the intervention vs comparison communities, nighttime injury crashes declined by 10% and crashes in which the driver had been drinking declined by 6%. Assault injuries observed in emergency departments declined by 43% in the intervention communities vs the comparison communities, and all hospitalized assault injuries declined by 2%. Conclusion A coordinated, comprehensive, community-based intervention can reduce high-risk alcohol consumption and alcohol-related injuries resulting from motor vehicle crashes and assaults.	Pacific Inst Res & Evaluat, Prevent Res Ctr, Berkeley, CA 94704 USA; Pacific Inst Res & Evaluat, Landover, MD USA; Pacific Inst Res & Evaluat, Rockville, MD USA; PARTS, Salinas, CA USA; Pacific Inst Res & Evaluat, Prevent Res Ctr, Oceanside, CA USA	Pacific Institute for Research & Evaluation (PIRE); Pacific Institute for Research & Evaluation (PIRE); Pacific Institute for Research & Evaluation (PIRE); Pacific Institute for Research & Evaluation (PIRE)	Holder, HD (corresponding author), Pacific Inst Res & Evaluat, Prevent Res Ctr, 2150 Shattuck Ave,Suite 900, Berkeley, CA 94704 USA.			Saltz, Robert/0000-0002-6373-7670; Grube, Joel/0000-0003-1099-8743	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009146] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09146] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Borges G, 1998, ADDICTION, V93, P103, DOI 10.1046/j.1360-0443.1998.93110310.x; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; Grube JW, 1997, ADDICTION, V92, pS251, DOI 10.1111/j.1360-0443.1997.tb02995.x; Gruenewald PJ, 1997, EVALUATION REV, V21, P209, DOI 10.1177/0193841X9702100205; Gruenewald PJ, 1996, ADDICTION, V91, P967, DOI 10.1111/j.1360-0443.1996.tb03594.x; GRUENEWALD PJ, 1996, ADDICTION, V91, P1627; Hingson R, 1996, AM J PUBLIC HEALTH, V86, P791, DOI 10.2105/AJPH.86.6.791; Holder HD, 1997, ADDICTION, V92, pS189, DOI 10.1111/j.1360-0443.1997.tb02991.x; Holder HD, 1997, ADDICTION, V92, pS155, DOI 10.1111/j.1360-0443.1997.tb02989.x; KANN L, 1993, PUBLIC HEALTH REP, V108, P47; Kennedy BP, 1996, RISK ANAL, V16, P565, DOI 10.1111/j.1539-6924.1996.tb01101.x; MASSEY JT, 1988, TELEPHONE SURVEY MET; Reynolds RI, 1997, ADDICTION, V92, pS261, DOI 10.1111/j.1360-0443.1997.tb02996.x; Saltz RF, 1997, ADDICTION, V92, pS237, DOI 10.1111/j.1360-0443.1997.tb02994.x; SALTZ RF, 1992, COMMUNITY PREVENTION, P35; SCRIBNER RA, 1995, AM J PUBLIC HEALTH, V85, P335, DOI 10.2105/AJPH.85.3.335; Stout RL, 1994, REPORT NATL I ALCOHO, VII; STOUT RL, 1992, COMMUNITY PREVENTION, P121; Treno AJ, 1997, J STUD ALCOHOL, V58, P372, DOI 10.15288/jsa.1997.58.372; Treno AJ, 1997, EVALUATION REV, V21, P133, DOI 10.1177/0193841X9702100201; Treno AJ, 1998, ADDICTION, V93, P113, DOI 10.1046/j.1360-0443.1998.93111311.x; VALOIS RF, 1995, J ADOLESCENT HEALTH, V16, P26, DOI 10.1016/1054-139X(95)94070-O; Voas RB, 1997, ADDICTION, V92, pS201, DOI 10.1111/j.1360-0443.1997.tb02992.x; Wagenaar AC, 2000, ADDICTION, V95, P209, DOI 10.1046/j.1360-0443.2000.9522097.x; Wagenaar AC, 2000, J STUD ALCOHOL, V61, P85, DOI 10.15288/jsa.2000.61.85; WECHSLER H, 1994, JAMA-J AM MED ASSOC, V272, P1672, DOI 10.1001/jama.272.21.1672; ZADOR P, 1989, ALCOHOL RELATED RISK	27	269	271	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2341	2347		10.1001/jama.284.18.2341	http://dx.doi.org/10.1001/jama.284.18.2341			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369NU	11066184	Bronze			2022-12-28	WOS:000165074500028
J	Berkwits, M				Berkwits, M			CAPTURE! SHOCK! EXCITE! Clinical trial acronyms and the "branding" of clinical research	ANNALS OF INTERNAL MEDICINE			English	Article							AVID TRIAL; ANTIARRHYTHMICS; ACTIVATION		Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Berkwits, M (corresponding author), Univ Penn Hlth Syst, Div Gen Internal Med, Philadelphia Vet Affairs Med Ctr, 1229 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	berkwits@mail.med.upenn.edu						[Anonymous], 1986, LANCET, V2, P57; Bargh J. A., 1997, ADV SOC COG, VX, P1; BARGH JA, 1992, J PERS SOC PSYCHOL, V62, P893, DOI 10.1037/0022-3514.62.6.893; Bargh JA, 1996, J EXP SOC PSYCHOL, V32, P104, DOI 10.1006/jesp.1996.0005; Cafferata Patricia, 1989, COGNITIVE AFFECTIVE; Cheng TO, 1999, AM HEART J, V137, P726, DOI 10.1016/S0002-8703(99)70230-9; Doll R, 1998, BMJ-BRIT MED J, V317, P1217, DOI 10.1136/bmj.317.7167.1217; ERLICH J, 1995, NY TIMES, V3, P36; FAZIO RH, 1986, J PERS SOC PSYCHOL, V50, P229, DOI 10.1037/0022-3514.50.2.229; Ferguson JJ, 1999, CIRCULATION, V100, P570, DOI 10.1161/01.CIR.100.6.570; Fogoros RN, 1997, AM J CARDIOL, V80, P762, DOI 10.1016/S0002-9149(97)00510-9; GOLEMAN D, 1995, NY TIMES, V8, pC1; Greenberg BH, 1999, CIRCULATION, V100, P1032, DOI 10.1161/01.CIR.100.10.1032; HART S, 1998, BRANDS NEW WEALTH CR; JAFARY F, 2000, LATE BREAKING CLIN T; KELLER KL, 1993, J MARKETING, V57, P1, DOI 10.2307/1252054; Keller KL, 1998, J MARKETING, V62, P48, DOI 10.2307/1251802; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; MEYERSLEVY J, 1989, J CONSUM RES, V16, P197, DOI 10.1086/209208; Morris DC, 1999, J AM COLL CARDIOL, V34, P1; Robertson K., 1989, J CONSUM MARK, V6, P61, DOI [DOI 10.1108/EUM0000000002563, 10.1108/EUM0000000002563]; Singer I, 1997, AM J CARDIOL, V80, P766, DOI 10.1016/S0002-9149(97)00511-0; The University Group Diabetes Program, 1970, DIABETES S2, V19, P747; Topol CE, 2000, LANCET, V355, P337	25	20	20	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					755	759		10.7326/0003-4819-133-9-200011070-00039	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00039			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369PC	11074930				2022-12-28	WOS:000165075300029
J	Jamtveit, B; Austrheim, H; Malthe-Sorenssen, A				Jamtveit, B; Austrheim, H; Malthe-Sorenssen, A			Accelerated hydration of the Earth's deep crust induced by stress perturbations	NATURE			English	Article							SHEAR ZONES; ECLOGITIZATION; GRANULITES; FRACTURES; ECLOGITE; NORWAY; MODEL	The metamorphic cycle associated with the formation of mountain belts produces a lower crust containing little or no free fluid(1,2). The introduction of external fluids to dry and impermeable volumes of the Earth's crust is thus a prerequisite for the retrogressive metamorphism later observed in such regimes. Such metamorphism can cause significant changes in the crust's physical properties, including its density, rheology and elastic properties(3,4). On a large scale, the introduction of fluids requires the presence of high-permeability channels, such as faults or fractures, which are the result of external tectonic stresses. But extensive interaction between externally derived fluids and the fractured rock requires efficient mass transport away from the initial fractures into the rock itself, and this transport often occurs over distances much longer than expected from grain-boundary diffusion. Here we present both field observations and a simple network model that demonstrate how the transport of fluids into initially dry rock can be accelerated by perturbations in the local stress field caused by reactions with fluids. We also show that the morphology of reaction fronts separating `dry' from `wet' rocks depends on the anisotropy of the external stress field.	Univ Oslo, Dept Geol, Fluid Rock Interact Grp, N-0316 Oslo, Norway; Univ Oslo, Dept Phys, Fluid Rock Interact Grp, N-0316 Oslo, Norway	University of Oslo; University of Oslo	Jamtveit, B (corresponding author), Univ Oslo, Dept Geol, Fluid Rock Interact Grp, POB 1047 Blindern, N-0316 Oslo, Norway.		Malthe-Sørenssen, Anders/C-2015-2015; Austrheim, Håkon/AAT-7057-2021	Malthe-Sørenssen, Anders/0000-0001-8138-3995; Jamtveit, Bjorn/0000-0001-5700-1803				ALLEN DMD, 1954, RELAXATION METHODS; AUSTRHEIM H, 1987, EARTH PLANET SC LETT, V81, P221, DOI 10.1016/0012-821X(87)90158-0; AUSTRHEIM H, 1991, TERRA NOVA, V3, P492, DOI 10.1111/j.1365-3121.1991.tb00184.x; BINGEN B, 1998, MINERALOGICAL MAGA A, V62, P161; CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47; DE ARCANGELIS L, 1985, J PHYS LETT-PARIS, V46, pL585, DOI 10.1051/jphyslet:019850046013058500; Farver JR, 1999, J METAMORPH GEOL, V17, P669; HERRMANN HJ, 1989, PHYS REV B, V39, P637, DOI 10.1103/PhysRevB.39.637; Herrmann HJ., 1990, STAT MODELS FRACTURE; JAMTVEIT B, 1990, CONTRIB MINERAL PETR, V104, P184, DOI 10.1007/BF00306442; Kirkaldy J. S., 1999, GROWTH DISSOLUTION P, P189; Malthe-Sorenssen A, 1998, PHYS REV E, V58, P5548, DOI 10.1103/PhysRevE.58.5548; ROARK RJ, FORMULAS SRESS STRAI; Rockow KM, 1997, J METAMORPH GEOL, V15, P401, DOI 10.1111/j.1525-1314.1997.00028.x; STURT BA, 1975, NATURE, V253, P595, DOI 10.1038/253595a0; WHEELER J, 1987, CONTRIB MINERAL PETR, V97, P397, DOI 10.1007/BF00372002; YAKOBSON BI, 1991, PHYS REV LETT, V67, P1590, DOI 10.1103/PhysRevLett.67.1590; Yardley BWD, 1997, FLUID FLOW AND TRANSPORT IN ROCKS, P99; Yardley BWD, 1997, J GEOPHYS RES-SOL EA, V102, P12173, DOI 10.1029/97JB00508	19	108	109	1	31	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					75	78		10.1038/35040537	http://dx.doi.org/10.1038/35040537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081509				2022-12-28	WOS:000165050400053
J	Kuo, SC; McGrath, JL				Kuo, SC; McGrath, JL			Steps and fluctuations of Listeria monocytogenes during actin-based motility	NATURE			English	Article							PARTICLE TRACKING; INTERFEROMETRY; MECHANICS; FILAMENT; PROTEINS; COMPLEX; DOMAIN	The actin-based motility of the bacterium, Listeria monocytogenes, is a model system for understanding motile cell functions involving actin polymerization(1). Although the biochemical and genetic aspects of Listeria motility have been intensely studied(2-5), biophysical data are sparse(6). Here we have used high-resolution laser tracking to follow the trailing ends of Listeria moving in the lamellae of COS7 cells. We found that pauses during motility occur frequently and that episodes of step-like motion often show pauses spaced at about 5.4 nm, which corresponds to the spatial periodicity of F-actin(7). We occasionally observed smaller steps (<3 nm), as well as periods of motion with no obvious pauses. Clearly, bacteria do not sense cytoplasmic viscoelasticity because they fluctuate 20 times less than adjacent lipid droplets. Instead, bacteria bind their own actin 'tails', and the anchoring proteins can 'step' along growing filaments within the actin tail. Because positional fluctuations are unusually small, the forces of association and propulsion must be very strong. Our data disprove the brownian ratchet model(8) and limit alternative models, such as the 'elastic' brownian ratchet(9) or the 'molecular' ratchet(4,10).	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University	Kuo, SC (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 720 Rutland Ave, Baltimore, MD 21205 USA.	skuo@bme.jhu.edu		McGrath, James/0000-0003-2017-8335	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059285] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059285] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allersma MW, 1998, BIOPHYS J, V74, P1074, DOI 10.1016/S0006-3495(98)74031-7; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; DENK W, 1989, P NATL ACAD SCI USA, V86, P5371, DOI 10.1073/pnas.86.14.5371; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Gerbal F, 2000, EUR BIOPHYS J BIOPHY, V29, P134, DOI 10.1007/s002490050258; Gerbal F, 1999, PRAMANA-J PHYS, V53, P155, DOI 10.1007/s12043-999-0147-z; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; KUO SC, 1991, J CELL SCI, P135; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; Mason TG, 1997, PHYS REV LETT, V79, P3282, DOI 10.1103/PhysRevLett.79.3282; MCGRATH JL, 2000, IN PRESS BIOPHYS J; Mehta AD, 1997, P NATL ACAD SCI USA, V94, P7927, DOI 10.1073/pnas.94.15.7927; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Olbris DJ, 2000, BBA-MOL CELL RES, V1495, P140, DOI 10.1016/S0167-4889(99)00156-1; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; Pralle A, 1999, MICROSC RES TECHNIQ, V44, P378, DOI 10.1002/(SICI)1097-0029(19990301)44:5<378::AID-JEMT10>3.0.CO;2-Z; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; Reif F., 1965, FUNDAMENTALS STAT TH; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Theriot JA, 2000, TRAFFIC, V1, P19, DOI 10.1034/j.1600-0854.2000.010104.x; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	28	101	103	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					1026	1029		10.1038/35039544	http://dx.doi.org/10.1038/35039544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069185				2022-12-28	WOS:000090032500049
J	McAuley, L; Pham, B; Tugwell, P; Moher, D				McAuley, L; Pham, B; Tugwell, P; Moher, D			Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?	LANCET			English	Article							CONTROLLED TRIALS; EMPIRICAL-EVIDENCE; RANDOMIZED TRIALS; CLINICAL RESEARCH; PUBLICATION BIAS; UNPUBLISHED DATA; METAANALYSIS; QUALITY	Background The inclusion of only a subset of all available evidence in a meta-analysis may introduce biases and threaten its validity; this is particularly likely if the subset of included studies differ from those not included, which may be the case for published and grey literature (unpublished studies, with limited distribution). We set out to examine whether exclusion of grey literature, compared with its inclusion in meta-analysis, provides different estimates of the effectiveness of interventions assessed in randomised trials. Methods From a random sample of 135 meta-analyses, we identified and retrieved 33 publications that included both grey and published primary studies. The 33 publications contributed 41 separate meta-analyses from several disease areas. General characteristics of the meta-analyses and associated studies and outcome data at the trial level were collected. We explored the effects of the inclusion of grey literature on the quantitative results using logistic-regression analyses. Findings 33% of the meta-analyses were found to include some form of grey literature. The grey literature, when included, accounts for between 4.% and 75% of the studies in a meta-analysis. On average, published work, compared with grey literature, yielded significantly larger estimates of the intervention effect by 15% (ratio of odds ratios=1.15 [95% CI 1.04-1.28]). Excluding abstracts from the analysis further compounded the exaggeration (1.3 [1.0-1.60]). Interpretation The exclusion of grey literature from meta-analyses can lead to exaggerated estimates of intervention effectiveness. In general, meta-analysts should attempt to identify, retrieve, and include all reports, grey and published, that meet predefined inclusion criteria.	Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Paediat, Ottawa, ON K1N 6N5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa	Moher, D (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Thomas C Chalmers Ctr Systemat Reviews, Room R226,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Moher, David/0000-0003-2434-4206				BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BROWN KH, 1994, PEDIATRICS, V93, P17; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Khan KS, 1996, FERTIL STERIL, V65, P939, DOI 10.1016/S0015-0282(16)58265-X; LAST JM, 1995, DICT EPIDEMIOLOGY; Man-Son-Hing M, 1998, J GEN INTERN MED, V13, P600, DOI 10.1046/j.1525-1497.1998.00182.x; MCAULEY LM, 1999, INFLUENCE GREY LIT M; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; PAGLIARO L, 1992, ANN INTERN MED, V117, P59, DOI 10.7326/0003-4819-117-1-59; POYNARD T, 1994, VASA-J VASCULAR DIS, V23, P244; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172	17	518	525	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1228	1231		10.1016/S0140-6736(00)02786-0	http://dx.doi.org/10.1016/S0140-6736(00)02786-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072941				2022-12-28	WOS:000089724900012
J	Hannah, ME				Hannah, ME			Search for best tocolytic for preterm labour	LANCET			English	Editorial Material							RITODRINE; INDOMETHACIN; NIFEDIPINE; TRIAL		Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Obstet & Gynecol, Toronto, ON M5G 1N8, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Hannah, ME (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Obstet & Gynecol, Toronto, ON M5G 1N8, Canada.							Abramov Y, 2000, OBSTET GYNECOL, V95, P482, DOI 10.1016/S0029-7844(99)00578-5; Agustines LA, 2000, AM J OBSTET GYNECOL, V182, P1113, DOI 10.1067/mob.2000.105386; Goldenberg RL, 2000, NEW ENGL J MED, V342, P1500, DOI 10.1056/NEJM200005183422007; GYERVAI K, 1999, OBSTET GYNECOL, V94, P869; HANNAH ME, 1995, J SOC OBSTET GYNAECO, V17, P1089; Kok JH, 1998, BRIT J OBSTET GYNAEC, V105, P162, DOI 10.1111/j.1471-0528.1998.tb10046.x; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; Lye SJ, 1998, FETAL MATERNAL MED R, V10, P121, DOI DOI 10.1017/S096553959800031X); MOUTQUIN JM, 1992, NEW ENGL J MED, V327, P308; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; Oei SG, 1999, ACTA OBSTET GYN SCAN, V78, P783, DOI 10.1034/j.1600-0412.1999.780908.x; Panter KR, 1999, BRIT J OBSTET GYNAEC, V106, P467, DOI 10.1111/j.1471-0528.1999.tb08300.x; Papatsonis DNM, 1997, OBSTET GYNECOL, V90, P230, DOI 10.1016/S0029-7844(97)00182-8; Papatsonis DNM, 2000, OBSTET GYNECOL, V95, P477, DOI 10.1016/S0029-7844(99)00596-7; Smith GN, 1999, BRIT J OBSTET GYNAEC, V106, P736, DOI 10.1111/j.1471-0528.1999.tb08376.x	15	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					699	700		10.1016/S0140-6736(00)02626-X	http://dx.doi.org/10.1016/S0140-6736(00)02626-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085687				2022-12-28	WOS:000088948200007
J	Soong, RK; Bachand, GD; Neves, HP; Olkhovets, AG; Craighead, HG; Montemagno, CD				Soong, RK; Bachand, GD; Neves, HP; Olkhovets, AG; Craighead, HG; Montemagno, CD			Powering an inorganic nanodevice with a biomolecular motor	SCIENCE			English	Article							GAMMA-SUBUNIT; WILD-TYPE; F-1-ATPASE; ROTATION; FORCE; NM	Biomolecular motors such as F-1-adenosine triphosphate synthase (F-1-ATPase) and myosin are similar in size, and they generate forces compatible with currently producible nanoengineered structures. We have engineered individual biomolecular motors and nanoscale inorganic systems, and we describe their integration in a hybrid nanomechanical device powered by a biomolecular motor. The device consisted of three components: an engineered substrate, an F-1-ATPase biomolecular motor; and fabricated nanopropellers. Rotation of the nanopropeller was initiated with 2 mM adenosine triphosphate and inhibited by sodium azide.	Cornell Univ, Nanobiotechnol Ctr, Ithaca, NY 14853 USA; Cornell Univ, Dept Agr & Biol Engn, Ithaca, NY 14853 USA; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Montemagno, CD (corresponding author), Cornell Univ, Nanobiotechnol Ctr, Ithaca, NY 14853 USA.	cdm11@cornell.edu	Neves, Herc/K-6873-2019	Bachand, George/0000-0002-3169-9980; Neves, Hercules/0000-0003-2211-356X				Bachand GD, 2000, BIOMED MICRODEVICES, V2, P179, DOI 10.1023/A:1009924327649; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Carr DW, 1999, APPL PHYS LETT, V75, P920, DOI 10.1063/1.124554; Carr DW, 1998, J VAC SCI TECHNOL B, V16, P3821, DOI 10.1116/1.590416; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; JEFFREY DJ, 1981, Q J MECH APPL MATH, V34, P129, DOI 10.1093/qjmam/34.2.129; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; MARCUS RB, 1990, APPL PHYS LETT, V56, P236, DOI 10.1063/1.102841; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Montemagno C, 1999, NANOTECHNOLOGY, V10, P225, DOI 10.1088/0957-4484/10/3/301; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Sone J, 1999, NANOTECHNOLOGY, V10, P135, DOI 10.1088/0957-4484/10/2/306; Soong RK, 1999, 1999 INTERNATIONAL CONFERENCE ON MODELING AND SIMULATION OF MICROSYSTEMS, P95; STRYER L, 1999, BIOCHEMISTRY-US, P445; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	20	494	519	3	166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1555	1558		10.1126/science.290.5496.1555	http://dx.doi.org/10.1126/science.290.5496.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090349				2022-12-28	WOS:000165446200044
J	Iezzoni, LI				Iezzoni, LI			A 44-year old woman with difficulty walking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY-OF-LIFE; ELDERLY PATIENTS; GERIATRIC REHABILITATION; FUNCTIONAL DISABILITY; AMBULATORY PATIENTS; PHYSICAL THERAPY; GAIT DISORDERS; PRIMARY-CARE; BALANCE; EQUIPMENT		Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Charles A Dana Res Inst, Boston, MA 02215 USA; Harvard Thorndike Lab, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard University	Iezzoni, LI (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Abresch R T, 1998, Phys Med Rehabil Clin N Am, V9, P233; ADAMS PF, 1995, VITAL HLTH STAT, V10; Alexander NB, 1996, J AM GERIATR SOC, V44, P434, DOI 10.1111/j.1532-5415.1996.tb06417.x; Andriacchi R, 1997, AM J PHYS MED REHAB, V76, pS17; AshtonMiller JA, 1996, ARCH PHYS MED REHAB, V77, P446, DOI 10.1016/S0003-9993(96)90032-5; BURNS TJ, 1990, ARCH PHYS MED REHAB, V71, P138; CALKINS DR, 1994, J GEN INTERN MED, V9, P590, DOI 10.1007/BF02599291; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; Cashman NR, 1999, NEUROLOGY, V53, pS50; Cassel CK, 1999, HEALTH AFFAIR, V18, P118, DOI 10.1377/hlthaff.18.1.118; Chan L, 1999, ARCH PHYS MED REHAB, V80, P642, DOI 10.1016/S0003-9993(99)90166-1; Dal Bello-Haas V, 1998, PHYS THER, V78, P1312, DOI 10.1093/ptj/78.12.1312; DeJong G, 1997, AM J PHYS MED REHAB, V76, pS2; DeLisa J, 1998, REHABILITATION MED P, P3; *DEP GER HLTH, 1996, GUID US ASS TECHN EV; Foley MP, 1996, PHYS THER, V76, P1313, DOI 10.1093/ptj/76.12.1313; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; Gaal RP, 1997, J REHABIL RES DEV, V34, P58; GANS BM, 1993, ARCH PHYS MED REHAB, V74, pS15; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HOENIG H, 1993, CLIN GERIATR MED, V9, P883, DOI 10.1016/S0749-0690(18)30384-7; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Iezzoni LI, 2000, AM J PUBLIC HEALTH, V90, P955, DOI 10.2105/AJPH.90.6.955; IEZZONI LI, IN PRESS J GEN INTER; Jeka JJ, 1997, PHYS THER, V77, P476, DOI 10.1093/ptj/77.5.476; JOYCE BM, 1991, AM FAM PHYSICIAN, V43, P535; KANE RL, 1994, PHYS THER, V74, P425, DOI 10.1093/ptj/74.5.425; Karp G., 1998, CHOOSING WHEELCHAIR; Karp Gary, 1999, LIFE WHEELS ACTIVE W; KERRIGAN DC, 1998, REHABILITATION MED P, P167; Kuan TS, 1999, ARCH PHYS MED REHAB, V80, P777, DOI 10.1016/S0003-9993(99)90227-7; KUMAR R, 1995, ARCH PHYS MED REHAB, V76, P1173, DOI 10.1016/S0003-9993(95)80129-4; LaPlante M P, 1992, Adv Data, P1; Ludolph AC, 1999, NEUROLOGY, V53, pS46; Maeda A, 1998, ARCH PHYS MED REHAB, V79, P994, DOI 10.1016/S0003-9993(98)90100-9; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MANTON KG, 1993, GERONTOLOGIST, V33, P168, DOI 10.1093/geront/33.2.168; MATHIAS S, 1986, ARCH PHYS MED REHAB, V67, P387; Miles-Tapping C, 1995, PHYSICAL OCCUPATIONA, V12, P31, DOI DOI 10.1080/J148V12N04_03; *NAT COUNC DIS, 1993, STUD FIN ASS TECHN D, P50; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; OLIN GL, 1999, HLTH HLTH CARE MED P, P77; OLIVER M, 1996, UNDERSTANDING DISABI, P97; Pope A. M, 1997, ENABLING AM ASSESSIN; POPE AM, 1991, DISABILITY AM NATL A; *PRES ADV COMM CON, 1997, CONS BILL RIGHTS RES, P45; Ragnarsson K. T, 1998, REHABILITATION MED P, P651; REDFORD JB, 1993, ARCH PHYS MED REHAB, V74, P877, DOI 10.1016/0003-9993(93)90016-4; Rogers JC, 1991, INT J TECHNOLOGY AGI, V4, P153; SACKS O, 1993, LEG STAND ON, P107; Scherer MJ, 1996, DISABIL REHABIL, V18, P439, DOI 10.3109/09638289609165907; Sherman SE, 1998, J GEN INTERN MED, V13, P817, DOI 10.1046/j.1525-1497.1998.00245.x; Silani V, 1999, NEUROLOGY, V53, pS37; Smith PS, 1999, PHYS THER, V79, P423, DOI 10.1093/ptj/79.4.423; Stone D., 1984, DISABLED STATE; Stuifbergen A, 1990, FAM COMMUNITY HEALTH, V13, P11; Sudarsky L, 1994, OFFICE PRACTICE MED, P761; TINETTI ME, 1993, J AM GERIATR SOC, V41, P315, DOI 10.1111/j.1532-5415.1993.tb06710.x; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1988, JAMA-J AM MED ASSOC, V259, P1190, DOI 10.1001/jama.259.8.1190; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Verbrugge LM, 1997, AM J PUBLIC HEALTH, V87, P384, DOI 10.2105/AJPH.87.3.384; WARREN CG, 1990, J REHABIL RES DEV S, V2, P74; *WHO, 1997, ICIDH2 INT CLASS IMP; WICKIZER TM, 1995, MED CARE, V33, P383, DOI 10.1097/00005650-199504000-00005; WRIGHT DL, 1992, PHYS THER, V72, P306, DOI 10.1093/ptj/72.4.306	69	7	7	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2632	2639		10.1001/jama.284.20.2632	http://dx.doi.org/10.1001/jama.284.20.2632			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	373NU	11086372				2022-12-28	WOS:000165296200039
J	Kim, RJ; Wu, E; Rafael, A; Chen, EL; Parker, MA; Simonetti, O; Klocke, FJ; Bonow, RO; Judd, RM				Kim, RJ; Wu, E; Rafael, A; Chen, EL; Parker, MA; Simonetti, O; Klocke, FJ; Bonow, RO; Judd, RM			The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; LEFT-VENTRICULAR DYSFUNCTION; DOSE DOBUTAMINE ECHOCARDIOGRAPHY; GADOLINIUM-DTPA; BYPASS SURGERY; ISCHEMIC CARDIOMYOPATHY; HIBERNATING MYOCARDIUM; INFARCTED MYOCARDIUM; VIABILITY ASSESSMENT; VIABLE MYOCARDIUM	Background: Recent studies indicate that magnetic resonance imaging (MRI) after the administration of contrast material can be used to distinguish between reversible and irreversible myocardial ischemic injury regardless of the extent of wall motion or the age of the infarct. We hypothesized that the results of contrast-enhanced MRI can be used to predict whether regions of abnormal ventricular contraction will improve after revascularization in patients with coronary artery disease. Methods: Gadolinium-enhanced MRI was performed in 50 patients with ventricular dysfunction before they underwent surgical or percutaneous revascularization. The transmural extent of hyperenhanced regions was postulated to represent the transmural extent of nonviable myocardium. The extent of regional contractility at the same locations was determined by cine MRI before and after revascularization in 41 patients. Results: Contrast-enhanced MRI showed hyperenhancement of myocardial tissue in 40 of 50 patients before revascularization. In all patients with hyperenhancement the difference in image intensity between hyperenhanced regions and regions without hyperenhancement was more than 6 SD. Before revascularization, 804 of the 2093 myocardial segments analyzed (38 percent) had abnormal contractility, and 694 segments (33 percent) had some areas of hyperenhancement. In an analysis of all 804 dysfunctional segments, the likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement before revascularization increased (P<0.001). For instance, contractility increased in 256 of 329 segments (78 percent) with no hyperenhancement before revascularization, but in only 1 of 58 segments with hyperenhancement of more than 75 percent of tissue. The percentage of the left ventricle that was both dysfunctional and not hyperenhanced before revascularization was strongly related to the degree of improvement in the global mean wall-motion score (P<0.001) and the ejection fraction (P<0.001) after revascularization. Conclusions: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization. (N Engl J Med 2000;343:1445-53.) (C) 2000, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Biomed Engn, Chicago, IL 60611 USA; Siemens Med Syst Inc, Chicago, IL USA	Northwestern University; Northwestern University; Northwestern University; Siemens AG	Kim, RJ (corresponding author), Northwestern Univ, Sch Med, Feinberg Cardiovasc Res Inst, 303 E Chicago Ave,Tarry 12-733, Chicago, IL 60611 USA.	r-kim4@northwestern.edu	Simonetti, Orlando P./E-4098-2011; Kim, Raymond J/B-1426-2008	Wu, Edwin/0000-0002-0771-8395	NHLBI NIH HHS [R29-HL53411, R01-HL63268] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063268, R29HL053411] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altman D.G., 1991, PRACTICAL STAT MED R; ARNESE M, 1995, CIRCULATION, V91, P2748, DOI 10.1161/01.CIR.91.11.2748; Beller GA, 1996, CIRCULATION, V94, P2681, DOI 10.1161/01.CIR.94.11.2681; Bonow RO, 1996, CIRCULATION, V94, P2674, DOI 10.1161/01.CIR.94.11.2674; BRAUNWALD E, 1986, J AM COLL CARDIOL, V8, P1467, DOI 10.1016/S0735-1097(86)80325-4; Chaudhry FA, 1999, J AM COLL CARDIOL, V34, P730, DOI 10.1016/S0735-1097(99)00252-1; Dakik HA, 1997, CIRCULATION, V96, P2892, DOI 10.1161/01.CIR.96.9.2892; DEROOS A, 1989, RADIOLOGY, V172, P717, DOI 10.1148/radiology.172.3.2772179; Di Carli MF, 1998, J THORAC CARDIOV SUR, V116, P997, DOI 10.1016/S0022-5223(98)70052-2; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; EICHSTAEDT HW, 1989, CARDIOVASC DRUG THER, V3, P779, DOI 10.1007/BF01857631; FORCE T, 1986, CIRCULATION, V73, P1360, DOI 10.1161/01.CIR.73.6.1360; GALLI M, 1994, CIRCULATION, V90, P1386, DOI 10.1161/01.CIR.90.3.1386; Haas F, 1997, J AM COLL CARDIOL, V30, P1693, DOI 10.1016/S0735-1097(97)00375-6; HOLMAN ER, 1993, AM J CARDIOL, V71, P1036, DOI 10.1016/0002-9149(93)90569-X; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; LIMA JAC, 1995, CIRCULATION, V92, P1117, DOI 10.1161/01.CIR.92.5.1117; MAES A, 1994, CIRCULATION, V90, P735, DOI 10.1161/01.CIR.90.2.735; MARWICK TH, 1992, CIRCULATION, V85, P1347, DOI 10.1161/01.CIR.85.4.1347; *MATHS, 1999, S PLUS 2000 GUID STA, V1; Pagley PR, 1997, CIRCULATION, V96, P793; PerroneFilardi P, 1996, CIRCULATION, V94, P2712, DOI 10.1161/01.CIR.94.11.2712; PERRONEFILARDI P, 1995, CIRCULATION, V91, P2556, DOI 10.1161/01.CIR.91.10.2556; RAGOSTA M, 1993, CIRCULATION, V87, P1630, DOI 10.1161/01.CIR.87.5.1630; RAHIMTOOLA SH, 1985, CIRCULATION, V72, P123; Samady H, 1999, CIRCULATION, V100, P1298, DOI 10.1161/01.CIR.100.12.1298; SIMONETTI O, IN PRESS RADIOLOGY; TAMAKI N, 1995, CIRCULATION, V91, P1697, DOI 10.1161/01.CIR.91.6.1697; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; VANDERWALL EE, 1990, BRIT HEART J, V63, P12; VANROSSUM AC, 1990, AM J CARDIOL, V65, P845, DOI 10.1016/0002-9149(90)91425-6; WESBEY GE, 1984, RADIOLOGY, V153, P165, DOI 10.1148/radiology.153.1.6473778	32	2211	2309	3	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1445	1453		10.1056/NEJM200011163432003	http://dx.doi.org/10.1056/NEJM200011163432003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078769				2022-12-28	WOS:000165271300003
J	Wisse, B; Sniderman, AD				Wisse, B; Sniderman, AD			Severe mitral regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Wisse, B (corresponding author), Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada.								0	2	2	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1386	1386		10.1056/NEJM200011093431906	http://dx.doi.org/10.1056/NEJM200011093431906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070103				2022-12-28	WOS:000165152800006
J	Pasquinelli, AE; Reinhart, BJ; Slack, F; Martindale, MQ; Kuroda, MI; Maller, B; Hayward, DC; Ball, EE; Degnan, B; Muller, P; Spring, J; Srinivasan, A; Fishman, M; Finnerty, J; Corbo, J; Levine, M; Leahy, P; Davidson, E; Ruvkun, G				Pasquinelli, AE; Reinhart, BJ; Slack, F; Martindale, MQ; Kuroda, MI; Maller, B; Hayward, DC; Ball, EE; Degnan, B; Muller, P; Spring, J; Srinivasan, A; Fishman, M; Finnerty, J; Corbo, J; Levine, M; Leahy, P; Davidson, E; Ruvkun, G			Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA	NATURE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; CAENORHABDITIS-ELEGANS; GENETIC INTERFERENCE; LIN-14	Two small RNAs regulate the timing of Caenorhabditis elegans development(1,2). Transition from the first to the second larval stage fates requires the 22-nucleotide lin-4 RNA(1,3,4), and transition from late larval to adult cell fates requires the 21-nucleotide let-7 RNA 2. The lin-4 and let-7 RNA genes are not homologous to each other, but are each complementary to sequences in the 3' untranslated regions of a set of protein-coding target genes that are normally negatively regulated by the RNAs1,2,5,6. Here we have detected let-7 RNAs of similar to 21 nucleotides in samples from a wide range of animal species, including vertebrate, ascidian, hemichordate, mollusc, annelid and arthropod, but not in RNAs from several cnidarian and poriferan species, Saccharomyces cerevisiae, Escherichia coli or Arabidopsis. We did not detect lin-4 RNA in these species. We found that let-7 temporal regulation is also conserved: let-7 RNA expression is first detected at late larval stages in C. elegans and Drosophila, at 48 hours after fertilization in zebrafish, and in adult stages of annelids and molluscs. The let-7 regulatory RNA may control late temporal transitions during development across animal phylogeny.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Hawaii, Pacific Biomed Res Ctr, Kewalo Marine Lab, Honolulu, HI 96813 USA; Baylor Univ, Howard Hughes Med Inst, Houston, TX 77030 USA; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Univ Queensland, Dept Zool & Entomol, Brisbane, Qld 4072, Australia; Univ Basel, Inst Zool, CH-4051 Basel, Switzerland; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Yale University; University of Hawaii System; Baylor University; Howard Hughes Medical Institute; Australian National University; University of Queensland; University of Basel; Harvard University; Massachusetts General Hospital; Boston University; University of California System; University of California Berkeley; California Institute of Technology	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Ball, Eldon E/C-9261-2009	Ball, Eldon E/0000-0002-6052-1495; Corbo, Joseph/0000-0002-9323-7140; Hayward, David/0000-0003-2937-2425; Levine, Michael/0000-0001-7629-0081; Degnan, Bernard/0000-0001-7573-8518; Slack, Frank/0000-0001-8263-0409	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045744] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30 AR046032] Funding Source: Medline; NIGMS NIH HHS [R01 GM045744] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; CHALFIE M, 1981, CELL, V24, P59, DOI 10.1016/0092-8674(81)90501-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	14	1707	1913	9	194	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					86	89		10.1038/35040556	http://dx.doi.org/10.1038/35040556			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081512				2022-12-28	WOS:000165050400056
J	Ng, V; Zanazzi, G; Timpl, R; Talts, JF; Salzer, JL; Brennan, PJ; Rambukkana, A				Ng, V; Zanazzi, G; Timpl, R; Talts, JF; Salzer, JL; Brennan, PJ; Rambukkana, A			Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae	CELL			English	Article							ALPHA-DYSTROGLYCAN BINDING; SCHWANN-CELLS; G-DOMAIN; LAMININ; LEPROSY; MEMBRANE; MYELINATION; ADHESION; PERLECAN; RECEPTOR	The cell wall of pathogenic mycobacteria is abundant with complex glycolipids whose roles in disease pathogenesis are mostly unknown. Here, we provide evidence for the involvement of the specific trisaccharide unit of the phenolic glycolipid-1 (PGL-1) of Mycobacterium leprae in determining the bacterial predilection to the peripheral nerve. PGL-1 binds specifically to the native laminin-2 in the basal lamina of Schwann cell-axon units. This binding is mediated by the alpha 2LG1, alpha 2LG4, and alpha 2LG5 modules present in the naturally cleaved fragments of the peripheral nerve laminin alpha2 chain, and is inhibited by the synthetic terminal trisaccharide of PGL-1. PGL-1 is involved in the M. leprae invasion of Schwann cells through the basal lamina in a laminin-2-dependent pathway. The results indicate a novel role of a bacterial glycolipid in determining the nerve predilection of a human pathogen.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Rockefeller University; New York University; New York University; Max Planck Society; Colorado State University	Rambukkana, A (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.	rambuka@rockvax.rockefeller.edu		Salzer, James/0000-0001-9126-7197; rambukkana, anura/0000-0002-6286-9145; Talts, Jan/0000-0001-5777-5411				Adams LB, 2000, INT J LEPROSY, V68, P1; Anderson RJ, 1932, PHYSIOL REV, V12, P0166, DOI 10.1152/physrev.1932.12.2.166; Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; BRENNAN PJ, 1984, J BIOSCIENCES, V6, P685, DOI 10.1007/BF02702710; BRENNAN PJ, 1989, REV INFECT DIS, V11, pS420; BUNGE MB, 1986, ANN NY ACAD SCI, V486, P241, DOI 10.1111/j.1749-6632.1986.tb48077.x; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHAN J, 1989, P NATL ACAD SCI USA, V86, P2453, DOI 10.1073/pnas.86.7.2453; CHATTERJEE D, 1989, INFECT IMMUN, V57, P322, DOI 10.1128/IAI.57.2.322-330.1989; CHATTERJEE D, 1988, CARBOHYD RES, V183, P241, DOI 10.1016/0008-6215(88)84078-3; CHURCH HJ, 1988, BIOCHEM J, V332, P491; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; Engvall E, 1996, J CELL BIOCHEM, V61, P493; FUJIWARA T, 1987, CARBOHYD RES, V163, P41, DOI 10.1016/0008-6215(87)80163-5; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUNTER SW, 1982, J BIOL CHEM, V257, P5072; HUNTER SW, 1981, J BACTERIOL, V147, P728, DOI 10.1128/JB.147.3.728-735.1981; JOB CK, 1989, INT J LEPROSY, V57, P532; JOHNSON PC, 1997, TXB NEUROPATHOLOGY, P1233; KOLK AHJ, 1985, ANN INST PASTEUR MIC, V136B, P217, DOI 10.1016/S0769-2609(85)80046-6; LUMSDEN CE, 1959, LEPROSY THEORY PRACT, P221; Marques MAM, 1998, INFECT IMMUN, V66, P2625, DOI 10.1128/IAI.66.6.2625-2631.1998; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; MUKHERJEE R, 1986, INT J LEPROSY, V54, P632; NEILL MA, 1988, J EXP MED, V167, P30, DOI 10.1084/jem.167.1.30; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Rambukkana A, 2000, TRENDS MICROBIOL, V8, P23, DOI 10.1016/S0966-842X(99)01647-9; RASTOGI N, 1986, CURR MICROBIOL, V13, P237, DOI 10.1007/BF01568645; Sasaki T, 1999, GUIDEBOOK EXTRACELLU, P434; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; Shimoji Y, 1999, P NATL ACAD SCI USA, V96, P9857, DOI 10.1073/pnas.96.17.9857; Smith WCS, 1997, LEPROSY REV, V68, P195; STONER GL, 1979, LANCET, V2, P994; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; WEBSTER HDF, 1973, DEV BIOL, V32, P401, DOI 10.1016/0012-1606(73)90250-9; *WHO, 1998, WEEKLY EPIDEMIOLO S2, V76, P133; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YOUNG DB, 1983, SCIENCE, V221, P1057, DOI 10.1126/science.6348948; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0	48	141	144	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					511	524		10.1016/S0092-8674(00)00142-2	http://dx.doi.org/10.1016/S0092-8674(00)00142-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081637	Bronze			2022-12-28	WOS:000090144100016
J	Bailey, PL; Lu, JK; Pace, NL; Orr, JA; White, JL; Hamber, EA; Slawson, MH; Crouch, DJ; Rollins, DE				Bailey, PL; Lu, JK; Pace, NL; Orr, JA; White, JL; Hamber, EA; Slawson, MH; Crouch, DJ; Rollins, DE			Effects of intrathecal morphine on the ventilatory response to hypoxia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESPIRATORY DEPRESSION; ISOCAPNIC HYPOXIA; SUSTAINED HYPOXIA; NORMAL ADULTS; HYPERCAPNIA; ANALGESIA; HUMANS; PAIN; MANAGEMENT	Background: Intrathecal administration of morphine produces intense analgesia, but it depresses respiration, an effect that can be life-threatening. Whether intrathecal morphine affects the ventilatory response to hypoxia, however, is not known. Methods: We randomly assigned 30 men to receive one of three study treatments in a double-blind fashion: intravenous morphine (0.14 mg per kilogram of body weight) with intrathecal placebo; intrathecal morphine (0.3 mg) with intravenous placebo; or intravenous and intrathecal placebo. The selected doses of intravenous and intrathecal morphine produce similar degrees of analgesia. The ventilatory response to hypercapnia, the subsequent response to acute hypoxia during hypercapnic breathing (targeted end-tidal partial pressures of expired oxygen and carbon dioxide, 45 mm Hg), and the plasma levels of morphine and morphine metabolites were measured at base line (before drug administration) and 1, 2, 4, 6, 8, 10, and 12 hours after drug administration. Results: At base line, the mean (+/-SD) values for the ventilatory response to hypoxia (calculated as the difference between the minute ventilation during the second full minute of hypoxia and the fifth minute of hypercapnic ventilation) were similar in the three groups: 38.3+/-23.2 liters per minute in the placebo group, 33.5+/-16.4 liters per minute in the intravenous-morphine group, and 30.2+/-11.6 liters per minute in the intrathecal-morphine group (P=0.61). The overall ventilatory response to hypoxia (the area under the curve) was significantly lower after either intravenous morphine (20.2+/-10.8 liters per minute) or intrathecal morphine (14.5+/-6.4 liters per minute) than after placebo (36.8+/-19.2 liters per minute) (P=0.003). Twelve hours after treatment, the ventilatory response to hypoxia in the intrathecal-morphine group (19.9+/-8.9 liters per minute), but not in the intravenous-morphine group (30.5+/-15.8 liters per minute), remained significantly depressed as compared with the response in the placebo group (40.9+/-19.0 liters per minute) (P=0.02 for intrathecal morphine vs. placebo). Plasma concentrations of morphine and morphine metabolites either were not detectable after intrathecal morphine or were much lower after intrathecal morphine than after intravenous morphine. Conclusions: Depression of the ventilatory response to hypoxia after the administration of intrathecal morphine is similar in magnitude to, but longer-lasting than, that after the administration of an equianalgesic dose of intravenous morphine.	Univ Rochester, Dept Anesthesiol, Rochester, NY 14642 USA; Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA; Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT USA	University of Rochester; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bailey, PL (corresponding author), Univ Rochester, Dept Anesthesiol, 601 Elmwood AveBox 604, Rochester, NY 14642 USA.							AFIFI MS, 1990, ANESTH ANALG, V71, P377; BAILEY PL, 1986, ANESTH ANALG, V65, P605; BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; BAXTER AD, 1994, CAN J ANAESTH, V41, P87, DOI 10.1007/BF03009796; Berkenbosch A, 1997, ANESTHESIOLOGY, V86, P1342, DOI 10.1097/00000542-199706000-00016; Bisgard G.E., 1995, REGULATION BREATHING, P617; Cartwright CR, 1998, ANESTHESIOLOGY, V89, P612, DOI 10.1097/00000542-199809000-00009; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; Christrup LL, 1997, ACTA ANAESTH SCAND, V41, P116, DOI 10.1111/j.1399-6576.1997.tb04625.x; Dahan A, 1996, ANESTHESIOLOGY, V85, P60, DOI 10.1097/00000542-199607000-00009; Dahan A, 1998, ANESTHESIOLOGY, V88, P903, DOI 10.1097/00000542-199804000-00009; EASTON PA, 1988, J APPL PHYSIOL, V64, P521, DOI 10.1152/jappl.1988.64.2.521; EASTON PA, 1986, J APPL PHYSIOL, V61, P906, DOI 10.1152/jappl.1986.61.3.906; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; GLASS PSA, 1984, ANESTHESIOLOGY, V60, P256, DOI 10.1097/00000542-198403000-00024; Gonzalex C, 1995, REGULATION BREATHING, P391; KRYGER MH, 1976, AM REV RESPIR DIS, V114, P333; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Pedersen MEF, 1997, J APPL PHYSIOL, V83, P1110, DOI 10.1152/jappl.1997.83.4.1110; RAWAL N, 1987, BRIT J ANAESTH, V59, P791, DOI 10.1093/bja/59.6.791; SANTIAGO TV, 1979, J APPL PHYSIOL, V47, P112, DOI 10.1152/jappl.1979.47.1.112; Slawson MH, 1999, J ANAL TOXICOL, V23, P468, DOI 10.1093/jat/23.6.468; STOELTING RK, 1989, ANESTH ANALG, V68, P707; TEMP JA, 1992, ANESTHESIOLOGY, V77, P1116, DOI 10.1097/00000542-199212000-00012; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013; WEIL JV, 1975, NEW ENGL J MED, V292, P1103, DOI 10.1056/NEJM197505222922106; WEIL JV, 1976, CHEST, V70, P124, DOI 10.1378/chest.70.1_Supplement.124; Wiklund RA, 1997, NEW ENGL J MED, V337, P1215, DOI 10.1056/NEJM199710233371707; YAKSH TL, 1976, SCIENCE, V192, P1357, DOI 10.1126/science.1273597	30	89	91	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1228	+		10.1056/NEJM200010263431705	http://dx.doi.org/10.1056/NEJM200010263431705			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071674				2022-12-28	WOS:000090014100005
J	Hospers, JJ; Postma, DS; Rijcken, B; Weiss, ST; Schouten, JP				Hospers, JJ; Postma, DS; Rijcken, B; Weiss, ST; Schouten, JP			Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study	LANCET			English	Article							NONSPECIFIC BRONCHIAL RESPONSIVENESS; COMMUNITY-BASED POPULATION; SKIN-TEST REACTIVITY; RESPIRATORY SYMPTOMS; HYPERRESPONSIVENESS; DECLINE; EOSINOPHILIA; ATOPY; ADULTS; ASTHMA	Background Smoking and airway lability, which is expressed by histamine airway hyper-responsiveness, are known risk factors for development of respiratory symptoms. Smoking is also associated with increased mortality risks. We studied whether airway hyper-responsiveness is associated with increased mortality, and whether this risk was independent of smoking and reduced lung function. Methods We followed up 2008 inhabitants of the communities of Vlagtwedde, Vlaardingen, and Meppel (Netherlands), who had histamine challenge test data, from 1964-72 for 30 years. Follow-up was 99% successful (29 patients lost to follow-up) with 1453 participants alive and 526 deaths (246 died from cardiovascular disease, 54 from lung cancer, and 21 from chronic obstructive pulmonary disease [COPD]). Findings Mortality from COPD increased with more severe hyper-responsiveness; relative risks of 3.83 (95% CI 0.97-15.1), 4.40 (1.16-16.7), 4.78 (1.27-18.0), 6.69 (1.71-26.1), and 15.8 (3.72-67.1) were associated with histamine thresholds of 32 g/L, 16 g/L, 8 g/L, 4 g/L, and 1 g/L, respectively, compared with no hyper-responsiveness. These risks were adjusted for sex, age, smoking, lung function, body-mass index, positive skin tests, eosinophilia, asthma, and city of residence. Interpretation Increased histamine airway hyperresponsiveness predicts mortality from COPD. Although this trend was more pronounced in smokers, an increasing proportion of COPD deaths with increasing hyperresponsiveness was also present among individuals who had never smoked.	Univ Groningen, Dept Epidemiol & Stat, NL-9713 AV Groningen, Netherlands; Univ Groningen, Dept Pulmonol, NL-9713 AV Groningen, Netherlands; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA USA	University of Groningen; University of Groningen; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Schouten, JP (corresponding author), Univ Groningen, Dept Epidemiol & Stat, NL-9713 AV Groningen, Netherlands.	j.p.schouten@med.rug.nl			NHLBI NIH HHS [R03 HL49460] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL049460] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNESI I, 1987, B EUR PHYSIOPATH RES, V23, P397; Bailey KV, 1995, B WORLD HEALTH ORGAN, V73, P673; BEATY TH, 1985, J CHRON DIS, V38, P703, DOI 10.1016/0021-9681(85)90024-4; *BRIT MRC COMM RES, 1966, INSTR US QUEST RESP; Burchfiel CM, 1997, CHEST, V112, P87, DOI 10.1378/chest.112.1.87; CHAILLEUX E, 1992, REV MAL RESPIR, V9, P603; COX DR, 1972, J R STAT SOC B, V34, P187; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; Freund K M, 1993, Ann Epidemiol, V3, P417, DOI 10.1016/1047-2797(93)90070-K; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; Hospers JJ, 1999, AM J EPIDEMIOL, V150, P482; Jansen DF, 1997, RESP MED, V91, P121, DOI 10.1016/S0954-6111(97)90048-2; MACKENBACH JP, 1988, GEZONDHEIDSZORG VERM, P329; MACKENBACH JP, 1988, MORTALITY MED CARE; Mensinga Tjeert T., 1994, Annals of Epidemiology, V4, P382; MENSINGA TT, 1992, AM REV RESPIR DIS, V146, P638, DOI 10.1164/ajrccm/146.3.638; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225, DOI 10.1164/ajrccm/140.1.225; PARKER DR, 1990, AM REV RESPIR DIS, V141, P589, DOI 10.1164/ajrccm/141.3.589; POSTMA DS, 1991, AM REV RESPIR DIS, V143, P1458, DOI 10.1164/ajrccm/143.6.1458; Postma DS, 1997, EUR RESPIR REV, V7, P159; PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377, DOI 10.1164/ajrccm.151.5.7735588; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; VANDERLENDE R, 1981, CLIN RES PROC, V17, P775; VANDERLENDE R, 1969, EPIDEMIOLOGY CHRONIC; VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656, DOI 10.1164/ajrccm/151.3_Pt_1.656; WEISS ST, 1995, AM J EPIDEMIOL, V142, P493, DOI 10.1093/oxfordjournals.aje.a117665; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1	33	146	155	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1313	1317		10.1016/S0140-6736(00)02815-4	http://dx.doi.org/10.1016/S0140-6736(00)02815-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073020	Bronze			2022-12-28	WOS:000089858300012
J	Wilkins, MR; Gibbs, JSR; Shovlin, CL				Wilkins, MR; Gibbs, JSR; Shovlin, CL			A gene for primary pulmonary hypertension	LANCET			English	Editorial Material							ENDOGLIN; PROTEIN		Hammersmith Hosp, Imperial Coll, Sch Med, London W12 0NN, England	Imperial College London	Wilkins, MR (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, London W12 0NN, England.							Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; Deng ZM, 2000, AM J HUM GENET, V67, P737, DOI 10.1086/303059; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Nichols WC, 1997, NAT GENET, V15, P277, DOI 10.1038/ng0397-277; Soda H, 1998, ANTI-CANCER DRUG, V9, P327, DOI 10.1097/00001813-199804000-00006	9	12	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1207	1208		10.1016/S0140-6736(00)02777-X	http://dx.doi.org/10.1016/S0140-6736(00)02777-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072932				2022-12-28	WOS:000089724900003
J	Toppet, M; Fall, ABK; Ferster, A; Fondu, P; Melot, H; Vanhaelen-Fastre, R; Vanhaelen, M				Toppet, M; Fall, ABK; Ferster, A; Fondu, P; Melot, H; Vanhaelen-Fastre, R; Vanhaelen, M			Antisickling activity of sodium cromoglicate in sickle-cell disease	LANCET			English	Article							CROMOLYN	Two groups of patients with sickle-cell disease were given a single dose of sodium cromoglicate by inhalation or nasal route. The striking decrease in sickle cells after treatment by both routes lends support to the role of sodium cromoglicate in sickle-cell disease treatment.	Free Univ Brussels, Inst Pharm, Lab Pharmacognosie & Bromatol, B-1050 Brussels, Belgium; Hop Univ Des Enfants Reine Fabiola, Unite Hamatooncol, Brussels, Belgium; Free Univ Brussels, Hop Univ Brugmann, Hematol Lab, B-1050 Brussels, Belgium; Free Univ Brussels, Hop Univ Erasme, Serv Soins Intens, B-1050 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vanhaelen, M (corresponding author), Free Univ Brussels, Inst Pharm, Lab Pharmacognosie & Bromatol, B-1050 Brussels, Belgium.			MELOT, Christian/0000-0002-6172-0330				Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; Fall ABK, 1998, BRIT J HAEMATOL, V103, P957, DOI 10.1046/j.1365-2141.1998.01106.x; Janssen LJ, 1998, EUR RESPIR J, V12, P50, DOI 10.1183/09031936.98.12010050; REINSPRECHT M, 1992, BIOCHEM BIOPH RES CO, V188, P957, DOI 10.1016/0006-291X(92)91325-K; Toppet M., 1993, NOUVELLE REV FRANCAI, V35, P512	5	17	17	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					309	309		10.1016/S0140-6736(00)02508-3	http://dx.doi.org/10.1016/S0140-6736(00)02508-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071188				2022-12-28	WOS:000088305900014
J	Haber, D				Haber, D			Roads leading to breast cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ATM		Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Haber, D (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Wang Y, 2000, GENE DEV, V14, P927; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	10	22	24	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1566	1568		10.1056/NEJM200011233432111	http://dx.doi.org/10.1056/NEJM200011233432111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087889				2022-12-28	WOS:000165410900011
J	Waise, A; Belchetz, PE				Waise, A; Belchetz, PE			Lesson of the week - Unsuspected central hypothyroidism	BRITISH MEDICAL JOURNAL			English	Review									Friarage Hosp, Dept Clin Biochem, Northallerton DL6 1JG, N Yorkshire, England; Gen Infirm, Dept Med, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Waise, A (corresponding author), Friarage Hosp, Dept Clin Biochem, Northallerton DL6 1JG, N Yorkshire, England.							BARTH JH, 1995, ANN CLIN BIOCHEM, V32, P442, DOI 10.1177/000456329503200502; BELCHETZ PE, 1976, P ROY SOC MED, V69, P428, DOI 10.1177/003591577606900614; BELCHETZ PE, 1985, BRIT MED J, V291, P247, DOI 10.1136/bmj.291.6490.247; CALDWELL G, 1985, LANCET, V1, P1117; Clayton RN, 1997, PITUITARY TUMOURS RE; MANDELL RJ, 1985, LANCET, V1, P1455; MORI T, 1987, CLIN ENDOCRINOL, V27, P1, DOI 10.1111/j.1365-2265.1987.tb00833.x; WHEELER MJ, 1994, DIS THYROID	8	18	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1275	1277		10.1136/bmj.321.7271.1275	http://dx.doi.org/10.1136/bmj.321.7271.1275			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082092	Green Published			2022-12-28	WOS:000165445800030
J	Crawley, L; Payne, R; Bolden, J; Payne, T; Washington, P; Williams, S				Crawley, L; Payne, R; Bolden, J; Payne, T; Washington, P; Williams, S		Initiative Improve Palliative End	Palliative and end-of-life care in the African American community	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; ADVANCE DIRECTIVES; MEASURING QUALITY; RACIAL VARIATION; PAIN MANAGEMENT; DECISION-MAKING; RACE; ETHNICITY; BLACK; ATTITUDES		Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Balm Gilead End Life Initiat Cooper Green Hosp, Birmingham, AL USA; Harlem Palliat Care Network, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Dept Pain & Symptom Res, Houston, TX 77030 USA; Tuskegee Univ, Natl Ctr Bioeth Res & Hlth Care, Tuskegee, AL 36088 USA	Stanford University; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Tuskegee University	Crawley, L (corresponding author), Stanford Univ, Ctr Biomed Eth, 701 Welch Rd,Bldg A,Suite 1105, Palo Alto, CA 94304 USA.	lcrawley@stanford.edu						Al-Jeilani M, 1987, Acta Neurochir Suppl (Wien), V38, P132; ANGELOU M, 1997, NORTON ANTHOLOGY AFR, P2039; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; Burrs F A, 1995, Hosp J, V10, P15; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; Clayton L A, 1993, J Health Care Poor Underserved, V4, P83; CRAWLEY L, 2000, CTR LIT MED HLTH PRO, V12, P5; CRAWLEY L, 1999, ANN M NAT MED ASS AU; DULA A, 1994, CLIN GERIATR MED, V10, P419, DOI 10.1016/S0749-0690(18)30330-6; DULA A, 1994, CAMB Q HEALTHC ETHIC, V3, P347, DOI 10.1017/S0963180100005168; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; Freeman HP, 2000, NEW ENGL J MED, V342, P1045, DOI 10.1056/NEJM200004063421411; Geiger HJ, 1996, NEW ENGL J MED, V335, P815, DOI 10.1056/NEJM199609123351110; GERBNER G, 1981, NEW ENGL J MED, V305, P901, DOI 10.1056/NEJM198110083051530; Gordon A K, 1996, Hosp J, V11, P49, DOI 10.1300/J011v11n01_04; Gordon A K, 1995, Hosp J, V10, P65; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Hauser JM, 1997, CAMB Q HEALTHC ETHIC, V6, P58, DOI 10.1017/S0963180100007611; Hoffman-Goetz L, 1999, PSYCHO-ONCOL, V8, P36, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<36::AID-PON330>3.0.CO;2-8; HOOKS B, 2000, OTHER SIDE, V36, P43; Horner RD, 1998, CANC TREAT, P99; JOHNSON JW, 1992, TRIALS TRIBULATIONS, P171; Jones MR, 2000, STROKE, V31, P563, DOI 10.1161/01.STR.31.3.563; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; Komaromy M, 1996, NEW ENGL J MED, V334, P1305, DOI 10.1056/NEJM199605163342006; KRIEGER N, 1993, AM J PUBLIC HEALTH, V83, P1086, DOI 10.2105/AJPH.83.8.1086; Kumasaka L, 1996, AM J NURS, V96, P45, DOI 10.1097/00000446-199606000-00044; Low JF, 1997, AM J OCCUP THER, V51, P215, DOI 10.5014/ajot.51.3.215; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MARABLE M, 1994, MEDIA STUD J, V8, P11; MBITI JS, 1991, INTRO AFRICAN RELIG, P116; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Mebane EW, 1999, J AM GERIATR SOC, V47, P579, DOI 10.1111/j.1532-5415.1999.tb02573.x; MESSNER SF, 1992, CRIMINOLOGY, V30, P421, DOI 10.1111/j.1745-9125.1992.tb01111.x; Murphy ST, 1996, J LAW MED ETHICS, V24, P108, DOI 10.1111/j.1748-720X.1996.tb01843.x; NHPCO, FACTS FIG HOSP CAR A; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Phillips RS, 1996, J GEN INTERN MED, V11, P387, DOI 10.1007/BF02600183; Reese DJ, 1999, SOC WORK, V44, P549, DOI 10.1093/sw/44.6.549; Rossler D, 1987, Acta Neurochir Suppl (Wien), V38, P127; Signorielli N., 1993, MASS MEDIA IMAGES IM, P37; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; Todd KH, 2000, ANN EMERG MED, V35, P11, DOI 10.1016/S0196-0644(00)70099-0; TROPH S, 1999, ST LOUIS J REV, V29, P1; *US DEP HHS, HLTH PEOPL 2010	48	219	219	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2518	2521		10.1001/jama.284.19.2518	http://dx.doi.org/10.1001/jama.284.19.2518			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074786				2022-12-28	WOS:000165183800029
J	Meisel, A; Snyder, L; Quill, T				Meisel, A; Snyder, L; Quill, T			Seven legal barriers to end-of-life care - Myths, realities, and grains of truth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; PALLIATIVE CARE; TERMINAL SEDATION; ADVANCE DIRECTIVES; MALPRACTICE CLAIMS; SLOW EUTHANASIA; DECISION-MAKING; SUPREME-COURT; MANAGEMENT; DIALOGUE	Objective The American College of Physicians-American Society of Internal Medicine (ACP-ASIM) End-of-Life Care Consensus Panel was convened in 1997 to identify clinical, ethical, and policy problems in end-of-life care, to analyze critically the available evidence and guidelines, and to offer consensus recommendations on how to improve care of the dying. Topic selection and content presentation were carefully debated to maximize the project's focus on providing practical clinical and other guidance to clinicians who are not specialists in palliative care. This statement examines current legal myths, realities, and grains of truth in end-of-life care. Participants The Consensus Panel comprises 13 medical and bioethics experts, clinicians, and educators in care at the end of life selected by the Ethics and Human Rights Committee, College leadership, and the Center for Ethics and Professionalism at the ACP-ASIM. Evidence A literature review including a MEDLINE search of articles from 1970-1998 and review of end-of-life care literature and organizational bibliographies was conducted. Unpublished sources were also identified by participants, as was anecdotal clinical experience. Consensus Process The draft statement was debated by panel members over a series of 3 to 4 meetings. For this statement, the initial draft and subsequent revised drafts were discussed in 1998-1999. The statement then underwent external peer review and revision before panel approval and the journal peer review process. Conclusions Legal myths about end-of-life care can undermine good care and ethical medical practice. In addition, at times ethics, clinical judgment, and the law conflict, Patients (or families) and physicians can find themselves considering clinical actions that are ethically appropriate, but raise legal concerns. The 7 major legal myths regarding end-of-life care are: (1) forgoing life-sustaining treatment for patients without decision-making capacity requires evidence that this was the patient's actual wish; (2) withholding or withdrawing of artificial fluids and nutrition from terminally ill or permanently unconscious patients is illegal; (3) risk management personnel must be consulted before life-sustaining medical treatment may be terminated; (4) advance directives must comply with specific forms, are not transferable between states, and govern all future treatment decisions; oral advance directives are unenforceable; (5) if a physician prescribes or administers high doses of medication to relieve pain or other discomfort in a terminally ill patient, resulting in death, he/she will be criminally prosecuted; (6) when a terminally ill patient's suffering is overwhelming despite palliative care, and he/she requests a hastened death, there are no legally permissible options to ease suffering; and (7) the 1997 Supreme Court decisions outlawed physician-assisted suicide. Many legal barriers to end-of-life care are more mythical than real, but sometimes there is a grain of truth. Physicians must know the law of the state in which they practice.	Amer Coll Physicians, Ctr Eth & Professionalism, Amer Soc Internal Med, Philadelphia, PA 19106 USA; Univ Pittsburgh, Sch Law, Ctr Med Eth, Pittsburgh, PA 15260 USA; Genesee Hosp, Dept Med, Rochester, NY 14607 USA	American College of Physicians; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Snyder, L (corresponding author), Amer Coll Physicians, Ctr Eth & Professionalism, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@mail.acponline.org						Alpers A, 1998, J LAW MED ETHICS, V26, P308, DOI 10.1111/j.1748-720X.1998.tb01678.x; Asch DA, 1996, NEW ENGL J MED, V334, P1374, DOI 10.1056/NEJM199605233342106; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BREITBART W, 1997, OXFORD TXB PALLIATIV, P437; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Duffy FD, 1998, ANN INTERN MED, V128, P139, DOI 10.7326/0003-4819-128-2-199801150-00011; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Field MJ, 1997, APPROACHING DEATH IM; Garcia J. L. A., 1995, ENCY BIOETHICS, P636; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Jacobson JA, 1997, J CLIN ETHIC, V8, P359; Johnson SH, 1996, J LAW MED ETHICS, V24, P319, DOI 10.1111/j.1748-720X.1996.tb01874.x; KAPP MB, 1996, J HLTH CARE RISK MAN, V16, P411; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Marco CA, 1997, ACAD EMERG MED, V4, P898, DOI 10.1111/j.1553-2712.1997.tb03816.x; Meisel A, 1995, AM J LAW MED, V21, P335; MEISEL A, 1991, ARCH INTERN MED, V151, P1497, DOI 10.1001/archinte.151.8.1497; MEISEL A, 1995, RIGHT DIE; MEISEL A, 1999, U MD J HLTH CARE LAW, V2, P201; Meisel Alan, 1992, Kennedy Institute of Ethics Journal, V2, P309; Miller FG, 2000, ANN INTERN MED, V132, P470, DOI 10.7326/0003-4819-132-6-200003210-00008; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher David, 1994, MD Law Rev, V53, P1255; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; Shapiro RS, 1996, J LAW MED ETHICS, V24, P360, DOI 10.1111/j.1748-720X.1996.tb01879.x; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003	37	116	117	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2495	2501		10.1001/jama.284.19.2495	http://dx.doi.org/10.1001/jama.284.19.2495			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074780				2022-12-28	WOS:000165183800024
J	Ogon, M; Sepp, NT; Wimmer, C; Behensky, H				Ogon, M; Sepp, NT; Wimmer, C; Behensky, H			A surgical wound infection?	LANCET			English	Article							PYODERMA-GANGRENOSUM		Univ Innsbruck, Dept Orthopaed Surg, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Dermatol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Ogon, M (corresponding author), Univ Innsbruck, Dept Orthopaed Surg, Anichstr 35, A-6020 Innsbruck, Austria.	Michael.Ogon@uibk.ac.at						Brunsting LA, 1930, ARCH DERMATOL SYPH, V22, P655, DOI 10.1001/archderm.1930.01440160053009; Callen JP, 1998, LANCET, V351, P581, DOI 10.1016/S0140-6736(97)10187-8; RAN RP, 1993, ANN THORAC SURG, V55, P1016; SCHWAEGERLE SM, 1988, J AM ACAD DERMATOL, V18, P559, DOI 10.1016/S0190-9622(88)70080-8; Sepp NT, 1999, DERMATOLOGY AT THE MILLENNIUM, P535	5	12	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1652	1652		10.1016/S0140-6736(00)03161-5	http://dx.doi.org/10.1016/S0140-6736(00)03161-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089826				2022-12-28	WOS:000165249200015
J	Ishihara, K; Ohara, S; Yamamoto, H				Ishihara, K; Ohara, S; Yamamoto, H			Direct condensation of carboxylic acids with alcohols catalyzed by hafnium(IV) salts	SCIENCE			English	Article							EFFICIENT CATALYST; ORGANIC-SYNTHESIS; ESTERIFICATION; ACYLATION; TRIFLUOROMETHANESULFONATE; TRANSESTERIFICATION	In order to promote atom efficiency in synthesis and to avoid the generation of environmental waste, the use of stoichiometric amounts of condensing reagents OF excess substrates should be avoided. In esterification, excesses of either carboxylic acids or alcohols are normally needed. We show that the direct condensation of equimolar amounts of carboxylic acids and alcohols can be achieved with the use of hafnium(IV) salts, such as commercially available hafnium(IV) chloride and hafnium(IV) tert-butoxide. The present method can be applied to direct polyesterification and may be suitable for large-scale operations.	Nagoya Univ, Core Res Evolut Sci & Technol, Japan Sci & Technol, Grad Sch Engn,Chikusa Ku, Nagoya, Aichi 4648603, Japan; Nagoya Univ, Res Ctr Adv Waste & Emiss Management, Chikusa Ku, Nagoya, Aichi 4648603, Japan	Japan Science & Technology Agency (JST); Nagoya University; Nagoya University	Yamamoto, H (corresponding author), Nagoya Univ, Core Res Evolut Sci & Technol, Japan Sci & Technol, Grad Sch Engn,Chikusa Ku, Nagoya, Aichi 4648603, Japan.	yamamoto@cc.nagoya-u.ac.jp	Yamamoto, Hisashi/G-6344-2011					Anastas P. T., 1998, GREEN CHEM THEORY PR; BLOSSEY EC, 1973, TETRAHEDRON LETT, P1823; CHEN Z, 1984, CHEM LETT, P1085, DOI 10.1246/cl.1984.1085; HACHIYA I, 1995, B CHEM SOC JPN, V68, P2053, DOI 10.1246/bcsj.68.2053; HINO M, 1981, CHEM LETT, P1671, DOI 10.1246/cl.1981.1671; Ishihara K, 2000, MACROMOLECULES, V33, P3511, DOI 10.1021/ma000085o; Ishihara K, 1996, J ORG CHEM, V61, P4196, DOI 10.1021/jo9606564; Ishihara K, 1996, SYNLETT, P265; Ishihara K, 1996, J ORG CHEM, V61, P4560, DOI 10.1021/jo952237x; IZUMI Y, 1981, CHEM LETT, P663, DOI 10.1246/cl.1981.663; KADABA PK, 1972, SYNTH-INT J METHODS, P628; Kobayashi S, 1997, B CHEM SOC JPN, V70, P267, DOI 10.1246/bcsj.70.267; KUMAR AK, 1987, TETRAHEDRON LETT, V28, P3713, DOI 10.1016/S0040-4039(00)96364-0; Larock R. C., 1989, COMPREHENSIVE ORGANI, P966; LOWRENCE WW, 1971, TETRAHEDRON LETT, P3453; Masaki Y, 1997, CHEM LETT, P55, DOI 10.1246/cl.1997.55; NAKAO R, 1981, B CHEM SOC JPN, V54, P1267, DOI 10.1246/bcsj.54.1267; OGAWA T, 1994, J CHEM SOC PERK T 1, P3473, DOI 10.1039/p19940003473; OLAH GA, 1908, SYNTHESIS-STUTTGART, P929; OTERA J, 1991, J ORG CHEM, V56, P5307, DOI 10.1021/jo00018a019; OTTON J, 1988, J POLYM SCI POL CHEM, V26, P2199, DOI 10.1002/pola.1988.080260816; SANDLER SR, 1992, POLYM SYNTHESIS, V1, pCH2; STELIOU K, 1980, J AM CHEM SOC, V102, P7578, DOI 10.1021/ja00545a038; SUZUKI K, 1994, PURE APPL CHEM, V66, P1557, DOI 10.1351/pac199466071557; TAKAHASHI K, 1989, B CHEM SOC JPN, V62, P2353, DOI 10.1246/bcsj.62.2353; TANABE K, 1980, Patent No. 115570; WHITE JF, 1977, Patent No. 75684	27	310	327	2	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1140	1142		10.1126/science.290.5494.1140	http://dx.doi.org/10.1126/science.290.5494.1140			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073448				2022-12-28	WOS:000165228200041
J	Gershon, D				Gershon, D			Structural genomics - from cottage industry to industrial revolution	NATURE			English	Article									Nature Med, New Technol, London, England		Gershon, D (corresponding author), Nature Med, New Technol, London, England.								0	10	10	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					273	274		10.1038/35041771	http://dx.doi.org/10.1038/35041771			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089986				2022-12-28	WOS:000165180400059
J	Mas, P; Devlin, PF; Panda, S; Kay, SA				Mas, P; Devlin, PF; Panda, S; Kay, SA			Functional interaction of phytochrome B and cryptochrome 2	NATURE			English	Article							LIGHT RECEPTOR CRYPTOCHROME-2; SIGNAL-TRANSDUCTION; ARABIDOPSIS; PROTEIN; PHOTORECEPTORS; TRANSLOCATION; NUCLEUS	Light is a crucial environmental signal that controls many photomorphogenic and circadian responses in plants(1). Perception and transduction of light is achieved by at least two principal groups of photoreceptors, phytochromes and cryptochromes(2,3). Phytochromes are red/far-red light-absorbing receptors encoded by a gene family of five members (phyA to phyE)(2,4) in Arabidopsis. Cryptochrome 1 (cry1), cryptochrome 2 (cry2) and phototropin are the blue/ultraviolet-A light receptors that have been characterized in Arabidopsis(5). Previous studies showed that modulation of many physiological responses in plants is achieved by genetic interactions between different photoreceptors(6); however, little is known about the nature of these interactions and their roles in the signal transduction pathway. Here we show the genetic interaction that occurs between the Arabidopsis photoreceptors phyB and cry2 in the control of flowering time, hypocotyl elongation and circadian period by the clock. PhyB interacts directly with cry2 as observed in co-immunoprecipitation experiments with transgenic Arabidopsis plants overexpressing cry2. Using fluorescent resonance energy transfer microscopy, we show that phyB and cry2 interact in nuclear speckles that are formed in a light-dependent fashion.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Natl Sci Fdn, Ctr Biol Timing, La Jolla, CA 92037 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevek@scripps.edu	Mas, Paloma/B-8215-2016; Kay, Steve A/F-6025-2011; Panda, Satchidananda/J-6891-2012	Mas, Paloma/0000-0002-3780-8041; Kay, Steve A/0000-0002-0402-2878; Devlin, Paul/0000-0002-0168-3793				Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Bastiaens PIH, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P136; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; Casal JJ, 2000, PHOTOCHEM PHOTOBIOL, V71, P1, DOI 10.1562/0031-8655(2000)071&lt;0001:PCPPII&gt;2.0.CO;2; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Chory J, 1997, PLANT CELL, V9, P1225, DOI 10.1105/tpc.9.7.1225; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gadella TWJ, 1999, TRENDS PLANT SCI, V4, P287, DOI 10.1016/S1360-1385(99)01426-0; Guo HW, 1999, PLANT J, V19, P279, DOI 10.1046/j.1365-313X.1999.00525.x; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; Kendric RE, 1994, PHOTOMORPHOGENESIS P; Kircher S, 1999, PLANT CELL, V11, P1445, DOI 10.1105/tpc.11.8.1445; Kleiner O, 1999, PLANT J, V19, P289, DOI 10.1046/j.1365-313X.1999.00535.x; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Mockler TC, 1999, DEVELOPMENT, V126, P2073; Nelson DC, 2000, CELL, V101, P331, DOI 10.1016/S0092-8674(00)80842-9; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Somers DE, 2000, CELL, V101, P319, DOI 10.1016/S0092-8674(00)80841-7; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; WHETLAM GC, 1998, PLANT CELL ENVIRON, V20, P752; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Yamaguchi R, 1999, J CELL BIOL, V145, P437, DOI 10.1083/jcb.145.3.437; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	30	311	333	6	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					207	211		10.1038/35041583	http://dx.doi.org/10.1038/35041583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089975				2022-12-28	WOS:000165180400047
J	Engelmann, J; Hanke, W; Mogdans, J; Bleckmann, H				Engelmann, J; Hanke, W; Mogdans, J; Bleckmann, H			Neurobiology - Hydrodynamic stimuli and the fish lateral line	NATURE			English	Article									Univ Bonn, Inst Zool, D-53115 Bonn, Germany	University of Bonn	Engelmann, J (corresponding author), Univ Bonn, Inst Zool, Poppelsdorfer Schloss, D-53115 Bonn, Germany.							[Anonymous], 1994, PROGR ZOOL; Batschelet E., 1981, CIRCULAR STAT BIOL; BLECKMANN H, 1990, BRAIN BEHAV EVOLUT, V35, P240, DOI 10.1159/000115870; Denton E.J., 1989, P229; DIJKGRAAF S, 1963, BIOL REV, V38, P51, DOI 10.1111/j.1469-185X.1963.tb00654.x; Hanke W, 2000, J EXP BIOL, V203, P1193; JAKUBOWSKI M, 1967, ACTA BIOL CRACOV ZOO, V10, P69; KROESE ABA, 1992, J NEUROPHYSIOL, V68, P2212, DOI 10.1152/jn.1992.68.6.2212; Marshall N. B., 1971, EXPLORATIONS LIFE FI; Montgomery JC, 1997, NATURE, V389, P960, DOI 10.1038/40135; Northcutt R.G., 1989, P17	11	162	168	0	24	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					51	52		10.1038/35040706	http://dx.doi.org/10.1038/35040706			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081502				2022-12-28	WOS:000165050400046
J	Smith, SD; Huxman, TE; Zitzer, SF; Charlet, TN; Housman, DC; Coleman, JS; Fenstermaker, LK; Seemann, JR; Nowak, RS				Smith, SD; Huxman, TE; Zitzer, SF; Charlet, TN; Housman, DC; Coleman, JS; Fenstermaker, LK; Seemann, JR; Nowak, RS			Elevated CO2 increases productivity and invasive species success in an arid ecosystem	NATURE			English	Article							NET PRIMARY PRODUCTION; PERFORMANCE; ENRICHMENT	Arid ecosystems, which occupy about 20% of the earth's terrestrial surface area, have been predicted to be one of the most responsive ecosystem types to elevated atmospheric CO2 and associated global climate change(1-3). Here we show, using free-air CO2 enrichment (FACE) technology in an intact Mojave Desert ecosystem(4), that new shoot production of a dominant perennial shrub is doubled by a 50% increase in atmospheric CO2 concentration in a high rainfall year. However, elevated CO2 does not enhance production in a drought year. We also found that aboveground production and seed rain of an invasive annual grass increases more at elevated CO2 than in several species of native annuals. Consequently, elevated CO2 might enhance the longterm success and dominance of exotic annual grasses in the region. This shift in species composition in favour of exotic annual grasses, driven by global change, has the potential to accelerate the fire cycle, reduce biodiversity and alter ecosystem function in the deserts of western North America.	Univ Nevada, Dept Biol Sci, Las Vegas, NV 89154 USA; Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Desert Res Inst, Div Earth & Ecosyst Sci, Reno, NV 89512 USA; Desert Res Inst, Div Earth & Ecosyst Sci, Reno, NV 89119 USA; Univ Nevada, Dept Environm & Resource Sci, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; Nevada System of Higher Education (NSHE); Desert Research Institute NSHE; Nevada System of Higher Education (NSHE); University of Nevada Reno	Smith, SD (corresponding author), Univ Nevada, Dept Biol Sci, Las Vegas, NV 89154 USA.			Seemann, Jeffrey/0000-0002-5160-175X				BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; BROWN JH, 1990, SCIENCE, V250, P1705, DOI 10.1126/science.250.4988.1705; DeLucia EH, 1999, SCIENCE, V284, P1177, DOI 10.1126/science.284.5417.1177; Hamerlynck EP, 2000, J ARID ENVIRON, V44, P425, DOI 10.1006/jare.1999.0615; HENDREY GR, 1994, AGR FOREST METEOROL, V70, P3, DOI 10.1016/0168-1923(94)90044-2; HUNTER R, 1991, GREAT BASIN NAT, V51, P176; Huxman TE, 1999, FUNCT ECOL, V13, P769, DOI 10.1046/j.1365-2435.1999.00366.x; Huxman TE, 1998, OECOLOGIA, V114, P202, DOI 10.1007/s004420050437; Huxman TE, 1998, PLANT CELL ENVIRON, V21, P1153, DOI 10.1046/j.1365-3040.1998.00379.x; Jordan DN, 1999, GLOB CHANGE BIOL, V5, P659, DOI 10.1046/j.1365-2486.1999.00255.x; Knapp PA, 1998, GLOBAL ECOL BIOGEOGR, V7, P259, DOI 10.2307/2997600; MACK RN, 1981, AGRO-ECOSYSTEMS, V7, P145, DOI 10.1016/0304-3746(81)90027-5; MAYEUX HS, 1994, ECOLOGY MANAGEMENT A, P95; MELGOZA G, 1990, OECOLOGIA, V83, P7, DOI 10.1007/BF00324626; MELILLO JM, 1993, NATURE, V363, P234, DOI 10.1038/363234a0; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; NOYMEIR I, 1973, ANNU REV ECOL SYST, V4, P51; SAGE RF, 1996, CARBON DIOXIDE POPUL, P231; Schlesinger WH, 1996, ECOLOGY, V77, P364, DOI 10.2307/2265615; Smith SD, 1987, FUNCT ECOL, V1, P139, DOI 10.2307/2389717; Smith S.D., 1997, PHYSIOLOGICAL ECOLOG; Strain BR, 1983, CO2 PLANTS RESPONSE; YOUNG JA, 1978, J RANGE MANAGE, V31, P283, DOI 10.2307/3897603	23	414	468	9	281	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					79	82		10.1038/35040544	http://dx.doi.org/10.1038/35040544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081510				2022-12-28	WOS:000165050400054
J	Liedtke, W; Choe, Y; Marti-Renom, MA; Bell, AM; Denis, CS; Sali, A; Hudspeth, AJ; Friedman, JM; Heller, S				Liedtke, W; Choe, Y; Marti-Renom, MA; Bell, AM; Denis, CS; Sali, A; Hudspeth, AJ; Friedman, JM; Heller, S			Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor	CELL			English	Article							CAENORHABDITIS-ELEGANS; LAMINA TERMINALIS; CAPSAICIN-RECEPTOR; ION-CHANNEL; SENSITIVITY; NEURONS; RAT; MECHANOTRANSDUCTION; IDENTIFICATION; TRANSDUCTION	The detection of osmotic stimuli is essential for all organisms, yet few osmoreceptive proteins are known, none of them in vertebrates. By employing a candidate-gene approach based on genes encoding members of the TRP superfamily of ion channels, we cloned cDNAs encoding the vanilloid receptor-related osmotically activated channel (VR-OAC) from the rat, mouse, human, and chicken. This novel cation-selective channel is gated by exposure to hypotonicity within the physiological range. In the central nervous system, the channel is expressed in neurons of the circumventricular organs, neurosensory cells responsive to systemic osmotic pressure. The channel also occurs in other neurosensory cells, including inner-ear hair cells, sensory neurons, and Merkel cells.	Rockefeller Univ, Mol Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Sensory Neurosci, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Heller, S (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	hellers@epl.meei.harvard.edu	Liedtke, Wolfgang/GNH-1878-2022; Marti-Renom, Marc/A-1836-2010; Marti-Renom, Marc A./Y-8803-2019; Liedtke, Wolfgang B/G-4633-2011	Marti-Renom, Marc/0000-0002-0151-4279; Marti-Renom, Marc A./0000-0002-0151-4279; 	Howard Hughes Medical Institute Funding Source: Medline; NIDCD NIH HHS [R01 DC000241, DC00317, F32 DC000317, R01 DC000241-26] Funding Source: Medline; NIDDK NIH HHS [R01 DK041096, DK41096, R01 DK041096-18] Funding Source: Medline; NIGMS NIH HHS [R01 GM054762-13, R29 GM054762, GM54762, R01 GM054762] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, R29GM054762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000241, F32DC000317] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ANDRES KH, 1973, HDB SENSORY PHYSIOLO, V2, P3; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Bisley JW, 1996, BRAIN RES, V720, P25, DOI 10.1016/0006-8993(96)00079-0; Bourque CW, 1997, ANNU REV PHYSIOL, V59, P601, DOI 10.1146/annurev.physiol.59.1.601; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619, DOI 10.1152/ajpcell.1998.275.2.C619; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Colbert HA, 1997, J NEUROSCI, V17, P8259; Dehnhardt G, 1998, J EXP BIOL, V201, P3023; Denton DA, 1996, P NATL ACAD SCI USA, V93, P7397, DOI 10.1073/pnas.93.14.7397; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; FUCCI D, 1976, PERCEPT MOTOR SKILL, V43, P263, DOI 10.2466/pms.1976.43.1.263; Gu GQ, 1996, P NATL ACAD SCI USA, V93, P6577, DOI 10.1073/pnas.93.13.6577; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heller S, 1998, P NATL ACAD SCI USA, V95, P11400, DOI 10.1073/pnas.95.19.11400; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; KERNAN M, 1995, CURR OPIN NEUROBIOL, V5, P443, DOI 10.1016/0959-4388(95)80003-4; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; McKinley M.J., 1990, HUMAN NERVOUS SYSTEM, P415; McKinley MJ, 1999, AM J PHYSIOL-REG I, V276, pR673, DOI 10.1152/ajpregu.1999.276.3.R673; MCKINLEY MJ, 1992, PROG BRAIN RES, V91, P395; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Meyer J, 1998, J NEUROSCI, V18, P6748; O'Neill R R, 1989, Appl Theor Electrophor, V1, P163; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; Retief J D, 2000, Methods Mol Biol, V132, P243; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; SIBBALD JR, 1988, BRAIN RES, V461, P205, DOI 10.1016/0006-8993(88)90251-X; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; THRASHER TN, 1982, ENDOCRINOLOGY, V110, P1837, DOI 10.1210/endo-110-5-1837; Touchman JW, 2000, GENOME RES, V10, P165, DOI 10.1101/gr.10.2.165; TRAVIS KA, 1993, AM J PHYSIOL, V264, pR1200, DOI 10.1152/ajpregu.1993.264.6.R1200; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Weitz J, 1941, J EXP PSYCHOL, V28, P21, DOI 10.1037/h0059426; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761; [No title captured]	43	977	1045	0	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					525	535		10.1016/S0092-8674(00)00143-4	http://dx.doi.org/10.1016/S0092-8674(00)00143-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081638	Green Accepted, Bronze			2022-12-28	WOS:000090144100017
J	Adam, D				Adam, D			Clean and green ... but are they mean?	NATURE			English	Article							IONIC LIQUIDS											Adams CJ, 2000, GREEN CHEM, V2, P21, DOI 10.1039/a908167d; Adams CJ, 1998, CHEM COMMUN, P2097; Blanchard LA, 1999, NATURE, V399, P28, DOI 10.1038/19887; Carmichael AJ, 1999, ORG LETT, V1, P997, DOI 10.1021/ol9907771; Cull SG, 2000, BIOTECHNOL BIOENG, V69, P227; Hitzler MG, 1997, CHEM COMMUN, P1667, DOI 10.1039/a704371f; Leitner W, 2000, NATURE, V405, P129, DOI 10.1038/35012181; McClain JB, 1996, SCIENCE, V274, P2049, DOI 10.1126/science.274.5295.2049; Olivier-Bourbigou H., 1999, PET TECHNOL Q, V04, P141; Sarbu T, 2000, NATURE, V405, P165, DOI 10.1038/35012040	10	88	90	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					938	940		10.1038/35039717	http://dx.doi.org/10.1038/35039717			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069156	Bronze			2022-12-28	WOS:000090032500014
J	Walker, JJ				Walker, JJ			Pre-eclampsia	LANCET			English	Article							PREGNANCY-INDUCED HYPERTENSION; ELEVATED LIVER-ENZYMES; PLATELETS HELLP-SYNDROME; ACUTE-RENAL-FAILURE; LOW-DOSE ASPIRIN; SEVERE PREECLAMPSIA; PREVENT PREECLAMPSIA; GROWTH-RETARDATION; MATERNAL MORBIDITY; SPIRAL ARTERIES	Pre-eclampsia is associated with significant morbidity and mortality for mother and baby, but it resolves completely post partum. Despite a steady reduction in maternal mortality from the disorder in more developed countries, it remains one of the most common reasons for a woman to die during pregnancy. The disorder starts with a placental trigger followed by a maternal systemic response. Because both this systemic response and the woman's reaction to it are inconsistent, the clinical presentation varies in time and substance, with many different organ systems affected. With the increasing understanding of the disease process, there have been advances in management, such as antihypertensive therapy, magnesium sulphate, and fluid restriction.	St Jamess Univ Hosp, Dept Obstet & Gynaecol, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Walker, JJ (corresponding author), St Jamess Univ Hosp, Dept Obstet & Gynaecol, Leeds LS9 7TF, W Yorkshire, England.		Zhou, Xinyi/AAP-5893-2021	Walker, James/0000-0002-8922-083X				ARNGRIMSSON R, 1990, BRIT J OBSTET GYNAEC, V97, P762, DOI 10.1111/j.1471-0528.1990.tb02569.x; BENEDETTI TJ, 1985, AM J OBSTET GYNECOL, V152, P330, DOI 10.1016/S0002-9378(85)80222-2; Bosio PM, 1999, OBSTET GYNECOL, V94, P978, DOI 10.1016/S0029-7844(99)00430-5; Brown MA, 1996, MED J AUSTRALIA, V165, P360, DOI 10.5694/j.1326-5377.1996.tb125017.x; Brown MA, 1999, CLIN EXP HYPERTENS, V21, P907, DOI 10.3109/10641969909061019; Brown MA, 1998, LANCET, V352, P777, DOI 10.1016/S0140-6736(98)03270-X; BROWN MA, 1989, CLIN SCI, V77, P599, DOI 10.1042/cs0770599; Caritis S, 1998, NEW ENGL J MED, V338, P701, DOI 10.1056/NEJM199803123381101; Chan ADS, 1999, J CLIN ULTRASOUND, V27, P35, DOI 10.1002/(SICI)1097-0096(199901)27:1<35::AID-JCU6>3.0.CO;2-K; COLLINS R, 1994, ANY ANTIHYPERTENSIVE; COTTON DB, 1985, AM J OBSTET GYNECOL, V151, P762, DOI 10.1016/0002-9378(85)90515-0; CUNNINGHAM FG, 1995, AM J OBSTET GYNECOL, V172, P1291, DOI 10.1016/0002-9378(95)91495-1; *DEP HLTH, 1999, WHY MOTH DIE REP CON; DOUBILET PM, 1995, AM J ROENTGENOL, V164, P709, DOI 10.2214/ajr.164.3.7863900; Dubinsky T, 1997, AM J ROENTGENOL, V168, P827, DOI 10.2214/ajr.168.3.9057543; DULEY L, 1995, LANCET, V345, P1455; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; DULEY L, 1999, ANTICONVULSANTS PREE; Gartner HV, 1998, EUR J OBSTET GYN R B, V77, P11, DOI 10.1016/S0301-2115(97)00219-4; Hogg B, 1999, AM J OBSTET GYNECOL, V181, P1096, DOI 10.1016/S0002-9378(99)70088-8; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; Knight M, 2000, ANTIPLATELET AGENTS; Leitch CR, 1997, BRIT J OBSTET GYNAEC, V104, P917, DOI 10.1111/j.1471-0528.1997.tb14351.x; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Lie RT, 1998, BRIT MED J, V316, P1343, DOI 10.1136/bmj.316.7141.1343; Lydakis C, 1999, AM J HYPERTENS, V12, P541, DOI 10.1016/S0895-7061(99)00031-X; Macara L, 1996, PLACENTA, V17, P37, DOI 10.1016/S0143-4004(05)80642-3; MAGANN EF, 1994, J SOC GYNECOL INVEST, V1, P206, DOI 10.1177/107155769400100305; Magee LA, 1999, BMJ-BRIT MED J, V318, P1332, DOI 10.1136/bmj.318.7194.1332; Martin JN, 1999, AM J OBSTET GYNECOL, V180, P1407, DOI 10.1016/S0002-9378(99)70026-8; MEEKINS JW, 1994, BRIT J OBSTET GYNAEC, V101, P669, DOI 10.1111/j.1471-0528.1994.tb13182.x; Merrill JD, 1998, CLIN PERINATOL, V25, P983, DOI 10.1016/S0095-5108(18)30093-9; Naqvi R, 1996, RENAL FAILURE, V18, P681, DOI 10.3109/08860229609047694; Nassar AH, 1998, AM J OBSTET GYNECOL, V179, P1210, DOI 10.1016/S0002-9378(98)70133-4; Pavlakis SG, 1999, J CHILD NEUROL, V14, P277, DOI 10.1177/088307389901400502; Pijnenborg R, 1998, PLACENTA, V19, P231, DOI 10.1016/S0143-4004(98)90054-6; Pipkin FB, 1999, BIOL NEONATE, V76, P325, DOI 10.1159/000014175; PLOUIN PF, 1982, ARCH MAL COEUR VAISS, V75, P5; RAMANATHAN J, 1988, AM J OBSTET GYNECOL, V159, P650, DOI 10.1016/S0002-9378(88)80027-9; Redman CWG, 1999, AM J OBSTET GYNECOL, V180, P499, DOI 10.1016/S0002-9378(99)70239-5; ROBERTS JM, 1995, AM J OBSTET GYNECOL, V173, P978, DOI 10.1016/0002-9378(95)90393-3; Salha O, 1999, HUM REPROD, V14, P2268, DOI 10.1093/humrep/14.9.2268; Saphier CJ, 1998, SEMIN PERINATOL, V22, P118, DOI 10.1016/S0146-0005(98)80044-X; Saudan P, 1998, BRIT J OBSTET GYNAEC, V105, P1177, DOI 10.1111/j.1471-0528.1998.tb09971.x; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P1313, DOI 10.1016/S0002-9378(96)70047-9; Sharma SK, 1999, ANESTHESIOLOGY, V90, P385, DOI 10.1097/00000542-199902000-00009; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; SIBAI BM, 1983, OBSTET GYNECOL, V61, P571; SIBAI BM, 1995, AM J OBSTET GYNECOL, V172, P125, DOI 10.1016/0002-9378(95)90099-3; SIBAI BM, 1984, AM J OBSTET GYNECOL, V150, P728, DOI 10.1016/0002-9378(84)90676-8; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; SIBAI BM, 1982, OBSTET GYNECOL, V59, P153; Sibai BM, 1998, AM J OBSTET GYNECOL, V179, P1275, DOI 10.1016/S0002-9378(98)70146-2; SIBAI BM, 1993, AM J OBSTET GYNECOL, V169, P1000, DOI 10.1016/0002-9378(93)90043-I; Stratta P, 1996, RENAL FAILURE, V18, P575, DOI 10.3109/08860229609047680; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; WALKER JJ, 1991, CLIN PERINATOL, V18, P845, DOI 10.1016/S0095-5108(18)30499-8; Walker JJ, 1996, EUR J OBSTET GYN R B, V65, P127, DOI 10.1016/0028-2243(95)02318-M; WALKER JJ, 1993, BRIT J HOSP MED, V50, P225; Witlin AG, 1998, OBSTET GYNECOL, V92, P883, DOI 10.1016/S0029-7844(98)00277-4	60	483	514	1	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1260	1265		10.1016/S0140-6736(00)02800-2	http://dx.doi.org/10.1016/S0140-6736(00)02800-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072961				2022-12-28	WOS:000089724900042
J	de Goyet, CD				de Goyet, CD			Stop propagating disaster myths	LANCET			English	Editorial Material									WHO, PAHO, Emergency Preparedness & Disaster Relief Coordina, Washington, DC 20037 USA	Pan American Health Organization; World Health Organization	de Goyet, CD (corresponding author), WHO, PAHO, Emergency Preparedness & Disaster Relief Coordina, Washington, DC 20037 USA.								0	60	61	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					762	764		10.1016/S0140-6736(00)02642-8	http://dx.doi.org/10.1016/S0140-6736(00)02642-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085709				2022-12-28	WOS:000088948200041
J	Bulaj, ZJ; Ajioka, RS; Phillips, JD; LaSalle, BA; Jorde, LB; Griffen, LM; Edwards, CQ; Kushner, JP				Bulaj, ZJ; Ajioka, RS; Phillips, JD; LaSalle, BA; Jorde, LB; Griffen, LM; Edwards, CQ; Kushner, JP			Disease-related conditions in relatives of patients with hemochromatosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; EXPRESSION; GENE	Background: Hemochromatosis occurs in approximately 5 white people per 1000 and is usually due to homozygosity for mutations in the HLA-linked HFE gene. Although screening has been proposed, the proportion of homozygotes with conditions related to hemochromatosis is uncertain. Methods: We studied the prevalence of disease-related conditions among relatives of probands with hemochromatosis. We identified probands who presented to a clinic with signs or symptoms of hemochromatosis or who had elevated transferrin-saturation values. We identified homozygous relatives, mainly siblings, on the basis of HLA identity with the proband and by HFE genotyping. Disease-related conditions were cirrhosis, hepatic fibrosis, elevated aminotransferase values, and hemochromatotic arthropathy. Results: We identified 214 homozygous relatives of 291 homozygous probands. Of the 113 men in this group (mean age, 41 years), 96 (85 percent) had iron overload, and 43 (38 percent) had at least one disease-related condition. Of the 52 men over 40 years of age, 27 (52 percent) had at least one disease-related condition. Of the 101 female homozygous relatives (mean age, 44 years), 69 (68 percent) had iron overload, and 10 (10 percent) had at least one disease-related condition. Of the 43 women over 50 years of age, 7 (16 percent) had at least one disease-related condition. If the proband had a disease-related condition, relatives who were men were more likely to have morbidity than if the proband had no disease-related condition. Conclusions: A substantial number of homozygous relatives of patients with hemochromatosis - more commonly men than women - have conditions related to hemochromatosis that have yet to be detected clinically. (N Engl J Med 2000;343:1529-35.) (C) 2000, Massachusetts Medical Society.	Univ Utah, Sch Med, Dept Med, Div Hematol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Gen Clin Res Ctr, Salt Lake City, UT 84132 USA; LDS Hosp, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Kushner, JP (corresponding author), Univ Utah, Sch Med, Dept Med, Div Hematol, 4C-416,50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK020503, R01DK020503, R01DK020630] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42014] Funding Source: Medline; NIDDK NIH HHS [DK-20503, DK-20630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams PC, 2000, HEPATOLOGY, V31, P1160, DOI 10.1053/he.2000.6984; ADAMS PC, 1991, AM J MED, V90, P445; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; *BOLT BER NEWM, 1997, PROPHET; BOTHWELL TH, 1995, METABOLIC MOL BASES, V2, P2237; Bulaj ZJ, 2000, BLOOD, V95, P1565, DOI 10.1182/blood.V95.5.1565.005k42_1565_1571; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; DANIEL WW, 1999, BIOSTATISTICS FDN AN; EDWARDS CQ, 1977, NEW ENGL J MED, V297, P7, DOI 10.1056/NEJM197707072970102; EDWARDS CQ, 1982, CLIN HAEMATOL, V11, P411; EDWARDS CQ, 1981, PROG HEMATOL, V12, P43; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; EDWARDS CQ, 1999, WINTROBES CLIN HEMAT, V1, P1056; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; LEBOEUF RC, 1995, J LAB CLIN MED, V126, P128; Levy JE, 1999, BLOOD, V94, P9, DOI 10.1182/blood.V94.1.9.413a43_9_11; McDonnell SM, 1999, AM J MED, V106, P619, DOI 10.1016/S0002-9343(99)00120-5; Moirand R, 1997, ANN INTERN MED, V127, P105, DOI 10.7326/0003-4819-127-2-199707150-00002; Olynyk JK, 1999, NEW ENGL J MED, V341, P718, DOI 10.1056/NEJM199909023411002; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; Witte DL, 2000, HEMOCHROMATOSIS: GENETICS, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT, P519	24	154	157	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1529	1535		10.1056/NEJM200011233432104	http://dx.doi.org/10.1056/NEJM200011233432104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087882				2022-12-28	WOS:000165410900004
J	Jelinek, GA				Jelinek, GA			Ketorolac versus morphine for severe pain - Ketorolac is more effective, cheaper and has fewer side effects	BRITISH MEDICAL JOURNAL			English	Editorial Material									Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia	University of Western Australia	Jelinek, GA (corresponding author), Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia.							Derlet RW, 2000, ANN EMERG MED, V35, P63, DOI 10.1016/S0196-0644(00)70105-3; Erwich M., 1997, EMERGEN MED, V9, P181; Gillis JC, 1997, DRUGS, V53, P139, DOI 10.2165/00003495-199753010-00012; Jelinek G, 1995, THESIS U W AUSTR; Jelinek GA, 1999, MED J AUSTRALIA, V171, P231, DOI 10.5694/j.1326-5377.1999.tb123626.x; KROCHMAL P, 1994, AM J EMERG MED, V12, P265, DOI 10.1016/0735-6757(94)90135-X; Rainer TH, 2000, BMJ-BRIT MED J, V321, P1247, DOI 10.1136/bmj.321.7271.1247; Shih FY, 1999, AM J EMERG MED, V17, P198, DOI 10.1016/S0735-6757(99)90061-X; Strom BL, 1996, JAMA-J AM MED ASSOC, V275, P376, DOI 10.1001/jama.275.5.376; TRAMER MR, 1999, DARE980293	10	19	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1236	1237		10.1136/bmj.321.7271.1236	http://dx.doi.org/10.1136/bmj.321.7271.1236			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082068	Green Published			2022-12-28	WOS:000165445800002
J	Zerzan, J; Stearns, S; Hanson, L				Zerzan, J; Stearns, S; Hanson, L			Access to palliative care and hospice in nursing homes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENT ASSESSMENT INSTRUMENT; OF-LIFE CARE; ALZHEIMERS-DISEASE; PAIN; QUALITY; MANAGEMENT; SURVIVAL; CRITERIA; DEMENTIA; PATIENT	Nursing homes are the site of death for many elderly patients with incurable chronic illness, yet dying nursing home residents have limited access to palliative care and hospice. The probability that a nursing home will be the site of death increased from 18.7% in 1986 to 20.0% by 1993. Dying residents experience high rates of untreated pain and other symptoms. They and their family members are isolated from social and spiritual support. Hospice improves end-of-life care for dying nursing home residents by improving pain control, reducing hospitalization, and reducing use of tube feeding, but it is rarely used. For example, in 1997 only 13% of hospice enrollees were in nursing homes while 87% were in private homes, and 70% of nursing homes had no hospice patients. Hospice use varies by region, and rates of use are associated with nursing home administrators' attitudes toward hospice and contractual obligations. Current health policy discourages use of palliative care and hospice for dying nursing home residents. Quality standards and reimbursement rules provide incentives for restorative care and technologically intensive treatments rather than labor-intensive palliative care, Reimbursement incentives, contractual requirements, and concerns about health care fraud also limit its use. Changes in health policy, quality standards, and reimbursement incentives are essential to improve access to palliative care and hospice for dying nursing home residents.	Univ N Carolina, Div Gen Med, Dept Hlth Policy & Adm, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ N Carolina, Ctr Hlth Eth & Policy, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; Oregon Health & Science University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Hanson, L (corresponding author), Univ N Carolina, Div Gen Med, Dept Hlth Policy & Adm, Sch Publ Hlth, CB 7110,5035 Old Clin Bldg, Chapel Hill, NC 27599 USA.			Hanson, Laura/0000-0001-5120-6058				Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; BRODER M, 1996, MED ETHICS POLICIES; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; COLLOPY B, 1991, HASTINGS CENT REP  S, V21, P1; DEGNER LF, 1991, CANCER NURS, V14, P246, DOI 10.1097/00002820-199114050-00004; FERRELL BA, 1995, ANN INTERN MED, V123, P681, DOI 10.7326/0003-4819-123-9-199511010-00007; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Fries BE, 1997, J AM GERIATR SOC, V45, P994, DOI 10.1111/j.1532-5415.1997.tb02972.x; Hanson L. C., 1999, JGIM, V14, P101; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; HAUPT BJ, 1998, ADV DATA, V299, P1; Hayley DC, 1996, ARCH INTERN MED, V156, P249, DOI 10.1001/archinte.156.3.249; *HLTH CAR FIN ADM, 1997, MED PROGR MAN STAT M; HOLTZMAN J, 1994, J AM GERIATR SOC, V42, P275, DOI 10.1111/j.1532-5415.1994.tb01751.x; Institute of Medicine, 1986, IMPR QUAL CAR NURS H; Jones B, 1997, Hosp J, V12, P41; KEAY TJ, 1994, J AM GERIATR SOC, V42, P853, DOI 10.1111/j.1532-5415.1994.tb06557.x; Keay TJ, 1998, AM FAM PHYSICIAN, V57, P491; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KIDDER D, 1992, HEALTH SERV RES, V27, P195; LELAND J, 1996, NURSE HOME EC, V3, P8; LINN MW, 1989, INT J AGING HUM DEV, V28, P305, DOI 10.2190/JA0E-9T0Y-H2K8-QBV6; Luchins DJ, 1997, J AM GERIATR SOC, V45, P1054, DOI 10.1111/j.1532-5415.1997.tb05966.x; McMillan A, 1990, Health Care Financ Rev, V12, P1; Miller S C, 1998, J Palliat Med, V1, P367, DOI 10.1089/jpm.1998.1.367; Miller SC, 2000, OUTCOMES UTILIZATION; Mor V, 1997, J AM GERIATR SOC, V45, P1002, DOI 10.1111/j.1532-5415.1997.tb02973.x; Murphy K, 1997, J AM GERIATR SOC, V45, P1104, DOI 10.1111/j.1532-5415.1997.tb05974.x; *N CAR DIV FAC SER, 1997, ANN HOSP LIC DAT S 1; *NAT HOSP ORG, 1999, HOSP FACT SHEET; *NAT HOSP ORG MED, 1996, MED GUID DET PROGN S; OBRIEN LA, 1995, JAMA-J AM MED ASSOC, V274, P1775, DOI 10.1001/jama.274.22.1775; Petrisek AC, 1999, GERONTOLOGIST, V39, P279, DOI 10.1093/geront/39.3.279; Phillips CD, 1997, J AM GERIATR SOC, V45, P986, DOI 10.1111/j.1532-5415.1997.tb02971.x; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SENGSTAKEN EA, 1993, J AM GERIATR SOC, V41, P541, DOI 10.1111/j.1532-5415.1993.tb01892.x; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; *US DEP HHS OFF IN, 1993, OEI129200550 US DEP; *US DEP HHS OFF IN, 1997, OEI059500250 US DEP; *US DEP HHS OFF IN, 1997, OEI059500251 US DEP; *US GEN ACC OFF, 1996, GAOHEHS96145; Vladeck BC, 1996, JAMA-J AM MED ASSOC, V275, P425; VOLICER L, 1994, J AM GERIATR SOC, V42, P597, DOI 10.1111/j.1532-5415.1994.tb06856.x; von Gunten C F, 1996, Oncology (Williston Park), V10, P1070; Watt C K, 1997, Am J Hosp Palliat Care, V14, P63, DOI 10.1177/104990919701400204; Watt K, 1996, Am J Hosp Palliat Care, V13, P47, DOI 10.1177/104990919601300616; WEINER J, 1994, JAMA-J AM MED ASSOC, V271, P1525, DOI 10.1001/jama.271.19.1525; WEISSMAN DE, 1995, J PAIN SYMPTOM MANAG, V10, P292, DOI 10.1016/0885-3924(95)00006-K; Wilson SA, 1996, GERIATR NURS, V17, P6, DOI 10.1016/S0197-4572(96)80004-8; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x; WON A, 1999, ANN LONG TERM CARE, V7, P92; 1987, FED REG, V56, P48865	54	110	109	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2489	2494		10.1001/jama.284.19.2489	http://dx.doi.org/10.1001/jama.284.19.2489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074779				2022-12-28	WOS:000165183800023
J	Trevathan, E				Trevathan, E			Epilepsy syndrome-specific anti-epileptic drug therapy for children	LANCET			English	Editorial Material							LENNOX-GASTAUT-SYNDROME; INFANTILE SPASMS; RANDOMIZED TRIAL; SEIZURES		Washington Univ, St Louis Childrens Hosp, Sch Med, Paediat Epilepsy Ctr,Dept Neurol, St Louis, MO 63110 USA; Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Paediat, St Louis, MO 63110 USA	St. Louis Children's Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Trevathan, E (corresponding author), Washington Univ, St Louis Childrens Hosp, Sch Med, Paediat Epilepsy Ctr,Dept Neurol, St Louis, MO 63110 USA.			Trevathan, Edwin/0000-0003-2370-5970				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Baram TZ, 1996, PEDIATRICS, V97, P375; Cereghino JJ, 2000, NEUROLOGY, V55, P236, DOI 10.1212/WNL.55.2.236; Chiron C, 1997, EPILEPSY RES, V26, P389, DOI 10.1016/S0920-1211(96)01006-6; *FDA, 1998, FED REGISTER, V63, P66631; *FELB STUD GROUP L, 1993, NEW ENGL J MED, V7, P29; Frank LM, 1999, EPILEPSIA, V40, P973, DOI 10.1111/j.1528-1157.1999.tb00805.x; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; Motte J, 1997, NEW ENGL J MED, V337, P1807, DOI 10.1056/NEJM199712183372504; Sachdeo RC, 1999, NEUROLOGY, V52, P1882, DOI 10.1212/WNL.52.9.1882	10	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1623	1624		10.1016/S0140-6736(00)03151-2	http://dx.doi.org/10.1016/S0140-6736(00)03151-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089816				2022-12-28	WOS:000165249200005
J	Moret, Y; Schmid-Hempel, P				Moret, Y; Schmid-Hempel, P			Survival for immunity: The price of immune system activation for bumblebee workers	SCIENCE			English	Article							TRADE-OFFS; LIPOPOLYSACCHARIDE; RESISTANCE; HEMOLYMPH; POPULATIONS; PARASITISM; DROSOPHILA; INSECTS; COSTS; BEE	Parasites do not always harm their hosts because the immune system keeps an infection at bay. Ironically, the cost of using immune defenses could itself reduce host' fitness. This indirect cost of parasitism is often not visible because of compensatory resource intake. Here, workers of the bumblebee, Bombus terrestris, were challenged with Lipopolysaccharides and micro-latex beads to induce their immune system under starvation (i.e., not allowing compensatory intake). Compared with controls, survival of induced workers was significantly reduced (by 50 to 70%).	ETH Zurich, ETH Zentrum, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Moret, Y (corresponding author), ETH Zurich, ETH Zentrum, NW, CH-8092 Zurich, Switzerland.		Moret, Yannick/I-9282-2012					ASHIDA M, 1982, P 3 INT C INV PATH B, P81; AZUMI K, 1991, DEV COMP IMMUNOL, V15, P9, DOI 10.1016/0145-305X(91)90042-W; BOOTS M, 1993, FUNCT ECOL, V7, P528, DOI 10.2307/2390128; CARTAR RV, 1991, CAN ENTOMOL, V123, P283, DOI 10.4039/Ent123283-2; CASTEELSJOSSON K, 1994, J BIOL CHEM, V269, P28569; Demas GE, 1997, AM J PHYSIOL-REG I, V273, pR1631, DOI 10.1152/ajpregu.1997.273.5.R1631; Heinrich B., 1979, BUMBLEBEE EC; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; JOMORI T, 1990, EUR J BIOCHEM, V190, P201, DOI 10.1111/j.1432-1033.1990.tb15565.x; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P539, DOI 10.1016/0965-1748(94)90089-2; KATO Y, 1994, INSECT BIOCHEM MOLEC, V24, P547, DOI 10.1016/0965-1748(94)90090-6; KONIG C, 1995, P ROY SOC B-BIOL SCI, V260, P225, DOI 10.1098/rspb.1995.0084; Kraaijeveld AR, 1997, NATURE, V389, P278, DOI 10.1038/38483; LENSKI RE, 1988, EVOLUTION, V42, P425, DOI 10.1111/j.1558-5646.1988.tb04149.x; Nordling D, 1998, P ROY SOC B-BIOL SCI, V265, P1291, DOI 10.1098/rspb.1998.0432; RATTCLIFE NA, 1979, INSECT  HEMOCYTES, P331; RATTCLIFE NA, 1985, INT REV CYTOL, V97, P183; Rees JA, 1997, INSECT BIOCHEM MOLEC, V27, P413, DOI 10.1016/S0965-1748(97)00013-1; Schmid-Hempel P, 1998, MONOGRAPHS BEHAV ECO; SCHMIDHEMPEL P, 1990, INSECT SOC, V37, P14, DOI 10.1007/BF02223812; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; SHYKOFF JA, 1991, APIDOLOGIE, V22, P117, DOI 10.1051/apido:19910204; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0; Yan G, 1997, EVOLUTION, V51, P441, DOI [10.2307/2411116, 10.1111/j.1558-5646.1997.tb02431.x]	25	810	826	2	266	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1166	1168		10.1126/science.290.5494.1166	http://dx.doi.org/10.1126/science.290.5494.1166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073456				2022-12-28	WOS:000165228200049
J	Covington, WW				Covington, WW			Helping western forests heal - The prognosis is poor for US forest ecosystems	NATURE			English	Editorial Material									No Arizona Univ, Ecol Restorat Inst, Flagstaff, AZ 86011 USA	Northern Arizona University	Covington, WW (corresponding author), No Arizona Univ, Ecol Restorat Inst, POB 15018, Flagstaff, AZ 86011 USA.							2000, NATURE, V407, P5	1	109	110	0	19	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					135	136						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089949				2022-12-28	WOS:000165180400017
J	Hanfland, M; Syassen, K; Christensen, NE; Novikov, DL				Hanfland, M; Syassen, K; Christensen, NE; Novikov, DL			New high-pressure phases of lithium	NATURE			English	Article							X-RAY-DIFFRACTION; CRYSTAL-STRUCTURE; TRANSITIONS; COMPRESSION; EQUATION; RUBIDIUM; CESIUM; STATE; GPA	Lithium is considered a 'simple' metal because, under ordinary conditions of pressure and temperature, the motion of conduction electrons is only weakly perturbed by interactions with the cubic lattice of atomic cores. It was recently predicted(1) that at pressures below 100 GPa, dense Li may undergo several structural transitions, possibly leading to a 'paired-atom' phase with low symmetry and near-insulating properties. Here we report synchrotron X-ray diffraction measurements that confirm that Li undergoes pronounced structural changes under pressure. Near 39 GPa, the element transforms from a high-pressure face-centred-cubic phase, through an intermediate rhombohedral modification, to a cubic polymorph with 16 atoms per unit cell. This cubic phase has not been observed previously in any element; unusually, its calculated electronic density of states exhibits a pronounced semimetal-like minimum near the Fermi energy. We present total-energy calculations that provide theoretical support for the observed phase transition sequence. Our calculations indicate a large stability range of the 16-atom cubic phase relative to various other crystal structures tested here.	Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus C, Denmark; Arthur D Little Inc, Cambridge, MA 02140 USA	Max Planck Society; European Synchrotron Radiation Facility (ESRF); Aarhus University	Syassen, K (corresponding author), Max Planck Inst Festkorperforsch, Heisenbergstr 1, D-70569 Stuttgart, Germany.	syassen@servix.mpi-stuttgard.mpg.de						ANDERSEN OK, 1975, PHYS REV B, V12, P3060, DOI 10.1103/PhysRevB.12.3060; BOETTGER JC, 1985, PHYS REV B, V32, P3391, DOI 10.1103/PhysRevB.32.3391; Fortov VE, 1999, JETP LETT+, V70, P628, DOI 10.1134/1.568226; Hanfland M, 1999, SOLID STATE COMMUN, V112, P123, DOI 10.1016/S0038-1098(99)00322-1; LIN TH, 1986, PHYS REV B, V33, P807, DOI 10.1103/PhysRevB.33.807; Martin RM, 1999, NATURE, V400, P117, DOI 10.1038/22009; MCMAHAN AK, 1984, PHYS REV B, V29, P5982, DOI 10.1103/PhysRevB.29.5982; METHFESSEL M, 1988, PHYS REV B, V38, P1537, DOI 10.1103/PhysRevB.38.1537; MORI Y, 2000, SCI TECHNOLOGY HIGH; Neaton JB, 1999, NATURE, V400, P141, DOI 10.1038/22067; Nelmes RJ, 1998, SEMICONDUCT SEMIMET, V54, P145, DOI 10.1016/S0080-8784(08)60231-8; O'Keefe M., 1996, CRYSTAL STRUCTURE I; OLIJNYK H, 1983, PHYS LETT A, V99, P381, DOI 10.1016/0375-9601(83)90298-0; OLINGER B, 1983, SCIENCE, V219, P1071, DOI 10.1126/science.219.4588.1071; OVERHAUSER AW, 1984, PHYS REV LETT, V53, P64, DOI 10.1103/PhysRevLett.53.64; OVERHAUSER AW, 1968, PHYS REV, V167, P691, DOI 10.1103/PhysRev.167.691; Pearson W. B., 1967, HDB LATTICE SPACINGS, V2; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Schwarz U, 1999, PHYS REV LETT, V83, P4085, DOI 10.1103/PhysRevLett.83.4085; Schwarz U, 1998, PHYS REV LETT, V81, P2711, DOI 10.1103/PhysRevLett.81.2711; Singh D.J., 2006, PLANEWAVES PSEUDOPOT, Vsecond; SMITH HG, 1990, PHYS REV B, V41, P1231, DOI 10.1103/PhysRevB.41.1231; STERNHEIMER R, 1950, PHYS REV, V78, P235, DOI 10.1103/PhysRev.78.235; STRUZHKIN VV, 1999, B AM PHYS SOC, V44, P1489; TAKEMURA K, 1982, PHYS REV LETT, V49, P1772, DOI 10.1103/PhysRevLett.49.1772; VAKS VG, 1989, J PHYS-CONDENS MAT, V1, P5319, DOI 10.1088/0953-8984/1/32/001; VONSCHNERING HG, 1987, ANGEW CHEM INT EDIT, V26, P1059, DOI 10.1002/anie.198710593; Wells A.F., 1984, STRUCTURAL INORGANIC; WINZENICK M, 1994, PHYS REV B, V50, P12381, DOI 10.1103/PhysRevB.50.12381	29	320	326	7	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					174	178		10.1038/35041515	http://dx.doi.org/10.1038/35041515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089965				2022-12-28	WOS:000165180400037
J	Merke, DP; Chrousos, GP; Eisenhofer, G; Weise, M; Keil, MF; Rogol, AD; Van Wyk, JJ; Bornstein, SR				Merke, DP; Chrousos, GP; Eisenhofer, G; Weise, M; Keil, MF; Rogol, AD; Van Wyk, JJ; Bornstein, SR			Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL ADRENAL-HYPERPLASIA; LIQUID-CHROMATOGRAPHY; CATECHOLAMINES; PLASMA; METANEPHRINES; METABOLISM; DISEASE; STRESS	Background: Glucocorticoids are essential for the normal development and functioning of the adrenal medulla. Whether adrenomedullary structure and function are normal in patients with congenital adrenal hyperplasia is not known. Methods: We measured plasma and urinary catecholamines and plasma metanephrines in 38 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (25 children with the salt-wasting form and 13 with the simple virilizing form), 39 age-matched normal subjects, and 20 patients who had undergone bilateral adrenalectomy. Adrenal specimens obtained from three other patients with 21-hydroxylase deficiency who had undergone bilateral adrenalectomy and specimens obtained at autopsy from eight other patients were examined histologically. Results: Plasma epinephrine and metanephrine concentrations and urinary epinephrine excretion were 40 to 80 percent lower in the patients with congenital adrenal hyperplasia than in the normal subjects (P<0.05), and the values were lowest in the patients with the most severe deficits in cortisol production. Urinary epinephrine excretion and plasma epinephrine concentrations were at or below the limit of detection of the assay in 8 (21 percent) of the patients with congenital adrenal hyperplasia and in 19 (95 percent) of the patients who had undergone adrenalectomy. In the group of patients with congenital adrenal hyperplasia, plasma epinephrine and metanephrine concentrations and urinary epinephrine excretion were approximately 50 percent lower in those who had been hospitalized for adrenal crises than in those who had not. In three patients with congenital adrenal hyperplasia who had undergone bilateral adrenalectomy, the formation of the adrenal medulla was incomplete, and electron-microscopical studies revealed a depletion of secretory vesicles in chromaffin cells. Conclusions: Congenital adrenal hyperplasia compromises both the development and the functioning of the adrenomedullary system. (N Engl J Med 2000;343:1362-8.) (C) 2000, Massachusetts Medical Society.	NIH, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; NICHHD, Pediat & Reprod Endocrinol Branch, Bethesda, MD 20892 USA; NINDS, Clin Neurocardiol Sect, Bethesda, MD 20892 USA; Univ Virginia Hlth Syst, Charlottesville, VA USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Virginia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Merke, DP (corresponding author), NIH, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 13S260,10 Ctr Dr,MSC 1932, Bethesda, MD 20892 USA.		Eisenhofer, Graeme/AAU-9829-2021; Rogol, A.D./H-5871-2019	Eisenhofer, Graeme/0000-0002-8601-9903; Rogol, A.D./0000-0002-7526-3142	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; Bornstein SR, 1999, FASEB J, V13, P1185, DOI 10.1096/fasebj.13.10.1185; BORNSTEIN SR, 1995, CLIN ENDOCRINOL, V42, P215, DOI 10.1111/j.1365-2265.1995.tb01866.x; Bornstein SR, 1999, J CLIN ENDOCR METAB, V84, P1729; BORNSTEIN SR, 1994, J CLIN ENDOCR METAB, V78, P225, DOI 10.1210/jcem.78.1.7507122; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P301; EhrhartBornstein M, 1997, HORM METAB RES, V29, P30, DOI 10.1055/s-2007-978976; EHRHARTBORNSTEIN M, 1995, ENDOCR RES, V21, P13, DOI 10.3109/07435809509030417; EISENHOFER G, 1995, CLIN SCI, V88, P533, DOI 10.1042/cs0880533; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Gunther DF, 1997, J CLIN ENDOCR METAB, V82, P3324, DOI 10.1210/jc.82.10.3324; HINDE FRJ, 1984, BRIT MED J, V289, P1603, DOI 10.1136/bmj.289.6458.1603; LENDERS JWM, 1993, CLIN CHEM, V39, P97; Ludwig J., 1979, CURRENT METHODS AUTO; Merke DP, 1997, JAMA-J AM MED ASSOC, V277, P1073, DOI 10.1001/jama.277.13.1073; Merke DP, 1999, NEW ENGL J MED, V340, P1121, DOI 10.1056/NEJM199904083401416; MOYER TP, 1979, CLIN CHEM, V25, P256; New MI, 1998, ANNU REV MED, V49, P311, DOI 10.1146/annurev.med.49.1.311; Swerdlow AJ, 1998, J PEDIATR-US, V133, P516, DOI 10.1016/S0022-3476(98)70060-5; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; Wells SA, 1998, J CLIN ENDOCR METAB, V83, P3041, DOI 10.1210/jc.83.9.3041; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; WORTSMAN J, 1984, AM J MED, V77, P779, DOI 10.1016/0002-9343(84)90512-6; Wurtman R J, 1971, Adv Metab Disord, V5, P53; WURTMAN RJ, 1966, ENDOCRINOLOGY, V79, P608, DOI 10.1210/endo-79-3-608	26	158	164	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1362	1368		10.1056/NEJM200011093431903	http://dx.doi.org/10.1056/NEJM200011093431903			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070100				2022-12-28	WOS:000165152800003
J	Delclaux, C; L'Her, E; Alberti, C; Mancebo, J; Abroug, F; Conti, G; Guerin, C; Schortgen, F; Lefort, Y; Antonelli, M; Lepage, E; Lemaire, F; Brochard, L				Delclaux, C; L'Her, E; Alberti, C; Mancebo, J; Abroug, F; Conti, G; Guerin, C; Schortgen, F; Lefort, Y; Antonelli, M; Lepage, E; Lemaire, F; Brochard, L			Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOGENIC PULMONARY-EDEMA; PNEUMOCYSTIS-CARINII PNEUMONIA; MECHANICAL VENTILATION; DISTRESS SYNDROME; NONINVASIVE VENTILATION; FAILURE; THERAPY; CPAP; SUPPORT	Context Continuous positive airway pressure (CPAP) is widely used in the belief that it may reduce the need for intubation and mechanical ventilation in patients with acute hypoxemic respiratory insufficiency. Objective To compare the physiologic effects and the clinical efficacy of CPAP vs standard oxygen therapy in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency. Design, Setting, and Patients Randomized, concealed, and unblinded trial of 123 consecutive adult patients who were admitted to 6 intensive care units between September 1997 and January 1999 with a PaO2/FIO2 ratio of 300 mm Hg or less due to bilateral pulmonary edema (n=102 with acute lung injury and n=21 with cardiac disease). Interventions Patients were randomly assigned to receive oxygen therapy alone (n=61) or oxygen therapy plus CPAP (n=62). Main Outcome Measures Improvement in PaO2/FIO2 ratio, rate of endotracheal intubation at any time during the study, adverse events, length of hospital stay, mortality, and duration of ventilatory assistance, compared between the CPAP and standard treatment groups. Results Among the CPAP vs standard therapy groups, respectively, causes of respiratory failure (pneumonia, 54% and 55%), presence of cardiac disease (33% and 35%), severity at admission, and hypoxemia (median [5th-95th percentile] PaO2/FIO2 ratio, 140 [59-288] mm Hg vs 148 [62-283] mm Hg; P=.43) were similarly distributed. After 1 hour of treatment, subjective responses to treatment (P<.001) and median (5th-95th percentile) PaO2/FIO2 ratios were greater with CPAP (203 [45-431] mm Hg vs 151 [73-482] mm Hg; P=.02), No further difference in respiratory indices was observed between the groups. Treatment with CPAP failed to reduce the endotracheal intubation rate (21 [34%] vs 24 [39%] in the standard therapy group; P=.53), hospital mortality (19 [31%] vs 18 [30%]; P=.89), or median (5th-95th percentile) intensive care unit length of stay (6.5 [1-57] days vs 6.0 [1-36] days; P=.43), A higher number of adverse events occurred with CPAP treatment (18 vs 6; P=.01), Conclusion In this study, despite early physiologic improvement, CPAP neither reduced the need for intubation nor improved outcomes in patients with acute hypoxemic, nonhypercapnic respiratory insufficiency primarily due to acute lung injury.	Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, Med Intens Care Unit, F-94010 Creteil, France; Univ Paris, INSERM, U492, Creteil, France; Cavalle Blanche Hosp, Med Intens Care Unit, Brest, France; St Pau Hosp, Intens Care Unit, Barcelona, Spain; La Sapienza Univ Hosp, Intens Care Unit, Rome, Italy; Croix Rousse Hosp, Med Intens Care Unit, Lyon, France; St Louis Hosp, Dept Biostat, Paris, France; Henri Mondor Hosp, Dept Biostat, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Brest; Sapienza University Rome; University Hospital Sapienza Rome; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Brochard, L (corresponding author), Assistance Publ Hop Paris, Hop Henri Mondor, Serv Reanimat Med, Med Intens Care Unit, F-94010 Creteil, France.		Antonelli, Massimo/K-9915-2016; Antonelli, Massimo/F-9848-2010; guerin, claude/H-5692-2014; Abroug, Fekri/ABI-6564-2022; Abroug, Fekri/ADJ-0934-2022	Antonelli, Massimo/0000-0003-3007-1670; guerin, claude/0000-0003-4700-6672; Abroug, Fekri/0000-0002-5626-5329; Schortgen, Frederique/0000-0003-1756-7508				Antonelli M, 1998, NEW ENGL J MED, V339, P429, DOI 10.1056/NEJM199808133390703; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; BRANSON RD, 1995, RESP CARE EQUIPMENT, P470; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; CARLSSON C, 1981, INTENS CARE MED, V7, P225, DOI 10.1007/BF01702624; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; GACHOT B, 1992, INTENS CARE MED, V18, P155, DOI 10.1007/BF01709239; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GREGG RW, 1990, CRIT CARE MED, V18, P21, DOI 10.1097/00003246-199001000-00006; GREGORY GA, 1971, NEW ENGL J MED, V284, P1333, DOI 10.1056/NEJM197106172842401; Guerin C, 1997, INTENS CARE MED, V23, P1024, DOI 10.1007/s001340050452; HURST JM, 1985, J TRAUMA, V25, P1065; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; Keenan SP, 1997, CRIT CARE MED, V25, P1685, DOI 10.1097/00003246-199710000-00018; Kelly AM, 1997, AUST NZ J MED, V27, P319, DOI 10.1111/j.1445-5994.1997.tb01985.x; L'HerE, 1998, Eur J Emerg Med, V5, P313; LeGall JR, 1996, JAMA-J AM MED ASSOC, V276, P802, DOI 10.1001/jama.276.10.802; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; ROUBY JJ, 1992, INTENS CARE MED, V18, P69, DOI 10.1007/BF01705035; Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983; URETZKY G, 1980, CRIT CARE MED, V8, P486, DOI 10.1097/00003246-198009000-00002; VENUS B, 1979, CHEST, V76, P257, DOI 10.1378/chest.76.3.257; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761	29	307	321	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2352	2360		10.1001/jama.284.18.2352	http://dx.doi.org/10.1001/jama.284.18.2352			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066186	Bronze			2022-12-28	WOS:000165074500030
J	Felson, DT; Lawrence, RC; Hochberg, MC; McAlindon, T; Dieppe, PA; Minor, MA; Blair, SN; Berman, BM; Fries, JF; Weinberger, M; Lorig, KR; Jacobs, JJ; Goldberg, V				Felson, DT; Lawrence, RC; Hochberg, MC; McAlindon, T; Dieppe, PA; Minor, MA; Blair, SN; Berman, BM; Fries, JF; Weinberger, M; Lorig, KR; Jacobs, JJ; Goldberg, V			Osteoarthritis: New insights - Part 2: Treatment approaches	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SERIOUS GASTROINTESTINAL COMPLICATIONS; RANDOMIZED CONTROLLED TRIAL; TOTAL HIP-ARTHROPLASTY; HEALTH-CARE COSTS; RHEUMATOID-ARTHRITIS; KNEE OSTEOARTHRITIS; ARTICULAR-CARTILAGE; PEPTIC-ULCER; DOUBLE-BLIND	Osteoarthritis is the most common form of arthritis, affecting millions of people in the United States. It is a complex disease whose etiology bridges biomechanics and biochemistry. Evidence is growing for the role of systemic factors, such as genetics, diet, estrogen use, and bone density, and local biomechanical factors, such as muscle weakness, obesity, and joint laxity. These risk factors are particularly important in the weight-bearing joints, and modifying them may help prevent osteoarthritis-related pain and disability. Major advances in management to reduce pain and disability are yielding a panoply of available treatments ranging from nutriceuticals to chondrocyte transplantation, new oral antiinflammatory medications, and health education. This article is part 2 of a two-part summary of a National Institutes of Health conference that brought together experts in osteoarthritis from diverse backgrounds and provided a multidisciplinary and comprehensive summary of recent advances in the prevention of osteoarthritis onset, progression, and disability. Part 2 focuses on treatment approaches; evidence for the efficacy of commonly used oral therapies is reviewed and information on alternative therapies, including nutriceuticals and acupuncture, is presented. Biomechanical interventions, such as exercise and bracing, and behavioral interventions directed toward enhancing self-management are reviewed. Current surgical approaches are described and probable future biotechnology-oriented approaches to treatment are suggested.	NIAMSD, NIH, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Bristol, MRC Hlth Serv Res Collaborat, Bristol, Avon, England; Univ Missouri, Columbia, MO USA; Cooper Inst Aerob Res, Dallas, TX USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Indiana Univ, Indianapolis, IN 46204 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Boston University; University System of Maryland; University of Maryland Baltimore; University of Bristol; University of Missouri System; University of Missouri Columbia; Cooper Institute; Stanford University; Indiana University System; Indiana University-Purdue University Indianapolis; Rush University; Case Western Reserve University	Lawrence, RC (corresponding author), NIAMSD, NIH, Bldg 45 Room 5AS-37G, Bethesda, MD 20892 USA.		Fries, James F/F-6271-2011; Jacobs, Joshua/AGG-8284-2022	Felson, David/0000-0002-2668-2447				[Anonymous], 1996, JAMA, V276, P241; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BAICI A, 1980, BIOCHEM PHARMACOL, V29, P1723, DOI 10.1016/0006-2952(80)90131-8; BAICI A, 1984, CHEM-BIOL INTERACT, V51, P1, DOI 10.1016/0009-2797(84)90015-2; Bassleer C, 1998, OSTEOARTHR CARTILAGE, V6, P427, DOI 10.1053/joca.1998.0146; BERMAN BM, 1995, OSTEOARTHR CARTILAGE, V3, P139, DOI 10.1016/S1063-4584(05)80046-9; Berman BM, 1999, RHEUMATOLOGY, V38, P346, DOI 10.1093/rheumatology/38.4.346; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; BUCKWALTER JA, 1998, AM ACAD ORTHOPAEDIC, P487; Cannon G, 1998, ARTHRITIS RHEUM, V41, pS196; CAPLAN AI, 1997, CLIN ORTHOP RELAT R, V342, P254; Chang RW, 1996, JAMA-J AM MED ASSOC, V275, P858, DOI 10.1001/jama.275.11.858; CHRISTENSEN BV, 1992, ACTA ANAESTH SCAND, V36, P519, DOI 10.1111/j.1399-6576.1992.tb03511.x; Chu CR, 1999, CLIN ORTHOP RELAT R, P159; CLEMENTJONES V, 1980, LANCET, V2, P946; Cronan TA, 1997, ARTHRIT CARE RES, V10, P99, DOI 10.1002/art.1790100205; CUSHNAGHAN J, 1994, BRIT MED J, V308, P753, DOI 10.1136/bmj.308.6931.753; CZITROM AA, 1990, J BONE JOINT SURG AM, V72A, P574, DOI 10.2106/00004623-199072040-00016; Dalgin Paul, 1997, Arthritis and Rheumatism, V40, pS86; DEAL CL, 1991, CLIN THER, V13, P383; DEANDRADE JR, 1965, J BONE JOINT SURG AM, VA 47, P313, DOI 10.2106/00004623-196547020-00008; DEGENNARO F, 1992, LITER RHUMATOLOGICA, V14, P53; Dickens W, 1989, COMPLEMENT MED RES, V3, P5, DOI DOI 10.1186/AR3254; Eccles M, 1998, BRIT MED J, V317, P526; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ekstrom P, 1996, SCAND J GASTROENTERO, V31, P753, DOI 10.3109/00365529609010347; Ernst E, 1997, SCAND J RHEUMATOL, V26, P444, DOI 10.3109/03009749709065717; ETTINGER WH, 1994, MED SCI SPORT EXER, V26, P1435; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; EZZO J, IN PRESS SCI BASIS A; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Font-Rodriguez DE, 1997, CLIN ORTHOP RELAT R, P79; Fries JF, 1997, J RHEUMATOL, V24, P1378; FURST DE, 1994, ARTHRITIS RHEUM-US, V37, P1, DOI 10.1002/art.1780370102; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GARELLA S, 1984, MEDICINE, V63, P165, DOI 10.1097/00005792-198405000-00003; GARRETT JC, 1994, CLIN ORTHOP RELAT R, V303, P33; GAW AC, 1975, NEW ENGL J MED, V293, P375, DOI 10.1056/NEJM197508212930803; GHIA JN, 1976, PAIN, V2, P285, DOI 10.1016/0304-3959(76)90006-3; GOLDBERG V, 1999, AM AC ORTH SURG INST, P48; GOLDBERG VM, 1995, OSTEOARTHRITIC DISOR, P357; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GROSS AE, 1992, BIOLOGY AND BIOMECHANICS OF TRAUMATIZED SYNOVIAL JOINT : THE KNEE AS A MODEL, P123; HAN J, 1997, NIH CONS DEV C AC PR, P55; Hangody L, 1998, ORTHOPEDICS, V21, P751, DOI 10.3928/0147-7447-19980701-04; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Henrich WL, 1996, AM J KIDNEY DIS, V27, P162, DOI 10.1016/S0272-6386(96)90046-3; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; HOLZER SS, 1996, AM J MANAG CARE S, V2, pS15; HORLICK SG, 1993, CLIN J SPORT MED, V3, P251, DOI DOI 10.1097/00042752-199310000-00006; Hubbard R, 1998, ARTHRITIS RHEUM, V41, pS196; Hunter W., 1743, SURGEON, V42, P514, DOI [10.1098/rstl.1742.0079, DOI 10.1098/RSTL.1742.0079)]; Hurley MV, 1998, BRIT J RHEUMATOL, V37, P1181; Hylek EM, 1998, JAMA-J AM MED ASSOC, V279, P657, DOI 10.1001/jama.279.9.657; Jacobs, 1994, J Am Acad Orthop Surg, V2, P212; Jacobs JJ, 1998, J BONE JOINT SURG AM, V80A, P268, DOI 10.2106/00004623-199802000-00015; JUNNILA SYT, 1982, AM J ACUPUNCTURE, V10, P341; Keating E M, 1993, Orthop Rev, V22, P921; Keefe FJ, 1996, ARTHRIT CARE RES, V9, P279, DOI 10.1002/1529-0131(199608)9:4<279::AID-ANR1790090413>3.0.CO;2-6; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; LAUPACIS A, 1994, J ARTHROPLASTY, V9, P481, DOI 10.1016/0883-5403(94)90093-0; Lavernia CJ, 1997, CLIN ORTHOP RELAT R, P134; LEWITH GT, 1984, SOC SCI MED, V19, P1367, DOI 10.1016/0277-9536(84)90026-1; LORIG K, 1985, ARTHRITIS RHEUM, V28, P680, DOI 10.1002/art.1780280612; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; LUNDEBERG T, 1991, Pain Clinic, V4, P155; Maisiak R, 1996, ARTHRITIS RHEUM-US, V39, P1391, DOI 10.1002/art.1780390818; MALCHAU H, 1998, 65 ANN M AM AC ORTH; MAROSSY K, 1981, BIOCHIM BIOPHYS ACTA, V659, P351, DOI 10.1016/0005-2744(81)90061-9; Mazzeo RS, 1998, MED SCI SPORT EXER, V30, P992, DOI 10.1097/00005768-199806000-00033; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Millis MB, 1996, AAOS INSTR COURS LEC, V45, P209; MINOR M A, 1991, Annals of Behavioral Medicine, V13, P117; MINOR MA, 1989, ARTHRITIS RHEUM, V32, P1396, DOI 10.1002/anr.1780321108; Molsberger A, 1994, Schmerz, V8, P37, DOI 10.1007/BF02527508; MURRAY DG, 1995, JAMA-J AM MED ASSOC, V273, P1950, DOI 10.1001/jama.1995.03520480070043; NAPPI G, 1982, ACUPUNCTURE ELECTRO, V7, P93, DOI 10.3727/036012982816952125; O'Reilly SC, 1999, ANN RHEUM DIS, V58, P15, DOI 10.1136/ard.58.1.15; OUTERBRIDGE HK, 1995, J BONE JOINT SURG AM, V77A, P65, DOI 10.2106/00004623-199501000-00009; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERLAU R, 1995, AM J SPORT MED, V23, P251, DOI 10.1177/036354659502300221; Pollo F E, 1998, Am J Knee Surg, V11, P47; Pollo FE, 1998, IEEE ENG MED BIOL, V17, P32; Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; RADIN EL, 1971, ARTHRITIS RHEUM, V14, P356, DOI 10.1002/art.1780140306; Rao JK, 1999, ANN INTERN MED, V131, P409, DOI 10.7326/0003-4819-131-6-199909210-00003; RASKIN JB, 1995, ANN INTERN MED, V123, P344, DOI 10.7326/0003-4819-123-5-199509010-00004; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RIES MD, 1995, CLIN ORTHOP RELAT R, V313, P169; Roebuck KA, 1999, J BONE JOINT SURG AM, V81A, P599, DOI 10.2106/00004623-199905000-00001; Ronca F, 1998, OSTEOARTHR CARTILAGE, V6, P14, DOI 10.1016/S1063-4584(98)80006-X; Roth SH, 1998, J RHEUMATOL, V25, P1358; Saag K, 1998, ARTHRITIS RHEUM, V41, pS196; SASAKI T, 1987, CLIN ORTHOP RELAT R, P181; Schiodt FV, 1997, NEW ENGL J MED, V337, P1112, DOI 10.1056/NEJM199710163371602; Schmalzried TP, 1999, J BONE JOINT SURG AM, V81A, P115, DOI 10.2106/00004623-199901000-00016; SEIFERT CF, 1993, PHARMACOTHERAPY, V13, P391; SETNIKAR I, 1986, ARZNEIMITTELFORSCH, V36-1, P729; Silas S, 1999, B RHEUM DIS, V48, P1; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon L S, 1996, Fam Med, V28, P204; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; SIMON SR, 1972, J BIOMECH, V5, P267, DOI 10.1016/0021-9290(72)90042-5; Slemenda C, 1997, ANN INTERN MED, V127, P97, DOI 10.7326/0003-4819-127-2-199707150-00001; Smalley WE, 1996, GASTROENTEROL CLIN N, V25, P373, DOI 10.1016/S0889-8553(05)70253-3; Stux G, 1995, BASICS ACUPUNCTURE; SuperioCabuslay E, 1996, ARTHRIT CARE RES, V9, P292, DOI 10.1002/1529-0131(199608)9:4<292::AID-ANR1790090414>3.0.CO;2-4; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; Takeda W, 1994, Arthritis Care Res, V7, P118, DOI 10.1002/art.1790070304; THOMAS M, 1991, AM J CHINESE MED, V19, P95, DOI 10.1142/S0192415X91000156; Towheed TE, 1997, SEMIN ARTHRITIS RHEU, V26, P755, DOI 10.1016/S0049-0172(97)80043-1; Towheed TE, 1997, J RHEUMATOL, V24, P349; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Uebelhart D, 1998, OSTEOARTHR CARTILAGE, V6, P6, DOI 10.1016/S1063-4584(98)80005-8; VACHA J, 1984, ARZNEIMITTELFORSCH, V34-1, P607; Van Baar ME, 1999, ARTHRITIS RHEUM-US, V42, P1361, DOI 10.1002/1529-0131(199907)42:7<1361::AID-ANR9>3.0.CO;2-9; WATSON MC, 1998, COCHRANE LIB, P3; Weinberger M, 1998, ANN RHEUM DIS, V57, P196, DOI 10.1136/ard.57.4.196; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; WEINBERGER M, 1993, ARTHRITIS RHEUM, V36, P243, DOI 10.1002/art.1780360216; WEINBERGER M, 1986, SOC SCI MED, V23, P899, DOI 10.1016/0277-9536(86)90218-2; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; YASUDA K, 1987, CLIN ORTHOP RELAT R, P162; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104; 1999, MED LETT DRUGS THER, V41, P11	135	355	370	0	82	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					726	737		10.7326/0003-4819-133-9-200011070-00015	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00015			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	369PC	11074906				2022-12-28	WOS:000165075300008
J	Rudolph, RE; Vaughan, TL; Storer, B				Rudolph, RE; Vaughan, TL; Storer, B			Segment length and risk for neoplastic progression in patients with Barrett esophagus - Response	ANNALS OF INTERNAL MEDICINE			English	Letter									Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Rudolph, RE (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.								0	5	5	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					748	748		10.7326/0003-4819-133-9-200011070-00026	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00026			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074917				2022-12-28	WOS:000165075300016
J	Knowles, SR; Uetrecht, J; Shear, NH				Knowles, SR; Uetrecht, J; Shear, NH			Idiosyncratic drug reactions: the reactive metabolite syndromes	LANCET			English	Article							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; ANTICONVULSANT HYPERSENSITIVITY SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; MICROSOMAL EPOXIDE HYDROLASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; SERUM SICKNESS; INVITRO ASSESSMENT; CARBAMAZEPINE; MINOCYCLINE	Idiosyncratic drug reactions are unpredictable reactions that can result in significant morbidity and mortality. Severe reactions are often characterised by fever and internal organ involvement. Despite progress in the identification of reactive metabolites believed to be the cause of idiosyncratic reactions, the basic mechanisms remain elusive, Furthermore, because of the lack of consensus regarding definition of these syndromes, reporting, and therefore epidemiological data, are often unreliable. Research is needed to explore further the pathophysiology of these reactions, so that better diagnostic tests and treatment methods can be developed.	Sunnybrook & Womens Coll Hlth Sci Ctr, Div Clin Pharmacol E240, Dept Med, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Div Dermatol, Dept Med, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Div Drug Safety Clin, Dept Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Shear, NH (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Div Clin Pharmacol E240, Dept Med, Sunnybrook Site, Toronto, ON M4N 3M5, Canada.							Akin E, 1998, PEDIATRICS, V101, P926, DOI 10.1542/peds.101.5.926; BARONE CM, 1993, J ORAL MAXIL SURG, V51, P264, DOI 10.1016/S0278-2391(10)80171-5; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; CRIBB AE, 1992, CLIN PHARMACOL THER, V51, P522, DOI 10.1038/clpt.1992.57; FINE JD, 1995, NEW ENGL J MED, V333, P1475, DOI 10.1056/NEJM199511303332207; GAEDIGK A, 1994, PHARMACOGENETICS, V4, P142, DOI 10.1097/00008571-199406000-00005; GAFFNEY K, 1996, BR J RHEUMATOL, V35, P1326; GENNIS MA, 1991, AM J MED, V91, P631, DOI 10.1016/0002-9343(91)90216-K; GIOUD M, 1982, ARTHRITIS RHEUM, V25, P407, DOI 10.1002/art.1780250408; Gough A, 1996, BRIT MED J, V312, P169; Grammer LC, 1996, JAMA-J AM MED ASSOC, V275, P1152; GREEN VJ, 1995, BIOCHEM PHARMACOL, V50, P1353, DOI 10.1016/0006-2952(95)02009-8; GUPTA A, 1992, CLIN PHARMACOL THER, V51, P56, DOI 10.1038/clpt.1992.8; HECKBERT SR, 1990, AM J EPIDEMIOL, V132, P336, DOI 10.1093/oxfordjournals.aje.a115663; HESS E, 1988, NEW ENGL J MED, V318, P1460, DOI 10.1056/NEJM198806023182209; Ju C, 1999, J PHARMACOL EXP THER, V288, P51; Knowles SR, 1996, ARCH DERMATOL, V132, P934, DOI 10.1001/archderm.132.8.934; LAWLEY TJ, 1984, NEW ENGL J MED, V311, P1407, DOI 10.1056/NEJM198411293112204; LOWERY N, 1994, J PEDIATR-US, V125, P325, DOI 10.1016/S0022-3476(94)70220-9; Masson C, 1996, J RHEUMATOL, V23, P2160; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; Munns AJ, 1997, CHEM RES TOXICOL, V10, P1049, DOI 10.1021/tx9700836; Park BE, 1998, CHEM RES TOXICOL, V11, P969, DOI 10.1021/tx980058f; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; PATTERSON R, 1994, ANN ALLERGY, V73, P27; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; PRENDIVILLE JS, 1989, J PEDIATR-US, V115, P881, DOI 10.1016/S0022-3476(89)80736-X; Puig L, 1996, CONTACT DERMATITIS, V34, P435, DOI 10.1111/j.1600-0536.1996.tb02255.x; RICHENS A, 1994, EPILIPSIA, V35, P37; Rieder MJ, 1997, PEDIATR CLIN N AM, V44, P93, DOI 10.1016/S0031-3955(05)70465-X; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Schlienger RG, 1998, NEUROLOGY, V51, P1172, DOI 10.1212/WNL.51.4.1172; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHEAR NH, 1988, J CLIN INVEST, V82, P1826, DOI 10.1172/JCI113798; SPIELBERG SP, 1981, J PHARMACOL EXP THER, V217, P386; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; STRICKER BHC, 1989, DIGEST DIS SCI, V34, P1576, DOI 10.1007/BF01537113; Tennis P, 1997, NEUROLOGY, V49, P542, DOI 10.1212/WNL.49.2.542; Uetrecht JP, 1999, CHEM RES TOXICOL, V12, P387, DOI 10.1021/tx980249i; VIAL T, 1992, ANN PHARMACOTHER, V26, P910, DOI 10.1177/106002809202600708; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; VITTORIO C, 1995, ARCH INTERN MED, V15, P2285; Warren E, 1997, PHARMACOTHERAPY, V17, P900; WILSON T, 1978, BRIT MED J, V2, P1583; Wolkenstein P, 1998, LANCET, V352, P1586, DOI 10.1016/S0140-6736(98)02197-7; YUNG RL, 1994, RHEUM DIS CLIN N AM, V20, P61	47	243	255	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1587	1591		10.1016/S0140-6736(00)03137-8	http://dx.doi.org/10.1016/S0140-6736(00)03137-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075787				2022-12-28	WOS:000165134500037
J	Redeker, KR; Wang, NY; Low, JC; McMillan, A; Tyler, SC; Cicerone, RJ				Redeker, KR; Wang, NY; Low, JC; McMillan, A; Tyler, SC; Cicerone, RJ			Emissions of methyl halides and methane from rice paddies	SCIENCE			English	Article							HIGHER-PLANTS; OZONE; BROMIDE; FIELDS; VOLATILIZATION; CHLOROMETHANE; EXCHANGE; IODINE	Methyl halide gases are important sources of atmospheric inorganic halogen compounds, which in turn are central reactants in many stratospheric and tropospheric chemical processes. By observing emissions of methyl chloride, methyl bromide, and methyl iodide from flooded California rice fields, we estimate the impact of rice agriculture on the atmospheric budgets of these gases. Factors influencing methyl halide emissions are stage of rice growth, soil organic content, halide concentrations, and field-water management. Extrapolating our data implies that about 1 percent of atmospheric methyl bromide and 5 percent of methyl iodide arise from rice fields worldwide. Unplanted flooded fields emit as much methyl chloride as planted, flooded rice fields.	Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Cicerone, RJ (corresponding author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.		Redeker, Kelly/AAV-3821-2020	Redeker, Kelly/0000-0002-1903-2286; McMillan, Andrew/0000-0003-4652-3360				ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; Bossio DA, 1999, SOIL BIOL BIOCHEM, V31, P1313, DOI 10.1016/S0038-0717(99)00050-4; Carpenter LJ, 1999, J GEOPHYS RES-ATMOS, V104, P1679, DOI 10.1029/98JD02746; Chanton JP, 1997, GLOBAL BIOGEOCHEM CY, V11, P15, DOI 10.1029/96GB03761; Cicerone R. J., 1992, Global Biogeochemical Cycles, V6, P233, DOI 10.1029/92GB01412; Davis D, 1996, J GEOPHYS RES-ATMOS, V101, P2135, DOI 10.1029/95JD02727; Gan J, 1997, J ENVIRON QUAL, V26, P1107, DOI 10.2134/jeq1997.00472425002600040023x; Gan J, 1998, GEOPHYS RES LETT, V25, P3595, DOI 10.1029/98GL52697; Harper DB, 1999, NEW PHYTOL, V142, P5, DOI 10.1046/j.1469-8137.1999.00382.x; Jeffers PM, 1998, GEOPHYS RES LETT, V25, P43, DOI 10.1029/97GL03476; MURAMATSU Y, 1995, ATMOS ENVIRON, V29, P21, DOI 10.1016/1352-2310(94)00220-F; Platt U, 1995, FARADAY DISCUSS, V100, P175, DOI 10.1039/fd9950000175; Rhew RC, 2000, NATURE, V403, P292, DOI 10.1038/35002043; SAINI HS, 1995, PLANT CELL ENVIRON, V18, P1027, DOI 10.1111/j.1365-3040.1995.tb00613.x; Sander R, 1997, TELLUS B, V49, P522, DOI 10.1034/j.1600-0889.49.issue5.8.x; Sass RL, 1999, J GEOPHYS RES-ATMOS, V104, P26943, DOI 10.1029/1999JD900081; SASS RL, 1994, GLOBAL BIOGEOCHEM CY, V8, P135, DOI 10.1029/94GB00588; Saxena D, 1998, APPL ENVIRON MICROB, V64, P2831; SOLOMON S, 1994, J GEOPHYS RES-ATMOS, V99, P20491, DOI 10.1029/94JD02028; *U PHIL COLL AGR C, 1967, RICE PROD MAN, P21; vanderGon HAC, 1996, GLOBAL BIOGEOCHEM CY, V10, P1, DOI 10.1029/95GB03460; Varner RK, 1999, GEOPHYS RES LETT, V26, P2433, DOI 10.1029/1999GL900587; YUNG YL, 1980, J ATMOS SCI, V37, P339, DOI 10.1175/1520-0469(1980)037<0339:ABAOPI>2.0.CO;2	23	163	168	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					966	969		10.1126/science.290.5493.966	http://dx.doi.org/10.1126/science.290.5493.966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062125	Green Published			2022-12-28	WOS:000165103200044
J	Wallenfang, MR; Seydoux, G				Wallenfang, MR; Seydoux, G			Polarization of the anterior-posterior axis of C. elegans is a microtubule-directed process	NATURE			English	Article							CAENORHABDITIS-ELEGANS; EMBRYOS; POLARITY; GRANULES; SEGREGATION; KINASE; PAR-1; LOCALIZATION; DISRUPTION; SPINDLE	In Caenorhabditis elegans, polarity along the anterior-posterior (A/P) axis is established shortly after fertilization and is determined by the sperm, whose position specifies the posterior end of the embryo(1). Although many factors required for the establishment of A/P polarity have been described(2,3), the nature of the spatial cue provided by the sperm remains unknown. Here we show that a microtubule-organizing centre is necessary and sufficient to establish several aspects of A/P polarity. In wildtype embryos, appearance of the first molecular asymmetries along the A/P axis correlates with and requires nucleation of microtubules by the sperm-derived centrosomes (sperm asters). In mutant embryos arrested in meiosis, sperm asters fail to form, and posterior is defined by the position of the persistent meiotic spindle rather than by the position of the sperm. Together, our data indicate that the primary spatial cue for A/P polarity in C. elegans derives from microtubules emanating from the sperm asters. Our findings support a parallel(4-7) between C. elegans zygotes and other cells, such as Drosophila oocytes, which rely on microtubules to regulate polarity.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Seydoux, G (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	gseydoux@jhmi.edu	SEYDOUX, Geraldine/AAA-2005-2020	Seydoux, Geraldine/0000-0001-8257-0493				ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; Bohm H, 1997, CURR BIOL, V7, P603, DOI 10.1016/S0960-9822(06)00260-0; Bowerman B, 1998, CURR TOP DEV BIOL, V39, P73, DOI 10.1016/S0070-2153(08)60453-6; Boxem M, 1999, DEVELOPMENT, V126, P2227; Boyd L, 1996, DEVELOPMENT, V122, P3075; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Furuta T, 2000, MOL BIOL CELL, V11, P1401, DOI 10.1091/mbc.11.4.1401; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HILL DP, 1990, DEVELOPMENT, V108, P159; Hird SN, 1996, DEVELOPMENT, V122, P1303; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; Morris J, 2000, SCIENCE, V288, P1759, DOI 10.1126/science.288.5472.1759; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; Rose LS, 1998, ANNU REV GENET, V32, P521, DOI 10.1146/annurev.genet.32.1.521; Sadler PL, 2000, DEVELOPMENT, V127, P355; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Shulman JM, 2000, CELL, V101, P377, DOI 10.1016/S0092-8674(00)80848-X; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Tenenhaus C, 1998, DEV BIOL, V200, P212, DOI 10.1006/dbio.1998.8940; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Tomancak P, 2000, NAT CELL BIOL, V2, P458, DOI 10.1038/35017101; van Eeden F, 1999, CURR OPIN GENET DEV, V9, P396, DOI 10.1016/S0959-437X(99)80060-4	29	148	165	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					89	92		10.1038/35040562	http://dx.doi.org/10.1038/35040562			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081513				2022-12-28	WOS:000165050400057
J	Harland, SJ				Harland, SJ			Conundrum of the hereditary component of testicular cancer	LANCET			English	Editorial Material							CRYPTORCHIDISM; DENMARK		UCL, Dept Oncol, London W1P 8BT, England	University of London; University College London	Harland, SJ (corresponding author), UCL, Dept Oncol, London W1P 8BT, England.							Dieckmann KP, 1997, CANCER, V80, P1954, DOI 10.1002/(SICI)1097-0142(19971115)80:10<1954::AID-CNCR12>3.0.CO;2-X; EKBOM A, 1998, NEOPLASTIC TRANSFORM, P225; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; FORMAN D, 1992, BRIT J CANCER, V65, P225; Geddes M, 1993, CANC ITALIAN MIGRANT; HARLAND SJ, 1997, GERM CELL TUMOURS, V4, P17; Heimdal K, 1996, BRIT J CANCER, V73, P964, DOI 10.1038/bjc.1996.173; *INT TEST CANC LIN, 1998, NEOPL TRANSF TEST GE, P65; LEAHY MG, 1995, HUM MOL GENET, V4, P1551, DOI 10.1093/hmg/4.9.1551; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; Moller H, 1996, INT J CANCER, V66, P287, DOI 10.1002/(SICI)1097-0215(19960503)66:3<287::AID-IJC2>3.0.CO;2-V; Parkin DM, 1997, INT J CANCER, V70, P654, DOI 10.1002/(SICI)1097-0215(19970317)70:6&lt;654::AID-IJC5&gt;3.0.CO;2-U; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477	14	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1455	1456		10.1016/S0140-6736(00)02863-4	http://dx.doi.org/10.1016/S0140-6736(00)02863-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081522				2022-12-28	WOS:000090067300003
J	Watkins, NJ; Segault, V; Charpentier, B; Nottrott, S; Fabrizio, P; Bachi, A; Wilm, M; Rosbash, M; Branlant, C; Luhrmann, R				Watkins, NJ; Segault, V; Charpentier, B; Nottrott, S; Fabrizio, P; Bachi, A; Wilm, M; Rosbash, M; Branlant, C; Luhrmann, R			A common core RNP structure shared between the small nucleoar box C/D RNPs and the spliceosomal U4 snRNP	CELL			English	Article							PRE-RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; MASS-SPECTROMETRY; RIBONUCLEOPROTEIN PARTICLE; BINDING PROTEIN; GUIDE SNORNAS; TRI-SNRNP; U3 SNRNA; IDENTIFICATION; SEQUENCE	The box C/D snoRNAs function in directing 2'-O-methylation and/or as chaperones in the processing of ribosomal RNA. We show here that Snu13p (15.5kD in human), a component of the U4/U6.U5 tri-snRNP, is also associated with the box C/D snoRNAs. Indeed, genetic depletion of Snu13p in yeast leads to a major defect in RNA metabolism. The box C/D motif can be folded into a stem-internal loop-stem structure, almost identical to the 15.5kD binding site in the U4 snRNA. Consistent with this, the box C/D motif binds Snu13p/15.5kD in vitro. The similarities in structure and function observed between the U4 snRNP (chaperone for U6) and the box C/D snoRNPs raises the interesting possibility that these particles may have evolved from a common ancestral RNP.	Max Planck Inst Biophys Chem, Abt Zellulare Biochem, D-37070 Gottingen, Germany; UHP Nancy 1, CNRS,Fac Sci, UMR 7567, Lab Maturat ARN & Enzymol Mol, F-54506 Vandoeuvre Les Nancy, France; Brandeis Univ, Howard Hughes Med Inst, Dept Biol, Waltham, MA 02454 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Brandeis University; Howard Hughes Medical Institute; European Molecular Biology Laboratory (EMBL)	Luhrmann, R (corresponding author), Max Planck Inst Biophys Chem, Abt Zellulare Biochem, Fassberg 11, D-37070 Gottingen, Germany.	luehrmann@imt.uni-marburg.de	bachi, angela/B-3527-2015	bachi, angela/0000-0003-4842-6556; CHARPENTIER, Bruno/0000-0003-2955-2987; Wilm, Matthias/0000-0002-5461-6834; Branlant, Christiane/0000-0003-4728-5499; Watkins, Nicholas/0000-0003-1256-3874				Bachellerie JP, 1997, TRENDS BIOCHEM SCI, V22, P257, DOI 10.1016/S0968-0004(97)01057-8; BASERGA SJ, 1991, EMBO J, V10, P2645, DOI 10.1002/j.1460-2075.1991.tb07807.x; FABRIZIO P, 1994, SCIENCE, V264, P261, DOI 10.1126/science.8146658; Fatica A, 2000, RNA, V6, P88, DOI 10.1017/S1355838200991623; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Guthrie C, 1991, METHODS ENZYMOL, V194; Hughes JMX, 1996, J MOL BIOL, V259, P645, DOI 10.1006/jmbi.1996.0346; KIMURA J, 1987, FEBS LETT, V224, P65, DOI 10.1016/0014-5793(87)80423-4; Kiss-Laszlo Z, 1998, EMBO J, V17, P797, DOI 10.1093/emboj/17.3.797; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; LUBBEN B, 1993, NUCLEIC ACIDS RES, V21, P5377, DOI 10.1093/nar/21.23.5377; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Mereau A, 1997, J MOL BIOL, V273, P552, DOI 10.1006/jmbi.1997.1320; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Nottrott S, 1999, EMBO J, V18, P6119, DOI 10.1093/emboj/18.21.6119; PARKER KA, 1987, MOL CELL BIOL, V7, P2899, DOI 10.1128/MCB.7.8.2899; Samarsky DA, 1998, MOL CELL BIOL, V18, P3431, DOI 10.1128/MCB.18.6.3431; SEGAULT V, 1992, NUCLEIC ACIDS RES, V20, P3443, DOI 10.1093/nar/20.13.3443; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 1999, P NATL ACAD SCI USA, V96, P7226, DOI 10.1073/pnas.96.13.7226; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; VORM O, 1994, BIOL MASS SPECTROM, V23, P734, DOI 10.1002/bms.1200231204; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Watkins NJ, 1998, RNA, V4, P582, DOI 10.1017/S1355838298980128; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WISE JA, 1991, METHOD ENZYMOL, V194, P405; Xia L, 1997, RNA, V3, P17	36	282	286	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					457	466		10.1016/S0092-8674(00)00137-9	http://dx.doi.org/10.1016/S0092-8674(00)00137-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081632	Bronze			2022-12-28	WOS:000090144100011
J	Moore, GJ; Bebchuk, JM; Wilds, IB; Chen, G; Menji, HK				Moore, GJ; Bebchuk, JM; Wilds, IB; Chen, G; Menji, HK			Lithium-induced increase in human brain grey matter	LANCET			English	Article							BCL-2	Rodent studies have shown that lithium exerts neurotrophic or neuroprotective effects. We used three-dimensional magnetic resonance imaging and brain segmentation to study pharmacologically-induced increases in grey matter volume with chronic lithium use in patients with bipolar mood disorder. Grey-matter volume increased after 4 weeks of treatment. The increases in grey matter probably occurred because of neurotrophic effects.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Wayne State University	Moore, GJ (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 4201 St Antoine,UHC-9B, Detroit, MI 48201 USA.		Chen, Guang/A-2570-2017; anand, amit/A-7222-2009; Moore, Gregory J/E-7184-2010	Moore, Gregory J/0000-0001-8541-3194	NIMH NIH HHS [MH59107] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059107] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Moore GJ, 2000, BIOL PSYCHIAT, V48, P1, DOI 10.1016/S0006-3223(00)00252-3	5	503	515	2	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1241	1242		10.1016/S0140-6736(00)02793-8	http://dx.doi.org/10.1016/S0140-6736(00)02793-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072948				2022-12-28	WOS:000089724900019
J	Hindmarsh, PC; Geary, MPP; Rodeck, CH; Jackson, MR; Kingdom, JCP				Hindmarsh, PC; Geary, MPP; Rodeck, CH; Jackson, MR; Kingdom, JCP			Effect of early maternal iron stores on placental weight and structure	LANCET			English	Article							HEMOGLOBIN CONCENTRATION; BLOOD-PRESSURE; GROWTH-FACTOR; BIRTH-WEIGHT; FETAL GROWTH; PREGNANCY; ANEMIA; DEFICIENCY; ANGIOGENESIS; NEWBORN	Background Large placental size and low birthweight have been implicated as factors predicting high blood pressure in adulthood. Maternal anaemia has been suggested as a link. We investigated the interaction between maternal iron status and other factors known to influence birthweight and placental size. Methods In a prospective study of 1650 low-risk, singleton, caucasian pregnancies, we related placental size and birthweight to maternal iron status, socioeconomic status, and parity. Placental morphology was assessed in 17 randomly chosen primigravid pregnancies. Findings Parity was an important determinant of birthweight (mean standard deviation score -0.13 [SD 0.90] para 0; -0.24 [0. 90] para 1; 0.32 [1.1] para 2; 0.21 [1.1] para greater than or equal to 3; p<0.0001) and placental weight (mean 655 g [SD 130]; 679 g [122]; 675 g [139]; 694 g [157], respectively; p=0.01). Cigarette smoking influenced birthweight only. Socioeconomic status had little effect after correction for parity. In addition to parity, the factors influencing placental weight were maternal height, weight, and serum ferritin concentration at booking, but not haemoglobin concentration. Serum ferritin concentrations were associated with folate intake and parity. In the placental morphology subset, serum ferritin concentration was inversely related to overall measures of peripheral villous capillarisation. Haemoglobin concentration showed no such association. Interpretation These findings show a relation between maternal anaemia and placental size and birthweight across the normal range for these measures. Low ferritin concentrations in early pregnancy were associated with increased placental vascularisation at term. The association between ferritin concentration and folate supplementation emphasises the importance of preconceptional health, particularly in women at high risk of iron deficiency.	UCL, London Ctr Paediat Endocrinol, London, England; UCL, Dept Obstet & Gynaecol, London, England; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Program Dev & Fetal Hlth, Toronto, ON M5G 1X5, Canada	University of London; University College London; University of London; University College London; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Hindmarsh, PC (corresponding author), Middlesex Hosp, Cobbold Labs, London W1N 8AA, England.	p.hindmarsh@ucl.ac.uk	Hindmarsh, P C/C-4964-2008; Kingdom, John/A-3247-2013; Kingdom, John/AAF-2145-2020					Allen LH, 1997, NUTR REV, V55, P91, DOI 10.1111/j.1753-4887.1997.tb06460.x; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; Burton GJ, 1996, PLACENTA, V17, P49, DOI 10.1016/S0143-4004(05)80643-5; BUTLER NR, 1972, BMJ-BRIT MED J, V2, P127, DOI 10.1136/bmj.2.5806.127; CROWE C, 1995, J PHYSIOL-LONDON, V488, P515, DOI 10.1113/jphysiol.1995.sp020986; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graham C. H., 1999, Placenta, V20; HOWE DT, 1995, BRIT J OBSTET GYNAEC, V102, P213, DOI 10.1111/j.1471-0528.1995.tb09096.x; JACKSON MR, 1987, PLACENTA, V8, P487, DOI 10.1016/0143-4004(87)90077-4; Kadyrov M, 1998, LANCET, V352, P1747, DOI 10.1016/S0140-6736(98)02069-8; KALTREIDER F, 1980, CLIN OBSTET GYNECOL, V23, P17; Khaliq A, 1999, LAB INVEST, V79, P151; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; Kingdom JCP, 1999, ADV EXP MED BIOL, V474, P259; Lao T. T., 1999, Placenta, V20; Lao TT, 1997, PLACENTA, V18, P593, DOI 10.1016/0143-4004(77)90015-7; Moore VM, 1996, ARCH DIS CHILD, V74, P538, DOI 10.1136/adc.74.6.538; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; RESHETNIKOVA OS, 1995, AM J OBSTET GYNECOL, V173, P724, DOI 10.1016/0002-9378(95)90330-5; Robinson S, 1998, BRIT J NUTR, V79, P249, DOI 10.1079/BJN19980042; Shore VH, 1997, PLACENTA, V18, P657, DOI 10.1016/S0143-4004(97)90007-2; Singla PN, 1997, J TROP PEDIATRICS, V43, P89, DOI 10.1093/tropej/43.2.89; STEER P, 1995, BMJ-BRIT MED J, V310, P489, DOI 10.1136/bmj.310.6978.489; STOZ F, 1987, Z GEBURTSH PERINATOL, V191, P81; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864	30	51	52	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					719	723		10.1016/S0140-6736(00)02630-1	http://dx.doi.org/10.1016/S0140-6736(00)02630-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085691				2022-12-28	WOS:000088948200011
J	Craighead, HG				Craighead, HG			Nanoelectromechanical systems	SCIENCE			English	Review							LONG DNA-MOLECULES; FABRICATION; SILICON; SEPARATION; RESONANCE	Nanoelectromechanical systems are evolving, with new scientific studies and technical applications emerging. Mechanical devices are shrinking in thickness and width to reduce mass, increase resonant frequency, and lower the force constants of these systems. Advances in the field include improvements in fabrication processes and new methods for actuating and detecting motion at the nanoscale. Lithographic approaches are capable of creating freestanding objects in silicon and other materials, with thickness and lateral dimensions down to about 20 nanometers. Similar processes can make channels or pores of comparable dimensions, approaching the molecular scale. This allows access to a new experimental regime and suggests new applications in sensing and molecular interactions.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA	Cornell University	Craighead, HG (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.							BASSOUS E, 1977, APPL PHYS LETT, V31, P135, DOI 10.1063/1.89587; Brewer G.R., 1980, ELECT BEAM TECHNOLOG; Carr DW, 1999, APPL PHYS LETT, V75, P920, DOI 10.1063/1.124554; Carr DW, 1998, J VAC SCI TECHNOL B, V16, P3821, DOI 10.1116/1.590416; Carr DW, 1997, J VAC SCI TECHNOL B, V15, P2760, DOI 10.1116/1.589722; Chou CF, 1999, P NATL ACAD SCI USA, V96, P13762, DOI 10.1073/pnas.96.24.13762; Chou CF, 2000, ELECTROPHORESIS, V21, P81, DOI 10.1002/(SICI)1522-2683(20000101)21:1<81::AID-ELPS81>3.0.CO;2-#; Cleland AN, 1996, APPL PHYS LETT, V69, P2653, DOI 10.1063/1.117548; CRAIGHEAD H, 2000, SOL STAT SENS ACT WO, P26; CRAIGHEAD HG, 1984, J APPL PHYS, V55, P4430, DOI 10.1063/1.333015; Davis ZJ, 2000, J VAC SCI TECHNOL B, V18, P612, DOI 10.1116/1.591247; Erbe A, 1998, APPL PHYS LETT, V73, P3751, DOI 10.1063/1.122883; Evoy S, 1999, J APPL PHYS, V86, P6072, DOI 10.1063/1.371656; Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316; HAMMEL PC, 1995, J LOW TEMP PHYS, V101, P59, DOI 10.1007/BF00754562; Han J, 1999, J VAC SCI TECHNOL A, V17, P2142, DOI 10.1116/1.581740; Han J, 2000, SCIENCE, V288, P1026, DOI 10.1126/science.288.5468.1026; Han JY, 2000, P SOC PHOTO-OPT INS, V4177, P42; Harnett CK, 2000, APPL PHYS LETT, V76, P2466, DOI 10.1063/1.126378; Hornbeck L. J., 1998, TEXAS INSTRUMENTS TE, V15, P7; Ilic B, 2000, APPL PHYS LETT, V77, P450, DOI 10.1063/1.127006; ILIC B, 2000, 198 M EL SOC PHOEN A; Kitahara A, 1984, ELECT PHENOMENA INTE; KWONG YK, 1989, J VAC SCI TECHNOL B, V7, P2020, DOI 10.1116/1.584670; MADOU M, 1997, FUNDAMENTALS MICROFA, P217; Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079; NEWELL WE, 1968, SCIENCE, V161, P1320, DOI 10.1126/science.161.3848.1320; PETERSEN KE, 1978, IEEE T ELECTRON DEV, V25, P1241, DOI 10.1109/T-ED.1978.19259; Poncharal P, 1999, SCIENCE, V283, P1513, DOI 10.1126/science.283.5407.1513; Reed BW, 1999, PHYS REV B, V60, P5641, DOI 10.1103/PhysRevB.60.5641; ROYLANCE LM, 1979, IEEE T ELECTRON DEV, V26, P1911, DOI 10.1109/T-ED.1979.19795; RUGAR D, 1992, NATURE, V360, P563, DOI 10.1038/360563a0; SIDLES JA, 1992, PHYS REV LETT, V68, P1124, DOI 10.1103/PhysRevLett.68.1124; SMITH CG, 1987, J VAC SCI TECHNOL B, V5, P314, DOI 10.1116/1.583891; Soares LL, 2000, J VAC SCI TECHNOL B, V18, P713, DOI 10.1116/1.591264; Soong RK, 2000, SCIENCE, V290, P1555, DOI 10.1126/science.290.5496.1555; Sze S. M., 1994, SEMICONDUCTOR SENSOR; Turner SW, 1998, PROG BIOM O, V3258, P114, DOI 10.1117/12.304369; Turner SW, 1998, J VAC SCI TECHNOL B, V16, P3835, DOI 10.1116/1.590419; TURNER SW, 2000, THESIS CORNELL U ITH; Van Kessel PF, 1998, P IEEE, V86, P1687, DOI 10.1109/5.704274; van Oudenaarden A, 1999, SCIENCE, V285, P1046, DOI 10.1126/science.285.5430.1046; VANDENBERG A, 2000, P MUTAS 2000 M ENSCH; Vettiger P, 2000, IBM J RES DEV, V44, P323, DOI 10.1147/rd.443.0323; Wang K, 1999, PROC IEEE MICR ELECT, P453, DOI 10.1109/MEMSYS.1999.746871; WOLFE J, 1999, 43 INT C EL ION PHOT; Zalalutdinov M, 2000, APPL PHYS LETT, V77, P3287, DOI 10.1063/1.1326035; 5583668	48	1333	1413	10	305	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1532	1535		10.1126/science.290.5496.1532	http://dx.doi.org/10.1126/science.290.5496.1532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090343				2022-12-28	WOS:000165446200038
J	McDonald, PH; Chow, CW; Miller, WE; Laporte, SA; Field, ME; Lin, FT; Davis, RJ; Lefkowitz, RJ				McDonald, PH; Chow, CW; Miller, WE; Laporte, SA; Field, ME; Lin, FT; Davis, RJ; Lefkowitz, RJ			beta-Arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-KINASE; CLATHRIN ADAPTER; COMPLEX; ENDOCYTOSIS; CELLS; YEAST	beta -Arrestins, originally discovered in the context of heterotrimeric guanine nucleotide binding protein-coupled receptor (GPCR) desensitization, also function in internalization and signaling of these receptors. We identified c-Jun amino-terminal kinase 3 (JNK3) as a binding partner of beta -arrestin 2 using a yeast two-hybrid screen and by coimmunoprecipitation from mouse brain extracts or cotransfected COS-7 cells. The upstream JNK activators apoptosis signal-regulating kinase 1 (ASK1) and mitogen-activated protein kinase (MAPK) kinase 4 were also found in complex with beta -arrestin 2. cellular transfection of beta -arrestin 2 caused cytosolic retention of JNK3 and enhanced JNK3 phosphorylation stimulated by ASK1. Moreover, stimulation of the angiotensin II type 1A receptor activated JNK3 and triggered the colocalization of beta -arrestin 2 and active JNK3 to intracellular vesicles. Thus, beta -arrestin 2 acts as a scaffold protein, which brings the spatial distribution and activity of this MAPK module under the control of a GPCR.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Laporte, Stephane A/F-3282-2012; Chow, Chung-Wai/AAP-5533-2020; Lefkowitz, Robert/AAW-2649-2021; Laporte, Stephane/ABC-4228-2021	Chow, Chung-Wai/0000-0001-9344-8522; Laporte, Stephane/0000-0002-0633-543X	NCI NIH HHS [CA85422, CA65861] Funding Source: Medline; NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065861, R01CA085422] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MCDONALD PJ, UNPUB; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	25	600	626	2	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1574	1577		10.1126/science.290.5496.1574	http://dx.doi.org/10.1126/science.290.5496.1574			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090355				2022-12-28	WOS:000165446200050
J	Orth, K; Xu, ZH; Mudgett, MB; Bao, ZQ; Palmer, LE; Bliska, JB; Mangel, WF; Staskawicz, B; Dixon, JE				Orth, K; Xu, ZH; Mudgett, MB; Bao, ZQ; Palmer, LE; Bliska, JB; Mangel, WF; Staskawicz, B; Dixon, JE			Disruption of signaling by Yersinia effector YopJ, a ubiquitin-like protein protease	SCIENCE			English	Article							CAMPESTRIS PV VESICATORIA; AVIRULENCE GENE AVRRXV; NF-KAPPA-B; ALPHA PRODUCTION; DOWN-REGULATION; ACTIVATION; INHIBITION; SUPPRESSION; EXPRESSION; RESISTANCE	Homologs of the Yersinia virulence effector YopJ are found in both plant and animal bacterial pathogens, as well as plant symbionts. These YopJ family members were shown to act as cysteine proteases. The catalytic triad of the protease was required for inhibition of the mitogen-activated protein kinase (MAPK) and nuclear factor kappaB (NF-kappaB) signaling in animal cells and for induction of Localized cell death in plants. The substrates for YopJ were shown to be highly conserved ubiquitin-like molecules, which are covalently added to numerous regulatory proteins. YopJ family members exert their pathogenic effect on cells by disrupting this posttranslational modification.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; SUNY Stony Brook, Sch Med, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	University of Michigan System; University of Michigan; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Brookhaven National Laboratory	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NIAID NIH HHS [AI41599] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI041599, R01AI041599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Ciesiolka LD, 1999, MOL PLANT MICROBE IN, V12, P35, DOI 10.1094/MPMI.1999.12.1.35; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MINSAVAGE GV, 1990, MOL PLANT MICROBE IN, V3, P41, DOI 10.1094/MPMI-3-041; MUDGETT MB, UNPUB; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; ORTH K, UNPUB; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	25	423	447	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 24	2000	290	5496					1594	1597		10.1126/science.290.5496.1594	http://dx.doi.org/10.1126/science.290.5496.1594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090361				2022-12-28	WOS:000165446200056
J	Wilcox, AJ; Dunson, D; Baird, DD				Wilcox, AJ; Dunson, D; Baird, DD			The timing of the "fertile window" in the menstrual cycle: day specific estimates from a prospective study	BRITISH MEDICAL JOURNAL			English	Article							PROGESTERONE METABOLITES; URINARY ESTROGEN; OVULATION; PREGNANCY; CONCEPTION	Objectives To provide specific estimates of the likely occurrence of the six fertile days (the "fertile window") during the menstrual cycle. Design Prospective cohort study. Participants 221 healthy women who were planning a pregnancy. Main outcome measures The timing of ovulation in 696 menstrual cycles, estimated using urinary metabolites of oestrogen and progesterone. Results The fertile window occurred during a broad range of days in the menstrual cycle. On every day between days 6 and 21, women had a minimum of 10% probability of being in their fertile window. Women cannot predict a sporadic late ovulation; 4-6% of women whose cycles had not yet resumed were potentially fertile in the fifth week of their cycle. Conclusions In only about 30% of women is the fertile window entirely within the days of the menstrual cycle identified by clinical guidelines-that is, between days 10 and 17. Most women reach their fertile window earlier and others much later. Women should be advised that the timing of the fertile window can be highly unpredictable, even if their cycles are usually regular.	NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilcox, AJ (corresponding author), NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA.		Wilcox, Allen J/C-7723-2019; Baird, Donna D/D-5214-2017	Wilcox, Allen J/0000-0002-3376-1311; Baird, Donna D/0000-0002-5544-2653	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES040011, Z01ES044003, ZIAES044003, ZIAES049003, Z01ES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arevalo M, 1999, CONTRACEPTION, V60, P357, DOI 10.1016/S0010-7824(99)00106-7; Baird DD, 1999, FERTIL STERIL, V71, P40, DOI 10.1016/S0015-0282(98)00419-1; BAIRD DD, 1991, STAT MED, V10, P255, DOI 10.1002/sim.4780100209; BAIRD DD, 1995, EPIDEMIOLOGY, V6, P547, DOI 10.1097/00001648-199509000-00015; Beckmann C. R. B., 1998, OBSTET GYNECOLOGY; Dunson DB, 1999, HUM REPROD, V14, P1835, DOI 10.1093/humrep/14.7.1835; DUNSON DB, 2000, IN PRESS STAT MED; Guida N, 1999, FERTIL STERIL, V72, P900, DOI 10.1016/S0015-0282(99)00365-9; Lamprecht VM, 1996, CONTRACEPTION, V54, P339, DOI 10.1016/S0010-7824(96)00202-8; LENTON EA, 1984, BRIT J OBSTET GYNAEC, V91, P685, DOI 10.1111/j.1471-0528.1984.tb04831.x; Pryll W., 1916, MUENCHENER MED WOCHE, V45, P1579; ROYSTON JP, 1982, BIOMETRICS, V38, P397, DOI 10.2307/2530453; *TECHN GUID COMP W, 1996, POP REP J, V44, P14; TRELOAR AE, 1967, INT J FERTIL, V12, P77; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILCOX AJ, 1985, FERTIL STERIL, V44, P366; Wilcox AJ, 1998, HUM REPROD, V13, P394, DOI 10.1093/humrep/13.2.394; WILCOX AJ, 1995, NEW ENGL J MED, V333, P517	18	269	274	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1259	1262		10.1136/bmj.321.7271.1259	http://dx.doi.org/10.1136/bmj.321.7271.1259			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082086	Green Published, Bronze			2022-12-28	WOS:000165445800025
J	Badovinac, VP; Tvinnereim, AR; Harty, JT				Badovinac, VP; Tvinnereim, AR; Harty, JT			Regulation of antigen-specific CD8(+) T cell homeostasis by perforin and interferon-gamma	SCIENCE			English	Article							MHC CLASS-I; LISTERIA-MONOCYTOGENES; RESPONSES; IMMUNITY; MEMORY; TNF; IMMUNODOMINANCE; MECHANISMS; EFFICIENCY; INFECTION	T cell memory depends on factors that regulate expansion and death of these cells after antigenic stimulation. Mice deficient in perforin and interferon-gamma (IFN-gamma) exhibited increased expansion, altered immunodominance, and decreased death of antigen-specific CD8(+) T cells after infection with an attenuated strain of Listeria monocytogenes, which was cleared from these mice. Expansion of CD8(+) T cells was controlled by perforin, whereas IFN-gamma regulated immunodominance and the death phase. Thus, perforin and IFN-gamma regulate distinct elements of CD8(+) T cell homeostasis independently of their role as antimicrobial effector molecules.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Harty, JT (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	john-harty@uiowa.edu	badovinac, Vladimir/O-7760-2015	Harty, John/0000-0001-7266-2802; Badovinac, Vladimir/0000-0003-3180-2439	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042767, T32AI007511, R01AI042767, R29AI036864, R37AI042767] Funding Source: NIH RePORTER; NIAID NIH HHS [T32AI07511, AI42767, AI36864] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Badovinac VP, 2000, J IMMUNOL, V164, P6444, DOI 10.4049/jimmunol.164.12.6444; Badovinac VP, 2000, J IMMUNOL METHODS, V238, P107, DOI 10.1016/S0022-1759(00)00153-8; BADOVINAC VP, UNPUB; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Busch DH, 1999, J EXP MED, V189, P701, DOI 10.1084/jem.189.4.701; Busch DH, 1998, J IMMUNOL, V160, P4441; Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Goldrath AW, 1999, NATURE, V402, P255, DOI 10.1038/35005508; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Klenerman P, 1998, NATURE, V394, P482, DOI 10.1038/28860; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nacy C A, 1988, Adv Exp Med Biol, V239, P1; Nguyen LT, 2000, EUR J IMMUNOL, V30, P683, DOI 10.1002/1521-4141(200002)30:2<683::AID-IMMU683>3.3.CO;2-X; PAMER EG, 1994, J IMMUNOL, V152, P686; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; Reich A, 2000, EUR J IMMUNOL, V30, P678, DOI 10.1002/1521-4141(200002)30:2<678::AID-IMMU678>3.3.CO;2-H; Sad S, 1996, J EXP MED, V184, P1543, DOI 10.1084/jem.184.4.1543; Schwarz K, 2000, J IMMUNOL, V165, P768, DOI 10.4049/jimmunol.165.2.768; Shen H, 1998, CELL, V92, P535, DOI 10.1016/S0092-8674(00)80946-0; Slifka MK, 2000, J IMMUNOL, V164, P208, DOI 10.4049/jimmunol.164.1.208; Sourdive DJD, 1998, J EXP MED, V188, P71, DOI 10.1084/jem.188.1.71; TISHON A, 1995, VIROLOGY, V212, P244, DOI 10.1006/viro.1995.1477; Vijh S, 1997, J IMMUNOL, V158, P3366; Vijh S, 1998, J IMMUNOL, V160, P3971; VILLANUEVA MS, 1994, IMMUNITY, V1, P479, DOI 10.1016/1074-7613(94)90090-6; White DW, 1999, J IMMUNOL, V162, P980; Yewdell JTW, 1999, ANNU REV IMMUNOL, V17, P51, DOI 10.1146/annurev.immunol.17.1.51	37	375	389	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1354	1357		10.1126/science.290.5495.1354	http://dx.doi.org/10.1126/science.290.5495.1354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082062				2022-12-28	WOS:000165379800048
J	Krause, PJ; Lepore, T; Sikand, VK; Gadbaw, JJ; Burke, G; Telford, SR; Brassard, P; Pearl, D; Azlanzadeh, J; Christianson, D; McGrath, D; Spielman, A				Krause, PJ; Lepore, T; Sikand, VK; Gadbaw, JJ; Burke, G; Telford, SR; Brassard, P; Pearl, D; Azlanzadeh, J; Christianson, D; McGrath, D; Spielman, A			Atovaquone and azithromycin for the treatment of babesiosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN GRANULOCYTIC EHRLICHIOSIS; IXODES-DAMMINI; LYME-DISEASE; MICROTI; INFECTION; TRANSFUSION; PARASITEMIA; DIAGNOSIS; ORGANISM; MALARIA	Background: Babesiosis is a tick-borne, malaria-like illness known to be enzootic in southern New England. A course of clindamycin and quinine is the standard treatment, but this regimen frequently causes adverse reactions and occasionally fails. A promising alternative treatment is atovaquone plus azithromycin. Methods: We conducted a prospective, nonblinded, randomized trial of the two regimens in 58 subjects with non-life-threatening babesiosis on Nantucket, Massachusetts; on Block Island, Rhode Island; and in southern Connecticut. The subjects were assigned to receive either atovaquone (750 mg every 12 hours) and azithromycin (500 mg on day 1 and 250 mg per day thereafter) for seven days (40 subjects) or clindamycin (600 mg every 8 hours) and quinine (650 mg every 8 hours) for seven days (18 subjects). Results: Adverse effects were reported by 15 percent of the subjects who received atovaquone and azithromycin, as compared with 72 percent of those who received clindamycin and quinine (P<0.001). The most common adverse effects with atovaquone and azithromycin were diarrhea and rash (each in 8 percent of the subjects); with clindamycin and quinine the most common adverse effects were tinnitus (39 percent), diarrhea (33 percent), and decreased hearing (28 percent). Symptoms had resolved three months after the start of therapy in 65 percent of those who received atovaquone and azithromycin and 73 percent of those who received clindamycin and quinine (P=0.66), and after six months no patient in either group had symptoms. Three months after the completion of the assigned regimen, no parasites could be seen on microscopy, and no Babesia microti DNA was detected in the blood of any subject. Conclusions: For the treatment of babesiosis, a regimen of atovaquone and azithromycin is as effective as a regimen of clindamycin and quinine and is associated with fewer adverse reactions. (N Engl J Med 2000;343:1454-8.) (C) 2000, Massachusetts Medical Society.	Connecticut Childrens Med Ctr, Dept Pediat, Div Infect Dis, Hartford, CT 06106 USA; Connecticut Childrens Med Ctr, Div Res, Hartford, CT 06106 USA; Univ Connecticut, Sch Med, Hartford, CT 06112 USA; Nantucket Cottage Hosp, Nantucket, MA USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Lawrence & Mem Hosp, Dept Med, Div Infect Dis, New London, CT USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Brown Univ, Sch Med, Dept Med, Providence, RI 02912 USA; Univ Connecticut, Sch Med, Dept Lab Med, Farmington, CT 06032 USA	Connecticut Children's Medical Center; Connecticut Children's Medical Center; University of Connecticut; Tufts University; Harvard University; Harvard T.H. Chan School of Public Health; Brown University; University of Connecticut	Krause, PJ (corresponding author), Connecticut Childrens Med Ctr, Dept Pediat, Div Infect Dis, Hartford, CT 06106 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019693, R01AI042402, R37AI019693, R29AI037993] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-37993, AI-19693, AI-42402] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Bonoan JT, 1998, HEART LUNG, V27, P424, DOI 10.1016/S0147-9563(98)90089-9; Falagas ME, 1996, CLIN INFECT DIS, V22, P809, DOI 10.1093/clinids/22.5.809; GARNHAM PCC, 1980, T ROY SOC TROP MED H, V74, P153, DOI 10.1016/0035-9203(80)90232-1; GELFAND JA, 1995, MANDELL DOUGLAS BENN, V2, P2497; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P978; Herwaldt BL, 1996, ANN INTERN MED, V124, P643, DOI 10.7326/0003-4819-124-7-199604010-00004; KRAUSE PJ, 1994, J INFECT DIS, V169, P923, DOI 10.1093/infdis/169.4.923; Krause PJ, 1996, JAMA-J AM MED ASSOC, V275, P1657, DOI 10.1001/jama.275.21.1657; Krause PJ, 1996, J CLIN MICROBIOL, V34, P2791, DOI 10.1128/JCM.34.11.2791-2794.1996; Krause PJ, 1998, NEW ENGL J MED, V339, P160, DOI 10.1056/NEJM199807163390304; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1995, NEW ENGL J MED, V332, P298, DOI 10.1056/NEJM199502023320504; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; Shih CM, 1997, J CLIN MICROBIOL, V35, P450, DOI 10.1128/JCM.35.2.450-454.1997; SPIELMAN A, 1985, ANNU REV ENTOMOL, V30, P439, DOI 10.1146/annurev.en.30.010185.002255; STEKETEE RW, 1985, JAMA-J AM MED ASSOC, V253, P2675, DOI 10.1001/jama.253.18.2675; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; Wittner M, 1996, AM J TROP MED HYG, V55, P219, DOI 10.4269/ajtmh.1996.55.219; WITTNER M, 1982, ANN INTERN MED, V96, P601, DOI 10.7326/0003-4819-96-5-601; 1990, MMWR MORB MORTAL WKL, V39, P19	25	230	237	2	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 16	2000	343	20					1454	1458		10.1056/NEJM200011163432004	http://dx.doi.org/10.1056/NEJM200011163432004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373CR	11078770				2022-12-28	WOS:000165271300004
J	Chiron, C; Marchand, MC; Tran, A; Rey, E; d'Athis, P; Vincent, J; Dulac, O; Pons, G				Chiron, C; Marchand, MC; Tran, A; Rey, E; d'Athis, P; Vincent, J; Dulac, O; Pons, G		STICLO Study Grp	Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial	LANCET			English	Article							LENNOX-GASTAUT-SYNDROME; NEWLY-DIAGNOSED EPILEPSY; DOUBLE-BLIND; CHILDREN; VIGABATRIN; CARBAMAZEPINE; LAMOTRIGINE; METABOLISM; VALPROATE; CHILDHOOD	Background Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial. Methods After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. Patients then received stiripentol in an open fashion. Responders were defined as having more than 50% reduction in the frequency of clonic (or tonic-clonic) seizures during the second month of the double-blind period compared with baseline. Findings 15 (71%) patients were responders on stiripentol (including nine free of clonic or tonic-clonic seizures), whereas there was only one (5%) on placebo (none were seizure free; stiripentol 95% CI 52.1-90.7 vs placebo 0-14.6). The 95% CI of the difference was 42.2-85.7. Percentage of change from baseline was higher on stiripentol (-69%) than on placebo (+7%), p<0.0001. 21 patients on stiripentol had moderate side-effects (drowsiness, loss of appetite) compared with eight on placebo, but side-effects disappeared when the dose of comedication was decreased in 12 of the 21 cases. Interpretation This controlled trial shows the antiepileptic efficacy, of add-on stiripentol in children with SMEI. The results also provide good reason to focus studies on a specific epilepsy syndrome-a small sample of patients is sufficient to show the efficacy that might have been missed in a heterogeneous population.	Hop St Vincent de Paul, Serv Neuropediat, F-75674 Paris 14, France; Hop St Vincent de Paul, INSERM, U29, F-75674 Paris 14, France; Univ Paris 05, Paris, France; Biocodex, Montrouge, France; Univ Hosp, Dijon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Dijon Bourgogne	Chiron, C (corresponding author), Hop St Vincent de Paul, Serv Neuropediat, 82 Ave Denfert Rochereau, F-75674 Paris 14, France.		Chiron, Catherine/E-8506-2016	Chiron, Catherine/0000-0002-9096-1694				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Bare MA, 1998, J CHILD NEUROL, V13, P498, DOI 10.1177/088307389801301006; Bialer M, 1999, EPILEPSY RES, V34, P1, DOI 10.1016/S0920-1211(98)00108-9; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Chadwick D, 1999, LANCET, V354, P13, DOI 10.1016/S0140-6736(98)10531-7; CHIRON C, 1991, J CHILD NEUROL, V6, pS52; Chiron C, 1996, EPILEPSY RES, V25, P209, DOI 10.1016/S0920-1211(96)00028-9; Chiron C, 1997, EPILEPSY RES, V26, P389, DOI 10.1016/S0920-1211(96)01006-6; Dravet Charlotte, 1992, P75; DULAC O, 1998, CHALLENGE EPILEPSY N, P121; ELTERMAN R, 1997, EPILEPSIA, V38, pS131; *FELB STUD GROUP L, 1993, NEW ENGL J MED, V7, P29; Guerreiro MM, 1997, EPILEPSY RES, V27, P205, DOI 10.1016/S0920-1211(97)00025-9; Guerrini R, 1998, EPILEPSIA, V39, pS2, DOI 10.1111/j.1528-1157.1998.tb05118.x; LEVY RH, 1987, EPILEPSIA, V28, P605; Lortie A, 1997, J CHILD NEUROL, V12, P253, DOI 10.1177/088307389701200407; LUNA D, 1989, EPILEPSIA, V30, P430, DOI 10.1111/j.1528-1157.1989.tb05322.x; Motte J, 1997, NEW ENGL J MED, V337, P1807, DOI 10.1056/NEJM199712183372504; Perez J, 1999, EPILEPSIA, V40, P1618, DOI 10.1111/j.1528-1157.1999.tb02048.x; PETERS AC, 1996, EPILEPSIA, V37, P118; POISSON M, 1984, ARZNEIMITTEL-FORSCH, V34-1, P199; Sachdeo RC, 1999, NEUROLOGY, V52, P1882, DOI 10.1212/WNL.52.9.1882; SCHLUMBERGER E, 1994, EPILEPSIA, V35, P359, DOI 10.1111/j.1528-1157.1994.tb02445.x; Tran A, 1996, EUR J CLIN PHARMACOL, V50, P497, DOI 10.1007/s002280050147; Wallace SJ, 1998, EPILEPSY RES, V29, P147, DOI 10.1016/S0920-1211(97)00080-6	25	381	390	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1638	1642		10.1016/S0140-6736(00)03157-3	http://dx.doi.org/10.1016/S0140-6736(00)03157-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089822				2022-12-28	WOS:000165249200011
J	Young, RC				Young, RC			The sounds of silence - No news about cancer prevention is good news	NATURE			English	Editorial Material									Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Young, RC (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.								0	3	3	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					141	141		10.1038/35041645	http://dx.doi.org/10.1038/35041645			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089950	Bronze			2022-12-28	WOS:000165180400020
J	Nikolaus, S; Raedler, A; Kuhbacher, T; Sfikas, N; Folsch, UR; Schreiber, S				Nikolaus, S; Raedler, A; Kuhbacher, T; Sfikas, N; Folsch, UR; Schreiber, S			Mechanisms in failure of infliximab for Crohn's disease	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; INFLAMMATORY BOWEL-DISEASE; NF-KAPPA-B; MONOCLONAL-ANTIBODY CA2; FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVATION; ACTIVITY INDEX; DRUG-TREATMENT; TRIAL; INTERLEUKIN-1-BETA	Background Expression of tumour necrosis factor-alpha (TNF-alpha) is increased in patients with Crohn's disease. Nuclear factor kappa B (NF kappaB) controls transcription of inflammation genes. Treatment with monoclonal antibodies to TNF (infliximab) in refractory Crohn's disease results in a remission rate of 30-50% after 4 weeks. We aimed to assess the clinical and immunological mechanism of failure to respond to infliximab. Methods 24 patients with steroid refractory, chronic active Crohn's disease (Crohn's disease activity index [CDAI]>200), who showed an inflammatory manifestation in the sigmoid colon, had a single infusion of infliximab (5 mg/kg bodyweight) and were followed up for 16 weeks. Secretion capacity for TNF-alpha was assessed in whole-blood cytokine assays and nuclear concentrations of NF kappaB p65 were determined in colonic mucosal biopsy samples. Findings 21 (88%) of 24 patients were in remission (CDAI<150) after 1 week, ten (42%) at 4 weeks, five (21%) at 8 weeks, and two (8%) of 24 at 12 and 16 weeks. Six (29%) of 21 patients who reached remission in week 1 relapsed at week 4, 13 (62%) at week 8, 17 (81%) at week 12, and 19 (90%) at week 16. Infliximab downregulated secretion of TNF-<alpha> in all patients to undetectable concentrations (day 1 after Infusion). Relapsers were characterised by a rise in TNF-alpha secretion capacity and by increase of mucosal nuclear NF kappaB p65 before reactivation of clinical symptoms. Interpretation Infliximab greatly improved clinical symptoms in 88% of patients with Crohn's disease after 1 week. Response in some patients was of short duration. Reactivation of the mucosal and the systemic immune system preceded clinical relapse.	Univ Kiel, Dept Med 1, D-24105 Kiel, Germany; Tabea Ctr Inflammatory Bowel Dis, Hamburg, Germany	University of Kiel	Schreiber, S (corresponding author), Univ Kiel, Dept Med 1, D-24105 Kiel, Germany.	Schreiber@mucosa.de	Kuehbacher, Tanja/H-4745-2012					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bauditz J, 1997, GUT, V40, P470, DOI 10.1136/gut.40.4.470; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; CANDY S, 1995, GUT, V37, P674, DOI 10.1136/gut.37.5.674; D'Haens G, 1999, GASTROENTEROLOGY, V116, P1029, DOI 10.1016/S0016-5085(99)70005-3; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Ehrenpreis ED, 1999, GASTROENTEROLOGY, V117, P1271, DOI 10.1016/S0016-5085(99)70276-3; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; ISAACS KL, 1992, GASTROENTEROLOGY, V103, P1587, DOI 10.1016/0016-5085(92)91182-4; Kaiser GC, 1999, GASTROENTEROLOGY, V116, P602, DOI 10.1016/S0016-5085(99)70182-4; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; Mascheretti S, 2000, GASTROENTEROLOGY, V118, pA335, DOI 10.1016/S0016-5085(00)83435-6; MUNKHOLM P, 1995, SCAND J GASTROENTERO, V30, P699, DOI 10.3109/00365529509096316; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; Nikolaus S, 2000, HEPATO-GASTROENTEROL, V47, P71; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rutgeerts P, 1999, GASTROENTEROLOGY, V117, P761, DOI 10.1016/S0016-5085(99)70332-X; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schmidt M, 2000, GASTROENTEROLOGY, V118, pA664, DOI 10.1016/S0016-5085(00)84792-7; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Schreiber S, 1999, LANCET, V353, P459, DOI 10.1016/S0140-6736(98)03339-X; SCHREIBER S, 2000, IN PRESS GASTROENTER; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Stack WA, 1997, LANCET, V349, P521, DOI 10.1016/S0140-6736(97)80083-9; STEVENS C, 1992, DIGEST DIS SCI, V37, P818, DOI 10.1007/BF01300378; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Vasiliauskas EA, 1999, GASTROENTEROLOGY, V117, P1278, DOI 10.1016/S0016-5085(99)70277-5	40	119	123	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	2000	356	9240					1475	1479		10.1016/S0140-6736(00)02871-3	http://dx.doi.org/10.1016/S0140-6736(00)02871-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081530				2022-12-28	WOS:000090067300011
J	Black, DL				Black, DL			Protein diversity from alternative splicing: A challenge for bioinformatics and post-genome biology	CELL			English	Review							SEQUENCE; DNA		Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Black, DL (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles MRL 5-748,675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	dougb@microbio.lifesci.ucla.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Croft L, 2000, NAT GENET, V24, P340, DOI 10.1038/74153; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Haussler D, 1998, TRENDS BIOTECHNOL, P12, DOI 10.1016/S0167-7799(98)00129-2; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kent WJ, 2000, NUCLEIC ACIDS RES, V28, P91, DOI 10.1093/nar/28.1.91; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Morrison M, 1997, P NATL ACAD SCI USA, V94, P9782, DOI 10.1073/pnas.94.18.9782; Rubin GM, 2000, SCIENCE, V287, P2222, DOI 10.1126/science.287.5461.2222; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; THACKERAY JR, 1995, GENETICS, V141, P203; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2	20	435	467	1	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 27	2000	103	3					367	370		10.1016/S0092-8674(00)00128-8	http://dx.doi.org/10.1016/S0092-8674(00)00128-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081623	Bronze			2022-12-28	WOS:000090144100002
J	Page, RL; Joglar, JA; Kowal, RC; Zagrodzky, JD; Nelson, LL; Ramaswamy, K; Barbera, SJ; Hamdan, MH; McKenas, DK				Page, RL; Joglar, JA; Kowal, RC; Zagrodzky, JD; Nelson, LL; Ramaswamy, K; Barbera, SJ; Hamdan, MH; McKenas, DK			Use of automated external defibrillators by a US airline.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; TRANSTHORACIC VENTRICULAR DEFIBRILLATION; PUBLIC-ACCESS DEFIBRILLATION; CARDIAC LIFE-SUPPORT; BIPHASIC WAVE-FORM; ARREST; PROFESSIONALS; STATEMENT; COMMITTEE; SURVIVAL	Background: Passengers who have ventricular fibrillation aboard commercial aircraft rarely survive, owing to the delay in obtaining emergency care and defibrillation. Methods: In 1997, a major U.S. airline began equipping its aircraft with automated external defibrillators. Flight attendants were trained in the use of the defibrillator and applied the device when passengers had a lack of consciousness, pulse, or respiration. The automated external defibrillator was also used as a monitor for other medical emergencies, generally at the direction of a passenger who was a physician. The electrocardiogram that was obtained during each use of the device was analyzed by two arrhythmia specialists for appropriateness of use. We analyzed data on all 200 instances in which the defibrillators were used between June 1, 1997, and July 15, 1999. Results: Automated external defibrillators were used for 200 patients (191 on the aircraft and 9 in the terminal), including 99 with documented loss of consciousness. Electrocardiographic data were available for 185 patients. The administration of shock was advised in all 14 patients who had electrocardiographically documented ventricular fibrillation, and no shock was advised in the remaining patients (sensitivity and specificity of the defibrillator in identifying ventricular fibrillation, 100 percent). The first shock successfully defibrillated the heart in 13 patients (defibrillation was withheld in 1 case at the family's request). The rate of survival to discharge from the hospital after shock with the automated external defibrillator was 40 percent. A total of 36 patients either died or were resuscitated after cardiac arrest. No complications arose from use of the automated external defibrillator as a monitor in conscious passengers. Conclusions: The use of the automated external defibrillator aboard commercial aircraft is effective, with an excellent rate of survival to discharge from the hospital after conversion of ventricular fibrillation. There are not likely to be complications when the device is used as a monitor in the absence of ventricular fibrillation.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol,Sect Clin Cardiac Electrophysiol, Dallas, TX 75390 USA; Amer Airlines, Ft Worth, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Page, RL (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Cardiol,Sect Clin Cardiac Electrophysiol, Rm CS7-102,5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Page, Richard L./L-5501-2014	Page, Richard L./0000-0001-5603-1330				ALDRETE JA, 1983, SOUTHERN MED J, V76, P12; ANDERSON RN, 1997, MONTHLY VITAL STAT R, V45, P2; Bardy GH, 1996, CIRCULATION, V94, P2507, DOI 10.1161/01.CIR.94.10.2507; Becker L, 1998, CIRCULATION, V97, P2106, DOI 10.1161/01.CIR.97.21.2106; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; CHEN PS, 1986, CIRCULATION, V73, P1022, DOI 10.1161/01.CIR.73.5.1022; CUMMINS RO, 1988, JAMA-J AM MED ASSOC, V259, P1983, DOI 10.1001/jama.259.13.1983; Cummins RO, 1998, CIRCULATION, V97, P1654, DOI 10.1161/01.CIR.97.16.1654; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Donaldson E, 1996, AUST NZ J SURG, V66, P431, DOI 10.1111/j.1445-2197.1996.tb00777.x; GRUNDY JW, 2000, CIRCULATION, V100, P1703; Mittal S, 1999, J AM COLL CARDIOL, V34, P1595, DOI 10.1016/S0735-1097(99)00363-0; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; ORourke RA, 1997, CIRCULATION, V96, P2775, DOI 10.1161/01.CIR.96.9.2775; Page RL, 1998, CIRCULATION, V97, P1429; Ruckman RF, 1999, J AIR LAW COMMER, V65, P77; Smith SC, 1998, CIRCULATION, V97, P1321, DOI 10.1161/01.CIR.97.13.1321; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; WADE B, 1999, NY TIMES        0706, P24; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEISFELDT ML, 1995, CIRCULATION, V92, P2740, DOI 10.1161/01.CIR.92.9.2740; 2000, J AM COLL CARDIOL, V35, P825; 2000, FED REG         0524, V65, P33702	23	430	435	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1210	1216		10.1056/NEJM200010263431702	http://dx.doi.org/10.1056/NEJM200010263431702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071671				2022-12-28	WOS:000090014100002
J	Edwards, IR; Aronson, JK				Edwards, IR; Aronson, JK			Adverse drug reactions: definitions, diagnosis, and management	LANCET			English	Article							EVENTS	We define an adverse drug reaction as "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product." Such reactions are currently reported by use of WHO's Adverse Reaction Terminology, which will eventually become a subset of the International Classification of Diseases. Adverse drug reactions are classified into six types (with mnemonics): dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure). Timing, the pattern of illness, the results of investigations, and rechallenge can help attribute causality to a suspected adverse drug reaction. Management includes withdrawal of the drug if possible and specific treatment of its effects. Suspected adverse drug reactions should be reported. Surveillance methods can detect reactions and prove associations.	Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England; WHO, Collaborating Ctr Int Drug Monitoring, Uppsala Monitoring Ctr, Uppsala, Sweden	Radcliffe Infirmary; World Health Organization	Aronson, JK (corresponding author), Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.							BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bowdler J, 1997, EFFECTIVE COMMUNICAT; EDWARDS IR, 2000, MEYLERS SIDE EFFECTS, pR27; FERNER RE, 1999, SIDE EFFECTS DRUGS A, pR23; GELBERG A, 1991, DRUG INF J, V25, P19; Grahame-Smith DG, 1984, OXFORD TXB CLIN PHAR, P132; HARTIGANGO KY, IN PRESS SIDE EFFECT; LANCTOT KL, 1994, J CLIN PHARMACOL, V34, P142, DOI 10.1002/j.1552-4604.1994.tb03978.x; LAURENCE D, 1998, DICT PHARM ALLIED TO, P8; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEE A, 1997, BRIT MED J, V315, P520; Meyboom R., 1992, PHARMACOEPIDEM DR S, V1, P87; OLSSON S, IN PRESS SIDE EFFECT; Rawlins M., 1977, TXB ADVERSE DRUG REA, P10; Royer RJ, 1997, PHARMACOEPIDEM DR S, V6, pS43, DOI 10.1002/(SICI)1099-1557(199710)6:3+<S43::AID-PDS308>3.3.CO;2-U; Stephens M.D.B., 1998, DETECTION NEW ADVERS, P32; STEPHENS MBD, 1987, ADVERSE DRUG REACT, V1, P1; *WHO, 1972, TECH REP SER WHO, V498; *WHO, 1991, MIO3722A WHO; WHO Collaborating Centre for International Drug Monitoring, 1992, INT MONITORING ADVER; Wood KL, 1994, PHARMACOEPIDEM DR S, V3, P7; Wood S. M., 1993, Pharmaceutical Medicine (London), V7, P203; [No title captured]; [No title captured]	24	1643	1703	4	96	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1255	1259		10.1016/S0140-6736(00)02799-9	http://dx.doi.org/10.1016/S0140-6736(00)02799-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072960				2022-12-28	WOS:000089724900041
J	Cologne, JB; Preston, DL				Cologne, JB; Preston, DL			Longevity of atomic-bomb survivors	LANCET			English	Article							REGRESSION-MODELS; MORTALITY; RADIATION	Background Conflicting claims have been made regarding biological and health consequences of exposure to low doses of radiation. Studies have suggested that certain low-dose exposed atomic-bomb survivors live longer than their peers. Earlier studies in other radiation-exposed populations demonstrated life shortening from mortality from cancer but lacked dosimetry and relied on comparison groups which may introduce bias because of lack of comparability. We have re-examined the effect of radiation on life expectancy in one cohort of survivors of the atomic bombings of Hiroshima and Nagasaki, Japan. Methods We did a prospective cohort study of 120 321 survivors. The study encompasses 45 years of mortality follow-up with radiation-dose estimates available for most cohort members. We calculated relative mortality rates and survival distribution using internal comparison (cohort-based estimation of background mortality). Findings Median life expectancy decreased with increasing radiation dose at a rate of about 1.3 years per Gy, but declined more rapidly at high doses. Median loss of life among cohort members with estimated doses below 1 Gy was about 2 months, but among the small number of cohort members with estimated doses of 1 Gy or more it was 2.6 years. Median loss of life among all individuals with greater-than-zero dose estimates was about 4 months. Interpretation These results are important in light of the recent finding that radiation significantly increases mortality rates for causes other than cancer. The results do not support claims that survivors exposed to certain doses of radiation live longer than comparable unexposed individuals. Because the cohort was intentionally constructed to contain a higher proportion of high-dose atomic-bomb survivors, average loss of life among all exposed atomic-bomb survivors would be less than the 4 months found for the study cohort.	Radiat Effects Res Fdn, Dept Stat, Minami Ku, Hiroshima 7320815, Japan	Radiation Effects Research Foundation - Japan	Cologne, JB (corresponding author), Radiat Effects Res Fdn, Dept Stat, Minami Ku, 5-2 Hijiyama Pk, Hiroshima 7320815, Japan.	cologne@rerf.or.jp		Cologne, John/0000-0003-1540-6639				Andersen P. K., 2012, STAT MODELS BASED CO; BEEBE GW, 1978, LATE RADIOLOGICAL EF, P3; COX DR, 1972, J R STAT SOC B, V34, P187; *FRENCH AC SCI, 1997, 38 FRENCH AC SCI; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HAYAKAWA N, 1989, Hiroshima Journal of Medical Sciences, V38, P53; Hendee WR, 1998, MED PHYS, V25, P1407, DOI 10.1118/1.598312; Hoel DG, 1998, HEALTH PHYS, V75, P241, DOI 10.1097/00004032-199809000-00002; Hosmer D. W., 1999, APPL SURVIVAL ANAL; KONDO S, 1993, HLTH EFFECTS LOW LEV, P27; MATSUURA M, 1992, INT CONGR SER, V1013, P67; METTLER FA, 1995, MED EFFECTRS IONIZIN, P280; MINE M, 1990, INT J RADIAT BIOL, V58, P1035, DOI 10.1080/09553009014552341; OKAJIMA S, 1985, RADIAT RES, V103, P419, DOI 10.2307/3576764; OKUMURA Y, 1997, IAEATECDOC976; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Roesch WC, 1987, US JAPAN JOINT REASS; SELTSER R, 1965, AM J EPIDEMIOL, V81, P2, DOI 10.1093/oxfordjournals.aje.a120493; Shimizu Y, 1999, RADIAT RES, V152, P374, DOI 10.2307/3580222; SMITH PG, 1981, BRIT J RADIOL, V54, P187, DOI 10.1259/0007-1285-54-639-187; SMITH PG, 1982, BRIT MED J, V284, P449, DOI 10.1136/bmj.284.6314.449; STEHNEY AF, 1978, LATE BIOL EFFECTS IO, P333; THOMPSON D, 1997, TIME            0623, P50; THOMPSON DE, 1994, RAD RES S, V137, P17; *UN SCI COMM EFF A, 1982, 669 UN SCI COMM EFF; WARRICK J, 1997, WASHINGTON POST 0609, pA3	26	63	71	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					303	307		10.1016/S0140-6736(00)02506-X	http://dx.doi.org/10.1016/S0140-6736(00)02506-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071186				2022-12-28	WOS:000088305900012
J	Greengold, NL				Greengold, NL			No time to say hello good-bye	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2564	2565		10.1001/jama.284.20.2564	http://dx.doi.org/10.1001/jama.284.20.2564			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086344				2022-12-28	WOS:000165296200001
J	Kamhawi, S; Belkaid, Y; Modi, G; Rowton, E; Sacks, D				Kamhawi, S; Belkaid, Y; Modi, G; Rowton, E; Sacks, D			Protection against cutaneous Leishmaniasis resulting from bites of uninfected sand flies	SCIENCE			English	Article							EXPERIMENTAL TRANSMISSION; INTERFERON-GAMMA; VECTOR SALIVA; NATURAL MODEL; DIPTERA; MICE; IMMUNOLOGY; MODULATION; HAMSTERS; MEXICANA	Despite the fact that Leishmania are transmitted exclusively by sand flies, none of the experimental models of Leishmaniasis have established infection via sand fly bites. Here we describe a reproducible murine model of Leishmania major infection transmitted by Phlebotomus papatasi. Prior exposure of mice to bites of uninfected sand flies conferred powerful protection against Leishmania major that was associated with a strong delayed-type hypersensitivity response and with interferon-gamma production at the site of parasite delivery. These results have important implications for the epidemiology of cutaneous leishmaniasis and suggest a vaccination strategy against this and possibly other vector-borne diseases.	NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Entomol, Washington, DC 20307 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center	Sacks, D (corresponding author), NIAID, Parasit Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	dsacks@nih.gov	Rowton, Edgar D/A-4474-2012; Rowton, Edgar D./A-1975-2011	Rowton, Edgar D./0000-0002-1979-1485; Belkaid, Yasmine/0000-0001-9962-3571	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000256, Z01AI000256] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEACH R, 1985, AM J TROP MED HYG, V34, P278, DOI 10.4269/ajtmh.1985.34.278; Belkaid Y, 1998, J EXP MED, V188, P1941, DOI 10.1084/jem.188.10.1941; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 1996, J IMMUNOL METHODS, V199, P5, DOI 10.1016/S0022-1759(96)00117-2; Brossard M, 1997, MED VET ENTOMOL, V11, P270, DOI 10.1111/j.1365-2915.1997.tb00406.x; CROSS ML, 1993, J MED ENTOMOL, V30, P725, DOI 10.1093/jmedent/30.4.725; Fayyazi A, 1999, ARCH DERMATOL RES, V291, P485, DOI 10.1007/s004030050442; Kang KF, 1996, J IMMUNOL, V156, P1402; KILLICKKENDRICK R, 1977, PROC R SOC SER B-BIO, V196, P105, DOI 10.1098/rspb.1977.0032; LAINSON R, 1977, NATURE, V266, P628, DOI 10.1038/266628a0; LAWYER PG, 1990, T ROY SOC TROP MED H, V84, P229, DOI 10.1016/0035-9203(90)90266-H; LAWYER PG, 1987, J MED ENTOMOL, V24, P458, DOI 10.1093/jmedent/24.4.458; Mbow ML, 1998, J IMMUNOL, V161, P5571; POZIO E, 1985, T ROY SOC TROP MED H, V79, P524, DOI 10.1016/0035-9203(85)90085-9; RIBEIRO JMC, 1989, EXP PARASITOL, V69, P104, DOI 10.1016/0014-4894(89)90177-X; Sugaya M, 1999, J INVEST DERMATOL, V113, P350, DOI 10.1046/j.1523-1747.1999.00697.x; Takashima A, 1996, Semin Immunol, V8, P333, DOI 10.1006/smim.1996.0044; TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436; Wikel SK, 1999, BIOSCIENCE, V49, P311, DOI 10.2307/1313614; Wikel SK, 1999, INT J PARASITOL, V29, P851, DOI 10.1016/S0020-7519(99)00042-9; Willadsen P, 1999, PARASITOL TODAY, V15, P258, DOI 10.1016/S0169-4758(99)01472-6; Zeidner NS, 1999, PARASITE IMMUNOL, V21, P35, DOI 10.1046/j.1365-3024.1999.00199.x	22	254	267	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1351	1354		10.1126/science.290.5495.1351	http://dx.doi.org/10.1126/science.290.5495.1351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082061				2022-12-28	WOS:000165379800047
J	Martin, DK; Emanuel, LL; Singer, PA				Martin, DK; Emanuel, LL; Singer, PA			Planning for the end of life	LANCET			English	Article							SUSTAINING TREATMENT PREFERENCES; ADVANCE DIRECTIVES; CARE; DECISIONS; HIV		Univ Toronto, Joint Ctr Bioeth, Toronto, ON M5G 1L4, Canada; Northwestern Univ, Evanston, IL USA	University of Toronto; Northwestern University	Singer, PA (corresponding author), Univ Toronto, Joint Ctr Bioeth, 88 Coll St, Toronto, ON M5G 1L4, Canada.	peter.singer@utoronto.ca						*BRIT MED ASS, 1995, ADV STAT MED TREATM; *BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; Doukas David J, 1992, Ethics Behav, V2, P51, DOI 10.1207/s15327019eb0201_4; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; EMANUEL LL, 1995, J AM GERIATR SOC, V43, P440, DOI 10.1111/j.1532-5415.1995.tb05821.x; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hines SC, 1999, ANN INTERN MED, V130, P825, DOI 10.7326/0003-4819-130-10-199905180-00016; *I MED, 1997, APPR DEATH IMPR CAR; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lambert P, 1990, Law Med Health Care, V18, P202, DOI 10.1111/j.1748-720X.1990.tb00023.x; Landry FJ, 1997, J GEN INTERN MED, V12, P412, DOI 10.1046/j.1525-1497.1997.00072.x; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MOWER WR, 1993, ARCH INTERN MED, V153, P375, DOI 10.1001/archinte.153.3.375; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; Ramsay S, 1999, LANCET, V354, P1361, DOI 10.1016/S0140-6736(99)90182-4; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SINGER PA, 1995, J AM SOC NEPHROL, V6, P1410; Singer PA, 1997, J GEN INTERN MED, V12, P729, DOI 10.1046/j.1525-1497.1997.07157.x; SINGER PA, 1994, LANCET, V344, P594, DOI 10.1016/S0140-6736(94)91971-2; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; TENO JM, 1994, HASTINGS CENT REP, V24, pS32, DOI 10.2307/3563482; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; VIRMANI J, 1994, ARCH INTERN MED, V154, P909, DOI 10.1001/archinte.154.8.909	30	75	79	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1672	1676		10.1016/S0140-6736(00)03168-8	http://dx.doi.org/10.1016/S0140-6736(00)03168-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	372TB	11089839				2022-12-28	WOS:000165249200037
J	Allman, BE; McMahon, PJ; Nugent, KA; Paganin, D; Jacobson, DL; Arif, M; Werner, SA				Allman, BE; McMahon, PJ; Nugent, KA; Paganin, D; Jacobson, DL; Arif, M; Werner, SA			Imaging - Phase radiography with neutrons	NATURE			English	Article									Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia; Natl Inst Stand & Technol, Phys Lab, Gaithersburg, MD 20899 USA; Univ Missouri, Dept Phys & Astron, Columbia, MO 65211 USA	University of Melbourne; National Institute of Standards & Technology (NIST) - USA; University of Missouri System; University of Missouri Columbia	Allman, BE (corresponding author), Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia.	k.nugent@physics.unimelb.edu.au	Nugent, Keith A/J-2699-2012; paganin, david m/B-9717-2009; Nugent, Keith A/I-4154-2016	Nugent, Keith A/0000-0003-1522-8991; Nugent, Keith A/0000-0002-4281-3478; Paganin, David/0000-0002-7758-7140				Allman BE, 2000, J OPT SOC AM A, V17, P1732, DOI 10.1364/JOSAA.17.001732; Bajt S, 2000, ULTRAMICROSCOPY, V83, P67, DOI 10.1016/S0304-3991(99)00174-6; Barty A, 1998, OPT LETT, V23, P817, DOI 10.1364/OL.23.000817; Dietze M, 1996, NUCL INSTRUM METH A, V377, P320, DOI 10.1016/0168-9002(96)00203-3; GUREYEV TE, 1995, J OPT SOC AM A, V12, P1942, DOI 10.1364/JOSAA.12.001942; Nugent KA, 1996, PHYS REV LETT, V77, P2961, DOI 10.1103/PhysRevLett.77.2961; Paganin D, 1998, PHYS REV LETT, V80, P2586, DOI 10.1103/PhysRevLett.80.2586; SCHLENKER M, 1986, PHYSICA B & C, V137, P309, DOI 10.1016/0378-4363(86)90336-0; TEAGUE MR, 1983, J OPT SOC AM, V73, P1434, DOI 10.1364/JOSA.73.001434; Zernike F, 1942, PHYSICA, V9, P686, DOI 10.1016/S0031-8914(42)80035-X	10	151	159	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					158	159		10.1038/35041626	http://dx.doi.org/10.1038/35041626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089960				2022-12-28	WOS:000165180400031
J	Lamping, DL; Constantinovici, N; Roderick, P; Normand, C; Henderson, L; Harris, S; Brown, E; Gruen, R; Victor, C				Lamping, DL; Constantinovici, N; Roderick, P; Normand, C; Henderson, L; Harris, S; Brown, E; Gruen, R; Victor, C			Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: a prospective cohort study	LANCET			English	Article							SF-36 HEALTH SURVEY; RENAL-REPLACEMENT THERAPY; SURVEY QUESTIONNAIRE; RATIONING DEBATE; SURVIVAL; DISEASE; BRITAIN; ENGLAND; CARE; AGE	Background Evidence-based health policy is urgently needed to meet the increasing demand for health services among elderly people, particularly for expensive technologies such as renal-replacement therapy. Age has been used to ration dialysis, although not always explicitly, despite the lack of rigorous empirical evidence about how elderly people fare on dialysis. We undertook a comprehensive assessment of outcomes in patients 70 years or over. Methods We did a 12-month prospective cohort study of outcomes in 221 patients with end-stage renal failure aged 70 years or over recruited from four hospital-based renal units, We assessed 1-year survival in 125 incident patients (70-86 years) and disease burden (hospital admissions, quality of life, costs) in 174 prevalent patients (70-93 years). Findings 1-year survival rates were: 71% overall; 80%, 69%, and 54% in patients 70-74 years, 75-79 years, and 80 years and older, respectively (p=0008); and 88%, 71%, and 64% in patients with no, one, or two or more comorbid conditions, respectively (p=0056), Cox regression analyses showed that mortality was significantly associated with age 80 years and older (relative risk 2.79 [95% CI 1.28-6.93]) and peripheral vascular disease (2.83 [1.29-6.17]), but not with diabetes, ischaemic heart disease, cerebrovascular disease, chronic obstructive airways disease, sex, or treatment method. In terms of disease burden, hospital admissions represent a low proportion of costs and was not required by a third of patients, mental quality of life in elderly dialysis patients was similar to that of elderly people in the general population, and the average annual cost per patient of pound 20 802 (US$31 200) (68% dialysis treatment, 1% transport, 19% inpatient hospital admissions, 12% medications) was within the range of other life-extending interventions. Interpretation Our results suggest that age alone should not be used as a barrier to referral and treatment and emphasise the need to consider the benefits of dialysis in elderly people. Indicators of the ability to benefit from treatment, rather than chronological age, should be used to develop policies that ensure equal access to care for all.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England; Kensington & Chelsea & Westminster Hlth Author, Dept Publ Hlth, London, England; Royal Free & UCL, Dept Primary Care & Populat Sci, London, England; Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton, Hants, England; Charing Cross Hosp, Dept Renal Med, London, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of Southampton; Imperial College London; St Georges University London	Lamping, DL (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England.	donna.lamping@lshtm.ac.uk		Normand, Charles/0000-0002-0885-5754; Victor, Christina/0000-0002-4213-3974				ANSELL D, 1999, 2 UK REN REG; Barrett BJ, 1997, AM J KIDNEY DIS, V29, P214, DOI 10.1016/S0272-6386(97)90032-9; Bosanquet N, 1993, Health Trends, V25, P146; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Chandna SM, 1999, BRIT MED J, V318, P217; *CIPFA, 1997, PERS SOC SERV STAT H; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; Davies R, 1997, NEPHROL DIAL TRANSPL, V12, P2512, DOI 10.1093/ndt/12.12.2512; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; *DEP HLTH, 1994, REP HLTH CAR STRAT U; Drummond MF, 2015, METHODS EC EVALUATIO; Evans JG, 1997, BRIT MED J, V314, P822, DOI 10.1136/bmj.314.7083.822; Graham B, 1997, BRIT J GEN PRACT, V47, P170; Haycox A, 1996, J Manag Med, V10, P6, DOI 10.1108/02689239610113487; HAYES V, 1995, AGE AGEING, V24, P120, DOI 10.1093/ageing/24.2.120; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; KHAN IH, 1996, QJM, V89, P397; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Mallick N, 1999, NEPHROL DIAL TRANSPL, V14, P37, DOI 10.1093/ndt/14.1.37; Mallick NP, 1997, NEPHROL DIAL TRANSPL, V12, P25; *REN ASS ROYAL COL, 1997, TREATM AD PAT REN FA; Roderick PJ, 1998, QJM-MON J ASSOC PHYS, V91, P581, DOI 10.1093/qjmed/91.8.581; Stanton J, 1999, SOC SCI MED, V49, P1169, DOI 10.1016/S0277-9536(99)00158-6; *US REN DAT SYST, 1991, AM J KIDNEY DIS S, V18, P17; Varekamp I, 1998, SOC SCI MED, V47, P113, DOI 10.1016/S0277-9536(98)00012-4; WARE JE, 1994, SF36 PHYSICAL MENTAL; WATKINS PJ, 1989, BRIT MED J, V299, P1135; Williams A, 1997, BRIT MED J, V314, P820, DOI 10.1136/bmj.314.7083.820; Wonderling D, 1996, BRIT MED J, V312, P1274, DOI 10.1136/bmj.312.7041.1274	32	260	277	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1543	1550		10.1016/S0140-6736(00)03123-8	http://dx.doi.org/10.1016/S0140-6736(00)03123-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	370QV	11075766				2022-12-28	WOS:000165134500008
J	Nanke, Y; Kotake, S; Akama, H; Yamagata, H; Kamatani, N				Nanke, Y; Kotake, S; Akama, H; Yamagata, H; Kamatani, N			Multiple distal interphalangeal joint dislocation	LANCET			English	Article									Natl Murayama Hosp, Tokyo, Japan; Tokyo Womens Med Univ, Inst Rheumatol, Tokyo 1620054, Japan	Tokyo Women's Medical University	Nanke, Y (corresponding author), Tokyo Womens Med Univ, Inst Rheumatol, Tokyo 1620054, Japan.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1550	1550		10.1016/S0140-6736(00)03124-X	http://dx.doi.org/10.1016/S0140-6736(00)03124-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075767	Bronze			2022-12-28	WOS:000165134500009
J	Calignano, A; Katona, I; Desarnaud, F; Giuffrida, A; La Rana, G; Mackie, K; Freund, TF; Piomelli, D				Calignano, A; Katona, I; Desarnaud, F; Giuffrida, A; La Rana, G; Mackie, K; Freund, TF; Piomelli, D			Bidirectional control of airway responsiveness by endogenous cannabinoids	NATURE			English	Article							RAT-BRAIN MICROSOMES; GUINEA-PIG; SELECTIVE ANTAGONIST; CB1 RECEPTORS; RELEASE; COUGH; INHIBITION; ANANDAMIDE; SR141716A; NEURONS	Smoking marijuana or administration of its main active constituent, Delta (9)-tetrahydrocannabinol (Delta (9)-THC), may exert potent dilating effects on human airways(1-4). But the physiological significance of this observation and its potential therapeutic value are obscured by the fact that some asthmatic patients respond to these compounds with a paradoxical bronchospasm(3,5). The mechanisms underlying these contrasting responses remain unresolved. Here we show that the endogenous cannabinoid anandamide exerts dual effects on bronchial responsiveness in rodents: it strongly inhibits bronchospasm and cough evoked by the chemical irritant, capsaicin, but causes bronchospasm when the constricting tone exerted by the vagus nerve is removed. Both effects are mediated through peripheral CB1 cannabinoid receptors found on axon terminals of airway nerves. Biochemical analyses indicate that anandamide is synthesized in lung tissue on calcium-ion stimulation, suggesting that locally generated anandamide participates in the intrinsic control of airway responsiveness. In support of this conclusion, the CB1 antagonist SR141716A enhances capsaicin-evoked bronchospasm and cough. Our results may account for the contrasting bronchial actions of cannabis-like drugs in humans, and provide a framework for the development of more selective cannabinoid-based agents for the treatment of respiratory pathologies.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Hungarian Acad Sci, Inst Expt Med, H-1450 Budapest, Hungary; Univ Naples Federico II, Dept Pharmacol, I-80131 Naples, Italy; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	University of California System; University of California Irvine; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; University of Naples Federico II; University of Washington; University of Washington Seattle	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	piomelli@uci.edu	Mackie, Ken/E-3715-2013; Katona, Istvan/D-9729-2011; Mackie, Kenneth P/B-7358-2011; Giuffrida, Andrea/H-3770-2013	Mackie, Ken/0000-0001-8501-6199; Katona, Istvan/0000-0003-2808-3330; Giuffrida, Andrea/0000-0002-3773-0694; CALIGNANO, Antonio/0000-0002-1742-3179				ABBOUD RT, 1976, CHEST, V70, P480, DOI 10.1378/chest.70.4.480; [Anonymous], 2000, SCI MARIJUANA; BARNES PJ, 1992, PHYSIOL REV, V72, P699, DOI 10.1152/physrev.1992.72.3.699; BOLSER DC, 1995, EUR J PHARMACOL, V276, pR1, DOI 10.1016/0014-2999(95)00118-5; Cadas H, 1997, J NEUROSCI, V17, P1226; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Coutts AA, 1997, BRIT J PHARMACOL, V121, P1557, DOI 10.1038/sj.bjp.0701301; CSIFFARY A, 1990, BRAIN RES, V506, P215, DOI 10.1016/0006-8993(90)91253-D; DESARNAUD F, 1995, J BIOL CHEM, V270, P6030, DOI 10.1074/jbc.270.11.6030; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; Karlsson JA, 1999, PULM PHARMACOL THER, V12, P215, DOI 10.1006/pupt.1999.0207; Katona I, 1999, J NEUROSCI, V19, P4544; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Rice W, 1997, EUR J PHARMACOL, V327, P227, DOI 10.1016/S0014-2999(97)89665-3; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SAMHOUN MN, 1984, PROSTAGLANDINS, V27, P711, DOI 10.1016/0090-6980(84)90009-1; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Szallasi A, 1999, PHARMACOL REV, V51, P159; TASHKIN DP, 1977, AM REV RESPIR DIS, V115, P57; TASHKIN DP, 1975, AM REV RESPIR DIS, V112, P377; VACHON L, 1973, NEW ENGL J MED, V288, P985, DOI 10.1056/NEJM197305102881902; VanHoozen BE, 1997, CLIN REV ALLERG IMMU, V15, P243, DOI 10.1007/BF02737700; Widdicombe JG, 1998, RESP PHYSIOL, V114, P5, DOI 10.1016/S0034-5687(98)00076-0; Zygmunt PM, 2000, TRENDS PHARMACOL SCI, V21, P43, DOI 10.1016/S0165-6147(99)01430-3	30	140	150	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 2	2000	408	6808					96	101		10.1038/35040576	http://dx.doi.org/10.1038/35040576			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081515	Green Submitted			2022-12-28	WOS:000165050400059
J	Knapp, S				Knapp, S			What's in a name? Linnaeus' marginal jottings created order out of botanical chaos.	NATURE			English	Editorial Material									Nat Hist Museum, Dept Bot, London SW7 5BD, England	Natural History Museum London	Knapp, S (corresponding author), Nat Hist Museum, Dept Bot, Cromwell Rd, London SW7 5BD, England.								0	9	8	0	2	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					33	33		10.1038/35040663	http://dx.doi.org/10.1038/35040663			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081489	Bronze			2022-12-28	WOS:000165050400033
J	Boers, M				Boers, M			Value of magnetic resonance imaging in rheumatoid arthritis?	LANCET			English	Editorial Material									Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Boers, M (corresponding author), Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands.							Boers M, 1998, J RHEUMATOL, V25, P198; CONAGHAN P, IN PRESS J RHEUMATOL; FRYBACK DG, 1991, MED DECIS MAKING, V11, P88, DOI 10.1177/0272989X9101100203; Klarlund M, 2000, ANN RHEUM DIS, V59, P521, DOI 10.1136/ard.59.7.521; LASSERE M, IN PRESS J RHEUMATOL; McGonagle D, 1998, LANCET, V352, P1137, DOI 10.1016/S0140-6736(97)12004-9; OSTERGAARD M, IN PRESS J RHEUMATOL; PETERFY CG, IN PRESS J RHEUMATOL; VanderHeijde DMFM, 1996, BAILLIERE CLIN RHEUM, V10, P435, DOI 10.1016/S1521-6942(96)80007-6	9	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1458	1459						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081524				2022-12-28	WOS:000090067300005
J	Greene, MT				Greene, MT			High achiever - The discovery of the stratosphere laid the foundations of geophysics	NATURE			English	Editorial Material									Univ Puget Sound, Dept Hist, Tacoma, WA 98416 USA		Greene, MT (corresponding author), Univ Puget Sound, Dept Hist, Tacoma, WA 98416 USA.			Greene, Mott/0000-0002-4864-1806					0	2	2	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					947	947		10.1038/35039642	http://dx.doi.org/10.1038/35039642			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069160	Bronze			2022-12-28	WOS:000090032500022
J	Shim, M; Guyot-Sionnest, P				Shim, M; Guyot-Sionnest, P			N-type colloidal semiconductor nanocrystals	NATURE			English	Article							QUANTUM DOTS; CONDUCTING FILMS; POLYMER	Colloidal semiconductor nanocrystals(1,2) combine the physical and chemical properties of molecules with the optoelectronic properties of semiconductors. Their colour is highly controllable, a direct consequence of quantum confinement on the electronic states(3). Such nanocrystals are a form of 'artificial atoms' (ref. 4) that may rnd applications in optoelectronic systems such as light-emitting diodes(5,6) and photovoltaic cells(7), or as components of future nanoelectronic devices. The ability to control the electron occupation (especially in n-type or p-type nanocrystals) is important for tailoring the electrical and optical properties, and should lead to a wider range of practical devices. But conventional doping by introducing impurity atoms has been unsuccessful so far: impurities tend to be expelled from the small crystalline cores (as observed for magnetic impurities(8)), and thermal ionization of the impurities (which provides free carriers) is hindered by strong confinement. Here we report the fabrication of n-type nanocrystals using an electron transfer approach commonly employed in the field of conducting organic polymers(9). We find that semiconductor nanocrystals prepared as colloids can be made n-type, with electrons in quantum confined states.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA	University of Chicago	Shim, M (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.		Shim, Moonsub/A-7875-2009	Shim, Moonsub/0000-0001-7781-1029				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016; CHIANG CK, 1978, J AM CHEM SOC, V100, P1013, DOI 10.1021/ja00471a081; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; DABBOUSI BO, 1995, APPL PHYS LETT, V66, P1316, DOI 10.1063/1.113227; Guyot-Sionnest P, 1998, APPL PHYS LETT, V72, P686, DOI 10.1063/1.120846; HADDON RC, 1991, NATURE, V350, P320, DOI 10.1038/350320a0; HOYER P, 1994, CHEM PHYS LETT, V221, P379, DOI 10.1016/0009-2614(94)00287-8; HOYER P, 1993, BER BUNSEN PHYS CHEM, V97, P630, DOI 10.1002/bbpc.19930970416; KAMAT PV, 1994, PROG REACT KINET MEC, V19, P277; Lee RS, 1997, NATURE, V388, P255, DOI 10.1038/40822; Mikulec FV, 2000, J AM CHEM SOC, V122, P2532, DOI 10.1021/ja991249n; Miller R. J. D., 1995, SURFACE ELECT TRANSF; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nirmal M, 1999, ACCOUNTS CHEM RES, V32, P407, DOI 10.1021/ar9700320; Norris DJ, 1996, PHYS REV B, V53, P16338, DOI 10.1103/PhysRevB.53.16338; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Shim M, 1999, J CHEM PHYS, V111, P6955, DOI 10.1063/1.479988; Shim M, 2000, J PHYS CHEM B, V104, P1494, DOI 10.1021/jp994107o	21	425	446	2	178	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					981	983		10.1038/35039577	http://dx.doi.org/10.1038/35039577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069172				2022-12-28	WOS:000090032500036
J	Trichopoulos, D				Trichopoulos, D			Short-term and long-term effects of iron deficiency in utero	LANCET			English	Editorial Material							INFANT; FETAL; RISK		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Trichopoulos, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.							BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; FORSDAHL A, 1978, J EPIDEMIOL COMMUN H, V32, P34, DOI 10.1136/jech.32.1.34; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864	6	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					696	696		10.1016/S0140-6736(00)02623-4	http://dx.doi.org/10.1016/S0140-6736(00)02623-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085684				2022-12-28	WOS:000088948200004
J	Kotani, N; Kushikata, T; Hashimoto, H; Kimura, F; Muraoka, M; Yodono, M; Asai, M; Matsuki, A				Kotani, N; Kushikata, T; Hashimoto, H; Kimura, F; Muraoka, M; Yodono, M; Asai, M; Matsuki, A			Intrathecal methylprednisolone for intractable postherpetic neuralgia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROSPINAL-FLUID; PAIN; INTERLEUKIN-8; THERAPY; CORTICOSTEROIDS; COMPLICATIONS; MENINGITIS; INJECTION; ACETATE; RATS	Background: There is no effective treatment for intractable postherpetic neuralgia. Because there is evidence that postherpetic neuralgia has an inflammatory component, we assessed treatment with intrathecally administered methylprednisolone to reduce pain in patients with this disorder. Methods: We enrolled 277 patients who had had intractable postherpetic neuralgia for at least one year, 270 of whom were followed for two years. The patients were randomly assigned to receive intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients), lidocaine alone (3 ml of 3 percent lidocaine, 91 patients), or no treatment (90 patients) once per week for up to four weeks. Each weekly dose was injected into the lumbar intrathecal space. Pain was evaluated before randomization, at the end of the treatment period, and then four weeks, one year, and two years later. Samples of cerebrospinal fluid were obtained for measurement of interleukin-8 before and at the end of the treatment period. Results: There was minimal change in the degree of pain in the lidocaine-only and control groups during and after the treatment period. In the methylprednisolone-lidocaine group, the intensity and area of pain decreased, and the use of the nonsteroidal antiinflammatory drug diclofenac declined by more than 70 percent four weeks after the end of treatment. No complications related to intrathecal methylprednisolone were observed. Before treatment, the concentrations of interleukin-8 in the cerebrospinal fluid were inversely related to the duration of neuralgia in all the patients (r=-0.49, P<0.001). In the patients who received methylprednisolone, interleukin-8 concentrations decreased by 50 percent, and this decrease correlated with the duration of neuralgia and with the extent of global pain relief (P<0.001 for both comparisons). Conclusions: The results of this trial indicate that the intrathecal administration of methylprednisolone is an effective treatment for postherpetic neuralgia. (N Engl J Med 2000;343:1514-9.) (C) 2000, Massachusetts Medical Society.	Hirosaki Univ, Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan	Hirosaki University	Kotani, N (corresponding author), Hirosaki Univ, Sch Med, Dept Anesthesiol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.			kushikata, tetsuya/0000-0003-4263-0177				ABRAM SE, 1978, ANESTH ANALG, V57, P313; ABRAM SE, 1994, ANESTHESIOLOGY, V81, P1198, DOI 10.1097/00000542-199411000-00013; Burgener I, 1998, J NEUROIMMUNOL, V89, P182, DOI 10.1016/S0165-5728(98)00134-9; CHINO N, 1974, ARCH PHYS MED REHAB, V55, P33; CUNHA FQ, 1991, BRIT J PHARMACOL, V104, P765, DOI 10.1111/j.1476-5381.1991.tb12502.x; DEVOR M, 1985, PAIN, V22, P127, DOI 10.1016/0304-3959(85)90173-3; DOUGHERTY JH, 1978, J NEUROSURG, V48, P1023, DOI 10.3171/jns.1978.48.6.1023; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; ENDO H, 1994, CLIN EXP IMMUNOL, V96, P31; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; Gazvani MR, 1998, HUM REPROD, V13, P1957, DOI 10.1093/humrep/13.7.1957; GRACELY RH, 1993, PAIN, V52, P251, DOI 10.1016/0304-3959(93)90141-B; HALL ED, 1982, INT REV NEUROBIOL, V23, P165, DOI 10.1016/S0074-7742(08)60625-X; Hodgson PS, 1999, ANESTH ANALG, V88, P797, DOI 10.1097/00000539-199904000-00023; Johansson A, 1997, REGION ANESTH, V22, P59, DOI 10.1016/S1098-7339(06)80057-X; Kikuchi A, 1999, REGION ANESTH PAIN M, V24, P287, DOI 10.1016/S1098-7339(99)90101-3; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEVINE SJ, 1993, AM J PHYSIOL, V265, P360; NELSON DA, 1973, ACTA NEUROL SCAND, V49, P176; NELSON DA, 1988, ARCH NEUROL-CHICAGO, V45, P804, DOI 10.1001/archneur.1988.00520310122029; NELSON DA, 1993, SPINE, V18, P278, DOI 10.1097/00007632-199302000-00018; PARKHURST RD, 1971, NEUROLOGY, V21, P906, DOI 10.1212/WNL.21.9.906; RIVERA VM, 1981, NEUROLOGY, V31, P1060, DOI 10.1212/WNL.31.8.1060; ROCHE J, 1984, MED J AUSTRALIA, V140, P281, DOI 10.5694/j.1326-5377.1984.tb104038.x; ROWBOTHAM MC, 1994, SEMIN NEUROL, V14, P247, DOI 10.1055/s-2008-1041083; SEHGAL AD, 1963, ARCH NEUROL-CHICAGO, V9, P64, DOI 10.1001/archneur.1963.00460070074007; SEHGAL ARJUN D., 1960, CLEVELAND CLIN QUART, V27, P198; SEKI T, 1993, IMMUNOLOGY, V80, P333; Tarkowski E, 1997, CLIN EXP IMMUNOL, V110, P492, DOI 10.1046/j.1365-2249.1997.4621483.x; VATES TS, 1977, DEL MED J, V49, P331; WATSON CPN, 1991, PAIN, V44, P105, DOI 10.1016/0304-3959(91)90124-G; WILKINSON HA, 1992, CLIN J PAIN, V8, P49, DOI 10.1097/00002508-199203000-00010; Yamashiro H, 1990, Masui, V39, P106	33	199	210	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1514	1519		10.1056/NEJM200011233432102	http://dx.doi.org/10.1056/NEJM200011233432102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087880	Bronze			2022-12-28	WOS:000165410900002
J	El-Hussein, AE; Schnell, E; Chetkovich, DM; Nicoll, RA; Bredt, DS				El-Hussein, AE; Schnell, E; Chetkovich, DM; Nicoll, RA; Bredt, DS			PSD-95 involvement in maturation of excitatory synapses	SCIENCE			English	Article							SUPPRESSOR GENE DLG; KINASE-LIKE DOMAIN; INTRAMOLECULAR INTERACTION; PROTEIN; FAMILY	PSD-95 is a neuronal PDZ protein that associates with receptors and cytoskeletal elements at synapses, but whose function is uncertain. We found that overexpression of PSD-95 in hippocampal neurons can drive maturation of glutamatergic synapses. PSD-95 expression enhanced postsynaptic clustering and activity of glutamate receptors. Postsynaptic expression of PSD-95 also enhanced maturation of the presynaptic terminal. These effects required synaptic clustering of PSD-95 but did not rely on its guanylate kinase domain. PSD-95 expression also increased the number and size of dendritic spines. These results demonstrate that PSD-95 can orchestrate synaptic development and are suggestive of roles for PSD-95 in synapse stabilization and plasticity.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bredt, DS (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	bredt@itsa.ucsf.edu	Chetkovich, Dane/AAV-5457-2021	Schnell, Eric/0000-0002-5623-5015				Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Brenman JE, 1996, J NEUROSCI, V16, P7407; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gomperts SN, 2000, J NEUROSCI, V20, P2229; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; Rao A, 1998, J NEUROSCI, V18, P1217; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000	28	930	973	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	2000	290	5495					1364	1368						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082065				2022-12-28	WOS:000165379800051
J	Daaleman, TP; VandeCreek, L				Daaleman, TP; VandeCreek, L			Placing religion and spirituality in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ASSISTED SUICIDE; BREAST-CANCER; PHYSICIANS; ATTITUDES; BELIEFS; ADULTS; DEATH; OLDER		Univ Kansas, Med Ctr, Dept Family Med, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Hist & Philosophy Med, Ctr Aging, Kansas City, KS 66160 USA; Healthcare Chaplaincy, New York, NY USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Daaleman, TP (corresponding author), Univ Kansas, Med Ctr, Dept Family Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.	tdaalema@kumc.edu		Daaleman, Timothy/0000-0002-1649-4266				Antonovsky A., 1987, UNRAVELING MYSTERY H; Bradshaw A, 1996, SOC SCI MED, V43, P409, DOI 10.1016/0277-9536(95)00406-8; Brady MJ, 1999, PSYCHO-ONCOLOGY, V8, P417, DOI 10.1002/(SICI)1099-1611(199909/10)8:5<417::AID-PON398>3.0.CO;2-4; BRODY H, 1992, HEALERS POWER; BYOCK R, 1997, DYING WELL PROSPECT; CASSEL CK, 1999, PRINCIPLES CARE PATI; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Coward D. D, 1989, NURS SCI QUART, V3, P162; Cunningham AJ, 1998, PSYCHO-ONCOL, V7, P508, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<508::AID-PON376>3.0.CO;2-7; Daaleman TP, 1998, ARCH FAM MED, V7, P548, DOI 10.1001/archfami.7.6.548; DAALEMAN TP, 1997, BIOETHICS FORUM, V13, P49; Dorff Elliot N, 1991, Conserv Jud, V43, P3; Dow KH, 1996, BREAST CANCER RES TR, V39, P261, DOI 10.1007/BF01806154; DOYLE D., 1999, OXFORD TXB PALLIATIV; DUBOSE ER, 1999, PHYSICIAN ASSISTED S; ELLISON CG, 1991, J HEALTH SOC BEHAV, V32, P80, DOI 10.2307/2136801; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1998, JAMA-J AM MED ASSOC, V280, P507, DOI 10.1001/jama.280.6.507; FITCHETT G, 1998, PSYCHO-ONCOLOGY, P790; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; *GEN ASS UN UN, 1988, RIGHT DIE DIGN P GEN; Holland JC, 1998, PSYCHO-ONCOL, V7, P460, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<460::AID-PON328>3.0.CO;2-R; *I MED, 1997, APPR DEATH IMPR CAR; JENKINS RA, 1988, SOC SCI MED, V26, P625, DOI 10.1016/0277-9536(88)90027-5; Kaczorowski J M, 1989, Hosp J, V5, P105; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KRAUSE N, 1989, J GERONTOL, V44, pS4, DOI 10.1093/geronj/44.1.S4; Larson DB, 1998, SCI RES SPIRITUALITY; Lazarus RS., 1984, STRESS APPRAISAL COP; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Mathew L M, 1986, Clin Geriatr Med, V2, P617; MEIER DE, 1998, NEW ENGL J MED, V338, P967; *NAT C CATH BISH, 1994, ETH REL DIR CATH HLT; Neimeyer R. A., 1994, DEATH ANXIETY HDB RE; OCONNELL LJ, 1995, WESTERN J MED, V163, P231; Pargament K.I., 1997, PSYCHOL RELIG COPING; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; POST SG, 1995, J LAW MED ETHICS, V23, P20, DOI 10.1111/j.1748-720X.1995.tb01326.x; REED PG, 1987, RES NURS HEALTH, V10, P335, DOI 10.1002/nur.4770100507; Seale C, 1998, CONSTRUCTING DEATH S; SEIDLITZ L, 1995, J AM GERIATR SOC, V43, P993, DOI 10.1111/j.1532-5415.1995.tb05563.x; Smith Elizabeth D., 1993, Journal of Psychosocial Oncology, V11, P89; SPIEGEL D, 1989, LANCET, V2, P888; Sullivan M, 1998, J AM GERIATR SOC, V46, P1251, DOI 10.1111/j.1532-5415.1998.tb04541.x; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; THOMPSON SC, 1988, J SOC CLIN PSYCHOL, V7, P260, DOI 10.1521/jscp.1988.7.2-3.260; Van Ness Peter, 1996, SPIRITUALITY SECULAR; *WHO, 1990, TECHN REP SER WHO, V804; Wulff David M., 1997, PSYCHOL RELIG CLASSI; Wuthnow Robert, 1998, HEAVEN SPIRITUALITY	51	109	110	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2514	2517		10.1001/jama.284.19.2514	http://dx.doi.org/10.1001/jama.284.19.2514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074785				2022-12-28	WOS:000165183800028
J	Linsley, BK; Wellington, GM; Schrag, DP				Linsley, BK; Wellington, GM; Schrag, DP			Decadal sea surface temperature variability in the subtropical South Pacific from 1726 to 1997 AD	SCIENCE			English	Article							NORTH PACIFIC; CLIMATE VARIABILITY; PORITES CORALS; NEW-CALEDONIA; CALIBRATION; RATIOS; ENSO; OSCILLATION; HEMISPHERE; ATMOSPHERE	We present a 271-year record of Sr/Ca variability in a coral from Rarotonga in the South Pacific gyre. Calibration with monthly sea surface temperature (SST) from satellite and ship measurements made in a grid measuring 1 degrees by 1 degrees over the period from 1981 to 1997 indicates that this Sr/Ca record is an excellent proxy for SST, Comparison with SST from ship measurements made since 1950 in a grid measuring 5 degrees by 5 degrees also shows that the Sr/Ca data accurately record decadal changes in SST. The entire Sr/Ca record back to 1726 shows a distinct pattern of decadal variability, with repeated decadal and interdecadal SST regime shifts greater than 0.75 degreesC. Comparison with decadal climate variability in the North Pacific, as represented by the Pacific Decadal Oscillation index (1900-1997), indicates that several of the largest decadal-scale SST variations at Rarotonga are coherent with SST regime shifts in the North Pacific. This hemispheric symmetry suggests that tropical forcing may be an important factor in at least some of the decadal variability observed in the Pacific Ocean.	SUNY Albany, Dept Earth & Atmospher Sci, Albany, NY 12222 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Harvard Univ, Dept Earth & Planetary Sci, Lab Geochem Oceanog, Cambridge, MA 02138 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; University of Houston System; University of Houston; Harvard University	Linsley, BK (corresponding author), SUNY Albany, Dept Earth & Atmospher Sci, ES 351, Albany, NY 12222 USA.			Linsley, Braddock/0000-0003-2085-0662				Alibert C, 1997, PALEOCEANOGRAPHY, V12, P345, DOI 10.1029/97PA00318; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Cole JE, 2000, SCIENCE, V287, P617, DOI 10.1126/science.287.5453.617; Crowley TJ, 1997, PALEOCEANOGRAPHY, V12, P633, DOI 10.1029/97PA01348; Deser C, 1996, J CLIMATE, V9, P1840, DOI 10.1175/1520-0442(1996)009<1840:UOTVIT>2.0.CO;2; DEVILLIERS S, 1994, GEOCHIM COSMOCHIM AC, V58, P197, DOI 10.1016/0016-7037(94)90457-X; Garreaud RD, 1999, J CLIMATE, V12, P2113, DOI 10.1175/1520-0442(1999)012<2113:IEAIEL>2.0.CO;2; Gershunov A., 1999, EOS T AM GEOPHYS UN, V80, P25, DOI [DOI 10.1029/99EO00019, 10.1029/99EO00019]; GRAHAM NE, 1994, CLIM DYNAM, V10, P135, DOI 10.1007/BF00210626; JACOBS GA, 1994, NATURE, V370, P360, DOI 10.1038/370360a0; Johnson GC, 1999, J PHYS OCEANOGR, V29, P3073, DOI 10.1175/1520-0485(1999)029<3073:IPFFTS>2.0.CO;2; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; LAMB HH, 1970, PHILOS T R SOC S-A, V266, P425, DOI 10.1098/rsta.1970.0010; LATIF M, 1994, SCIENCE, V266, P634, DOI 10.1126/science.266.5185.634; LINSLEY BK, UNPUB; Linsley RK, 2000, PALEOCEANOGRAPHY, V15, P322; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; MINOBE S, 1997, RES LETT, V24, P638; Peterson RG, 1998, J GEOPHYS RES-OCEANS, V103, P24573, DOI 10.1029/98JC01947; Quinn TM, 1998, PALEOCEANOGRAPHY, V13, P412, DOI 10.1029/98PA00401; RAMPINO MR, 1982, QUATERNARY RES, V18, P127, DOI 10.1016/0033-5894(82)90065-5; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; Schrag DP, 1999, PALEOCEANOGRAPHY, V14, P97, DOI 10.1029/1998PA900025; Shen CC, 1996, GEOCHIM COSMOCHIM AC, V60, P3849, DOI 10.1016/0016-7037(96)00205-0; STOTHERS RB, 1984, SCIENCE, V224, P1191, DOI 10.1126/science.224.4654.1191; Trenberth K.E., 1991, TELECONNECTIONS LINK, P13; TRENBERTH KE, 1990, B AM METEOROL SOC, V71, P988, DOI 10.1175/1520-0477(1990)071<0988:ROICCI>2.0.CO;2; TRENBERTH KE, 1994, CLIM DYNAM, V9, P303, DOI 10.1007/BF00204745; TSUCHIYA M, 1989, PROG OCEANOGR, V23, P101, DOI 10.1016/0079-6611(89)90012-8; Wellington GM, 1996, PALEOCEANOGRAPHY, V11, P467, DOI 10.1029/96PA01023; White WB, 1998, J GEOPHYS RES-OCEANS, V103, P21335, DOI 10.1029/98JC01706; Zhang Y, 1997, J CLIMATE, V10, P1004, DOI 10.1175/1520-0442(1997)010<1004:ELIV>2.0.CO;2	32	194	205	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1145	1148		10.1126/science.290.5494.1145	http://dx.doi.org/10.1126/science.290.5494.1145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073450				2022-12-28	WOS:000165228200043
J	Albert, CM; Mittleman, MA; Chae, CU; Lee, IM; Hennekens, CH; Manson, JE				Albert, CM; Mittleman, MA; Chae, CU; Lee, IM; Hennekens, CH; Manson, JE			Triggering of sudden death from cardiac causes by vigorous exertion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; TIME PHYSICAL-ACTIVITY; LEISURE-TIME; CASE-CROSSOVER; EXERCISE; RISK; MORTALITY; MEN; FITNESS	Background Retrospective and cross-sectional data suggest that vigorous exertion can trigger cardiac arrest or sudden death and that habitual exercise may diminish this risk. However, the role of physical activity in precipitating or preventing sudden death from cardiac causes has not been assessed prospectively in a large number of subjects. Methods We used a prospective, nested case crossover design within the Physicians Health Study to compare the risk of sudden death during and up to 30 minutes after an episode of vigorous exertion with that during periods of lighter exertion or none. We then evaluated whether habitual vigorous exercise modified the risk of sudden death that was associated with vigorous exertion. In addition, the relation of vigorous exercise to the overall risk of sudden death and nonsudden death from coronary heart disease was assessed. Results During 12 years of follow-up, 122 sudden deaths were confirmed among the 21,481 male physicians who were initially free of self-reported cardiovascular disease and who provided information on their habitual level of exercise at base line. The relative risk of sudden death during and up to 30 minutes after vigorous exertion was 16.9 (95 percent confidence interval, 10.5 to 27.0; P < 0.001). However, the absolute risk of sudden death during any particular episode of vigorous exertion was extremely low (1 sudden death per 1.51 million episodes of exertion). Habitual vigorous exercise attenuated the relative risk of sudden death that was associated with an episode of vigorous exertion (P value for trend = 0.006). The base-line level of exercise was not associated with the overall risk of subsequent sudden death. Conclusions These prospective data from a study of U.S. male physicians suggest that habitual vigorous exercise diminishes the risk of sudden death during vigorous exertion. (N Engl J Med 2000; 343:1355-61.) (C) 2000, Massachusetts Medical Society.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth Med, Miami, FL USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; University of Miami	Albert, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.		Lee, I-Min/ABD-5409-2021	Albert, Christine/0000-0002-2081-1121; Mittleman, Murray/0000-0001-9788-7274	NCI NIH HHS [CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-34595, 1-K08-HL-03783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, K08HL003783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Burke AP, 1999, JAMA-J AM MED ASSOC, V281, P921, DOI 10.1001/jama.281.10.921; CHAE CU, 1997, CIRCULATION S1, V96, P303; COBB LA, 1986, J AM COLL CARDIOL, V7, P215, DOI 10.1016/S0735-1097(86)80284-4; COX DR, 1972, J R STAT SOC B, V34, P187; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HULL SS, 1994, CIRCULATION, V89, P548, DOI 10.1161/01.CIR.89.2.548; KANNEL WB, 1982, JAMA-J AM MED ASSOC, V248, P3143; KANNEL WB, 1982, ANN NY ACAD SCI, V382, P3, DOI 10.1111/j.1749-6632.1982.tb55203.x; KOHL HW, 1992, EPIDEMIOL REV, V14, P37, DOI 10.1093/oxfordjournals.epirev.a036091; KOHL HW, 1988, AM J EPIDEMIOL, V127, P1228, DOI 10.1093/oxfordjournals.aje.a114915; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; LEE IM, 1992, AM J EPIDEMIOL, V135, P915, DOI 10.1093/oxfordjournals.aje.a116387; Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1; Lemaitre RN, 1999, ARCH INTERN MED, V159, P686, DOI 10.1001/archinte.159.7.686; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91, DOI 10.1093/oxfordjournals.aje.a117550; MORRIS JN, 1980, LANCET, V2, P1207; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1975, NEW ENGL J MED, V292, P545, DOI 10.1056/NEJM197503132921101; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PERONNET F, 1981, J APPL PHYSIOL, V51, P812, DOI 10.1152/jappl.1981.51.4.812; Rothman K., 1998, MODERN EPIDEMIOLOGY, P253; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; WANNAMETHEE G, 1995, CIRCULATION, V91, P1749, DOI 10.1161/01.CIR.91.6.1749; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WILLICH SN, 1993, CIRCULATION, V87, P1442, DOI 10.1161/01.CIR.87.5.1442; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302	39	650	659	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1355	1361		10.1056/NEJM200011093431902	http://dx.doi.org/10.1056/NEJM200011093431902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070099				2022-12-28	WOS:000165152800002
J	Betts, RA				Betts, RA			Offset of the potential carbon sink from boreal forestation by decreases in surface albedo	NATURE			English	Article							CLIMATE-CHANGE; VEGETATION FEEDBACKS; GLOBAL CLIMATE; SNOW COVER; MODEL; SEQUESTRATION; WATER; GCM	Carbon uptake by forestation is one method proposed(1) to reduce net carbon dioxide emissions to the atmosphere and so limit the radiative forcing of climate change(2). But the overall impact of forestation on climate will also depend on other effects associated with the creation of new forests. In particular, the albedo of a forested landscape is generally lower than that of cultivated land, especially when snow is lying(3-9), and decreasing albedo exerts a positive radiative forcing on climate. Here I simulate the radiative forcings associated with changes in surface albedo as a result of forestation in temperate and boreal forest areas, and translate these forcings into equivalent changes in local carbon stock for comparison with estimated carbon sequestration potentials(10-12). I suggest that in many boreal forest areas, the positive forcing induced by decreases in albedo can offset the negative forcing that is expected from carbon sequestration. Some high-latitude forestation activities may therefore increase climate change, rather than mitigating it as intended.	Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England	Met Office - UK; Hadley Centre	Betts, RA (corresponding author), Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England.		Betts, Richard A/P-8976-2015	Betts, Richard A/0000-0002-4929-0307				Betts RA, 1997, NATURE, V387, P796, DOI 10.1038/42924; BONAN GB, 1995, CLIMATIC CHANGE, V29, P145, DOI 10.1007/BF01094014; BONAN GB, 1992, NATURE, V359, P716, DOI 10.1038/359716a0; Cao MK, 1998, NATURE, V393, P249, DOI 10.1038/30460; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Cox PM, 1999, CLIM DYNAM, V15, P183, DOI 10.1007/s003820050276; DOUVILLE H, 1997, CLIM DYNAM, V13, P57; Edwards JM, 1996, Q J ROY METEOR SOC, V122, P689, DOI 10.1002/qj.49712253107; Essery R, 1997, ANN GLACIOL, V25, P362, DOI 10.3189/S0260305500014282; Gedney N, 2000, GEOPHYS RES LETT, V27, P3053, DOI 10.1029/2000GL011794; HANSEN J, 1983, MON WEATHER REV, V111, P609, DOI 10.1175/1520-0493(1983)111<0609:ETDGMF>2.0.CO;2; Harding RJ, 1996, J CLIMATE, V9, P2778, DOI 10.1175/1520-0442(1996)009<2778:TEBOTW>2.0.CO;2; KEELING CD, 1998, NDP001 CARB DIOX INF; Kondratyev K. Ya., 1982, Land Surface Processes in Atmospheric General Circulation Models. World Climate Research Programme Study Conference, P463; Levis S, 1999, GEOPHYS RES LETT, V26, P747, DOI 10.1029/1999GL900107; Myhre G, 1998, GEOPHYS RES LETT, V25, P2715, DOI 10.1029/98GL01908; NABUURS GJ, 1995, CAN J FOREST RES, V25, P1157, DOI 10.1139/x95-128; NILSSON S, 1995, CLIMATIC CHANGE, V30, P267, DOI 10.1007/BF01091928; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; POSEY JW, 1964, GEOFIS INT, V4, P333; ROBINSON DA, 1984, J CLIM APPL METEOROL, V23, P1626, DOI 10.1175/1520-0450(1984)023<1626:AOADSC>2.0.CO;2; SCHIMEL D, 1995, CLIMATE CHANGE 1995, P65; Sharratt BS, 1998, AGR FOREST METEOROL, V89, P269, DOI 10.1016/S0168-1923(97)00071-3; THOMAS G, 1992, Q J ROY METEOR SOC, V118, P469, DOI 10.1002/qj.49711850505; *UNFCCC, 1999, UNEPIUC992 UNFCCC; *UNFCCC, 1998, UNEPINC982 UNFCCC; Watson RT, 2000, LAND USE LAND USE CH; WILLMOTT CJ, 1985, J CLIMATOL, V5, P589, DOI 10.1002/joc.3370050602; WILSON MF, 1985, J CLIMATOL, V5, P119, DOI 10.1002/joc.3370050202; WOODWARD FI, 1995, GLOBAL BIOGEOCHEM CY, V9, P471, DOI 10.1029/95GB02432	30	683	713	10	247	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 9	2000	408	6809					187	190		10.1038/35041545	http://dx.doi.org/10.1038/35041545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089969				2022-12-28	WOS:000165180400041
J	Khalil, EAG; El Hassan, AM; Zijlstra, EE; Mukhtar, MM; Ghalib, HW; Musa, B; Ibrahim, ME; Kamil, AA; Elsheikh, M; Babiker, A; Modabber, F				Khalil, EAG; El Hassan, AM; Zijlstra, EE; Mukhtar, MM; Ghalib, HW; Musa, B; Ibrahim, ME; Kamil, AA; Elsheikh, M; Babiker, A; Modabber, F			Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan	LANCET			English	Article							CUTANEOUS LEISHMANIASIS; PLUS BCG; KALA-AZAR; SKIN-TEST; IMMUNE-RESPONSE; SOUTHERN SUDAN; DONOVANI; IRAN; MICE	Background Visceral leishmaniasis is a major cause of morbidity and mortality in the Sudan. Drug treatment is expensive, and drug resistance is becoming increasingly common. Safe, effective, and cheap vaccines are needed. We report the results of a vaccine trial against human visceral leishmaniasis. Methods We undertook a double-blind randomised trial to test the safety and efficacy of an autoclaved Leishmania major (ALM) promastigote vaccine (1 mg per dose). Of 5093 volunteers screened, 2306 had negative leishmanin skin tests and reciprocal titres of less than 6400 in the direct agglutination test, They were randomly assigned two doses of ALM mixed with BCG or BCG alone. Volunteers were followed up for 2 years. The primary endpoint was clinical visceral leishmaniasis or post-kala-azar dermal leishmaniasis, Analyses were by intention to treat. Findings Side-effects were confined to the injection site. The cumulative frequency of visceral leishmaniasis at 2 years did not differ significantly between the group assigned ALM plus BCG and that assigned BCG alone (133/1155 [11.5%] vs 141/1151 [12.3%], p=0.6). The vaccine efficacy was 6% (95% CI -18 to 25), The proportion of individuals showing leishmanin skin conversion was significantly higher in the ALM plus BCG group than in the BCG alone group throughout follow-up (303 [30%] vs 72 [7%] at 42 days). Individuals whose leishmanin test converted after vaccination (induration greater than or equal to5 mm) had a significantly lower frequency of visceral leishmaniasis than non-responders (27/375 [7.2%] vs 210/1660 [12.746], p=0.003). Interpretation We found no evidence that two doses of ALM plus BCG offered significant protective immunity against visceral leishmaniasis compared with BCG alone. Leishmanin skin conversion with an induration of 5 mm or more in either group was associated with protection from the disease.	Univ Khartoum, Inst Endem Dis, Leishmaniasis Res Grp, Khartoum, Sudan; Univ Khartoum, Fac Math Sci, Khartoum, Sudan; King Saud Univ, Abha, Saudi Arabia; UCL, Sch Med, MRC, Clin Trials Unit, London W1N 8AA, England; UNDP, World Bank, WHO Special Programme Res & Training Trop Dis, Geneva, Switzerland	University of Khartoum; University of Khartoum; King Saud University; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School; The World Bank; World Health Organization	Khalil, EAG (corresponding author), Univ Khartoum, Inst Endem Dis, Leishmaniasis Res Grp, POB 45235, Khartoum, Sudan.	eltahir@usa.net	Abdel-Rahman, Manar/R-4652-2016	Abdel-Rahman, Manar/0000-0001-9968-9853; Khalil, Eltahir/0000-0002-5165-6902				ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572; CASTES M, 1994, VACCINE, V12, P1041, DOI 10.1016/0264-410X(94)90342-5; DEBEER P, 1990, LANCET, V335, P224, DOI 10.1016/0140-6736(90)90313-T; Dube A, 1998, PARASITOLOGY, V116, P219, DOI 10.1017/S0031182097002175; ELHASSAN AM, 1993, T ROY SOC TROP MED H, V87, P387; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; JARECKIBLACK JC, 1988, ANN CLIN LAB SCI, V18, P72; Khalil EAG, 1998, ANN TROP MED PARASIT, V92, P151, DOI 10.1080/00034989859988; Momeni AZ, 1999, VACCINE, V17, P466, DOI 10.1016/S0264-410X(98)00220-5; NASCIMENTO MDSB, 1993, T ROY SOC TROP MED H, V87, P91, DOI 10.1016/0035-9203(93)90439-W; PEREA WA, 1989, LANCET, V2, P1222, DOI 10.1016/S0140-6736(89)91834-5; RACHAMIM N, 1993, J IMMUNOL, V150, P2322; SATTI MH, 1958, SUDAN MED J, V1, P98; Sharifi I, 1998, LANCET, V351, P1540, DOI 10.1016/S0140-6736(98)09552-X; SMARKOVSKI LL, 1977, INFECT IMMUNOL, V18, P561; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; WEINTRAUB J, 1977, J IMMUNOL, V118, P2288; ZIJLSTRA EE, 1994, AM J TROP MED HYG, V51, P826, DOI 10.4269/ajtmh.1994.51.826; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P365, DOI 10.1016/0035-9203(91)90293-8	19	178	181	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1565	1569		10.1016/S0140-6736(00)03128-7	http://dx.doi.org/10.1016/S0140-6736(00)03128-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075771				2022-12-28	WOS:000165134500013
J	Marsh, JCW				Marsh, JCW			Treatment of aplastic anaemia: first do no harm	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; ANEMIA		Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW19 6PW, England	St Georges University London	Marsh, JCW (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Haematol, London SW19 6PW, England.							Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Deeg H J, 1999, Biol Blood Marrow Transplant, V5, P243, DOI 10.1053/bbmt.1999.v5.pm10465104; Deeg HJ, 1998, BLOOD, V91, P3637; Marsh JCW, 1998, LANCET, V351, P1830, DOI 10.1016/S0140-6736(05)78801-2; Passweg JR, 1997, BLOOD, V90, P858; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; Socie G, 2000, SEMIN HEMATOL, V37, P91; THOMAS ED, 1976, EXP HEMATOL, V4, P97; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; 1999, THERAPEUTIC DRUGS, P349	11	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1536	1537		10.1016/S0140-6736(00)03117-2	http://dx.doi.org/10.1016/S0140-6736(00)03117-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075760				2022-12-28	WOS:000165134500002
J	Tisdale, JF; Dunn, DE; Geller, N; Plante, M; Nunez, O; Dunbar, CE; Barrett, AJ; Walsh, TJ; Rosenfeld, SJ; Young, NS				Tisdale, JF; Dunn, DE; Geller, N; Plante, M; Nunez, O; Dunbar, CE; Barrett, AJ; Walsh, TJ; Rosenfeld, SJ; Young, NS			High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; SAA-WORKING-PARTY; PULMONARY ASPERGILLOSIS; ANTITHYMOCYTE GLOBULIN; MULTIPLE-SCLEROSIS; CYCLOSPORINE-A; ANEMIA; IMMUNOSUPPRESSION; RECOVERY; THERAPY	Background High-dose cyclophosphamide has been proposed as an alternative immunosuppressive agent for treatment of severe aplastic anaemia, with a response rate similar to that with regimens containing antithymocyte globulin (ATG) but neither relapse nor clonal haematological complications. We undertook a phase ill, prospective, randomised trial to compare response rates to immunosuppression with either high-dose cyclophosphamide plus ciclosporin or conventional immunosuppression with ATG plus ciclosporin in previously untreated patients. Methods Between June. 1997, and March. 2000, 31 patients were enrolled. 15 were assigned cyclophosphamide (1 h intravenous infusion of 50 mg/kg daily for 4 days) and 16 were assigned ATG (40 mg/kg daily for 4 days); both groups received ciclosporin, initially at 12 mg/kg daily with adjustment to maintain concentrations at 200-400 mug/L, for 6 months. The primary endpoint was haematological response (no longer meeting criteria for severe aplastic anaemia). The trial was terminated prematurely after three early deaths in the cyclophosphamide group. Analyses were by intention to treat. Findings Median follow-up was 21.9 months (range 1-33), There was excess morbidity in the cyclophosphamide group (invasive fungal infections, four cyclophosphamide vs no ATG patients; p=0.043) as well as excess early mortality (three deaths within the first 3 months cyclophosphamide vs no ATG patients; p=0.101). There was no significant difference at 6 months after treatment in the overall response rates among evaluable patients (six of 13 [46%] cyclophosphamide vs nine of 12 [75%] ATG). Interpretation A longer period of observation will be necessary to assess the secondary endpoints of relapse and late clonal complications as well as disease-free and overall survival. However, cyclophosphamide seems a dangerous choice for treatment of this disorder. given the good results achievable with standard therapy.	NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Tisdale, JF (corresponding author), NIDDKD, Mol & Clin Hematol Branch, NIH, Bldg 10,Room 9N116, Bethesda, MD 20892 USA.	johntis@intra.niddk.nih.gov		Dunbar, Cynthia/0000-0002-7645-838X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002342, ZIAHL002315, Z01HL002315, Z01HL002342] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3; Bacigalupo A, 2000, BLOOD, V95, P1931, DOI 10.1182/blood.V95.6.1931; BARAN DT, 1976, NEW ENGL J MED, V295, P1522, DOI 10.1056/NEJM197612302952708; BERENGUER J, 1994, ANTIMICROB AGENTS CH, V38, P1303, DOI 10.1128/AAC.38.6.1303; BRINKMAN CJJ, 1984, ACTA NEUROL SCAND, V69, P90, DOI 10.1111/j.1600-0404.1984.tb07784.x; Brodsky RA, 1996, BLOOD, V87, P491, DOI 10.1182/blood.V87.2.491.bloodjournal872491; Brodsky RA, 1999, BLOOD, V94, p674A; Brodsky Robert A., 1998, Current Opinion in Oncology, V10, P95, DOI 10.1097/00001622-199803000-00002; DEVITA S, 1991, CLIN EXP RHEUMATOL, V9, P179; Dunn DE, 1999, ANN INTERN MED, V131, P401, DOI 10.7326/0003-4819-131-6-199909210-00002; FOX DA, 1994, RHEUM DIS CLIN N AM, V20, P265; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; Fuhrer M, 1998, KLIN PADIATR, V210, P173, DOI 10.1055/s-2008-1043875; GERSON SL, 1984, ANN INTERN MED, V100, P345, DOI 10.7326/0003-4819-100-3-345; GOMEZMORALES E, 2000, BLOOD, V94, P176; Hinterberger W, 1997, ANN INTERN MED, V126, P116, DOI 10.7326/0003-4819-126-2-199701150-00004; Jin JY, 1996, BRIT J HAEMATOL, V94, P510, DOI 10.1046/j.1365-2141.1996.d01-1831.x; KIM JH, 1989, REV INFECT DIS, V11, P677; LOCASCIULLI A, 1990, BONE MARROW TRANSPL, V6, P211; MATHE G, 1970, BMJ-BRIT MED J, V2, P131, DOI 10.1136/bmj.2.5702.131; MICKEY MR, 1987, ARCH NEUROL-CHICAGO, V44, P371, DOI 10.1001/archneur.1987.00520160013006; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; PORCELLINI A, 1984, EXP HEMATOL, V12, P863; ROILIDES E, 1994, ANTIMICROB AGENTS CH, V38, P2883, DOI 10.1128/AAC.38.12.2883; ROSENFELD SJ, 1995, BLOOD, V85, P3058, DOI 10.1182/blood.V85.11.3058.bloodjournal85113058; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; Socie G, 2000, SEMIN HEMATOL, V37, P91; THOMAS ED, 1976, EXP HEMATOL, V4, P97; TRAINOR KJ, 1976, J NATL CANCER I, V57, P1237, DOI 10.1093/jnci/57.6.1237; VALENTE RM, 1994, SEMIN NEUROL, V14, P380, DOI 10.1055/s-2008-1041098; WALSH TJ, 1994, CLIN INFECT DIS, V18, P793, DOI 10.1093/clinids/18.5.793; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367	33	101	110	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1554	1559		10.1016/S0140-6736(00)03126-3	http://dx.doi.org/10.1016/S0140-6736(00)03126-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075769				2022-12-28	WOS:000165134500011
J	Mann, J				Mann, J			Stemming the tide of diabetes mellitus	LANCET			English	Editorial Material							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE INTERVENTION; PREVENTION; PROGRAM		Univ Otago, Dept Human Nutr, Dunedin, New Zealand; Univ Otago, Dept Med, Dunedin, New Zealand	University of Otago; University of Otago	Mann, J (corresponding author), Univ Otago, Dept Human Nutr, Dunedin, New Zealand.							Bourn DM, 1996, DIABETIC MED, V13, P938, DOI 10.1002/(SICI)1096-9136(199611)13:11<938::AID-DIA274>3.0.CO;2-P; Bray GA, 1999, DIABETES CARE, V22, P623; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Daniel M, 1999, DIABETES CARE, V22, P1993, DOI 10.2337/diacare.22.12.1993; Eriksson J, 1999, DIABETOLOGIA, V42, P793, DOI 10.1007/s001250051229; Ferrannini E, 1997, DIABETES METAB REV, V13, P81; Macaulay AC, 1997, PREV MED, V26, P779, DOI 10.1006/pmed.1997.0241; MANN JI, 2000, EUR J CLIN NUTR, V54, P353; ODEA K, 1984, DIABETES, V33, P596, DOI 10.2337/diabetes.33.6.596; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Rowley KG, 2000, DIABETES CARE, V23, P898, DOI 10.2337/diacare.23.7.898; Russell D.G., 1999, KEY RESULTS 1997 NAT; Wing RR, 1998, DIABETES CARE, V21, P350, DOI 10.2337/diacare.21.3.350; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397	14	13	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1454	1455		10.1016/S0140-6736(00)02862-2	http://dx.doi.org/10.1016/S0140-6736(00)02862-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081521				2022-12-28	WOS:000090067300002
J	Santisteban, MS; Kalashnikova, T; Smith, MM				Santisteban, MS; Kalashnikova, T; Smith, MM			Histone H2A.Z regulates transcription and is partially redundant with nucleosome remodeling complexes	CELL			English	Article							YEAST PHO5 PROMOTER; RNA-POLYMERASE-II; C-TERMINAL DOMAIN; SWI-SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; IN-VIVO; TETRAHYMENA-THERMOPHILA; POSITIONED NUCLEOSOMES; CHROMATIN STRUCTURE; NEGATIVE REGULATOR	Nucleosomes impose a block to transcription that can be overcome in vivo by remodeling complexes such as SNF/SWI and histone modification complexes such as SAGA. Mutations in the major core histones relieve transcriptional repression and bypass the requirement for SNF/SWI and SAGA. We have found that the variant histone H2A.Z regulates gene transcription, and deletion of the gene encoding H2A.Z strongly increases the requirement for SNF/SWI and SAGA. This synthetic genetic interaction is seen at the level of single genes and acts downstream of promoter nucleosome reorganization. H2A.Z is preferentially crosslinked in vivo to intergenic DNA at the PHO5 and GAL1 loci, and this association changes with transcriptional activation. These results describe a novel pathway for regulating transcription using variant histones to modulate chromatin structure.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Smith, MM (corresponding author), Univ Virginia, Dept Microbiol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1986, J BIOL CHEM, V261, P1941; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; BERGMAN LW, 1983, J BIOL CHEM, V258, P7223; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CARLSON M, 1981, GENETICS, V98, P25; CARR AM, 1994, MOL GEN GENET, V245, P628, DOI 10.1007/BF00282226; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARKADAMS CD, 1988, GENE DEV, V2, P150, DOI 10.1101/gad.2.2.150; Clarkson MJ, 1999, NATURE, V399, P694, DOI 10.1038/21436; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dhillon N, 2000, MOL CELL, V6, P769, DOI 10.1016/S1097-2765(00)00076-9; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; ERNST SG, 1987, NUCLEIC ACIDS RES, V15, P4629, DOI 10.1093/nar/15.11.4629; Gaudreau L, 1997, CELL, V89, P55, DOI 10.1016/S0092-8674(00)80182-8; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GUARENTE L, 1993, TRENDS GENET, V9, P362, DOI 10.1016/0168-9525(93)90042-G; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; HARVEY RP, 1983, P NATL ACAD SCI-BIOL, V80, P2819, DOI 10.1073/pnas.80.10.2819; Haswell ES, 1999, MOL CELL BIOL, V19, P2817; HATCH CL, 1983, SCIENCE, V221, P468, DOI 10.1126/science.6306766; HATCH CL, 1988, NUCLEIC ACIDS RES, V16, P1113, DOI 10.1093/nar/16.3.1113; HIRSCHHORN JN, 1995, MOL CELL BIOL, V15, P1999; Iouzalen N, 1996, NUCLEIC ACIDS RES, V24, P3947, DOI 10.1093/nar/24.20.3947; Jackson JD, 1996, TRENDS BIOCHEM SCI, V21, P466, DOI 10.1016/S0968-0004(96)20028-3; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; Kurumizaka H, 1997, MOL CELL BIOL, V17, P6953, DOI 10.1128/MCB.17.12.6953; Leach TJ, 2000, J BIOL CHEM, V275, P23267, DOI 10.1074/jbc.M910206199; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Meluh PB, 1999, METHOD ENZYMOL, V304, P414; Mizzen C, 1998, COLD SPRING HARB SYM, V63, P469, DOI 10.1101/sqb.1998.63.469; OHNISHI ST, 1978, ANAL BIOCHEM, V88, P347, DOI 10.1016/0003-2697(78)90432-3; Perez-Martin J, 1998, MOL CELL BIOL, V18, P4157, DOI 10.1128/MCB.18.7.4157; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Prelich G, 1997, MOL CELL BIOL, V17, P2057, DOI 10.1128/MCB.17.4.2057; Recht J, 1999, EMBO J, V18, P229, DOI 10.1093/emboj/18.1.229; Roberts SM, 1997, GENETICS, V147, P451; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SIMCHEN G, 1984, P NATL ACAD SCI-BIOL, V81, P2431, DOI 10.1073/pnas.81.8.2431; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; VANDAAL A, 1990, J MOL EVOL, V30, P449, DOI 10.1007/BF02101116; VANDAAL A, 1988, NUCLEIC ACIDS RES, V16, P7487, DOI 10.1093/nar/16.15.7487; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wechser MA, 1997, EMBO J, V16, P2086, DOI 10.1093/emboj/16.8.2086; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WHITE EM, 1988, NUCLEIC ACIDS RES, V16, P179, DOI 10.1093/nar/16.1.179; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Yona E, 1996, FEBS LETT, V382, P97, DOI 10.1016/0014-5793(96)00159-7	66	257	265	2	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					411	422		10.1016/S0092-8674(00)00133-1	http://dx.doi.org/10.1016/S0092-8674(00)00133-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081628	Bronze			2022-12-28	WOS:000090144100007
J	Traynor, AE; Schroeder, J; Rosa, RM; Cheng, D; Stefka, J; Mujais, S; Baker, S; Burt, RK				Traynor, AE; Schroeder, J; Rosa, RM; Cheng, D; Stefka, J; Mujais, S; Baker, S; Burt, RK			Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; AUTOIMMUNE-DISEASE; PERIPHERAL-BLOOD; DELAYED-HYPERSENSITIVITY; MORTALITY; NEPHRITIS; MICE; MORBIDITY; THERAPY; RATIO	Background Patients with systemic lupus erythematosus (SLE) who experience persistent multiorgan dysfunction, despite standard doses of intravenous cyclophosphamide, represent a subset of patients at high risk of early death. We investigated the safety and efficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients. Methods From 1996, we selected patients with persistent SLE despite use of cyclophosphamide, Patients underwent dose-intense immune suppression and autologous haemopoietic stem-cell (CD34) infusion. Peripheral blood lymphocytes were analysed by flow cytometry, ELISA, and T-cell-receptor spectratyping before and after transplantation. We mobilised autologous haemopoietic stem cells with 2.0 g/m(2) cyclophosphamide and 10 mu g/kg granulocyte colony stimulating factor daily, enriched with CD34-positive selection, and reinfused after immunosuppression with 200 mg/kg cyclophosphamide, 1 g methylprednisolone, and 90 mg/kg equine antithymocyte globulin, Results Nine patients underwent stem-cell mobilisation but two were excluded before transplantation because of infection. The remaining seven received high-dose chemotherapy and stem-cell infusion. Median time to an absolute neutrophil count higher than 0.5x10(9)/L and nontransfused platelet count higher than 20x10(9)/L was 9 days (range 8-11) and 11 days (10-13), respectively, At a median follow-up of 25 months (12-40), all patients were free from signs of active lupus. Renal, cardiac, pulmonary, and serological markers, and T-cell phenotype and repertoire had normalised, Interpretation Patients remained free from active lupus and improved continuously after transplantation, with no immunosuppressive medication or small residual doses of prednisone, T-cell repertoire diversity and responsiveness was restored. Durability of remission remains to be established.	Northwestern Univ, Div Immunotherapy Autoimmune Dis, Robert H Lurie Canc Ctr, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Div Nephrol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Div Pulm Med, Chicago, IL 60611 USA	Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; Northwestern University	Traynor, AE (corresponding author), NW Mem Hosp, 250 E Super,Wesley Pavil,Room 168, Chicago, IL 60611 USA.			Burt, Richard K/0000-0002-0922-4145				ABUSHAKRA M, 1995, J RHEUMATOL, V22, P1265; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; Brodsky RA, 1998, ANN INTERN MED, V129, P1031, DOI 10.7326/0003-4819-129-12-199812150-00007; Burt RK, 1998, BLOOD, V92, P3505, DOI 10.1182/blood.V92.10.3505.422k48_3505_3514; Burt RK, 1997, NEW ENGL J MED, V337, P1777, DOI 10.1056/NEJM199712113372416; Cervera R, 1999, MEDICINE, V78, P167, DOI 10.1097/00005792-199905000-00003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORREIA P, 1985, BMJ-BRIT MED J, V290, P126, DOI 10.1136/bmj.290.6462.126; Crispin JC, 1998, SCAND J IMMUNOL, V48, P196; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; Fouillard L, 1999, LUPUS, V8, P320, DOI 10.1191/096120399678847894; GRAY JD, 1994, J EXP MED, V180, P1937, DOI 10.1084/jem.180.5.1937; Hagiwara E, 1996, ARTHRITIS RHEUM, V39, P379, DOI 10.1002/art.1780390305; HAHN BH, 1973, AM J MED, V55, P25, DOI 10.1016/0002-9343(73)90146-0; HORWITZ DA, 1972, ARTHRITIS RHEUM-US, V15, P353, DOI 10.1002/art.1780150406; Horwitz DA, 1998, ARTHRITIS RHEUM, V41, P838, DOI 10.1002/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S; Ikehara S, 1987, Prog Clin Biol Res, V229, P131; KARUSSIS DM, 1995, CLIN EXP IMMUNOL, V100, P111; Marmont AM, 1997, LUPUS, V6, P545, DOI 10.1177/096120339700600613; Musso M, 1998, LUPUS, V7, P492, DOI 10.1191/096120398678920424; RENGARAJU M, 1995, LUPUS S2, V4, P82; Rosen O, 2000, ARTHRITIS RES, V2, P327, DOI 10.1186/ar107; Su CC, 1997, LUPUS, V6, P449, DOI 10.1177/096120339700600507; Urowitz MB, 1999, LUPUS, V8, P253, DOI 10.1191/096120399678847821; Wakeland EK, 1997, J CLIN IMMUNOL, V17, P272, DOI 10.1023/A:1027370514198; Wang BY, 1997, P NATL ACAD SCI USA, V94, P12065, DOI 10.1073/pnas.94.22.12065; Wang BY, 1999, P NATL ACAD SCI USA, V96, P3012, DOI 10.1073/pnas.96.6.3012; YOCUM MW, 1975, ARTHRITIS RHEUM, V18, P193, DOI 10.1002/art.1780180301	28	171	192	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					701	707		10.1016/S0140-6736(00)02627-1	http://dx.doi.org/10.1016/S0140-6736(00)02627-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085688				2022-12-28	WOS:000088948200008
J	Vincent, JL				Vincent, JL			Need for intensivists in intensive-care units	LANCET			English	Editorial Material							RESOURCE UTILIZATION; OUTCOMES		Free Univ Brussels, Erasme Hosp, Dept Intens Care, B-1070 Brussels, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vincent, JL (corresponding author), Free Univ Brussels, Erasme Hosp, Dept Intens Care, 808 Route Lennik, B-1070 Brussels, Belgium.			Vincent, Jean-Louis/0000-0001-6011-6951				Bach PB, 1998, AM J RESP CRIT CARE, V158, P1410, DOI 10.1164/ajrccm.158.5.9804042; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; Ghorra S, 1999, ANN SURG, V229, P163, DOI 10.1097/00000658-199902000-00001; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; LI TC, 1984, JAMA-J AM MED ASSOC, V252, P2027; Multz AS, 1998, AM J RESP CRIT CARE, V157, P1468, DOI 10.1164/ajrccm.157.5.9708039; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Rosen BS, 1999, AUST NZ J OPHTHALMOL, V27, P153, DOI 10.1046/j.1440-1606.1999.00174.x; TAN IKS, 2000, CRIT CARE SHOCK, V1, P1; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Trunkey DD, 1999, ANN SURG, V229, P172, DOI 10.1097/00000658-199902000-00002; Vincent JL, 1997, INTENS CARE MED, V23, P1181, DOI 10.1007/s001340050479	13	47	47	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					695	696		10.1016/S0140-6736(00)02622-2	http://dx.doi.org/10.1016/S0140-6736(00)02622-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085683				2022-12-28	WOS:000088948200003
J	De Poortere, EP; Tutuc, E; Papadakis, SJ; Shayegan, M				De Poortere, EP; Tutuc, E; Papadakis, SJ; Shayegan, M			Resistance spikes at transitions between quantum Hall ferromagnets	SCIENCE			English	Article							TILTED MAGNETIC-FIELDS; PHASE-TRANSITION; ELECTRON; ANISOTROPY; SYSTEM	We report a manifestation of first-order magnetic transitions in two-dimensional electron systems. This phenomenon occurs in aluminum arsenide quantum wells with sufficiently low carrier densities and appears as a set of hysteretic spikes in the resistance of a sample placed in crossed parallel and perpendicular magnetic fields, each spike occurring at the transition between states with different partial magnetizations. Our experiments thus indicate that the presence of magnetic domains at the transition starkly increases dissipation, an effect also suspected in other ferromagnetic materials. Analysis of the positions of the transition spikes allows us to deduce the change in exchange-correlation energy across the magnetic transition, which in turn will help improve our understanding of metallic ferromagnetism.	Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA	Princeton University	De Poortere, EP (corresponding author), Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA.	poortere@ee.princeton.edu						Antropov VP, 1999, J MAGN MAGN MATER, V200, P148, DOI 10.1016/S0304-8853(99)00425-4; Ceperley D, 1999, NATURE, V397, P386, DOI 10.1038/17011; CLARK RG, 1990, SPRINGER SERIES SOLI, V97, P168; Daneshvar AJ, 1997, PHYS REV LETT, V79, P4449, DOI 10.1103/PhysRevLett.79.4449; EISENSTEIN JP, 1989, PHYS REV LETT, V62, P1540, DOI 10.1103/PhysRevLett.62.1540; ENGEL LW, 1992, PHYS REV B, V45, P3418, DOI 10.1103/PhysRevB.45.3418; Eom J, 2000, SCIENCE, V289, P2320, DOI 10.1126/science.289.5488.2320; Jungwirth T, 1998, PHYS REV LETT, V81, P2328, DOI 10.1103/PhysRevLett.81.2328; JUNGWIRTH T, UNPUB; JUNGWIRTH T, IN PRESS PHYS REV B; Kisker E., 1987, METALLIC MAGNETISM, P57; KOCH S, 1993, PHYS REV B, V47, P4048, DOI 10.1103/PhysRevB.47.4048; LAY TS, 1993, APPL PHYS LETT, V62, P3120, DOI 10.1063/1.109128; Lilliehook D, 2000, PHYS REV B, V62, P7303, DOI 10.1103/PhysRevB.62.7303; MACDONALD AH, 1986, PHYS REV B, V33, P8336, DOI 10.1103/PhysRevB.33.8336; Papadakis SJ, 1999, PHYS REV B, V59, pR12743, DOI 10.1103/PhysRevB.59.R12743; Piazza V, 1999, NATURE, V402, P638, DOI 10.1038/45189; SCHIFFER P, 1995, PHYS REV LETT, V75, P3336, DOI 10.1103/PhysRevLett.75.3336; VANKESTEREN HW, 1988, PHYS REV LETT, V61, P129, DOI 10.1103/PhysRevLett.61.129; Viret M, 2000, PHYS REV LETT, V85, P3962, DOI 10.1103/PhysRevLett.85.3962; Young DP, 1999, NATURE, V397, P412, DOI 10.1038/17081	22	145	145	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1546	1549		10.1126/science.290.5496.1546	http://dx.doi.org/10.1126/science.290.5496.1546			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090346	Green Submitted			2022-12-28	WOS:000165446200041
J	Manhapra, A; Borzak, S				Manhapra, A; Borzak, S			Regular review - Treatment possibilities for unstable angina	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACUTE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; Q-WAVE; TROPONIN-T; UNFRACTIONATED HEPARIN; RISK STRATIFICATION; PROGNOSTIC VALUE; ELEVATED LEVELS		Henry Ford Heart & Vasc Inst, Div Cardiovasc Med, Detroit, MI 48202 USA	Henry Ford Health System	Borzak, S (corresponding author), Henry Ford Heart & Vasc Inst, Div Cardiovasc Med, K-14, Detroit, MI 48202 USA.	sborzak1@hfhs.org						ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Biasucci LM, 1999, SCAND J CLIN LAB INV, V59, P12; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 1999, CIRCULATION, V100, P2045, DOI 10.1161/01.CIR.100.20.2045; Braunwald E, 1998, CIRCULATION, V98, P2219, DOI 10.1161/01.CIR.98.21.2219; BRAUNWALD E, 2000, PUBLICATION AGENCY H; BRAUNWALD E, 2000, IN PRESS ACC AHA GUI; Brown KA, 1999, CIRCULATION, V100, P2060, DOI 10.1161/01.CIR.100.20.2060; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Cannon CP, 1997, J AM COLL CARDIOL, V30, P133, DOI 10.1016/S0735-1097(97)00160-5; *CAPTURE INV, 1997, LANCET, V350, P744; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; COHEN M, 1999, CLIN CARDIOL S6, V22, pV12; Crea F, 1997, AM J CARDIOL, V80, pE10, DOI 10.1016/S0002-9149(97)00483-9; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GIBSON RS, 1986, NEW ENGL J MED, V315, P423, DOI 10.1056/NEJM198608143150704; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; Guerrero RAA, 1999, EUR HEART J, V20, P1553; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Hansen JF, 1997, AM J CARDIOL, V79, P738, DOI 10.1016/S0002-9149(96)00860-0; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; Klein W, 1997, CIRCULATION, V96, P61; KLEIN W, 1998, CIRCULATION, V97, P413; Kong DF, 1999, CIRCULATION, V100, P2049, DOI 10.1161/01.CIR.100.20.2049; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; Lincoff AM, 1997, J AM COLL CARDIOL, V30, P149, DOI 10.1016/S0735-1097(97)00110-1; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lloyd-Jones D, 1998, AM J CARDIOL, V81, P1182, DOI 10.1016/S0002-9149(98)00155-6; Love BB, 1998, DRUG SAFETY, V19, P89, DOI 10.2165/00002018-199819020-00002; Mark DB, 1998, CIRCULATION, V97, P1702, DOI 10.1161/01.CIR.97.17.1702; Milazzo D, 1999, AM J CARDIOL, V84, P459, DOI 10.1016/S0002-9149(99)00333-1; Neuhaus KL, 1999, HEART, V82, pI8, DOI 10.1136/hrt.82.2008.i8; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; PEDERSEN TR, 1994, LANCET, V344, P1383; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Phibbs B, 1999, J AM COLL CARDIOL, V33, P576; Roberts R, 1998, CIRCULATION, V98, P1831, DOI 10.1161/01.CIR.98.18.1831; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Savonitto S, 1999, JAMA-J AM MED ASSOC, V281, P707, DOI 10.1001/jama.281.8.707; *SCAND SIMV SURV S, 1998, LANCET, V339, P1349; Simoons ML, 1997, LANCET, V349, P1429; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; The PRISM-PLUS Investigators, 1998, NEW ENGL J MED, V339, P415; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; THEROUX P, 1985, J AM COLL CARDIOL, V5, P717, DOI 10.1016/S0735-1097(85)80400-9; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 1996, LANCET, V347, P561; Wallentin L, 1999, LANCET, V354, P701; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; WALLENTIN L, 1990, LANCET, V336, P827; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; Weitz JI, 1997, NEW ENGL J MED, V337, P1567; YANG ZH, 1995, CHINESE MED J-PEKING, V108, P626; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X; Yusuf S, 1999, LANCET, V353, P429; Yusuf S, 2000, NEW ENGL J MED, V342, P145; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2250; Zaacks SM, 1999, J AM COLL CARDIOL, V33, P107, DOI 10.1016/S0735-1097(98)00553-1; Zimmerman J, 1999, CIRCULATION, V99, P1671, DOI 10.1161/01.CIR.99.13.1671	75	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2000	321	7271					1269	1275		10.1136/bmj.321.7271.1269	http://dx.doi.org/10.1136/bmj.321.7271.1269			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082091	Green Published			2022-12-28	WOS:000165445800029
J	Oates, L				Oates, L			The courts' role in decisions about medical treatment	BRITISH MEDICAL JOURNAL			English	Article									Official Solicitors Off, London WC2A 1DD, England		Oates, L (corresponding author), Official Solicitors Off, London WC2A 1DD, England.							[Anonymous], 1999, GUIDANCE DECISION MA; RE C, 1999, FAMILY LAW REPORTS, V2, P1004; Re M, 1999, FAMILY LAW REPORTS; RE O, 1993, FAMILY LAW REPORTS, V2, P149; RE R, 1993, FAMILY LAW REPORTS, V2, P757; Re S, 1993, FAMILY LAW REPORTS; RE W, 1993, FAMILY LAW REPORTS, V1, P1; 1995, GUIDANCE DOCTORS LAW; 1998, FAMILY LAW REPORTS, V2, P728; 1996, FAMILY LAW REPORTS, V2, P111; 1996, FAMILY LAW REPORTS, V2, P375; 2000, FAMILY COURT REPORTS, V1, P193	12	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1282	1284		10.1136/bmj.321.7271.1282	http://dx.doi.org/10.1136/bmj.321.7271.1282			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082095	Green Published			2022-12-28	WOS:000165445800032
J	Bristow, M				Bristow, M			Etomoxir: a new approach to treatment of chronic heart failure	LANCET			English	Editorial Material							FATTY-ACID OXIDATION; RAT-HEART; DIABETES-MELLITUS; INHIBITION; HYPERTROPHY		Univ Colorado, Hlth Sci Ctr, Dept Cardiol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Bristow, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Cardiol, 4200 E 9th Ave, Denver, CO 80262 USA.		bristow, michael r/G-7850-2011					ABDELALEEM S, 1994, HORM METAB RES, V26, P88, DOI 10.1055/s-2007-1000779; Bristow MR, 1998, LANCET, V352, P8; COLLIER GR, 1993, HORM METAB RES, V25, P9, DOI 10.1055/s-2007-1002035; Dillmann W H, 1986, Adv Exp Med Biol, V194, P469; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; HEYLIGER CE, 1982, BASIC RES CARDIOL, V77, P610, DOI 10.1007/BF01908314; Lowes BD, 1998, CIRCULATION, V98, P361; Lowes Brian D., 1999, Journal of the American College of Cardiology, V33, p216A; RATHEISER K, 1991, METABOLISM, V40, P1185, DOI 10.1016/0026-0495(91)90214-H; RUPP H, 1994, MOL CELL BIOCHEM, V132, P69, DOI 10.1007/BF00925676; Schmidt-Schweda S, 2000, CLIN SCI, V99, P27, DOI 10.1042/CS19990235; SHIMOYAMA H, 1998, J CARD FAIL, V4, P121; Turcani M, 1999, BRIT J PHARMACOL, V126, P501, DOI 10.1038/sj.bjp.0702312; Turcani M, 1997, CIRCULATION, V96, P3681; ZarainHerzberg A, 1996, FASEB J, V10, P1303, DOI 10.1096/fasebj.10.11.8836044	15	59	61	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1621	1622		10.1016/S0140-6736(00)03149-4	http://dx.doi.org/10.1016/S0140-6736(00)03149-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089814				2022-12-28	WOS:000165249200003
J	Coutsoudis, A				Coutsoudis, A			Promotion of exclusive breastfeeding in the face of the HIV pandemic	LANCET			English	Editorial Material							IMPACT; COHORT		Univ KwaZulu Natal, Dept Paediat & Child Hlth, ZA-4001 Durban, South Africa	University of Kwazulu Natal	Coutsoudis, A (corresponding author), Univ KwaZulu Natal, Dept Paediat & Child Hlth, ZA-4001 Durban, South Africa.							[Anonymous], 1998, HIV INF FEED GUID DE; Cesar JA, 1999, BRIT MED J, V318, P1316, DOI 10.1136/bmj.318.7194.1316; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Leach A, 1999, ANN TROP PAEDIATR, V19, P33, DOI 10.1080/02724939992617; Perera BJC, 1999, J TROP PEDIATRICS, V45, P115, DOI 10.1093/tropej/45.2.115; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25, DOI 10.2105/AJPH.89.1.25; TAREN D, 2000, 13 INT AIDS C DURB S; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	11	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1620	1621		10.1016/S0140-6736(00)03148-2	http://dx.doi.org/10.1016/S0140-6736(00)03148-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089813				2022-12-28	WOS:000165249200002
J	Fenton, AM; Hammill, SC; Rea, RF; Low, PA; Shen, WK				Fenton, AM; Hammill, SC; Rea, RF; Low, PA; Shen, WK			Vasovagal syncope	ANNALS OF INTERNAL MEDICINE			English	Review							HEAD-UP TILT; NEURALLY-MEDIATED SYNCOPE; RECURRENT UNEXPLAINED SYNCOPE; LEFT-VENTRICULAR DIMENSIONS; PLACEBO-CONTROLLED TRIAL; RENAL NERVE ACTIVITY; UPRIGHT TILT; UNKNOWN ORIGIN; TABLE TEST; NEUROCARDIOGENIC SYNCOPE	Background: Vasovagal syncope is the most common type of syncope and is one of the most difficult types to manage. Purpose: This article reviews the status of mechanisms, diagnosis, and management of vasovagal syncope. Data Sources: MEDLINE search for English-language and German-language articles on vasovagal syncope published up to June 1999. Study Selection: case reports and series, clinical trials, research investigations, and review articles from peer-reviewed journals. Data Extraction: Findings were summarized and discussed individually. Summaries were made in table format. Statistical analysis of combined data was inappropriate because of differences among studies in patient selection, testing, and follow-up. Data Synthesis: The population of patients with vasovagal syncope is highly heterogeneous. Triggers of vasovagal syncope are likely to be protean, and many potential central and peripheral triggers have been identified. The specific mechanisms underlying the interactions among decreased preload, sympathetic and parasympathetic modulation, vasodilation, and cardioinhibition remain unknown. Tilt-table testing is a widely used diagnostic tool. The test results should be interpreted in the context of patients' clinical presentations and with an understanding of the sensitivity and specificity of the test. Assessment of therapeutic outcomes has been difficult, primarily because of patient heterogeneity, the large number of pharmacologic agents available for therapy, and the sporadic nature of the syndrome complex. Conclusions: Vasovagal syncope is a common clinical syndrome that has complex and variable mechanisms and is difficult to manage. Advancements are being made in laboratory investigations of its triggering mechanisms. Randomized, controlled trials of pharmacologic and nonpharmacologic interventions are needed. Mechanism-targeted therapeutic trials may improve clinical outcomes.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Shen, WK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.				NINDS NIH HHS [PPG NS 32952] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOUD FM, 1993, NEW ENGL J MED, V328, P1117, DOI 10.1056/NEJM199304153281510; ABISAMRA F, 1988, PACE, V11, P1202, DOI 10.1111/j.1540-8159.1988.tb03973.x; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BARCROFT H, 1945, J PHYSIOL-LONDON, V104, P161, DOI 10.1113/jphysiol.1945.sp004113; BARRACO RA, 1988, BRAIN RES BULL, V20, P129, DOI 10.1016/0361-9230(88)90016-0; Benditt DG, 1996, J AM COLL CARDIOL, V28, P263, DOI 10.1016/0735-1097(96)00236-7; BLAIR DA, 1959, J PHYSIOL-LONDON, V148, P633, DOI 10.1113/jphysiol.1959.sp006312; BLANC JJ, 1993, AM J CARDIOL, V72, P469, DOI 10.1016/0002-9149(93)91145-8; BROOKS R, 1993, AM J CARDIOL, V71, P1289, DOI 10.1016/0002-9149(93)90542-K; CALKINS H, 1995, AM J MED, V98, P365, DOI 10.1016/S0002-9343(99)80315-5; CALKINS H, 1993, AM J MED, V95, P473, DOI 10.1016/0002-9343(93)90329-N; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; COX MM, 1995, J AM COLL CARDIOL, V26, P1293, DOI 10.1016/0735-1097(95)00320-7; DEBUITLEIR M, 1993, AM J CARDIOL, V71, P304, DOI 10.1016/0002-9149(93)90795-E; Di Girolamo E, 1999, J AM COLL CARDIOL, V33, P1227, DOI 10.1016/S0735-1097(98)00694-9; Dietz NM, 1997, J APPL PHYSIOL, V82, P1785, DOI 10.1152/jappl.1997.82.6.1785; DIETZ NM, 1994, J PHYSIOL-LONDON, V480, P361, DOI 10.1113/jphysiol.1994.sp020366; EVANS RG, 1989, J PHYSIOL-LONDON, V419, P15, DOI 10.1113/jphysiol.1989.sp017858; FENTON A, 1996, PACE, V19, P616; FISH FA, 1992, AM J CARDIOL, V70, P605, DOI 10.1016/0002-9149(92)90199-9; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FITZPATRICK AP, 1993, J AM COLL CARDIOL, V21, P1132, DOI 10.1016/0735-1097(93)90235-S; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; Foster Michael, 1888, TXB PHYSL; GOLDSTEIN DS, 1982, AM HEART J, V104, P1071, DOI 10.1016/0002-8703(82)90442-2; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; GRUBB BP, 1992, PACE, V15, P1477, DOI 10.1111/j.1540-8159.1992.tb02921.x; GRUBB BP, 1992, J AM GERIATR SOC, V40, P1123, DOI 10.1111/j.1532-5415.1992.tb01801.x; GRUBB BP, 1993, PACE, V16, P458, DOI 10.1111/j.1540-8159.1993.tb01608.x; GRUBB BP, 1991, AM J MED, V90, P6, DOI 10.1016/0002-9343(91)90499-N; GRUBB BP, 1991, CIRCULATION, V84, P1157, DOI 10.1161/01.CIR.84.3.1157; HUNTER J, 1837, WORKS J HUNTER NOTES; JARISCH A., 1939, ARCH EXP PATH U PHARMAKOL, V193, P355; Joyner M, 1997, CLIN AUTONOMIC DISOR, P61; KAPOOR WN, 1982, JAMA-J AM MED ASSOC, V247, P2687, DOI 10.1001/jama.247.19.2687; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; KAUFMANN H, 1995, NEUROLOGY, V45, pS12; KENNY RA, 1986, LANCET, V1, P1352; KORNER PI, 1971, PHYSIOL REV, V51, P312, DOI 10.1152/physrev.1971.51.2.312; Lee TM, 1996, CLIN CARDIOL, V19, P137, DOI 10.1002/clc.4960190212; LURIE KG, 1993, AM J CARDIOL, V72, P1286, DOI 10.1016/0002-9149(93)90298-Q; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MATSUKAWA K, 1993, JPN J PHYSIOL, V43, P473, DOI 10.2170/jjphysiol.43.473; MIZUMAKI K, 1995, J AM COLL CARDIOL, V26, P164, DOI 10.1016/0735-1097(95)00120-O; MORGAN DA, 1988, AM J PHYSIOL, V255, pH496, DOI 10.1152/ajpheart.1988.255.3.H496; Morgan-Hughes N J, 1994, Clin Auton Res, V4, P125, DOI 10.1007/BF01845776; Morillo CA, 1996, AM J CARDIOL, V77, P521, DOI 10.1016/S0002-9149(97)89348-4; MORILLO CA, 1993, J AM COLL CARDIOL, V22, P1843, DOI 10.1016/0735-1097(93)90767-U; MORITA H, 1988, CIRC RES, V63, P165, DOI 10.1161/01.RES.63.1.165; MORITA H, 1985, CIRC RES, V57, P788, DOI 10.1161/01.RES.57.5.788; NATALE A, 1995, CIRCULATION, V92, P54, DOI 10.1161/01.CIR.92.1.54; OBERG B, 1972, ACTA PHYSIOL SCAND, V85, P164, DOI 10.1111/j.1748-1716.1972.tb05247.x; PERNA GP, 1990, AM J CARDIOL, V65, P929, DOI 10.1016/0002-9149(90)91442-9; PETERSEN M, 1994, BRIT HEART J, V71, P274; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; Raviele A, 1999, CIRCULATION, V99, P1452, DOI 10.1161/01.CIR.99.11.1452; RAVIELE A, 1995, AM J CARDIOL, V76, P267, DOI 10.1016/S0002-9149(99)80079-4; RAVIELE A, 1994, AM HEART J, V127, P103, DOI 10.1016/0002-8703(94)90515-0; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; REA RF, 1993, J CARDIOVASC ELECTR, V4, P587, DOI 10.1111/j.1540-8167.1993.tb01246.x; Rowell LB, 1993, HUMAN CARDIOVASCULAR, P118; Ruiz GA, 1996, CLIN CARDIOL, V19, P215, DOI 10.1002/clc.4960190315; SCHERRER U, 1990, NEW ENGL J MED, V322, P602, DOI 10.1056/NEJM199003013220906; SCHOBEL HP, 1992, CIRC RES, V70, P172, DOI 10.1161/01.RES.70.1.172; SHALEV Y, 1991, J AM COLL CARDIOL, V18, P746, DOI 10.1016/0735-1097(91)90798-E; Shastry S, 1998, J APPL PHYSIOL, V85, P830, DOI 10.1152/jappl.1998.85.3.830; Sheldon R, 1996, CIRCULATION, V93, P973, DOI 10.1161/01.CIR.93.5.973; SHELDON R, 1992, AM J CARDIOL, V69, P1300, DOI 10.1016/0002-9149(92)91225-S; SHELDON R, 1992, J AM COLL CARDIOL, V19, P773, DOI 10.1016/0735-1097(92)90517-Q; Shen WK, 1997, AM J CARDIOL, V80, P817, DOI 10.1016/S0002-9149(97)00529-8; Shen WK, 1996, J AM COLL CARDIOL, V28, P146, DOI 10.1016/0735-1097(96)00100-3; Shen WK, 1999, J AM COLL CARDIOL, V33, P985, DOI 10.1016/S0735-1097(98)00658-5; SHEN WK, 1997, CLIN AUTONOMIC DISOR, P649; SJOSTRAND T, 1973, ACTA PHYSIOL SCAND, V89, P39, DOI 10.1111/j.1748-1716.1973.tb05495.x; SMITH OA, 1984, ANNU REV NEUROSCI, V7, P43, DOI 10.1146/annurev.ne.07.030184.000355; SRA JS, 1991, ANN INTERN MED, V114, P1013, DOI 10.7326/0003-4819-114-12-1013; SRA JS, 1994, AM J CARDIOL, V73, P33, DOI 10.1016/0002-9149(94)90723-4; STRASBERG B, 1989, AM HEART J, V118, P923, DOI 10.1016/0002-8703(89)90225-1; THAMES MD, 1978, CIRC RES, V43, P512, DOI 10.1161/01.RES.43.4.512; VANLIESHOUT JJ, 1991, CLIN SCI, V81, P575, DOI 10.1042/cs0810575; Voice RA, 1998, AM J CARDIOL, V81, P346, DOI 10.1016/S0002-9149(97)00915-6; von Bezold A., 1867, UNTERSUCHUNGEN PHYSL, V1, P75; Wallbridge DR, 1996, EUR HEART J, V17, P1729; WALLIN BG, 1982, J AUTONOM NERV SYST, V6, P287; WALLIN BG, 1988, AUTONOMIC FAILURE TX, P177; Ward CR, 1998, HEART, V79, P45, DOI 10.1136/hrt.79.1.45; WAXMAN MB, 1993, J AM COLL CARDIOL, V21, P1138, DOI 10.1016/0735-1097(93)90236-T; WAXMAN MB, 1989, AM J CARDIOL, V63, P58, DOI 10.1016/0002-9149(89)91076-X; XIAO CC, 1992, AM J CARDIOL, V69, P755	90	115	145	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					714	725		10.7326/0003-4819-133-9-200011070-00014	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00014			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074905				2022-12-28	WOS:000165075300007
J	Kalderon, D				Kalderon, D			Transducing the Hedgehog signal	CELL			English	Review							EXPRESSION		Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Kalderon, D (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.							Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Aza-Blanc P, 1999, TRENDS GENET, V15, P458, DOI 10.1016/S0168-9525(99)01869-7; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; DeCamp DL, 2000, J BIOL CHEM, V275, P26322, DOI 10.1074/jbc.M004055200; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; McMahon AP, 2000, CELL, V100, P185, DOI 10.1016/S0092-8674(00)81555-X; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008	13	158	179	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 27	2000	103	3					371	374		10.1016/S0092-8674(00)00129-X	http://dx.doi.org/10.1016/S0092-8674(00)00129-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	368YB	11081624	Bronze			2022-12-28	WOS:000090144100003
J	Levin, B				Levin, B			Dietary intake and recurrence of colorectal adenoma	LANCET			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Div Canc Prevent, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Levin, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Canc Prevent, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; *WHO, 1997, WORLD HLTH REP	6	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 14	2000	356	9238					1286	1287		10.1016/S0140-6736(00)02806-3	http://dx.doi.org/10.1016/S0140-6736(00)02806-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073010				2022-12-28	WOS:000089858300002
J	Shortt, SED				Shortt, SED			Can Alberta buck stampede of healthcare globalisation?	LANCET			English	Editorial Material									Queens Univ, Queens Hlth Policy Unit, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Shortt, SED (corresponding author), Queens Univ, Queens Hlth Policy Unit, Kingston, ON K7L 3N6, Canada.							APPLETON B, 1999, MARKET LIMITATIONS H, P87; *DEP EXT AFF INT T, 2000, TRAD NEG AGR TRAD SE; EVANS RG, 2000, PRIVATE HIGHWAY ONE; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Player S, 1999, Health Serv J, V109, P28; Price D, 1999, LANCET, V354, P1889, DOI 10.1016/S0140-6736(99)11060-2; RACHLIS M, 2000, REV ALB PRIV HOSP PR; *WORLD TRAD ORG, 2000, INTRO GATS; *WORLD TRAD ORG, 1998, HLTH SOC SERV BACKGR, P5	9	0	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1291	1292		10.1016/S0140-6736(00)02810-5	http://dx.doi.org/10.1016/S0140-6736(00)02810-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073014				2022-12-28	WOS:000089858300006
J	Sharp, D				Sharp, D			Medicine and the law, Europe	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Sharp, D (corresponding author), The Lancet, London WC1X 8RR, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1212	1212		10.1016/S0140-6736(00)02782-3	http://dx.doi.org/10.1016/S0140-6736(00)02782-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072937				2022-12-28	WOS:000089724900008
J	[Anonymous]				[Anonymous]			Does lung cancer need a lapel ribbon?	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 7	2000	356	9237					1205	1205						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072930				2022-12-28	WOS:000089724900001
J	Yaffe, K; Lui, LY; Grady, D; Cauley, J; Kramer, J; Cummings, SR				Yaffe, K; Lui, LY; Grady, D; Cauley, J; Kramer, J; Cummings, SR			Cognitive decline in women in relation to non-protein-bound oestradiol concentrations	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; CENTRAL-NERVOUS-SYSTEM; BONE-MINERAL DENSITY; ALZHEIMERS-DISEASE; POSTMENOPAUSAL WOMEN; OLDER WOMEN; DOUBLE-BLIND; RISK; SERUM; ESTRADIOL	Background Previous studies have found no association between serum concentrations of total oestradiol and cognitive function, but these measurements may not reflect concentrations of hormone available to the brain. We tested the hypothesis that concentrations of non-protein-bound (free) and loosely bound (bioavailable) sex hormones are associated with cognitive function in older women. Methods We measured cognitive performance with a modified mini mental status examination (mMMSE) at baseline (1986-88) and 6 years later in 425 women (65 years or older). Concentrations of non-protein-bound and bioavailable oestradiol and total and non-protein-bound testosterone were measured by RIA in serum samples taken at baseline. Findings Initial cognitive scores did not differ by tertile of non-protein-bound oestradiol, bioavailable oestradiol, or testosterone. Cognitive impairment (a decrease of 3 points or more in mMMSE score) occurred in five (5%) of 94 women in the high tertile for non-protein-bound oestradiol and in 17 (16%) of 106 in the low tertile (odds ratio 0.3 [95% CI 0.1-0.8]). After adjustment for age, years of education, body-mass index, current oestrogen use, history of surgical menopause, and baseline mMMSE score, the odds ratio was 0.3 (0.1-0.9), The results were similar for bioavailable oestradiol (five [5%] vs 15 [15%]; adjusted odds ratio 0.3 [0.1-1.0]). There was no association between risk of cognitive impairment and serum testosterone. Interpretation Women with high serum concentrations of non-protein-bound and bioavailable oestradiol, but not testosterone, were less likely to develop cognitive impairment than women with low concentrations. This finding supports the hypothesis that higher concentrations of endogenous oestrogens prevent cognitive decline.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Psychiat, Box 111G,4150 Clement St, San Francisco, CA 94121 USA.		Cauley, Jane A/N-4836-2015; Bibi, Raquel/K-5835-2012	Cauley, Jane A/0000-0003-0752-4408; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05394, AG05407] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asthana S, 1999, PSYCHONEUROENDOCRINO, V24, P657, DOI 10.1016/S0306-4530(99)00020-7; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BARRETTCONNOR E, 1993, JAMA-J AM MED ASSOC, V269, P2637, DOI 10.1001/jama.269.20.2637; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BRENNER DE, 1994, AM J EPIDEMIOL, V140, P262, DOI 10.1093/oxfordjournals.aje.a117245; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; HANKINSON SE, 1995, CANCER EPIDEM BIOMAR, V4, P649; Jacobs DM, 1998, NEUROLOGY, V50, P368, DOI 10.1212/WNL.50.2.368; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Khosla S, 1998, J CLIN ENDOCR METAB, V83, P2266, DOI 10.1210/jc.83.7.2266; McEwen BS, 1999, J CLIN ENDOCR METAB, V84, P1790, DOI 10.1210/jc.84.6.1790; MONTANO MM, 1995, BIOL REPROD, V53, P1198, DOI 10.1095/biolreprod53.5.1198; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PARDRIDGE WM, 1980, AM J PHYSIOL, V239, pE103, DOI 10.1152/ajpendo.1980.239.1.E103; Polo-Kantola P, 1998, OBSTET GYNECOL, V91, P459, DOI 10.1016/S0029-7844(97)00700-X; Resnick SM, 1997, NEUROLOGY, V49, P1491, DOI 10.1212/WNL.49.6.1491; SCHWARZ S, 1992, NEUROENDOCRINOLOGY, V55, P174, DOI 10.1159/000126112; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SHERWIN BB, 1994, EXP GERONTOL, V29, P423, DOI 10.1016/0531-5565(94)90021-3; SHERWIN BB, 1988, PSYCHONEUROENDOCRINO, V13, P345, DOI 10.1016/0306-4530(88)90060-1; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; Yaffe K, 1999, J AM GERIATR SOC, V47, P1176, DOI 10.1111/j.1532-5415.1999.tb05196.x; Yaffe K, 1998, J AM GERIATR SOC, V46, P816, DOI 10.1111/j.1532-5415.1998.tb02713.x	30	186	191	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					708	712		10.1016/S0140-6736(00)02628-3	http://dx.doi.org/10.1016/S0140-6736(00)02628-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085689				2022-12-28	WOS:000088948200009
J	Tamaoki, J; Kondo, M; Sakai, N; Aoshiba, K; Tagaya, E; Nakata, J; Isono, K; Nagai, A				Tamaoki, J; Kondo, M; Sakai, N; Aoshiba, K; Tagaya, E; Nakata, J; Isono, K; Nagai, A		Tokyo Joshi Idai Asthma Res Grp	Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study	LANCET			English	Article							BRONCHIAL RESPONSIVENESS; MILD ASTHMA; INFLAMMATION; MODEL	Background Th2 cytokines play an important part in the pathogenesis of asthma. Our aim was to study the effect of suplatast tosilate, a selective Th2 cytokine inhibitor, on asthma control and asthma exacerbations during reduction of inhaled corticosteroid dose in patients with steroid-dependent asthma. Methods 85 patients with moderate to severe asthma taking high doses (greater than or equal to 1500 mu g per day) of inhaled beclometasone dipropionate, were assigned suplatast tosilate (100 mg three times daily) or placebo for 8 weeks in a double-blind, randomised, parallel-group, multicentre trial. During the first 4 weeks, other medications remained unchanged (add-on phase); during the next 4 weeks, the doses of beclometasone were halved (steroid-reduction phase). Main outcome measures were pulmonary function, asthma symptoms, and use of beta(2)-agonists. Findings Data were available from 77 patients. During the add-on phase, suplatast tosilate treatment, compared with placebo, was associated with higher forced expiratory volume in 1 s (mean difference between groups for changes from baseline at week 4, 0.20 L [95% CI 0.16-0.24], p=0.043), morning peak expiratory flow (18.6 L/min [14.1-23.1], p=0.037), and less diurnal variation in peak expiratory flow rate, asthma symptom scores (7.1[6.6-7.6], p=0.029), and serum concentrations of eosinophil cationic protein and IgE. In the steroid-reduction phase, pulmonary function, asthma symptoms, and use of beta(2)-agonist deteriorated significantly more in the placebo group than in the suplatast group. Interpretation Treatment with a Th2 cytokine inhibitor in steroid-dependent asthma improves pulmonary function and symptom control, and allows a decrease in dose of inhaled corticosteroid without significant side-effects. Some improvements in pharmacokinetics are, however, needed.	Tokyo Womens Med Univ, Sch Med, Dept Med 1, Shinjuku Ku, Tokyo 1628666, Japan; Seirei Hamamatsu Gen Hosp, Dept Internal Med, Hamamatsu, Shizuoka, Japan; Kureha Gen Hosp, Dept Med, Fukushima, Japan; Nagashio Hosp, Dept Med, Tokyo, Japan; Kurihashi Saiseikai Hosp, Dept Pulm Med, Kurihashi, Saitama, Japan	Tokyo Women's Medical University	Tamaoki, J (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Med 1, Shinjuku Ku, Tokyo 1628666, Japan.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; BIANCO S, 1995, J ALLERGY CLIN IMMUN, V95, P937, DOI 10.1016/S0091-6749(95)70092-7; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254, DOI 10.1165/ajrcmb.12.3.7873190; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54, DOI 10.1165/ajrcmb.13.1.7598937; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; KODA A, 1991, AGENT ACTION SUPPL, V34, P369; Kon OM, 1999, INT ARCH ALLERGY IMM, V118, P133, DOI 10.1159/000024049; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360, DOI 10.1165/ajrcmb.13.3.7654390; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; MULLARKEY MF, 1988, NEW ENGL J MED, V318, P603, DOI 10.1056/NEJM198803103181004; *NAT ASTHM ED PREV, 1997, NIH PUB; *NAT HEART LUNG BL, 1995, NIH PUB; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71, DOI 10.1164/ajrccm/146.1.71; Sano Y, 1997, CHEST, V112, P862, DOI 10.1378/chest.112.3.862-a; SPENCE DPS, 1994, AM J RESP CRIT CARE, V149, P1142, DOI 10.1164/ajrccm.149.5.8173754; STREET NE, 1991, FASEB J, V5, P171, DOI 10.1096/fasebj.5.2.1825981; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; YAMAYA H, 1995, LIFE SCI, V56, P1647, DOI 10.1016/0024-3205(95)00132-P; YANAGIHARA Y, 1993, JPN J PHARMACOL, V61, P31, DOI 10.1254/jjp.61.31; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	23	107	114	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 22	2000	356	9226					273	278		10.1016/S0140-6736(00)02501-0	http://dx.doi.org/10.1016/S0140-6736(00)02501-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071181				2022-12-28	WOS:000088305900007
J	Epstein, AM; Ayanian, JZ; Keogh, JH; Noonan, SJ; Armistead, N; Cleary, PD; Weissman, JS; David-Kasdan, JA; Carlson, D; Fuller, J; Marsh, D; Conti, RM				Epstein, AM; Ayanian, JZ; Keogh, JH; Noonan, SJ; Armistead, N; Cleary, PD; Weissman, JS; David-Kasdan, JA; Carlson, D; Fuller, J; Marsh, D; Conti, RM			Racial disparities in access to renal transplantation - Clinically appropriate or due to underuse or overuse?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY ANGIOGRAPHY; REVASCULARIZATION PROCEDURES; SURGICAL-PROCEDURES; MEDICAL PROCEDURES; DISEASE; RACE; QUALITY; LIFE; CANDIDATES; RECIPIENTS	Background: Despite abundant evidence of racial disparities in the use of surgical procedures, it is uncertain whether these disparities reflect racial differences in clinical appropriateness or overuse or underuse of care. Methods: We performed a literature review and used an expert panel to develop criteria for determining the appropriateness of renal transplantation for patients with end-stage renal disease. Using data from five states and the District of Columbia on patients who had started to undergo dialysis in 1996 or 1997, we selected a random sample of 1518 patients (age range, 18 to 54 years), stratified according to race and sex. We classified the appropriateness of patients as candidates for transplantation and analyzed data on rates of referral to a transplantation center for evaluation, placement on a waiting list, and receipt of a transplant according to race. Results: Black patients were less likely than white patients to be rated as appropriate candidates for transplantation according to appropriateness criteria based on expert opinion (71 blacks [9.0 percent] vs. 152 whites [20.9 percent]) and were more likely to have had incomplete evaluations (368 [46.5 percent] vs. 282 [38.8 percent], P<0.001 for the overall chi-square). Among patients considered to be appropriate candidates for transplantation, blacks were less likely than whites to be referred for evaluation, according to the chart review (90.1 percent vs. 98.0 percent, P=0.008), to be placed on a waiting list (71.0 percent vs. 86.7 percent, P=0.007), or to undergo transplantation (16.9 percent vs. 52.0 percent, P<0.001). Among patients classified as inappropriate candidates, whites were more likely than blacks to be referred for evaluation (57.8 percent vs. 38.4 percent), to be placed on a waiting list (30.9 percent vs. 17.4 percent), and to undergo transplantation (10.3 percent vs. 2.2 percent, P<0.001 for all three comparisons). Conclusions: Racial disparities in rates of renal transplantation stem from differences in clinical characteristics that affect appropriateness as well as from underuse of transplantation among blacks and overuse among whites. Reducing racial disparities will require efforts to distinguish their specific causes and the development of interventions tailored to address them. (N Engl J Med 2000;343:1537-44.) (C) 2000, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; CliGnosis, Boston, MA USA; Midatlantic Renal Coalit, Midlothian, VA USA; Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA; Renal Network Upper Midwest, St Paul, MN USA; Network 8, Jackson, MS USA; So Calif Renal Dis Council, Hollywood, CA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.		Cleary, Paul/AAF-7048-2019	Conti, Rena/0000-0002-4190-1839	NIMH NIH HHS [F31 MH070201] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH070201] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELIXHAUSER A, 1994, AHCPR PUBL; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; Hata Y, 1998, TRANSPLANTATION, V65, P208; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; Institute of Medicine Committee on Clinical Practice Guidelines, 1992, GUID CLIN PRACT DEV; Kasiske BL, 1998, J AM SOC NEPHROL, V9, P2142; KASISKE BL, 1995, J AM SOC NEPHROL, V6, P1; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KASISKE BL, 1992, SEMIN NEPHROL, V12, P284; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LEAP LL, 1991, CORONARY ARTERY BYPA; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; *REN DAT SYST, 1999, USRDS 1999 ANN DAT R; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; SIMMONS RG, 1990, AM J KIDNEY DIS, V15, P201, DOI 10.1016/S0272-6386(12)80763-3; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; *UN NETW ORG SHAR, 2000, UNOS POL 3 5 ALL CAD; *UN NETW ORG SHAR, 2000, 199 ANN REP US SCI R; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	40	463	464	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 23	2000	343	21					1537	U8		10.1056/NEJM200011233432106	http://dx.doi.org/10.1056/NEJM200011233432106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	375PR	11087884	Green Accepted			2022-12-28	WOS:000165410900006
J	Walsh, JME; Dolan, NC; Charney, P				Walsh, JME; Dolan, NC; Charney, P			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Review							PROGESTIN REPLACEMENT THERAPY; BREAST-CANCER; MENOPAUSAL ESTROGEN; DOMESTIC VIOLENCE; RISK-FACTORS; SEX; PREVENTION; PHYSICIANS; EXERCISE; HISTORY		Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94115 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Norwalk Hosp, Norwalk, CT 06856 USA	University of California System; University of California San Francisco; Northwestern University	Walsh, JME (corresponding author), Univ Calif San Francisco, Div Gen Internal Med, 1701 Divsadero,Box 1732, San Francisco, CA 94115 USA.	jmwalsh@itsa.ucsf.edu						Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Charney P, 1999, CORONARY ARTERY DIS; Clarke J, 1999, ARCH INTERN MED, V159, P1920, DOI 10.1001/archinte.159.16.1920; Diamant AL, 1999, ARCH INTERN MED, V159, P2730, DOI 10.1001/archinte.159.22.2730; Dunn N, 1999, BRIT MED J, V318, P1579, DOI 10.1136/bmj.318.7198.1579; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Frost MH, 2000, JAMA-J AM MED ASSOC, V284, P319, DOI 10.1001/jama.284.3.319; Grisso JA, 1999, NEW ENGL J MED, V341, P1899, DOI 10.1056/NEJM199912163412506; Hu FB, 1999, ARCH INTERN MED, V159, P1061, DOI 10.1001/archinte.159.10.1061; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Longnecker MP, 1996, CANCER EPIDEM BIOMAR, V5, P961; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; Mouton CP, 1999, J WOMEN HEALTH GEN-B, V8, P1173, DOI 10.1089/jwh.1.1999.8.1173; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rhodes JC, 1999, JAMA-J AM MED ASSOC, V282, P1934, DOI 10.1001/jama.282.20.1934; Roach K, 2000, ANN INTERN MED, V133, P209, DOI 10.7326/0003-4819-133-3-200008010-00013; Sanders SA, 1999, JAMA-J AM MED ASSOC, V281, P275, DOI 10.1001/jama.281.3.275; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schuchter LM, 2000, ANN INTERN MED, V133, P615, DOI 10.7326/0003-4819-133-8-200010170-00014; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Vaccarino V, 1999, NEW ENGL J MED, V341, P217, DOI 10.1056/NEJM199907223410401; Walsh JME, 1999, AM J PREV MED, V16, P307, DOI 10.1016/S0749-3797(99)00021-5; Warshaw C, 1999, ANN INTERN MED, V131, P619, DOI 10.7326/0003-4819-131-8-199910190-00012; Wee CC, 1999, JAMA-J AM MED ASSOC, V282, P1583, DOI 10.1001/jama.282.16.1583; Wilson PWF, 1999, ARCH INTERN MED, V159, P1104, DOI 10.1001/archinte.159.10.1104	26	1	3	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					808	814		10.7326/0003-4819-133-10-200011210-00014	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00014			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085844				2022-12-28	WOS:000165321200007
J	Long, J; Walsh, D; Ritchie, DAW; Russell, F				Long, J; Walsh, D; Ritchie, DAW; Russell, F			Corneal donation in the accident and emergency department: observational study	BRITISH MEDICAL JOURNAL			English	Article							TISSUE		Monklands Hosp, Airdrie ML6 0JS, Scotland; Univ Glasgow, Western Infirm, Renal Unit, Glasgow G11 6NT, Lanark, Scotland; Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland; Royal Alexandra Hosp, Paisley PA2 9PN, Renfrew, Scotland	Monklands Hospital; University of Glasgow	Long, J (corresponding author), Monklands Hosp, Airdrie ML6 0JS, Scotland.		Ritchie, David/K-2206-2014	Ritchie, David/0000-0002-9844-8350				DIAMOND GA, 1987, AM J OPHTHALMOL, V302, P149; LEWIS LM, 1993, AM J EMERG MED, V11, P347, DOI 10.1016/0735-6757(93)90165-8; LOWENSTEIN A, 1991, ISRAEL J MED SCI, V27, P79; Magrath HP, 1999, J ACCID EMERG MED, V16, P117; *UK TRANSPL SUPP S, 1999, STAT PREP UK TRANSPL	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1263	1264		10.1136/bmj.321.7271.1263	http://dx.doi.org/10.1136/bmj.321.7271.1263			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082088	Bronze, Green Published			2022-12-28	WOS:000165445800027
J	Fussmann, GF; Ellner, SP; Shertzer, KW; Hairston, NG				Fussmann, GF; Ellner, SP; Shertzer, KW; Hairston, NG			Crossing the Hopf bifurcation in a live predator-prey system	SCIENCE			English	Article							CHEMOSTAT CULTURE; ESCHERICHIA-COLI; COMPLEX DYNAMICS; FOOD-CHAINS; CYCLES; CHAOS; TIME	Population biologists have Long been interested in the oscillations in population size displayed by many organisms in the field and Laboratory. A wide range of deterministic mathematical models predict that these fluctuations can be generated internally by nonlinear interactions among species and, if correct, would provide important insights for understanding and predicting the dynamics of interacting populations. We studied the dynamical behavior of a two-species aquatic Laboratory community encompassing the interactions between a demographically structured herbivore population, a primary producer, and a mineral resource, yet still amenable to description and parameterization using a mathematical model. The qualitative dynamical behavior of our experimental system, that is, cycles, equilibria, and extinction, is highly predictable by a simple nonlinear model.	Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; N Carolina State Univ, Dept Stat, Biomath Program, Raleigh, NC 27695 USA	Cornell University; University of North Carolina; North Carolina State University	Fussmann, GF (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Corson Hall, Ithaca, NY 14853 USA.			Fussmann, Gregor/0000-0001-9576-0122; Shertzer, Kyle/0000-0001-7196-5959				Aoki S, 1996, FISHERIES SCI, V62, P8, DOI 10.2331/fishsci.62.8; BORAAS ME, 1980, AM SOC LIMNOL OCEANO, V3, P173; Constantino R.F, 1995, NATURE, V375, P227; DENT VE, 1976, ARCH MICROBIOL, V109, P187, DOI 10.1007/BF00425134; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; Gragnani A, 1998, B MATH BIOL, V60, P703, DOI 10.1006/bulm.1997.0039; HALBACH U, 1970, OECOLOGIA, V4, P176, DOI 10.1007/BF00377100; HALBACH U, 1974, ARCH HYDROBIOL, V73, P273; HASTINGS A, 1991, ECOLOGY, V72, P896, DOI 10.2307/1940591; HOLLING C. S., 1959, CANADIAN ENT, V91, P293; JOST JL, 1973, J THEOR BIOL, V41, P461, DOI 10.1016/0022-5193(73)90056-8; JOST JL, 1973, J BACTERIOL, V113, P834, DOI 10.1128/JB.113.2.834-840.1973; Khibnik AI, 1997, P ROY SOC B-BIOL SCI, V264, P1049, DOI 10.1098/rspb.1997.0145; KOT M, 1992, B MATH BIOL, V54, P619, DOI 10.1016/S0092-8240(05)80079-5; LUCKINBILL LS, 1973, ECOLOGY, V54, P1320, DOI 10.2307/1934194; MAY RM, 1972, SCIENCE, V177, P900, DOI 10.1126/science.177.4052.900; McCann K, 1998, NATURE, V395, P794, DOI 10.1038/27427; McCauley E, 1999, NATURE, V402, P653, DOI 10.1038/45223; NISBET RM, 1983, BIOTECHNOL BIOENG, V25, P301, DOI 10.1002/bit.260250122; ROSENZWE.ML, 1971, SCIENCE, V171, P385, DOI 10.1126/science.171.3969.385; Strogatz S.H., 1994, NONLINEAR DYNAMICS C; TISCHNER R, 1979, PLANTA, V146, P287, DOI 10.1007/BF00387800	23	281	291	2	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1358	1360		10.1126/science.290.5495.1358	http://dx.doi.org/10.1126/science.290.5495.1358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082063				2022-12-28	WOS:000165379800049
J	Wolfe, J; Klar, N; Grier, HE; Duncan, J; Salem-Schatz, S; Emanuel, EJ; Weeks, JC				Wolfe, J; Klar, N; Grier, HE; Duncan, J; Salem-Schatz, S; Emanuel, EJ; Weeks, JC			Understanding of prognosis among parents of children who died of cancer - Impact on treatment goals and integration of palliative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC ONCOLOGY; PERSPECTIVES; PREFERENCES; GUIDELINES; PATIENT	Context Parents' understanding of prognosis or decision making about palliative care for children who die of cancer is largely unknown. However, a more accurate under standing of prognosis could alter treatment goals and expectations and lead to more effective care. Objectives To evaluate parental understanding of prognosis in children who die of cancer and to assess the association of this factor with treatment goals and the palliative care received by children. Design, Setting, and Participants Survey, conducted between September 1997 and August 1998, of 103 parents of children who received treatment at the Dana-Farber Cancer Institute and Children's Hospital, Boston, Mass, and who died of cancer between 1990 and 1997 (72 % of those eligible and those located) and 42 pediatric oncologists. Main Outcome Measure Timing of parental understanding that the child had no realistic chance for cure compared with the timing of physician understanding of this prognosis, as documented in the medical record. Results Parents first recognized that the child had no realistic chance for cure a mean (SD) of 106 (150) days before the child's death, while physician recognition occurred earlier at 206 (330) days before death. Among children who died of progressive disease, the group characterized by earlier recognition of this prognosis by both parents and physicians had earlier discussions of hospice care (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.01 -1.06; P=.01), better parental ratings of the quality of home care (OR, 3.31; 95% CI, 1.15-9.54; P=.03), earlier institution of a do-not-resuscitate order (OR, 1.03; 95% CI, 1.00-1.06; P=.02), less use of cancer-directed therapy during the last month of life (OR, 2.80; 95% CI, 1.05-7.50; P=.04), and higher likelihood that the goal of cancer-directed therapy identified by both physician and parent was to lessen suffering (OR, 5.17; 95% CI, 1.86-14.4; P=.002 for physician and OR, 6.56; 95% CI, 1.54-27.86; P=.01 for parents). Conclusion Considerable delay exists in parental recognition that children have no realistic chance for cure, but earlier recognition of this prognosis by both physicians and parents is associated with a stronger emphasis on treatment directed at lessening suffering and greater integration of palliative care.	Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Div Prevent Oncol Canc Care Ontario, Toronto, ON, Canada; NIH, Dept Clin Bioeth, Bethesda, MD 20892 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Cancer Care Ontario; National Institutes of Health (NIH) - USA	Wolfe, J (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 44 Binney St, Boston, MA 02115 USA.				AHRQ HHS [5 T32 HS00063] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000063] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; [Anonymous], 1996, JAMA-J AM MED ASSOC, V275, P1232; Billings J A, 1998, J Palliat Med, V1, P73, DOI 10.1089/jpm.1998.1.73; Cherny NI, 1996, HEMATOL ONCOL CLIN N, V10, P261, DOI 10.1016/S0889-8588(05)70338-5; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Frager G, 1996, J PALLIATIVE CARE, V12, P9; Houston K, 1995, Continuum, V15, P9; James L, 1997, J Pediatr Oncol Nurs, V14, P83, DOI 10.1177/104345429701400207; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEWIS C, 1988, J PEDIATR-US, V112, P378, DOI 10.1016/S0022-3476(88)80316-0; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Masera G, 1999, MED PEDIATR ONCOL, V32, P44, DOI 10.1002/(SICI)1096-911X(199901)32:1<44::AID-MPO9>3.0.CO;2-P; MAUER AM, 1987, AM J PEDIAT HEMATOL, V9, P58; PRONZATO P, 1994, SUPPORT CARE CANCER, V2, P242, DOI 10.1007/BF00365729; Pyke-Grimm K A, 1999, J Pediatr Oncol Nurs, V16, P13, DOI 10.1016/S1043-4542(99)90003-6; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Ross LF, 1997, HASTINGS CENT REP, V27, P41, DOI 10.2307/3527717; Rothenbacher D, 1997, EUR J CANCER, V33, P1184, DOI 10.1016/S0959-8049(97)00034-8; Sanders J, 1997, PEDIATRICS, V99, P139; Saunders C, 1979, OMEGA, V10, P302; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Schroeder M. R., 1997, CONTINUUM, V17, P3; Shelton TL, 1999, J DEV BEHAV PEDIATR, V20, P117, DOI 10.1097/00004703-199904000-00008; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; TULSKY JA, 1995, J GEN INTERN MED, V10, P436, DOI 10.1007/BF02599915; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506	31	328	328	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 15	2000	284	19					2469	2475		10.1001/jama.284.19.2469	http://dx.doi.org/10.1001/jama.284.19.2469			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	371MY	11074776	Bronze			2022-12-28	WOS:000165183800020
J	Gale, C; Oakley-Browne, M				Gale, C; Oakley-Browne, M			Anxiety disorder	BRITISH MEDICAL JOURNAL			English	Review							GENERALIZED ANXIETY; BENZODIAZEPINE USE; ANTIDEPRESSANTS; EFFICACY; RISK; METAANALYSIS; ALPRAZOLAM; BUSPIRONE; SYMPTOMS		Univ Auckland, Div Psychiat, Auckland 1003, New Zealand	University of Auckland	Gale, C (corresponding author), Univ Auckland, Div Psychiat, 4th Floor,3 Ferncroft St, Auckland 1003, New Zealand.		Gale, Christopher Kennington/C-6513-2009	Gale, Christopher Kennington/0000-0001-8032-765X				ANDREWS G, 1995, AUST NZ J PSYCHIAT, V29, P124, DOI 10.3109/00048679509075901; BERNSTEIN JG, 1995, HDB DRUG THERAPY PSY, P401; Brantley PJ, 1999, J NERV MENT DIS, V187, P435, DOI 10.1097/00005053-199907000-00007; Davidson JRT, 1999, J CLIN PSYCHIAT, V60, P528, DOI 10.4088/JCP.v60n0805; Dolovich LR, 1998, BMJ-BRIT MED J, V317, P839, DOI 10.1136/bmj.317.7162.839; DUKES PD, 1992, NEW ZEAL MED J, V105, P25; DUKES PD, 1992, NZ MED J, V105, P135; Durham R. C., 1999, BEHAV COGN PSYCHOTH, V27, P19; Figueira ML, 1999, HUM PSYCHOPHARM CLIN, V14, P171, DOI 10.1002/(SICI)1099-1077(199904)14:3<171::AID-HUP80>3.0.CO;2-7; FRASER NC, 1980, BRIT MED J, V280, P1595, DOI 10.1136/bmj.280.6231.1595; Gould RA, 1997, BEHAV THER, V28, P285, DOI 10.1016/S0005-7894(97)80048-2; Hoehn-Saric R, 1998, ACTA PSYCHIAT SCAND, V98, P32, DOI 10.1111/j.1600-0447.1998.tb05964.x; Judd LL, 1998, ACTA PSYCHIAT SCAND, V98, P6, DOI 10.1111/j.1600-0447.1998.tb05960.x; KESSLER RC, 1992, ARCH GEN PSYCHIAT, V51, P8; Kilic C, 1999, PSYCHOL MED, V29, P225, DOI 10.1017/S003329179800734X; Kulin NA, 1998, CAN FAM PHYSICIAN, V44, P2081; Liu B, 1998, LANCET, V351, P1303, DOI 10.1016/S0140-6736(97)09528-7; LUI BA, 1996, CAN MED ASSOC J, V155, P519; MENDELS J, 1986, J CLIN PSYCHIAT, V47, P170; PEARN J, 1984, BMJ-BRIT MED J, V288, P44, DOI 10.1136/bmj.288.6410.44; RICKELS K, 1993, ARCH GEN PSYCHIAT, V50, P884; Rocca P, 1997, ACTA PSYCHIAT SCAND, V95, P444, DOI 10.1111/j.1600-0447.1997.tb09660.x; Sramek JJ, 1996, J CLIN PSYCHIAT, V57, P287; Thapa PB, 1998, NEW ENGL J MED, V339, P875, DOI 10.1056/NEJM199809243391303; Thomas RE, 1998, CAN FAM PHYSICIAN, V44, P799; TYRER P, 1990, ANXIOLYTIC JUNGLE NE, P23; van Harten PN, 1998, AM J PSYCHIAT, V155, P565, DOI 10.1176/ajp.155.4.565	27	11	13	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1204	1207		10.1136/bmj.321.7270.1204	http://dx.doi.org/10.1136/bmj.321.7270.1204			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	374RA	11073514	Green Published			2022-12-28	WOS:000165357100031
J	Sickles, EA				Sickles, EA			Galactography and other imaging investigations of nipple discharge	LANCET			English	Editorial Material							EXCISION		Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Sickles, EA (corresponding author), Univ Calif San Francisco, Sch Med, Dept Radiol, San Francisco, CA 94143 USA.							CARDENOSA G, 1991, RADIOLOGY, V181, P751, DOI 10.1148/radiology.181.3.1947092; Dawes LG, 1998, SURGERY, V124, P685, DOI 10.1067/msy.1998.91362; Dennis MA, 2000, AM J ROENTGENOL, V174, P1263, DOI 10.2214/ajr.174.5.1741263; Dinkel HP, 2000, BRIT J RADIOL, V73, P706, DOI 10.1259/bjr.73.871.11089460; Hild F, 1998, EUR J CANCER PREV, V7, pS57, DOI 10.1097/00008469-199802001-00011; LEIS HP, 1989, WORLD J SURG, V13, P736, DOI 10.1007/BF01658424; LOGANYOUNG W, 1994, BREAST CANC PRACTICA, P193; NEWMAN HF, 1983, NEW YORK STATE J MED, V83, P928; Orel SG, 2000, RADIOLOGY, V216, P248, DOI 10.1148/radiology.216.1.r00jn28248; RISSANEN T, 1993, J CLIN ULTRASOUND, V21, P497, DOI 10.1002/jcu.1870210804; Rovno HDS, 1999, AM J ROENTGENOL, V172, P151, DOI 10.2214/ajr.172.1.9888758; TABAR L, 1983, RADIOLOGY, V149, P31, DOI 10.1148/radiology.149.1.6611939; Van Zee KJ, 1998, CANCER, V82, P1874	13	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 11	2000	356	9242					1622	1623		10.1016/S0140-6736(00)03150-0	http://dx.doi.org/10.1016/S0140-6736(00)03150-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089815				2022-12-28	WOS:000165249200004
J	Esteller, M; Garcia-Foncillas, J; Andion, E; Goodman, SN; Hidalgo, OF; Vanaclocha, V; Baylin, SB; Herman, JG				Esteller, M; Garcia-Foncillas, J; Andion, E; Goodman, SN; Hidalgo, OF; Vanaclocha, V; Baylin, SB; Herman, JG			Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ALKYLTRANSFERASE; METHYLATION; O-6-BENZYLGUANINE; CHEMOTHERAPY; SURVIVAL; PROTEIN; BRAIN	Background: The DNA-repair enzyme O(sup 6)-methylguanine-DNA methyltransferase (MGMT) inhibits the killing of tumor cells by alkylating agents. MGMT activity is controlled by a promoter; methylation of the promoter silences the gene in cancer, and the cells no longer produce MGMT. We examined gliomas to determine whether methylation of the MGMT promoter is related to the responsiveness of the tumor to alkylating agents. Methods: We analyzed the MGMT promoter in tumor DNA by a methylation-specific polymerase-chain-reaction assay. The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU). The molecular data were correlated with the clinical outcome. Results: The MGMT promoter was methylated in gliomas from 19 of 47 patients (40 percent). This finding was associated with regression of the tumor and prolonged overall and disease-free survival. It was an independent and stronger prognostic factor than age, stage, tumor grade, or performance status. Conclusions: Methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents. (N Engl J Med 2000;343:1350-4.) (C) 2000, Massachusetts Medical Society.	Johns Hopkins Oncol Ctr, Div Canc Biol, Baltimore, MD 21231 USA; Johns Hopkins Oncol Ctr, Div Biostat, Baltimore, MD 21231 USA; Clin Univ, Dept Oncol, Cell Therapy Area, Biotechnol Lab, Pamplona, Spain	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Navarra	Herman, JG (corresponding author), Johns Hopkins Oncol Ctr, Div Canc Biol, 1650 Orleans, Baltimore, MD 21231 USA.		Garcia-Foncillas, Jesus/E-6857-2010; Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Goodman, Steven/0000-0002-3872-5723; J, Garcia-Foncillas/0000-0002-7591-8006				Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belanich M, 1996, CANCER RES, V56, P783; COLVIN M, 1981, CANCER TREAT REP, V65, P89; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Dolan ME, 1997, CLIN CANCER RES, V3, P837; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, CANCER RES, V60, P2368; Friedman HS, 1998, J CLIN ONCOL, V16, P3570, DOI 10.1200/JCO.1998.16.11.3570; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jaeckle KA, 1998, J CLIN ONCOL, V16, P3310, DOI 10.1200/JCO.1998.16.10.3310; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Qian XLC, 1997, CANCER RES, V57, P3672; Silber JR, 1999, CLIN CANCER RES, V5, P807; Silber JR, 1998, CANCER RES, V58, P1068; SILBER JR, 1993, CANCER RES, V53, P3416; Teicher Beverly A., 1997, P405; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612	19	1656	1737	1	89	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1350	1354		10.1056/NEJM200011093431901	http://dx.doi.org/10.1056/NEJM200011093431901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070098	Green Published, Bronze			2022-12-28	WOS:000165152800001
J	Bath, J; Wu, LJ; Errington, J; Wang, JC				Bath, J; Wu, LJ; Errington, J; Wang, JC			Role of Bacillus subtilis SpoIIIE in DNA transport across the mother cell-prespore division septum	SCIENCE			English	Article							ESCHERICHIA-COLI; PARTITIONING PROTEIN; CHROMOSOME; SEGREGATION; TEMPLATE; TRANSCRIPTION; LOCALIZATION; REPLICATION; REGIONS	The SpoIIIE protein of Bacillus subtilis is required for chromosome segregation during spore formation. The COOH-terminal cytoplasmic part of SpoIIIE was shown to be a DNA-dependent adenosine triphosphatase (ATPase) capable of tracking along DNA in the presence of ATP, and the NH2-terminal part of the protein was found to mediate its Localization to the division septum. Thus, during sporulation, SpoIIIE appears to act as a DNA pump that actively moves one of the replicated pair of chromosomes into the prespore. The presence of SpoIIIE homologs in a broad range of bacteria suggests that this mechanism for active transport of DNA may be widespread.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Harvard University; University of Oxford	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Errington, Jeff/G-1832-2011; Bath, Jonathan/E-9569-2011	Errington, Jeff/0000-0002-6977-9388; Bath, Jonathan/0000-0002-7144-662X; Wu, Ling Juan/0000-0003-2432-8820	NATIONAL CANCER INSTITUTE [R01CA047958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER; NCI NIH HHS [CA47958] Funding Source: Medline; NIGMS NIH HHS [GM24544] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1972, P NATL ACAD SCI USA, V69, P143, DOI 10.1073/pnas.69.1.143; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; OSTRANDER EA, 1990, SCIENCE, V249, P1261, DOI 10.1126/science.2399463; SHARPE ME, 1995, P NATL ACAD SCI USA, V92, P8630, DOI 10.1073/pnas.92.19.8630; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WU LJ, 1995, GENE DEV, V9, P1316, DOI 10.1101/gad.9.11.1316; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014; Wu LJ, 1997, EMBO J, V16, P2161, DOI 10.1093/emboj/16.8.2161; YANG L, 1989, P NATL ACAD SCI USA, V86, P6121, DOI 10.1073/pnas.86.16.6121	14	158	160	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					995	997		10.1126/science.290.5493.995	http://dx.doi.org/10.1126/science.290.5493.995			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062134				2022-12-28	WOS:000165103200053
J	Chow, E; Lin, SY; Johnson, SG; Villeneuve, PR; Joannopoulos, JD; Wendt, JR; Vawter, GA; Zubrzycki, W; Hou, H; Alleman, A				Chow, E; Lin, SY; Johnson, SG; Villeneuve, PR; Joannopoulos, JD; Wendt, JR; Vawter, GA; Zubrzycki, W; Hou, H; Alleman, A			Three-dimensional control of light in a two-dimensional photonic crystal slab	NATURE			English	Article							NEAR-INFRARED WAVELENGTHS; BAND-GAP STRUCTURES; WAVE-GUIDE; CONFINEMENT; MODES	Optoelectronic devices are increasingly important in communication and information technology. To achieve the necessary manipulation of light (which carries information in optoelectronic devices), considerable efforts are directed at the development of photonic crystals-periodic dielectric materials that have so-called photonic bandgaps, which prohibit the propagation of photons having energies within the bandgap region. Straightforward application of the bandgap concept is generally thought to require three-dimensional (3D) photonic crystals(1-5); their two-dimensional (2D) counterparts confine light in the crystal plane(6,7), but not in the perpendicular z direction, which inevitably leads to diffraction losses. Nonetheless, 2D photonic crystals still attract interest(8-15) because they are potentially more amenable to fabrication by existing techniques and diffraction losses need not seriously impair utility. Here we report the fabrication of a waveguide-coupled photonic crystal slab (essentially a free-standing 2D photonic crystal) with a strong 2D bandgap at wavelengths of about 1.5 mum, yet which is capable of fully controlling light in all three dimensions. These features confirm theoretical calculations(16,17) on the possibility of achieving 3D light control using 2D bandgaps, with index guiding providing control in the third dimension, and raise the prospect of being able to realize unusual photonic-crystal devices, such as thresholdless lasers(1).	Sandia Natl Labs, Albuquerque, NM 87185 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	United States Department of Energy (DOE); Sandia National Laboratories; Massachusetts Institute of Technology (MIT)	Lin, SY (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.		Joannopoulos, John D/E-6401-2013	Johnson, Steven/0000-0001-7327-4967				Benisty H, 1999, J LIGHTWAVE TECHNOL, V17, P2063, DOI 10.1109/50.802996; Fan SH, 1998, PHYS REV LETT, V80, P960, DOI 10.1103/PhysRevLett.80.960; Fleming JG, 1999, OPT LETT, V24, P49, DOI 10.1364/OL.24.000049; Foresi JS, 1997, NATURE, V390, P143, DOI 10.1038/36514; Gruning U, 1996, THIN SOLID FILMS, V276, P151, DOI 10.1016/0040-6090(95)08077-5; HO KM, 1994, SOLID STATE COMMUN, V89, P413, DOI 10.1016/0038-1098(94)90202-X; Joannoupoulos J.D., 1995, PHOTONIC CRYSTALS; JOHN S, 1991, PHYS TODAY, V44, P32, DOI 10.1063/1.881300; Johnson SG, 1998, OPT LETT, V23, P1855, DOI 10.1364/OL.23.001855; Johnson SG, 1999, PHYS REV B, V60, P5751, DOI 10.1103/PhysRevB.60.5751; Kanskar M, 1997, APPL PHYS LETT, V70, P1438, DOI 10.1063/1.118570; KISH FA, 1991, APPL PHYS LETT, V59, P1755, DOI 10.1063/1.106240; KITTEL C, 1976, INTRO SOLID STATE PH, P185; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; Labilloy D, 1997, PHYS REV LETT, V79, P4147, DOI 10.1103/PhysRevLett.79.4147; LIN SY, 1994, J MOD OPTIC, V41, P385, DOI 10.1080/09500349414550391; Lin SY, 1998, SCIENCE, V282, P274, DOI 10.1126/science.282.5387.274; Lin SY, 1998, NATURE, V394, P251, DOI 10.1038/28343; OZBAY E, 1994, PHYS REV B, V50, P1945, DOI 10.1103/PhysRevB.50.1945; ROBERTSON WM, 1992, PHYS REV LETT, V68, P2023, DOI 10.1103/PhysRevLett.68.2023; Rosenberg A, 1996, OPT LETT, V21, P830, DOI 10.1364/OL.21.000830; SOUKOULIS CM, 1993, NATO ASI SERIES B, V308; Villeneuve PR, 1998, IEE P-OPTOELECTRON, V145, P384, DOI 10.1049/ip-opt:19982467; YABLONOVITCH E, 1993, J OPT SOC AM B, V10, P283, DOI 10.1364/JOSAB.10.000283	24	348	381	2	135	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					983	986		10.1038/35039583	http://dx.doi.org/10.1038/35039583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069173	Green Submitted			2022-12-28	WOS:000090032500037
J	Gamlin, PD; Yoon, K				Gamlin, PD; Yoon, K			An area for vergence eye movement in primate frontal cortex	NATURE			English	Article							OCULAR ACCOMMODATION; SMOOTH-PURSUIT; MACAQUE; FIELD; NEURONS; MONKEY; NUCLEUS; RESPONSES; PATHWAYS; CELLS	To view objects at different distances, humans rely on vergence eye movements to appropriately converge or diverge the eyes and on ocular accommodation to focus the object(1,2). Despite the importance of these coordinated eye movements (the 'near response') very little is known about the role of the cerebral cortex in their control. As near-response neurons exist within the nucleus reticularis tegmenti pontis(3), which receives input from the frontal eye field region of frontal cortex(4-6), and this cortical region is known to be involved in saccadic(7-9) and smooth-pursuit eye movements(10-12), we propose that a nearby region might play a role in vergence and ocular accommodation. Here we provide evidence from rhesus monkeys that a region of frontal cortex located immediately anterior to the saccade-related frontal eye field region is involved in vergence and ocular accommodation, and in the sensorimotor transformations required for these eye movements. We conclude that the macaque frontal cortex is involved in the control of all voluntary eye movements, and suggest that the definition of the frontal eye fields should be expanded to include this region.	Univ Alabama, Vis Sci Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Gamlin, PD (corresponding author), Univ Alabama, Vis Sci Res Ctr, Birmingham, AL 35294 USA.		Gamlin, Paul/W-2169-2019	Gamlin, Paul/0000-0002-2966-4762				BIZZI E, 1968, EXP BRAIN RES, V6, P69; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Dias EC, 1995, J NEUROPHYSIOL, V74, P2744, DOI 10.1152/jn.1995.74.6.2744; Ferraina S, 2000, J NEUROPHYSIOL, V83, P625, DOI 10.1152/jn.2000.83.1.625; FISCHER B, 1979, PROC R SOC SER B-BIO, V204, P409, DOI 10.1098/rspb.1979.0036; GAMLIN PDR, 1994, J NEUROPHYSIOL, V72, P2368, DOI 10.1152/jn.1994.72.5.2368; Gamlin PDR, 1999, OPHTHAL PHYSL OPT, V19, P81, DOI 10.1046/j.1475-1313.1999.00434.x; GAMLIN PDR, 1995, J NEUROPHYSIOL, V73, P2115, DOI 10.1152/jn.1995.73.5.2115; Gamlin PDR, 1996, EYE, V10, P167, DOI 10.1038/eye.1996.42; GAMLIN PDR, 1992, J NEUROPHYSIOL, V67, P64, DOI 10.1152/jn.1992.67.1.64; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634, DOI 10.1152/jn.1994.72.4.1634; HUERTA MF, 1986, J COMP NEUROL, V253, P415, DOI 10.1002/cne.902530402; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; JUDGE SJ, 1986, J NEUROPHYSIOL, V55, P915, DOI 10.1152/jn.1986.55.5.915; LEICHNETZ GR, 1984, J COMP NEUROL, V228, P388, DOI 10.1002/cne.902280307; LYNCH JC, 1987, EXP BRAIN RES, V68, P437; MacAvoy MG, 1991, CEREB CORTEX, V1, P95, DOI 10.1093/cercor/1.1.95; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; MUSTARI MJ, 1988, J NEUROPHYSIOL, V60, P664, DOI 10.1152/jn.1988.60.2.664; NEWSOME WT, 1988, J NEUROPHYSIOL, V60, P604, DOI 10.1152/jn.1988.60.2.604; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P339, DOI 10.1113/jphysiol.1961.sp006812; SCHOR CM, 1992, OPTOMETRY VISION SCI, V69, P258, DOI 10.1097/00006324-199204000-00002; STANTON GB, 1988, J COMP NEUROL, V271, P473, DOI 10.1002/cne.902710402; Zee DS., 1999, NEUROLOGY EYE MOVEME; Zhang HY, 1998, J NEUROPHYSIOL, V79, P1255, DOI 10.1152/jn.1998.79.3.1255; ZHANG Y, 1992, J NEUROPHYSIOL, V67, P944, DOI 10.1152/jn.1992.67.4.944	28	144	145	2	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1003	1007		10.1038/35039506	http://dx.doi.org/10.1038/35039506			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069179				2022-12-28	WOS:000090032500043
J	Boaz, M; Smetana, S; Weinstein, T; Matas, Z; Gafter, U; Iaina, A; Knecht, A; Weissgarten, Y; Brunner, D; Fainaru, M; Green, MS				Boaz, M; Smetana, S; Weinstein, T; Matas, Z; Gafter, U; Iaina, A; Knecht, A; Weissgarten, Y; Brunner, D; Fainaru, M; Green, MS			Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial	LANCET			English	Article							VITAMIN-E; CEREBROVASCULAR-DISEASE; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; IN-VITRO; HEMODIALYSIS; FAILURE; MORTALITY; CHAOS	Background Excess cardiovascular mortality has been documented in chronic haemodialysis patients. Oxidative stress is greater in haemodialysis patients with prevalent cardiovascular disease than in those without, suggesting a role for oxidative stress in excess cardiovascular disease in haemodialysis. We investigated the effect of high-dose vitamin E supplementation on cardiovascular disease outcomes in haemodialysis patients with pre-existing cardiovascular disease. Methods Haemodialysis patients with pre-existing cardiovascular disease (n=196) aged 40-75 years at baseline from six dialysis centres were enrolled and randomised to receive 800 IU/day vitamin E or matching placebo. Patients were followed for a median 519 days. The primary endpoint was a composite variable consisting of: myocardial infarction (fatal and non-fatal), ischaemic stroke, peripheral vascular disease (excluding the arteriovenous fistula), and unstable angina. Secondary outcomes included each of the component outcomes, total mortality, and cardiovascular-disease mortality. Findings A total of 15 (16%) of the 97 patients assigned to vitamin E and 33 (33%) of the 99 patients assigned to placebo had a primary endpoint (relative risk 0.46 [95% CI 0.27-0.78], p=0.014). Five (5.1%) patients assigned to vitamin E and 17 (17.2%) patients assigned to placebo had myocardial infarction (0.3 [0.11-0.78], p=0.016). No significant differences in other secondary endpoints, cardiovascular disease, or total mortality were detected. Interpretation In haemodialysis patients with prevalent cardiovascular disease, supplementation with 800 IU/day vitamin E reduces composite cardiovascular diesease endpoints and myocardial infarction.	E Wolfson Med Ctr, Inst Nephrol, IL-58100 Holon, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel; E Wolfson Med Ctr, Biochem Lab, IL-58100 Holon, Israel; E Wolfson Med Ctr, Inst Physiol Hyg, IL-58100 Holon, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Lipid Res Lab, IL-69978 Tel Aviv, Israel; Israel Ctr Dis Control, Tel Hashomer, Israel; Rabin Med Ctr, Dept Nephrol, Petah Tiqwa, Israel; Ichilov Med Ctr, Dept Nephrol, Tel Aviv, Israel; Chaim Sheba Med Ctr, Dept Nephrol, IL-52621 Tel Hashomer, Israel; Asaf Harofeh Med Ctr, Dept Nephrol, Zrifin, Israel	Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Chaim Sheba Medical Center	Boaz, M (corresponding author), E Wolfson Med Ctr, Inst Nephrol, IL-58100 Holon, Israel.		Boaz, Mona/O-6940-2014	Boaz, Mona/0000-0002-3920-7549; Green, Manfred S./0000-0002-9753-5612				BETO JA, 1995, J AM DIET ASSOC, V95, P898, DOI 10.1016/S0002-8223(95)00248-0; BIRD RP, 1984, METHOD ENZYMOL, V105, P299; Boaz M, 1999, KIDNEY INT, V56, P1078, DOI 10.1046/j.1523-1755.1999.00613.x; Boaz M, 1999, AM J KIDNEY DIS, V34, P438, DOI 10.1016/S0272-6386(99)70070-3; Devaraj S, 1998, CURR OPIN LIPIDOL, V9, P11, DOI 10.1097/00041433-199802000-00004; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; DUARGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Gutteridge J M, 1976, Lab Pract, V25, P25; HARNETT JD, 1995, AM J KIDNEY DIS, V25, pS3, DOI 10.1016/0272-6386(95)90673-8; ISLAM KN, ATHEROSCLEROSIS 20, V150, P217; Leppala JM, 2000, ARTERIOSCL THROM VAS, V20, P230, DOI 10.1161/01.ATV.20.1.230; LOUGHREY CM, 1994, Q J MED, V87, P679; Mitchinson MJ, 1999, LANCET, V353, P381, DOI 10.1016/S0140-6736(05)74955-2; Mune M, 1999, KIDNEY INT, V56, pS126, DOI 10.1016/S0085-2538(15)46619-0; PANZETTA O, 1995, CLIN NEPHROL, V44, P303; PARFREY PS, 1993, AM J KIDNEY DIS, V21, P77, DOI 10.1016/S0272-6386(12)80726-8; Pryor WA, 2000, FREE RADICAL BIO MED, V28, P141, DOI 10.1016/S0891-5849(99)00224-5; RITZ E, 1993, AM J KIDNEY DIS, V21, P113, DOI 10.1016/0272-6386(93)70102-5; Steiner M, 1999, NUTR REV, V57, P306, DOI 10.1111/j.1753-4887.1999.tb06903.x; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TOBOREK M, 1992, METABOLISM, V41, P1229, DOI 10.1016/0026-0495(92)90014-2; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; YUKAWA S, 1995, NEPHROL DIAL TRANSPL, V10, P1; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; ZIMA T, 1993, BIOCHEM MOL BIOL INT, V29, P531	25	810	844	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1213	1218		10.1016/S0140-6736(00)02783-5	http://dx.doi.org/10.1016/S0140-6736(00)02783-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072938				2022-12-28	WOS:000089724900009
J	Corcoran, M				Corcoran, M			It wasn't all your fault doctor!	LANCET			English	Editorial Material									Bevan Ashford Solicitors, Bristol BS1 4TT, Avon, England		Corcoran, M (corresponding author), Bevan Ashford Solicitors, Bristol BS1 4TT, Avon, England.								0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1212	1212		10.1016/S0140-6736(00)02780-X	http://dx.doi.org/10.1016/S0140-6736(00)02780-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	361LQ	11072935				2022-12-28	WOS:000089724900006
J	Zornberg, GL; Jick, H				Zornberg, GL; Jick, H			Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study	LANCET			English	Article							PRACTICE RESEARCH DATABASE; SUDDEN-DEATH; THROMBOSIS; CLOZAPINE	Background Antipsychotic drugs have been associated with an increased risk of adverse events such as venous thromboembolism. Our aim was to assess this risk in users of conventional antipsychotic drugs who had been diagnosed with first-time, idiopathic venous thromboembolism. Methods From a baseline population of 29 952 recipients of conventional and atypical antipsychotic drugs aged younger than 60 years, we identified 42 individuals with idiopathic venous thromboembolism and 172 matched controls. We compared risk of current and recent use of antipsychotic drugs with non-use before the index date in cases and controls. Findings Current exposure to conventional antipsychotic drugs was associated with a significantly increased risk of idiopathic venous thromboembolism compared with nonuse (adjusted odds ratio 7.1 [95% CI 2.3-21.97]). Although we found no difference between phenothiazines, thioxanthenes, or other conventional antipsychotic drugs, low potency antipsychotic drugs drugs such as chlorpromazine and thioridazine were more strongly associated with venous thromboembolism (odds ratio 24.1 [3.3-172.7]) than were high potency antipsychotic drugs such as haloperidol (3.3 [0.8-13.2]). The risk for Venous thrombosis was highest during the first few months of conventional antipsychotic drug use. Interpretation Current exposure to conventional antipsychotic drugs significantly increases the risk of idiopathic Venous thromboembolism in men and women younger than 60 years of age.	Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Zornberg, GL (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA.			Jick, Hershel/0000-0003-4270-5992				BOULLIN DJ, 1978, PLATELETS MULTODICIP, P389; CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408; HAFNER H, 1965, COMPR PSYCHIAT, V6, P25, DOI 10.1016/S0010-440X(65)80005-0; Hagg S, 2000, LANCET, V355, P1155, DOI 10.1016/S0140-6736(00)02066-3; HOLLISTER LE, 1965, JAMA-J AM MED ASSOC, V192, P93; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KETAI R, 1979, AM J PSYCHIAT, V136, P112; Lacika S, 1999, CAN J PSYCHIAT, V44, P396; Lilleng Peer, 1995, Tidsskrift for den Norske Laegeforening, V115, P3026; Marder SR, 1998, AM PSYCHIAT PRESS TX, P309; MEIEREWERT K, 1967, DEUT MED WOCHENSCHR, V92, P2174, DOI 10.1055/s-0028-1106111; ORR MW, 1976, BRIT J CLIN PHARMACO, V3, P925, DOI 10.1111/j.1365-2125.1976.tb00648.x; ROCHEBAYARD P, 1990, CHEST, V6, P1545; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; Suttmann I, 2000, LANCET, V355, P842, DOI 10.1016/S0140-6736(05)72453-3; TURBOTT J, 1984, AUST NZ J PSYCHIAT, V18, P91, DOI 10.3109/00048678409161042; UNGVARI G, 1980, PHARMACOPSYCHIATRY, V113, P29; Vandenbroucke JP, 1998, THROMB HAEMOSTASIS, V79, P511; VARIA I, 1983, PSYCHOSOMATICS, V24, P1097, DOI 10.1016/S0033-3182(83)73114-2; Walker AM, 1997, EPIDEMIOLOGY, V8, P671, DOI 10.1097/00001648-199710000-00010; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7	23	198	204	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 7	2000	356	9237					1219	1223		10.1016/S0140-6736(00)02784-7	http://dx.doi.org/10.1016/S0140-6736(00)02784-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	361LQ	11072939				2022-12-28	WOS:000089724900010
J	Nosten, F; van Vugt, M; Price, R; Luxemburger, C; Thway, KL; Brockman, A; McGready, R; ter Kuile, F; Looareesuwan, S; White, NJ				Nosten, F; van Vugt, M; Price, R; Luxemburger, C; Thway, KL; Brockman, A; McGready, R; ter Kuile, F; Looareesuwan, S; White, NJ			Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study	LANCET			English	Article							BURMESE BORDER; MONOCLONAL-ANTIBODIES; ELISA DEVELOPMENT; BED NETS; SPOROZOITES; EPIDEMIOLOGY; PREVENTION; PREGNANCY; AREA	Background Worsening drug resistance in Plasmodium falciparum malaria is a major threat to health in tropical countries. We did a prospective study of malaria incidence and treatment in an area of highly multidrug-resistant P falciparum malaria. Methods We assessed incidence of P falciparum malaria and the in-vivo responses to mefloquine treatment over 13 years in two large camps for displaced Karen people on the northwest border of Thailand. During this time, the standard mefloquine dose was first increased, and then combined artesunate and mefloquine was introduced as first-line treatment for uncomplicated P falciparum malaria. Findings Early detection and treatment controlled P falciparum malaria initially while mefloquine was effective (cure rate with mefloquine [15 mg/kg] and sulphadoxine-pyrimethamine in 1985, 98% [95% CI 97-100]), but as mefloquine resistance developed, the cure rate fell (71% [67-77] in 1990). A similar pattern was seen for high-dose (25 mg/kg) mefloquine monotherapy from 1990-94. Since the general deployment of the artesunate-mefloquine combination in 1994, the cure rate increased again to almost 100% from 1998 onwards, and there has been a sustained decline in the incidence of P falciparum malaria in the study area. In-vitro susceptibility of P falciparum to mefloquine has improved significantly (p=0.003). Interpretation In this area of low malaria transmission, early diagnosis and treatment with combined artesunate and mefloquine has reduced the incidence of P falciparum malaria and halted the progression of mefloquine resistance. We recommend that antimalarial drugs should be combined with artemisinin or a derivative to protect them against resistance.	Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; Shoklo Malaria Res Unit, Mae Sot, Thailand; Amsterdam Med Ctr, Dept Infect Dis Trop Med & AIDS, Amsterdam, Netherlands; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England; Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA	Mahidol University; Mahidol University; University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford; Centers for Disease Control & Prevention - USA	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		White, Nick/AAC-6527-2019; Nosten, Francois/AAC-5509-2019; McGready, Rose/A-3290-2014; Kuile, Feiko ter/ABD-6681-2020; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; McGready, Rose/0000-0003-1621-3257; Kuile, Feiko ter/0000-0003-3663-5617; Price, Richard/0000-0003-2000-2874	Wellcome Trust [091625] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brockman A, 1999, AM J TROP MED HYG, V60, P14, DOI 10.4269/ajtmh.1999.60.14; BROCKMAN A, 2000, IN PRESS T R SOC MED; CHILDS G E, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P438; DOLAN G, 1993, T ROY SOC TROP MED H, V87, P620, DOI 10.1016/0035-9203(93)90262-O; LUXEMBURGER C, 1994, T ROY SOC TROP MED H, V88, P155, DOI 10.1016/0035-9203(94)90273-9; Luxemburger C, 1997, T ROY SOC TROP MED H, V91, P256, DOI 10.1016/S0035-9203(97)90066-3; Luxemburger C, 1996, T ROY SOC TROP MED H, V90, P105, DOI 10.1016/S0035-9203(96)90102-9; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Nosten F, 1998, Med Trop (Mars), V58, P45; NOSTEN F, 1987, B WORLD HEALTH ORGAN, V65, P891; NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8; Sharma YD, 1996, ACTA TROP, V62, P135, DOI 10.1016/S0001-706X(96)00031-9; TERKUILE FO, 1992, J INFECT DIS, V166, P1393, DOI 10.1093/infdis/166.6.1393; TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; WEBSTER HK, 1985, AM J TROP MED HYG, V34, P228, DOI 10.4269/ajtmh.1985.34.228; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2; WIRTZ RA, 1987, B WORLD HEALTH ORGAN, V65, P39; WIRTZ RA, 1991, MED VET ENTOMOL, V5, P17, DOI 10.1111/j.1365-2915.1991.tb00515.x; WIRTZ RA, 1992, J MED ENTOMOL, V29, P854, DOI 10.1093/jmedent/29.5.854	24	382	397	0	38	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					297	302		10.1016/S0140-6736(00)02505-8	http://dx.doi.org/10.1016/S0140-6736(00)02505-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071185				2022-12-28	WOS:000088305900011
J	Relling, MV; Pui, CH; Sandlund, JT; Rivera, GK; Hancock, ML; Boyett, JM; Schuetz, EG; Evans, WE				Relling, MV; Pui, CH; Sandlund, JT; Rivera, GK; Hancock, ML; Boyett, JM; Schuetz, EG; Evans, WE			Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; DOSE METHOTREXATE; CHILDREN; THERAPY; PHARMACODYNAMICS; PHARMACOKINETICS; 6-MERCAPTOPURINE; TRANSPLANTATION; IDENTIFICATION; INHIBITION	Background Many antileukaemic agents or their metabolites are inactivated by liver enzymes. Most anticonvulsant drugs induce drug-metabolising enzymes and thereby increase the clearance of anticancer agents. We investigated whether anticonvulsants compromise the efficacy of cancer chemotherapy. Methods We identified whom of 716 children treated consecutively for acute lymphoblastic leukaemia at a single academic hospital in the USA between 1984 and 1994 received treatment for 30 days or longer with anticonvulsants (phenytoin, phenobarbital, carbamazepine, or a combination) at the same time as antileukaemic therapy. Cox's proportional-hazards models were used to assess the prognostic significance of anticonvulsants on event-free survival and risk of haematological and central-nervous-system (CNS) relapse, with stratification for treatment protocol. Findings 40 (5.6%) of 716 patients received anticonvulsants. Use of these drugs was associated with age over 10 years (p=0.003), non-hyperdiploid leukaemia (p=0.031), and T-cell immunophenotype (p=0.022), After adjustment for age and ploidy, anticonvulsant therapy was significantly related to worse event-free survival (hazard ratio 2.67 [95% CI 1.50-4.76]; p=0.0009), haematological relapse (3.40 [1.69-6.88]; p=0.0006), and CNS relapse (2.90 [1.01-8.28]; p=0.047) among the 566 patients with B-lineage leukaemia, No such associations were seen among the 114 patients with T-cell leukaemia (p=0.61, 0.35, and 0.53, respectively). Faster clearance of teniposide (p=0.0001) and methotrexate (p=0.051), but not cytarabine (p=0.26) was found among patients receiving anticonvulsants. Interpretation Long-term anticonvulsant therapy increases the systemic clearance of several antileukaemic agents and is associated with lower efficacy of chemotherapy. Alternatives to enzyme;inducing anticonvulsants should be prescribed for patients receiving chemotherapy for acute lymphoblastic leukaemia.	St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Pharm, Memphis, TN 38163 USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Relling, MV (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.		Schuetz, Erin/N-8087-2018; Pui, Ching-Hon/N-8076-2018; Relling, Mary/N-5032-2018; Evans, William E./C-2069-2012	Pui, Ching-Hon/0000-0003-0303-5658; Evans, William E./0000-0002-9333-5322	NCI NIH HHS [CA20180, CA36401, CA51001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036401, R01CA051001, P01CA020180, R37CA036401, R29CA051001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER DK, 1992, J CLIN ONCOL, V10, P311, DOI 10.1200/JCO.1992.10.2.311; CAMITTA B, 1994, J CLIN ONCOL, V12, P1383, DOI 10.1200/JCO.1994.12.7.1383; Chessells JM, 2000, BRIT J HAEMATOL, V108, P204; CONNEY AH, 1967, PHARMACOL REV, V19, P317; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; EVANS WE, 1983, CLIN PHARMACOL THER, V33, P301, DOI 10.1038/clpt.1983.37; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; EVANS WE, 1986, NEW ENGL J MED, V314, P471, DOI 10.1056/NEJM198602203140803; FREY BM, 1984, EUR J CLIN INVEST, V14, P1, DOI 10.1111/j.1365-2362.1984.tb00695.x; Gentile DM, 1996, J PHARMACOL EXP THER, V277, P105; KATKI AG, 1987, CHEM-BIOL INTERACT, V62, P237, DOI 10.1016/0009-2797(87)90025-1; Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; MURPHY JA, 1995, LANCET, V346, P443, DOI 10.1016/S0140-6736(95)92816-2; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; OCHS JJ, 1984, LANCET, V2, P1422; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; REICH SD, 1976, CANCER RES, V36, P3803; Relling MV, 1999, BLOOD, V93, P2817; RELLING MV, 1994, MOL PHARMACOL, V45, P352; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RODMAN JH, 1994, J CLIN ONCOL, V12, P2390, DOI 10.1200/JCO.1994.12.11.2390; SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; Steinherz PG, 1996, J CLIN ONCOL, V14, P389, DOI 10.1200/JCO.1996.14.2.389; Stram DO, 1996, BIOMETRICS, V52, P1079, DOI 10.2307/2533069; Veerman AJP, 1996, J CLIN ONCOL, V14, P911, DOI 10.1200/JCO.1996.14.3.911; Villikka K, 1999, CLIN PHARMACOL THER, V66, P589, DOI 10.1016/S0009-9236(99)90067-X; WASSNER SJ, 1976, J PEDIATR-US, V88, P134, DOI 10.1016/S0022-3476(76)80745-7; WINICK NJ, 1992, J NATL CANCER I, V84, P252, DOI 10.1093/jnci/84.4.252	31	130	134	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 22	2000	356	9226					285	290		10.1016/S0140-6736(00)02503-4	http://dx.doi.org/10.1016/S0140-6736(00)02503-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336MJ	11071183				2022-12-28	WOS:000088305900009
J	Terskikh, A; Fradkov, A; Ermakova, G; Zaraisky, A; Tan, P; Kajava, AV; Zhao, XN; Lukyanov, S; Matz, M; Kim, S; Weissman, I; Siebert, P				Terskikh, A; Fradkov, A; Ermakova, G; Zaraisky, A; Tan, P; Kajava, AV; Zhao, XN; Lukyanov, S; Matz, M; Kim, S; Weissman, I; Siebert, P			"Fluorescent timer": Protein that changes color with time	SCIENCE			English	Article							GENE; MUTANTS; XANF-1	We generated a mutant of the red fluorescent protein drFP583. The mutant (E5) changes its fluorescence from green to red over time. The rate of color conversion is independent of protein concentration and therefore can be used to trace time-dependent expression. We used in vivo labeling with E5 to measure expression from the heat shock-dependent promoter in Caenorhabditis elegans and from the Otx-2 promoter in developing Xenopus embryos. Thus, E5 is a "fluorescent timer" that can be used to monitor both activation and downregulation of target promoters on the whole-organism scale.	Stanford Univ, Sch Med, Stanford, CA 94305 USA; Russian Acad Sci, Inst Bioorgan Chem, Moscow 117871, Russia; NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA; Clontech Labs, Palo Alto, CA 94303 USA	Stanford University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Terskikh, A (corresponding author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.	Alexey.Terskikh@Stanford.edu	Terskikh, Alexey/U-8407-2019; Zaraisky, Andrey G/Q-2323-2016; Matz, Mikhail V/K-4392-2017; Kajava, Andrey V/E-1107-2014; Lukyanov, Sergey/F-9140-2014; Lukyanov, Sergey/HIU-0305-2022	Zaraisky, Andrey G/0000-0003-4681-8169; Matz, Mikhail V/0000-0001-5453-9819; Kajava, Andrey V/0000-0002-2342-6886; 	FIC NIH HHS [1 RO3 TW01362-01] Funding Source: Medline; CENTER FOR INFORMATION TECHNOLOGY [Z01CT000259] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW001362] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; EHRIG T, 1995, FEBS LETT, V367, P163, DOI 10.1016/0014-5793(95)00557-P; Ermakova GV, 1999, DEVELOPMENT, V126, P4513; ETKIN LD, 1987, DEVELOPMENT, V99, P15; Galliot B, 2000, TRENDS GENET, V16, P1, DOI 10.1016/S0168-9525(99)01888-0; HELM R, 1994, P NATL ACAD SCI USA, V91, P12501; HELM R, 1995, NATURE, V373, P663; JONES D, 1989, DNA-J MOLEC CELL BIO, V8, P481, DOI 10.1089/dna.1.1989.8.481; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; OKKEMA PG, 1993, GENETICS, V135, P385; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZARAISKY AG, 1995, DEVELOPMENT, V121, P3839	16	306	342	4	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 24	2000	290	5496					1585	1588		10.1126/science.290.5496.1585	http://dx.doi.org/10.1126/science.290.5496.1585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	376EX	11090358				2022-12-28	WOS:000165446200053
J	Bernstein, CN; Blanchard, JF; Leslie, W; Wajda, A; Yu, BN				Bernstein, CN; Blanchard, JF; Leslie, W; Wajda, A; Yu, BN			The incidence of fracture among patients with inflammatory dowel disease - A population-based cohort study	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; BOWEL-DISEASE; CROHNS-DISEASE; ULCERATIVE-COLITIS; OSTEOPOROSIS; SUPPLEMENTATION; PREVENTION; DIAGNOSIS; ACCURACY	Background: The clinical significance of the high prevalence of osteopenia in inflammatory bowel disease is unclear. Objective: To determine whether persons with inflammatory bowel disease have increased incidence of fracture. Design: Population-based matched cohort study. Setting: Manitoba, Canada. Patients: Patients with inflammatory bower disease in the University of Manitoba IBD Database (n = 6027) were matched to 10 randomly selected persons in the general population without inflammatory bowel disease (n = 60 270) by year, age, sex, and postal area of residence. Measurements: The incidence of hospitalization for hip fracture was determined on the basis of hospital discharge abstracts. Outpatient medical billing records and hospital discharge abstracts were used to calculate the incidence of spine, rib, and forearm fractures. Rates were calculated on the basis of person-years of follow-up for 1984 to 1997. Results: Persons with inflammatory bower disease had significantly increased incidence of fractures at the spine (incidence rate ratio [IRR], 1.74 [95% Cl, 1.34 to 2.24]; P < 0.001), hip (IRR, 1.59 [Cl, 1.27 to 2.00]; P < 0.001), wrist/forearm (IRR, 1.33 [Cl, 1.11 to 1.58]; P = 0.001), and rib (IRR, 1.25 [Cl, 1.02 to 1.52]; P = 0.03) and of any of these fractures (IRR, 1.41 [Cl, 1.27 to 1.56]; P < 0.001). Conclusion: The incidence of fracture among persons with inflammatory bowel disease is 40% greater than that in the general population.	Univ Manitoba, Gastroenterol Sect, John Buhler Res Ctr, Winnipeg, MB R3E 3P4, Canada; Manitoba Hlth, Winnipeg, MB, Canada	University of Manitoba	Bernstein, CN (corresponding author), Univ Manitoba, Gastroenterol Sect, John Buhler Res Ctr, 804F-715 McDermot Ave, Winnipeg, MB R3E 3P4, Canada.	cbernst@cc.umanitoba.ca						Bernstein CN, 1999, AM J EPIDEMIOL, V149, P916, DOI 10.1093/oxfordjournals.aje.a009735; Bernstein CN, 1996, ALIMENT PHARM THERAP, V10, P777, DOI 10.1046/j.1365-2036.1996.63205000.x; BERNSTEIN CN, 1999, TRENDS INFLAMMATORY, P147; BERNSTEIN CN, 1997, GASTROENTEROL INT, V10, P71; CLEMENTS D, 1993, GUT, V34, P1543, DOI 10.1136/gut.34.11.1543; COMPSTON JE, 1995, ALIMENT PHARM THER, V9, P237; Fox KM, 1998, J AM GERIATR SOC, V46, P745, DOI 10.1111/j.1532-5415.1998.tb03810.x; Fries W, 1998, AM J GASTROENTEROL, V93, P2339, DOI 10.1016/S0002-9270(98)00566-8; Gennari C, 1986, Clin Rheum Dis, V12, P637; GHOSH S, 1994, GASTROENTEROLOGY, V107, P1031, DOI 10.1016/0016-5085(94)90227-5; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V267, P2238; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; Robinson RJ, 1998, ALIMENT PHARM THERAP, V12, P699; ROOS LL, 1989, SOC SCI MED, V28, P175, DOI 10.1016/0277-9536(89)90145-7; Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502; SEELEY DG, 1991, ANN INTERN MED, V115, P837, DOI 10.7326/0003-4819-115-11-837; SILVENNOINEN JA, 1995, GUT, V37, P71, DOI 10.1136/gut.37.1.71; VOGELSANG H, 1995, EUR J GASTROEN HEPAT, V7, P609	20	342	354	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					795	799		10.7326/0003-4819-133-10-200011210-00012	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085842				2022-12-28	WOS:000165321200005
J	Macdonald, CE; Wicks, AC; Playford, RJ				Macdonald, CE; Wicks, AC; Playford, RJ			Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GASTROESOPHAGEAL REFLUX DISEASE; ESOPHAGUS; ADENOCARCINOMA; METAPLASIA	Objectives To review the benefit of an endoscopic surveillance programme for patients with Barrett's oesophagus. Design Observational study. Setting University teaching hospital. Participants 409 patients in whom Barrett's oesophagus was identified during 1984-94; 143 were entered into the annual surveillance programme. Main outcome measures Development of dysplasia and cancer and mortality. Results The average period of surveillance was 4.4 years; 55 patients were reassessed in 1994 but only eight remained in the programme in 1999, withdrawal being due to death (not from carcinoma of the oesophagus), illness, or frailty. Five of the patients who entered surveillance developed carcinoma of the oesophagus. Only one cancer was identified as a result of a surveillance endoscopy, the others being detected during endoscopy to investigate altered symptoms. Of the 266 patients who were not suitable for surveillance, one died from oesophageal cancer and 103 from other causes. Surveillance has resulted in 745 endoscopies and about 3000 biopsy specimens. Conclusion The current surveillance strategy has limited value, and it may be appropriate to restrict surveillance to patients with additional risk factors such as stricture, ulcer, or long segment (> 80 mm) Barrett's oesophagus.	Hammersmith Hosp, Dept Gastroenterol, London W12 0NN, England; Leicester Gen Hosp NHS Trust, Leicester LE5 4PW, Leics, England	Imperial College London; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Playford, RJ (corresponding author), Hammersmith Hosp, Dept Gastroenterol, London W12 0NN, England.	r.playford@ic.ac.uk		Playford, Raymond/0000-0003-1235-8504				CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; Caygill CPJ, 1999, EUR J CANCER PREV, V8, P539, DOI 10.1097/00008469-199912000-00010; DENT J, 1991, J GASTROEN HEPATOL, V6, P1, DOI 10.1111/j.1440-1746.1991.tb01137.x; Jankowski JA, 1999, AM J PATHOL, V154, P965, DOI 10.1016/S0002-9440(10)65346-1; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; Macdonald CE, 1997, GUT, V41, P303, DOI 10.1136/gut.41.3.303; Smith AM, 1999, BRIT J SURG, V86, P276, DOI 10.1046/j.1365-2168.1999.01015.x; Spechler SJ, 1996, GASTROENTEROLOGY, V110, P614, DOI 10.1053/gast.1996.v110.agast960614; SPECHLER SJ, 1984, GASTROENTEROLOGY, V87, P927; Wilson JMG, 1968, PRINCIPLES PRACTICE; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X; Wright TA, 1996, GUT, V39, P574, DOI 10.1136/gut.39.4.574	13	166	168	2	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	2000	321	7271					1252	1255		10.1136/bmj.321.7271.1252	http://dx.doi.org/10.1136/bmj.321.7271.1252			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	376ET	11082084	Green Published, Bronze			2022-12-28	WOS:000165445800023
J	Buffett, BA; Garnero, EJ; Jeanloz, R				Buffett, BA; Garnero, EJ; Jeanloz, R			Sediments at the top of Earth's core	SCIENCE			English	Article							SHEAR-VELOCITY MODEL; MANTLE BOUNDARY; HIGH-PRESSURE; LIQUID-IRON; SEISMIC EVIDENCE; PARTIAL MELT; LAYER; BASE; COMPACTION; CONDUCTIVITY	Unusual physical properties at the core-mantle boundary have been inferred from seismic and geodetic observations in recent years. We show how both types of observations can be explained by a Layer of silicate sediments, which accumulate at the top of the core as Earth cools. Compaction of the sediments expels most of the Liquid iron but Leaves behind a small amount of core material, which is entrained in mantle convection and may account for the isotopic signatures of core material in some hot spot plumes. Extraction of Light elements from the Liquid core also enhances the vigor of convection in the core and may increase the power available to the geodynamo.	Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of British Columbia; Arizona State University; Arizona State University-Tempe; University of California System; University of California Berkeley	Buffett, BA (corresponding author), Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada.	buffet@eos.ubc.ca						ALLEGRE CJ, 1995, EARTH PLANET SC LETT, V134, P515, DOI 10.1016/0012-821X(95)00123-T; BIRCH F, 1964, J GEOPHYS RES, V69, P4377, DOI 10.1029/JZ069i020p04377; BLOXHAM J, 1991, REV GEOPHYS, V29, P97, DOI 10.1029/90RG02470; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; BUFFETT BA, 1992, J GEOPHYS RES-SOL EA, V97, P19581, DOI 10.1029/92JB00977; Castle JC, 2000, EARTH PLANET SC LETT, V176, P311, DOI 10.1016/S0012-821X(00)00027-3; COURTILLOT V, 1984, GEOPHYS J ROY ASTR S, V78, P619, DOI 10.1111/j.1365-246X.1984.tb01965.x; de Wijs GA, 1998, NATURE, V392, P805, DOI 10.1038/33905; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Garnero EJ, 1998, GEODYNAMICS-US, V28, P319; Garnero EJ, 1996, GEOPHYS RES LETT, V23, P977, DOI 10.1029/95GL03603; Garnero EJ, 1999, GEOPHYS RES LETT, V26, P377, DOI 10.1029/1998GL900319; Garnero EJ, 2000, GEOPHYS RES LETT, V27, P2777, DOI 10.1029/2000GL008498; GOARANT F, 1992, J GEOPHYS RES-SOL EA, V97, P4477, DOI 10.1029/92JB00018; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; ITO E, 1995, J GEOPHYS RES-SOL EA, V100, P5901, DOI 10.1029/94JB02645; JEANLOZ R, 1980, GEOPHYS J ROY ASTR S, V62, P505, DOI 10.1111/j.1365-246X.1980.tb02588.x; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; KNITTLE E, 1989, GEOPHYS RES LETT, V16, P609, DOI 10.1029/GL016i007p00609; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; MATHEWS P, UNPUB; MATHEWS PM, 1992, ANNU REV EARTH PL SC, V20, P469; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; Mitrovica JX, 1997, J GEOPHYS RES-SOL EA, V102, P2751, DOI 10.1029/96JB03175; MORI J, 1995, J GEOPHYS RES-SOL EA, V100, P20359, DOI 10.1029/95JB02243; POIRIER JP, 1992, PHYS EARTH PLANET IN, V73, P29, DOI 10.1016/0031-9201(92)90105-5; Revenaugh J, 1997, SCIENCE, V277, P670, DOI 10.1126/science.277.5326.670; SCOTT DR, 1984, GEOPHYS RES LETT, V11, P1161, DOI 10.1029/GL011i011p01161; SHANKLAND TJ, 1993, NATURE, V366, P453, DOI 10.1038/366453a0; SHIRLEY DN, 1986, J GEOL, V94, P795, DOI 10.1086/629088; SOLOMATOV VS, 1993, EARTH PLANET SC LETT, V120, P387, DOI 10.1016/0012-821X(93)90252-5; STEVENSON DJ, 1981, SCIENCE, V214, P611, DOI 10.1126/science.214.4521.611; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Sumita I, 1996, GEOPHYS J INT, V124, P502, DOI 10.1111/j.1365-246X.1996.tb07034.x; WATT JP, 1976, REV GEOPHYS, V14, P541, DOI 10.1029/RG014i004p00541; Williams Q, 1996, SCIENCE, V273, P1528, DOI 10.1126/science.273.5281.1528; WILLIAMS Q, 1987, SCIENCE, V236, P181, DOI 10.1126/science.236.4798.181	40	205	211	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 17	2000	290	5495					1338	1342		10.1126/science.290.5495.1338	http://dx.doi.org/10.1126/science.290.5495.1338			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	375BN	11082058				2022-12-28	WOS:000165379800044
J	McMahon, AJ; Fischbacher, CM; Frame, SH; MacLeod, MCM				McMahon, AJ; Fischbacher, CM; Frame, SH; MacLeod, MCM			Impact of laparoscopic cholecystectomy: a population-based study	LANCET			English	Article							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; BILIARY-TRACT DISEASE; MINILAPAROTOMY CHOLECYSTECTOMY; RANDOMIZED TRIAL; COMPLICATIONS; VOLUME; EXPERIENCE; HOSPITALS; STATEWIDE; OUTCOMES	Background We assessed the effect of the introduction of laparoscopic cholecystectomy on surgical outcomes in routine practice. Methods Hospital discharge and death-certificate data were linked for all patients undergoing cholecystectomy (n=85 120) in Scottish public-sector hospitals (n=51) between January, 1981, and June, 1999. The primary endpoints were cholecystectomy rate, hospital stay, and postoperative mortality. Regression methods were used to examine the effect of laparoscopic experience and surgeon caseload on postoperative mortality and hospital stay. Findings From 1989 to 1999, the proportion of cholecystectomies done laparoscopically rose from none to 80%, and the age-standardised cholecystectomy rate increased by 20% (95% CI 15-26). Postoperative mortality did not change in the 1990s (odds ratio 0.99 [0.7-1.4], p=0.99). The mean postoperative hospital stay fell from 8.0 (SD 3.7) to 2.9 (3.2) days. There was wide variation between hospitals in the proportion of cholecystectomies done laparoscopically and in average hospital stay. For individual surgeons, increasing laparoscopic experience and annual caseload were associated with higher proportions of laparoscopic procedures and shorter hospital stays. Postoperative mortality was higher during the first ten laparoscopic cholecystectomies done by a surgeon (compared with >200 procedures, odds ratio 2.3 [1.2-4.6], p=0.015). Interpretation The laparoscopic method reduced hospital stay but had no overall effect on postoperative mortality. Studies to assess the appropriateness of the increased cholecystectomy rate are merited. The wide variation in the proportion done laparoscopically, together with evidence of better results for surgeons doing more procedures, suggests scope for further reductions in hospital stay and morbidity.	N Glasgow Univ Hosp NHS Trust, Stobhill Hosp, Dept Surg, Glasgow G21 3UW, Lanark, Scotland; Univ Newcastle, Dept Epidemiol & Publ Hlth, Newcastle, NSW 2308, Australia; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Newcastle; NHS National Services Scotland	McMahon, AJ (corresponding author), N Glasgow Univ Hosp NHS Trust, Stobhill Hosp, Dept Surg, Glasgow G21 3UW, Lanark, Scotland.	andrew@mcmahon.com		Fischbacher, Colin/0000-0003-3090-1857				BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; Chen AY, 1998, ANN SURG, V227, P12, DOI 10.1097/00000658-199801000-00003; CLAVIEN PA, 1992, ANN SURG, V216, P618, DOI 10.1097/00000658-199212000-00002; Cohen MM, 1996, CAN MED ASSOC J, V154, P491; DEZIEL DJ, 1993, AM J SURG, V165, P9, DOI 10.1016/S0002-9610(05)80397-6; ERICKSON RA, 1995, GASTROENTEROLOGY, V109, P252, DOI 10.1016/0016-5085(95)90292-9; ESCARCE JJ, 1995, JAMA-J AM MED ASSOC, V273, P1581, DOI 10.1001/jama.273.20.1581; Ferreira M R, 1999, Eff Clin Pract, V2, P49; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; GO PMNYH, 1993, BRIT J SURG, V80, P1180, DOI 10.1002/bjs.1800800938; Hanan EL, 1999, SURGERY, V125, P223; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Harley K, 1996, Health Bull (Edinb), V54, P410; KANE RL, 1995, J AM COLL SURGEONS, V180, P136; Khuri SF, 1999, ANN SURG, V230, P414, DOI 10.1097/00000658-199909000-00014; MCMAHON AJ, 1993, BRIT J SURG, V80, P1593, DOI 10.1002/bjs.1800801233; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MCMAHON AJ, 1995, BRIT J SURG, V82, P1378, DOI 10.1002/bjs.1800821028; MCMAHON AJ, 1995, BRIT J SURG, V82, P307, DOI 10.1002/bjs.1800820308; NEWMAN CL, 1995, AM SURGEON, V61, P226; ORLANDO R, 1993, ARCH SURG-CHICAGO, V128, P494; PHILLIPS EH, 1994, AM SURGEON, V60, P316; *REG GEN SCOTL, 1998, ANN REP; Rutledge R, 1996, J AM COLL SURGEONS, V183, P31; SPIRO HM, 1992, LANCET, V339, P167, DOI 10.1016/0140-6736(92)90221-N; STEINER CA, 1996, NEW ENGL J MED, V330, P403; SUC B, 1992, ANN CHIR, V46, P219; Varghese JC, 1999, CLIN RADIOL, V54, P513, DOI 10.1016/S0009-9260(99)90848-6; Wallace DH, 1997, BRIT J SURG, V84, P1680	29	101	104	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1632	1637		10.1016/S0140-6736(00)03156-1	http://dx.doi.org/10.1016/S0140-6736(00)03156-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089821				2022-12-28	WOS:000165249200010
J	Wilmshurst, PT; Nightingale, S; Walsh, KP; Morrison, WL				Wilmshurst, PT; Nightingale, S; Walsh, KP; Morrison, WL			Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons	LANCET			English	Article							PATENT FORAMEN OVALE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSCRANIAL DOPPLER; CRYPTOGENIC STROKE; DIVERS; SICKNESS; EMBOLISM; AUTOPSY; AURA	Background A relation between migraine with aura and cardiac right-to-left shunts has been reported. Right-to-left shunts are also associated with stroke and certain forms of decompression illness. We investigated the effect of closure of right-to-left shunts on migraine symptoms. Methods A consultant neurologist, who was unaware of information about residual shunt, undertook a structured interview with individuals who had had transcatheter closure of an atrial septal defect or patent foramen ovale to assess how the procedure affected migraine symptoms. Findings 37 of 40 consecutive patients who had had a closure procedure (to permit resumption of diving after decompression illness in 29, after stroke when paradoxical thromboembolism was suspected in four, or to close a large atrial septal defect in lour) could be contacted. 21 (57%) had a history of migraine before the procedure (with aura in 16, without aura in five). 11 individuals had fortification spectra in the period immediately after closure. During long-term follow-up, no migraine symptoms were reported by seven individuals who had previously had migraine with aura and three who had previously had migraine without aura. Eight others who had had migraine with aura before closure reported improvement in frequency and severity of migraines. Three tone migraine with aura, two migraine without aura) reported no alteration in migraine episodes. Interpretation These observations suggest a causal association between right-to-left shunts and migraine with aura. There may be a subgroup of patients who have severe migraine associated with a large right-to-left shunt in whom closure of the atrial defect may improve or abolish migraine.	Royal Shrewsbury Hosp, Dept Cardiol, Shrewsbury SY3 8XQ, Salop, England; Royal Shrewsbury Hosp, Dept Neurol, Shrewsbury SY3 8XQ, Salop, England; Our Ladys Hosp Sick Children, Dept Cardiol, Dublin 12, Ireland; Ctr Cardiothorac, Dept Cardiol, Liverpool, Merseyside, England	Our Ladys Children Hospital Crumlin	Wilmshurst, PT (corresponding author), Royal Shrewsbury Hosp, Dept Cardiol, Shrewsbury SY3 8XQ, Salop, England.							Anzola GP, 1999, NEUROLOGY, V52, P1622, DOI 10.1212/WNL.52.8.1622; CABANES L, 1993, STROKE, V24, P1865, DOI 10.1161/01.STR.24.12.1865; Del Sette M, 1998, CEREBROVASC DIS, V8, P327, DOI 10.1159/000015875; Engel GL, 1944, WAR MED, V5, P304; FERRARI MD, 1997, BLUE BOOKS PRACTICAL, P120; Germonpre P, 1998, J APPL PHYSIOL, V84, P1622, DOI 10.1152/jappl.1998.84.5.1622; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HAUSMANN D, 1995, J AM COLL CARDIOL, V26, P1030, DOI 10.1016/0735-1097(95)00288-9; HOMMA S, 1994, STROKE, V25, P582, DOI 10.1161/01.STR.25.3.582; LANCE JW, 1993, WOLFFS HEADACHE OTHE, P59; MOON RE, 1989, LANCET, V1, P513; SANDLER M, 1972, LANCET, V1, P618; Schneider B, 1996, AM J CARDIOL, V77, P1202, DOI 10.1016/S0002-9149(96)00163-4; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; VANCAMP G, 1993, AM J CARDIOL, V71, P596, DOI 10.1016/0002-9149(93)90518-H; VIK A, 1993, UNDERSEA HYPERBAR M, V20, P121; Walsh KP, 1999, HEART, V81, P257, DOI 10.1136/hrt.81.3.257; WEBSTER MWI, 1988, LANCET, V2, P11; Wilmshurst, 1996, LANCET, V348, P1392; WILMSHURST P, 1994, CLIN SCI, V86, P297; Wilmshurst P, 2000, CLIN SCI, V99, P65, DOI 10.1042/CS19990338; Wilmshurst P, 1996, LANCET, V348, P752, DOI 10.1016/S0140-6736(05)65638-3; WILMSHURST P, IN PRESS CLIN SCI; WILMSHURST PT, 1989, LANCET, V2, P1302	24	299	321	2	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1648	1651		10.1016/S0140-6736(00)03160-3	http://dx.doi.org/10.1016/S0140-6736(00)03160-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089825				2022-12-28	WOS:000165249200014
J	Black, CT; Murray, CB; Sandstrom, RL; Sun, SH				Black, CT; Murray, CB; Sandstrom, RL; Sun, SH			Spin-dependent tunneling in self-assembled cobalt-nanocrystal superlattices	SCIENCE			English	Article							INSULATING GRANULAR SYSTEMS; 2-DIMENSIONAL ARRAYS; MAGNETORESISTANCE; JUNCTIONS; CONDUCTIVITY; TEMPERATURE; BARRIER; FILMS	Self-assembled devices composed of periodic arrays of 10-nanometer-diameter cobalt nanocrystals display spin-dependent electron transport. Current-voltage characteristics are well described by single-electron tunneling in a uniform array. At temperatures below 20 kelvin, device magnetoresistance ratios are on the order of 10%, approaching the maximum predicted for ensembles of cobalt islands with randomly oriented preferred magnetic axes. Low-energy spin-flip scattering suppresses magnetoresistance with increasing temperature and bias-voltage.	IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Black, CT (corresponding author), IBM Corp, Div Res, TJ Watson Res Ctr, Yorktown Hts, NY 10598 USA.	ctblack@us.ibm.com						Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; Bezryadin A, 1999, APPL PHYS LETT, V74, P2699, DOI 10.1063/1.123941; Bruckl H, 1998, PHYS REV B, V58, pR8893, DOI 10.1103/PhysRevB.58.R8893; Coey JMD, 1998, PHYS REV LETT, V80, P3815, DOI 10.1103/PhysRevLett.80.3815; Inoue J, 1996, PHYS REV B, V53, P11927, DOI 10.1103/PhysRevB.53.R11927; Jansen R, 1998, J APPL PHYS, V83, P6682, DOI 10.1063/1.367545; LAIKHTMAN B, 1989, PHYS LETT A, V139, P257, DOI 10.1016/0375-9601(89)90151-5; Lebreton C, 1998, MICROELECTRON ENG, V42, P507, DOI 10.1016/S0167-9317(98)00118-X; MALLINSON JC, 1996, MAGNETO RESISTIVE HE, P103; MIDDLETON AA, 1993, PHYS REV LETT, V71, P3198, DOI 10.1103/PhysRevLett.71.3198; Mitani S, 1998, J MAGN MAGN MATER, V177, P919, DOI 10.1016/S0304-8853(97)00498-8; Mitani S, 1998, PHYS REV LETT, V81, P2799, DOI 10.1103/PhysRevLett.81.2799; Moodera JS, 1997, APPL PHYS LETT, V70, P3050, DOI 10.1063/1.118168; NEUGEBAUER CA, 1962, J APPL PHYS, V33, P74, DOI 10.1063/1.1728531; Parkin SSP, 1999, J APPL PHYS, V85, P5828, DOI 10.1063/1.369932; Peng DL, 1999, APPL PHYS LETT, V74, P76, DOI 10.1063/1.122956; Petit C, 1999, ADV MATER, V11, P1198, DOI 10.1002/(SICI)1521-4095(199910)11:14<1198::AID-ADMA1198>3.0.CO;2-6; RIMBERG AJ, 1995, PHYS REV LETT, V74, P4714, DOI 10.1103/PhysRevLett.74.4714; ROBERTSON J, 1990, MATER SCI FORUM, V52, P125; SHENG P, 1973, PHYS REV LETT, V31, P44, DOI 10.1103/PhysRevLett.31.44; Sun S, 1999, MATER RES SOC SYMP P, V577, P385, DOI 10.1557/PROC-577-385; Sun SH, 2000, SCIENCE, V287, P1989, DOI 10.1126/science.287.5460.1989; Takahashi S, 1999, J MAGN MAGN MATER, V198-99, P143, DOI 10.1016/S0304-8853(98)01006-3; TEDROW PM, 1973, PHYS REV B, V7, P318, DOI 10.1103/PhysRevB.7.318; Tezuka N, 1998, JPN J APPL PHYS 2, V37, pL218, DOI 10.1143/JJAP.37.L218; TIGHE TS, 1993, PHYS REV B, V47, P1145, DOI 10.1103/PhysRevB.47.1145; Zhu T, 1999, PHYS REV B, V60, P11918, DOI 10.1103/PhysRevB.60.11918	27	624	642	0	174	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 10	2000	290	5494					1131	1134		10.1126/science.290.5494.1131	http://dx.doi.org/10.1126/science.290.5494.1131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073445				2022-12-28	WOS:000165228200038
J	Holmberg, J; Clarke, DL; Frisen, J				Holmberg, J; Clarke, DL; Frisen, J			Regulation of repulsion versus adhesion by different splice forms of an Eph receptor	NATURE			English	Article							NEURAL-TUBE DEFECTS; RETINAL AXON GUIDANCE; TYROSINE KINASE; IN-VITRO; EPHRINS; IDENTIFICATION; MORPHOGENESIS; EXPRESSION; LIGANDS; GROWTH	Eph tyrosine kinase receptors and their membrane-bound ephrin ligands mediate cell interactions and participate in several developmental processes(1-4). Ligand binding to an Eph receptor results in tyrosine phosphorylation of the kinase domain, and repulsion of axonal growth cones and migrating cells. Here we report that a subpopulation of ephrin-A5 null mice display neural tube defects resembling anencephaly in man. This is caused by the failure of the neural folds to fuse in the dorsal midline, suggesting that ephrin-A5, in addition to its involvement in cell repulsion(5,6), can participate in cell adhesion. During neurulation, ephrin-A5 is coexpressed with its cognate receptor EphA7 in cells at the edges of the dorsal neural folds. Three different EphA7 splice variants(7,8), a full-length form and two truncated versions lacking kinase domains, are expressed in the neural folds. Co-expression of an endogenously expressed truncated form of EphA7 suppresses tyrosine phosphorylation of the full-length EphA7 receptor and shifts the cellular response from repulsion to adhesion in vitro. We conclude that alternative usage of different splice forms of a tyrosine kinase receptor can mediate cellular adhesion or repulsion during embryonic development.	Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Frisen, J (corresponding author), Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.	jonas.frisen@cmb.ki.se						Botto LD, 1999, NEW ENGL J MED, V341, P1509, DOI 10.1056/NEJM199911113412006; Castellani V, 1998, J NEUROSCI, V18, P4663; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CIOSSEK T, 1995, ONCOGENE, V10, P97; Ciossek T, 1999, MOL BRAIN RES, V74, P231, DOI 10.1016/S0169-328X(99)00285-5; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Fleming A, 1998, SCIENCE, V280, P2107, DOI 10.1126/science.280.5372.2107; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; Gao PP, 2000, J NEUROSCI RES, V60, P427, DOI 10.1002/(SICI)1097-4547(20000515)60:4<427::AID-JNR1>3.3.CO;2-4; George SE, 1998, CELL, V92, P633, DOI 10.1016/S0092-8674(00)81131-9; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Holder N, 1999, DEVELOPMENT, V126, P2033; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KALLEN B, 1994, TERATOLOGY, V50, P322, DOI 10.1002/tera.1420500503; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wikstrom K, 1996, EXP CELL RES, V227, P360, DOI 10.1006/excr.1996.0285; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	30	279	290	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 9	2000	408	6809					203	206		10.1038/35041577	http://dx.doi.org/10.1038/35041577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371LL	11089974				2022-12-28	WOS:000165180400046
J	Crowther, MA; Julian, J; McCarty, D; Douketis, J; Kovacs, M; Biagoni, L; Schnurr, T; McGinnis, J; Gent, M; Hirsh, J; Ginsberg, J				Crowther, MA; Julian, J; McCarty, D; Douketis, J; Kovacs, M; Biagoni, L; Schnurr, T; McGinnis, J; Gent, M; Hirsh, J; Ginsberg, J			Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial	LANCET			English	Article							ANTICOAGULATION; THERAPY	Background Warfarin-associated coagulopathy is a frequent clinical complication. We aimed to assess whether treatment with vitamin K is safe and more effective than placebo in rapidly lowering the international normalised ratio (INR) into the therapeutic range in over anticoagulated patients receiving warfarin. Methods We did a multicentre, double-blind, placebo-controlled, randomised trial in five tertiary care hospitals. In this study, patients receiving warfarin who had an INR value between 4.5 and 10.0, and who did not have an indication for the immediate normalisation of their INR, had their warfarin withheld, and were randomly allocated to receive either 1 mg of vitamin K or placebo orally. The primary outcome measure was the INR value on the day after treatment. Secondary outcome measures included INR values on subsequent days, and the risk of haemorrhage and recurrent thrombosis over a 3 month follow-up period. Findings Patients given vitamin K had a more rapid decrease in the INR than those given placebo (25 of 45 [56%] vs nine of 44 [20%] patients with INR valves of 1.8-3.2 on the day after treatment, respectively, p=0.001; odds ratio [OR] 0.21, 95% CI 0.07-0.57). Fewer patients given Vitamin K had bleeding episodes during the follow-up period than those given placebo (two [4%] vs eight [17%] patients, respectively, p=0.050; OR 0.87, 95% CI 0.019-0.999). Interpretation Low dose oral vitamin K is more effective than placebo for the rapid lowering of raised INR values in patients taking warfarin.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Hamilton Civ Hosp, Res Ctr, Hamilton, ON, Canada; Univ Western Ontario, Dept Med, London, ON, Canada	McMaster University; McMaster University; McMaster University; Western University (University of Western Ontario)	Crowther, MA (corresponding author), St Josephs Hosp, Room L208, Hamilton, ON L8N 4A6, Canada.	crowthrm@fhs.csu.mcmaster.ca	ginsberg, jeffrey s/ABC-1065-2020; Douketis, James/AAO-5659-2021					Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; Crowther MA, 1998, THROMB HAEMOSTASIS, V79, P1116; GLOVER JJ, 1995, CHEST, V108, P987, DOI 10.1378/chest.108.4.987; Gullov AL, 1999, ARCH INTERN MED, V159, P1322, DOI 10.1001/archinte.159.12.1322; Hylck EM, 2000, ARCH INTERN MED, V160, P1612, DOI 10.1001/archinte.160.11.1612; LANDEFELD CS, 1989, AM J MED, V87, P153; PENGO V, 1993, BLOOD COAGUL FIBRIN, V4, P739, DOI 10.1097/00001721-199304050-00010; Weibert RT, 1997, ANN INTERN MED, V126, P959, DOI 10.7326/0003-4819-126-12-199706150-00005	8	125	132	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	2000	356	9241					1551	1553		10.1016/S0140-6736(00)03125-1	http://dx.doi.org/10.1016/S0140-6736(00)03125-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075768				2022-12-28	WOS:000165134500010
J	Horton, R				Horton, R			African AIDS beyond Mbeki: tripping into anarchy	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							BERESFORD D, 2000, GUARDIAN        1025, P16; Nyazema N. Z., 2000, Central African Journal of Medicine, V46, P89; THOMAS A, 2000, DRUG DEALS MED DEV H; *UNDP, 2000, HUM DEV REP 2000, P83	4	16	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 4	2000	356	9241					1541	1542		10.1016/S0140-6736(00)03122-6	http://dx.doi.org/10.1016/S0140-6736(00)03122-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370QV	11075765				2022-12-28	WOS:000165134500007
J	Zhang, DH; Collins, MA; Lee, SY				Zhang, DH; Collins, MA; Lee, SY			First-principles theory for the H+H2O, D2O reactions	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACES; VIBRATIONAL-STATE CONTROL; REACTION DYNAMICS; OH+H-2->H2O+H REACTION; BIMOLECULAR REACTIONS; SCATTERING-THEORY; CROSS-SECTIONS; OH PRODUCT; QUANTUM; CHEMISTRY	A full quantum dynamical study of the reactions of a hydrogen atom with water, on an accurate ab initio potential energy surface, is reported. The theoretical results are compared with available experimental data for the exchange and abstraction reactions in H + D2O and H + H2O. Clear agreement between theory and experiment is revealed for available thermal rate coefficients and the effects of vibrational excitation of the reactants. The excellent agreement between experiment and theory on integral cross sections for the exchange reaction is unprecedented beyond atom-diatom reactions. However, the experimental cross sections for abstraction are Larger than the theoretical values by more than a factor of 10. Further experiments are required to resolve this.	Natl Univ Singapore, Dept Computat Sci, Singapore 119260, Singapore; Natl Univ Singapore, Dept Chem, Singapore 119260, Singapore; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	National University of Singapore; National University of Singapore; Australian National University	Zhang, DH (corresponding author), Natl Univ Singapore, Dept Computat Sci, Singapore 119260, Singapore.							Alagia M, 1996, CHEM PHYS, V207, P389, DOI 10.1016/0301-0104(95)00422-X; Barnes PW, 1999, FARADAY DISCUSS, V113, P167, DOI 10.1039/a902348h; Bettens RPA, 1999, J CHEM PHYS, V111, P816, DOI 10.1063/1.479368; Bettens RPA, 2000, J CHEM PHYS, V112, P10162, DOI 10.1063/1.481657; BOWMAN JM, 1995, ANNU REV PHYS CHEM, V46, P169, DOI 10.1146/annurev.pc.46.100195.001125; BRONIKOWSKI MJ, 1991, J CHEM PHYS, V95, P8647, DOI 10.1063/1.461243; BRONIKOWSKI MJ, 1993, J PHYS CHEM-US, V97, P2204, DOI 10.1021/j100112a022; Brownsword RA, 1997, J PHYS CHEM A, V101, P6448, DOI 10.1021/jp970816v; Brownsword RA, 1996, CHEM PHYS LETT, V259, P375, DOI 10.1016/0009-2614(96)00825-1; CLARY DC, 1994, J PHYS CHEM-US, V98, P10678, DOI 10.1021/j100093a004; COHEN N, 1979, J PHYS CHEM-US, V83, P46, DOI 10.1021/j100464a009; Collins MA, 1999, J CHEM PHYS, V111, P9924, DOI 10.1063/1.480344; Crim FF, 1999, ACCOUNTS CHEM RES, V32, P877, DOI 10.1021/ar950046a; Crim FF, 1996, J PHYS CHEM-US, V100, P12725, DOI 10.1021/jp9604812; de Aspuru GO, 1998, J PHYS CHEM A, V102, P9631, DOI 10.1021/jp982433i; Hawthorne G, 1998, J CHEM PHYS, V108, P4693, DOI 10.1063/1.475926; JACOBS A, 1994, J CHEM PHYS, V100, P1936, DOI 10.1063/1.466546; JORDAN MJT, 1995, J CHEM PHYS, V102, P5647, DOI 10.1063/1.469296; KLEINERMANNS K, 1984, APPL PHYS B-PHOTO, V34, P5, DOI 10.1007/BF00697457; KOPPE S, 1994, CAN J CHEM, V72, P615, DOI 10.1139/v94-086; MICHAEL JV, 1988, J PHYS CHEM-US, V92, P3853, DOI 10.1021/j100324a035; MILLER WH, 1990, ANNU REV PHYS CHEM, V41, P245; NEUHAUSER D, 1992, SCIENCE, V257, P519, DOI 10.1126/science.257.5069.519; POLANYI JC, 1972, ACCOUNTS CHEM RES, V5, P161, DOI 10.1021/ar50053a001; Schatz GC, 1999, FARADAY DISCUSS, V113, P151, DOI 10.1039/a901950b; Schatz GC, 1996, J PHYS CHEM-US, V100, P12839, DOI 10.1021/jp953344y; SCHATZ GC, 1980, CHEM PHYS LETT, V73, P21, DOI 10.1016/0009-2614(80)85193-1; SINHA A, 1991, J CHEM PHYS, V94, P4928, DOI 10.1063/1.460578; SINHA A, 1990, J CHEM PHYS, V92, P6333, DOI 10.1063/1.458312; Thompson KC, 1998, J CHEM PHYS, V108, P8302, DOI 10.1063/1.476259; WALCH SP, 1980, J CHEM PHYS, V72, P1303, DOI 10.1063/1.439193; Zare RN, 1998, SCIENCE, V279, P1875, DOI 10.1126/science.279.5358.1875; ZHANG DH, 1993, J CHEM PHYS, V99, P5615, DOI 10.1063/1.465954; Zhang DH, 1999, J CHEM PHYS, V110, P4435, DOI 10.1063/1.478327; Zhang DH, 1996, J CHEM PHYS, V104, P4544, DOI 10.1063/1.471203	36	194	198	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 3	2000	290	5493					961	963		10.1126/science.290.5493.961	http://dx.doi.org/10.1126/science.290.5493.961			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062123				2022-12-28	WOS:000165103200042
J	Rutherford, S; D'Hondt, S				Rutherford, S; D'Hondt, S			Early onset and tropical forcing of 100,000-year Pleistocene glacial cycles	NATURE			English	Article							ICE AGES; CLIMATE; OSCILLATION; EVOLUTION; RECORDS; PHASE	Between 1.5 and 0.6 Myr ago, the period of the Earth's glacial cycles changed from 41 kyr, the period of the Earth's obliquity cycles, to 100 kyr, the period of the Earth's orbital eccentricity(1,2), which has a much smaller effect on global insolation. The timing of this transition and its causes pose one of the most perplexing problems in palaeoclimate research(3). Here we use complex demodulation to examine the phase evolution of precession and semiprecession cycles-the latter of which are phase-coupled to both precession and eccentricity-in the tropical and extra- tropical Atlantic Ocean. We find that about 1.5 Myr ago, tropical semiprecession cycles (with periods of about 11.5 kyr) started to propagate to higher latitudes, coincident with a growing amplitude envelope of the 100-kyr cycles. Evidence from numerical models suggests that cycles of about 10 kyr in length may be required to explain the high amplitude of the 100-kyr cycles(4). Combining our results with consideration of a modern analogue, we conclude that increased heat flow across the equator or from the tropics to higher latitudes around 1.5 Myr ago strengthened the semiprecession cycle in the Northern Hemisphere, and triggered the transition to sustained 100-kyr glacial cycles.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of Rhode Island	Rutherford, S (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.							Bickert T., 1997, P ODP SCI RESULTS, V154, P229; BLOEMENDAL J, 1995, EARTH PLANET SC LETT, V131, P371, DOI 10.1016/0012-821X(95)00016-6; Bloomfeld P., 1976, FOURIER ANAL TIME SE, P1; CHEN Y, 1995, MATH COMPUT MODEL, V21, P47, DOI 10.1016/0895-7177(95)00078-G; Clemens SC, 1996, SCIENCE, V274, P943, DOI 10.1126/science.274.5289.943; Clement AC, 1999, PALEOCEANOGRAPHY, V14, P441, DOI 10.1029/1999PA900013; deMenocal PB, 1995, PALEOCLIMATE AND EVOLUTION, WITH EMPHASIS ON HUMAN ORIGINS, P262; DEMENOCAL PB, 1995, SCIENCE, V270, P53, DOI 10.1126/science.270.5233.53; DHondt S, 1996, GEOLOGY, V24, P611, DOI 10.1130/0091-7613(1996)024<0611:OMRTTC>2.3.CO;2; Hagelberg T, 1991, PALEOCEANOGRAPHY, V6, P729, DOI 10.1029/91PA02281; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; HERBERT TD, 1986, NATURE, V321, P739, DOI 10.1038/321739a0; LETREUT H, 1983, J GEOPHYS RES-OCEANS, V88, P5167, DOI 10.1029/JC088iC09p05167; MAASCH KA, 1990, J GEOPHYS RES-ATMOS, V95, P1955, DOI 10.1029/JD095iD02p01955; McIntyre A, 1996, SCIENCE, V274, P1867, DOI 10.1126/science.274.5294.1867; MERLE J, 1980, OCEANOL ACTA, V3, P455; MOLFINO B, 1990, PALEOCEANOGRAPHY, V5, P977; PARK J, 1993, J GEOPHYS RES-SOL EA, V98, P447, DOI 10.1029/92JB01815; Raymo ME, 1989, PALEOCEANOGRAPHY, V4, P413, DOI 10.1029/PA004i004p00413; RAYMO ME, 1990, EARTH PLANET SC LETT, V97, P353, DOI 10.1016/0012-821X(90)90051-X; RAYMO ME, 1986, INITIAL REPORTS DEEP, P895; Rial JA, 1999, SCIENCE, V285, P564, DOI 10.1126/science.285.5427.564; Rodwell MJ, 1999, NATURE, V398, P320, DOI 10.1038/18648; Ruddiman WF, 1989, PALEOCEANOGRAPHY, V4, P353, DOI 10.1029/PA004i004p00353; RUDDIMAN WF, 1987, INITIAL REPORTS DEEP, V96, P1251; RUDDIMAN WF, 1986, INITIAL REPORTS DEEP, V96, P855; SALTZMAN B, 1994, PALEOCEANOGRAPHY, V9, P767, DOI 10.1029/94PA02289; SERVAIN J, 1986, J GEOPHYS RES-OCEANS, V91, P14181, DOI 10.1029/JC091iC12p14181; SHORT DA, 1991, QUATERNARY RES, V35, P157, DOI 10.1016/0033-5894(91)90064-C; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208	30	123	155	1	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 2	2000	408	6808					72	75		10.1038/35040533	http://dx.doi.org/10.1038/35040533			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	11081508				2022-12-28	WOS:000165050400052
J	Amelung, F; Jonsson, S; Zebker, H; Segall, P				Amelung, F; Jonsson, S; Zebker, H; Segall, P			Widespread uplift and 'trapdoor' faulting on Galapagos volcanoes observed with radar interferometry	NATURE			English	Article							LANDERS EARTHQUAKE; DEFORMATION; ARCHIPELAGO	Volcanic uplift, caused by the accumulation of magma in subsurface reservoirs, is a common precursor to eruptions(1,2). But, for some volcanoes, uplift of metres or more has not yet led to an eruption(3). Here we present displacement maps of volcanoes in the Galapagos Islands, constructed using satellite radar interferometry, that might help explain this dichotomy. We show that all but one of the seven volcanoes on the islands of Isabela and Fernandina deformed during 1992-99. Cerro Azul and Fernandina erupted(4-6) during the observation period and show evidence of inflation, co-eruptive deflation and shallow dyke intrusion. In contrast, the largest volcano, Sierra Negra, has not erupted, yet exhibits spatially and temporally variable deformation, with a maximum uplift of 2.7 m between 1992 and 1999, which can be modelled by a shallow inflating sill. Inflation during 1997-98, however, was accompanied by 'trapdoor' faulting on a steeply dipping fracture system within the caldera. Repeated trapdoor faulting over geological time has formed an arcuate intra-caldera ridge within Sierra Negra and may have acted to relax stresses above the magma chamber, inhibiting summit eruptions. Similar processes may help explain large uplift unaccompanied by eruptive activity at other volcanoes.	Stanford Univ, Dept Geophys, Stanford, CA 94305 USA	Stanford University	Jonsson, S (corresponding author), Stanford Univ, Dept Geophys, Mitchell Bldg, Stanford, CA 94305 USA.	amelung@pgd.hawaii.edu; jonsson@pangea.stanford.edu	Amelung, Falk/J-9042-2012; Jonsson, Sigurjon/G-4353-2015	Jonsson, Sigurjon/0000-0001-5378-7079; zebker, howard/0000-0001-9931-5237				Allan JF, 2000, J GEOPHYS RES-SOL EA, V105, P6017, DOI 10.1029/1999JB900417; Bonafede M, 1998, J VOLCANOL GEOTH RES, V81, P137, DOI 10.1016/S0377-0273(97)00071-1; Briole P, 1997, GEOPHYS RES LETT, V24, P37, DOI 10.1029/96GL03705; CERVELLI P, 1997, IN PRESS J GEOPHYS R; Dvorak JJ, 1997, REV GEOPHYS, V35, P343, DOI 10.1029/97RG00070; GEIST D, 1994, B VOLCANOL, V56, P243, DOI 10.1007/BF00302078; Geist D, 1998, J PETROL, V39, P953, DOI 10.1093/petrology/39.5.953; GOLDSTEIN RM, 1988, RADIO SCI, V23, P713, DOI 10.1029/RS023i004p00713; Jonsson S, 1999, GEOPHYS RES LETT, V26, P1077, DOI 10.1029/1999GL900108; KANAMORI H, 1975, B SEISMOL SOC AM, V65, P1073; Lawson CL, 1974, SOLVING LEAST SQUARE; Lipman PW, 1981, US GEOL SURV PROF PA, V1250, P143; MASSONNET D, 1993, NATURE, V364, P138, DOI 10.1038/364138a0; Massonnet D, 1998, REV GEOPHYS, V36, P441, DOI 10.1029/97RG03139; Mouginis-Mark PJ, 2000, B VOLCANOL, V62, P188, DOI 10.1007/s004450000078; MouginisMark PJ, 1996, GEOPHYS RES LETT, V23, P3767, DOI 10.1029/96GL03280; MURRAY JB, 1988, J VOLCANOL GEOTH RES, V35, P121, DOI 10.1016/0377-0273(88)90010-8; Naumann T, 2000, B VOLCANOL, V61, P497, DOI 10.1007/s004450050001; NEWHALL CG, 1988, USGS B, V1855, P509; REYNOLDS RW, 1995, GEOL SOC AM BULL, V107, P1398, DOI 10.1130/0016-7606(1995)107<1398:PVASDO>2.3.CO;2; ROWLAND SK, 1994, B VOLCANOL, V56, P271, DOI 10.1007/s004450050036; SIMKIN R, 1994, VOLCANOES WORLD; STEVENS NF, IN PRESS J GEOPHYS R; Wicks C, 1998, SCIENCE, V282, P458, DOI 10.1126/science.282.5388.458; ZEBKER HA, 1994, J GEOPHYS RES-SOL EA, V99, P19617, DOI 10.1029/94JB01179	26	265	275	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 26	2000	407	6807					993	996		10.1038/35039604	http://dx.doi.org/10.1038/35039604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069176				2022-12-28	WOS:000090032500040
J	Dalton, R				Dalton, R			US Geological Survey needs more resources, says draft report	NATURE			English	News Item																			0	0	0	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					933	933		10.1038/35039695	http://dx.doi.org/10.1038/35039695			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069150	Bronze			2022-12-28	WOS:000090032500008
J	Freitas-Junior, LH; Bottius, E; Pirrit, LA; Deitsch, KW; Scheidig, C; Guinet, F; Nehrbass, U; Wellems, TE; Scherf, A				Freitas-Junior, LH; Bottius, E; Pirrit, LA; Deitsch, KW; Scheidig, C; Guinet, F; Nehrbass, U; Wellems, TE; Scherf, A			Frequent ectopic recombination of virulence factor genes in telomeric chromosome clusters of P-falciparum	NATURE			English	Article							PARASITE PLASMODIUM-FALCIPARUM; ANTIGENIC VARIATION; INFECTED ERYTHROCYTES; ACQUIRED-IMMUNITY; CEREBRAL MALARIA; ADHERENCE; SURFACE; TRANSCRIPTION; EXPRESSION; PHENOTYPES	Persistent and recurrent infections by Plasmodium falciparum malaria parasites result from the ability of the parasite to undergo antigenic variation and evade host immune attack(1,2). P. falciparum parasites generate high levels of variability in gene families that comprise virulence determinants of cytoadherence and antigenic variation(3-7), such as the var genes. These genes encode the major variable parasite protein (PfEMP-1), and are expressed in a mutually exclusive manner at the surface of the erythrocyte infected by P. falciparum(8-12). Here we identify a mechanism by which var gene sequences undergo recombination at frequencies much higher than those expected from homologous crossover events alone(13). These recombination events occur between sub-telomeric regions of heterologous chromosomes, which associate in clusters near the nuclear periphery in asexual blood-stage parasites or in bouquet-like configurations near one pole of the elongated nuclei in sexual parasite forms. We propose that the alignment of var genes in heterologous chromosomes facilitates gene conversion and promotes the diversity of antigenic and adhesive phenotypes. The association of virulence factors with a specific nuclear subcompartment may also have implications for variation during mitotic recombination in asexual blood stages.	Inst Pasteur, Unite Biol Interact Hote Parasite, CNRS, URA 1960, F-75724 Paris 15, France; Inst Pasteur, Lab Biol Cellulaire Noyau, CNRS, URA 1773, F-75724 Paris, France; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Scherf, A (corresponding author), Inst Pasteur, Unite Biol Interact Hote Parasite, CNRS, URA 1960, 25 Rue Dr Roux, F-75724 Paris 15, France.		Freitas-Junior, Lucio H/C-8677-2011; Scherf, Artur/A-9674-2014	Freitas-Junior, Lucio H/0000-0002-8904-7897; Scherf, Artur/0000-0003-2411-3328; Nehrbass, Ulf/0000-0002-7028-8076	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000483, Z01AI000483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BIGGS BA, 1992, J IMMUNOL, V149, P2047; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; Carter R, 1993, Methods Mol Biol, V21, P67; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; DERNBURG AF, 1995, TELOMERES, P295; Ersfeld K, 1997, SCIENCE, V276, P611, DOI 10.1126/science.276.5312.611; Figueiredo LM, 2000, MOL BIOCHEM PARASIT, V106, P169, DOI 10.1016/S0166-6851(99)00199-1; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gupta S, 1999, PARASITOL TODAY, V15, P497, DOI 10.1016/S0169-4758(99)01559-8; Gupta S, 1999, P ROY SOC B-BIOL SCI, V266, P33, DOI 10.1098/rspb.1999.0600; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; HINTERBERG K, 1994, EMBO J, V13, P4174, DOI 10.1002/j.1460-2075.1994.tb06735.x; KIMURA E, 1990, GENE, V91, P57, DOI 10.1016/0378-1119(90)90162-K; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SCHERF A, 1988, EMBO J, V7, P1129, DOI 10.1002/j.1460-2075.1988.tb02922.x; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	32	381	385	0	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1018	1022		10.1038/35039531	http://dx.doi.org/10.1038/35039531			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069183				2022-12-28	WOS:000090032500047
J	Price, MP; Lewin, GR; McIlwrath, SL; Cheng, C; Xie, JH; Heppenstall, PA; Stucky, CL; Mannsfeldt, AG; Brennan, TJ; Drummond, HA; Qiao, J; Benson, CJ; Tarr, DE; Hrstka, RF; Yang, BL; Williamson, RA; Welsh, MJ				Price, MP; Lewin, GR; McIlwrath, SL; Cheng, C; Xie, JH; Heppenstall, PA; Stucky, CL; Mannsfeldt, AG; Brennan, TJ; Drummond, HA; Qiao, J; Benson, CJ; Tarr, DE; Hrstka, RF; Yang, BL; Williamson, RA; Welsh, MJ			The mammalian sodium channel BNC1 is required for normal touch sensation	NATURE			English	Article							ROOT GANGLION-CELLS; SENSORY NEURONS; CAENORHABDITIS-ELEGANS; NA+ CHANNEL; DEGENERIN MDEG; ION CHANNELS; HAIRY SKIN; SUBUNIT; NOCICEPTORS; PROTONS	Of the vertebrate senses, touch is the least understood at the molecular level. The ion channels that form the core of the mechanosensory complex and confer touch sensitivity remain unknown(1-3). However, the similarity of the brain sodium channel 1 (BNC1)(4-6) to nematode proteins involved in mechanotransduction indicated that it might be a part of such a mechanosensor(7,8). Here we show that disrupting the mouse BNC1 gene markedly reduces the sensitivity of a specific component of mechanosensation: low-threshold rapidly adapting mechanoreceptors. In rodent hairy skin these mechanoreceptors are excited by hair movement(2). Consistent with this function, we found BNC1 in the lanceolate nerve endings that lie adjacent to and surround the hair follicle(9). Although BNC1 has been proposed to have a role in pH sensing(10,11), the acid-evoked current in cultured sensory neurons and the response of acid-stimulated nociceptors were normal in BNC1 null mice. These data identify the BNC1 channel as essential for the normal detection of light touch and indicate that BNC1 may be a central component of a mechanosensory complex.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Anesthesia, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Max Delbruck Ctr Mol Med, Dept Neurosci, Growth Factors & Regenerat Grp, D-13092 Berlin, Germany	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA.		Tarr, D Ellen K/H-7295-2019; Lewin, Gary R/B-8028-2011	Tarr, D Ellen K/0000-0003-1604-4545; Benson, Christopher/0000-0001-6600-8193; Brennan, Timothy/0000-0002-0150-5145; Lewin, Gary/0000-0002-2890-6352; Welsh, Michael/0000-0002-1646-6206				Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 1999, CIRC RES, V84, P921; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; DRUMMOND HA, IN PRESS BRAIN RES; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; Fricke B, 2000, CELL TISSUE RES, V299, P327; GarciaAnoveros J, 1997, ANNU REV NEUROSCI, V20, P567, DOI 10.1146/annurev.neuro.20.1.567; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; HALATA Z, 1993, J INVEST DERMATOL, V101, pS75, DOI 10.1111/1523-1747.ep12362877; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JOHNSON KO, 1992, ANNU REV NEUROSCI, V15, P227, DOI 10.1146/annurev.ne.15.030192.001303; KOERBER HR, 1988, J NEUROPHYSIOL, V60, P1584, DOI 10.1152/jn.1988.60.5.1584; Koltzenburg M, 1997, J NEUROPHYSIOL, V78, P1841, DOI 10.1152/jn.1997.78.4.1841; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mannsfeldt AG, 1999, MOL CELL NEUROSCI, V13, P391, DOI 10.1006/mcne.1999.0761; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; McDonald FJ, 1999, P NATL ACAD SCI USA, V96, P1727, DOI 10.1073/pnas.96.4.1727; Perl ER, 1992, SENSORY NEURONS DIVE, P3; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Rusch A, 1999, HEARING RES, V131, P170, DOI 10.1016/S0378-5955(99)00030-1; STEEN KH, 1992, J NEUROSCI, V12, P86; Stucky CL, 1999, J NEUROSCI, V19, P6497; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229	30	381	402	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1007	1011		10.1038/35039512	http://dx.doi.org/10.1038/35039512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069180				2022-12-28	WOS:000090032500044
J	Conde-Agudelo, A; Belizan, JM				Conde-Agudelo, A; Belizan, JM			Maternal morbidity and mortality associated with interpregnancy interval: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH INTERVALS; RISK; PREGNANCIES; OUTCOMES; AGE; WOMEN	Objective To study the impact of interpregnancy interval on maternal morbidity and mortality. Design Retrospective cross sectional study with data from the Perinatal Information System database of the Latin American Centre for Perinatology and Human Development, Montevideo, Uruguay. Setting Latin America and the Caribbean, 1985-97. Participants 456 889 parous women delivering singleton infants. Main outcome measures Crude and adjusted odds ratios of the effects of short and long interpregnancy intervals on maternal death, third trimester bleeding, premature rupture of membranes, postpartum haemorrhage, puerperal endometritis, and anaemia. Results Short (<6 months) and long (> 59 months) interpregnancy intervals were observed for 2.8% and 19.5% of women, respectively. After adjustment for major confounding factors, compared with those conceiving at 18 to 23 months after a previous birth, women with interpregnancy intervals of 5 months or less had higher risks for maternal death (odds ratio 2.54; 95% confidence interval 1.22 to 5.38), third trimester bleeding (1.73; 1.42 to 2.24), premature rupture of membranes (1.72; 1.53 to 1.93), puerperal endometritis (1.33; 1.22 to 1.45), and anaemia (1.30; 1.18 to 1.43). Compared with women with interpregnancy intervals of 18 to 23 months, women with interpregnancy intervals longer than 59 months had significantly increased risks of pre-eclampsia (1.83; 1.72 to 1.94) and eclampsia (1.80; 1.38 to 2.32). Conclusions Interpregnancy intervals less than 6 months and longer than 59 months are associated with an increased risk of adverse maternal outcomes.	WHO, Pan Amer Hlth Org, Div Hlth Promot & Protect, Latin Amer Ctr Perinatol & Human Dev CLAP, Montevideo, Uruguay	Pan American Health Organization; World Health Organization	Conde-Agudelo, A (corresponding author), WHO, Pan Amer Hlth Org, Div Hlth Promot & Protect, Latin Amer Ctr Perinatol & Human Dev CLAP, Montevideo, Uruguay.			Belizan, Jose/0000-0002-8412-3010				ALGER LS, 1986, CLIN OBSTET GYNECOL, V29, P758, DOI 10.1097/00003081-198612000-00005; ANANDALAKSHMY PN, 1993, J FAM WELFARE, V39, P1; Ananth CV, 1996, OBSTET GYNECOL, V88, P511, DOI 10.1016/0029-7844(96)00236-0; COBO E, 1985, REV COLOMB OBSTET GI, V36, P79; Diaz-Rossello Jose Luis, 1998, Current Opinion in Pediatrics, V10, P117, DOI 10.1097/00008480-199804000-00001; Eastman NJ, 1944, AM J OBSTET GYNECOL, V47, P445, DOI 10.1016/S0002-9378(15)32197-9; *I MED NAT AC SCI, 1992, NUTR PREGN LACT IMPL; Khan KS, 1998, ACTA OBSTET GYN SCAN, V77, P395, DOI 10.1034/j.1600-0412.1998.770407.x; Khoshnood B, 1998, AM J EPIDEMIOL, V148, P798; Klerman LV, 1998, AM J PUBLIC HEALTH, V88, P1182, DOI 10.2105/AJPH.88.8.1182; Lazovic N, 1996, Srp Arh Celok Lek, V124, P307; LIBOMBO A, 1994, GYNECOL OBSTET INVES, V38, P198, DOI 10.1159/000292479; Mahfouz Ahmed A. R., 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P84; MILLER JE, 1991, FAM PLANN PERSPECT, V23, P62, DOI 10.2307/2135451; NAEYE RL, 1983, OBSTET GYNECOL, V61, P210; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; Ronsmans C, 1998, STUD FAMILY PLANN, V29, P282, DOI 10.2307/172274; SCHWARCZ R, 1987, Journal of Perinatal Medicine, V15, P9; Shults RA, 1999, EPIDEMIOLOGY, V10, P250, DOI 10.1097/00001648-199905000-00010; Simini F, 1999, LANCET, V354, P75, DOI 10.1016/S0140-6736(05)75345-9; Trupin LS, 1996, EPIDEMIOLOGY, V7, P240, DOI 10.1097/00001648-199605000-00004; WINKVIST A, 1992, AM J PUBLIC HEALTH, V82, P691, DOI 10.2105/AJPH.82.5.691; Zhu BP, 1999, NEW ENGL J MED, V340, P589, DOI 10.1056/NEJM199902253400801	23	279	294	6	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	2000	321	7271					1255	1259		10.1136/bmj.321.7271.1255	http://dx.doi.org/10.1136/bmj.321.7271.1255			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	376ET	11082085	Bronze, Green Published			2022-12-28	WOS:000165445800024
J	Meyer, UA				Meyer, UA			Pharmacogenetics and adverse drug reactions	LANCET			English	Article							METABOLISM; HUMANS; METAANALYSIS; POLYMORPHISM; GENOTYPE; ENZYME; GENE	Polymorphisms in the genes that code for drug-metabolising enzymes, drug transporters, drug receptors, and ion channels can affect an individual's risk of having an adverse drug reaction, or can alter the efficacy of drug treatment in that individual. Mutant alleles at a single gene locus are the best studied individual risk factors for adverse drug reactions, and include many genes coding for drug-metabolising enzymes. These genetic polymorphisms of drug metabolism produce the phenotypes of "poor metabolisers" or "ultrarapid metabolisers" of numerous drugs. Together, such phenotypes make up a substantial proportion of the population. Pharmacogenomic techniques allow efficient analysis of these risk factors, and genotyping tests have the potential to optimise drug therapy in the future.	Univ Basel, Biozentrum, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland.	Urs-A.Meyer@unibas.ch						Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Arranz MJ, 1998, SCHIZOPHR RES, V32, P93, DOI 10.1016/S0920-9964(98)00032-2; Bertilsson L, 1997, ACTA PSYCHIAT SCAND, V96, P14; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Chou WH, 2000, J CLIN PSYCHOPHARM, V20, P246, DOI 10.1097/00004714-200004000-00019; Dalen P, 1998, CLIN PHARMACOL THER, V63, P444, DOI 10.1016/S0009-9236(98)90040-6; Drews J, 1997, NAT BIOTECHNOL, V15, P1318, DOI 10.1038/nbt1297-1318; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Furuta T, 1999, CLIN PHARMACOL THER, V66, P265, DOI 10.1016/S0009-9236(99)70034-2; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; Hansen T, 1998, DIABETES, V47, P598, DOI 10.2337/diabetes.47.4.598; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Ingelman-Sundberg M, 1999, TRENDS PHARMACOL SCI, V20, P342, DOI 10.1016/S0165-6147(99)01363-2; Iyer L, 1998, EUR J CANCER, V34, P1493, DOI 10.1016/S0959-8049(98)00230-5; Kalow W, 1998, PHARMACOGENETICS, V8, P283; Kidd RS, 1999, PHARMACOGENETICS, V9, P71, DOI 10.1097/00008571-199902000-00010; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lessard E, 1999, PHARMACOGENETICS, V9, P435; Liggett SB, 2000, J ALLERGY CLIN IMMUN, V105, pS487, DOI 10.1016/S0091-6749(00)90048-4; MEYER UA, 1991, PHARMACOGENETICS, V1, P66, DOI 10.1097/00008571-199111000-00002; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Miners JO, 1998, BRIT J CLIN PHARMACO, V45, P525, DOI 10.1046/j.1365-2125.1998.00721.x; Navis G, 1999, J MOL MED, V77, P781, DOI 10.1007/s001099900063; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; Raimundo S, 2000, PHARMACOGENETICS, V10, P577, DOI 10.1097/00008571-200010000-00001; Roses AD, 2000, LANCET, V355, P1358, DOI 10.1016/S0140-6736(00)02126-7; Sindrup SH, 1995, PHARMACOGENETICS, V5, P335, DOI 10.1097/00008571-199512000-00001; Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19	28	395	419	0	33	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 11	2000	356	9242					1667	1671		10.1016/S0140-6736(00)03167-6	http://dx.doi.org/10.1016/S0140-6736(00)03167-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	372TB	11089838				2022-12-28	WOS:000165249200036
J	Midgley, RSJ; Kerr, DJ				Midgley, RSJ; Kerr, DJ			ABC of colorectal cancer - Adjuvant therapy	BRITISH MEDICAL JOURNAL			English	Review									Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Midgley, RSJ (corresponding author), Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.			Kerr, Rachel/0000-0002-7240-3269				GRAY R, 1997, GUIDANCE COMMISSIONI; Gray RG, 2000, LANCET, V355, P1588; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Midgley RS, 1997, CANCER TREAT REV, V23, P135, DOI 10.1016/S0305-7372(97)90035-9	4	20	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1208	+		10.1136/bmj.321.7270.1208	http://dx.doi.org/10.1136/bmj.321.7270.1208			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073515	Green Published			2022-12-28	WOS:000165357100032
J	Toma, T				Toma, T			High paracetamol intake may be linked with asthma	BRITISH MEDICAL JOURNAL			English	News Item																		Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; 2000, THORAX, V55, P882; 2000, RESP J, V16, P1	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	2000	321	7270					1178	1178						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374RA	11073506				2022-12-28	WOS:000165357100023
J	Nakayama, T; Yonekura-Sakakibara, K; Sato, T; Kikuchi, S; Fukui, Y; Fukuchi-Mizutani, M; Ueda, T; Nakao, M; Tanaka, Y; Kusumi, T; Nishino, T				Nakayama, T; Yonekura-Sakakibara, K; Sato, T; Kikuchi, S; Fukui, Y; Fukuchi-Mizutani, M; Ueda, T; Nakao, M; Tanaka, Y; Kusumi, T; Nishino, T			Aureusidin synthase: A polyphenol oxidase homolog responsible for flower coloration	SCIENCE			English	Article							CLONING; EXPRESSION; CLEAVAGE	Aurones are plant flavonoids that provide yellow color to the flowers of some popular ornamental plants, such as snapdragon and cosmos. In this study, we have identified an enzyme responsible for the synthesis of aurone from chalcones in the yellow snapdragon flower, The enzyme (aureusidin synthase) is a 39-kilodalton, copper-containing glycoprotein catalyzing the hydroxylation and/or oxidative cyclization of the precursor chalcones, 2',4',6',4-tetrahydroxychalcone and 2',4',6',3,4-pentahydroxychalcone. The complementary DNA encoding aureusidin synthase is expressed in the petals of aurone-containing varieties, DNA sequence analysis revealed that aureusidin synthase belongs to the plant polyphenol oxidase family, providing an unequivocal example of the function of the polyphenol oxidase homolog in plants, i.e., flower coloration.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; Suntory Ltd, Inst Fundamental Res, Shimamoto, Osaka 6188503, Japan; Kobe Gakuin Univ, Kobe, Hyogo 6512180, Japan	Tohoku University; Suntory Holdings Ltd; Kobe Gakuin University	Nakayama, T (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.		Yonekura-Sakakibara, Keiko/J-8749-2014	Yonekura-Sakakibara, Keiko/0000-0002-0409-1523				BATESMITH EC, 1951, NATURE, V167, P688, DOI 10.1038/167688a0; Brouillard R., 1993, FLAVONOIDS ADV RES 1, P565; CLARKE JT, 1964, ANN NY ACAD SCI, V121, P428, DOI 10.1111/j.1749-6632.1964.tb14214.x; DRY IB, 1994, PLANT MOL BIOL, V26, P495, DOI 10.1007/BF00039560; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; JOY RW, 1995, PLANT PHYSIOL, V107, P1083, DOI 10.1104/pp.107.4.1083; Klabunde T, 1998, NAT STRUCT BIOL, V5, P1084, DOI 10.1038/4193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RATHMELL WG, 1972, BIOCHEM J, V127, P125, DOI 10.1042/bj1270125; ROBINSON SP, 1992, PLANT PHYSIOL, V99, P317, DOI 10.1104/pp.99.1.317; SANCHEZFERRER A, 1995, BBA-PROTEIN STRUCT M, V1247, P1; SATO T, IN PRESS PLANT SCI; SHIMOKORIYAMA M, 1953, J AM CHEM SOC, V75, P2277, DOI 10.1021/ja01105a532; Tanaka Y, 1998, PLANT CELL PHYSIOL, V39, P1119, DOI 10.1093/oxfordjournals.pcp.a029312; THYGESEN PW, 1995, PLANT PHYSIOL, V109, P525, DOI 10.1104/pp.109.2.525; VAUGHN KC, 1988, PHYSIOL PLANTARUM, V72, P659, DOI 10.1111/j.1399-3054.1988.tb09180.x; YONEKURASAKAKIB.K, UNPUB	17	156	185	4	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1163	1166		10.1126/science.290.5494.1163	http://dx.doi.org/10.1126/science.290.5494.1163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073455				2022-12-28	WOS:000165228200048
J	Shimizu, E; Tang, YP; Rampon, C; Tsien, JZ				Shimizu, E; Tang, YP; Rampon, C; Tsien, JZ			NMDA receptor-dependent synaptic reinforcement as a crucial process for memory consolidation	SCIENCE			English	Article							LONG-TERM POTENTIATION; GLUTAMATE RECEPTORS; HIPPOCAMPUS; EXPRESSION; IMPAIRMENT; MICE; REACTIVATION; PLASTICITY; KNOCKOUT; AMNESIA	The hippocampal CA1 region is crucial for converting new memories into Long-term memories, a process believed to continue for week(s) after initial Learning. By developing an inducible, reversible, and CA1-specific knockout technique, we could switch N-methyl-D-aspartate (NMDA) receptor function off or on in CA1 during the consolidation period. Our data indicate that memory consolidation depends on the reactivation of the NMDA receptor, possibly to reinforce site-specific synaptic modifications to consolidate memory traces. Such a synaptic reinforcement process may also serve as a cellular means by which the new memory is transferred from the hippocampus to the cortex for permanent storage.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Tsien, JZ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Shimizu, Eiji/K-4637-2017; Tang, Ya-Ping/A-1035-2011	Shimizu, Eiji/0000-0002-6741-9338; Tang, Ya-Ping/0000-0002-0445-4072; rampon, claire/0000-0001-8551-8682				Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN NJ, 1997, MEMORY AMNESIA HIPPO; DAVIS M, 1987, PSYCHOL LEARNING MEM; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huerta PT, 2000, NEURON, V25, P473, DOI 10.1016/S0896-6273(00)80909-5; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Kudrimoti HS, 1999, J NEUROSCI, V19, P4090; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; McHugh TJ, 1996, CELL, V87, P1339, DOI 10.1016/S0092-8674(00)81828-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Sutherland GR, 2000, CURR OPIN NEUROBIOL, V10, P180, DOI 10.1016/S0959-4388(00)00079-9; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tsien JZ, 2000, CURR OPIN NEUROBIOL, V10, P266, DOI 10.1016/S0959-4388(00)00070-2; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 2000, SCI AM, V282, P62, DOI 10.1038/scientificamerican0400-62; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	34	434	507	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 10	2000	290	5494					1170	1174		10.1126/science.290.5494.1170	http://dx.doi.org/10.1126/science.290.5494.1170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	372HL	11073458				2022-12-28	WOS:000165228200051
J	Pauk, J; Huang, ML; Brodie, SJ; Wald, A; Koelle, DM; Schacker, T; Celum, C; Selke, S; Corey, L				Pauk, J; Huang, ML; Brodie, SJ; Wald, A; Koelle, DM; Schacker, T; Celum, C; Selke, S; Corey, L			Mucosal shedding of human herpesvirus 8 in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; KAPOSIS-SARCOMA; HUMAN-HERPESVIRUS-8 DNA; SEXUAL TRANSMISSION; PERIPHERAL-BLOOD; INFECTED PERSONS; GENE-EXPRESSION; HOMOSEXUAL MEN; IN-VIVO	Background: Epidemiologic studies suggest that human herpesvirus 8 (HHV-8) is sexually transmitted among men who have sex with men; however, the mode of transmission is unclear. Methods: To evaluate the patterns of shedding of HHV-8, we obtained mucosal-secretion samples from a cohort of HHV-8-seropositive men who had sex with men and had no clinical evidence of Kaposi's sarcoma. Quantitative polymerase-chain-reaction (PCR) assays, in situ PCR assays, and in situ RNA hybridization were used to identify potential sources of infectious HHV-8. Results: We detected HHV-8 in at least one mucosal sample from 30 of 50 men who were seropositive for HHV-8 (60 percent). Overall, HHV-8 was detected in 30 percent of oropharyngeal samples, as compared with 1 percent of anal and genital samples (P<0.001). In 39 percent of the HHV-8-seropositive men, HHV-8 was detected in saliva on more than 35 percent of the consecutive days on which samples were obtained. The median log titer of HHV-8 from the oral cavity was approximately 2.5 times as high as the titer at all other sites. In situ hybridization studies indicated that HHV-8 DNA and messenger RNA were present in oral epithelial cells. Among 92 men who had sex with men and who were seronegative for the human immunodeficiency virus (HIV), a history of sex with a partner who had Kaposi's sarcoma, deep kissing with an HIV-positive partner, and the use of amyl nitrite capsules ("poppers'') or inhaled nitrites were independent risk factors for infection with HHV-8. Conclusions: Oral exposure to infectious saliva is a potential risk factor for the acquisition of HHV-8 among men who have sex with men. Hence, currently recommended safer sex practices may not protect against HHV-8 infection. (N Engl J Med 2000;343:1369-77.) (C) 2000, Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Minnesota System; University of Minnesota Twin Cities	Corey, L (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis, 1100 Fairview Ave N D3-100, Seattle, WA 98109 USA.		Koelle, David/Q-6529-2016; Wald, Anna/B-6272-2012	Koelle, David/0000-0003-1255-9023; Wald, Anna/0000-0003-3486-6438	NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029] Funding Source: Medline; NIAID NIH HHS [AI30731, AI31576] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angeloni A, 1998, J INFECT DIS, V177, P1715, DOI 10.1086/517429; BERREY MM, IN PRESS J INFECT DI; Blackbourn DJ, 1999, J INFECT DIS, V179, P237, DOI 10.1086/314570; Blackbourn DJ, 1997, AIDS, V11, P249, DOI 10.1097/00002030-199702000-00016; Boldogh I, 1996, CLIN INFECT DIS, V23, P406, DOI 10.1093/clinids/23.2.406; Bosch ML, 1999, J GEN VIROL, V80, P467, DOI 10.1099/0022-1317-80-2-467; Brodie Scott J., 2000, P97; Brodie SJ, 1999, AM J PATHOL, V154, P1453, DOI 10.1016/S0002-9440(10)65400-4; Brodie SJ, 1998, J VIROL, V72, P5599, DOI 10.1128/JVI.72.7.5599-5609.1998; Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707; BRODIE SJ, 1995, AM J PATHOL, V146, P250; Brodie SJ, 1999, NAT MED, V5, P34, DOI 10.1038/4716; Calabro M L, 1998, J Hum Virol, V1, P207; Calabro ML, 1999, J INFECT DIS, V179, P1534, DOI 10.1086/314765; Chandran B, 1998, VIROLOGY, V243, P208, DOI 10.1006/viro.1998.9055; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CONE RW, 1993, J CLIN MICROBIOL, V31, P1262, DOI 10.1128/JCM.31.5.1262-1267.1993; CONE RW, 1994, J CLIN MICROBIOL, V32, P2633; Corbellino M, 1996, NEW ENGL J MED, V335, P1237, DOI 10.1056/NEJM199610173351614; DiAlberti L, 1997, J INFECT DIS, V175, P703, DOI 10.1093/infdis/175.3.703; Diamond C, 1997, J INFECT DIS, V176, P775, DOI 10.1086/517299; Diamond C, 1998, J VIROL, V72, P6223, DOI 10.1128/JVI.72.7.6223-6227.1998; Dukers NHTM, 2000, AM J EPIDEMIOL, V151, P213, DOI 10.1093/oxfordjournals.aje.a010195; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Koelle DM, 1997, J INFECT DIS, V176, P94, DOI 10.1086/514045; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; O'Brien TR, 1999, J INFECT DIS, V180, P1010, DOI 10.1086/315039; Oksenhendler E, 1998, NEW ENGL J MED, V338, P1585, DOI 10.1056/NEJM199805283382204; Olsen SJ, 1998, AIDS, V12, P1921, DOI 10.1097/00002030-199814000-00024; Pellett PE, 1999, J CLIN MICROBIOL, V37, P1298, DOI 10.1128/JCM.37.5.1298-1301.1999; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; Renwick N, 1998, AIDS, V12, P2481, DOI 10.1097/00002030-199818000-00018; REYNOLDS P, 1993, AM J EPIDEMIOL, V137, P19, DOI 10.1093/oxfordjournals.aje.a116598; Rezza G, 1998, INT J CANCER, V77, P361, DOI 10.1002/(SICI)1097-0215(19980729)77:3&lt;361::AID-IJC9&gt;3.0.CO;2-M; Ryncarz AJ, 1999, J CLIN MICROBIOL, V37, P1941, DOI 10.1128/JCM.37.6.1941-1947.1999; Schacker T, 1998, ANN INTERN MED, V128, P21, DOI 10.7326/0003-4819-128-1-199801010-00004; Sitas F, 1999, NEW ENGL J MED, V340, P1863, DOI 10.1056/NEJM199906173402403; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; Smith NA, 1999, J INFECT DIS, V180, P600, DOI 10.1086/314926; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Vieira J, 1997, J VIROL, V71, P7083, DOI 10.1128/JVI.71.9.7083-7087.1997; VIEIRA J, IN PRESS J VIROL; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Whitby D, 2000, BRIT J CANCER, V82, P702, DOI 10.1054/bjoc.1999.0983; Zerr DM, 2000, J CLIN MICROBIOL, V38, P1981, DOI 10.1128/JCM.38.5.1981-1983.2000; Zhong WD, 1996, P NATL ACAD SCI USA, V93, P6641, DOI 10.1073/pnas.93.13.6641	50	328	339	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 9	2000	343	19					1369	1377		10.1056/NEJM200011093431904	http://dx.doi.org/10.1056/NEJM200011093431904			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370ZH	11070101				2022-12-28	WOS:000165152800004
J	Vergunst, AC; Schrammeijer, B; den Dulk-Ras, A; de Vlaam, CMT; Regensburg-Tuink, TJG; Hooykaas, PJJ				Vergunst, AC; Schrammeijer, B; den Dulk-Ras, A; de Vlaam, CMT; Regensburg-Tuink, TJG; Hooykaas, PJJ			VirB/D4-dependent protein translocation from Agrobacterium into plant cells	SCIENCE			English	Article							VIRULENCE SYSTEM; DNA TRANSFER; T-DNA; TUMEFACIENS; TRANSFORMATION; GENE; VIRF	The Agrobacterium VirB/D4 transport system mediates the transfer of a nucleoprotein T complex into plant cells, Leading to crown gall disease. In addition, several Virulence proteins must somehow be transported to fulfill a function in planta. Here, we used fusions between Cre recombinase and VirE2 or VirF to directly demonstrate protein translocation into plant cells. Transport of the proteins was monitored by a Cre-mediated in planta recombination event resulting in a selectable phenotype and depended on the VirB/D4 transport system but did not require transferred DNA.	Leiden State Univ, Inst Mol Plant Sci, Clusius Lab, NL-2333 AL Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Hooykaas, PJJ (corresponding author), Leiden State Univ, Inst Mol Plant Sci, Clusius Lab, Wassenaarseweg 64, NL-2333 AL Leiden, Netherlands.	hooykaas@rulbim.leidenuniv.nl	Hooykaas, Paul JJ/S-4256-2017; Vergunst, Annette C./O-5139-2017	Hooykaas, Paul JJ/0000-0002-9736-6927; Vergunst, Annette C./0000-0002-4359-1491				BEIJERSBERGEN A, 1992, SCIENCE, V256, P1324, DOI 10.1126/science.256.5061.1324; BUNDOCK P, 1995, EMBO J, V14, P3206, DOI 10.1002/j.1460-2075.1995.tb07323.x; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; CITOVSKY V, 1992, SCIENCE, V256, P1802, DOI 10.1126/science.1615325; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; de Groot MJA, 1998, NAT BIOTECHNOL, V16, P839, DOI 10.1038/nbt0998-839; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Hansen G, 1999, CURR TOP MICROBIOL, V240, P21; Hooykaas PJJ, 2000, BIOLOGY OF PLANT-MICROBE INTERACTIONS, VOL 2, P159; HOOYKAAS PJJ, 1994, ANNU REV PHYTOPATHOL, V32, P157, DOI 10.1146/annurev.py.32.090194.001105; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Lai EM, 2000, TRENDS MICROBIOL, V8, P361, DOI 10.1016/S0966-842X(00)01802-3; MOZO T, 1992, MOL GEN GENET, V236, P1; OTTEN L, 1985, MOL GEN GENET, V199, P189, DOI 10.1007/BF00330258; OW DW, 1995, CRIT REV PLANT SCI, V14, P239, DOI 10.1080/713608117; REGENSBURGTUINK AJG, 1993, NATURE, V363, P69, DOI 10.1038/363069a0; Schrammeijer B, 1998, MOL PLANT MICROBE IN, V11, P429, DOI 10.1094/MPMI.1998.11.5.429; Vergunst AC, 1998, PLANT MOL BIOL, V38, P393, DOI 10.1023/A:1006024500008; Vergunst AC, 1998, METH MOL B, V82, P227; VERGUNST AC, UNPUB; Zupan JR, 1998, CURR OPIN MICROBIOL, V1, P649, DOI 10.1016/S1369-5274(98)80110-0	21	298	337	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 3	2000	290	5493					979	982		10.1126/science.290.5493.979	http://dx.doi.org/10.1126/science.290.5493.979			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370BV	11062129				2022-12-28	WOS:000165103200048
J	Brightling, CE; Monteiro, W; Ward, R; Parker, D; Morgan, MDL; Wardlaw, AJ; Pavord, ID				Brightling, CE; Monteiro, W; Ward, R; Parker, D; Morgan, MDL; Wardlaw, AJ; Pavord, ID			Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial	LANCET			English	Article							AIR-FLOW OBSTRUCTION; INHALED CORTICOSTEROIDS; AIRWAYS OBSTRUCTION; CHRONIC-BRONCHITIS; ASTHMA; INFLAMMATION; SMOKERS; COPD; BUDESONIDE; MILD	Background Some patients wit chronic obstructive pulmonary disease (COPD) respond toe corticosteroid therapy. Whether these patients have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic airway inflammation. Methods We did a randomised, double-blind, crossover trial. Patients who had COPD treated with bronchodilators only were assigned placebo and 30 mg prednisolone daily for 2 weeks each, in a random order, separated by a 4-week washout period. Before and after each treatment period, we assessed patients with spirometry, symptom scores, the chronic respiratory disease questionnaire (CRQ), incremental shuttle walk test, and induced sputum. Analysis was done by intention to treat. Findings 83 patients were recruited, of whom 67 were randomised. The geometric mean sputum eosinophil count fell significantly after prednisolone (from 2.4% to 0.4%; mean difference six-fold [95% CI 3.1-11.4]) but not after placebo. Other sputum cell counts did not change. After stratification into tertiles by baseline eosinophil count, postbronchodilator forced expiratory volume in 1 s (FEV1) and total scores on the CRQ improved progressively after prednisolone from the lowest to the highest eosinophilic tertile, compared with placebo. The mean change in postbronchodilator FEV1, total CRQ score, and shuttle walk distance with prednisolone compared with placebo in the highest tertile was 0.19 L (0.06-0.32), 0.62 (0.31-0.93), and 20 m (5-35), respectively. Interpretation Our findings suggest that eosinophilic airway inflammation contributes to airflow obstruction and symptoms in some patients with COPD and that the short-term effects of prednisolone are due to modification of this feature of the inflammatory response. The possibility that sputum eosinophilia identifies a subgroup of patients who particularly respond to long-term treatment with inhaled corticosteroids should be investigated.	Glenfield Gen Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Brightling, CE (corresponding author), Glenfield Gen Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.			Pavord, Ian/0000-0002-4288-5973; brightling, chris/0000-0002-9345-4903; Wardlaw, Andrew/0000-0001-6583-0791				Barnes NC, 1998, LANCET, V351, P766, DOI 10.1016/S0140-6736(98)22011-3; Boushey HA, 1999, NEW ENGL J MED, V340, P1990, DOI 10.1056/NEJM199906243402509; Brightling CE, 1999, EUR RESPIR J, V14, P1228, DOI 10.1183/09031936.99.14512289; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406, DOI 10.1164/ajrccm.160.2.9810100; *BRIT THOR SOC, 1997, THORAX S1, V52, P9; Burge PS, 2000, BMJ-BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley PMA, 1999, THORAX, V54, P3, DOI 10.1136/thx.54.1.3; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529, DOI 10.1164/ajrccm.155.5.9154853; CLIFTON M, 1962, LANCET, V1, P1311; Confalonieri M, 1998, THORAX, V53, P583, DOI 10.1136/thx.53.7.583; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277, DOI 10.1164/ajrccm.158.4.9802078; GUYATT GH, 1987, THORAX, V136, P1285; Hunter CJ, 1999, RESP MED, V93, P345, DOI 10.1016/S0954-6111(99)90317-7; JANOFF A, 1983, AM REV RESPIR DIS, V127, P540, DOI 10.1164/arrd.1983.127.5.540; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Matsumoto K, 1998, EUR RESPIR J, V12, P387, DOI 10.1183/09031936.98.12020387; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; PIZZICHINI E, 1996, AM J RESP CRIT CARE, V154, P808; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646, DOI 10.1164/ajrccm.150.6.7952628; SHIM C, 1978, J ALLERGY CLIN IMMUN, V62, P363, DOI 10.1016/0091-6749(78)90137-9; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; TWEEDDALE PM, 1987, THORAX, V42, P87; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112	29	421	439	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1480	1485		10.1016/S0140-6736(00)02872-5	http://dx.doi.org/10.1016/S0140-6736(00)02872-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367NA	11081531				2022-12-28	WOS:000090067300012
J	Nabel, GJ; Sullivan, NJ				Nabel, GJ; Sullivan, NJ			Antibodies and resistance to natural HIV infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL DEPLETION; VIREMIA		NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Nabel, GJ (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.							Baba TW, 2000, NAT MED, V6, P200, DOI 10.1038/72309; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318; Metzner KJ, 2000, J EXP MED, V191, P1921, DOI 10.1084/jem.191.11.1921; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Stahl-Hennig C, 1999, SCIENCE, V285, P1261, DOI 10.1126/science.285.5431.1261; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427	7	13	14	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	2000	343	17					1263	1265		10.1056/NEJM200010263431711	http://dx.doi.org/10.1056/NEJM200010263431711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366PQ	11071680				2022-12-28	WOS:000090014100011
J	Seemann, J; Jokitalo, E; Pypaert, M; Warren, G				Seemann, J; Jokitalo, E; Pypaert, M; Warren, G			Matrix proteins can generate the higher order architecture of the Golgi apparatus	NATURE			English	Article							COILED-COIL PROTEINS; BREFELDIN-A; ENDOPLASMIC-RETICULUM; TRANSPORT; ER; DOMAIN; CELLS; REDISTRIBUTION; CISTERNAE; MEMBRANES	The Golgi apparatus in animal cells comprises a reticulum of linked stacks in the pericentriolar and often in the juxtanuclear regions of the cell(1). The unique architecture of this organelle is thought to depend on the cytoskeleton(2) and cytoplasmic matrix proteins(3,4)-the best characterized being the golgin family of fibrous, coiled-coil proteins and the GRASP family of stacking proteins(5-10). Here we show that these matrix proteins can be separated from oligosaccharide-modifying enzymes in the Golgi stack without affecting their ability to form a ribbon-like reticulum in the correct location near to the nucleus. Our data suggest that the Golgi is a structural scaffold that can exist independently of, but is normally populated by, the enzyme-containing membranes that modify transiting cargo. This new concept of the Golgi further indicates that the Golgi may be an autonomous organelle rather than one that is in simple dynamic equilibrium with the endoplasmic reticulum.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Bioctr, Inst Biotechnol, Electron Microscopy Unit, Helsinki 00014, Finland	Yale University	Warren, G (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St,POB 208002, New Haven, CT 06520 USA.		Jokitalo, Eija/C-8375-2009	Jokitalo, Eija/0000-0002-4159-6934				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; CLUETT EB, 1992, J CELL SCI, V103, P773; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; Kjer-Nielsen L, 1999, CURR BIOL, V9, P385, DOI 10.1016/S0960-9822(99)80168-7; Linstedt AD, 1999, CURR BIOL, V9, pR893, DOI 10.1016/S0960-9822(00)80077-9; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Pepperkok R, 1998, J CELL SCI, V111, P1877; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROWE PM, 1995, MOL MED TODAY, V1, P257, DOI 10.1016/S1357-4310(95)90961-3; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Shorter J, 1999, EMBO J, V18, P4949, DOI 10.1093/emboj/18.18.4949; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	29	206	212	2	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 26	2000	407	6807					1022	1026		10.1038/35039538	http://dx.doi.org/10.1038/35039538			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366XX	11069184				2022-12-28	WOS:000090032500048
J	Vandenbroucke-Grauls, CMJE				Vandenbroucke-Grauls, CMJE			Clean hands closer to the bedside	LANCET			English	Editorial Material							RESISTANT STAPHYLOCOCCUS-AUREUS		Univ Hosp Vrije Univ, Dept Med Microbiol & Infect Control, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Vandenbroucke-Grauls, CMJE (corresponding author), Univ Hosp Vrije Univ, Dept Med Microbiol & Infect Control, NL-1007 MB Amsterdam, Netherlands.		Vandenbroucke-Grauls, Christina/AAO-7953-2020	Vandenbroucke-Grauls, Christina/0000-0003-2074-1597				Chaix C, 1999, JAMA-J AM MED ASSOC, V282, P1745, DOI 10.1001/jama.282.18.1745; Cookson B, 1999, BRIT MED J, V318, P686; Glass C, 1999, BRIT MED J, V318, P518, DOI 10.1136/bmj.318.7182.518; Larson E, 1999, CLIN INFECT DIS, V29, P1287, DOI 10.1086/313468; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Rotter ML, 1997, PREVENTION CONTROL N, P691; Vandenbroucke-Grauls CMJE, 1998, REV MED MICROBIOL, V9, P109; Voss A, 1997, INFECT CONT HOSP EP, V18, P205	8	6	6	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 14	2000	356	9238					1290	1291		10.1016/S0140-6736(00)02809-9	http://dx.doi.org/10.1016/S0140-6736(00)02809-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363VL	11073013				2022-12-28	WOS:000089858300005
J	London, SJ; Yuan, JM; Chung, FL; Gao, YT; Coetzee, GA; Ross, RK; Yu, MC				London, SJ; Yuan, JM; Chung, FL; Gao, YT; Coetzee, GA; Ross, RK; Yu, MC			Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: a prospective study of men in Shanghai, China	LANCET			English	Article							DIETARY ISOTHIOCYANATES; GSTT1 POLYMORPHISMS; CIGARETTE-SMOKING; NULL GENOTYPE; GSTM1; VEGETABLES; METABOLISM; SINGAPORE; BROCCOLI; SPROUTS	Background Dietary isothiocyanates inhibit lung carcinogenesis in laboratory animals but human data are limited. Glutathione S-transferases M1 and T1 (GSTM1 and GSTT1) conjugate isothiocyanates leading to more rapid elimination, Common deletion polymorphisms of GSTM1 and GSTT1 abolish enzyme activity. We hypothesised that chemopreventive effects of isothiocyanates might be heightened when enzymes that enhance their elimination are lacking. Methods We examined the relation between total isothiocyanate concentrations in urine, collected before diagnosis, and the subsequent risk of lung cancer among 232 incident cases of lung cancer and 710 matched controls from a cohort of 18 244 men in Shanghai, China, followed from 1986 to 1997. Homozygous deletion of the GSTM1 and GSTT1 genes were determined by PCR. Findings Individuals with detectable isothiocyanates in the urine were at decreased risk of lung cancer (smoking-adjusted relative risk for lung cancer=0.65 [95% CI 0.43-0.97]). This protective effect of isothiocyanates was seen primarily among individuals with homozygous deletion of GSTT1 (0.36 [0.20-0.63]) and particularly with deletion of both GSTM1 and GSTT1 (0.28 [0.13-0.57]). Interpretation Isothiocyanates appeared to reduce lung-cancer risk in this cohort of Chinese men. Reduction in risk was strongest among persons genetically deficient in enzymes that rapidly eliminate these chemopreventive compounds.	NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA USA; Amer Hlth Fdn, Div Carcinogenesis & Mol Epidemiol, Valhalla, NY 10595 USA; Shanghai Canc Inst, Shanghai, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Southern California; American Health Foundation; Shanghai Jiao Tong University	London, SJ (corresponding author), NIEHS, Epidemiol Branch, POB 12233,MD A3-05, Res Triangle Pk, NC 27709 USA.		Coetzee, Gerhard/AAG-8439-2019; coetzee, Gerhard/AAT-6203-2020; Gao, Yu/HGE-1937-2022; London, Stephanie/C-3734-2019	London, Stephanie/0000-0003-4911-5290; Yuan, Jian-Min/0000-0002-4620-3108; Coetzee, Gerhard/0000-0001-8820-8364	NATIONAL CANCER INSTITUTE [R01CA043092, R35CA053890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048, Z01ES043012, Z01ES049019, Z01ES049018, Z01ES049017, Z01ES025045] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA53890, R01 CA043092, R01 CA43092, R01 CA043092-20] Funding Source: Medline; NIEHS NIH HHS [5P30 ES07048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arand M, 1996, ANAL BIOCHEM, V236, P184, DOI 10.1006/abio.1996.0153; CHUNG FL, 1992, CANCER EPIDEM BIOMAR, V1, P383; Chung FL, 1998, CANCER EPIDEM BIOMAR, V7, P103; Chung FL, 1997, J CELL BIOCHEM, P76; CHUNG FL, 1992, CANC CHEMOPREVENTION; DAVIS FG, 1993, NUTR CANCER, V20, P241, DOI 10.1080/01635589309514292; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Hecht SS, 1999, J NUTR, V129, p768S, DOI 10.1093/jn/129.3.768S; Kelsey KT, 1997, CANCER CAUSE CONTROL, V8, P554, DOI 10.1023/A:1018434027502; Ketterer B, 1998, FREE RADICAL RES, V28, P647, DOI 10.3109/10715769809065820; Ketterer B, 1998, CANCER EPIDEM BIOMAR, V7, P645; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Lampe J. W., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P213; LEE EJD, 1995, PHARMACOGENETICS, V5, P332, DOI 10.1097/00008571-199510000-00010; Lin HJ, 1998, CANCER EPIDEM BIOMAR, V7, P647; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Nestle M, 1997, P NATL ACAD SCI USA, V94, P11149, DOI 10.1073/pnas.94.21.11149; Potter JD, 1996, IARC SCI PUBL, V139, P61; PRE J, 1991, CLIN CHIM ACTA, V204, P87, DOI 10.1016/0009-8981(91)90220-7; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Rothman N, 1996, CANCER EPIDEM BIOMAR, V5, P979; Seow A, 1998, CANCER EPIDEM BIOMAR, V7, P775; Shapiro TA, 1998, CANCER EPIDEM BIOMAR, V7, P1091; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Van Lieshout EMM, 1998, ONCOL REP, V5, P959; Verhagen H, 1997, CANCER LETT, V114, P127, DOI 10.1016/S0304-3835(97)04641-7; Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733; Woodson K, 1999, CANCER EPIDEM BIOMAR, V8, P965; Yu R, 1998, CANCER RES, V58, P402; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646; ZHANG YS, 1995, BIOCHEM BIOPH RES CO, V206, P748, DOI 10.1006/bbrc.1995.1106	33	338	350	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 26	2000	356	9231					724	729		10.1016/S0140-6736(00)02631-3	http://dx.doi.org/10.1016/S0140-6736(00)02631-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347UU	11085692				2022-12-28	WOS:000088948200012
J	Markovic, SN; Inwards, DJ; Frigas, EA; Phyliky, RP				Markovic, SN; Inwards, DJ; Frigas, EA; Phyliky, RP			Acquired C1 esterase inhibitor deficiency	ANNALS OF INTERNAL MEDICINE			English	Review							HEREDITARY ANGIONEUROTIC EDEMA; C1-ESTERASE INHIBITOR; C1-INHIBITOR DEFICIENCY; RECURRENT ANGIOEDEMA; TRANEXAMIC ACID; THERAPY; PARAPROTEINEMIA; CONCENTRATE; PROPHYLAXIS; ANTIBODIES	Acquired C1 esterase inhibitor deficiency is a rare condition associated with autoimmune or low-grade lymphoproliferative disorders. Adults or elderly patients are most commonly affected. The diagnosis is suspected when patients present with recurrent angioedema and low serum levels of C4 with normal levels of C3. Low levels of Clq and low C1 esterase inhibitor activity confirm the diagnosis. In this paper, we summarize experience with 22 cases of acquired C1 esterase inhibitor deficiency in the context of a review of the published literature on diagnosis and treatment of this condition.	Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, Rochester, MN 55901 USA	Mayo Clinic	Markovic, SN (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, 200 1st St SW, Rochester, MN 55901 USA.							ALSENZ J, 1989, BEHRING I MITT, V84, P165; Bauernschmitt R, 1998, INTENS CARE MED, V24, P635, DOI 10.1007/s001340050629; BORK K, 1989, J ALLERGY CLIN IMMUN, V83, P677, DOI 10.1016/0091-6749(89)90082-1; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; CASALI P, 1978, ACTA HAEMATOL-BASEL, V59, P277, DOI 10.1159/000207773; CICARDI M, 1985, Complement, V2, P133; CICARDI M, 1993, AM J MED, V95, P169, DOI 10.1016/0002-9343(93)90257-P; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; COLMAN RW, 1976, ANN INTERN MED, V85, P399, DOI 10.7326/0003-4819-85-3-399; CUGNO M, 1994, J ALLERGY CLIN IMMUN, V93, P870, DOI 10.1016/0091-6749(94)90380-8; Davis A E 3rd, 1989, Immunodefic Rev, V1, P207; DAY NK, 1976, CLIN EXP IMMUNOL, V26, P189; DERMER A, 1993, HEMATOLOGICA, V78, P408; DONALDSON VH, 1992, J LAB CLIN MED, V119, P397; Farkas H, 1999, Z GASTROENTEROL, V37, P513; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; FRIGAS E, 1989, MAYO CLIN PROC, V64, P1269, DOI 10.1016/S0025-6196(12)61290-7; Gerencer M, 1997, AIDS RES HUM RETROV, V13, P813, DOI 10.1089/aid.1997.13.813; GORDON EH, 1983, ANN ALLERGY, V51, P349; HEDA GD, 1990, BLOOD, V75, P2401; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; JONES RR, 1979, BRIT J DERMATOL, V101, P711, DOI 10.1111/j.1365-2133.1979.tb05652.x; MASSA MC, 1982, J AM ACAD DERMATOL, V7, P255, DOI 10.1016/S0190-9622(82)70115-X; MATHUR R, 1993, POSTGRAD MED J, V69, P646, DOI 10.1136/pgmj.69.814.646; NILSEN A, 1980, ACTA MED SCAND, V207, P123; OLTVAI ZN, 1991, LAB INVEST, V65, P381; Osler W, 1888, AM J MED SCI, V95, P362; PASCUAL M, 1987, AM J MED, V83, P959, DOI 10.1016/0002-9343(87)90659-0; PASQUALI JL, 1984, INT ARCH ALLER A IMM, V74, P284, DOI 10.1159/000233560; QUINCKE H, 1882, DERMATOLOGIE, V1, P129; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; WASSERFALLEN JB, 1995, J ALLERGY CLIN IMMUN, V95, P124, DOI 10.1016/S0091-6749(95)70160-5	32	110	115	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2000	132	2					144	150		10.7326/0003-4819-132-2-200001180-00009	http://dx.doi.org/10.7326/0003-4819-132-2-200001180-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	275ZZ	11085856				2022-12-28	WOS:000084852300008
J	Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J				Williams, JW; Mulrow, CD; Chiquette, E; Noel, PH; Aguilar, C; Cornell, J			A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary	ANNALS OF INTERNAL MEDICINE			English	Review							SEROTONIN REUPTAKE INHIBITORS; NATIONAL-COMORBIDITY-SURVEY; RANDOMIZED CLINICAL-TRIALS; LONG-TERM TREATMENT; ST-JOHNS WORT; PRIMARY-CARE; DOUBLE-BLIND; MAJOR DEPRESSION; TRICYCLIC ANTIDEPRESSANTS; DISCONTINUATION RATES	Background: Depressive disorders are persistent, recurring illnesses that cause great suffering for patients and their families. Purpose: To evaluate the benefits and adverse effects of newer pharmacotherapies and herbal treatments for depressive disorders in adults and adolescents. Data Sources: English-language and non-English-language literature from 1980 to January 1998 was identified from a specialized registry of controlled trials, meta-analyses, and experts. Study Selection: Randomized trials evaluating newer antidepressants (such as serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and St. John's wort) that reported clinical outcomes were selected. Data Extraction: Two persons independently abstracted data that were then synthesized descriptively; some data were pooled by using a random-effects model. Data Synthesis: Of 315 eligible trials, most evaluated antidepressants in adults with major depression, were conducted among outpatients, and examined acute-phase treatment. Newer antidepressants were more effective than placebo for major depression (relative benefit, 1.6 [95% CI, 1.5 to 1.7]) and dysthymia (relative benefit, 1.7 [CI, 1.3 to 2.3]). They were effective among older adults and primary care patients. Efficacy did not differ among newer agents or between newer and older agents. Hypericum (St. John's wort) was more effective than placebo for mild to moderate depression (risk ratio, 1.9 [Cl, 1.2 to 2.8]), but publication bias may have inflated the estimate of benefit. Newer and older antidepressants did not differ for overall discontinuation rates, but side effect profiles varied significantly. Data were insufficient for determining the efficacy of newer antidepressants for subsyndromal depression, depression with coexisting medical or psychiatric illness, or depression in adolescents. Conclusions: Newer antidepressants are clearly effective in treating depressive disorders in diverse settings. Because of similar efficacy, both newer and older antidepressants should be considered when making treatment decisions. Better information is urgently needed on the efficacy of newer antidepressants in patients with nonmajor depression and in special populations, including adolescents.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Kerrville, TX USA	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Williams, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio Evidence Based Practice Ctr, 7703 Floyd Curl Dr,Mail Code 7879, San Antonio, TX 78229 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558; Noel, Polly/0000-0002-1519-7489	PHS HHS [290-97-0012] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON IM, 1995, BMJ-BRIT MED J, V310, P1433, DOI 10.1136/bmj.310.6992.1433; ANGST J, 1995, J CLIN PSYCHOPHARM, V15, pS16, DOI 10.1097/00004714-199508001-00004; ANTON SF, 1994, PSYCHOPHARMACOL BULL, V30, P165; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; BEASLEY CM, 1992, INT CLIN PSYCHOPHARM, V6, P35, DOI 10.1097/00004850-199206006-00006; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGMANN R, 1993, TW NEUROLOGIE PSYCHI, P7235; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boyer P, 1996, EUR PSYCHIAT, V11, pS135, DOI 10.1016/0924-9338(96)85188-1; BREMNER JD, 1995, J CLIN PSYCHIAT, V56, P519; Brown C, 1995, GEN HOSP PSYCHIAT, V17, P414, DOI 10.1016/0163-8343(95)00072-0; BYRNE MM, 1989, ACTA PSYCHIAT SCAND, V80, P138, DOI 10.1111/j.1600-0447.1989.tb07194.x; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P839, DOI 10.1111/j.1532-5415.1994.tb06555.x; CHURCHILL R, 1998, SYSTEMATIC REV META, P2; CLAGHORN JL, 1992, J CLIN PSYCHIAT, V53, P434; CONTE HR, 1986, ARCH GEN PSYCHIAT, V43, P471; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; Cucherat M, 1996, ENCEPHALE, V22, P378; DELINISTULA A, 1995, J AFFECT DISORDERS, V35, P21, DOI 10.1016/0165-0327(95)00034-K; Devane CL, 1996, J CLIN PSYCHIAT, V57, P55; DITZLER K, 1994, COMPLEMENT THER MED, V2, P5; Donoghue J, 1996, BRIT MED J, V313, P861; DUNBAR GC, 1993, ACTA PSYCHIAT SCAND, V87, P302, DOI 10.1111/j.1600-0447.1993.tb03376.x; DUNBAR GC, 1995, PHARMACOLOGY, V51, P137, DOI 10.1159/000139327; EGGER M, 1997, BRIT MED J, V314, P629; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; Entsuah AR, 1995, PSYCHOPHARMACOL BULL, V31, P759; FAWCETT J, 1995, J CLIN PSYCHIAT, V56, P37; FRANCHINI L, 1994, J AFFECT DISORDERS, V32, P225, DOI 10.1016/0165-0327(94)90085-X; Franchini L, 1997, J CLIN PSYCHIAT, V58, P104, DOI 10.4088/JCP.v58n0303; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE, P5; FREEMANTLE N, 1998, SELECTIVE SEROTONIN, P2; GOLDSTEIN DJ, 1993, CLIN PHARMACOL THER, V54, P245, DOI 10.1038/clpt.1993.144; GOODNICK PJ, 1995, J CLIN PSYCHIAT, V56, P128; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; GREENBERG RP, 1992, J CONSULT CLIN PSYCH, V60, P664, DOI 10.1037/0022-006X.60.5.664; GREENBERG RP, 1994, J NERV MENT DIS, V182, P547, DOI 10.1097/00005053-199410000-00003; HELLERSTEIN DJ, 1993, AM J PSYCHIAT, V150, P1169; HENRY JA, 1995, BRIT MED J, V310, P221, DOI 10.1136/bmj.310.6974.221; Hoffmann J, 1979, ZFA (Stuttgart), V55, P776; HORNIG M, 1998, ALTERNATIVE MED ALER, V1, P4; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; Hotopf M, 1996, BRIT J PSYCHIAT, V168, P404, DOI 10.1192/bjp.168.4.404; Hotopf M, 1997, BRIT J PSYCHIAT, V170, P120, DOI 10.1192/bjp.170.2.120; HOTOPF M, 1998, SYSTEMATIC REV TREAT, P2; Hunkeler E, 1998, INT J PSYCHIAT MED, V28, P389; IBOR JJL, 1993, EUR PSYCHIAT, V8, pS17; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; Kasper S, 1996, INT CLIN PSYCHOPHARM, V11, P35, DOI 10.1097/00004850-199609004-00005; Kasper S, 1995, INT CLIN PSYCHOPHARM, V10, P25, DOI 10.1097/00004850-199512004-00005; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katzelnick D, 1998, INT J PSYCHIAT MED, V28, P391; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KNIEBEL R, 1988, Z ALLG MED, V64, P689; LIMA MS, 1998, COMP DRUGS VERSUS PL, P2; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; LINDE K, 1998, ST JOHNS WORT DEPRES, P2; Mandoki MW, 1997, PSYCHOPHARMACOL BULL, V33, P149; McCusker J, 1998, ARCH INTERN MED, V158, P705, DOI 10.1001/archinte.158.7.705; MONTGOMERY DE, 1995, MODAL ANAL, V10, P1; MONTGOMERY SA, 1995, INT CLIN PSYCHOPHARM, V9, P33, DOI 10.1097/00004850-199501004-00005; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P35, DOI 10.1097/00004850-199403001-00006; MONTGOMERY SA, 1994, INT CLIN PSYCHOPHARM, V9, P47, DOI 10.1097/00004850-199400910-00008; MONTGOMERY SA, 1993, INT CLIN PSYCHOPHARM, V8, P189, DOI 10.1097/00004850-199300830-00009; Mulrow CD, 1998, PSYCHOPHARMACOL BULL, V34, P409; MULROW CD, 1999, AHCPR PUBLICATION; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; *N ENGL EV BAS GUI, 1998, CHOIC ANT DEPR PRIM; PARNETTI L, 1993, DRUG INVEST, V6, P181, DOI 10.1007/BF03259242; PEDEN JG, 1995, TREATMENTS PSYCHIAT, P1330; PERSAD E, 1990, CAN J PSYCHIAT, V35, P175, DOI 10.1177/070674379003500214; Persons JB, 1996, ARCH GEN PSYCHIAT, V53, P283; Philipp M, 1999, BRIT MED J, V319, P1534, DOI 10.1136/bmj.319.7224.1534; Puech A, 1997, INT CLIN PSYCHOPHARM, V12, P99, DOI 10.1097/00004850-199703000-00005; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REH C, 1992, THERAPIEWOCHE, V42, P1576; Rost K, 1998, INT J PSYCHIAT MED, V28, P398; SALZMANN E, 1995, NEUROPSYCHOBIOLOGY, V31, P68, DOI 10.1159/000119175; Schmidt U, 1993, Fortschr Med, V111, P339; SIMEON JG, 1990, PROG NEURO-PSYCHOPH, V14, P791, DOI 10.1016/0278-5846(90)90050-Q; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Smeraldi E, 1998, J AFFECT DISORDERS, V48, P47, DOI 10.1016/S0165-0327(97)00139-0; Sobin C, 1996, BRIT J PSYCHIAT, V169, P322, DOI 10.1192/bjp.169.3.322; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stahl S, 1997, ACTA PSYCHIAT SCAND, V96, P22, DOI 10.1111/j.1600-0447.1997.tb05955.x; Stassen HH, 1996, PHARMACOPSYCHIATRY, V29, P87, DOI 10.1055/s-2007-979551; Steffens D C, 1997, Depress Anxiety, V6, P10, DOI 10.1002/(SICI)1520-6394(1997)6:1<10::AID-DA2>3.0.CO;2-9; STEGER W, 1985, Z ALLG MED, V61, P914; Szegedi A, 1997, PHARMACOPSYCHIATRY, V30, P97, DOI 10.1055/s-2007-979490; TAYLOR D, 1995, BRIT J PSYCHIAT, V167, P575, DOI 10.1192/bjp.167.5.575; Thase ME, 1996, ARCH GEN PSYCHIAT, V53, P777; Thase ME, 1997, ARCH GEN PSYCHIAT, V54, P1009; TOLLEFSON GD, 1994, J CLIN PSYCHOPHARM, V14, P163; TRINIDADE E, 1997, 19973E19974E CCOHTA; *US DEP HHS, 1993, AHCPR PUBL; Vanelle JM, 1997, BRIT J PSYCHIAT, V170, P345, DOI 10.1192/bjp.170.4.345; VANMOFFAERT M, 1989, NEW TRENDS EXPT CLIN, V5, P167; Vorbach EU, 1997, PHARMACOPSYCHIATRY, V30, P81, DOI 10.1055/s-2007-979524; VORBACH EU, 1994, J GERIATR PSYCHIA S1, V7, P519; Wagner W, 1992, Drugs, V43 Suppl 2, P48; Warshaw MG, 1996, J CLIN PSYCHIAT, V57, P158; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; Wheatley D, 1997, PHARMACOPSYCHIATRY, V30, P77, DOI 10.1055/s-2007-979523; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568; Williams JW, 1999, ARCH FAM MED, V8, P58, DOI 10.1001/archfami.8.1.58; WILSON K, 1998, REV ANTIDEPRESSANT D, P2; Witte B, 1995, Fortschr Med, V113, P404; 1993, AM J PSYCHIAT S4, V150, pR3	114	275	283	0	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 2	2000	132	9					743	756		10.7326/0003-4819-132-9-200005020-00011	http://dx.doi.org/10.7326/0003-4819-132-9-200005020-00011			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	308VT	10787370				2022-12-28	WOS:000086734100010
J	Biggar, RJ; Frisch, M				Biggar, RJ; Frisch, M			Estimating the risk of cancer in children with AIDS - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA; Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen, Denmark	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Aarhus University; Statens Serum Institut	Biggar, RJ (corresponding author), NCI, Viral Epidemiol Branch, Bethesda, MD 20892 USA.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Gallagher, Brian/0000-0001-9794-6721					0	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2593	2594		10.1001/jama.284.20.2593	http://dx.doi.org/10.1001/jama.284.20.2593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086360				2022-12-28	WOS:000165296200021
J	Gallagher, B; Wang, ZY				Gallagher, B; Wang, ZY			Estimating the risk of cancer in children with AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							NON-HODGKINS-LYMPHOMA; KAPOSIS-SARCOMA		New York State Dept Hlth, Div Epidemiol, Albany, NY 12237 USA	State University of New York (SUNY) System	Gallagher, B (corresponding author), New York State Dept Hlth, Div Epidemiol, Albany, NY 12237 USA.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Gallagher, Brian/0000-0001-9794-6721				Biggar RJ, 2000, JAMA-J AM MED ASSOC, V284, P205, DOI 10.1001/jama.284.2.205; Biggar RJ, 1996, INT J CANCER, V68, P754; Franceschi S, 1998, BRIT J CANCER, V78, P966, DOI 10.1038/bjc.1998.610; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Grulich AE, 1999, AIDS, V13, P839, DOI 10.1097/00002030-199905070-00014	5	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2593	2593		10.1001/jama.284.20.2593	http://dx.doi.org/10.1001/jama.284.20.2593			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086360				2022-12-28	WOS:000165296200020
J	Graner, J				Graner, J			Physicians and patient spirituality	ANNALS OF INTERNAL MEDICINE			English	Letter									Mayo Clin, Rochester, MN 55906 USA	Mayo Clinic	Graner, J (corresponding author), Mayo Clin, Rochester, MN 55906 USA.							COPP J, 2000, ST ANTHONY MESSENGER, V107, P23; Post SG, 2000, ANN INTERN MED, V132, P578, DOI 10.7326/0003-4819-132-7-200004040-00010; TIGERTT WD, 1983, J HIST MED ALL SCI, V38, P259, DOI 10.1093/jhmas/38.3.259	3	10	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 7	2000	133	9					748	748		10.7326/0003-4819-133-9-200011070-00028	http://dx.doi.org/10.7326/0003-4819-133-9-200011070-00028			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369PC	11074920				2022-12-28	WOS:000165075300018
J	Markovic, SN; Inwards, DJ; Phyliky, RP				Markovic, SN; Inwards, DJ; Phyliky, RP			Acquired C1 esterase inhibitor deficiency - In Response	ANNALS OF INTERNAL MEDICINE			English	Letter									Mayo Clin, Rochester, MN 55905 USA	Mayo Clinic	Markovic, SN (corresponding author), Mayo Clin, Rochester, MN 55905 USA.								0	110	115	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 21	2000	133	10					839	839		10.7326/0003-4819-133-10-200011210-00025	http://dx.doi.org/10.7326/0003-4819-133-10-200011210-00025			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374AA	11085856				2022-12-28	WOS:000165321200017
J	Behrman, AJ				Behrman, AJ			Long-term prognosis of hepatitis C virus infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Penn Hlth Syst, Dept Emergency Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Behrman, AJ (corresponding author), Univ Penn Hlth Syst, Dept Emergency Med, Philadelphia, PA 19104 USA.		Strathdee, Steffanie A/B-9042-2009					[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450	5	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2592	2592		10.1001/jama.284.20.2592	http://dx.doi.org/10.1001/jama.284.20.2592			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086357				2022-12-28	WOS:000165296200018
J	Stany, MP				Stany, MP			Health risks of cigar smoking	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Kentucky, Coll Med, Lexington, KY 40506 USA	University of Kentucky	Stany, MP (corresponding author), Univ Kentucky, Coll Med, Lexington, KY 40506 USA.							Baker F, 2000, JAMA-J AM MED ASSOC, V284, P735, DOI 10.1001/jama.284.6.735; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; Papadakis JA, 2000, J R SOC PROMO HEALTH, V120, P11, DOI 10.1177/146642400012000111; *US DEP HHS, 1998, NIH PUBL, P105; *US DHEW, 1998, NIH PUBL, P21	5	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	2000	284	18					2320	2321		10.1001/jama.284.18.2320	http://dx.doi.org/10.1001/jama.284.18.2320			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	369NU	11066176				2022-12-28	WOS:000165074500020
J	Thomas, DL; Strathdee, SA; Vlahov, D				Thomas, DL; Strathdee, SA; Vlahov, D			Long-term prognosis of hepatitis C virus infection - Reply	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Johns Hopkins Univ, Infect Dis Grp, Baltimore, MD 21204 USA	Johns Hopkins University	Thomas, DL (corresponding author), Johns Hopkins Univ, Infect Dis Grp, Baltimore, MD 21204 USA.		Strathdee, Steffanie A/B-9042-2009					DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003	4	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 22	2000	284	20					2592	2593		10.1001/jama.284.20.2592	http://dx.doi.org/10.1001/jama.284.20.2592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373NU	11086357				2022-12-28	WOS:000165296200019
